1	HPLC	O
2	phosphopeptide	O
3	mapping	O
4	,	O
5	amino	O
6	acid	O
7	sequencing	O
8	,	O
9	and	O
10	site	O
11	-	O
12	directed	O
13	mutagenesis	O
14	determined	O
15	that	O
16	NCLK	B
17	phosphorylates	O
18	Ser	O
19	(	O
20	67	O
21	)	O
22	of	O
23	I	B
24	-	I
25	1	I
26	.	O

1	Compared	O
2	to	O
3	controls	O
4	,	O
5	both	O
6	UB	O
7	and	O
8	OCS	O
9	rats	O
10	showed	O
11	a	O
12	small	O
13	but	O
14	significant	O
15	post	O
16	-	O
17	operative	O
18	reduction	O
19	in	O
20	the	O
21	nocturnality	O
22	of	O
23	drinking	O
24	.	O

1	Because	O
2	the	O
3	mutant	O
4	defective	O
5	in	O
6	DNA	O
7	binding	O
8	also	O
9	fails	O
10	to	O
11	stimulate	O
12	Abf1	B
13	ARS1	O
14	DNA	O
15	-	O
16	binding	O
17	activity	O
18	,	O
19	our	O
20	results	O
21	suggest	O
22	that	O
23	Cdc6	B
24	DNA	O
25	-	O
26	binding	O
27	activity	O
28	may	O
29	play	O
30	a	O
31	pivotal	O
32	role	O
33	in	O
34	the	O
35	initiation	O
36	of	O
37	DNA	O
38	replication	O
39	.	O

1	This	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	assess	O
7	the	O
8	role	O
9	of	O
10	additional	O
11	diagnostic	O
12	laparoscopy	O
13	in	O
14	the	O
15	preoperative	O
16	staging	O
17	of	O
18	patients	O
19	with	O
20	adenocarcinoma	O
21	of	O
22	the	O
23	esophagus	O
24	,	O
25	gastric	O
26	cancer	O
27	and	O
28	pancreatic	O
29	cancer	O
30	prior	O
31	to	O
32	intended	O
33	curative	O
34	surgery	O
35	.	O

1	Coronary	O
2	T1	O
3	and	O
4	T2	O
5	weighted	O
6	images	O
7	were	O
8	obtained	O
9	.	O

1	For	O
2	EPV	O
3	3	O
4	,	O
5	10	O
6	,	O
7	or	O
8	40	O
9	,	O
10	the	O
11	bias	O
12	exceeded	O
13	25	O
14	%	O
15	for	O
16	7	O
17	,	O
18	3	O
19	,	O
20	and	O
21	1	O
22	in	O
23	the	O
24	8	O
25	-	O
26	predictor	O
27	model	O
28	respectively	O
29	,	O
30	when	O
31	a	O
32	conventional	O
33	selection	O
34	criterion	O
35	was	O
36	used	O
37	(	O
38	alpha	O
39	=	O
40	0	O
41	.	O
42	05	O
43	).	O

1	Tolterodine	O
2	users	O
3	were	O
4	7	O
5	.	O
6	5	O
7	times	O
8	more	O
9	likely	O
10	to	O
11	have	O
12	received	O
13	another	O
14	spasmolytic	O
15	drug	O
16	(	O
17	RR	O
18	7	O
19	.	O
20	5	O
21	,	O
22	95	O
23	%	O
24	CI	O
25	4	O
26	.	O
27	8	O
28	to	O
29	11	O
30	.	O
31	9	O
32	).	O

1	Alterations	O
2	in	O
3	DNase	B
4	I	I
5	reactivity	O
6	of	O
7	the	O
8	GC	O
9	-	O
10	response	O
11	element	O
12	region	O
13	suggest	O
14	that	O
15	GC	B
16	receptor	I
17	-	I
18	GC	I
19	complexes	I
20	may	O
21	associate	O
22	,	O
23	in	O
24	a	O
25	transient	O
26	manner	O
27	,	O
28	with	O
29	the	O
30	promoter	O
31	in	O
32	the	O
33	actively	O
34	transcribing	O
35	control	O
36	state	O
37	.	O

1	Chenodeoxycholic	O
2	acid	O
3	(	O
4	cheno	O
5	)	O
6	and	O
7	ursodeoxycholic	O
8	acid	O
9	(	O
10	urso	O
11	)	O
12	dissolve	O
13	cholesterol	O
14	gallstones	O
15	in	O
16	man	O
17	.	O

1	The	O
2	C	O
3	/	O
4	D	O
5	ratio	O
6	was	O
7	equal	O
8	to	O
9	or	O
10	over	O
11	0	O
12	.	O
13	6	O
14	in	O
15	9	O
16	cases	O
17	(	O
18	16	O
19	eyes	O
20	),	O
21	and	O
22	the	O
23	values	O
24	were	O
25	inconsistent	O
26	between	O
27	both	O
28	eyes	O
29	in	O
30	55	O
31	%	O
32	of	O
33	the	O
34	patients	O
35	.	O

1	Shc	B
2	stimulates	O
3	Ras	B
4	/	O
5	mitogen	B
6	-	I
7	activated	I
8	protein	I
9	kinase	I
10	(	O
11	MAPK	B
12	)	O
13	through	O
14	forming	O
15	a	O
16	complex	O
17	with	O
18	Grb2	B
19	at	O
20	the	O
21	phosphorylated	O
22	tyrosine	O
23	(	O
24	Y	O
25	)	O
26	residue	O
27	317	O
28	.	O

1	Plasma	O
2	membranes	O
3	of	O
4	cultured	O
5	cells	O
6	contain	O
7	high	O
8	affinity	O
9	receptors	O
10	for	O
11	high	B
12	density	I
13	lipoprotein	I
14	(	O
15	HDL	B
16	)	O
17	that	O
18	appear	O
19	to	O
20	mediate	O
21	removal	O
22	of	O
23	excess	O
24	intracellular	O
25	cholesterol	O
26	.	O

1	No	O
2	patient	O
3	with	O
4	bradyarrhythmia	O
5	-	O
6	related	O
7	SCD	O
8	had	O
9	manifest	O
10	atrioventricular	O
11	block	O
12	or	O
13	bundle	O
14	branch	O
15	block	O
16	.	O

1	Analysis	O
2	of	O
3	human	O
4	genomic	O
5	DNA	O
6	reveals	O
7	an	O
8	intronless	O
9	sequence	O
10	with	O
11	strong	O
12	homology	O
13	to	O
14	human	B
15	G	I
16	alpha	I
17	q	I
18	cDNA	I
19	.	O

1	Optical	O
2	-	O
3	absorption	O
4	spectra	O
5	,	O
6	crystal	O
7	-	O
8	field	O
9	energy	O
10	levels	O
11	,	O
12	and	O
13	transition	O
14	line	O
15	strengths	O
16	of	O
17	holmium	O
18	in	O
19	trigonal	O
20	Na3	O

1	Because	O
2	L	B
3	-	I
4	plastin	I
5	expression	O
6	in	O
7	tissue	O
8	-	O
9	specifically	O
10	regulated	O
11	in	O
12	both	O
13	humans	O
14	and	O
15	rodents	O
16	,	O
17	it	O
18	is	O
19	likely	O
20	that	O
21	similar	O
22	mechanisms	O
23	regulate	O
24	L	B
25	-	I
26	plastin	I
27	gene	I
28	expression	O
29	in	O
30	human	O
31	and	O
32	rodent	O
33	cells	O
34	and	O
35	that	O
36	they	O
37	could	O
38	be	O
39	identified	O
40	by	O
41	comparing	O
42	the	O
43	function	O
44	and	O
45	nucleotide	O
46	sequences	O
47	of	O
48	the	O
49	human	O
50	and	O
51	murine	O
52	L	B
53	-	I
54	plastin	I
55	gene	O
56	promoters	O
57	.	O

1	Moreover	O
2	,	O
3	when	O
4	added	O
5	to	O
6	the	O
7	osteoclast	O
8	cultures	O
9	,	O
10	mrIhh	B
11	-	I
12	N	I
13	markedly	O
14	stimulated	O
15	the	O
16	formation	O
17	of	O
18	resorption	O
19	pits	O
20	on	O
21	dentine	O
22	slices	O
23	.	O

1	Like	O
2	pineal	O
3	melatonin	O
4	,	O
5	serum	O
6	melatonin	O
7	was	O
8	high	O
9	at	O
10	mid	O
11	-	O
12	dark	O
13	and	O
14	low	O
15	at	O
16	mid	O
17	-	O
18	light	O
19	.	O

1	XXI	O
2	.	O

1	Management	O
2	of	O
3	hypertension	O
4	in	O
5	the	O
6	elderly	O
7	.	O

1	The	O
2	recovery	O
3	rates	O
4	for	O
5	the	O
6	MB	O
7	/	O
8	BacT	O
9	,	O
10	MGIT	O
11	960	O
12	,	O
13	and	O
14	solid	O
15	media	O
16	were	O
17	91	O
18	.	O
19	6	O
20	,	O
21	87	O
22	.	O
23	4	O
24	,	O
25	and	O
26	54	O
27	.	O
28	7	O
29	%,	O
30	respectively	O
31	,	O
32	for	O
33	all	O
34	mycobacteria	O
35	;	O
36	the	O
37	recovery	O
38	rates	O
39	were	O
40	93	O
41	.	O
42	6	O
43	,	O
44	88	O
45	.	O
46	9	O
47	,	O
48	and	O
49	63	O
50	.	O
51	4	O
52	%,	O
53	respectively	O
54	,	O
55	for	O
56	M	O
57	.	O
58	tuberculosis	O
59	complex	O
60	alone	O
61	,	O
62	and	O
63	87	O
64	.	O
65	5	O
66	,	O
67	84	O
68	.	O
69	4	O
70	,	O
71	and	O
72	37	O
73	.	O
74	5	O
75	%,	O
76	respectively	O
77	,	O
78	for	O
79	all	O
80	nontuberculous	O
81	mycobacteria	O
82	.	O

1	Insert2	O
2	contains	O
3	repetitive	O
4	non	O
5	-	O
6	Ig	B
7	-	O
8	related	O
9	sequences	O
10	and	O
11	a	O
12	small	B
13	Ig	I
14	-	I
15	related	I
16	sequence	I
17	.	O

1	Decreased	O
2	cardiac	O
3	glycogen	O
4	following	O
5	phenformin	O
6	injection	O
7	in	O
8	hyperglycemic	O
9	,	O
10	hyperinsulinemic	O
11	anaesthetized	O
12	rats	O
13	.	O

1	In	O
2	the	O
3	first	O
4	part	O
5	of	O
6	our	O
7	study	O
8	,	O
9	the	O
10	highest	O
11	mutagenicity	O
12	was	O
13	revealed	O
14	by	O
15	TA98	O
16	strain	O
17	without	O
18	enzymatic	O
19	activation	O
20	,	O
21	suggesting	O
22	a	O
23	direct	O
24	-	O
25	acting	O
26	mutagenicity	O
27	prevalence	O
28	in	O
29	diesel	O
30	particulate	O
31	.	O

1	Antidepressant	O
2	-	O
3	like	O
4	properties	O
5	of	O
6	some	O
7	serotonin	B
8	receptor	I
9	ligands	O
10	and	O
11	calcium	O
12	channel	O
13	antagonists	O
14	measured	O
15	with	O
16	the	O
17	forced	O
18	swimming	O
19	test	O
20	in	O
21	mice	O
22	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	pilin	B
6	gene	I
7	,	O
8	tcpA	B
9	,	O
10	is	O
11	dependent	O
12	upon	O
13	ToxR	B
14	and	O
15	upon	O
16	ToxT	B
17	.	O

1	The	O
2	incidence	O
3	of	O
4	cardiac	O
5	death	O
6	(	O
7	one	O
8	per	O
9	group	O
10	),	O
11	Q	O
12	wave	O
13	MI	O
14	(	O
15	propofol	O
16	,	O
17	n	O
18	=	O
19	7	O
20	;	O
21	midazolam	O
22	,	O
23	n	O
24	=	O
25	3	O
26	;	O
27	P	O
28	=	O
29	0	O
30	.	O
31	27	O
32	),	O
33	or	O
34	non	O
35	Q	O
36	wave	O
37	MI	O
38	(	O
39	propofol	O
40	,	O
41	n	O
42	=	O
43	16	O
44	;	O
45	midazolam	O
46	,	O
47	n	O
48	=	O
49	18	O
50	;	O
51	P	O
52	=	O
53	0	O
54	.	O
55	81	O
56	)	O
57	did	O
58	not	O
59	differ	O
60	between	O
61	treatment	O
62	groups	O
63	.	O

1	Pregnant	O
2	rats	O
3	were	O
4	exposed	O
5	to	O
6	one	O
7	of	O
8	the	O
9	following	O
10	:	O
11	(	O
12	1	O
13	)	O
14	10	O
15	%	O
16	O2	O
17	in	O
18	N2	O
19	or	O
20	100	O
21	%	O
22	O2	O
23	for	O
24	2	O
25	days	O
26	beginning	O
27	at	O
28	day	O
29	7	O
30	,	O
31	11	O
32	,	O
33	14	O
34	,	O
35	or	O
36	18	O
37	of	O
38	pregnancy	O
39	;	O
40	(	O
41	2	O
42	)	O
43	10	O
44	%	O
45	O2	O
46	in	O
47	N2	O
48	or	O
49	100	O
50	%	O
51	O2	O
52	for	O
53	10	O
54	h	O
55	/	O
56	day	O
57	beginning	O
58	at	O
59	day	O
60	7	O
61	;	O
62	or	O
63	(	O
64	3	O
65	)	O
66	14	O
67	-	O
68	11	O
69	%	O
70	O2	O
71	in	O
72	N2	O
73	continuously	O
74	beginning	O
75	at	O
76	day	O
77	14	O
78	till	O
79	day	O
80	21	O
81	when	O
82	they	O
83	were	O
84	sacrificed	O
85	.	O

1	It	O
2	has	O
3	repeatedly	O
4	been	O
5	shown	O
6	that	O
7	HCMV	O
8	IE1	B
9	/	O
10	IE2	B
11	can	O
12	independently	O
13	transactivate	O
14	HIV	B
15	-	I
16	1	I
17	LTR	I
18	.	O

1	Nip7p	B
2	-	O
3	depleted	O
4	cells	O
5	exhibited	O
6	the	O
7	same	O
8	defects	O
9	as	O
10	Nop8p	B
11	-	O
12	depleted	O
13	cells	O
14	,	O
15	except	O
16	that	O
17	they	O
18	accumulated	O
19	27S	B
20	precursors	I
21	.	O

1	The	O
2	patients	O
3	are	O
4	two	O
5	healthy	O
6	adult	O
7	males	O
8	.	O

1	This	O
2	led	O
3	to	O
4	the	O
5	conclusion	O
6	that	O
7	the	O
8	metatarsal	O
9	artery	O
10	should	O
11	be	O
12	used	O
13	for	O
14	toe	O
15	MP	O
16	joint	O
17	grafts	O
18	,	O
19	while	O
20	the	O
21	unilateral	O
22	proper	O
23	digital	O
24	artery	O
25	is	O
26	suitable	O
27	for	O
28	toe	O
29	PIP	O
30	joint	O
31	grafts	O
32	,	O
33	together	O
34	with	O
35	concomitant	O
36	or	O
37	dorsal	O
38	cutaneous	O
39	vein	O
40	.	O

1	We	O
2	used	O
3	expression	O
4	cloning	O
5	to	O
6	identify	O
7	interleukin	B
8	-	I
9	6	I
10	(	O
11	IL	B
12	-	I
13	6	I
14	)	O
15	as	O
16	one	O
17	factor	O
18	that	O
19	suppressed	O
20	growth	O
21	of	O
22	a	O
23	pre	O
24	-	O
25	B	O
26	-	O
27	cell	O
28	variant	O
29	line	O
30	,	O
31	1A9	O
32	-	O
33	M	O
34	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	P2	B
6	-	I
7	proximal	I
8	CTCF	I
9	binding	I
10	site	I
11	and	O
12	transient	O
13	-	O
14	cotransfection	O
15	experiments	O
16	demonstrate	O
17	that	O
18	CTCF	B
19	is	O
20	a	O
21	transcriptional	O
22	repressor	O
23	of	O
24	the	O
25	human	B
26	c	I
27	-	I
28	myc	I
29	gene	I
30	.	O

1	We	O
2	propose	O
3	that	O
4	the	O
5	reduced	O
6	responsiveness	O
7	of	O
8	CYP3A2	B
9	is	O
10	the	O
11	result	O
12	of	O
13	preferential	O
14	binding	O
15	of	O
16	COUP	B
17	-	I
18	TF	I
19	at	O
20	the	O
21	CYP3A2	B
22	DexRE	I
23	-	I
24	1	I
25	site	I
26	.	O

1	Somatostatin	B
2	gene	I
3	expression	O
4	in	O
5	pancreatic	O
6	islet	O
7	cells	O
8	is	O
9	directed	O
10	by	O
11	cell	O
12	-	O
13	specific	O
14	DNA	O
15	control	O
16	elements	O
17	and	O
18	DNA	O
19	-	O
20	binding	O
21	proteins	O
22	.	O

1	Low	O
2	-	O
3	dose	O
4	D	O
5	(	O
6	0	O
7	.	O
8	4	O
9	-	O
10	0	O
11	.	O
12	8	O
13	mg	O
14	)	O
15	and	O
16	DB	O
17	(	O
18	1	O
19	.	O
20	0	O
21	-	O
22	5	O
23	.	O
24	0	O
25	mg	O
26	)	O
27	did	O
28	not	O
29	significantly	O
30	alter	O
31	any	O
32	parameter	O
33	from	O
34	control	O
35	.	O

1	Identity	O
2	elements	O
3	in	O
4	tRNA	O
5	for	O
6	mono	O
7	-	O
8	and	O
9	dimethylation	O
10	reactions	O
11	by	O
12	the	O
13	recombinant	B
14	pfTrm1p	I
15	were	O
16	identified	O
17	using	O
18	in	O
19	vitro	O
20	T7	O
21	transcripts	O
22	of	O
23	33	O
24	variants	O
25	of	O
26	tRNA	B
27	(	I
28	Asp	I
29	)	I
30	and	O
31	tRNA	B
32	(	I
33	Phe	I
34	)	I
35	from	O
36	yeast	O
37	.	O

1	Osteocalcin	B
2	(	O
3	serum	B
4	bone	I
5	-	I
6	Gla	I
7	protein	I
8	,	O
9	sBGP	B
10	),	O
11	serum	B
12	alkaline	I
13	phosphatase	I
14	(	O
15	sAP	B
16	)	O
17	and	O
18	urinary	O
19	hydroxyproline	O
20	/	O
21	creatinine	O
22	ratio	O
23	(	O
24	uOH	O
25	-	O
26	Prol	O
27	/	O
28	creatinine	O
29	)	O
30	have	O
31	been	O
32	measured	O
33	in	O
34	21	O
35	patients	O
36	with	O
37	primary	O
38	hyperparathyroidism	O
39	(	O
40	PHPT	O
41	)	O
42	and	O
43	in	O
44	nine	O
45	patients	O
46	with	O
47	hypercalcaemia	O
48	of	O
49	malignancy	O
50	(	O
51	HM	O
52	).	O

1	Despite	O
2	the	O
3	favourable	O
4	natural	O
5	history	O
6	of	O
7	acute	O
8	BI	O
9	,	O
10	mild	O
11	,	O
12	moderate	O
13	,	O
14	and	O
15	severe	O
16	posttraumatic	O
17	changes	O
18	were	O
19	shown	O
20	to	O
21	appear	O
22	as	O
23	cicatricial	O
24	-	O
25	adhesive	O
26	and	O
27	atrophic	O
28	processes	O
29	,	O
30	intracerebral	O
31	cysts	O
32	,	O
33	porencephaly	O
34	,	O
35	which	O
36	result	O
37	in	O
38	posttraumatic	O
39	epilepsy	O
40	,	O
41	hydrocephalus	O
42	,	O
43	etc	O
44	.	O

1	In	O
2	patients	O
3	in	O
4	group	O
5	A	O
6	("	O
7	normal	O
8	"	O
9	CI	O
10	),	O
11	the	O
12	CI	O
13	,	O
14	heart	O
15	rate	O
16	and	O
17	the	O
18	mean	O
19	circumferential	O
20	fiber	O
21	shortening	O
22	velocity	O
23	(	O
24	mVCF	O
25	)	O
26	were	O
27	normal	O
28	,	O
29	but	O
30	the	O
31	TPR	O
32	was	O
33	increased	O
34	significantly	O
35	.	O

1	Nursing	O
2	home	O
3	discharges	O
4	in	O
5	clinical	O
6	practice	O
7	.	O

1	None	O
2	of	O
3	the	O
4	cystometrograms	O
5	showed	O
6	uninhibited	O
7	detrusor	O
8	contractions	O
9	.	O

1	Patients	O
2	were	O
3	subclassified	O
4	into	O
5	age	O
6	-	O
7	matched	O
8	groups	O
9	of	O
10	primary	O
11	untreated	O
12	cancer	O
13	(	O
14	21	O
15	),	O
16	recurrent	O
17	cancer	O
18	(	O
19	18	O
20	),	O
21	and	O
22	"	O
23	cured	O
24	"	O
25	patients	O
26	who	O
27	had	O
28	been	O
29	free	O
30	of	O
31	disease	O
32	for	O
33	at	O
34	least	O
35	9	O
36	months	O
37	(	O
38	16	O
39	).	O

1	Activation	O
2	of	O
3	PKA	B
4	by	O
5	8	O
6	-	O
7	bromo	O
8	-	O
9	cyclic	O
10	AMP	O
11	or	O
12	forskolin	O
13	,	O
14	and	O
15	inhibition	O
16	of	O
17	PKC	B
18	by	O
19	calphostin	O
20	C	O
21	,	O
22	resulted	O
23	in	O
24	a	O
25	significant	O
26	decrease	O
27	in	O
28	3TP	B
29	activity	O
30	as	O
31	well	O
32	as	O
33	in	O
34	vitro	O
35	ERK	B
36	kinase	I
37	activity	O
38	in	O
39	CRAC	O
40	.	O

1	The	O
2	cytosolic	O
3	glutathione	B
4	S	I
5	-	I
6	transferases	I
7	(	O
8	GSTs	B
9	,	O
10	EC	B
11	2	I
12	.	I
13	5	I
14	.	I
15	1	I
16	.	I
17	18	I
18	)	O
19	are	O
20	a	O
21	superfamily	O
22	of	O
23	dimeric	O
24	isoenzymes	O
25	which	O
26	catalyze	O
27	the	O
28	conjugation	O
29	of	O
30	electrophilic	O
31	substrates	O
32	with	O
33	glutathione	O
34	.	O

1	We	O
2	found	O
3	that	O
4	lung	O
5	cancer	O
6	tissues	O
7	of	O
8	positive	O
9	67Ga	O
10	scan	O
11	expressed	O
12	TFR	B
13	,	O
14	but	O
15	those	O
16	of	O
17	a	O
18	negative	O
19	scan	O
20	did	O
21	not	O
22	.	O

1	In	O
2	infected	O
3	mammalian	O
4	cells	O
5	,	O
6	the	O
7	ARV	B
8	G	I
9	and	O
10	GNS	B
11	genes	I
12	are	O
13	transcribed	O
14	primarily	O
15	as	O
16	a	O
17	polycistronic	O
18	mRNA	O
19	which	O
20	appears	O
21	to	O
22	extend	O
23	from	O
24	the	O
25	consensus	O
26	sequence	O
27	(	O
28	AACAG	O
29	)	O
30	at	O
31	the	O
32	start	O
33	of	O
34	the	O
35	G	B
36	gene	I
37	to	O
38	the	O
39	next	O
40	recognized	O
41	polyadenylation	O
42	signal	O
43	(	O
44	CATG	O
45	[	O
46	A	O
47	]	O
48	7	O
49	)	O
50	located	O
51	697	O
52	nucleotides	O
53	downstream	O
54	of	O
55	the	O
56	GNS	B
57	protein	I
58	termination	O
59	codon	O
60	.	O

1	The	O
2	gene	O
3	was	O
4	uniquely	O
5	mapped	O
6	with	O
7	odds	O
8	>	O
9	1	O
10	,	O
11	000	O
12	:	O
13	1	O
14	on	O
15	chromosome	O
16	3p	O
17	in	O
18	Centre	O
19	d	O
20	'	O
21	Etude	O
22	du	O
23	Polymorphisme	O
24	Humain	O
25	pedigrees	O
26	.	O

1	A	O
2	rabbit	O
3	antiserum	O
4	was	O
5	raised	O
6	against	O
7	a	O
8	synthetic	O
9	peptide	O
10	corresponding	O
11	to	O
12	a	O
13	hydrophilic	O
14	portion	O
15	of	O
16	the	O
17	translated	O
18	murine	O
19	cDNA	O
20	sequence	O
21	.	O

1	CONCLUSION	O
2	:	O
3	In	O
4	women	O
5	who	O
6	want	O
7	or	O
8	require	O
9	conservative	O
10	management	O
11	of	O
12	grade	O
13	4	O
14	prolapse	O
15	and	O
16	are	O
17	unable	O
18	to	O
19	retain	O
20	a	O
21	single	O
22	pessary	O
23	,	O
24	the	O
25	placement	O
26	of	O
27	two	O
28	pessaries	O
29	often	O
30	will	O
31	be	O
32	successful	O
33	.	O

1	Over	O
2	-	O
3	expression	O
4	of	O
5	Azf1p	B
6	in	O
7	the	O
8	yeast	O
9	cell	O
10	does	O
11	not	O
12	influence	O
13	the	O
14	expression	O
15	level	O
16	of	O
17	the	O
18	mitochondrial	B
19	transcription	I
20	factor	I
21	Mtf1p	I
22	,	O
23	indicating	O
24	that	O
25	the	O
26	influence	O
27	of	O
28	Azf1p	B
29	on	O
30	the	O
31	suppression	O
32	of	O
33	the	O
34	special	O
35	mitochondrial	B
36	RNA	I
37	polymerase	I
38	mutant	I
39	is	O
40	an	O
41	indirect	O
42	one	O
43	.	O

1	Mutations	O
2	within	O
3	the	O
4	C	O
5	terminus	O
6	of	O
7	c	B
8	-	I
9	fos	I
10	at	O
11	serine	O
12	residues	O
13	that	O
14	are	O
15	phosphorylation	O
16	targets	O
17	for	O
18	growth	O
19	factors	O
20	and	O
21	MAP	B
22	kinase	I
23	completely	O
24	abrogate	O
25	transactivation	O
26	and	O
27	block	O
28	potentiation	O
29	by	O
30	MAP	B
31	kinase	I
32	.	O

1	A	O
2	substantial	O
3	fraction	O
4	of	O
5	Cbl	B
6	was	O
7	constitutively	O
8	associated	O
9	with	O
10	Grb2	B
11	and	O
12	this	O
13	interaction	O
14	was	O
15	mediated	O
16	by	O
17	Grb2	B
18	SH3	I
19	domains	O
20	.	O

1	CONCLUSIONS	O
2	:	O
3	In	O
4	essential	O
5	hypertension	O
6	an	O
7	acute	O
8	protein	O
9	load	O
10	induces	O
11	a	O
12	decrease	O
13	in	O
14	GFR	O
15	that	O
16	may	O
17	normalize	O
18	under	O
19	antihypertensive	O
20	treatment	O
21	.	O

1	In	O
2	addition	O
3	,	O
4	C	B
5	/	I
6	EBP	I
7	beta	I
8	and	O
9	C	B
10	/	I
11	EBP	I
12	gamma	I
13	readily	O
14	heterodimerize	O
15	with	O
16	each	O
17	other	O
18	as	O
19	well	O
20	as	O
21	with	O
22	C	B
23	/	I
24	EBP	I
25	alpha	I
26	.	O

1	Arachnoid	O
2	cyst	O
3	.	O

1	We	O
2	studied	O
3	120	O
4	male	O
5	and	O
6	42	O
7	female	O
8	patients	O
9	with	O
10	early	O
11	CAD	O
12	who	O
13	were	O
14	unrelated	O
15	to	O
16	each	O
17	other	O
18	but	O
19	were	O
20	from	O
21	families	O
22	in	O
23	which	O
24	at	O
25	least	O
26	one	O
27	other	O
28	sibling	O
29	had	O
30	early	O
31	CAD	O
32	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	indicate	O
7	that	O
8	multiple	O
9	survival	O
10	pathways	O
11	are	O
12	triggered	O
13	via	O
14	this	O
15	receptor	O
16	,	O
17	whereas	O
18	NF	B
19	-	I
20	kappaB	I
21	/	O
22	Rel	B
23	and	O
24	PI	B
25	-	I
26	3K	I
27	are	O
28	crucial	O
29	for	O
30	CD40	B
31	-	O
32	induced	O
33	proliferation	O
34	.	O

1	The	O
2	3	O
3	-	O
4	hour	O
5	test	O
6	iodine	O
7	(	O
8	I	O
9	-	O
10	132	O
11	)	O
12	uptake	O
13	by	O
14	the	O
15	thyroid	O
16	in	O
17	children	O
18	with	O
19	growth	O
20	deficiency	O

1	Inhibition	O
2	of	O
3	erythromycin	O
4	synthesis	O
5	by	O
6	disruption	O
7	of	O
8	malonyl	B
9	-	I
10	coenzyme	I
11	A	I
12	decarboxylase	I
13	gene	I
14	eryM	I
15	in	O
16	Saccharopolyspora	O
17	erythraea	O
18	.	O

1	The	O
2	results	O
3	revealed	O
4	a	O
5	hierarchy	O
6	of	O
7	ligand	O
8	affinities	O
9	that	O
10	mirrored	O
11	their	O
12	adhesive	O
13	activity	O
14	(	O
15	rsVCAM	B
16	-	I
17	1	I
18	>	O
19	fibronectin	B
20	variants	I
21	containing	O
22	CS1	B
23	>>	O
24	other	O
25	fibronectin	B
26	variants	I
27	).	O

1	SUP46	B
2	is	O
3	implicated	O
4	in	O
5	translation	O
6	fidelity	O
7	and	O
8	encodes	O
9	the	O
10	ribosomal	B
11	protein	I
12	S13	I
13	.	O

1	In	O
2	view	O
3	of	O
4	these	O
5	results	O
6	,	O
7	simultaneous	O
8	pancreas	O
9	-	O
10	kidney	O
11	transplantation	O
12	appears	O
13	to	O
14	be	O
15	the	O
16	treatment	O
17	of	O
18	choice	O
19	for	O
20	Type	O
21	I	O
22	diabetic	O
23	patients	O
24	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	bradycardic	O
7	agents	O
8	alinidine	O
9	and	O
10	zatebradine	O
11	do	O
12	not	O
13	exert	O
14	antiarrhythmic	O
15	efficacy	O
16	against	O
17	SVT	O
18	induced	O
19	during	O
20	subacute	O
21	myocardial	O
22	infarction	O
23	in	O
24	conscious	O
25	dogs	O
26	.	O

1	Moreover	O
2	,	O
3	in	O
4	rats	O
5	allowed	O
6	to	O
7	choose	O
8	in	O
9	a	O
10	T	O
11	-	O
12	maze	O
13	between	O
14	immediate	O
15	-	O
16	but	O
17	-	O
18	small	O
19	vs	O
20	.	O
21	delayed	O
22	-	O
23	but	O
24	-	O
25	large	O
26	reward	O
27	,	O
28	BZP	O
29	significantly	O
30	decreased	O
31	the	O
32	frequency	O
33	with	O
34	which	O
35	the	O
36	delayed	O
37	reward	O
38	was	O
39	chosen	O
40	,	O
41	with	O
42	5	O
43	-	O
44	HT	O
45	uptake	O
46	blockers	O
47	producing	O
48	opposite	O
49	effects	O
50	.	O

1	Human	B
2	GATA	I
3	-	I
4	3	I
5	:	O
6	a	O
7	lineage	O
8	-	O
9	restricted	O
10	transcription	O
11	factor	O
12	that	O
13	regulates	O
14	the	O
15	expression	O
16	of	O
17	the	O
18	T	B
19	cell	I
20	receptor	I
21	alpha	I
22	gene	I
23	.	O

1	Interestingly	O
2	,	O
3	the	O
4	RNA	O
5	sequences	O
6	selected	O
7	by	O
8	the	O
9	mutated	O
10	zinc	B
11	knuckle	I
12	9G8	I
13	variant	I
14	are	O
15	efficiently	O
16	recognized	O
17	by	O
18	SRp20	B
19	,	O
20	in	O
21	agreement	O
22	with	O
23	the	O
24	fact	O
25	that	O
26	the	O
27	RBD	O
28	of	O
29	9G8	B
30	and	O
31	SRp20	B
32	are	O
33	similar	O
34	.	O

1	The	O
2	amplitudes	O
3	of	O
4	DPOAE	O
5	also	O
6	recovered	O
7	to	O
8	a	O
9	greater	O
10	extent	O
11	and	O
12	outer	O
13	hair	O
14	cell	O
15	losses	O
16	were	O
17	less	O
18	severe	O
19	in	O
20	the	O
21	R	O
22	-	O
23	PIA	O
24	-	O
25	treated	O
26	ears	O
27	.	O

1	Characterization	O
2	of	O
3	the	O
4	microtubule	O
5	binding	O
6	domain	O
7	of	O
8	microtubule	B
9	actin	I
10	crosslinking	I
11	factor	I
12	(	O
13	MACF	B
14	):	O
15	identification	O
16	of	O
17	a	O
18	novel	O
19	group	O
20	of	O
21	microtubule	B
22	associated	I
23	proteins	I
24	.	O

1	The	O
2	results	O
3	corroborate	O
4	the	O
5	idea	O
6	that	O
7	the	O
8	structure	O
9	of	O
10	relaxation	O
11	curves	O
12	contains	O
13	information	O
14	on	O
15	the	O
16	distance	O
17	scale	O
18	and	O
19	on	O
20	the	O
21	architecture	O
22	of	O
23	the	O
24	pore	O
25	space	O
26	,	O
27	even	O
28	if	O
29	it	O
30	is	O
31	difficult	O
32	to	O
33	extract	O
34	it	O
35	without	O
36	ambiguities	O
37	.	O

1	This	O
2	observation	O
3	cannot	O
4	be	O
5	explained	O
6	by	O
7	the	O
8	scanning	O
9	model	O
10	for	O
11	ribosomal	O
12	initiation	O
13	and	O
14	suggests	O
15	that	O
16	ribosomes	O
17	may	O
18	be	O
19	binding	O
20	directly	O
21	at	O
22	an	O
23	internal	O
24	mRNA	O
25	site	O
26	at	O
27	or	O
28	near	O
29	the	O
30	initiator	O
31	AUG	O
32	codon	O
33	for	O
34	the	O
35	C	B
36	protein	I
37	.	O

1	Mean	O
2	intake	O
3	of	O
4	vitamin	O
5	A	O
6	amounted	O
7	to	O
8	1	O
9	.	O
10	1	O
11	and	O
12	0	O
13	.	O
14	9	O
15	mg	O
16	RE	O
17	/	O
18	day	O
19	for	O
20	men	O
21	and	O
22	women	O
23	,	O
24	respectively	O
25	;	O
26	the	O
27	contributions	O
28	of	O
29	meat	O
30	,	O
31	fats	O
32	and	O
33	oils	O
34	,	O
35	vegetables	O
36	and	O
37	dairy	O
38	products	O
39	to	O
40	total	O
41	intake	O
42	were	O
43	35	O
44	%,	O
45	24	O
46	%,	O
47	16	O
48	%,	O
49	and	O
50	16	O
51	%,	O
52	respectively	O
53	.	O

1	These	O
2	mutations	O
3	create	O
4	stop	O
5	codons	O
6	in	O
7	exon	O
8	7	O
9	and	O
10	8	O
11	,	O
12	respectively	O
13	,	O
14	and	O
15	probably	O
16	result	O
17	in	O
18	truncated	O
19	proteins	O
20	lacking	O
21	HLH	O
22	-	O
23	Zip	O
24	or	O
25	Zip	O
26	structure	O
27	.	O

1	TBPf	O
2	is	O
3	defined	O
4	as	O
5	a	O
6	quotient	O
7	of	O
8	the	O
9	difference	O
10	of	O
11	the	O
12	first	O
13	and	O
14	the	O
15	second	O
16	measurement	O
17	:	O
18	TBPf	O
19	=	O
20	(	O
21	P1	O
22	-	O
23	P2	O
24	)/(	O
25	A1	O
26	-	O
27	A2	O
28	).	O

1	The	O
2	results	O
3	indicated	O
4	that	O
5	two	O
6	genes	O
7	(	O
8	citA	B
9	and	O
10	citB	B
11	)	O
12	have	O
13	separate	O
14	promoters	O
15	,	O
16	and	O
17	the	O
18	location	O
19	of	O
20	the	O
21	promoter	O
22	for	O
23	the	O
24	citB	B
25	gene	I
26	in	O
27	the	O
28	Tn3411	B
29	nucleotide	O
30	sequence	O
31	was	O
32	different	O
33	from	O
34	that	O
35	in	O
36	pMS185	O
37	.	O

1	Story	O
2	of	O
3	a	O
4	hospital	O
5	that	O
6	filmed	O
7	its	O
8	employee	O
9	orientation	O
10	program	O
11	.	O

1	In	O
2	cellular	O
3	supernatant	O
4	fraction	O
5	,	O
6	SHRSP	O
7	showed	O
8	a	O
9	decrease	O
10	of	O
11	magnesium	O
12	in	O
13	many	O
14	tissues	O
15	and	O
16	an	O
17	elevation	O
18	of	O
19	the	O
20	calcium	O
21	to	O
22	magnesium	O
23	ratio	O
24	when	O
25	compared	O
26	to	O
27	age	O
28	-	O
29	matched	O
30	WKY	O
31	and	O
32	SHRSR	O
33	.	O

1	Lethal	O
2	Tachmalcor	O
3	(	O
4	4	O
5	-(	O
6	3	O
7	'-	O
8	diethylamino	O
9	-	O
10	2	O
11	'-	O
12	hydroxypropyl	O
13	)-	O
14	ajmaline	O
15	)	O
16	poisoning	O
17	in	O
18	childhood	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	minimal	O
6	promoter	O
7	was	O
8	found	O
9	to	O
10	be	O
11	controlled	O
12	by	O
13	a	O
14	combination	O
15	of	O
16	the	O
17	activities	O
18	of	O
19	the	O
20	transcription	O
21	factors	O
22	Sp1	B
23	,	O
24	Sp3	B
25	,	O
26	and	O
27	NF	B
28	-	I
29	Y	I
30	.	O

1	Eight	O
2	-	O
3	four	O
4	ACOAs	O
5	were	O
6	tested	O
7	in	O
8	order	O
9	to	O
10	examine	O
11	the	O
12	fit	O
13	of	O
14	the	O
15	model	O
16	to	O
17	the	O
18	data	O
19	by	O
20	path	O
21	analysis	O
22	with	O
23	LISREL	O
24	VII	O
25	.	O

1	Eighty	O
2	patients	O
3	presenting	O
4	to	O
5	HGGM	O
6	with	O
7	non	O
8	-	O
9	Hodgkin	O
10	'	O
11	s	O
12	lymphomas	O
13	between	O
14	1962	O
15	and	O
16	1986	O
17	,	O
18	were	O
19	reviewed	O
20	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	the	O
12	response	O
13	rates	O
14	and	O
15	toxicity	O
16	of	O
17	two	O
18	regimens	O
19	containing	O
20	granulocyte	B
21	-	I
22	macrophage	I
23	-	I
24	colony	I
25	stimulating	I
26	factor	I
27	(	O
28	GM	B
29	-	I
30	CSF	I
31	)	O
32	in	O
33	combination	O
34	with	O
35	interleukin	B
36	-	I
37	2	I
38	(	O
39	IL	B
40	-	I
41	2	I
42	)	O
43	in	O
44	the	O
45	treatment	O
46	of	O
47	patients	O
48	with	O
49	metastatic	O
50	renal	O
51	cell	O
52	carcinoma	O
53	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	activation	O
6	of	O
7	these	O
8	enzymes	O
9	is	O
10	not	O
11	sufficient	O
12	for	O
13	the	O
14	acute	O
15	stimulation	O
16	of	O
17	glucose	O
18	transport	O
19	.	O

1	One	O
2	of	O
3	these	O
4	elements	O
5	,	O
6	the	O
7	homeodomain	B
8	-	I
9	binding	I
10	element	I
11	,	O
12	was	O
13	identified	O
14	to	O
15	mediate	O
16	negative	O
17	regulation	O
18	.	O

1	Cerebral125	B
2	albumin	I
3	was	O
4	increased	O
5	to	O
6	similar	O
7	proportions	O
8	in	O
9	those	O
10	groups	O
11	submitted	O
12	to	O
13	hyperosmolality	O
14	.	O

1	To	O
2	begin	O
3	to	O
4	examine	O
5	the	O
6	mechanism	O
7	controlling	O
8	expression	O
9	of	O
10	this	O
11	gene	O
12	during	O
13	the	O
14	cell	O
15	-	O
16	cycle	O
17	,	O
18	a	O
19	mouse	B
20	B	I
21	-	I
22	myb	I
23	5	I
24	'	I
25	flanking	I
26	sequence	I
27	was	O
28	isolated	O
29	from	O
30	a	O
31	cosmid	O
32	library	O
33	and	O
34	shown	O
35	to	O
36	promote	O
37	efficiently	O
38	the	O
39	transcription	O
40	of	O
41	a	O
42	luciferase	B
43	reporter	I
44	gene	I
45	when	O
46	transfected	O
47	into	O
48	NIH3T3	O
49	fibroblasts	O
50	.	O

1	Upstream	O
2	of	O
3	the	O
4	dra	B
5	gene	I
6	an	O
7	open	O
8	reading	O
9	frame	O
10	of	O
11	313	O
12	amino	O
13	acids	O
14	was	O
15	identified	O
16	.	O

1	Revascularization	O
2	after	O
3	anterior	O
4	maxillary	O
5	and	O
6	mandibular	O
7	osteotomy	O

1	Static	O
2	and	O
3	dynamic	O
4	compliance	O
5	was	O
6	measured	O
7	after	O
8	induction	O
9	of	O
10	anesthesia	O
11	,	O
12	before	O
13	and	O
14	immediately	O
15	after	O
16	filtration	O
17	in	O
18	the	O
19	operating	O
20	theater	O
21	,	O
22	1	O
23	hour	O
24	after	O
25	return	O
26	to	O
27	the	O
28	pediatric	O
29	intensive	O
30	care	O
31	unit	O
32	,	O
33	and	O
34	24	O
35	hours	O
36	after	O
37	the	O
38	operation	O
39	.	O

1	There	O
2	were	O
3	18	O
4	patients	O
5	with	O
6	Group	O
7	II	O
8	(	O
9	a	O
10	)	O
11	tumors	O
12	;	O
13	although	O
14	tumor	O
15	biopsy	O
16	was	O
17	attempted	O
18	on	O
19	eight	O
20	of	O
21	these	O
22	,	O
23	pathological	O
24	diagnosis	O
25	at	O
26	the	O
27	time	O
28	of	O
29	surgery	O
30	was	O
31	made	O
32	in	O
33	only	O
34	one	O
35	case	O
36	.	O

1	Venkatesan	O
2	,	O
3	and	O
4	D	O
5	.	O

1	Collectively	O
2	,	O
3	these	O
4	data	O
5	indicate	O
6	that	O
7	HIP	B
8	is	O
9	a	O
10	membrane	O
11	-	O
12	associated	O
13	HP	B
14	-	I
15	binding	I
16	protein	I
17	expressed	O
18	on	O
19	the	O
20	surface	O
21	of	O
22	normal	O
23	human	O
24	uterine	O
25	epithelia	O
26	and	O
27	uterine	O
28	epithelial	O
29	cell	O
30	lines	O
31	.	O

1	The	O
2	distributed	O
3	current	O
4	density	O
5	J	O
6	is	O
7	calculated	O
8	within	O
9	the	O
10	volume	O
11	defined	O
12	by	O
13	the	O
14	motor	O
15	unit	O
16	.	O

1	The	O
2	CAPLC1	B
3	protein	I
4	also	O
5	exhibited	O
6	several	O
7	unique	O
8	features	O
9	,	O
10	including	O
11	a	O
12	novel	O
13	stretch	O
14	of	O
15	18	O
16	-	O
17	19	O
18	amino	O
19	acid	O
20	residues	O
21	within	O
22	the	O
23	X	O
24	domain	O
25	and	O
26	an	O
27	unusually	O
28	long	O
29	N	O
30	-	O
31	terminus	O
32	which	O
33	did	O
34	not	O
35	contain	O
36	a	O
37	recognizable	O
38	EF	O
39	-	O
40	hand	O
41	Ca	O
42	(	O
43	2	O
44	+)-	O
45	binding	O
46	domain	O
47	.	O

1	N	O
2	.	O
3	van	O
4	Hoek	O
5	,	O
6	and	O
7	M	O
8	.	O

1	Further	O
2	,	O
3	the	O
4	reduction	O
5	in	O
6	5	O
7	-	O
8	hydroxytryptophan	O
9	(	O
10	5	O
11	-	O
12	HTP	O
13	)	O
14	accumulation	O
15	by	O
16	LSD	O
17	showed	O
18	regional	O
19	differences	O
20	in	O
21	inhibition	O
22	by	O
23	methiothepin	O
24	(	O
25	hypothalamus	O
26	greater	O
27	than	O
28	cortex	O
29	greater	O
30	than	O
31	striatum	O
32	)	O
33	which	O
34	paralleled	O
35	the	O
36	autoreceptor	O
37	antagonist	O
38	activity	O
39	of	O
40	methiothepin	O
41	in	O
42	vitro	O
43	.(	O
44	ABSTRACT	O
45	TRUNCATED	O
46	AT	O
47	250	O
48	WORDS	O
49	)	O

1	The	O
2	proposed	O
3	algorithm	O
4	consists	O
5	of	O
6	several	O
7	steps	O
8	.	O

1	Thereafter	O
2	,	O
3	the	O
4	aggregation	O
5	rose	O
6	to	O
7	the	O
8	initial	O
9	100	O
10	%	O
11	value	O
12	4	O
13	h	O
14	after	O
15	drug	O
16	application	O
17	and	O
18	remained	O
19	at	O
20	this	O
21	level	O
22	during	O
23	the	O
24	observation	O
25	period	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O

1	Axillary	O
2	nodal	O
3	status	O
4	,	O
5	tumour	O
6	progesterone	B
7	receptor	I
8	status	O
9	,	O
10	and	O
11	season	O
12	of	O
13	tumour	O
14	detection	O
15	significantly	O
16	influenced	O
17	survival	O
18	in	O
19	both	O
20	older	O
21	(	O
22	greater	O
23	than	O
24	50	O
25	yrs	O
26	)	O
27	and	O
28	younger	O
29	(	O
30	less	O
31	than	O
32	50	O
33	yrs	O
34	)	O
35	patients	O
36	.	O

1	Recently	O
2	,	O
3	a	O
4	protein	O
5	designated	O
6	GF14	B
7	has	O
8	been	O
9	isolated	O
10	that	O
11	is	O
12	associated	O
13	with	O
14	the	O
15	GBF	B
16	protein	I
17	complex	I
18	.	O

1	Growth	O
2	factor	O
3	stimulation	O
4	rapidly	O
5	induces	O
6	a	O
7	reversible	O
8	change	O
9	in	O
10	the	O
11	electrophoretic	O
12	mobility	O
13	of	O
14	the	O
15	ternary	O
16	complex	O
17	,	O
18	accompanied	O
19	by	O
20	increased	O
21	phosphorylation	O
22	of	O
23	the	O
24	Elk	B
25	-	I
26	1	I
27	C	I
28	-	I
29	terminal	I
30	region	I
31	and	O
32	by	O
33	the	O
34	activation	O
35	of	O
36	a	O
37	42	B
38	kd	I
39	cellular	I
40	Elk	I
41	-	I
42	1	I
43	kinase	I
44	.	O

1	Baseline	O
2	data	O
3	were	O
4	obtained	O
5	from	O
6	10	O
7	adults	O
8	.	O

1	Children	O
2	with	O
3	ADD	O
4	showed	O
5	an	O
6	attenuated	O
7	frontal	O
8	CNV	O
9	-	O
10	1	O
11	amplitude	O
12	and	O
13	a	O
14	trend	O
15	towards	O
16	increased	O
17	CNV	O
18	-	O
19	1	O
20	and	O
21	CNV	O
22	-	O
23	2	O
24	occipital	O
25	amplitudes	O
26	.	O

1	All	O
2	mutant	B
3	JCV	I
4	T	I
5	antigens	I
6	bound	O
7	to	O
8	JCV	O
9	and	O
10	SV40	O
11	origins	O
12	of	O
13	DNA	O
14	replication	O
15	.	O

1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	seizure	O
7	,	O
8	the	O
9	patient	O
10	was	O
11	asked	O
12	to	O
13	read	O
14	a	O
15	test	O
16	phrase	O
17	aloud	O
18	until	O
19	it	O
20	was	O
21	read	O
22	correctly	O
23	and	O
24	clearly	O
25	.	O

1	NH3	O
2	and	O
3	NO	O
4	interaction	O
5	with	O
6	Si	O
7	(	O
8	100	O
9	)-(	O
10	2	O
11	x	O
12	1	O
13	)	O
14	surfaces	O
15	.	O

1	An	O
2	abundant	O
3	1	O
4	.	O
5	1	O
6	-	O
7	kb	O
8	virion	O
9	-	O
10	sense	O
11	polyadenylated	O
12	RNA	O
13	and	O
14	four	O
15	complementary	O
16	-	O
17	sense	O
18	polyadenylated	O
19	RNAs	O
20	of	O
21	1	O
22	.	O
23	7	O
24	,	O
25	1	O
26	.	O
27	5	O
28	,	O
29	1	O
30	.	O
31	3	O
32	,	O
33	and	O
34	0	O
35	.	O
36	7	O
37	kb	O
38	have	O
39	been	O
40	identified	O
41	by	O
42	northern	O
43	blot	O
44	hybridization	O
45	,	O
46	confirming	O
47	the	O
48	bidirectional	O
49	transcription	O
50	strategy	O
51	implied	O
52	by	O
53	the	O
54	arrangement	O
55	of	O
56	ORFs	O
57	.	O

1	The	O
2	roll	O
3	-	O
4	over	O
5	test	O
6	to	O
7	predict	O
8	toxemia	O
9	in	O
10	pregnancy	O
11	.	O

1	In	O
2	14	O
3	patients	O
4	whose	O
5	PaCO2	O
6	was	O
7	greater	O
8	than	O
9	or	O
10	equal	O
11	to	O
12	39	O
13	torr	O
14	(	O
15	range	O
16	39	O
17	to	O
18	58	O
19	torr	O
20	)	O
21	and	O
22	clinical	O
23	asthma	O
24	score	O
25	was	O
26	6	O
27	or	O
28	greater	O
29	,	O
30	PaCO2	O
31	decreased	O
32	a	O
33	mean	O
34	of	O
35	11	O
36	.	O
37	7	O
38	torr	O
39	during	O
40	a	O
41	mean	O
42	of	O
43	8	O
44	.	O
45	1	O
46	hours	O
47	.	O

1	Endosonography	O
2	accurately	O
3	assessed	O
4	tumor	O
5	extension	O
6	in	O
7	two	O
8	T2	O
9	tumors	O
10	,	O
11	14	O
12	T3	O
13	tumors	O
14	,	O
15	and	O
16	seven	O
17	T4	O
18	tumors	O
19	.	O

1	The	O
2	wild	O
3	-	O
4	type	O
5	and	O
6	altered	O
7	forms	O
8	of	O
9	the	O
10	F	B
11	protein	I
12	were	O
13	expressed	O
14	in	O
15	BHK	O
16	-	O
17	21	O
18	and	O
19	HeLa	O
20	T4	O
21	cells	O
22	by	O
23	use	O
24	of	O
25	the	O
26	recombinant	B
27	vaccinia	I
28	virus	I
29	-	I
30	encoding	I
31	T7	I
32	polymerase	I
33	system	O
34	.	O

1	Deletion	O
2	analysis	O
3	indicates	O
4	that	O
5	TBP	B
6	and	O
7	hTAFII18	B
8	bind	O
9	to	O
10	distinct	O
11	domains	O
12	of	O
13	hTAFII28	B
14	.	O
15	hTAFII18	B
16	also	O
17	interacts	O
18	with	O
19	TBP	B
20	,	O
21	but	O
22	it	O
23	interacts	O
24	more	O
25	strongly	O
26	with	O
27	hTAFII28	B
28	and	O
29	hTAFII30	B
30	.	O

1	METHOD	O
2	:	O
3	50	O
4	consecutive	O
5	children	O
6	aged	O
7	from	O
8	6	O
9	months	O
10	to	O
11	17	O
12	years	O
13	were	O
14	included	O
15	into	O
16	the	O
17	study	O
18	which	O
19	comprised	O
20	questionnaires	O
21	of	O
22	patient	O
23	and	O
24	family	O
25	histories	O
26	,	O
27	serological	O
28	screening	O
29	tests	O
30	for	O
31	common	O
32	inhalational	O
33	allergens	O
34	(	O
35	CAP	O
36	SX1	O
37	),	O
38	and	O
39	determination	O
40	of	O
41	total	O
42	serum	B
43	immunoglobulin	I
44	E	I
45	(	O
46	IgE	B
47	)	O
48	and	O
49	of	O
50	latex	O
51	-	O
52	specific	O
53	serum	B
54	IgE	I
55	by	O
56	solid	O
57	-	O
58	phase	O
59	immunoassays	O
60	.	O

1	Paxillin	B
2	acts	O
3	as	O
4	an	O
5	adaptor	O
6	molecule	O
7	in	O
8	integrin	B
9	signaling	O
10	.	O

1	The	O
2	relatively	O
3	scanty	O
4	number	O
5	of	O
6	examples	O
7	,	O
8	which	O
9	could	O
10	be	O
11	justified	O
12	by	O
13	the	O
14	variety	O
15	and	O
16	complexity	O
17	of	O
18	combined	O
19	exposure	O
20	,	O
21	allows	O
22	to	O
23	conclude	O
24	that	O
25	life	O
26	-	O
27	style	O
28	factors	O
29	have	O
30	considerable	O
31	influence	O
32	on	O
33	interindividual	O
34	differences	O
35	in	O
36	susceptibility	O
37	to	O
38	xenobiotics	O
39	toxicity	O
40	.	O

1	Higher	O
2	CYP3A23	B
3	basal	O
4	activity	O
5	appears	O
6	to	O
7	be	O
8	due	O
9	to	O
10	an	O
11	E	O
12	-	O
13	box	O
14	in	O
15	3A23SiteA	B
16	that	O
17	interacts	O
18	with	O
19	USF1	B
20	,	O
21	a	O
22	ubiquitous	O
23	bHLH	B
24	/	I
25	leucine	I
26	zipper	I
27	transcription	I
28	factor	I
29	.	O

1	Apart	O
2	from	O
3	two	O
4	proline	O
5	-	O
6	rich	O
7	regions	O
8	(	O
9	amino	O
10	acids	O
11	1	O
12	-	O
13	117	O
14	and	O
15	239	O
16	-	O
17	270	O
18	),	O
19	p230	B
20	contains	O
21	a	O
22	very	O
23	high	O
24	frequency	O
25	of	O
26	heptad	O
27	repeats	O
28	,	O
29	characteristic	O
30	of	O
31	alpha	O
32	-	O
33	helices	O
34	that	O
35	form	O
36	dimeric	O
37	coiled	O
38	-	O
39	coil	O
40	structures	O
41	.	O
42	p230	B
43	also	O
44	includes	O
45	the	O
46	sequence	O
47	ESLALEELEL	O
48	(	O
49	amino	O
50	acids	O
51	538	O
52	-	O
53	546	O
54	),	O
55	a	O
56	motif	O
57	found	O
58	in	O
59	the	O
60	granin	B
61	family	I
62	of	O
63	acidic	O
64	proteins	O
65	present	O
66	in	O
67	secretory	O
68	granules	O
69	of	O
70	neuroendocrine	O
71	cells	O
72	.	O

1	Interestingly	O
2	,	O
3	an	O
4	increase	O
5	of	O
6	distance	O
7	per	O
8	se	O
9	did	O
10	not	O
11	have	O
12	a	O
13	deleterious	O
14	effect	O
15	on	O
16	translation	O
17	efficiency	O
18	.	O

1	We	O
2	recently	O
3	reported	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	PL	B
10	scramblase	I
11	of	O
12	human	O
13	(	O
14	HuPLSCR1	B
15	)	O
16	and	O
17	mouse	O
18	origin	O
19	,	O
20	respectively	O
21	.	O

1	Significantly	O
2	lower	O
3	heart	O
4	rate	O
5	reactivity	O
6	and	O
7	significantly	O
8	less	O
9	pronounced	O
10	left	O
11	temporal	O
12	artery	O
13	pulse	O
14	amplitude	O
15	responses	O
16	were	O
17	found	O
18	in	O
19	non	O
20	-	O
21	medicated	O
22	TH	O
23	subjects	O
24	than	O
25	in	O
26	controls	O
27	.	O

1	The	O
2	N	O
3	-	O
4	terminus	O
5	of	O
6	another	O
7	open	O
8	reading	O
9	frame	O
10	was	O
11	found	O
12	3	O
13	'	O
14	from	O
15	nifA	B
16	and	O
17	tentatively	O
18	identified	O
19	as	O
20	nifB	B
21	by	O
22	amino	O
23	acid	O
24	sequence	O
25	comparison	O
26	.	O

1	Members	O
2	of	O
3	the	O
4	mitogen	B
5	activated	I
6	protein	I
7	(	I
8	MAP	I
9	)	I
10	kinase	I
11	family	I
12	,	O
13	extracellular	B
14	signal	I
15	-	I
16	regulated	I
17	kinase	I
18	,	O
19	stress	B
20	-	I
21	activated	I
22	protein	I
23	kinase	I
24	-	I
25	1	I
26	/	O
27	c	B
28	-	I
29	Jun	I
30	NH2	I
31	-	I
32	terminal	I
33	kinase	I
34	,	O
35	and	O
36	p38	B
37	,	O
38	are	O
39	central	O
40	elements	O
41	that	O
42	transduce	O
43	the	O
44	signal	O
45	generated	O
46	by	O
47	growth	O
48	factors	O
49	,	O
50	cytokines	O
51	,	O
52	and	O
53	stressing	O
54	agents	O
55	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	beta	B
6	-	I
7	1	I
8	may	O
9	act	O
10	as	O
11	a	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	trans	O
17	-	O
18	acting	O
19	regulator	O
20	of	O
21	the	O
22	expression	O
23	of	O
24	the	O
25	beta	B
26	-	I
27	zein	I
28	gene	I
29	in	O
30	developing	O
31	maize	O
32	endosperm	O
33	.	O

1	This	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	clarify	O
7	the	O
8	location	O
9	of	O
10	a	O
11	transesophageal	O
12	echocardiographic	O
13	(	O
14	TEE	O
15	)	O
16	transducer	O
17	when	O
18	obtaining	O
19	the	O
20	short	O
21	-	O
22	axis	O
23	view	O
24	of	O
25	the	O
26	left	O
27	ventricle	O
28	(	O
29	S	O
30	-	O
31	LV	O
32	).	O

1	Restriction	O
2	analysis	O
3	and	O
4	Southern	O
5	hybridization	O
6	revealed	O
7	the	O
8	presence	O
9	of	O
10	Tn5422	B
11	in	O
12	all	O
13	the	O
14	plasmid	O
15	-	O
16	mediated	O
17	cadmium	O
18	-	O
19	resistant	O
20	L	O
21	.	O
22	monocytogenes	O
23	strains	O
24	tested	O
25	but	O
26	not	O
27	in	O
28	strains	O
29	encoding	O
30	cadmium	O
31	resistance	O
32	on	O
33	the	O
34	chromosome	O
35	.	O

1	Nodular	O
2	involvement	O
3	of	O
4	the	O
5	left	O
6	lung	O
7	and	O
8	infiltration	O
9	of	O
10	the	O
11	mucosa	O
12	of	O
13	the	O
14	left	O
15	lower	O
16	lobe	O
17	bronchus	O
18	followed	O
19	very	O
20	gradually	O
21	and	O
22	a	O
23	monoclonal	O
24	gammopathy	O
25	(	O
26	IgA	B
27	--	I
28	Type	I
29	Kappa	I
30	)	O
31	was	O
32	demonstrated	O
33	.	O

1	However	O
2	the	O
3	sequence	O
4	surrounding	O
5	the	O
6	transcription	O
7	start	O
8	site	O
9	CTCA	O
10	(+	O
11	1	O
12	)	O
13	TTCC	O
14	was	O
15	similar	O
16	to	O
17	the	O
18	consensus	O
19	CTCA	O
20	(+	O
21	1	O
22	)	O
23	NTCT	O
24	(	O
25	N	O
26	is	O
27	any	O
28	nucleoside	O
29	)	O
30	for	O
31	an	O
32	initiator	O
33	element	O
34	found	O
35	in	O
36	terminal	B
37	deoxynucleotidyltransferase	I
38	and	O
39	a	O
40	number	O
41	of	O
42	other	O
43	highly	O
44	regulated	O
45	genes	O
46	.	O

1	To	O
2	further	O
3	our	O
4	knowledge	O
5	about	O
6	the	O
7	systemic	O
8	humoral	O
9	immune	O
10	system	O
11	response	O
12	to	O
13	weak	O
14	hapten	O
15	-	O
16	syngeneic	O
17	or	O
18	allogeneic	O
19	protein	O
20	conjugates	O
21	(	O
22	corrosion	O
23	and	O
24	wear	O
25	products	O
26	of	O
27	metallic	O
28	orthopedic	O
29	devices	O
30	),	O
31	a	O
32	sensitive	O
33	enzyme	O
34	-	O
35	linked	O
36	immunosorbent	O
37	assay	O
38	(	O
39	ELISA	O
40	)	O
41	method	O
42	for	O
43	testing	O
44	for	O
45	antibody	O
46	(	O
47	humoral	O
48	immunity	O
49	)	O
50	to	O
51	metals	O
52	was	O
53	developed	O
54	.	O

1	Immunofluoresence	O
2	data	O
3	indicated	O
4	that	O
5	once	O
6	bound	O
7	to	O
8	the	O
9	mutant	O
10	receptor	O
11	,	O
12	fluorescent	O
13	-	O
14	labeled	O
15	RAP	B
16	co	O
17	-	O
18	localized	O
19	with	O
20	markers	O
21	of	O
22	the	O
23	endosomal	O
24	pathway	O
25	,	O
26	whereas	O
27	,	O
28	in	O
29	cells	O
30	expressing	O
31	the	O
32	wild	O
33	-	O
34	type	O
35	receptor	O
36	,	O
37	RAP	B
38	fluorescence	O
39	co	O
40	-	O
41	localized	O
42	with	O
43	lysosomal	O
44	markers	O
45	.	O

1	The	O
2	GAC1	B
3	gene	I
4	encodes	O
5	the	O
6	regulatory	O
7	subunit	O
8	for	O
9	a	O
10	type	B
11	1	I
12	serine	I
13	/	I
14	threonine	I
15	phosphoprotein	I
16	phosphatase	I
17	,	O
18	Glc7	B
19	.	O

1	The	O
2	authors	O
3	evaluate	O
4	the	O
5	clinical	O
6	efficacy	O
7	of	O
8	EMB	O
9	AZS	O
10	in	O
11	recurrent	O
12	ulcer	O
13	after	O
14	operation	O
15	on	O
16	the	O
17	stomach	O
18	caused	O
19	by	O
20	a	O
21	high	O
22	level	O
23	of	O
24	acid	O
25	production	O
26	and	O
27	ulcerative	O
28	gastroduodenal	O
29	bleeding	O
30	.	O

1	Limited	O
2	role	O
3	for	O
4	PCR	O
5	-	O
6	based	O
7	diagnosis	O
8	of	O
9	Whipple	O
10	'	O
11	s	O
12	disease	O
13	from	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	.	O

1	Escherichia	O
2	coli	O
3	JRG582	O
4	is	O
5	an	O
6	ampD	B
7	ampE	I
8	deletion	O
9	derivative	O
10	of	O
11	strain	O
12	HfrH	O
13	and	O
14	accordingly	O
15	it	O
16	is	O
17	derepressed	O
18	for	O
19	expression	O
20	of	O
21	the	O
22	cloned	O
23	inducible	O
24	beta	B
25	-	I
26	lactamase	I
27	gene	I
28	of	O
29	Citrobacter	O
30	freundii	O
31	,	O
32	carried	O
33	on	O
34	plasmid	O
35	pNU305	O
36	.	O

1	This	O
2	paper	O
3	summarises	O
4	the	O
5	experimental	O
6	evidence	O
7	upon	O
8	which	O
9	the	O
10	clinical	O
11	trials	O
12	of	O
13	aldose	B
14	reductase	I
15	inhibitors	O
16	in	O
17	diabetic	O
18	patients	O
19	have	O
20	been	O
21	initiated	O
22	and	O
23	the	O
24	results	O
25	of	O
26	published	O
27	drug	O
28	trials	O
29	in	O
30	these	O
31	patients	O
32	.	O

1	Production	O
2	of	O
3	C	B
4	mu	I
5	RNAs	I
6	,	O
7	unlike	O
8	mu	B
9	mRNAs	I
10	,	O
11	does	O
12	not	O
13	require	O
14	recombination	O
15	with	O
16	the	O
17	joining	B
18	region	I
19	(	O
20	JH	B
21	)	O
22	locus	O
23	.	O

1	The	O
2	Scales	O
3	of	O
4	Cognitive	O
5	Impairment	O
6	Rated	O
7	From	O
8	Institutional	O
9	Records	O
10	(	O
11	SCIRFIR	O
12	),	O
13	a	O
14	battery	O
15	based	O
16	on	O
17	commonly	O
18	used	O
19	dementia	O
20	rating	O
21	instruments	O
22	,	O
23	was	O
24	tested	O
25	on	O
26	the	O
27	records	O
28	of	O
29	26	O
30	chronically	O
31	institutionalized	O
32	,	O
33	elderly	O
34	schizophrenia	O
35	patients	O
36	,	O
37	for	O
38	the	O
39	purpose	O
40	of	O
41	retrospectively	O
42	evaluating	O
43	the	O
44	long	O
45	-	O
46	term	O
47	course	O
48	of	O
49	cognitive	O
50	change	O
51	in	O
52	schizophrenia	O
53	and	O
54	relating	O
55	it	O
56	to	O
57	available	O
58	autopsy	O
59	materials	O
60	.	O

1	Evaluation	O
2	of	O
3	left	O
4	ventricular	O
5	function	O
6	using	O
7	gated	O
8	planar	O
9	myocardial	O
10	imaging	O
11	with	O
12	Tc	O
13	-	O
14	99m	O
15	-	O
16	MIBI	O

1	Hematocrit	O
2	and	O
3	PaO2	O
4	did	O
5	not	O
6	change	O
7	.	O

1	As	O
2	the	O
3	length	O
4	of	O
5	the	O
6	fatty	O
7	acid	O
8	decreased	O
9	,	O
10	the	O
11	binding	O
12	affinity	O
13	was	O
14	reduced	O
15	;	O
16	myristic	O
17	acid	O
18	(	O
19	14	O
20	:	O
21	0	O
22	)	O
23	bound	O
24	with	O
25	a	O
26	K	O
27	(	O
28	d	O
29	)	O
30	of	O
31	1409	O
32	+/-	O
33	423	O
34	nM	O
35	,	O
36	but	O
37	medium	O
38	-	O
39	chain	O
40	(	O
41	decanoic	O
42	acid	O
43	,	O
44	10	O
45	:	O
46	0	O
47	)	O
48	and	O
49	short	O
50	-	O
51	chain	O
52	(	O
53	octanoic	O
54	acid	O
55	,	O
56	8	O
57	:	O
58	0	O
59	)	O
60	lipids	O
61	were	O
62	not	O
63	bound	O
64	at	O
65	all	O
66	.	O

1	RNase	B
2	protection	O
3	analyses	O
4	indicate	O
5	that	O
6	either	O
7	61	B
8	-	I
9	kDa	I
10	CaM	I
11	PDE	I
12	mRNA	I
13	or	O
14	structurally	O
15	related	O
16	transcripts	O
17	encoding	O
18	different	O
19	CaM	B
20	PDE	I
21	isoforms	I
22	are	O
23	expressed	O
24	in	O
25	a	O
26	tissue	O
27	-	O
28	specific	O
29	manner	O
30	.	O

1	Overexpression	O
2	of	O
3	EFG1	B
4	in	O
5	C	O
6	.	O
7	albicans	O
8	leads	O
9	to	O
10	enhanced	O
11	filamentous	O
12	growth	O
13	in	O
14	the	O
15	form	O
16	of	O
17	extended	O
18	pseudohyphae	O
19	in	O
20	liquid	O
21	and	O
22	on	O
23	solid	O
24	media	O
25	.	O

1	PCR	O
2	analysis	O
3	indicates	O
4	that	O
5	this	O
6	new	O
7	beta	B
8	-	I
9	adducin	I
10	isoform	I
11	is	O
12	expressed	O
13	in	O
14	fetal	O
15	brain	O
16	and	O
17	liver	O
18	,	O
19	bone	O
20	marrow	O
21	,	O
22	and	O
23	NT	O
24	-	O
25	2	O
26	(	O
27	neuroepithelial	O
28	)	O
29	cells	O
30	,	O
31	but	O
32	is	O
33	not	O
34	detected	O
35	in	O
36	several	O
37	other	O
38	tissues	O
39	.	O

1	Eight	O
2	of	O
3	14	O
4	infectious	O
5	or	O
6	inflammatory	O
7	lesions	O
8	could	O
9	be	O
10	detected	O
11	in	O
12	the	O
13	early	O
14	scan	O
15	(	O
16	4	O
17	-	O
18	6	O
19	h	O
20	p	O
21	.	O
22	i	O
23	.).	O

1	Polypeptides	O
2	of	O
3	the	O
4	same	O
5	apparent	O
6	sizes	O
7	are	O
8	detected	O
9	in	O
10	spores	O
11	of	O
12	a	O
13	cotE	B
14	null	O
15	mutant	O
16	,	O
17	on	O
18	which	O
19	basis	O
20	we	O
21	infer	O
22	that	O
23	the	O
24	products	O
25	of	O
26	the	O
27	cotJ	B
28	operon	I
29	are	O
30	required	O
31	for	O
32	the	O
33	normal	O
34	formation	O
35	of	O
36	the	O
37	inner	O
38	layers	O
39	of	O
40	the	O
41	coat	O
42	or	O
43	are	O
44	themselves	O
45	structural	O
46	components	O
47	of	O
48	the	O
49	coat	O
50	.	O

1	Characterization	O
2	of	O
3	a	O
4	human	B
5	alternatively	I
6	spliced	I
7	truncated	I
8	reduced	I
9	folate	I
10	carrier	I
11	increasing	O
12	folate	O
13	accumulation	O
14	in	O
15	parental	O
16	leukemia	O
17	cells	O
18	.	O

1	At	O
2	the	O
3	same	O
4	time	O
5	,	O
6	the	O
7	results	O
8	indicate	O
9	that	O
10	p53	B
11	plays	O
12	a	O
13	defensive	O
14	role	O
15	against	O
16	HBV	O
17	by	O
18	transcriptionally	O
19	repressing	O
20	the	O
21	HBV	B
22	core	I
23	promoter	I
24	through	O
25	liver	B
26	-	I
27	specific	I
28	enhancer	I
29	II	I
30	and	O
31	HBx	B
32	is	O
33	required	O
34	to	O
35	counteract	O
36	this	O
37	inhibitory	O
38	function	O
39	of	O
40	p53	B
41	.	O

1	In	O
2	untransformed	O
3	cells	O
4	,	O
5	three	O
6	major	O
7	proteins	O
8	coprecipitated	O
9	with	O
10	CRKL	B
11	,	O
12	identified	O
13	as	O
14	C3G	B
15	,	O
16	SOS	B
17	and	O
18	c	B
19	-	I
20	ABL	I
21	.	O

1	Chirality	O
2	-	O
3	glass	O
4	and	O
5	spin	O
6	-	O
7	glass	O
8	correlations	O
9	in	O
10	the	O
11	two	O
12	-	O
13	dimensional	O
14	random	O
15	-	O
16	bond	O
17	XY	O
18	model	O
19	.	O

1	A	O
2	second	O
3	isotype	O
4	of	O
5	Raja	B
6	immunoglobulin	I
7	heavy	I
8	chain	I
9	genes	I
10	has	O
11	been	O
12	detected	O
13	by	O
14	screening	O
15	a	O
16	spleen	O
17	cDNA	O
18	library	O
19	with	O
20	homologous	O
21	Raja	B
22	VH	I
23	-	O
24	and	O
25	CH1	B
26	-	O
27	specific	O
28	probes	O
29	complementing	O
30	the	O
31	respective	O
32	regions	O
33	of	O
34	the	O
35	mu	B
36	-	I
37	like	I
38	isotype	I
39	.	O

1	Grade	O
2	3	O
3	mucositis	O
4	was	O
5	reported	O
6	in	O
7	1	O
8	patient	O
9	.	O

1	The	O
2	phenotypes	O
3	of	O
4	the	O
5	ICP0	B
6	nonsense	O
7	mutants	O
8	were	O
9	intermediate	O
10	between	O
11	those	O
12	of	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	virus	O
18	and	O
19	7134	O
20	in	O
21	that	O
22	the	O
23	more	O
24	ICP0	B
25	-	I
26	coding	I
27	sequence	I
28	expressed	O
29	by	O
30	a	O
31	given	O
32	nonsense	O
33	mutant	O
34	,	O
35	the	O
36	more	O
37	wild	O
38	type	O
39	-	O
40	like	O
41	was	O
42	its	O
43	phenotype	O
44	.	O

1	Problems	O
2	common	O
3	to	O
4	pediatrics	O
5	and	O
6	anesthesiology	O

1	This	O
2	promoter	O
3	could	O
4	direct	O
5	the	O
6	constitutive	O
7	expression	O
8	of	O
9	the	O
10	reporter	O
11	beta	B
12	-	I
13	galactosidase	I
14	at	O
15	high	O
16	frequency	O
17	in	O
18	transfected	O
19	colonies	O
20	of	O
21	transformed	O
22	cells	O
23	that	O
24	express	O
25	L	B
26	-	I
27	plastin	I
28	constitutively	O
29	;	O
30	by	O
31	contrast	O
32	,	O
33	this	O
34	promoter	O
35	was	O
36	virtually	O
37	inactive	O
38	in	O
39	transfected	O
40	colonies	O
41	of	O
42	normal	O
43	fibroblasts	O
44	and	O
45	it	O
46	exhibited	O
47	a	O
48	low	O
49	frequency	O
50	of	O
51	constitutive	O
52	activation	O
53	in	O
54	transfected	O
55	colonies	O
56	of	O
57	in	O
58	vitro	O
59	SV40	O
60	-	O
61	transformed	O
62	fibroblasts	O
63	which	O
64	did	O
65	not	O
66	exhibit	O
67	L	B
68	-	I
69	plastin	I
70	expression	O
71	.	O

1	The	O
2	need	O
3	for	O
4	including	O
5	forensic	O
6	medical	O
7	expertise	O
8	in	O
9	the	O
10	list	O
11	of	O
12	urgent	O
13	criminal	O
14	investigative	O
15	actions	O

1	The	O
2	feed	O
3	given	O
4	to	O
5	young	O
6	broiler	O
7	chickens	O
8	was	O
9	contaminated	O
10	artificially	O
11	with	O
12	Salmonella	O
13	kedougou	O
14	,	O
15	a	O
16	serotype	O
17	associated	O
18	with	O
19	both	O
20	subclinical	O
21	infections	O
22	in	O
23	commercially	O
24	reared	O
25	chickens	O
26	and	O
27	food	O
28	poisoning	O
29	in	O
30	humans	O
31	.	O

1	Delayed	O
2	gallbladder	O
3	visualization	O
4	and	O
5	reduction	O
6	in	O
7	ejection	O
8	fraction	O
9	were	O
10	sensitive	O
11	but	O
12	nonspecific	O
13	indicators	O
14	of	O
15	biliary	O
16	disease	O
17	.	O

1	Here	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	for	O
7	a	O
8	model	O
9	in	O
10	which	O
11	mRNA	O
12	sequences	O
13	up	O
14	to	O
15	around	O
16	100	O
17	nucleotides	O
18	downstream	O
19	from	O
20	the	O
21	start	O
22	codon	O
23	of	O
24	21K	O
25	fold	O
26	back	O
27	and	O
28	base	O
29	-	O
30	pair	O
31	to	O
32	the	O
33	21K	O
34	translation	O
35	initiation	O
36	region	O
37	,	O
38	thereby	O
39	decreasing	O
40	the	O
41	translation	O
42	initiation	O
43	frequency	O
44	.	O

1	In	O
2	human	O
3	brain	O
4	,	O
5	contactin	B
6	was	O
7	first	O
8	identified	O
9	by	O
10	amino	O
11	terminal	O
12	and	O
13	peptide	O
14	sequencing	O
15	of	O
16	the	O
17	lentil	B
18	-	I
19	lectin	I
20	-	I
21	binding	I
22	glycoprotein	I
23	Gp135	I
24	.	O

1	Albumin	B
2	and	O
3	cyclic	O
4	AMP	O
5	levels	O
6	in	O
7	peritoneal	O
8	fluids	O
9	in	O
10	the	O
11	child	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	(	O
5	GGTP	B
6	)	O
7	activity	O
8	in	O
9	the	O
10	seminal	O
11	fluid	O

1	Inhibition	O
2	of	O
3	RNA2	B
4	translation	O
5	was	O
6	selective	O
7	,	O
8	with	O
9	no	O
10	effect	O
11	on	O
12	general	O
13	cellular	O
14	translation	O
15	or	O
16	translation	O
17	of	O
18	BMV	O
19	RNA1	B
20	-	O
21	encoded	O
22	replication	B
23	factor	I
24	1a	I
25	,	O
26	and	O
27	was	O
28	independent	O
29	of	O
30	p20	B
31	,	O
32	a	O
33	cellular	O
34	antagonist	O
35	of	O
36	DED1	B
37	function	O
38	in	O
39	translation	O
40	.	O

1	Autorosette	O
2	-	O
3	forming	O
4	cells	O
5	are	O
6	characterized	O
7	by	O
8	a	O
9	high	O
10	activity	O
11	of	O
12	alkaline	B
13	and	I
14	acid	I
15	phosphatases	I
16	and	O
17	low	O
18	NBT	O
19	-	O
20	test	O
21	values	O
22	.	O

1	Downstream	O
2	of	O
3	the	O
4	G	O
5	-	O
6	A	O
7	anastomosis	O
8	,	O
9	the	O
10	RD	O
11	,	O
12	CC	O
13	,	O
14	E	O
15	(	O
16	p	O
17	)	O
18	and	O
19	loop	O
20	areas	O
21	were	O
22	significantly	O
23	different	O
24	from	O
25	REF	O
26	,	O
27	but	O
28	significantly	O
29	different	O
30	from	O
31	A	O
32	-	O
33	A	O
34	.	O

1	The	O
2	Y	O
3	.	O
4	lipolytica	O
5	genomic	O
6	POT1	B
7	gene	O
8	was	O
9	disrupted	O
10	by	O
11	replacing	O
12	120	O
13	bp	O
14	of	O
15	its	O
16	coding	O
17	sequence	O
18	with	O
19	2	O
20	.	O
21	7	O
22	kbp	O
23	of	O
24	DNA	O
25	including	O
26	the	O
27	Y	O
28	.	O
29	lipolytica	O
30	LEU2	B
31	gene	I
32	.	O

1	In	O
2	the	O
3	first	O
4	series	O
5	of	O
6	experiments	O
7	,	O
8	Sprague	O
9	-	O
10	Dawley	O
11	male	O
12	rats	O
13	were	O
14	implanted	O
15	unilaterally	O
16	with	O
17	guide	O
18	cannulas	O
19	aimed	O
20	at	O
21	the	O
22	lateral	O
23	ventricle	O
24	.	O

1	Whereas	O
2	cDNA	O
3	hybridization	O
4	to	O
5	genomic	O
6	DNA	O
7	blots	O
8	indicated	O
9	a	O
10	small	O
11	subfamily	O
12	of	O
13	G0S19	B
14	genes	I
15	,	O
16	simple	O
17	patterns	O
18	of	O
19	bands	O
20	indicated	O
21	that	O
22	most	O
23	cDNAs	O
24	,	O
25	including	O
26	G0S30	B
27	cDNA	I
28	,	O
29	corresponded	O
30	to	O
31	single	O
32	-	O
33	copy	O
34	genes	O
35	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	data	O
6	indicate	O
7	that	O
8	the	O
9	VirD2	B
10	omega	I
11	domain	I
12	is	O
13	important	O
14	for	O
15	efficient	O
16	T	O
17	-	O
18	DNA	O
19	integration	O
20	.	O

1	The	O
2	pentafluorobenzyl	O
3	derivative	O
4	of	O
5	clonidine	O
6	yields	O
7	an	O
8	intense	O
9	ion	O
10	fragment	O
11	at	O
12	m	O
13	/	O
14	z	O
15	354	O
16	,	O
17	and	O
18	the	O
19	lower	O
20	limit	O
21	of	O
22	detection	O
23	is	O
24	0	O
25	.	O
26	025	O
27	ng	O
28	/	O
29	ml	O
30	for	O
31	a	O
32	1	O
33	-	O
34	ml	O
35	plasma	O
36	sample	O
37	.	O

1	The	O
2	requirement	O
3	of	O
4	3	O
5	'	O
6	complementarity	O
7	for	O
8	a	O
9	ligation	O
10	reaction	O
11	is	O
12	reaffirmed	O
13	by	O
14	results	O
15	from	O
16	1	O
17	nt	O
18	insertions	O
19	on	O
20	either	O
21	the	O
22	3	O
23	'-	O
24	or	O
25	5	O
26	'-	O
27	side	O
28	of	O
29	the	O
30	nick	O
31	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	intraarterial	O
6	neoadjuvant	O
7	chemotherapy	O
8	should	O
9	be	O
10	effective	O
11	on	O
12	advanced	O
13	cervical	O
14	cancer	O
15	.	O

1	Studies	O
2	using	O
3	an	O
4	inhibitor	O
5	or	O
6	a	O
7	mutant	B
8	Lb	I
9	proteinase	I
10	indicated	O
11	that	O
12	stimulation	O
13	of	O
14	IRES	O
15	-	O
16	driven	O
17	translation	O
18	is	O
19	mediated	O
20	via	O
21	proteolysis	O
22	of	O
23	some	O
24	cellular	O
25	component	O
26	(	O
27	s	O
28	).	O

1	The	O
2	95	O
3	%	O
4	confidence	O
5	values	O
6	(	O
7	2SD	O
8	)	O
9	for	O
10	the	O
11	change	O
12	in	O
13	Ros	O
14	required	O
15	to	O
16	exclude	O
17	natural	O
18	variability	O
19	were	O
20	0	O
21	.	O
22	39	O
23	,	O
24	0	O
25	.	O
26	50	O
27	and	O
28	0	O
29	.	O
30	53	O
31	cmH2O	O
32	l	O
33	-	O
34	1	O
35	s	O
36	,	O
37	respectively	O
38	.	O

1	A	O
2	range	O
3	of	O
4	normal	O
5	ventricular	O
6	measurements	O
7	for	O
8	the	O
9	EMI	O
10	scan	O
11	is	O
12	suggested	O
13	.	O

1	Basal	O
2	components	O
3	of	O
4	the	O
5	transcription	O
6	apparatus	O
7	(	O
8	RNA	B
9	polymerase	I
10	II	I
11	,	O
12	TATA	B
13	-	I
14	binding	I
15	protein	I
16	)	O
17	contain	O
18	activation	O
19	domains	O
20	:	O
21	is	O
22	the	O
23	repetitive	O
24	C	O
25	-	O
26	terminal	O
27	domain	O
28	(	O
29	CTD	O
30	)	O
31	of	O
32	RNA	B
33	polymerase	I
34	II	I
35	a	O
36	"	O
37	portable	O
38	enhancer	O
39	domain	O
40	"?	O
41	Regions	O
42	rich	O
43	in	O
44	serine	O
45	,	O
46	threonine	O
47	,	O
48	and	O
49	proline	O
50	residues	O
51	can	O
52	be	O
53	found	O
54	in	O
55	transcriptional	O
56	activation	O
57	domains	O
58	,	O
59	as	O
60	well	O
61	as	O
62	in	O
63	the	O
64	N	O
65	-	O
66	terminal	O
67	parts	O
68	of	O
69	mammalian	B
70	TATA	I
71	-	I
72	binding	I
73	proteins	I
74	,	O
75	where	O
76	they	O
77	are	O
78	interrupted	O
79	by	O
80	polyglutamine	O
81	stretches	O
82	.	O

1	This	O
2	interaction	O
3	inhibits	O
4	the	O
5	histone	B
6	acetyltransferase	I
7	activity	O
8	of	O
9	p300	B
10	,	O
11	resulting	O
12	in	O
13	drastic	O
14	reduction	O
15	of	O
16	nucleosomal	O
17	histone	B
18	acetylation	O
19	and	O
20	alteration	O
21	of	O
22	chromatin	O
23	structure	O
24	.	O

1	Early	O
2	treatment	O
3	mechanics	O
4	of	O
5	the	O
6	Class	O
7	II	O
8	division	O
9	2	O
10	malocclusion	O
11	.	O

1	The	O
2	maximum	O
3	stress	O
4	due	O
5	to	O
6	the	O
7	hygroscopic	O
8	examination	O
9	of	O
10	the	O
11	composite	O
12	was	O
13	0	O
14	.	O
15	74	O
16	kg	O
17	/	O
18	mm2	O
19	at	O
20	equilibrium	O
21	of	O
22	the	O
23	water	O
24	absorbed	O
25	of	O
26	the	O
27	composite	O
28	.	O

1	The	O
2	former	O
3	group	O
4	did	O
5	excrete	O
6	less	O
7	dry	O
8	fecal	O
9	material	O
10	compared	O
11	to	O
12	both	O
13	other	O
14	groups	O
15	.	O

1	For	O
2	higher	O
3	expression	O
4	of	O
5	lipA	B
6	in	O
7	S	O
8	.	O
9	lividans	O
10	,	O
11	the	O
12	gene	O
13	was	O
14	cloned	O
15	next	O
16	to	O
17	the	O
18	strong	O
19	aphII	B
20	promoter	I
21	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	and	O
5	electrophoretic	O
6	mobility	O
7	shift	O
8	assays	O
9	indicate	O
10	that	O
11	PBP	B
12	binds	O
13	to	O
14	the	O
15	half	O
16	-	O
17	site	O
18	of	O
19	each	O
20	palindrome	O
21	with	O
22	the	O
23	core	O
24	recognition	O
25	sequence	O
26	TGGGAG	O
27	.	O

1	Laboratory	O
2	studies	O
3	showed	O
4	that	O
5	the	O
6	direct	O
7	fluorescent	O
8	-	O
9	antibody	O
10	kits	O
11	were	O
12	the	O
13	least	O
14	sensitive	O
15	in	O
16	this	O
17	case	O
18	and	O
19	did	O
20	not	O
21	detect	O
22	fewer	O
23	than	O
24	10	O
25	(	O
26	4	O
27	)	O
28	elementary	O
29	bodies	O
30	per	O
31	ml	O
32	,	O
33	while	O
34	most	O
35	ELISA	O
36	kits	O
37	detected	O
38	between	O
39	130	O
40	and	O
41	600	O
42	elementary	O
43	bodies	O
44	per	O
45	ml	O
46	.	O

1	The	O
2	gene	B
3	encoding	I
4	human	I
5	tissue	I
6	-	I
7	type	I
8	plasminogen	I
9	activator	I
10	(	O
11	t	B
12	-	I
13	PA	I
14	)	O
15	is	O
16	regulated	O
17	in	O
18	a	O
19	cell	O
20	-	O
21	type	O
22	-	O
23	specific	O
24	manner	O
25	.	O

1	Cloning	O
2	of	O
3	a	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	CDC2	B
9	-	I
10	related	I
11	kinase	I
12	by	O
13	complementation	O
14	of	O
15	a	O
16	budding	B
17	yeast	I
18	cdc28	I
19	mutation	O
20	.	O

1	Candidate	O
2	tumor	O
3	suppressor	O
4	genes	O
5	,	O
6	Mts1	B
7	(	O
8	p16INK4a	B
9	)	O
10	and	O
11	Mts2	B
12	(	O
13	p15INK4b	B
14	),	O
15	have	O
16	been	O
17	mapped	O
18	to	O
19	this	O
20	region	O
21	,	O
22	but	O
23	by	O
24	Southern	O
25	blot	O
26	analysis	O
27	,	O
28	no	O
29	homozygous	O
30	deletions	O
31	were	O
32	detected	O
33	in	O
34	either	O
35	gene	O
36	.	O

1	The	O
2	effects	O
3	of	O
4	a	O
5	1	O
6	-	O
7	or	O
8	24	O
9	-	O
10	hour	O
11	pretreatment	O
12	regimen	O
13	with	O
14	monophosphoryl	O
15	lipid	O
16	A	O
17	(	O
18	MLA	O
19	,	O
20	35	O
21	micrograms	O
22	/	O
23	kg	O
24	i	O
25	.	O
26	v	O
27	.)	O
28	on	O
29	myocardial	O
30	stunning	O
31	produced	O
32	by	O
33	repetitive	O
34	coronary	O
35	occlusions	O
36	were	O
37	studied	O
38	in	O
39	barbital	O
40	-	O
41	anesthetized	O
42	dogs	O
43	.	O

1	The	O
2	potentially	O
3	SLE	O
4	-	O
5	inducing	O
6	drugs	O
7	are	O
8	reviewed	O
9	.	O

1	Disruption	O
2	of	O
3	re	O
4	-	O
5	replication	O
6	control	O
7	by	O
8	overexpression	O
9	of	O
10	human	B
11	ORC1	I
12	in	O
13	fission	O
14	yeast	O
15	.	O

1	Analysis	O
2	of	O
3	chromosomal	O
4	DNA	O
5	sequence	O
6	immediately	O
7	downstream	O
8	of	O
9	the	O
10	transposon	O
11	insertion	O
12	identified	O
13	two	O
14	open	O
15	reading	O
16	frames	O
17	,	O
18	designated	O
19	csrR	B
20	and	O
21	csrS	B
22	,	O
23	which	O
24	exhibited	O
25	sequence	O
26	similarity	O
27	to	O
28	bacterial	O
29	two	O
30	-	O
31	component	O
32	regulatory	O
33	systems	O
34	.	O

1	Effect	O
2	of	O
3	acute	O
4	and	O
5	chronic	O
6	psychogenic	O
7	stress	O
8	on	O
9	corticoadrenal	O
10	and	O
11	pituitary	B
12	-	I
13	thyroid	I
14	hormones	I
15	in	O
16	male	O
17	rats	O
18	.	O

1	Thirty	O
2	minutes	O
3	of	O
4	supine	O
5	restraint	O
6	decreased	O
7	DOPAC	O
8	concentrations	O
9	in	O
10	the	O
11	median	O
12	eminence	O
13	of	O
14	female	O
15	rats	O
16	that	O
17	were	O
18	not	O
19	exposed	O
20	to	O
21	ether	O
22	,	O
23	and	O
24	brief	O
25	exposure	O
26	to	O
27	ether	O
28	enhanced	O
29	this	O
30	effect	O
31	.	O

1	Epidemiologic	O
2	evidence	O
3	indicates	O
4	that	O
5	estrogen	O
6	replacement	O
7	therapy	O
8	after	O
9	menopause	O
10	increases	O
11	breast	O
12	cancer	O
13	risk	O
14	.	O

1	Plasma	B
2	renin	I
3	concentration	O
4	is	O
5	significantly	O
6	higher	O
7	in	O
8	the	O
9	subcapsular	O
10	venous	O
11	outflow	O
12	,	O
13	which	O
14	drains	O
15	the	O
16	superficial	O
17	cortex	O
18	,	O
19	than	O
20	in	O
21	the	O
22	deep	O
23	venous	O
24	outflow	O
25	,	O
26	which	O
27	drains	O
28	the	O
29	inner	O
30	half	O
31	of	O
32	the	O
33	cortex	O
34	and	O
35	medulla	O
36	of	O
37	the	O
38	cat	O
39	kidney	O
40	.	O

1	Both	O
2	proteins	O
3	were	O
4	shown	O
5	to	O
6	be	O
7	constitutively	O
8	associated	O
9	with	O
10	tubulin	B
11	.	O

1	Also	O
2	,	O
3	transient	O
4	overexpression	O
5	of	O
6	this	O
7	protein	O
8	in	O
9	C2C12	O
10	cells	O
11	reduced	O
12	the	O
13	transcription	O
14	of	O
15	a	O
16	CAT	B
17	-	O
18	reporter	O
19	regulated	O
20	by	O
21	an	O
22	E12	B
23	/	O
24	MyoD	B
25	driven	O
26	enhancer	O
27	.	O

1	Studied	O
2	groups	O
3	were	O
4	(	O
5	1	O
6	)	O
7	untreated	O
8	control	O
9	,	O
10	n	O
11	=	O
12	12	O
13	;	O
14	(	O
15	2	O
16	)	O
17	FK	O
18	-	O
19	1	O
20	,	O
21	n	O
22	=	O
23	8	O
24	;	O
25	(	O
26	3	O
27	)	O
28	FK	O
29	-	O
30	3	O
31	,	O
32	n	O
33	=	O
34	8	O
35	.	O

1	We	O
2	also	O
3	mapped	O
4	a	O
5	3	O
6	'-	O
7	polyadenylation	O
8	site	O
9	504bp	O
10	downstream	O
11	of	O
12	the	O
13	TGA	O
14	stop	O
15	codon	O
16	,	O
17	consistent	O
18	with	O
19	the	O
20	2	O
21	.	O
22	5kb	O
23	transcript	O
24	size	O
25	.	O

1	In	O
2	addition	O
3	to	O
4	a	O
5	previously	O
6	characterized	O
7	promoter	O
8	(	O
9	P1	O
10	),	O
11	we	O
12	now	O
13	show	O
14	the	O
15	existence	O
16	of	O
17	a	O
18	second	O
19	promoter	O
20	for	O
21	the	O
22	human	B
23	IL	I
24	-	I
25	5Ralpha	I
26	gene	I
27	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	separate	O
6	domains	O
7	of	O
8	FadR	B
9	required	O
10	for	O
11	DNA	O
12	binding	O
13	,	O
14	dimerization	O
15	,	O
16	and	O
17	ligand	O
18	binding	O
19	,	O
20	chimeric	O
21	protein	O
22	fusions	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	of	O
29	LexA	B
30	and	O
31	different	O
32	regions	O
33	of	O
34	FadR	B
35	were	O
36	constructed	O
37	.	O

1	Finally	O
2	,	O
3	some	O
4	point	O
5	mutations	O
6	in	O
7	the	O
8	Gag	B
9	-	O
10	Pol	B
11	PR	O
12	domain	O
13	inhibited	O
14	activation	O
15	of	O
16	RT	B
17	in	O
18	trans	O
19	by	O
20	a	O
21	wild	O
22	-	O
23	type	O
24	PR	B
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	correct	O
30	conformation	O
31	of	O
32	the	O
33	PR	B
34	domain	O
35	in	O
36	Gag	B
37	-	O
38	Pol	B
39	is	O
40	prerequisite	O
41	for	O
42	activation	O
43	of	O
44	RT	B
45	.	O

1	The	O
2	rear	O
3	silver	O
4	liquid	O
5	chamber	O
6	was	O
7	threefold	O
8	thick	O
9	to	O
10	17	O
11	MeV	O
12	protons	O
13	in	O
14	water	O
15	and	O
16	it	O
17	efficiently	O
18	produced	O
19	either	O
20	13N	O
21	by	O
22	the	O
23	16O	O
24	(	O
25	p	O
26	,	O
27	alpha	O
28	)	O
29	13N	O
30	reaction	O
31	or	O
32	[	O
33	18F	O
34	]	O
35	fluoride	O
36	ion	O
37	by	O
38	the	O
39	18O	O
40	(	O
41	p	O
42	,	O
43	n	O
44	)	O
45	18F	O
46	reaction	O
47	.	O

1	That	O
2	sequence	O
3	strongly	O
4	promoted	O
5	the	O
6	transcription	O
7	of	O
8	the	O
9	promotorless	O
10	chloramphenicol	B
11	acetyltranferase	I
12	(	O
13	CAT	B
14	)	O
15	gene	O
16	in	O
17	cells	O
18	of	O
19	pancreatic	O
20	origin	O
21	(	O
22	AR	O
23	-	O
24	42J	O
25	)	O
26	but	O
27	not	O
28	in	O
29	cells	O
30	of	O
31	non	O
32	-	O
33	pancreatic	O
34	origin	O
35	(	O
36	Rat	O
37	2	O
38	and	O
39	IEC	O
40	6	O
41	).	O

1	The	O
2	effect	O
3	of	O
4	independent	O
5	predictors	O
6	on	O
7	survival	O
8	was	O
9	examined	O
10	in	O
11	a	O
12	Cox	O
13	regression	O
14	model	O
15	with	O
16	adjustment	O
17	for	O
18	existing	O
19	illnesses	O
20	.	O

1	All	O
2	subjects	O
3	were	O
4	submitted	O
5	to	O
6	ECG	O
7	and	O
8	arterial	O
9	blood	O
10	pressure	O
11	determination	O
12	and	O
13	were	O
14	assayed	O
15	for	O
16	TSH	B
17	,	O
18	thyroid	O
19	hormone	O
20	,	O
21	PRL	B
22	,	O
23	glucose	O
24	,	O
25	creatinine	O
26	,	O
27	nitrogen	O
28	,	O
29	glutamine	B
30	transaminase	I
31	,	O
32	cholesterol	O
33	and	O
34	triglycerides	O
35	plasma	O
36	levels	O
37	before	O
38	therapy	O
39	(	O
40	T0	O
41	),	O
42	after	O
43	30	O
44	treatment	O
45	days	O
46	(	O
47	T30	O
48	)	O
49	and	O
50	after	O
51	a	O
52	15	O
53	days	O
54	washout	O
55	(	O
56	T45	O
57	).	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	N	O
7	-	O
8	and	O
9	C	O
10	-	O
11	terminal	O
12	mutations	O
13	are	O
14	required	O
15	to	O
16	inhibit	O
17	transrepression	O
18	by	O
19	FBR	B
20	protein	I
21	and	O
22	that	O
23	multiple	O
24	structural	O
25	mutations	O
26	accompanied	O
27	by	O
28	posttranslational	O
29	protein	O
30	modification	O
31	alter	O
32	gene	O
33	regulation	O
34	by	O
35	FBR	B
36	protein	I
37	.	O

1	ERV1	B
2	is	O
3	involved	O
4	in	O
5	the	O
6	cell	O
7	-	O
8	division	O
9	cycle	O
10	and	O
11	the	O
12	maintenance	O
13	of	O
14	mitochondrial	O
15	genomes	O
16	in	O
17	Saccharomyces	O
18	cerevisiae	O
19	.	O

1	Stringent	O
2	hybridization	O
3	of	O
4	EHS	B
5	-	I
6	1	I
7	back	O
8	to	O
9	primate	O
10	genomic	O
11	DNA	O
12	indicates	O
13	two	O
14	distinct	O
15	EHS	B
16	-	I
17	1	I
18	loci	I
19	in	O
20	normal	O
21	human	O
22	DNA	O
23	,	O
24	an	O
25	identical	O
26	band	O
27	pattern	O
28	in	O
29	chimpanzee	O
30	DNA	O
31	,	O
32	and	O
33	a	O
34	single	O
35	locus	O
36	in	O
37	rhesus	O
38	monkey	O
39	DNA	O
40	.	O

1	Replacing	O
2	the	O
3	aspartic	O
4	acid	O
5	with	O
6	a	O
7	lysine	O
8	but	O
9	not	O
10	with	O
11	an	O
12	alanine	O
13	or	O
14	valine	O
15	residue	O
16	allowed	O
17	formation	O
18	of	O
19	disulfide	O
20	-	O
21	linked	O
22	dimers	O
23	.	O

1	In	O
2	vitro	O
3	studies	O
4	with	O
5	blood	O
6	cells	O
7	incubated	O
8	with	O
9	acetate	O
10	or	O
11	bicarbonate	O
12	ions	O
13	in	O
14	concentrations	O
15	,	O
16	which	O
17	are	O
18	observed	O
19	in	O
20	vivo	O
21	during	O
22	hemodialysis	O
23	,	O
24	suggest	O
25	that	O
26	probably	O
27	these	O
28	ions	O
29	do	O
30	not	O
31	directly	O
32	affect	O
33	superoxide	O
34	anions	O
35	generation	O
36	,	O
37	erythrocyte	O
38	SOD	B
39	-	I
40	1	I
41	and	O
42	catalase	B
43	activities	O
44	and	O
45	erythrocyte	O
46	membrane	O
47	lipid	O
48	peroxidation	O
49	.	O

1	The	O
2	structural	O
3	changes	O
4	in	O
5	intra	O
6	-	O
7	acinar	O
8	artery	O
9	manifested	O
10	mainly	O
11	by	O
12	an	O
13	increase	O
14	in	O
15	number	O
16	of	O
17	muscular	O
18	artery	O
19	resulting	O
20	from	O
21	muscularization	O
22	of	O
23	precursor	O
24	cells	O
25	(	O
26	pericytes	O
27	and	O
28	intermediate	O
29	cells	O
30	)	O
31	located	O
32	within	O
33	partially	O
34	muscular	O
35	and	O
36	nonmuscular	O
37	arterial	O
38	wall	O
39	to	O
40	smooth	O
41	muscle	O
42	cell	O
43	,	O
44	and	O
45	by	O
46	the	O
47	medial	O
48	wall	O
49	thickened	O
50	due	O
51	to	O
52	hypertrophy	O
53	and	O
54	hyperplasia	O
55	of	O
56	smooth	O
57	muscle	O
58	cells	O
59	as	O
60	well	O
61	as	O
62	accumulation	O
63	of	O
64	a	O
65	large	O
66	amount	O
67	of	O
68	collagen	B
69	,	O
70	especially	O
71	the	O
72	type	B
73	1	I
74	collagen	I
75	.	O

1	In	O
2	only	O
3	two	O
4	patients	O
5	were	O
6	we	O
7	able	O
8	to	O
9	demonstrate	O
10	changes	O
11	suggestive	O
12	of	O
13	pulmonary	O
14	metastases	O
15	any	O
16	earlier	O
17	with	O
18	a	O
19	99mTc	O
20	-	O
21	EHDP	O
22	scan	O
23	than	O
24	with	O
25	chest	O
26	radiographs	O
27	and	O
28	one	O
29	of	O
30	these	O
31	resolved	O
32	spontaneously	O
33	.	O

1	Ras2p	B
2	activates	O
3	invasive	O
4	growth	O
5	using	O
6	either	O
7	of	O
8	two	O
9	downstream	O
10	signaling	O
11	pathways	O
12	,	O
13	the	O
14	filamentation	O
15	MAPK	B
16	(	O
17	Cdc42p	B
18	/	O
19	Ste20p	B
20	/	O
21	MAPK	B
22	)	O
23	cascade	O
24	or	O
25	the	O
26	cAMP	B
27	-	I
28	dependent	I
29	protein	I
30	kinase	I
31	(	O
32	Cyr1p	B
33	/	O
34	cAMP	O
35	/	O
36	PKA	B
37	)	O
38	pathway	O
39	.	O

1	Our	O
2	results	O
3	confirm	O
4	the	O
5	participation	O
6	of	O
7	intron	O
8	1	O
9	in	O
10	transcriptional	O
11	regulation	O
12	of	O
13	the	O
14	c	B
15	-	I
16	myb	I
17	gene	I
18	(	O
19	in	O
20	mouse	O
21	and	O
22	human	O
23	)	O
24	and	O
25	implicate	O
26	multiple	O
27	and	O
28	complex	O
29	regulatory	O
30	mechanisms	O
31	of	O
32	activation	O
33	during	O
34	myelomonocytic	O
35	differentiation	O
36	and	O
37	leukemic	O
38	cell	O
39	growth	O
40	control	O
41	.	O

1	Differential	O
2	regulation	O
3	of	O
4	the	O
5	pre	B
6	-	I
7	C	I
8	and	O
9	pregenomic	O
10	promoters	O
11	of	O
12	human	O
13	hepatitis	O
14	B	O
15	virus	O
16	by	O
17	members	O
18	of	O
19	the	O
20	nuclear	B
21	receptor	I
22	superfamily	I
23	.	O

1	Its	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	shows	O
7	extensive	O
8	homology	O
9	to	O
10	those	O
11	of	O
12	Drosophila	B
13	hsp70	I
14	,	O
15	trout	B
16	hsp70	I
17	,	O
18	Xenopus	B
19	hsp70	I
20	,	O
21	yeast	B
22	hsp70	I
23	,	O
24	and	O
25	some	O
26	homology	O
27	to	O
28	the	O
29	heat	B
30	-	I
31	inducible	I
32	dnaK	I
33	gene	I
34	product	I
35	of	O
36	Escherichia	O
37	coli	O
38	.	O

1	The	O
2	junctions	O
3	between	O
4	viral	O
5	and	O
6	cellular	O
7	sequences	O
8	were	O
9	determined	O
10	by	O
11	DNA	O
12	sequence	O
13	analysis	O
14	to	O
15	be	O
16	517	O
17	nucleotides	O
18	into	O
19	the	O
20	p30	B
21	sequence	I
22	and	O
23	1	O
24	,	O
25	920	O
26	nucleotides	O
27	into	O
28	the	O
29	polymerase	O
30	sequence	O
31	.	O

1	A	O
2	second	O
3	promoter	O
4	activity	O
5	was	O
6	identified	O
7	in	O
8	the	O
9	region	O
10	between	O
11	the	O
12	two	O
13	major	O
14	transcriptional	O
15	start	O
16	sites	O
17	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	have	O
8	isolated	O
9	and	O
10	sequenced	O
11	several	O
12	p15E	B
13	cDNA	I
14	gene	I
15	fragments	I
16	amplified	O
17	by	O
18	means	O
19	of	O
20	polymerase	O
21	chain	O
22	reaction	O
23	(	O
24	PCR	O
25	)	O
26	from	O
27	parental	O
28	(	O
29	P815	O
30	)	O
31	and	O
32	xenogenized	O
33	(	O
34	P815	O
35	/	O
36	DTIC	O
37	)	O
38	tumour	O
39	cells	O
40	.	O

1	MED1	B
2	has	O
3	a	O
4	weak	O
5	glycosylase	B
6	activity	O
7	on	O
8	the	O
9	mutagenic	O
10	adduct	O
11	3	O
12	,	O
13	N	O
14	(	O
15	4	O
16	)-	O
17	ethenocytosine	O
18	,	O
19	a	O
20	metabolite	O
21	of	O
22	vinyl	O
23	chloride	O
24	and	O
25	ethyl	O
26	carbamate	O
27	.	O

1	Effect	O
2	of	O
3	single	O
4	base	O
5	substitutions	O
6	at	O
7	glycine	O
8	-	O
9	870	O
10	codon	O
11	of	O
12	gramicidin	B
13	S	I
14	synthetase	I
15	2	I
16	gene	I
17	on	O
18	proline	O
19	activation	O
20	.	O

1	These	O
2	include	O
3	NPF	O
4	repeats	O
5	,	O
6	a	O
7	leucine	O
8	heptad	O
9	repeat	O
10	enriched	O
11	in	O
12	charged	O
13	residues	O
14	,	O
15	and	O
16	a	O
17	proline	O
18	-	O
19	rich	O
20	SH3	B
21	-	I
22	like	I
23	and	O
24	/	O
25	or	O
26	WW	O
27	domain	O
28	-	O
29	binding	O
30	site	O
31	in	O
32	the	O
33	N	O
34	-	O
35	terminal	O
36	domain	O
37	,	O
38	which	O
39	is	O
40	followed	O
41	by	O
42	a	O
43	membrane	O
44	core	O
45	containing	O
46	four	O
47	putative	O
48	transmembrane	O
49	spans	O
50	and	O
51	three	O
52	amphiphilic	O
53	segments	O
54	that	O
55	are	O
56	the	O
57	most	O
58	highly	O
59	conserved	O
60	structural	O
61	elements	O
62	.	O

1	Creutzfeldt	O
2	-	O
3	Jakob	O
4	disease	O
5	and	O
6	lyophilised	O
7	dura	O
8	mater	O
9	grafts	O
10	:	O
11	report	O
12	of	O
13	two	O
14	cases	O
15	.	O

1	Fgd3	B
2	and	O
3	FGD1	B
4	share	O
5	a	O
6	high	O
7	degree	O
8	of	O
9	sequence	O
10	identity	O
11	that	O
12	spans	O
13	>	O
14	560	O
15	contiguous	O
16	amino	O
17	acid	O
18	residues	O
19	.	O

1	The	O
2	inferred	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	cyanobacterial	B
9	HemB	I
10	protein	I
11	indicates	O
12	a	O
13	significant	O
14	difference	O
15	in	O
16	the	O
17	metal	O
18	cofactor	O
19	requirement	O
20	from	O
21	the	O
22	higher	O
23	-	O
24	plant	O
25	enzymes	O
26	,	O
27	which	O
28	was	O
29	confirmed	O
30	by	O
31	overexpression	O
32	and	O
33	biochemical	O
34	analysis	O
35	.	O

1	Activity	O
2	of	O
3	palgD	B
4	in	O
5	the	O
6	cysB	B
7	mutant	I
8	,	O
9	in	O
10	CHA	O
11	and	O
12	in	O
13	the	O
14	non	O
15	-	O
16	mucoid	O
17	strain	O
18	PAO	O
19	was	O
20	assessed	O
21	by	O
22	the	O
23	use	O
24	of	O
25	a	O
26	transcriptional	O
27	algD	B
28	-	O
29	xylE	B
30	fusion	O
31	.	O

1	Dynamic	O
2	decision	O
3	making	O
4	:	O
5	human	O
6	control	O
7	of	O
8	complex	O
9	systems	O
10	.	O

1	This	O
2	report	O
3	has	O
4	reviewed	O
5	some	O
6	of	O
7	the	O
8	reasons	O
9	for	O
10	treatment	O
11	failures	O
12	and	O
13	has	O
14	presented	O
15	a	O
16	philosophy	O
17	for	O
18	their	O
19	management	O
20	.	O

1	Each	O
2	group	O
3	received	O
4	15	O
5	ml	O
6	/	O
7	kg	O
8	of	O
9	either	O
10	6	O
11	%	O
12	pentafraction	O
13	,	O
14	6	O
15	%	O
16	pentastarch	O
17	,	O
18	or	O
19	plasma	O
20	followed	O
21	two	O
22	hours	O
23	later	O
24	by	O
25	1	O
26	.	O
27	5	O
28	micrograms	O
29	/	O
30	kg	O
31	/	O
32	0	O
33	.	O
34	5	O
35	hr	O
36	E	O
37	.	O

1	16	O
2	,	O
3	99	O
4	-	O
5	104	O
6	).	O

1	Despite	O
2	the	O
3	existence	O
4	of	O
5	30	O
6	cysteine	O
7	residues	O
8	,	O
9	carboxymethylation	O
10	prevented	O
11	the	O
12	formation	O
13	of	O
14	most	O
15	if	O
16	not	O
17	all	O
18	disulfide	O
19	bonds	O
20	that	O
21	otherwise	O
22	occurred	O
23	when	O
24	the	O
25	cells	O
26	were	O
27	sonicated	O
28	.	O

1	Thomas	O
2	'	O
3	Hospital	O
4	solution	O
5	(	O
6	with	O
7	95	O
8	%	O
9	O2	O
10	:	O
11	5	O
12	%	O
13	CO2	O
14	)	O
15	can	O
16	meet	O
17	the	O
18	metabolic	O
19	demand	O
20	of	O
21	the	O
22	ischaemic	O
23	myocardium	O
24	and	O
25	thus	O
26	increase	O
27	the	O
28	safe	O
29	duration	O
30	of	O
31	cardiac	O
32	arrest	O
33	.	O

1	Transcription	O
2	of	O
3	the	O
4	first	O
5	operon	O
6	coding	O
7	for	O
8	m	O
9	-	O
10	xylene	O
11	-	O
12	degrading	O
13	enzymes	O
14	on	O
15	the	O
16	TOL	O
17	plasmid	O
18	of	O
19	Pseudomonas	O
20	putida	O
21	is	O
22	activated	O
23	by	O
24	the	O
25	xylR	B
26	gene	I
27	product	I
28	in	O
29	the	O
30	presence	O
31	of	O
32	m	O
33	-	O
34	xylene	O
35	.	O

1	Wherever	O
2	the	O
3	site	O
4	of	O
5	the	O
6	conditioning	O
7	stimulation	O
8	,	O
9	these	O
10	modifications	O
11	disappeared	O
12	after	O
13	ischaemia	O
14	of	O
15	the	O
16	leg	O
17	.	O

1	Detection	O
2	of	O
3	congenital	O
4	hypothyroidism	O
5	in	O
6	26	O
7	,	O
8	282	O
9	newborn	O
10	infants	O

1	Key	O
2	areas	O
3	of	O
4	the	O
5	selection	O
6	process	O
7	including	O
8	medical	O
9	and	O
10	surgical	O
11	alternatives	O
12	to	O
13	transplantation	O
14	,	O
15	the	O
16	composition	O
17	of	O
18	the	O
19	transplant	O
20	work	O
21	-	O
22	up	O
23	,	O
24	specific	O
25	inclusion	O
26	criteria	O
27	as	O
28	well	O
29	as	O
30	specific	O
31	psychosocial	O
32	factors	O
33	and	O
34	specific	O
35	disease	O
36	etiologies	O
37	and	O
38	co	O
39	-	O
40	morbidities	O
41	that	O
42	might	O
43	represent	O
44	contraindications	O
45	were	O
46	extensively	O
47	reviewed	O
48	.	O

1	The	O
2	thrombolytic	O
3	effects	O
4	of	O
5	native	O
6	tissue	B
7	-	I
8	type	I
9	plasminogen	I
10	activator	I
11	(	O
12	AK	B
13	-	I
14	124	I
15	)	O
16	on	O
17	experimental	O
18	canine	O
19	coronary	O
20	thrombosis	O
21	.	O

1	Pretreatment	O
2	of	O
3	cells	O
4	with	O
5	the	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	-	I
11	extracellular	I
12	signal	I
13	-	I
14	regulated	I
15	kinase	I
16	kinase	I
17	(	O
18	MEK	B
19	)	O
20	inhibitor	O
21	U0126	O
22	inhibited	O
23	S6K2	B
24	activation	O
25	to	O
26	a	O
27	greater	O
28	extent	O
29	than	O
30	S6K1	B
31	.	O

1	The	O
2	micromethod	O
3	uses	O
4	microcuvettes	O
5	and	O
6	substitutes	O
7	ferrozine	O
8	for	O
9	the	O
10	bathophenanthroline	O
11	chromogen	O
12	of	O
13	the	O
14	ICSH	O
15	.	O

1	First	O
2	,	O
3	the	O
4	finding	O
5	of	O
6	a	O
7	monomeric	O
8	Alu	B
9	family	O
10	repeat	O
11	at	O
12	the	O
13	junction	O
14	between	O
15	nonhomology	O
16	block	O
17	I	O
18	and	O
19	homology	O
20	block	O
21	Y	O
22	of	O
23	the	O
24	alpha	B
25	2	I
26	gene	I
27	-	I
28	containing	I
29	unit	I
30	in	I
31	rhesus	I
32	macaque	I
33	suggests	O
34	that	O
35	the	O
36	dimeric	O
37	Alu	B
38	family	O
39	repeat	O
40	,	O
41	Alu	B
42	3	I
43	,	O
44	at	O
45	the	O
46	orthologous	O
47	position	O
48	in	O
49	human	O
50	was	O
51	generated	O
52	by	O
53	insertion	O
54	of	O
55	a	O
56	monomeric	O
57	Alu	B
58	family	O
59	repeat	O
60	into	O
61	the	O
62	3	O
63	'	O
64	end	O
65	of	O
66	another	O
67	preexisting	O
68	Alu	B
69	family	O
70	repeat	O
71	.	O

1	In	O
2	addition	O
3	,	O
4	an	O
5	mck1	B
6	mds1	I
7	mrk1	I
8	triple	O
9	disruptant	O
10	was	O
11	viable	O
12	.	O

1	The	O
2	protein	O
3	product	O
4	of	O
5	orfD	B
6	,	O
7	which	O
8	is	O
9	probably	O
10	a	O
11	new	O
12	tra	B
13	gene	I
14	(	O
15	named	O
16	traX	B
17	),	O
18	contains	O
19	65	O
20	%	O
21	hydrophobic	O
22	amino	O
23	acids	O
24	,	O
25	especially	O
26	rich	O
27	in	O
28	alanine	O
29	and	O
30	leucine	O
31	.	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	the	O
6	GAL7	B
7	5	I
8	'	I
9	flanking	I
10	region	I
11	has	O
12	many	O
13	features	O
14	common	O
15	to	O
16	those	O
17	of	O
18	multicellular	O
19	eukaryotic	O
20	genes	O
21	.	O

1	These	O
2	natural	O
3	antisense	O
4	S	B
5	transcripts	I
6	co	O
7	-	O
8	exist	O
9	with	O
10	several	O
11	less	O
12	abundant	O
13	sense	O
14	S	B
15	transcripts	I
16	.	O

1	Transvenous	O
2	serial	O
3	xeroradiography	O
4	.	O

1	The	O
2	4	O
3	-	O
4	AP	O
5	(	O
6	4	O
7	-	O
8	20	O
9	mM	O
10	)	O
11	effect	O
12	resulted	O
13	in	O
14	a	O
15	decrease	O
16	of	O
17	the	O
18	sensory	O
19	activity	O
20	,	O
21	which	O
22	was	O
23	fully	O
24	restored	O
25	by	O
26	TEA	O
27	or	O
28	Ba2	O
29	+.	O

1	The	O
2	in	O
3	vitro	O
4	relaxivity	O
5	of	O
6	the	O
7	complex	O
8	is	O
9	16	O
10	.	O
11	24	O
12	s	O
13	(-	O
14	1	O
15	)	O
16	mM	O
17	(-	O
18	1	O
19	).	O

1	CCAAT	B
2	displacement	I
3	protein	I
4	binds	O
5	to	O
6	and	O
7	negatively	O
8	regulates	O
9	human	O
10	papillomavirus	O
11	type	O
12	6	O
13	E6	B
14	,	O
15	E7	B
16	,	O
17	and	O
18	E1	B
19	promoters	O
20	.	O

1	Structure	O
2	-	O
3	function	O
4	analysis	O
5	of	O
6	the	O
7	Z	O
8	-	O
9	DNA	O
10	-	O
11	binding	O
12	domain	O
13	Zalpha	O
14	of	O
15	dsRNA	B
16	adenosine	I
17	deaminase	I
18	type	I
19	I	I
20	reveals	O
21	similarity	O
22	to	O
23	the	O
24	(	B
25	alpha	I
26	+	I
27	beta	I
28	)	I
29	family	I
30	of	O
31	helix	B
32	-	I
33	turn	I
34	-	I
35	helix	I
36	proteins	I
37	.	O

1	Anti	B
2	-	I
3	CRK	I
4	antibodies	I
5	detect	O
6	a	O
7	53kDa	O
8	protein	O
9	in	O
10	extracts	O
11	of	O
12	C	O
13	.	O
14	fasciculata	O
15	in	O
16	agreement	O
17	with	O
18	the	O
19	size	O
20	predicted	O
21	from	O
22	the	O
23	nucleotide	O
24	sequence	O
25	of	O
26	the	O
27	cloned	O
28	gene	O
29	.	O

1	Mature	O
2	and	O
3	old	O
4	B6AF1	O
5	and	O
6	B6D2F1	O
7	mice	O
8	were	O
9	given	O
10	acidified	O
11	tap	O
12	water	O
13	or	O
14	promethazine	O
15	HCl	O
16	(	O
17	a	O
18	phenothiazine	O
19	with	O
20	H1	B
21	receptor	I
22	blocking	O
23	activity	O
24	),	O
25	chlorpheniramine	O
26	(	O
27	an	O
28	H1	B
29	blocker	O
30	)	O
31	or	O
32	trifluoperazine	O
33	(	O
34	a	O
35	phenothiazine	O
36	with	O
37	no	O
38	H1	B
39	blocking	O
40	activity	O
41	)	O
42	in	O
43	their	O
44	drinking	O
45	water	O
46	,	O
47	and	O
48	the	O
49	effects	O
50	of	O
51	these	O
52	agents	O
53	on	O
54	bone	O
55	mineral	O
56	content	O
57	were	O
58	assessed	O
59	by	O
60	intermittently	O
61	measuring	O
62	the	O
63	24	O
64	-	O
65	h	O
66	whole	O
67	body	O
68	retention	O
69	of	O
70	Tc	O
71	99m	O
72	methylene	O
73	diphosphonate	O
74	(	O
75	Tc	O
76	99m	O
77	MDP	O
78	,	O
79	an	O
80	indicator	O
81	of	O
82	bone	O
83	metabolism	O
84	)	O
85	and	O
86	at	O
87	the	O
88	end	O
89	of	O
90	the	O
91	studies	O
92	by	O
93	determining	O
94	ash	O
95	weights	O
96	of	O
97	femur	O
98	,	O
99	ilium	O
100	and	O
101	sacrum	O
102	.	O

1	The	O
2	two	O
3	different	O
4	phosphoforms	O
5	of	O
6	STAT5	B
7	have	O
8	identical	O
9	in	O
10	vitro	O
11	DNA	O
12	binding	O
13	specificity	O
14	and	O
15	reactivity	O
16	with	O
17	tyrosine	O
18	phosphopeptides	O
19	,	O
20	but	O
21	differ	O
22	in	O
23	their	O
24	cellular	O
25	localization	O
26	.	O

1	Yeast	B
2	Gal11	I
3	protein	I
4	mediates	O
5	the	O
6	transcriptional	O
7	activation	O
8	signal	O
9	of	O
10	two	O
11	different	O
12	transacting	O
13	factors	O
14	,	O
15	Gal4	B
16	and	O
17	general	B
18	regulatory	I
19	factor	I
20	I	I
21	/	O
22	repressor	B
23	/	I
24	activator	I
25	site	I
26	binding	I
27	protein	I
28	1	I
29	/	I
30	translation	I
31	upstream	I
32	factor	I
33	.	O

1	The	O
2	antinociceptive	O
3	properties	O
4	,	O
5	as	O
6	measured	O
7	by	O
8	the	O
9	tail	O
10	-	O
11	flick	O
12	and	O
13	hot	O
14	-	O
15	plate	O
16	tests	O
17	,	O
18	and	O
19	the	O
20	motor	O
21	effects	O
22	of	O
23	an	O
24	intrathecally	O
25	-	O
26	administered	O
27	benzodiazepine	O
28	agonist	O
29	midazolam	O
30	,	O
31	alone	O
32	,	O
33	and	O
34	in	O
35	combination	O
36	with	O
37	morphine	O
38	,	O
39	was	O
40	examined	O
41	in	O
42	rats	O
43	.	O

1	Human	B
2	neuronal	I
3	Elav	I
4	-	I
5	like	I
6	proteins	I
7	contain	O
8	three	O
9	RNP	O
10	-	O
11	type	O
12	RNA	O
13	recognition	O
14	motifs	O
15	(	O
16	RRMs	O
17	).	O

1	The	O
2	proteins	O
3	encoded	O
4	downstream	O
5	of	O
6	rpoN	B
7	are	O
8	known	O
9	to	O
10	negatively	O
11	regulate	O
12	sigma	B
13	54	I
14	activity	O
15	.	O

1	OODG	O
2	is	O
3	a	O
4	diagnostic	O
5	method	O
6	permitting	O
7	assessment	O
8	of	O
9	ocular	O
10	pulse	O
11	curves	O
12	and	O
13	objective	O
14	determination	O
15	of	O
16	blood	O
17	pressures	O
18	in	O
19	the	O
20	ophthalmic	O
21	circulatory	O
22	system	O
23	(	O
24	retinal	O
25	and	O
26	ciliary	O
27	arterial	O
28	blood	O
29	pressures	O
30	)	O
31	simultaneously	O
32	for	O
33	both	O
34	eyes	O
35	,	O
36	without	O
37	dilatation	O
38	of	O
39	the	O
40	pupils	O
41	.	O

1	By	O
2	contrast	O
3	,	O
4	their	O
5	basal	O
6	adrenal	O
7	androgen	O
8	levels	O
9	were	O
10	significantly	O
11	decreased	O
12	compared	O
13	to	O
14	those	O
15	in	O
16	normal	O
17	subjects	O
18	on	O
19	both	O
20	the	O
21	day	O
22	on	O
23	and	O
24	the	O
25	day	O
26	off	O
27	prednisone	O
28	(	O
29	P	O
30	less	O
31	than	O
32	0	O
33	.	O
34	05	O
35	).	O

1	She	O
2	also	O
3	had	O
4	slight	O
5	weakness	O
6	of	O
7	the	O
8	upper	O
9	extremities	O
10	.	O

1	We	O
2	have	O
3	studied	O
4	the	O
5	biokinetics	O
6	of	O
7	BLM	O
8	labeled	O
9	with	O
10	indium	O
11	-	O
12	111	O
13	(	O
14	In	O
15	-	O
16	111	O
17	).	O

1	Analysis	O
2	of	O
3	Standard	O
4	Reference	O
5	Material	O
6	1846	O
7	,	O
8	Infant	O
9	Formula	O
10	,	O
11	gave	O
12	a	O
13	mean	O
14	value	O
15	of	O
16	0	O
17	.	O
18	95	O
19	+/-	O
20	0	O
21	.	O
22	088	O
23	mg	O
24	vitamin	O
25	K	O
26	/	O
27	kg	O
28	(	O
29	K	O
30	or	O
31	K1	O
32	?)	O
33	(	O
34	n	O
35	=	O
36	31	O
37	)	O
38	with	O
39	a	O
40	coefficient	O
41	of	O
42	variation	O
43	of	O
44	9	O
45	.	O
46	26	O
47	.	O

1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	B
6	cell	I
7	Ag	I
8	receptor	I
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	B
14	Fc	I
15	receptors	I
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	I
21	R	I
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O

1	Reliability	O
2	of	O
3	cervical	O
4	range	O
5	of	O
6	motion	O
7	using	O
8	the	O
9	OSI	O
10	CA	O
11	6000	O
12	spine	O
13	motion	O
14	analyser	O
15	on	O
16	asymptomatic	O
17	and	O
18	symptomatic	O
19	subjects	O
20	.	O

1	Erythema	O
2	exsudativum	O
3	multiforme	O
4	induced	O
5	by	O
6	granulocyte	B
7	colony	I
8	-	I
9	stimulating	I
10	factor	I
11	in	O
12	an	O
13	allogeneic	O
14	peripheral	O
15	blood	O
16	stem	O
17	cell	O
18	donor	O
19	.	O

1	PATIENTS	O
2	OR	O
3	OTHER	O
4	PARTICIPANTS	O
5	:	O
6	Twenty	O
7	children	O
8	met	O
9	the	O
10	criteria	O
11	for	O
12	being	O
13	learning	O
14	disabled	O
15	.	O

1	Restriction	O
2	maps	O
3	of	O
4	the	O
5	cloned	O
6	plasmids	O
7	revealed	O
8	that	O
9	their	O
10	chromosomal	O
11	inserts	O
12	consisted	O
13	of	O
14	overlapping	O
15	fragments	O
16	.	O

1	The	O
2	influence	O
3	of	O
4	a	O
5	mobile	O
6	pupil	O
7	on	O
8	the	O
9	response	O
10	in	O
11	the	O
12	DC	O
13	-	O
14	ERG	O
15	is	O
16	demonstrated	O
17	.	O

1	The	O
2	effect	O
3	of	O
4	dietary	O
5	zinc	O
6	deficiency	O
7	on	O
8	the	O
9	mossy	O
10	fiber	O
11	zinc	O
12	content	O
13	of	O
14	the	O
15	rat	O
16	hippocampus	O
17	.	O

1	Hailey	O
2	-	O
3	Hailey	O
4	disease	O
5	is	O
6	caused	O
7	by	O
8	mutations	O
9	in	O
10	ATP2C1	B
11	encoding	O
12	a	O
13	novel	O
14	Ca	O
15	(	O
16	2	O
17	+)	O
18	pump	O
19	.	O

1	Well	O
2	-	O
3	visualised	O
4	arteriograms	O
5	of	O
6	the	O
7	limbs	O
8	can	O
9	be	O
10	obtained	O
11	by	O
12	xeroradiography	O
13	after	O
14	rapid	O
15	manual	O
16	injection	O
17	of	O
18	contrast	O
19	-	O
20	medium	O
21	into	O
22	an	O
23	arm	O
24	vein	O
25	,	O
26	as	O
27	demonstrated	O
28	in	O
29	28	O
30	patients	O
31	.	O

1	These	O
2	and	O
3	other	O
4	data	O
5	presented	O
6	suggest	O
7	that	O
8	TAg	B
9	'	O
10	re	O
11	-	O
12	models	O
13	'	O
14	host	O
15	cell	O
16	transcription	O
17	factors	O
18	that	O
19	are	O
20	used	O
21	early	O
22	in	O
23	viral	O
24	infection	O
25	,	O
26	and	O
27	thereby	O
28	mimics	O
29	an	O
30	event	O
31	that	O
32	naturally	O
33	occurs	O
34	during	O
35	transformation	O
36	.	O

1	25	O
2	-	O
3	OH	O
4	-	O
5	D3	O
6	did	O
7	not	O
8	adversely	O
9	affect	O
10	animal	O
11	health	O
12	at	O
13	the	O
14	proposed	O
15	use	O
16	level	O
17	of	O
18	99	O
19	micrograms	O
20	/	O
21	kg	O
22	feed	O
23	when	O
24	replacing	O
25	vitamin	O
26	D3	O
27	in	O
28	turkey	O
29	rations	O
30	.	O

1	Regressing	O
2	microaneurysms	O
3	in	O
4	5	O
5	cases	O
6	of	O
7	hepatitis	O
8	B	O
9	virus	O
10	related	O
11	polyarteritis	O
12	nodosa	O
13	.	O

1	The	O
2	rCBF	O
3	ratio	O
4	was	O
5	mainly	O
6	reduced	O
7	in	O
8	frontal	O
9	lobes	O
10	(	O
11	65	O
12	%).	O

1	In	O
2	experiment	O
3	2	O
4	,	O
5	no	O
6	difference	O
7	in	O
8	gastric	O
9	emptying	O
10	of	O
11	40	O
12	%	O
13	peptone	O
14	or	O
15	25	O
16	%	O
17	glucose	O
18	was	O
19	found	O
20	between	O
21	rats	O
22	receiving	O
23	TPN	O
24	and	O
25	those	O
26	receiving	O
27	intragastric	O
28	nutrition	O
29	for	O
30	10	O
31	to	O
32	12	O
33	days	O
34	.	O

1	Rhizobium	O
2	meliloti	O
3	large	O
4	plasmid	O
5	pRmeGR4b	O
6	carries	O
7	the	O
8	nodulation	O
9	competitiveness	O
10	locus	O
11	nfe	B
12	responsible	O
13	for	O
14	the	O
15	nodulation	O
16	efficiency	O
17	and	O
18	competitive	O
19	ability	O
20	of	O
21	strain	O
22	GR4	O
23	on	O
24	alfalfa	O
25	roots	O
26	.	O

1	Shape	O
2	factor	O
3	correlated	O
4	well	O
5	with	O
6	hemodynamic	O
7	data	O
8	for	O
9	RV	O
10	/	O
11	LV	O
12	systolic	O
13	pressure	O
14	ratios	O
15	(	O
16	r	O
17	=	O
18	0	O
19	.	O
20	93	O
21	,	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	001	O
28	)	O
29	for	O
30	normalized	O
31	interventricular	O
32	pressure	O
33	differences	O
34	(	O
35	r	O
36	=	O
37	-	O
38	0	O
39	.	O
40	95	O
41	,	O
42	p	O
43	less	O
44	than	O
45	0	O
46	.	O
47	001	O
48	).	O

1	We	O
2	now	O
3	show	O
4	that	O
5	gp200	B
6	-	O
7	MR6	B
8	ligation	O
9	can	O
10	also	O
11	mimic	O
12	IL	B
13	-	I
14	4	I
15	and	O
16	have	O
17	an	O
18	anti	O
19	-	O
20	proliferative	O
21	pro	O
22	-	O
23	maturational	O
24	influence	O
25	within	O
26	the	O
27	immune	O
28	system	O
29	,	O
30	causing	O
31	up	O
32	-	O
33	regulation	O
34	of	O
35	co	O
36	-	O
37	stimulatory	O
38	molecules	O
39	on	O
40	B	O
41	lymphocytes	O
42	.	O

1	The	O
2	distal	O
3	portion	O
4	of	O
5	the	O
6	rat	B
7	insulin	I
8	I	I
9	gene	I
10	5	I
11	'-	I
12	flanking	I
13	DNA	I
14	contains	O
15	two	O
16	sequence	O
17	elements	O
18	,	O
19	the	O
20	Far	O
21	and	O
22	FLAT	O
23	elements	O
24	,	O
25	that	O
26	can	O
27	function	O
28	in	O
29	combination	O
30	,	O
31	but	O
32	not	O
33	separately	O
34	,	O
35	as	O
36	a	O
37	beta	O
38	-	O
39	cell	O
40	-	O
41	specific	O
42	transcriptional	O
43	enhancer	O
44	.	O

1	Polymerase	O
2	chain	O
3	reaction	O
4	analysis	O
5	of	O
6	ETS1	B
7	cDNA	I
8	identified	O
9	several	O
10	amplified	O
11	products	O
12	,	O
13	indicating	O
14	alternative	O
15	splicing	O
16	.	O

1	12	O
2	:	O
3	2684	O
4	-	O
5	2697	O
6	,	O
7	1998	O
8	):	O
9	a	O
10	key	O
11	step	O
12	of	O
13	this	O
14	model	O
15	is	O
16	the	O
17	activation	O
18	of	O
19	the	O
20	MAPK	B
21	Fus3p	I
22	through	O
23	the	O
24	G	O
25	(	O
26	betagamma	O
27	)-	O
28	dependent	O
29	relocalization	O
30	of	O
31	the	O
32	Ste5p	B
33	-	O
34	MAPK	B
35	cascade	O
36	to	O
37	the	O
38	plasma	O
39	membrane	O
40	.	O

1	Thus	O
2	,	O
3	prostacyclin	O
4	enhanced	O
5	the	O
6	autoregulative	O
7	property	O
8	of	O
9	the	O
10	inner	O
11	ear	O
12	vessels	O
13	.	O

1	Deletion	O
2	mapping	O
3	experiments	O
4	determined	O
5	that	O
6	the	O
7	sequences	O
8	required	O
9	for	O
10	full	O
11	activity	O
12	in	O
13	MSC	O
14	-	O
15	1	O
16	cells	O
17	were	O
18	included	O
19	within	O
20	619	O
21	bp	O
22	of	O
23	the	O
24	start	O
25	site	O
26	and	O
27	identified	O
28	several	O
29	regions	O
30	that	O
31	demonstrated	O
32	increased	O
33	luciferase	B
34	activity	O
35	:	O
36	the	O
37	-	O
38	583	O
39	bp	O
40	to	O
41	-	O
42	564	O
43	bp	O
44	,	O
45	-	O
46	503	O
47	bp	O
48	to	O
49	-	O
50	484	O
51	bp	O
52	,	O
53	and	O
54	-	O
55	114	O
56	bp	O
57	to	O
58	-	O
59	65	O
60	regions	O
61	.	O

1	Prognosis	O
2	of	O
3	asymptomatic	O
4	multiple	O
5	myeloma	O
6	.	O

1	Adrenergic	O
2	system	O
3	activation	O
4	,	O
5	indicated	O
6	by	O
7	metanephrine	O
8	/	O
9	epinephrine	O
10	ratio	O
11	,	O
12	increased	O
13	with	O
14	time	O
15	in	O
16	losing	O
17	males	O
18	,	O
19	except	O
20	that	O
21	after	O
22	one	O
23	month	O
24	of	O
25	cohabitation	O
26	,	O
27	turnover	O
28	returned	O
29	to	O
30	levels	O
31	that	O
32	equaled	O
33	those	O
34	of	O
35	control	O
36	animals	O
37	.	O

1	The	O
2	original	O
3	technique	O
4	was	O
5	developed	O
6	in	O
7	the	O
8	1960	O
9	'	O
10	s	O
11	to	O
12	analyze	O
13	the	O
14	inner	O
15	ear	O
16	fluid	O
17	as	O
18	a	O
19	diagnostic	O
20	procedure	O
21	(	O
22	i	O
23	.	O
24	e	O
25	.,	O
26	diagnostic	O
27	labyrinthotomy	O
28	)	O
29	in	O
30	acoustic	O
31	neuroma	O
32	suspects	O
33	.	O

1	Protein	B
2	S	I
3	levels	O
4	were	O
5	virtually	O
6	undetectable	O
7	at	O
8	the	O
9	time	O
10	of	O
11	admission	O
12	and	O
13	failed	O
14	to	O
15	respond	O
16	to	O
17	infusions	O
18	of	O
19	fresh	O
20	frozen	O
21	plasma	O
22	,	O
23	despite	O
24	correction	O
25	of	O
26	other	O
27	procoagulant	O
28	and	O
29	anticoagulant	O
30	factors	O
31	.	O

1	Unlike	O
2	wild	B
3	-	I
4	type	I
5	p53	I
6	,	O
7	the	O
8	delta	B
9	proAE	I
10	mutant	I
11	cDNA	I
12	can	O
13	be	O
14	stably	O
15	expressed	O
16	in	O
17	tumor	O
18	derived	O
19	cell	O
20	lines	O
21	with	O
22	few	O
23	immediate	O
24	detrimental	O
25	effects	O
26	.	O

1	Antisense	O
2	transcription	O
3	of	O
4	a	O
5	murine	B
6	FGFR	I
7	-	I
8	3	I
9	psuedogene	I
10	during	O
11	fetal	O
12	developement	O
13	.	O

1	The	O
2	rational	O
3	for	O
4	the	O
5	prophylactic	O
6	treatment	O
7	,	O
8	the	O
9	therapy	O
10	of	O
11	the	O
12	meningopathy	O
13	and	O
14	AIL	O
15	-	O
16	AIEOP	O
17	protocols	O
18	are	O
19	exposed	O
20	.	O

1	Such	O
2	transgenic	O
3	plants	O
4	should	O
5	enable	O
6	not	O
7	only	O
8	the	O
9	mutational	O
10	analysis	O
11	of	O
12	sequence	O
13	elements	O
14	within	O
15	the	O
16	replication	O
17	origin	O
18	region	O
19	,	O
20	but	O
21	also	O
22	the	O
23	construction	O
24	of	O
25	a	O
26	new	O
27	generation	O
28	of	O
29	vectors	O
30	for	O
31	gene	O
32	amplification	O
33	in	O
34	plants	O
35	,	O
36	based	O
37	on	O
38	a	O
39	minimal	O
40	virus	O
41	replicon	O
42	.	O

1	On	O
2	Days	O
3	1	O
4	and	O
5	14	O
6	,	O
7	most	O
8	young	O
9	and	O
10	elderly	O
11	subjects	O
12	exhibited	O
13	monoexponential	O
14	decline	O
15	in	O
16	bevantolol	O
17	plasma	O
18	concentrations	O
19	after	O
20	absorption	O
21	phase	O
22	.	O

1	Male	O
2	Japanese	O
3	quail	O
4	were	O
5	chronically	O
6	exposed	O
7	to	O
8	5000	O
9	ppm	O
10	manganese	O
11	(	O
12	Mn	O
13	)	O
14	as	O
15	particulate	O
16	manganese	O
17	oxide	O
18	(	O
19	Mn3O4	O
20	)	O
21	in	O
22	their	O
23	diet	O
24	from	O
25	hatching	O
26	to	O
27	75	O
28	days	O
29	of	O
30	age	O
31	.	O

1	These	O
2	experiments	O
3	delineate	O
4	a	O
5	186	O
6	-	O
7	bp	O
8	,	O
9	EBNA	B
10	-	I
11	2	I
12	-	O
13	responsive	O
14	cell	O
15	DNA	O
16	fragment	O
17	and	O
18	provide	O
19	firm	O
20	evidence	O
21	that	O
22	EBNA	B
23	-	I
24	2	I
25	transactivates	O
26	transcription	O
27	of	O
28	cell	O
29	genes	O
30	.	O

1	The	O
2	two	O
3	drugs	O
4	increase	O
5	the	O
6	rate	O
7	of	O
8	early	O
9	diastolic	O
10	filling	O
11	.	O

1	A	O
2	patient	O
3	with	O
4	an	O
5	infected	O
6	wound	O
7	or	O
8	one	O
9	on	O
10	a	O
11	primary	O
12	area	O
13	(	O
14	hands	O
15	,	O
16	feet	O
17	,	O
18	face	O
19	,	O
20	or	O
21	perineum	O
22	)	O
23	may	O
24	have	O
25	to	O
26	be	O
27	hospitalized	O
28	to	O
29	ensure	O
30	proper	O
31	care	O
32	.	O

1	Posttranslational	O
2	regulation	O
3	of	O
4	Ty1	B
5	retrotransposition	O
6	by	O
7	mitogen	B
8	-	I
9	activated	I
10	protein	I
11	kinase	I
12	Fus3	I
13	.	O

1	These	O
2	findings	O
3	indicate	O
4	that	O
5	hypergastrinemia	O
6	induced	O
7	by	O
8	surgical	O
9	removal	O
10	of	O
11	acid	O
12	-	O
13	producing	O
14	mucosa	O
15	in	O
16	the	O
17	rat	O
18	has	O
19	the	O
20	same	O
21	effects	O
22	on	O
23	oxyntical	O
24	mucosal	B
25	HDC	I
26	activity	O
27	,	O
28	histamine	O
29	concentration	O
30	and	O
31	ECL	O
32	cell	O
33	density	O
34	as	O
35	hypergastrinemia	O
36	induced	O
37	by	O
38	continuous	O
39	gastrin	B
40	infusion	O
41	or	O
42	by	O
43	long	O
44	-	O
45	term	O
46	treatment	O
47	with	O
48	effective	O
49	antisecretagogues	O
50	.	O

1	The	O
2	findings	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	iodine	O
8	deficiency	O
9	is	O
10	the	O
11	most	O
12	probable	O
13	cause	O
14	of	O
15	goiter	O
16	among	O
17	immigrants	O
18	of	O
19	the	O
20	1928	O
21	cohort	O
22	,	O
23	where	O
24	the	O
25	native	O
26	population	O
27	is	O
28	concerned	O
29	(	O
30	both	O
31	men	O
32	and	O
33	women	O
34	),	O
35	some	O
36	other	O
37	goitrogenic	O
38	factor	O
39	(	O
40	s	O
41	)	O
42	must	O
43	be	O
44	involved	O
45	.	O

1	Heat	O
2	-	O
3	inducible	O
4	CAT	B
5	activity	O
6	was	O
7	detectable	O
8	when	O
9	additional	O
10	sequences	O
11	from	O
12	the	O
13	native	O
14	promoter	O
15	containing	O
16	three	O
17	CCAAT	O
18	boxes	O
19	and	O
20	a	O
21	single	O
22	HSE	O
23	were	O
24	present	O
25	in	O
26	the	O
27	constructions	O
28	.	O

1	The	O
2	sequence	O
3	data	O
4	now	O
5	permit	O
6	a	O
7	detailed	O
8	interpretation	O
9	of	O
10	the	O
11	X	O
12	-	O
13	ray	O
14	crystallographic	O
15	structure	O
16	of	O
17	the	O
18	enzyme	O
19	and	O
20	the	O
21	cloning	O
22	and	O
23	expression	O
24	of	O
25	the	O
26	clostridial	O
27	gene	O
28	will	O
29	facilitate	O
30	site	O
31	-	O
32	directed	O
33	mutagenesis	O
34	.	O

1	This	O
2	newly	O
3	described	O
4	organism	O
5	was	O
6	difficult	O
7	to	O
8	identify	O
9	due	O
10	to	O
11	discrepancies	O
12	between	O
13	the	O
14	Vitek	O
15	and	O
16	API	O
17	20E	O
18	identification	O
19	systems	O
20	.	O

1	In	O
2	vitro	O
3	assessment	O
4	of	O
5	the	O
6	biocompatibility	O
7	of	O
8	dental	O
9	materials	O
10	--	O
11	the	O
12	millipore	O
13	filter	O
14	method	O
15	.	O

1	CREB	B
2	was	O
3	identified	O
4	as	O
5	one	O
6	of	O
7	the	O
8	protein	O
9	components	O
10	in	O
11	several	O
12	of	O
13	the	O
14	gel	O
15	shift	O
16	complexes	O
17	formed	O
18	with	O
19	the	O
20	variant	O
21	CRE	O
22	.	O

1	Proteasomes	O
2	are	O
3	the	O
4	multisubunit	O
5	protease	O
6	involved	O
7	in	O
8	the	O
9	generation	O
10	of	O
11	peptides	O
12	presented	O
13	by	O
14	MHC	B
15	class	I
16	I	I
17	molecules	I
18	.	O

1	The	O
2	rho	B
3	genes	I
4	comprise	O
5	an	O
6	evolutionarily	O
7	conserved	O
8	family	O
9	with	O
10	significant	O
11	homology	O
12	to	O
13	the	O
14	ras	B
15	oncogene	I
16	family	I
17	.	O

1	In	O
2	addition	O
3	,	O
4	depletion	O
5	of	O
6	Oct	B
7	-	I
8	1	I
9	from	O
10	the	O
11	nuclear	O
12	extract	O
13	by	O
14	using	O
15	Oct	B
16	-	I
17	1	I
18	-	O
19	specific	O
20	antiserum	O
21	or	O
22	a	O
23	sequence	O
24	-	O
25	specific	O
26	DNA	O
27	affinity	O
28	resin	O
29	decreased	O
30	in	O
31	vitro	O
32	transcription	O
33	from	O
34	the	O
35	wild	O
36	-	O
37	type	O
38	MMTV	O
39	promoter	O
40	to	O
41	a	O
42	level	O
43	identical	O
44	to	O
45	that	O
46	obtained	O
47	from	O
48	a	O
49	promoter	O
50	in	O
51	which	O
52	all	O
53	three	O
54	octamer	O
55	-	O
56	related	O
57	sequences	O
58	were	O
59	mutated	O
60	.	O

1	Positive	O
2	shifts	O
3	of	O
4	basal	O
5	skin	O
6	potentials	O
7	during	O
8	human	O
9	sleep	O
10	.	O

1	Of	O
2	110	O
3	previously	O
4	untreated	O
5	patients	O
6	who	O
7	had	O
8	entered	O
9	the	O
10	study	O
11	of	O
12	protocol	O
13	TCL821	O
14	,	O
15	96	O
16	were	O
17	evaluable	O
18	.	O

1	The	O
2	following	O
3	markers	O
4	were	O
5	looked	O
6	for	O
7	in	O
8	the	O
9	serum	O
10	,	O
11	skin	O
12	and	O
13	liver	O
14	of	O
15	all	O
16	patients	O
17	with	O
18	chronic	O
19	hepatitis	O
20	:	O
21	HBV	O
22	(	O
23	HBs	B
24	Ag	I
25	and	O
26	HBe	B
27	Ag	I
28	,	O
29	anti	B
30	-	I
31	HBs	I
32	,	O
33	anti	B
34	-	I
35	HBe	I
36	and	O
37	anti	B
38	-	I
39	HBc	I
40	in	O
41	the	O
42	serum	O
43	,	O
44	HBs	B
45	and	I
46	HBc	I
47	Ag	I
48	in	O
49	the	O
50	liver	O
51	);	O
52	non	B
53	-	I
54	A	I
55	non	I
56	-	I
57	B	I
58	(	O
59	non	B
60	-	I
61	A	I
62	,	I
63	non	I
64	-	I
65	B	I
66	Ag	I
67	and	I
68	antibody	I
69	,	O
70	anti	B
71	non	I
72	-	I
73	A	I
74	non	I
75	-	I
76	Bc	I
77	in	O
78	the	O
79	serum	O
80	,	O
81	non	B
82	-	I
83	A	I
84	,	I
85	non	I
86	-	I
87	Bc	I
88	Ag	I
89	in	O
90	the	O
91	liver	O
92	).	O

1	Urinary	O
2	excretion	O
3	of	O
4	oestrone	O
5	,	O
6	oestradiol	O
7	-	O
8	17	O
9	beta	O
10	and	O
11	oestriol	O
12	in	O
13	pregnancies	O
14	complicated	O
15	by	O
16	steroid	B
17	sulphatase	I
18	deficiency	O
19	.	O

1	In	O
2	an	O
3	ongoing	O
4	study	O
5	the	O
6	performance	O
7	of	O
8	the	O
9	SMSP	O
10	is	O
11	being	O
12	compared	O
13	with	O
14	that	O
15	of	O
16	the	O
17	Mini	O
18	Speech	O
19	Processor	O
20	(	O
21	MSP	O
22	).	O

1	Chem	O
2	.	O

1	Probable	O
2	progressive	O
3	multifocal	O
4	leukoencephalopathy	O
5	(	O
6	PML	O
7	)	O
8	was	O
9	diagnosed	O
10	on	O
11	the	O
12	basis	O
13	of	O
14	clinical	O
15	picture	O
16	and	O
17	magnetic	O
18	resonance	O
19	imaging	O
20	in	O
21	a	O
22	63	O
23	-	O
24	year	O
25	-	O
26	old	O
27	man	O
28	with	O
29	a	O
30	complete	O
31	remission	O
32	of	O
33	a	O
34	non	O
35	-	O
36	Hodgkin	O
37	'	O
38	s	O
39	lymphoma	O
40	.	O

1	The	O
2	matrix	O
3	surrounding	O
4	the	O
5	clusters	O
6	either	O
7	showed	O
8	a	O
9	normal	O
10	morphology	O
11	or	O
12	a	O
13	homogeneous	O
14	appearance	O
15	,	O
16	within	O
17	which	O
18	faint	O
19	cross	O
20	striations	O
21	but	O
22	no	O
23	distinctly	O
24	fibrillar	O
25	outlines	O
26	could	O
27	be	O
28	identified	O
29	.	O

1	The	O
2	proteins	O
3	differ	O
4	in	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	of	O
10	a	O
11	21	O
12	-	O
13	amino	O
14	-	O
15	acid	O
16	sequence	O
17	located	O
18	24	O
19	amino	O
20	acids	O
21	C	O
22	terminal	O
23	of	O
24	the	O
25	translational	O
26	initiation	O
27	codon	O
28	.	O

1	Early	O
2	disagnosis	O
3	of	O
4	cancer	O
5	--	O
6	50	O
7	per	O
8	cent	O
9	of	O
10	all	O
11	patients	O
12	could	O
13	be	O
14	cured	O

1	The	O
2	effects	O
3	of	O
4	two	O
5	levels	O
6	of	O
7	caffeine	O
8	ingestion	O
9	on	O
10	excess	O
11	postexercise	O
12	oxygen	O
13	consumption	O
14	in	O
15	untrained	O
16	women	O
17	.	O

1	Metal	O
2	coordination	O
3	compounds	O
4	of	O
5	thiabendazole	O
6	.	O

1	Expression	O
2	of	O
3	the	O
4	mouse	B
5	TSH	I
6	beta	I
7	gene	I
8	,	O
9	therefore	O
10	,	O
11	gives	O
12	rise	O
13	to	O
14	multiple	O
15	mRNAs	O
16	,	O
17	each	O
18	with	O
19	a	O
20	unique	O
21	5	O
22	'-	O
23	untranslated	O
24	region	O
25	.	O

1	Comparison	O
2	of	O
3	genomic	O
4	sequence	O
5	shows	O
6	that	O
7	the	O
8	ph	B
9	locus	I
10	has	O
11	been	O
12	duplicated	O
13	,	O
14	and	O
15	that	O
16	it	O
17	contains	O
18	proximal	O
19	and	O
20	distal	O
21	transcription	O
22	units	O
23	.	O

1	Striking	O
2	sequence	O
3	similarities	O
4	(	O
5	57	O
6	and	O
7	53	O
8	%)	O
9	were	O
10	observed	O
11	with	O
12	yeast	O
13	mitochondrial	O
14	proteins	O
15	,	O
16	SMF1	B
17	and	O
18	SMF2	B
19	,	O
20	especially	O
21	within	O
22	putative	O
23	functional	O
24	domains	O
25	:	O
26	exon	O
27	6	O
28	encoding	O
29	the	O
30	second	O
31	transmembrane	O
32	spanning	O
33	domain	O
34	,	O
35	site	O
36	of	O
37	the	O
38	murine	B
39	susceptibility	I
40	mutation	O
41	;	O
42	and	O
43	exon	O
44	11	O
45	encoding	O
46	a	O
47	conserved	O
48	transport	O
49	motif	O
50	.	O

1	Because	O
2	of	O
3	serious	O
4	infections	O
5	(	O
6	fever	O
7	larger	O
8	than	O
9	or	O
10	equal	O
11	to	O
12	101	O
13	degrees	O
14	F	O
15	.	O
16	granulocytes	O
17	less	O
18	than	O
19	1	O
20	,	O
21	000	O
22	/	O
23	mm	O
24	,	O
25	3	O
26	and	O
27	hospitalization	O
28	)	O
29	and	O
30	1	O
31	drug	O
32	death	O
33	in	O
34	the	O
35	first	O
36	4	O
37	patients	O
38	,	O
39	oral	O
40	calcium	O
41	leucovorin	O
42	,	O
43	20	O
44	to	O
45	30	O
46	mg	O
47	/	O
48	m2	O
49	orally	O
50	,	O
51	was	O
52	given	O
53	2	O
54	days	O
55	after	O
56	methotrexate	O
57	in	O
58	subsequent	O
59	treatment	O
60	cycles	O
61	.	O

1	Three	O
2	classes	O
3	of	O
4	test	O
5	objects	O
6	were	O
7	considered	O
8	:	O
9	(	O
10	1	O
11	)	O
12	a	O
13	multicompartment	O
14	test	O
15	object	O
16	for	O
17	31P	O
18	MRS	O
19	measurements	O
20	performed	O
21	with	O
22	slice	O
23	-	O
24	selective	O
25	sequences	O
26	;	O
27	(	O
28	2	O
29	)	O
30	a	O
31	two	O
32	-	O
33	compartment	O
34	test	O
35	object	O
36	for	O
37	volume	O
38	-	O
39	selection	O
40	1H	O
41	MRS	O
42	;	O
43	and	O
44	(	O
45	3	O
46	)	O
47	two	O
48	-	O
49	compartment	O
50	test	O
51	objects	O
52	for	O
53	assessing	O
54	the	O
55	performance	O
56	of	O
57	experimental	O
58	systems	O
59	using	O
60	ISIS	O
61	as	O
62	volume	O
63	localization	O
64	sequence	O
65	in	O
66	31P	O
67	MRS	O
68	.	O

1	A	O
2	large	O
3	deletion	O
4	in	O
5	the	O
6	CTD	B
7	-	I
8	binding	I
9	motif	I
10	blocks	O
11	down	O
12	-	O
13	regulation	O
14	but	O
15	does	O
16	not	O
17	affect	O
18	the	O
19	essential	O
20	function	O
21	of	O
22	Nrd1	B
23	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	showed	O
5	that	O
6	the	O
7	gene	O
8	was	O
9	525	O
10	bp	O
11	long	O
12	and	O
13	encoded	O
14	a	O
15	175	O
16	-	O
17	amino	O
18	-	O
19	acid	O
20	protein	O
21	with	O
22	a	O
23	molecular	O
24	weight	O
25	of	O
26	19	O
27	,	O
28	094	O
29	containing	O
30	a	O
31	21	O
32	-	O
33	residue	O
34	typical	O
35	lipoprotein	O
36	signal	O
37	peptide	O
38	and	O
39	consensus	O
40	prolipoprotein	O
41	processing	O
42	site	O
43	.	O

1	The	O
2	human	B
3	p100	I
4	protein	I
5	was	O
6	recently	O
7	identified	O
8	as	O
9	a	O
10	coactivator	O
11	of	O
12	the	O
13	Epstein	B
14	-	I
15	Barr	I
16	virus	I
17	nuclear	I
18	antigen	I
19	2	I
20	.	O

1	The	O
2	reduced	O
3	efficiency	O
4	in	O
5	the	O
6	glycosylase	B
7	activity	O
8	is	O
9	also	O
10	reflected	O
11	in	O
12	a	O
13	reduced	O
14	ability	O
15	of	O
16	S120K	B
17	MutY	I
18	to	O
19	prevent	O
20	DNA	O
21	mutations	O
22	in	O
23	vivo	O
24	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	P19	O
6	cells	O
7	revealed	O
8	that	O
9	expression	O
10	of	O
11	NDRF	B
12	/	O
13	NeuroD2	B
14	increased	O
15	the	O
16	transactivation	O
17	of	O
18	the	O
19	rat	B
20	insulin	I
21	promoter	I
22	element	I
23	3	I
24	(	O
25	RIPE3	B
26	)	O
27	enhancer	O
28	up	O
29	to	O
30	approximately	O
31	12	O
32	-	O
33	fold	O
34	and	O
35	that	O
36	co	O
37	-	O
38	expression	O
39	of	O
40	catalytically	O
41	active	O
42	form	O
43	of	O
44	PKN	B
45	,	O
46	but	O
47	not	O
48	kinase	O
49	-	O
50	deficient	O
51	derivative	O
52	,	O
53	resulted	O
54	in	O
55	a	O
56	further	O
57	threefold	O
58	increase	O
59	of	O
60	NDRF	B
61	/	O
62	NeuroD2	B
63	-	O
64	mediated	O
65	transcription	O
66	.	O

1	The	O
2	network	O
3	evolution	O
4	was	O
5	interpreted	O
6	by	O
7	an	O
8	approach	O
9	based	O
10	on	O
11	the	O
12	Flory	O
13	model	O
14	.	O

1	If	O
2	this	O
3	is	O
4	present	O
5	,	O
6	such	O
7	patients	O
8	should	O
9	be	O
10	closely	O
11	monitored	O
12	,	O
13	and	O
14	any	O
15	atypical	O
16	lesions	O
17	biopsied	O
18	.	O

1	This	O
2	exon	O
3	,	O
4	here	O
5	named	O
6	exon	O
7	0	O
8	,	O
9	contained	O
10	the	O
11	entire	O
12	5	O
13	'	O
14	untranslated	O
15	region	O
16	and	O
17	the	O
18	N	O
19	-	O
20	terminal	O
21	signal	O
22	sequence	O
23	of	O
24	the	O
25	polypeptide	O
26	.	O

1	Since	O
2	the	O
3	integrated	O
4	13h00	O
5	-	O
6	16h00	O
7	plasma	O
8	cortisol	O
9	estimation	O
10	is	O
11	cheaper	O
12	and	O
13	simpler	O
14	than	O
15	the	O
16	mean	O
17	13h00	O
18	-	O
19	16h00	O
20	plasma	O
21	cortisol	O
22	estimation	O
23	,	O
24	we	O
25	recommend	O
26	it	O
27	as	O
28	an	O
29	adjunct	O
30	in	O
31	the	O
32	diagnosis	O
33	of	O
34	Cushing	O
35	'	O
36	s	O
37	syndrome	O
38	.	O

1	Studies	O
2	of	O
3	lipogenesis	O
4	by	O
5	labelled	O
6	precursors	O
7	in	O
8	the	O
9	pregnant	O
10	rat	O
11	.	O

1	Several	O
2	7SL	B
3	RNA	I
4	-	I
5	encoding	I
6	sequences	I
7	and	O
8	various	O
9	intergenic	O
10	spacers	O
11	were	O
12	amplified	O
13	from	O
14	the	O
15	individual	O
16	HindIII	B
17	fragments	I
18	of	O
19	about	O
20	1	O
21	.	O
22	3	O
23	and	O
24	2	O
25	.	O
26	8	O
27	kb	O
28	.	O

1	The	O
2	complete	O
3	response	O
4	(	O
5	CR	O
6	)	O
7	rate	O
8	was	O
9	34	O
10	%	O
11	in	O
12	the	O
13	CODE	O
14	with	O
15	rhG	B
16	-	I
17	CSF	I
18	group	O
19	and	O
20	23	O
21	%	O
22	in	O
23	the	O
24	CODE	O
25	alone	O
26	group	O
27	;	O
28	the	O
29	median	O
30	survival	O
31	was	O
32	59	O
33	and	O
34	32	O
35	weeks	O
36	,	O
37	respectively	O
38	,	O
39	in	O
40	these	O
41	groups	O
42	(	O
43	P	O
44	=	O
45	0	O
46	.	O
47	004	O
48	).	O

1	These	O
2	mutants	O
3	grow	O
4	normally	O
5	in	O
6	3T6	O
7	mouse	O
8	fibroblast	O
9	cells	O
10	,	O
11	and	O
12	they	O
13	do	O
14	not	O
15	complement	O
16	the	O
17	wild	O
18	-	O
19	type	O
20	virus	O
21	in	O
22	coinfection	O
23	experiments	O
24	of	O
25	C2	O
26	myoblasts	O
27	.	O

1	Immunoglobulin	B
2	light	I
3	chain	I
4	(	O
5	IgL	B
6	)	O
7	diversity	O
8	is	O
9	generated	O
10	in	O
11	the	O
12	chicken	O
13	by	O
14	recombination	O
15	between	O
16	the	O
17	single	O
18	functional	O
19	variable	O
20	(	O
21	VL	B
22	)	O
23	and	O
24	joining	O
25	(	O
26	JL	B
27	)	O
28	gene	O
29	segments	O
30	and	O
31	subsequent	O
32	somatic	O
33	diversification	O
34	of	O
35	the	O
36	rearranged	O
37	VL	B
38	region	O
39	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	of	O
5	a	O
6	3213	O
7	bp	O
8	BamHI	B
9	-	O
10	ClaI	B
11	fragment	O
12	revealed	O
13	that	O
14	three	O
15	open	O
16	reading	O
17	frames	O
18	(	O
19	ORFs	O
20	)	O
21	were	O
22	encoded	O
23	in	O
24	the	O
25	same	O
26	orientation	O
27	.	O

1	SNAC	O
2	or	O
3	PBS	O
4	was	O
5	infused	O
6	for	O
7	6	O
8	.	O
9	5	O
10	h	O
11	,	O
12	beginning	O
13	30	O
14	min	O
15	before	O
16	ischemia	O
17	and	O
18	continuing	O
19	throughout	O
20	the	O
21	duration	O
22	of	O
23	reperfusion	O
24	.	O

1	Before	O
2	turnout	O
3	,	O
4	a	O
5	morantel	O
6	sustained	O
7	release	O
8	bolus	O
9	(	O
10	MSRB	O
11	)	O
12	was	O
13	administered	O
14	to	O
15	each	O
16	animal	O
17	in	O
18	the	O
19	"	O
20	treated	O
21	"	O
22	category	O
23	.	O

1	Hyperthyroidism	O
2	is	O
3	one	O
4	of	O
5	the	O
6	numerous	O
7	causes	O
8	of	O
9	infertility	O
10	and	O
11	recurrent	O
12	abortion	O
13	.	O

1	I	O
2	.	O

1	Initiation	O
2	of	O
3	translation	O
4	of	O
5	the	O
6	human	O
7	hepatitis	O
8	C	O
9	virus	O
10	(	O
11	HCV	O
12	)	O
13	RNA	O
14	genome	O
15	occurs	O
16	by	O
17	internal	O
18	ribosome	O
19	entry	O
20	into	O
21	the	O
22	5	O
23	'	O
24	noncoding	O
25	region	O
26	(	O
27	5	O
28	'	O
29	NCR	O
30	)	O
31	in	O
32	a	O
33	cap	O
34	-	O
35	independent	O
36	manner	O
37	.	O

1	We	O
2	also	O
3	identified	O
4	Sp1	B
5	,	O
6	Sp3	B
7	,	O
8	and	O
9	NGFI	B
10	-	I
11	A	I
12	/	O
13	Egr	B
14	-	I
15	1	I
16	as	O
17	the	O
18	primary	O
19	nuclear	O
20	transcription	O
21	factors	O
22	binding	O
23	to	O
24	TRE1	B
25	which	O
26	mediate	O
27	Tax	B
28	responsiveness	O
29	.	O

1	We	O
2	were	O
3	interested	O
4	in	O
5	studying	O
6	the	O
7	relationship	O
8	between	O
9	the	O
10	circadian	O
11	rhythm	O
12	in	O
13	body	O
14	temperature	O
15	and	O
16	24	O
17	-	O
18	h	O
19	variations	O
20	in	O
21	plasma	O
22	concentrations	O
23	of	O
24	iron	O
25	,	O
26	zinc	O
27	,	O
28	circulating	O
29	leukocyte	O
30	counts	O
31	,	O
32	and	O
33	plasma	O
34	interleukin	B
35	1	I
36	(	O
37	IL	B
38	-	I
39	1	I
40	)	O
41	activity	O
42	.	O

1	The	O
2	majority	O
3	of	O
4	the	O
5	cases	O
6	with	O
7	0	O
8	-	O
9	I	O
10	or	O
11	0	O
12	-	O
13	III	O
14	components	O
15	were	O
16	sm	O
17	.	O
18	cancer	O
19	.	O

1	This	O
2	structure	O
3	of	O
4	cucumisin	B
5	suggests	O
6	that	O
7	it	O
8	is	O
9	probably	O
10	synthesized	O
11	as	O
12	an	O
13	inactive	O
14	precursor	O
15	.	O

1	Gel	O
2	mobility	O
3	shift	O
4	assays	O
5	using	O
6	a	O
7	synthetic	O
8	E6	B
9	motif	I
10	detected	O
11	a	O
12	B	O
13	-	O
14	cell	O
15	-	O
16	specific	O
17	complex	O
18	in	O
19	addition	O
20	to	O
21	a	O
22	ubiquitous	O
23	band	O
24	found	O
25	also	O
26	in	O
27	T	O
28	cells	O
29	and	O
30	HeLa	O
31	cells	O
32	.	O

1	CDC31	B
2	is	O
3	required	O
4	for	O
5	SPB	O
6	duplication	O
7	and	O
8	encodes	O
9	a	O
10	calmodulin	B
11	-	I
12	like	I
13	protein	I
14	that	O
15	is	O
16	most	O
17	closely	O
18	related	O
19	to	O
20	caltractin	B
21	/	O
22	centrin	B
23	,	O
24	a	O
25	protein	O
26	associated	O
27	with	O
28	the	O
29	Chlamydomonas	O
30	basal	O
31	body	O
32	.	O

1	Two	O
2	predominant	O
3	effects	O
4	were	O
5	noted	O
6	:	O
7	(	O
8	i	O
9	)	O
10	the	O
11	Xaa	O
12	residue	O
13	in	O
14	the	O
15	dual	O
16	phosphorylation	O
17	motif	O
18	Thr	O
19	-	O
20	Xaa	O
21	-	O
22	Tyr	O
23	as	O
24	well	O
25	as	O
26	the	O
27	length	O
28	of	O
29	L12	O
30	influence	O
31	p38	B
32	substrate	O
33	specificity	O
34	,	O
35	and	O
36	(	O
37	ii	O
38	)	O
39	the	O
40	length	O
41	of	O
42	L12	O
43	plays	O
44	a	O
45	major	O
46	role	O
47	in	O
48	controlling	O
49	autophosphorylation	O
50	.	O

1	STUDY	O
2	DESIGN	O
3	:	O
4	Fine	O
5	needle	O
6	aspiration	O
7	cytologic	O
8	smears	O
9	from	O
10	21	O
11	cases	O
12	of	O
13	invasive	O
14	lobular	O
15	carcinoma	O
16	(	O
17	ILC	O
18	)	O
19	of	O
20	breast	O
21	were	O
22	subjected	O
23	to	O
24	detailed	O
25	cytomorphologic	O
26	analysis	O
27	.	O

1	A	O
2	favourable	O
3	response	O
4	was	O
5	achieved	O
6	with	O
7	a	O
8	combination	O
9	of	O
10	amphotericin	O
11	B	O
12	and	O
13	cotrimoxazole	O
14	.	O

1	Chlamydial	O
2	agents	O
3	were	O
4	isolated	O
5	from	O
6	the	O
7	semen	O
8	near	O
9	the	O
10	end	O
11	of	O
12	the	O
13	chlamydemic	O
14	phase	O
15	.	O

1	A	O
2	single	O
3	case	O
4	of	O
5	an	O
6	adenocarcinoma	O
7	,	O
8	arising	O
9	in	O
10	a	O
11	retroperitoneal	O
12	enterogenous	O
13	cyst	O
14	and	O
15	which	O
16	presented	O
17	as	O
18	a	O
19	left	O
20	renal	O
21	cyst	O
22	,	O
23	is	O
24	reported	O
25	.	O

1	The	O
2	standard	O
3	dosage	O
4	of	O
5	anti	B
6	-	I
7	D	I
8	currently	O
9	given	O
10	at	O
11	all	O
12	gestational	O
13	ages	O
14	is	O
15	1	O
16	ampoule	O
17	containing	O
18	125	O
19	micrograms	O
20	of	O
21	anti	B
22	-	I
23	D	I
24	.	O

1	Tl	O
2	-	O
3	201	O
4	uptake	O
5	ratio	O
6	of	O
7	the	O
8	right	O
9	ventricle	O
10	,	O
11	which	O
12	represents	O
13	the	O
14	ratio	O
15	of	O
16	total	O
17	counts	O
18	of	O
19	the	O
20	right	O
21	ventricle	O
22	to	O
23	counts	O
24	of	O
25	the	O
26	administered	O
27	dose	O
28	of	O
29	Tl	O
30	-	O
31	201	O
32	,	O
33	was	O
34	higher	O
35	in	O
36	COPD	O
37	,	O
38	especially	O
39	in	O
40	pulmonary	O
41	emphysema	O
42	and	O
43	B	O
44	type	O
45	COPD	O
46	by	O
47	Burrows	O
48	classification	O
49	than	O
50	in	O
51	controls	O
52	.	O

1	The	O
2	mean	O
3	extracted	O
4	concentration	O
5	of	O
6	flucloxacillin	O
7	obtained	O
8	at	O
9	operation	O
10	was	O
11	12	O
12	.	O
13	9	O
14	micrograms	O
15	/	O
16	ml	O
17	(	O
18	SD	O
19	5	O
20	.	O
21	25	O
22	)	O
23	in	O
24	synovial	O
25	fluid	O
26	;	O
27	2	O
28	.	O
29	9	O
30	micrograms	O
31	/	O
32	g	O
33	(	O
34	SD	O
35	3	O
36	.	O
37	59	O
38	)	O
39	in	O
40	synovium	O
41	;	O
42	2	O
43	.	O
44	0	O
45	micrograms	O
46	/	O
47	g	O
48	(	O
49	SD	O
50	1	O
51	.	O
52	48	O
53	)	O
54	in	O
55	cancellous	O
56	bone	O
57	and	O
58	1	O
59	.	O
60	3	O
61	micrograms	O
62	/	O
63	g	O
64	(	O
65	SD	O
66	1	O
67	.	O
68	25	O
69	)	O
70	in	O
71	cortical	O
72	bone	O
73	.	O

1	Diagnosis	O
2	of	O
3	unilateral	O
4	renal	O
5	artery	O
6	lesions	O
7	after	O
8	captopril	O
9	administration	O
10	.	O

1	Similarly	O
2	,	O
3	expression	O
4	of	O
5	a	O
6	transiently	O
7	transfected	O
8	wild	B
9	-	I
10	type	I
11	prothymosin	I
12	alpha	I
13	gene	I
14	as	O
15	the	O
16	reporter	O
17	was	O
18	not	O
19	affected	O
20	by	O
21	a	O
22	repertoire	O
23	of	O
24	myc	B
25	-	I
26	derived	I
27	genes	I
28	,	O
29	including	O
30	myc	B
31	itself	O
32	and	O
33	dominant	O
34	or	O
35	recessive	O
36	negative	O
37	myc	B
38	mutants	I
39	.	O

1	The	O
2	sequenced	O
3	cDNA	O
4	predicts	O
5	a	O
6	704	O
7	-	O
8	amino	O
9	acid	O
10	protein	O
11	80	O
12	%	O
13	identical	O
14	to	O
15	human	B
16	progelatinase	I
17	B	I
18	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	tested	O
7	this	O
8	notion	O
9	by	O
10	using	O
11	ligation	O
12	-	O
13	mediated	O
14	PCR	O
15	to	O
16	assess	O
17	the	O
18	formation	O
19	of	O
20	recombination	B
21	-	I
22	activating	I
23	gene	I
24	(	O
25	RAG	B
26	)-	O
27	dependent	O
28	double	O
29	-	O
30	strand	O
31	breaks	O
32	(	O
33	DSBs	O
34	)	O
35	at	O
36	RSSs	O
37	3	O
38	'	O
39	of	O
40	Ddelta3	B
41	and	O
42	5	O
43	'	O
44	of	O
45	Jdelta1	B
46	.	O

1	Refined	O
2	Cox	O
3	models	O
4	using	O
5	a	O
6	CD4	B
7	count	O
8	of	O
9	150	O
10	/	O
11	microL	O
12	rather	O
13	than	O
14	200	O
15	/	O
16	microL	O
17	to	O
18	distinguish	O
19	I0	O
20	and	O
21	I1	O
22	yielded	O
23	a	O
24	simplified	O
25	model	O
26	with	O
27	better	O
28	fit	O
29	to	O
30	the	O
31	observed	O
32	data	O
33	.	O

1	TMBr	B
2	-	I
3	1	I
4	is	O
5	identical	O
6	to	O
7	striated	B
8	muscle	I
9	alpha	I
10	-	I
11	tropomyosin	I
12	from	O
13	amino	O
14	acids	O
15	1	O
16	through	O
17	258	O
18	but	O
19	contains	O
20	a	O
21	novel	O
22	COOH	O
23	-	O
24	terminal	O
25	region	O
26	from	O
27	amino	O
28	acids	O
29	259	O
30	through	O
31	281	O
32	.	O

1	The	O
2	colony	B
3	-	I
4	stimulating	I
5	factors	I
6	(	O
7	CSFs	B
8	)	O
9	principally	O
10	involved	O
11	in	O
12	the	O
13	production	O
14	of	O
15	neutrophils	O
16	and	O
17	monocytes	O
18	are	O
19	granulocyte	B
20	CSF	I
21	,	O
22	granulocyte	B
23	-	I
24	macrophage	I
25	CSF	I
26	,	O
27	macrophage	B
28	CSF	I
29	,	O
30	and	O
31	interleukin	B
32	3	I
33	(	O
34	sometimes	O
35	called	O
36	multi	B
37	-	I
38	CSF	I
39	).	O

1	A	O
2	cause	O
3	of	O
4	increase	O
5	of	O
6	alkaline	B
7	phosphatase	I
8	in	O
9	children	O

1	D	O
2	.	O
3	melanogaster	O
4	HeT	B
5	-	I
6	A	I
7	coding	O
8	sequences	O
9	have	O
10	a	O
11	polymorphic	O
12	region	O
13	with	O
14	insertions	O
15	/	O
16	deletions	O
17	of	O
18	1	O
19	-	O
20	31	O
21	codons	O
22	and	O
23	many	O
24	nucleotide	O
25	changes	O
26	.	O

1	Amisulpride	O
2	400	O
3	mg	O
4	had	O
5	several	O
6	adverse	O
7	effects	O
8	on	O
9	psychomotor	O
10	and	O
11	,	O
12	although	O
13	less	O
14	severe	O
15	,	O
16	on	O
17	cognitive	O
18	performance	O
19	on	O
20	the	O
21	fifth	O
22	day	O
23	only	O
24	.	O

1	However	O
2	,	O
3	five	O
4	new	O
5	mutation	O
6	sites	O
7	(	O
8	S61	B
9	,	O
10	SL1	B
11	,	O
12	S29	B
13	,	O
14	SL11	B
15	,	O
16	SL196	B
17	and	O
18	SL126	B
19	)	O
20	are	O
21	unique	O
22	to	O
23	the	O
24	nrdB	B
25	intron	O
26	and	O
27	disrupt	O
28	self	O
29	-	O
30	splicing	O
31	.	O

1	Upon	O
2	analysis	O
3	of	O
4	the	O
5	tissue	O
6	distribution	O
7	of	O
8	AAMP	B
9	,	O
10	it	O
11	was	O
12	found	O
13	to	O
14	be	O
15	expressed	O
16	strongly	O
17	in	O
18	endothelial	O
19	cells	O
20	,	O
21	cytotrophoblasts	O
22	,	O
23	and	O
24	poorly	O
25	differentiated	O
26	colon	O
27	adenocarcinoma	O
28	cells	O
29	found	O
30	in	O
31	lymphatics	O
32	.	O

1	As	O
2	in	O
3	the	O
4	other	O
5	three	O
6	members	O
7	whose	O
8	gene	O
9	expression	O
10	is	O
11	altered	O
12	during	O
13	tumorigenesis	O
14	,	O
15	PI12	B
16	expression	O
17	was	O
18	found	O
19	to	O
20	be	O
21	down	O
22	-	O
23	regulated	O
24	in	O
25	tumor	O
26	brain	O
27	tissues	O
28	and	O
29	in	O
30	two	O
31	brain	O
32	cancer	O
33	cell	O
34	lines	O
35	:	O
36	U	O
37	-	O
38	87	O
39	MG	O
40	and	O
41	H4	O
42	.	O

1	The	O
2	mei4	B
3	+	I
4	gene	I
5	of	O
6	the	O
7	fission	O
8	yeast	O
9	Schizosaccharomyces	O
10	pombe	O
11	was	O
12	cloned	O
13	by	O
14	functional	O
15	complementation	O
16	.	O

1	Three	O
2	ORFs	O
3	(	O
4	9765orfR002	O
5	,	O
6	9765orfR011	O
7	and	O
8	9765orfR013	O
9	)	O
10	were	O
11	found	O
12	to	O
13	be	O
14	homologous	O
15	with	O
16	Schizosaccharomyces	O
17	pombe	O
18	polyadenylate	B
19	binding	I
20	protein	I
21	,	O
22	Escherichia	O
23	coli	O
24	hypothetical	O
25	38	O
26	.	O
27	1	O
28	-	O
29	kDa	O
30	protein	O
31	in	O
32	the	O
33	BCR	B
34	5	O
35	'	O
36	region	O
37	,	O
38	and	O
39	transcription	O
40	regulatory	O
41	protein	O
42	Swi3	B
43	,	O
44	respectively	O
45	.	O

1	Differential	O
2	expression	O
3	and	O
4	regulation	O
5	by	O
6	20	O
7	-	O
8	hydroxyecdysone	O
9	of	O
10	mosquito	O
11	ultraspiracle	O
12	isoforms	O
13	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	Studies	O
6	were	O
7	undertaken	O
8	in	O
9	9	O
10	isolated	O
11	guinea	O
12	pig	O
13	hearts	O
14	,	O
15	which	O
16	demonstrated	O
17	reverse	O
18	use	O
19	-	O
20	dependent	O
21	prolongation	O
22	of	O
23	cardiac	O
24	repolarization	O
25	by	O
26	100	O
27	nmol	O
28	/	O
29	L	O
30	domperidone	O
31	.	O

1	During	O
2	the	O
3	last	O
4	6	O
5	months	O
6	of	O
7	the	O
8	study	O
9	a	O
10	striking	O
11	change	O
12	in	O
13	epidemiology	O
14	concerning	O
15	hepatitis	O
16	A	O
17	was	O
18	seen	O
19	,	O
20	apparently	O
21	caused	O
22	by	O
23	a	O
24	steep	O
25	increase	O
26	in	O
27	the	O
28	incidence	O
29	of	O
30	this	O
31	type	O
32	of	O
33	hepatitis	O
34	among	O
35	drug	O
36	addicts	O
37	.	O

1	Dilutions	O
2	of	O
3	H	B
4	-	I
5	2b	I
6	or	I
7	H	I
8	-	I
9	2d	I
10	NP	I
11	peptides	I
12	indicated	O
13	that	O
14	3	O
15	-	O
16	4	O
17	logs	O
18	less	O
19	H	B
20	-	I
21	2b	I
22	NP	I
23	peptide	I
24	was	O
25	required	O
26	to	O
27	sensitize	O
28	syngeneic	O
29	target	O
30	cells	O
31	for	O
32	CTL	O
33	-	O
34	specific	O
35	lysis	O
36	,	O
37	suggesting	O
38	that	O
39	the	O
40	differing	O
41	affinities	O
42	of	O
43	H	O
44	-	O
45	2b	O
46	and	O
47	H	O
48	-	O
49	2d	O
50	major	B
51	histocompatibility	I
52	complex	I
53	molecules	I
54	for	O
55	their	O
56	peptides	O
57	likely	O
58	account	O
59	for	O
60	the	O
61	total	O
62	removal	O
63	of	O
64	NP	O
65	CTL	O
66	in	O
67	the	O
68	H	O
69	-	O
70	2b	O
71	mice	O
72	but	O
73	only	O
74	partial	O
75	removal	O
76	in	O
77	H	O
78	-	O
79	2d	O
80	mice	O
81	made	O
82	to	O
83	express	O
84	thymic	O
85	NP	O
86	.	O

1	A	O
2	series	O
3	of	O
4	5	O
5	'-	O
6	deletions	O
7	revealed	O
8	that	O
9	the	O
10	fragment	O
11	-	O
12	218	O
13	to	O
14	+	O
15	4	O
16	from	O
17	the	O
18	TSS	O
19	had	O
20	the	O
21	highest	O
22	promoter	O
23	activity	O
24	,	O
25	nearly	O
26	1000	O
27	-	O
28	fold	O
29	greater	O
30	than	O
31	the	O
32	promoterless	O
33	chloramphenicol	B
34	acetyltransferase	I
35	construct	I
36	.	O

1	In	O
2	one	O
3	of	O
4	these	O
5	tumors	O
6	the	O
7	observed	O
8	rearrangement	O
9	was	O
10	not	O
11	due	O
12	to	O
13	the	O
14	insertion	O
15	of	O
16	an	O
17	intact	O
18	MoMuLV	O
19	provirus	O
20	.	O

1	The	O
2	AD	O
3	components	O
4	were	O
5	markedly	O
6	more	O
7	dependent	O
8	on	O
9	the	O
10	affective	O
11	state	O
12	of	O
13	the	O
14	rat	O
15	then	O
16	was	O
17	the	O
18	V1	O
19	component	O
20	.	O

1	An	O
2	apparent	O
3	ufo	B
4	mRNA	I
5	overexpression	O
6	was	O
7	not	O
8	found	O
9	in	O
10	any	O
11	of	O
12	the	O
13	positive	O
14	leukemia	O
15	cell	O
16	lines	O
17	,	O
18	but	O
19	was	O
20	identified	O
21	in	O
22	the	O
23	drug	O
24	-	O
25	resistant	O
26	subclones	O
27	of	O
28	the	O
29	cervix	O
30	carcinoma	O
31	cell	O
32	line	O
33	HeLa	O
34	.	O

1	(	O
2	iv	O
3	)	O
4	The	O
5	accumulation	O
6	of	O
7	cyclin	B
8	D3	I
9	protein	I
10	in	O
11	Vero	O
12	cells	O
13	infected	O
14	with	O
15	an	O
16	alpha0	B
17	deletion	I
18	mutant	I
19	was	O
20	reduced	O
21	relative	O
22	to	O
23	that	O
24	of	O
25	cells	O
26	infected	O
27	with	O
28	wild	O
29	-	O
30	type	O
31	virus	O
32	or	O
33	a	O
34	recombinant	O
35	virus	O
36	in	O
37	which	O
38	the	O
39	deleted	O
40	alpha0	B
41	sequences	I
42	were	O
43	restored	O
44	.	O

1	Through	O
2	transient	O
3	transfection	O
4	of	O
5	NIH3T3	O
6	fibroblast	O
7	cells	O
8	and	O
9	gel	O
10	mobility	O
11	shift	O
12	assays	O
13	,	O
14	the	O
15	functional	O
16	binding	O
17	site	O
18	was	O
19	localized	O
20	to	O
21	a	O
22	short	O
23	region	O
24	(-	O
25	318	O
26	to	O
27	-	O
28	303	O
29	bp	O
30	from	O
31	the	O
32	transcription	O
33	start	O
34	site	O
35	)	O
36	which	O
37	has	O
38	a	O
39	CTCCC	O
40	sequence	O
41	.	O

1	In	O
2	the	O
3	commercially	O
4	available	O
5	intravenous	O
6	formulation	O
7	of	O
8	Cyclosporin	O
9	A	O
10	(	O
11	Sandimmun	O
12	),	O
13	polyoxyethylated	O
14	castor	O
15	oil	O
16	(	O
17	Cremophor	O
18	EL	O
19	)	O
20	is	O
21	used	O
22	as	O
23	a	O
24	solubilizing	O
25	agent	O
26	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	,	O
7	expression	O
8	,	O
9	and	O
10	biochemical	O
11	characterization	O
12	of	O
13	the	O
14	32	O
15	-	O
16	kDa	O
17	subunit	O
18	of	O
19	human	O
20	(	O
21	h	O
22	)	O
23	TFIID	B
24	,	O
25	termed	O
26	hTAFII32	B
27	.	O

1	Each	O
2	patient	O
3	had	O
4	measurable	O
5	LH	B
6	and	O
7	FSH	B
8	levels	O
9	,	O
10	with	O
11	pulsed	O
12	nocturnal	O
13	secretion	O
14	,	O
15	and	O
16	pubertal	O
17	LH	B
18	and	O
19	FSH	B
20	responses	O
21	to	O
22	LRH	B
23	.	O

1	Contrary	O
2	to	O
3	the	O
4	observation	O
5	made	O
6	with	O
7	other	O
8	S	O
9	.	O
10	pombe	O
11	genes	O
12	transcribed	O
13	in	O
14	the	O
15	budding	O
16	yeast	O
17	,	O
18	the	O
19	heterologous	O
20	actin	B
21	gene	I
22	transcript	I
23	is	O
24	initiated	O
25	39	O
26	nucleotides	O
27	upstream	O
28	of	O
29	the	O
30	initiation	O
31	start	O
32	site	O
33	used	O
34	in	O
35	the	O
36	homologous	O
37	yeast	O
38	.	O

1	Factors	O
2	affecting	O
3	the	O
4	inhibition	O
5	of	O
6	phagocytosis	O
7	by	O
8	chlorpromazine	O
9	.	O

1	We	O
2	observed	O
3	abundant	O
4	levels	O
5	of	O
6	Rev	B
7	-	O
8	erbA	B
9	alpha	I
10	mRNA	O
11	in	O
12	dividing	O
13	C2C12	O
14	myoblasts	O
15	,	O
16	which	O
17	were	O
18	suppressed	O
19	when	O
20	the	O
21	cells	O
22	differentiated	O
23	into	O
24	postmitotic	O
25	multinucleated	O
26	myotubes	O
27	.	O

1	Interestingly	O
2	,	O
3	the	O
4	avirulent	O
5	strain	O
6	H37Ra	O
7	showed	O
8	weak	O
9	hybridization	O
10	with	O
11	these	O
12	two	O
13	probes	O
14	,	O
15	suggesting	O
16	that	O
17	these	O
18	genes	O
19	might	O
20	have	O
21	been	O
22	deleted	O
23	in	O
24	the	O
25	avirulent	O
26	strain	O
27	or	O
28	are	O
29	present	O
30	in	O
31	limited	O
32	copy	O
33	numbers	O
34	as	O
35	opposed	O
36	to	O
37	those	O
38	in	O
39	the	O
40	virulent	O
41	strain	O
42	H37Rv	O
43	.	O

1	The	O
2	effect	O
3	of	O
4	zinc	O
5	deficiency	O
6	on	O
7	trace	O
8	metals	O
9	in	O
10	the	O
11	liver	O
12	,	O
13	spleen	O
14	,	O
15	kidney	O
16	,	O
17	pancreas	O
18	and	O
19	duodenum	O
20	was	O
21	investigated	O
22	in	O
23	the	O
24	control	O
25	and	O
26	zinc	O
27	-	O
28	deficient	O
29	rats	O
30	at	O
31	17	O
32	days	O
33	and	O
34	20	O
35	days	O
36	of	O
37	pregnancy	O
38	.	O

1	S	O
2	.,	O
3	K	O
4	.	O

1	Animal	O
2	experimental	O
3	and	O
4	clinical	O
5	applications	O
6	of	O
7	plates	O
8	,	O
9	screws	O
10	and	O
11	spinal	O
12	segmental	O
13	replacement	O
14	implants	O
15	made	O
16	of	O
17	this	O
18	composite	O
19	material	O
20	have	O
21	shown	O
22	good	O
23	results	O
24	so	O
25	far	O
26	.	O

1	Labile	O
2	LTR	B
3	-	I
4	binding	I
5	proteins	I
6	appear	O
7	to	O
8	be	O
9	essential	O
10	for	O
11	c	B
12	-	I
13	myc	I
14	hyperexpression	O
15	,	O
16	since	O
17	both	O
18	LTR	O
19	-	O
20	enhanced	O
21	transcription	O
22	and	O
23	the	O
24	activities	O
25	of	O
26	LTR	B
27	-	I
28	binding	I
29	proteins	I
30	are	O
31	specifically	O
32	decreased	O
33	after	O
34	inhibition	O
35	of	O
36	protein	O
37	synthesis	O
38	(	O
39	A	O
40	.	O

1	Thrombocyte	O
2	function	O
3	was	O
4	impaired	O
5	in	O
6	all	O
7	patients	O
8	,	O
9	characterized	O
10	by	O
11	a	O
12	diminished	O
13	platelet	O
14	shape	O
15	change	O
16	.	O

1	Systemic	O
2	impact	O
3	of	O
4	risk	O
5	-	O
6	sharing	O
7	arrangements	O
8	.	O

1	J	O
2	.	O

1	Using	O
2	this	O
3	reporter	O
4	gene	O
5	system	O
6	,	O
7	we	O
8	previously	O
9	showed	O
10	that	O
11	EPO	B
12	-	O
13	induced	O
14	activation	O
15	of	O
16	the	O
17	c	B
18	-	I
19	fos	I
20	promoter	I
21	can	O
22	be	O
23	detected	O
24	rapidly	O
25	and	O
26	sensitively	O
27	as	O
28	an	O
29	elevation	O
30	of	O
31	cellular	B
32	luciferase	I
33	activity	O
34	.	O

1	In	O
2	addition	O
3	,	O
4	in	O
5	vitro	O
6	mutagenesis	O
7	of	O
8	both	O
9	Engrailed	B
10	and	O
11	Pbx1	B
12	sites	I
13	indicated	O
14	that	O
15	other	O
16	unidentified	O
17	sites	O
18	are	O
19	responsible	O
20	for	O
21	the	O
22	transcriptional	O
23	enhancement	O
24	observed	O
25	with	O
26	the	O
27	intronic	O
28	fragment	O
29	.	O

1	TG	O
2	-	O
3	day	O
4	and	O
5	TG	O
6	-	O
7	night	O
8	were	O
9	19	O
10	.	O
11	4	O
12	+/-	O
13	6	O
14	.	O
15	1	O
16	%,	O
17	26	O
18	.	O
19	6	O
20	+/-	O
21	5	O
22	.	O
23	3	O
24	%,	O
25	(	O
26	750	O
27	mm3	O
28	<	O
29	T	O
30	.	O

1	Habituation	O
2	of	O
3	completely	O
4	isolated	O
5	neurons	O
6	of	O
7	the	O
8	edible	O
9	snail	O
10	to	O
11	electrical	O
12	stimulation	O
13	.	O

1	It	O
2	was	O
3	also	O
4	suggested	O
5	that	O
6	the	O
7	biological	O
8	activities	O
9	of	O
10	5	O
11	-	O
12	FU	O
13	,	O
14	ADM	O
15	and	O
16	MMC	O
17	in	O
18	FAMLIP	O
19	were	O
20	stable	O
21	in	O
22	FULIP	O
23	,	O
24	ADRLIP	O
25	and	O
26	MMCLIP	O
27	.	O

1	Conversely	O
2	,	O
3	the	O
4	central	O
5	regions	O
6	are	O
7	highly	O
8	variable	O
9	.	O

1	Fragments	O
2	and	O
3	analogs	O
4	of	O
5	the	O
6	hormone	O
7	ACTH	B
8	were	O
9	previously	O
10	shown	O
11	to	O
12	have	O
13	beneficial	O
14	effect	O
15	on	O
16	the	O
17	outcome	O
18	of	O
19	head	O
20	injury	O
21	,	O
22	while	O
23	elevated	O
24	levels	O
25	of	O
26	corticosterone	O
27	(	O
28	CS	O
29	)	O
30	exacerbate	O
31	it	O
32	.	O

1	In	O
2	comparison	O
3	with	O
4	normal	O
5	pregnant	O
6	women	O
7	and	O
8	normal	O
9	non	O
10	-	O
11	pregnant	O
12	women	O
13	,	O
14	women	O
15	with	O
16	PIH	O
17	showed	O
18	an	O
19	increase	O
20	in	O
21	heart	O
22	rate	O
23	,	O
24	suggesting	O
25	an	O
26	increased	O
27	peripheral	O
28	sympathetic	O
29	tone	O
30	,	O
31	and	O
32	an	O
33	initial	O
34	derangement	O
35	in	O
36	renal	O
37	function	O
38	as	O
39	shown	O
40	by	O
41	the	O
42	increase	O
43	in	O
44	serum	O
45	uric	O
46	acid	O
47	and	O
48	reduction	O
49	in	O
50	sodium	O
51	excretion	O
52	and	O
53	total	O
54	and	O
55	fractional	O
56	calcium	O
57	excretion	O
58	at	O
59	any	O
60	given	O
61	level	O
62	of	O
63	sodium	O
64	excretion	O
65	.	O

1	Trials	O
2	of	O
3	sevine	O
4	activity	O
5	against	O
6	mosquito	O
7	larvae	O

1	Molecular	O
2	characterization	O
3	and	O
4	expression	O
5	of	O
6	the	O
7	Erwinia	B
8	carotovora	I
9	hrpNEcc	I
10	gene	I
11	,	O
12	which	O
13	encodes	O
14	an	O
15	elicitor	O
16	of	O
17	the	O
18	hypersensitive	O
19	reaction	O
20	.	O

1	From	O
2	this	O
3	library	O
4	,	O
5	LEU2	B
6	and	O
7	HIS3	B
8	cDNAs	O
9	were	O
10	recovered	O
11	at	O
12	a	O
13	frequency	O
14	of	O
15	about	O
16	1	O
17	in	O
18	10	O
19	(	O
20	4	O
21	)	O
22	and	O
23	in	O
24	12	O
25	out	O
26	of	O
27	13	O
28	cases	O
29	these	O
30	were	O
31	expressed	O
32	in	O
33	a	O
34	galactose	O
35	-	O
36	dependent	O
37	manner	O
38	.	O

1	One	O
2	of	O
3	these	O
4	factors	O
5	,	O
6	HRF	B
7	-	I
8	1	I
9	,	O
10	recognizes	O
11	a	O
12	cis	O
13	element	O
14	consisting	O
15	of	O
16	an	O
17	inverted	O
18	palindromic	O
19	motif	O
20	.	O

1	Suggestive	O
2	evidence	O
3	was	O
4	obtained	O
5	that	O
6	cstA	B
7	is	O
8	involved	O
9	in	O
10	peptide	O
11	utilization	O
12	.	O

1	Surprisingly	O
2	,	O
3	there	O
4	is	O
5	no	O
6	sequence	O
7	homology	O
8	between	O
9	this	O
10	region	O
11	of	O
12	Ly	B
13	-	I
14	6E	I
15	and	O
16	the	O
17	established	O
18	consensus	O
19	for	O
20	the	O
21	interferon	B
22	-	I
23	stimulated	I
24	response	I
25	element	I
26	,	O
27	which	O
28	has	O
29	been	O
30	shown	O
31	functionally	O
32	important	O
33	to	O
34	all	O
35	previously	O
36	characterized	O
37	alpha	B
38	/	I
39	beta	I
40	interferon	I
41	-	O
42	inducible	O
43	promoters	O
44	.	O

1	No	O
2	consistent	O
3	correlation	O
4	between	O
5	blood	O
6	pressure	O
7	change	O
8	and	O
9	SCR	O
10	-	O
11	change	O
12	was	O
13	seen	O
14	.	O

1	However	O
2	,	O
3	the	O
4	mouse	O
5	has	O
6	previously	O
7	been	O
8	shown	O
9	to	O
10	possess	O
11	only	O
12	three	O
13	forms	O
14	of	O
15	ADH	B
16	.	O

1	The	O
2	human	O
3	cDNA	O
4	was	O
5	used	O
6	to	O
7	demonstrate	O
8	that	O
9	tumor	B
10	necrosis	I
11	factor	I
12	-	I
13	alpha	I
14	could	O
15	rapidly	O
16	stimulate	O
17	MARCKS	B
18	gene	I
19	transcription	O
20	in	O
21	the	O
22	human	O
23	promyelocytic	O
24	leukemia	O
25	cell	O
26	line	O
27	HL60	O
28	.	O

1	These	O
2	findings	O
3	suggest	O
4	one	O
5	potential	O
6	mechanism	O
7	for	O
8	direct	O
9	recruitment	O
10	of	O
11	distal	O
12	regulatory	O
13	regions	O
14	of	O
15	the	O
16	globin	B
17	loci	I
18	to	O
19	the	O
20	individual	O
21	promoters	O
22	.	O

1	In	O
2	the	O
3	VA	O
4	-	O
5	SMV	O
6	mode	O
7	,	O
8	the	O
9	connection	O
10	was	O
11	made	O
12	with	O
13	valved	O
14	conduits	O
15	from	O
16	the	O
17	LV	O
18	apex	O
19	(	O
20	inflow	O
21	)	O
22	to	O
23	the	O
24	ascending	O
25	aorta	O
26	(	O
27	outflow	O
28	)	O
29	(	O
30	n	O
31	=	O
32	11	O
33	)	O
34	or	O
35	to	O
36	the	O
37	DAo	O
38	(	O
39	n	O
40	=	O
41	12	O
42	).	O

1	According	O
2	to	O
3	the	O
4	changes	O
5	of	O
6	perfusion	O
7	defects	O
8	between	O
9	Ex	O
10	,	O
11	RD	O
12	and	O
13	ReI	O
14	images	O
15	,	O
16	they	O
17	were	O
18	classified	O
19	into	O
20	3	O
21	types	O
22	:	O
23	Type	O
24	I	O
25	;	O
26	perfusion	O
27	defect	O
28	on	O
29	the	O
30	RD	O
31	image	O
32	was	O
33	identical	O
34	to	O
35	ReI	O
36	image	O
37	(	O
38	75	O
39	%)	O
40	Type	O
41	I	O
42	was	O
43	divided	O
44	into	O
45	2	O
46	subgroups	O
47	whether	O
48	perfusion	O
49	defect	O
50	at	O
51	Ex	O
52	was	O
53	unchanged	O
54	(	O
55	Ia	O
56	,	O
57	42	O
58	%)	O
59	or	O
60	improved	O
61	(	O
62	Ib	O
63	,	O
64	33	O
65	%)	O
66	on	O
67	the	O
68	RD	O
69	image	O
70	.	O

1	The	O
2	complete	O
3	cDNA	O
4	sequence	O
5	of	O
6	human	B
7	betaV	I
8	spectrin	I
9	is	O
10	available	O
11	from	O
12	GenBank	O
13	(	O
14	TM	O
15	)	O
16	as	O
17	accession	O
18	number	O
19	.	O

1	Commutative	O
2	saccadic	O
3	generator	O
4	is	O
5	sufficient	O
6	to	O
7	control	O
8	a	O
9	3	O
10	-	O
11	D	O
12	ocular	O
13	plant	O
14	with	O
15	pulleys	O
16	.	O

1	To	O
2	study	O
3	the	O
4	mechanisms	O
5	as	O
6	well	O
7	as	O
8	magnitude	O
9	of	O
10	the	O
11	transmembrane	O
12	transfer	O
13	of	O
14	bacterial	O
15	products	O
16	from	O
17	the	O
18	dialysate	O
19	,	O
20	we	O
21	developed	O
22	a	O
23	computerized	O
24	in	O
25	vitro	O
26	dialysis	O
27	model	O
28	which	O
29	provides	O
30	continuous	O
31	pressure	O
32	recording	O
33	from	O
34	the	O
35	arterial	O
36	,	O
37	venous	O
38	,	O
39	dialysate	O
40	inflow	O
41	and	O
42	outflow	O
43	ports	O
44	.	O

1	Also	O
2	in	O
3	the	O
4	spectrum	O
5	of	O
6	mutants	O
7	with	O
8	TGN	O
9	sorting	O
10	defects	O
11	are	O
12	isolates	O
13	with	O
14	mutations	O
15	in	O
16	the	O
17	following	O
18	:	O
19	RIC1	B
20	,	O
21	encoding	O
22	a	O
23	product	O
24	originally	O
25	proposed	O
26	to	O
27	participate	O
28	in	O
29	ribosome	O
30	biogenesis	O
31	;	O
32	LUV1	B
33	,	O
34	encoding	O
35	a	O
36	product	O
37	potentially	O
38	involved	O
39	in	O
40	vacuole	O
41	and	O
42	microtubule	O
43	organization	O
44	;	O
45	and	O
46	INP53	B
47	,	O
48	encoding	O
49	a	O
50	synaptojanin	B
51	-	I
52	like	I
53	inositol	I
54	polyphosphate	I
55	5	I
56	-	I
57	phosphatase	I
58	.	O

1	The	O
2	various	O
3	available	O
4	data	O
5	strongly	O
6	suggesting	O
7	an	O
8	environmental	O
9	toxic	O
10	origin	O
11	for	O
12	the	O
13	"	O
14	sperm	O
15	fall	O
16	"	O
17	will	O
18	be	O
19	presented	O
20	as	O
21	well	O
22	as	O
23	the	O
24	most	O
25	frequently	O
26	suspected	O
27	class	O
28	of	O
29	substances	O
30	,	O
31	the	O
32	xenoestrogens	O
33	.	O

1	The	O
2	level	O
3	of	O
4	serum	B
5	creatine	I
6	kinase	I
7	was	O
8	significantly	O
9	high	O
10	2	O
11	days	O
12	after	O
13	ESWIB	O
14	,	O
15	but	O
16	it	O
17	recovered	O
18	in	O
19	a	O
20	week	O
21	.	O

1	The	O
2	unexpected	O
3	presence	O
4	of	O
5	the	O
6	tRNA	B
7	(	I
8	trp	I
9	)(	I
10	CCA	I
11	)-	I
12	gene	I
13	transcript	I
14	in	I
15	mitochondria	I
16	is	O
17	also	O
18	reported	O
19	.	O

1	Catha	O
2	edulis	O
3	,	O
4	a	O
5	plant	O
6	that	O
7	has	O
8	amphetamine	O
9	effects	O
10	.	O

1	It	O
2	could	O
3	also	O
4	inhibit	O
5	C1q	B
6	-	O
7	dependent	O
8	haemolysis	O
9	of	O
10	both	O
11	IgG	B
12	-	O
13	and	O
14	IgM	B
15	-	O
16	sensitized	O
17	erythrocytes	O
18	.	O

1	Deadenylation	O
2	and	O
3	decay	O
4	of	O
5	beta	B
6	-	I
7	globin	I
8	mRNA	I
9	in	O
10	K562	O
11	cells	O
12	is	O
13	extraordinarily	O
14	slow	O
15	compared	O
16	with	O
17	NIH	O
18	3T3	O
19	cells	O
20	,	O
21	suggesting	O
22	that	O
23	the	O
24	increased	O
25	stability	O
26	gained	O
27	by	O
28	beta	B
29	-	I
30	globin	I
31	mRNA	I
32	in	O
33	K562	O
34	cells	O
35	is	O
36	mainly	O
37	controlled	O
38	at	O
39	the	O
40	deadenylation	O
41	step	O
42	.	O

1	These	O
2	six	O
3	districts	O
4	have	O
5	an	O
6	area	O
7	of	O
8	34	O
9	,	O
10	000	O
11	km2	O
12	and	O
13	hold	O
14	a	O
15	population	O
16	of	O
17	30	O
18	million	O
19	.	O

1	A	O
2	surgical	O
3	technique	O
4	for	O
5	correcting	O
6	this	O
7	problem	O
8	is	O
9	described	O
10	.	O

1	These	O
2	losses	O
3	account	O
4	for	O
5	the	O
6	resistance	O
7	of	O
8	EDS	O
9	-	O
10	IV	O
11	collagen	B
12	to	O
13	cyanogen	O
14	bromide	O
15	and	O
16	mammalian	B
17	collagenase	I
18	digestion	O
19	.	O

1	Bitter	O
2	cassava	O
3	contains	O
4	cyanogenic	O
5	glycosides	O
6	;	O
7	processing	O
8	breaks	O
9	them	O
10	down	O
11	to	O
12	acetone	O
13	cyanohydrin	O
14	and	O
15	hydrogen	O
16	cyanide	O
17	.	O

1	Next	O
2	,	O
3	we	O
4	stably	O
5	overexpressed	O
6	wild	B
7	-	I
8	type	I
9	Shc	I
10	or	O
11	Y317F	B
12	mutant	I
13	Shc	I
14	into	O
15	HIRc	O
16	cells	O
17	.	O

1	Diabetes	O
2	care	O
3	:	O
4	a	O
5	guideline	O
6	to	O
7	the	O
8	facilities	O
9	needed	O
10	to	O
11	support	O
12	internationally	O
13	endorsed	O
14	standards	O
15	.	O

1	Taken	O
2	together	O
3	,	O
4	we	O
5	provide	O
6	evidence	O
7	for	O
8	the	O
9	existence	O
10	of	O
11	an	O
12	activator	O
13	,	O
14	NFE	B
15	,	O
16	which	O
17	in	O
18	combination	O
19	with	O
20	the	O
21	p50	B
22	and	O
23	c	B
24	-	I
25	Rel	I
26	proteins	I
27	,	O
28	are	O
29	part	O
30	of	O
31	the	O
32	transcription	O
33	factor	O
34	machinery	O
35	that	O
36	regulates	O
37	3	O
38	'	O
39	enhancer	O
40	activity	O
41	,	O
42	and	O
43	thus	O
44	the	O
45	control	O
46	of	O
47	the	O
48	IgH	B
49	locus	I
50	in	O
51	late	O
52	B	O
53	lymphocyte	O
54	development	O
55	.	O

1	The	O
2	negative	O
3	calcium	O
4	balance	O
5	with	O
6	hyperparathyroidemia	O
7	occurred	O
8	after	O
9	continuous	O
10	oral	O
11	administration	O
12	of	O
13	Cd	O
14	and	O
15	developed	O
16	via	O
17	increased	O
18	urinary	O
19	excretion	O
20	of	O
21	calcium	O
22	.	O

1	There	O
2	were	O
3	45	O
4	to	O
5	56	O
6	nt	O
7	differences	O
8	between	O
9	the	O
10	virulent	O
11	and	O
12	avirulent	O
13	groups	O
14	while	O
15	there	O
16	were	O
17	6	O
18	to	O
19	14	O
20	nt	O
21	differences	O
22	among	O
23	four	O
24	avirulent	O
25	strains	O
26	.	O

1	Vitrectomy	O
2	in	O
3	ocular	O
4	traumatology	O

1	Their	O
2	biosynthesis	O
3	proceeds	O
4	via	O
5	linear	O
6	precursors	O
7	that	O
8	become	O
9	branched	O
10	by	O
11	beta1	B
12	,	I
13	6	I
14	-	I
15	GlcNAc	I
16	transferases	I
17	(	O
18	IGnT6	O
19	,	O
20	GlcNAc	O
21	to	O
22	Gal	O
23	).	O

1	A	O
2	.	O

1	Both	O
2	fusion	O
3	proteins	O
4	form	O
5	stable	O
6	specific	O
7	complexes	O
8	with	O
9	a	O
10	short	O
11	DNA	O
12	duplex	O
13	harboring	O
14	the	O
15	CTGT	O
16	(	O
17	at	O
18	)	O
19	4ACAG	O
20	consensus	O
21	sequence	O
22	of	O
23	the	O
24	LexA	B
25	repressor	I
26	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	demonstrate	O
6	that	O
7	the	O
8	production	O
9	of	O
10	active	B
11	recombinant	I
12	telomerase	I
13	requires	O
14	a	O
15	factor	O
16	in	O
17	rabbit	O
18	reticulocyte	O
19	lysate	O
20	that	O
21	promotes	O
22	ribonucleoprotein	O
23	assembly	O
24	.	O

1	Saccharomyces	O
2	cerevisiae	O
3	contains	O
4	a	O
5	genetically	O
6	and	O
7	biochemically	O
8	proven	O
9	CAK	B
10	gene	I
11	,	O
12	CAK1	B
13	,	O
14	that	O
15	encodes	O
16	a	O
17	monomeric	O
18	44	B
19	-	I
20	kDa	I
21	Cak1p	I
22	protein	I
23	unrelated	O
24	to	O
25	Cdk7	B
26	.	O

1	A	O
2	careful	O
3	,	O
4	radiolabelled	O
5	tissue	O
6	-	O
7	distribution	O
8	study	O
9	is	O
10	warranted	O
11	to	O
12	elucidate	O
13	the	O
14	complicated	O
15	metabolic	O
16	fate	O
17	of	O
18	perhexiline	O
19	.	O

1	Letter	O
2	:	O
3	Is	O
4	actinic	O
5	(	O
6	solar	O
7	)	O
8	damage	O
9	the	O
10	provoking	O
11	cause	O
12	of	O
13	'	O
14	post	O
15	-	O
16	inflammatory	O
17	elastolysis	O
18	and	O
19	cutis	O
20	laxa	O
21	(	O
22	PECL	O
23	)'?	O

1	We	O
2	conclude	O
3	that	O
4	common	O
5	upstream	O
6	signals	O
7	cause	O
8	activation	O
9	of	O
10	Ras	B
11	and	O
12	TC21	B
13	,	O
14	but	O
15	activated	O
16	TC21	B
17	controls	O
18	cell	O
19	growth	O
20	via	O
21	distinct	O
22	Raf	B
23	-	O
24	independent	O
25	downstream	O
26	signaling	O
27	pathways	O
28	.	O

1	The	O
2	yeast	O
3	silent	B
4	information	I
5	regulator	I
6	Sir4p	I
7	anchors	O
8	and	O
9	partitions	O
10	plasmids	O
11	.	O

1	Similarly	O
2	,	O
3	the	O
4	N	O
5	-	O
6	terminal	O
7	cytoplasmic	O
8	domain	O
9	of	O
10	the	O
11	latent	B
12	membrane	I
13	protein	I
14	2A	I
15	(	O
16	LMP2A	B
17	)	O
18	of	O
19	the	O
20	Epstein	O
21	-	O
22	Barr	O
23	virus	O
24	(	O
25	EBV	O
26	)	O
27	contains	O
28	a	O
29	single	O
30	copy	O
31	of	O
32	the	O
33	Tyr	O
34	-	O
35	X	O
36	-	O
37	X	O
38	-	O
39	Leu	O
40	/	O
41	Ile	O
42	-	O
43	containing	O
44	motif	O
45	which	O
46	could	O
47	play	O
48	a	O
49	critical	O
50	role	O
51	in	O
52	B	O
53	cell	O
54	transformation	O
55	.	O

1	Takayasu	O
2	'	O
3	s	O
4	disease	O
5	:	O
6	association	O
7	with	O
8	HLA	B
9	-	I
10	B5	I
11	.	O

1	This	O
2	region	O
3	also	O
4	contains	O
5	a	O
6	gene	O
7	specifying	O
8	a	O
9	Leu	B
10	-	I
11	tRNA	I
12	precursor	I
13	and	O
14	a	O
15	remnant	O
16	of	O
17	a	O
18	tau	O
19	element	O
20	.	O

1	Treatment	O
2	and	O
3	staining	O
4	of	O
5	smears	O
6	and	O
7	sections	O
8	for	O
9	detection	O
10	of	O
11	microorganisms	O

1	CONCLUSION	O
2	:	O
3	Local	O
4	control	O
5	was	O
6	highest	O
7	with	O
8	Preop	O
9	in	O
10	patients	O
11	presenting	O
12	primarily	O
13	with	O
14	gross	O
15	disease	O
16	,	O
17	and	O
18	with	O
19	Postop	O
20	in	O
21	patients	O
22	presenting	O
23	primarily	O
24	following	O
25	gross	O
26	total	O
27	excision	O
28	.	O

1	Female	O
2	subjects	O
3	,	O
4	including	O
5	both	O
6	normal	O
7	subjects	O
8	and	O
9	idiopathic	O
10	calcium	O
11	stone	O
12	-	O
13	formers	O
14	,	O
15	have	O
16	higher	O
17	urinary	O
18	cyclic	O
19	AMP	O
20	levels	O
21	than	O
22	their	O
23	male	O
24	counterparts	O
25	,	O
26	and	O
27	this	O
28	difference	O
29	is	O
30	significant	O
31	when	O
32	urinary	O
33	cyclic	O
34	AMP	O
35	is	O
36	expressed	O
37	in	O
38	the	O
39	units	O
40	mumol	O
41	/	O
42	g	O
43	of	O
44	creatinine	O
45	.	O

1	Using	O
2	one	O
3	of	O
4	the	O
5	six	O
6	fragments	O
7	(	O
8	CPK3	B
9	-	I
10	8	I
11	),	O
12	we	O
13	isolated	O
14	a	O
15	2022	B
16	bp	I
17	cDNA	I
18	(	I
19	VrCDPK	I
20	-	I
21	1	I
22	)	I
23	from	O
24	a	O
25	Vigna	O
26	radiata	O
27	lambda	O
28	gt11	O
29	library	O
30	.	O

1	To	O
2	begin	O
3	to	O
4	understand	O
5	this	O
6	role	O
7	,	O
8	we	O
9	overexpressed	O
10	ATF	B
11	-	I
12	2	I
13	in	O
14	a	O
15	human	O
16	cancer	O
17	cell	O
18	line	O
19	.	O

1	The	O
2	protein	O
3	encoded	O
4	is	O
5	114	O
6	kDa	O
7	and	O
8	contains	O
9	eight	O
10	zinc	O
11	finger	O
12	motifs	O
13	,	O
14	seven	O
15	of	O
16	which	O
17	are	O
18	present	O
19	in	O
20	two	O
21	clusters	O
22	at	O
23	opposite	O
24	ends	O
25	of	O
26	the	O
27	molecule	O
28	.	O

1	Following	O
2	treatment	O
3	,	O
4	serum	O
5	estradiol	O
6	levels	O
7	were	O
8	higher	O
9	in	O
10	groups	O
11	E	O
12	+	O
13	T	O
14	and	O
15	E	O
16	than	O
17	in	O
18	group	O
19	C	O
20	.	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	fog	O
6	,	O
7	up	O
8	to	O
9	a	O
10	level	O
11	of	O
12	base	O
13	plus	O
14	fog	O
15	of	O
16	0	O
17	.	O
18	6	O
19	optical	O
20	density	O
21	units	O
22	,	O
23	had	O
24	no	O
25	influence	O
26	on	O
27	the	O
28	diagnostic	O
29	accuracy	O
30	in	O
31	the	O
32	absence	O
33	of	O
34	any	O
35	compensation	O
36	.	O

1	The	O
2	rate	O
3	-	O
4	limiting	O
5	step	O
6	for	O
7	telomerase	B
8	activity	O
9	seems	O
10	to	O
11	be	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	catalytic	O
17	subunit	O
18	of	O
19	the	O
20	enzyme	O
21	,	O
22	encoded	O
23	by	O
24	the	O
25	human	B
26	telomerase	I
27	reverse	I
28	transcriptase	I
29	(	O
30	hTERT	B
31	)	O
32	gene	O
33	.	O

1	Efficacy	O
2	was	O
3	determined	O
4	by	O
5	responses	O
6	to	O
7	question	O
8	3	O
9	(	O
10	ability	O
11	to	O
12	achieve	O
13	an	O
14	erection	O
15	)	O
16	and	O
17	question	O
18	4	O
19	(	O
20	ability	O
21	to	O
22	maintain	O
23	an	O
24	erection	O
25	)	O
26	of	O
27	the	O
28	15	O
29	-	O
30	item	O
31	International	O
32	Index	O
33	of	O
34	Erectile	O
35	Function	O
36	(	O
37	IIEF	O
38	).	O

1	Identification	O
2	of	O
3	five	O
4	new	O
5	genes	O
6	,	O
7	closely	O
8	related	O
9	to	O
10	the	O
11	interleukin	B
12	-	I
13	1beta	I
14	converting	I
15	enzyme	I
16	gene	I
17	,	O
18	that	O
19	do	O
20	not	O
21	encode	O
22	functional	O
23	proteases	O
24	.	O

1	The	O
2	'	O
3	field	O
4	of	O
5	stress	O
6	'	O
7	of	O
8	the	O
9	supervisory	O
10	nurse	O

1	Deleting	O
2	SNF1	B
3	repressed	O
4	meiosis	O
5	at	O
6	the	O
7	same	O
8	three	O
9	steps	O
10	that	O
11	were	O
12	inhibited	O
13	by	O
14	glucose	O
15	,	O
16	suggesting	O
17	that	O
18	glucose	O
19	blocks	O
20	meiosis	O
21	by	O
22	inhibiting	O
23	Snf1	B
24	.	O

1	Monitoring	O
2	changes	O
3	in	O
4	the	O
5	heart	O
6	rate	O
7	of	O
8	the	O
9	premature	O
10	fetus	O
11	during	O
12	tocolysis	O
13	with	O
14	the	O
15	beta	O
16	-	O
17	adrenomimetics	O
18	partusisten	O
19	and	O
20	Pre	O
21	-	O
22	par	O

1	In	O
2	the	O
3	first	O
4	group	O
5	,	O
6	0	O
7	.	O
8	02	O
9	%	O
10	Prazosin	O
11	(	O
12	0	O
13	.	O
14	5	O
15	mg	O
16	/	O
17	kg	O
18	)	O
19	was	O
20	administered	O
21	intravenously	O
22	for	O
23	1	O
24	.	O
25	5	O
26	hours	O
27	before	O
28	the	O
29	application	O
30	of	O
31	Oxy	O
32	-	O
33	Hb	O
34	or	O
35	PGF2	O
36	alpha	O
37	.	O

1	Not	O
2	even	O
3	extensive	O
4	pancreatic	O
5	resection	O
6	could	O
7	prevent	O
8	pancreatic	O
9	remnant	O
10	infection	O
11	.	O

1	On	O
2	catabolism	O
3	of	O
4	aminoketones	O
5	in	O
6	climacteric	O
7	age	O

1	Furthermore	O
2	,	O
3	in	O
4	vitro	O
5	decay	O
6	reaction	O
7	mixtures	O
8	supplemented	O
9	with	O
10	the	O
11	20	O
12	-	O
13	nt	O
14	sense	O
15	RNA	O
16	transcript	O
17	resulted	O
18	in	O
19	stabilization	O
20	of	O
21	R2	B
22	message	I
23	.	O

1	The	O
2	human	B
3	insulin	I
4	-	I
5	like	I
6	growth	I
7	factor	I
8	II	I
9	(	O
10	IGF	B
11	-	I
12	II	I
13	)	O
14	gene	O
15	contains	O
16	four	O
17	promoters	O
18	(	O
19	P1	O
20	,	O
21	P2	O
22	,	O
23	P3	O
24	and	O
25	P4	O
26	).	O

1	Cloning	O
2	,	O
3	sequencing	O
4	and	O
5	expression	O
6	of	O
7	the	O
8	3	B
9	-	I
10	phosphoglycerate	I
11	kinase	I
12	gene	I
13	of	O
14	Pyrococcus	O
15	woesei	O
16	in	O
17	Escherichia	O
18	coli	O
19	and	O
20	characterization	O
21	of	O
22	the	O
23	protein	O
24	.	O

1	From	O
2	August	O
3	1989	O
4	to	O
5	October	O
6	1990	O
7	,	O
8	83	O
9	pregnant	O
10	Chinese	O
11	women	O
12	were	O
13	the	O
14	subjects	O
15	for	O
16	measuring	O
17	the	O
18	levels	O
19	of	O
20	plasma	O
21	functional	O
22	antithrombin	B
23	III	I
24	(	O
25	AT	B
26	III	I
27	)	O
28	activity	O
29	.	O

1	Syndecan	B
2	-	I
3	4	I
4	is	O
5	a	O
6	focal	O
7	adhesion	O
8	component	O
9	,	O
10	and	O
11	this	O
12	interaction	O
13	may	O
14	both	O
15	localize	O
16	PKC	B
17	and	O
18	amplify	O
19	its	O
20	activity	O
21	at	O
22	sites	O
23	of	O
24	forming	O
25	adhesions	O
26	.	O

1	Transcription	O
2	of	O
3	the	O
4	six	O
5	EBNA	B
6	genes	I
7	,	O
8	which	O
9	are	O
10	expressed	O
11	in	O
12	EBV	O
13	-	O
14	immortalized	O
15	primary	O
16	B	O
17	cells	O
18	,	O
19	arises	O
20	from	O
21	one	O
22	of	O
23	two	O
24	promoters	O
25	,	O
26	Cp	B
27	and	O
28	Wp	B
29	,	O
30	located	O
31	near	O
32	the	O
33	left	O
34	end	O
35	of	O
36	the	O
37	viral	O
38	genome	O
39	.	O

1	Sp1	B
2	binds	O
3	the	O
4	CTC	O
5	repeat	O
6	with	O
7	an	O
8	affinity	O
9	,	O
10	KD	O
11	=	O
12	0	O
13	.	O
14	37	O
15	nM	O
16	,	O
17	at	O
18	least	O
19	as	O
20	high	O
21	as	O
22	the	O
23	consensus	O
24	GC	O
25	box	O
26	.	O

1	After	O
2	10	O
3	months	O
4	of	O
5	treatment	O
6	with	O
7	the	O
8	conjugated	O
9	estrogen	O
10	,	O
11	both	O
12	his	O
13	height	O
14	and	O
15	weight	O
16	showed	O
17	improvement	O
18	,	O
19	while	O
20	his	O
21	bone	O
22	mineral	O
23	density	O
24	and	O
25	bone	O
26	age	O
27	were	O
28	increased	O
29	.	O

1	Thus	O
2	,	O
3	in	O
4	stress	O
5	-	O
6	induced	O
7	arrhythmic	O
8	disease	O
9	as	O
10	well	O
11	as	O
12	in	O
13	ischemic	O
14	heart	O
15	disease	O
16	,	O
17	the	O
18	main	O
19	pathogenetic	O
20	links	O
21	are	O
22	outside	O
23	the	O
24	heart	O
25	,	O
26	but	O
27	they	O
28	differ	O
29	from	O
30	those	O
31	observed	O
32	in	O
33	ischemia	O
34	.	O

1	The	O
2	intron	O
3	RNA	O
4	consists	O
5	of	O
6	2492	O
7	nucleotides	O
8	which	O
9	can	O
10	be	O
11	folded	O
12	into	O
13	a	O
14	secondary	O
15	structure	O
16	with	O
17	all	O
18	the	O
19	expected	O
20	sequence	O
21	motifs	O
22	of	O
23	subgroup	O
24	-	O
25	IIA1	O
26	introns	O
27	(	O
28	Michel	O
29	et	O
30	al	O
31	.	O

1	The	O
2	levels	O
3	of	O
4	transactivation	O
5	are	O
6	correlated	O
7	with	O
8	the	O
9	respective	O
10	binding	O
11	affinities	O
12	of	O
13	the	O
14	response	O
15	elements	O
16	(	O
17	IRper	O
18	-	O
19	1	O
20	>	O
21	DR	O
22	-	O
23	4	O
24	>	O
25	IRhsp	O
26	-	O
27	1	O
28	).	O

1	The	O
2	partial	O
3	farm	O
4	budget	O
5	highlighted	O
6	the	O
7	importance	O
8	of	O
9	reducing	O
10	sub	O
11	-	O
12	clinical	O
13	lesions	O
14	in	O
15	a	O
16	feedlot	O
17	.	O

1	Thus	O
2	,	O
3	Sir	B
4	proteins	I
5	from	O
6	K	O
7	.	O
8	lactis	O
9	have	O
10	roles	O
11	in	O
12	both	O
13	silencing	O
14	and	O
15	telomere	O
16	length	O
17	maintenance	O
18	,	O
19	reflecting	O
20	conserved	O
21	functional	O
22	themes	O
23	.	O

1	However	O
2	,	O
3	with	O
4	the	O
5	alpha1	O
6	antagonist	O
7	prazosin	O
8	(	O
9	5	O
10	x	O
11	10	O
12	(-	O
13	8	O
14	)-	O
15	5	O
16	x	O
17	10	O
18	(-	O
19	7	O
20	)	O
21	M	O
22	),	O
23	no	O
24	relaxation	O
25	occurred	O
26	.	O

1	The	O
2	importance	O
3	of	O
4	this	O
5	new	O
6	epidemiological	O
7	profile	O
8	of	O
9	schistosomiasis	O
10	in	O
11	the	O
12	State	O
13	of	O
14	Pernambuco	O
15	relies	O
16	on	O
17	the	O
18	fact	O
19	that	O
20	it	O
21	can	O
22	be	O
23	related	O
24	with	O
25	the	O
26	drastic	O
27	human	O
28	interference	O
29	on	O
30	the	O
31	environment	O
32	.	O

1	However	O
2	,	O
3	we	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	a	O
9	p4	B
10	molecule	O
11	.	O

1	Summers	O
2	,	O
3	Virology	O
4	89	O
5	:	O
6	517	O
7	-	O
8	527	O
9	,	O
10	1978	O
11	).	O

1	The	O
2	rat	B
3	aldolase	I
4	C	I
5	gene	I
6	encodes	O
7	a	O
8	glycolytic	O
9	enzyme	O
10	strongly	O
11	expressed	O
12	in	O
13	adult	O
14	brain	O
15	.	O

1	We	O
2	found	O
3	that	O
4	PML	B
5	was	O
6	expressed	O
7	at	O
8	a	O
9	lower	O
10	level	O
11	in	O
12	S	O
13	,	O
14	G2	O
15	,	O
16	and	O
17	M	O
18	phases	O
19	and	O
20	at	O
21	a	O
22	significantly	O
23	higher	O
24	level	O
25	in	O
26	G1	O
27	phase	O
28	.	O

1	The	O
2	other	O
3	hypoglycaemic	O
4	patient	O
5	showed	O
6	an	O
7	exaggerated	O
8	insulin	B
9	release	O
10	in	O
11	response	O
12	to	O
13	tolbutamide	O
14	.	O

1	Therefore	O
2	,	O
3	ICSBP	B
4	may	O
5	be	O
6	involved	O
7	in	O
8	maintaining	O
9	submaximal	O
10	transcriptional	O
11	activity	O
12	of	O
13	IFN	B
14	-	O
15	inducible	O
16	genes	O
17	in	O
18	hematopoietic	O
19	cells	O
20	.	O

1	The	O
2	cDNA	O
3	was	O
4	expressed	O
5	in	O
6	Saccharomyces	O
7	cerevisiae	O
8	under	O
9	the	O
10	control	O
11	of	O
12	the	O
13	yeast	B
14	triose	I
15	phosphate	I
16	isomerase	I
17	promoter	I
18	.	O

1	Piperacillin	O
2	-	O
3	tazobactam	O
4	can	O
5	be	O
6	used	O
7	for	O
8	the	O
9	treatment	O
10	of	O
11	infections	O
12	caused	O
13	by	O
14	gram	O
15	-	O
16	negative	O
17	,	O
18	gram	O
19	-	O
20	positive	O
21	,	O
22	aerobic	O
23	,	O
24	and	O
25	anaerobic	O
26	bacteria	O
27	.	O

1	Immediately	O
2	before	O
3	surgery	O
4	patients	O
5	received	O
6	either	O
7	intravenous	O
8	hydrocortisone	O
9	100	O
10	mg	O
11	or	O
12	placebo	O
13	in	O
14	random	O
15	,	O
16	double	O
17	-	O
18	blind	O
19	order	O
20	.	O

1	Human	B
2	MN	I
3	/	I
4	CA9	I
5	gene	I
6	,	O
7	a	O
8	novel	O
9	member	O
10	of	O
11	the	O
12	carbonic	B
13	anhydrase	I
14	family	I
15	:	O
16	structure	O
17	and	O
18	exon	O
19	to	O
20	protein	O
21	domain	O
22	relationships	O
23	.	O

1	Recent	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	Cbl	B
7	,	O
8	the	O
9	120	O
10	-	O
11	kDa	O
12	protein	O
13	product	O
14	of	O
15	the	O
16	c	B
17	-	I
18	cbl	I
19	proto	I
20	-	I
21	oncogene	I
22	,	O
23	serves	O
24	as	O
25	a	O
26	substrate	O
27	of	O
28	a	O
29	number	O
30	of	O
31	receptor	B
32	-	I
33	coupled	I
34	tyrosine	I
35	kinases	I
36	and	O
37	forms	O
38	complexes	O
39	with	O
40	SH3	B
41	and	O
42	SH2	B
43	domain	O
44	-	O
45	containing	O
46	proteins	O
47	,	O
48	pointing	O
49	to	O
50	its	O
51	role	O
52	in	O
53	signal	O
54	transduction	O
55	.	O

1	NF	B
2	-	I
3	kappaB	I
4	,	O
5	which	O
6	is	O
7	probably	O
8	important	O
9	for	O
10	basal	O
11	activity	O
12	of	O
13	the	O
14	human	B
15	NOS	I
16	II	I
17	promoter	I
18	,	O
19	is	O
20	unlikely	O
21	to	O
22	function	O
23	as	O
24	a	O
25	major	O
26	effector	O
27	of	O
28	CM	O
29	in	O
30	DLD	O
31	-	O
32	1	O
33	cells	O
34	.	O

1	Side	O
2	effect	O
3	including	O
4	subjective	O
5	and	O
6	objective	O
7	symptoms	O
8	were	O
9	strictly	O
10	evaluated	O
11	in	O
12	163	O
13	cases	O
14	(	O
15	KS	O
16	-	O
17	R1	O
18	group	O
19	in	O
20	83	O
21	cases	O
22	,	O
23	oral	O
24	group	O
25	in	O
26	80	O
27	cases	O
28	),	O
29	but	O
30	the	O
31	incidence	O
32	rate	O
33	which	O
34	was	O
35	22	O
36	.	O
37	9	O
38	%	O
39	for	O
40	the	O
41	KS	O
42	-	O
43	R1	O
44	group	O
45	and	O
46	23	O
47	.	O
48	8	O
49	%	O
50	for	O
51	the	O
52	oral	O
53	group	O
54	showed	O
55	no	O
56	significant	O
57	difference	O
58	.	O

1	This	O
2	TC	B
3	-	I
4	II	I
5	enhanson	I
6	,	O
7	which	O
8	is	O
9	identical	O
10	to	O
11	the	O
12	kappa	B
13	B	I
14	motif	I
15	from	O
16	the	O
17	kappa	B
18	chain	I
19	enhancer	I
20	,	O
21	was	O
22	active	O
23	in	O
24	both	O
25	lymphoid	O
26	and	O
27	non	O
28	-	O
29	lymphoid	O
30	cells	O
31	,	O
32	which	O
33	contrasts	O
34	with	O
35	the	O
36	previously	O
37	reported	O
38	lymphoid	O
39	cell	O
40	specificity	O
41	of	O
42	the	O
43	kappa	B
44	B	I
45	motif	I
46	.	O

1	Generally	O
2	,	O
3	a	O
4	correlation	O
5	was	O
6	observed	O
7	between	O
8	highest	O
9	concentrations	O
10	of	O
11	CSF	B
12	immunoglobulins	I
13	and	O
14	degree	O
15	of	O
16	meningeal	O
17	inflammatory	O
18	response	O
19	,	O
20	even	O
21	if	O
22	this	O
23	was	O
24	a	O
25	component	O
26	of	O
27	other	O
28	neurological	O
29	diseases	O
30	.	O

1	Reagent	O
2	strips	O
3	are	O
4	frequently	O
5	used	O
6	in	O
7	the	O
8	practice	O
9	of	O
10	laboratory	O
11	medicine	O
12	as	O
13	well	O
14	as	O
15	outside	O
16	the	O
17	professional	O
18	laboratories	O
19	.	O

1	Fatal	O
2	encephalitis	O
3	in	O
4	a	O
5	patient	O
6	with	O
7	chronic	O
8	graft	O
9	-	O
10	versus	O
11	-	O
12	host	O
13	disease	O
14	.	O

1	Two	O
2	hundred	O
3	sixty	O
4	-	O
5	four	O
6	patients	O
7	scheduled	O
8	for	O
9	DCBM	O
10	were	O
11	randomized	O
12	to	O
13	receive	O
14	intravenously	O
15	geG	O
16	0	O
17	.	O
18	25	O
19	mg	O
20	(	O
21	geG	O
22	-	O
23	25	O
24	),	O
25	or	O
26	geG	O
27	0	O
28	.	O
29	5	O
30	mg	O
31	(	O
32	geG	O
33	-	O
34	50	O
35	),	O
36	or	O
37	HBB	O
38	20	O
39	mg	O
40	as	O
41	hypotonic	O
42	agent	O
43	.	O

1	The	O
2	Rlm1	B
3	protein	I
4	,	O
5	a	O
6	member	O
7	of	O
8	the	O
9	MADS	B
10	box	I
11	family	I
12	of	O
13	transcription	O
14	factors	O
15	,	O
16	functions	O
17	downstream	O
18	of	O
19	Mpk1	B
20	in	O
21	the	O
22	pathway	O
23	.	O

1	Hypoglycemic	O
2	and	O
3	antidiabetic	O
4	properties	O

1	Personal	O
2	satisfaction	O
3	in	O
4	nursing	O
5	:	O
6	an	O
7	encounter	O
8	with	O
9	extremely	O
10	hostile	O
11	patients	O

1	Altogether	O
2	,	O
3	the	O
4	results	O
5	demonstrate	O
6	that	O
7	the	O
8	two	O
9	isoforms	O
10	elicit	O
11	similar	O
12	responses	O
13	in	O
14	vivo	O
15	despite	O
16	differences	O
17	in	O
18	their	O
19	regulation	O
20	.	O

1	Our	O
2	study	O
3	was	O
4	addressed	O
5	to	O
6	the	O
7	synthesis	O
8	of	O
9	some	O
10	derivatives	O
11	of	O
12	this	O
13	sequence	O
14	in	O
15	order	O
16	to	O
17	obtain	O
18	both	O
19	peptide	O
20	substrates	O
21	suitable	O
22	for	O
23	the	O
24	detection	O
25	of	O
26	the	O
27	Src	B
28	-	O
29	like	O
30	tyrosine	B
31	kinase	I
32	activity	O
33	and	O
34	active	O
35	site	O
36	-	O
37	directed	O
38	inhibitors	O
39	specific	O
40	for	O
41	this	O
42	class	O
43	of	O
44	enzymes	O
45	.	O

1	This	O
2	review	O
3	summarizes	O
4	the	O
5	clinical	O
6	evidence	O
7	to	O
8	support	O
9	current	O
10	therapies	O
11	in	O
12	irritable	O
13	bowel	O
14	syndrome	O
15	(	O
16	IBS	O
17	).	O

1	5	O
2	(	O
3	Sunset	O
4	Yellow	O
5	FCF	O
6	)	O
7	were	O
8	determined	O
9	using	O
10	liquid	O
11	chromatography	O
12	/	O
13	mass	O
14	spectrometry	O
15	(	O
16	LC	O
17	/	O
18	MS	O
19	)	O
20	with	O
21	electrospray	O
22	ionization	O
23	.	O

1	M	B
2	-	I
3	66	I
4	identified	O
5	the	O
6	14	O
7	-	O
8	kDa	O
9	protein	O
10	in	O
11	another	O
12	MMTV	O
13	bearing	O
14	T	O
15	-	O
16	cell	O
17	lymphoma	O
18	,	O
19	EL	O
20	-	O
21	4	O
22	.	O

1	The	O
2	other	O
3	model	O
4	was	O
5	a	O
6	continuous	O
7	exponential	O
8	plus	O
9	constant	O
10	of	O
11	the	O
12	form	O
13	La	O
14	-	O
15	=	O
16	a	O
17	+	O
18	b	O
19	[	O
20	exp	O
21	(	O
22	cVO2	O
23	)].	O

1	State	O
2	-	O
3	approved	O
4	schools	O
5	of	O
6	nursing	O
7	--	O
8	R	O
9	.	O
10	N	O
11	.,	O
12	1972	O
13	.	O

1	The	O
2	poly	O
3	(	O
4	A	O
5	)	O
6	segment	O
7	of	O
8	the	O
9	RNA	O
10	was	O
11	selectively	O
12	cross	O
13	-	O
14	linked	O
15	to	O
16	the	O
17	72	O
18	,	O
19	000	O
20	-	O
21	molecular	O
22	-	O
23	weight	O
24	protein	O
25	(	O
26	72K	O
27	protein	O
28	).	O

1	In	O
2	serum	O
3	-	O
4	free	O
5	media	O
6	,	O
7	p50E4F	B
8	accelerated	O
9	E1A	B
10	-	O
11	induced	O
12	apoptosis	O
13	.	O

1	Cheung	O
2	and	O
3	S	O
4	.	O

1	The	O
2	expression	O
3	of	O
4	this	O
5	clone	O
6	in	O
7	a	O
8	wee1	B
9	/	O
10	mik1	B
11	-	O
12	deficient	O
13	mutant	O
14	causes	O
15	an	O
16	elongated	O
17	cell	O
18	phenotype	O
19	under	O
20	non	O
21	-	O
22	permissive	O
23	growth	O
24	conditions	O
25	.	O

1	The	O
2	plexiform	O
3	neurofibroma	O
4	and	O
5	multiple	O
6	localized	O
7	neurofibromas	O
8	are	O
9	characteristic	O
10	of	O
11	NF1	B
12	.	O

1	In	O
2	three	O
3	of	O
4	the	O
5	seven	O
6	,	O
7	inhalation	O
8	of	O
9	2	O
10	ml	O
11	normal	O
12	saline	O
13	produced	O
14	FEV1	O
15	falls	O
16	of	O
17	25	O
18	%	O
19	to	O
20	30	O
21	%,	O
22	but	O
23	these	O
24	falls	O
25	were	O
26	not	O
27	as	O
28	great	O
29	as	O
30	each	O
31	subject	O
32	'	O
33	s	O
34	reactions	O
35	to	O
36	the	O
37	test	O
38	solutions	O
39	.	O

1	In	O
2	addition	O
3	to	O
4	DNA	O
5	-	O
6	protein	O
7	interactions	O
8	,	O
9	protein	O
10	-	O
11	protein	O
12	interactions	O
13	with	O
14	partner	O
15	proteins	O
16	often	O
17	play	O
18	major	O
19	roles	O
20	in	O
21	targeting	O
22	ETS	B
23	-	I
24	domain	I
25	proteins	I
26	to	O
27	specific	O
28	promoters	O
29	.	O

1	We	O
2	have	O
3	addressed	O
4	these	O
5	issues	O
6	by	O
7	reconstituting	O
8	and	O
9	characterizing	O
10	the	O
11	KRAB	B
12	:	O
13	KAP	B
14	-	I
15	1	I
16	-	O
17	RBCC	B
18	interaction	O
19	using	O
20	purified	O
21	components	O
22	.	O

1	Cell	O
2	lines	O
3	are	O
4	checked	O
5	to	O
6	find	O
7	out	O
8	whether	O
9	they	O
10	develop	O
11	tumors	O
12	in	O
13	nude	O
14	mice	O
15	followed	O
16	by	O
17	an	O
18	analysis	O
19	of	O
20	the	O
21	karyotype	O
22	.	O

1	Two	O
2	patients	O
3	were	O
4	treated	O
5	with	O
6	both	O
7	regimens	O
8	.	O

1	The	O
2	men	O
3	self	O
4	-	O
5	selected	O
6	a	O
7	prescribed	O
8	diet	O
9	at	O
10	home	O
11	emphasizing	O
12	saturated	O
13	fat	O
14	as	O
15	the	O
16	visible	O
17	fat	O
18	for	O
19	1	O
20	week	O
21	.	O

1	Most	O
2	kinases	O
3	are	O
4	not	O
5	significantly	O
6	inhibited	O
7	by	O
8	roscovitine	O
9	.	O
10	cdc2	B
11	/	O
12	cyclin	B
13	B	I
14	,	O
15	cdk2	B
16	/	O
17	cyclin	B
18	A	I
19	,	O
20	cdk2	B
21	/	O
22	cyclin	B
23	E	I
24	and	O
25	cdk5	B
26	/	O
27	p35	B
28	only	O
29	are	O
30	substantially	O
31	inhibited	O
32	(	O
33	IC50	O
34	values	O
35	of	O
36	0	O
37	.	O
38	65	O
39	,	O
40	0	O
41	.	O
42	7	O
43	,	O
44	0	O
45	.	O
46	7	O
47	and	O
48	0	O
49	.	O
50	2	O
51	microM	O
52	,	O
53	respectively	O
54	).	O
55	cdk4	B
56	/	O
57	cyclin	B
58	D1	I
59	and	O
60	cdk6	B
61	/	O
62	cyclin	B
63	D2	I
64	are	O
65	very	O
66	poorly	O
67	inhibited	O
68	by	O
69	roscovitine	O
70	(	O
71	IC50	O
72	>	O
73	100	O
74	microM	O
75	).	O

1	Effect	O
2	of	O
3	2	O
4	-(	O
5	p	O
6	-	O
7	chlorophenyl	O
8	)	O
9	cyclopropylamine	O
10	on	O
11	5	O
12	-	O
13	hydroxyindole	O
14	concentration	O
15	and	O
16	monoamine	B
17	oxidase	I
18	activity	O
19	in	O
20	rat	O
21	brain	O
22	.	O

1	With	O
2	only	O
3	purified	O
4	T	B
5	antigen	I
6	in	O
7	the	O
8	presence	O
9	of	O
10	topoisomerase	B
11	I	I
12	to	O
13	unwind	O
14	purified	O
15	DNA	O
16	,	O
17	ori	O
18	-	O
19	auxiliary	O
20	sequences	O
21	strongly	O
22	facilitated	O
23	T	B
24	-	I
25	antigen	I
26	-	O
27	dependent	O
28	DNA	O
29	conformational	O
30	changes	O
31	consistent	O
32	with	O
33	melting	O
34	the	O
35	first	O
36	50	O
37	base	O
38	pairs	O
39	.	O

1	The	O
2	percentages	O
3	of	O
4	recovery	O
5	decreased	O
6	with	O
7	storage	O
8	time	O
9	,	O
10	although	O
11	the	O
12	addition	O
13	of	O
14	dispersant	O
15	(	O
16	Tris	O
17	-	O
18	Tween	O
19	80	O
20	)	O
21	before	O
22	storage	O
23	appeared	O
24	to	O
25	partially	O
26	prevent	O
27	adhesion	O
28	.	O

1	Studies	O
2	on	O
3	the	O
4	pathogenicity	O
5	of	O
6	ECHO	O
7	9	O
8	(	O
9	HILL	O
10	)	O
11	virus	O
12	and	O
13	its	O
14	mutants	O
15	for	O
16	suckling	O
17	mice	O

1	A	O
2	genomic	O
3	DNA	O
4	clone	O
5	encoding	O
6	oryzacystatin	B
7	(	O
8	Oc	B
9	),	O
10	a	O
11	cysteine	B
12	proteinase	I
13	inhibitor	O
14	(	O
15	cystatin	B
16	)	O
17	of	O
18	rice	O
19	,	O
20	was	O
21	isolated	O
22	from	O
23	a	O
24	lambda	O
25	EMBL3	O
26	phage	O
27	library	O
28	constructed	O
29	with	O
30	Sau3AI	B
31	partial	O
32	digests	O
33	of	O
34	rice	O
35	chromosomal	O
36	DNA	O
37	,	O
38	by	O
39	screening	O
40	with	O
41	an	O
42	oc	B
43	cDNA	I
44	as	O
45	a	O
46	probe	O
47	.	O

1	The	O
2	corn	O
3	and	O
4	mineral	O
5	oil	O
6	emulsions	O
7	were	O
8	almost	O
9	as	O
10	effective	O
11	as	O
12	milk	O
13	but	O
14	less	O
15	effective	O
16	than	O
17	sucrose	O
18	(	O
19	0	O
20	.	O
21	3M	O
22	)	O
23	in	O
24	stimulating	O
25	ingestion	O
26	.	O

1	The	O
2	newly	O
3	defined	O
4	region	O
5	contains	O
6	an	O
7	intron	O
8	that	O
9	may	O
10	be	O
11	alternatively	O
12	spliced	O
13	and	O
14	seven	O
15	polyadenylation	O
16	signal	O
17	sequences	O
18	.	O

1	At	O
2	4	O
3	wk	O
4	however	O
5	,	O
6	tumor	O
7	relapse	O
8	was	O
9	noted	O
10	in	O
11	6	O
12	of	O
13	7	O
14	group	O
15	4	O
16	responders	O
17	,	O
18	10	O
19	of	O
20	12	O
21	in	O
22	group	O
23	5	O
24	,	O
25	13	O
26	of	O
27	16	O
28	in	O
29	group	O
30	7	O
31	,	O
32	but	O
33	only	O
34	4	O
35	of	O
36	19	O
37	group	O
38	8	O
39	responders	O
40	(	O
41	p	O
42	less	O
43	than	O
44	.	O
45	001	O
46	group	O
47	8	O
48	versus	O
49	4	O
50	,	O
51	5	O
52	,	O
53	7	O
54	).	O

1	The	O
2	observation	O
3	of	O
4	late	O
5	effects	O
6	after	O
7	irradiations	O
8	or	O
9	after	O
10	space	O
11	flights	O
12	show	O
13	the	O
14	difficulties	O
15	encountered	O
16	in	O
17	assessing	O
18	radiative	O
19	risks	O
20	during	O
21	long	O
22	duration	O
23	space	O
24	flights	O
25	.	O

1	Inhibition	O
2	of	O
3	Fusarium	O
4	moniliforme	O
5	var	O
6	.	O
7	subglutinans	O
8	,	O
9	the	O
10	causal	O
11	agent	O
12	of	O
13	pine	O
14	pitch	O
15	canker	O
16	,	O
17	by	O
18	the	O
19	soil	O
20	bacterium	O
21	Arthrobacter	O
22	sp	O
23	.	O

1	Two	O
2	of	O
3	these	O
4	motifs	O
5	are	O
6	part	O
7	of	O
8	a	O
9	highly	O
10	conserved	O
11	and	O
12	inducible	O
13	dyad	O
14	symmetry	O
15	element	O
16	shown	O
17	previously	O
18	to	O
19	control	O
20	a	O
21	remote	O
22	IL	B
23	-	I
24	2	I
25	enhancer	I
26	and	O
27	the	O
28	CD18	B
29	promoter	I
30	.	O

1	All	O
2	clones	O
3	and	O
4	strains	O
5	produced	O
6	have	O
7	been	O
8	deposited	O
9	in	O
10	the	O
11	EUROFAN	O
12	genetic	O
13	stock	O
14	centre	O
15	(	O
16	EUROSCARF	O
17	,	O
18	Frankfurt	O
19	).	O

1	We	O
2	conclude	O
3	that	O
4	grade	O
5	III	O
6	BGCT	O
7	can	O
8	be	O
9	treated	O
10	by	O
11	modified	O
12	intralesional	O
13	excision	O
14	provided	O
15	the	O
16	articular	O
17	surfaces	O
18	and	O
19	part	O
20	of	O
21	the	O
22	metaphysis	O
23	are	O
24	intact	O
25	.	O

1	Ruddell	O
2	,	O
3	M	O
4	.	O

1	Transfection	O
2	experiments	O
3	demonstrated	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	(-	O
11	1894	O
12	to	O
13	+	O
14	37	O
15	)	O
16	of	O
17	the	O
18	mStaf	B
19	gene	I
20	drives	O
21	transcription	O
22	in	O
23	mouse	O
24	NMuMG	O
25	cells	O
26	and	O
27	that	O
28	a	O
29	construct	O
30	containing	O
31	a	O
32	fragment	O
33	from	O
34	-	O
35	387	O
36	to	O
37	+	O
38	37	O
39	showed	O
40	the	O
41	highest	O
42	transcriptional	O
43	activity	O
44	.	O

1	The	O
2	expressed	O
3	G1	B
4	-	O
5	G2	B
6	bound	O
7	to	O
8	both	O
9	hyaluronan	O
10	and	O
11	link	B
12	protein	I
13	indicating	O
14	that	O
15	the	O
16	immunoglobulin	B
17	-	I
18	fold	I
19	motif	I
20	and	O
21	proteoglycan	O
22	tandem	O
23	repeat	O
24	loops	O
25	of	O
26	the	O
27	G1	B
28	domain	I
29	were	O
30	correctly	O
31	folded	O
32	.	O

1	CONCLUSION	O
2	:	O
3	Treatment	O
4	of	O
5	sepsis	O
6	with	O
7	the	O
8	platelet	B
9	-	I
10	activating	I
11	factor	I
12	antagonist	O
13	BB	O
14	-	O
15	882	O
16	offers	O
17	no	O
18	advantage	O
19	over	O
20	placebo	O
21	on	O
22	survival	O
23	,	O
24	hemodynamic	O
25	status	O
26	,	O
27	respiratory	O
28	function	O
29	,	O
30	or	O
31	organ	O
32	failure	O
33	scores	O
34	.	O

1	Splicing	O
2	of	O
3	the	O
4	K	B
5	-	I
6	SAM	I
7	alternative	O
8	exon	O
9	of	O
10	the	O
11	fibroblast	B
12	growth	I
13	factor	I
14	receptor	I
15	2	I
16	gene	I
17	is	O
18	heavily	O
19	dependent	O
20	on	O
21	the	O
22	U	O
23	-	O
24	rich	O
25	sequence	O
26	IAS1	B
27	lying	O
28	immediately	O
29	downstream	O
30	from	O
31	its	O
32	5	O
33	'	O
34	splice	O
35	site	O
36	.	O

1	Both	O
2	quantitative	O
3	and	O
4	qualitative	O
5	analysis	O
6	of	O
7	individual	O
8	cytoarchitectonic	O
9	peculiarities	O
10	of	O
11	Meynart	O
12	'	O
13	s	O
14	nucleus	O
15	as	O
16	well	O
17	as	O
18	of	O
19	external	O
20	part	O
21	of	O
22	dorsomedial	O
23	nucleus	O
24	of	O
25	thalamus	O
26	was	O
27	performed	O
28	in	O
29	mentally	O
30	normal	O
31	individuals	O
32	.	O

1	Both	O
2	proprioceptive	O
3	and	O
4	electroreceptive	O
5	units	O
6	showed	O
7	a	O
8	progression	O
9	of	O
10	receptive	O
11	fields	O
12	from	O
13	anterior	O
14	to	O
15	posterior	O
16	body	O
17	in	O
18	the	O
19	rostral	O
20	to	O
21	caudal	O
22	direction	O
23	along	O
24	the	O
25	length	O
26	of	O
27	DGR	O
28	.	O

1	The	O
2	clinical	O
3	stage	O
4	was	O
5	I	O
6	(	O
7	T1N0M0	O
8	),	O
9	and	O
10	S2	O
11	sleeve	O
12	segmentectomy	O
13	with	O
14	lymph	O
15	node	O
16	dissection	O
17	(	O
18	R	O
19	2	O
20	b	O
21	)	O
22	was	O
23	performed	O
24	.	O

1	A	O
2	proportion	O
3	of	O
4	APC	B
5	wild	O
6	-	O
7	type	O
8	colon	O
9	carcinomas	O
10	and	O
11	melanomas	O
12	also	O
13	contains	O
14	constitutive	O
15	nuclear	O
16	Tcf	B
17	-	I
18	4	I
19	/	O
20	beta	B
21	-	I
22	catenin	I
23	complexes	O
24	as	O
25	a	O
26	result	O
27	of	O
28	dominant	O
29	mutations	O
30	in	O
31	the	O
32	N	O
33	terminus	O
34	of	O
35	beta	B
36	-	I
37	catenin	I
38	that	O
39	render	O
40	it	O
41	insensitive	O
42	to	O
43	downregulation	O
44	by	O
45	APC	B
46	,	O
47	GSK3	B
48	beta	I
49	,	O
50	and	O
51	Axin	B
52	/	O
53	Conductin	B
54	.	O

1	That	O
2	of	O
3	the	O
4	T2	B
5	gene	I
6	contains	O
7	numerous	O
8	potential	O
9	sites	O
10	for	O
11	binding	O
12	the	O
13	mammalian	B
14	transcription	I
15	factor	I
16	SP1	I
17	,	O
18	but	O
19	no	O
20	TATA	O
21	or	O
22	CCAAT	O
23	sequences	O
24	are	O
25	evident	O
26	near	O
27	to	O
28	its	O
29	5	O
30	'	O
31	end	O
32	,	O
33	although	O
34	these	O
35	latter	O
36	features	O
37	are	O
38	associated	O
39	with	O
40	the	O
41	human	B
42	T1	I
43	gene	I
44	.	O

1	Prolonged	O
2	suspension	O
3	induced	O
4	a	O
5	significant	O
6	change	O
7	in	O
8	the	O
9	geometric	O
10	configuration	O
11	of	O
12	the	O
13	femur	O
14	middiaphysis	O
15	by	O
16	increasing	O
17	the	O
18	minimum	O
19	diameter	O
20	(	O
21	12	O
22	%)	O
23	without	O
24	any	O
25	significant	O
26	alterations	O
27	in	O
28	cortical	O
29	area	O
30	,	O
31	density	O
32	,	O
33	mineral	O
34	,	O
35	and	O
36	collagen	B
37	concentrations	O
38	.	O

1	Of	O
2	270	O
3	patients	O
4	with	O
5	well	O
6	-	O
7	defined	O
8	drug	O
9	reactions	O
10	,	O
11	190	O
12	(	O
13	70	O
14	per	O
15	cent	O
16	)	O
17	gave	O
18	a	O
19	positive	O
20	response	O
21	to	O
22	the	O
23	mast	O
24	cell	O
25	test	O
26	.	O

1	We	O
2	also	O
3	review	O
4	the	O
5	role	O
6	of	O
7	grains	O
8	in	O
9	the	O
10	formation	O
11	of	O
12	complex	O
13	molecules	O
14	in	O
15	interstellar	O
16	molecular	O
17	clouds	O
18	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	proline	O
6	-	O
7	rich	O
8	domain	O
9	of	O
10	SOS1	B
11	is	O
12	involved	O
13	in	O
14	the	O
15	interaction	O
16	with	O
17	the	O
18	PLC	B
19	-	I
20	gamma1	I
21	SH3	I
22	domain	I
23	.	O

1	Transcripts	O
2	from	O
3	a	O
4	second	O
5	POU	B
6	-	I
7	domain	I
8	gene	I
9	,	O
10	Oct	B
11	-	I
12	25	I
13	,	O
14	were	O
15	present	O
16	at	O
17	low	O
18	levels	O
19	in	O
20	oocytes	O
21	and	O
22	early	O
23	embryos	O
24	and	O
25	were	O
26	dramatically	O
27	upregulated	O
28	during	O
29	early	O
30	gastrulation	O
31	.	O

1	This	O
2	article	O
3	describes	O
4	the	O
5	collaborative	O
6	care	O
7	of	O
8	the	O
9	woman	O
10	participating	O
11	in	O
12	maternal	O
13	blood	O
14	donation	O
15	for	O
16	intrauterine	O
17	transfusion	O
18	.	O

1	The	O
2	recently	O
3	developed	O
4	gamma	B
5	-	I
6	interferon	I
7	(	O
8	IFN	B
9	-	I
10	gamma	I
11	)	O
12	assay	O
13	system	O
14	for	O
15	the	O
16	diagnosis	O
17	of	O
18	bovine	O
19	tuberculosis	O
20	in	O
21	cattle	O
22	has	O
23	been	O
24	accredited	O
25	by	O
26	the	O
27	Standing	O
28	Committee	O
29	on	O
30	Agriculture	O
31	for	O
32	use	O
33	in	O
34	Australia	O
35	.	O

1	A	O
2	TATA	O
3	-	O
4	less	O
5	promoter	O
6	containing	O
7	binding	O
8	sites	O
9	for	O
10	ubiquitous	O
11	transcription	O
12	factors	O
13	mediates	O
14	cell	O
15	type	O
16	-	O
17	specific	O
18	regulation	O
19	of	O
20	the	O
21	gene	O
22	for	O
23	transcription	B
24	enhancer	I
25	factor	I
26	-	I
27	1	I
28	(	O
29	TEF	B
30	-	I
31	1	I
32	).	O

1	Influence	O
2	of	O
3	diet	O
4	on	O
5	urinary	O
6	VMA	O
7	excretion	O
8	.	O

1	The	O
2	effects	O
3	of	O
4	intracisternal	O
5	injection	O
6	(	O
7	i	O
8	.	O
9	c	O
10	.	O
11	i	O
12	.)	O
13	of	O
14	clonidine	O
15	(	O
16	1	O
17	microgram	O
18	kg	O
19	-	O
20	1	O
21	)	O
22	on	O
23	blood	O
24	pressure	O
25	and	O
26	heart	O
27	rate	O
28	were	O
29	studied	O
30	in	O
31	conscious	O
32	rabbits	O
33	with	O
34	an	O
35	implanted	O
36	catheter	O
37	in	O
38	the	O
39	cisterna	O
40	magna	O
41	.	O

1	A	O
2	study	O
3	of	O
4	chromosomes	O
5	of	O
6	lymphocytes	O
7	from	O
8	patients	O
9	treated	O
10	with	O
11	hycanthone	O
12	.	O

1	U73	B
2	contains	O
3	C	O
4	,	O
5	D	O
6	and	O
7	D	O
8	'	O
9	boxes	O
10	and	O
11	a	O
12	12	O
13	-	O
14	nucleotide	O
15	antisense	O
16	complementarity	O
17	to	O
18	the	O
19	28S	B
20	ribosomal	I
21	RNA	I
22	.	O

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	1	I
7	(	I
8	HIV	I
9	-	I
10	1	I
11	)	I
12	Rev	I
13	protein	I
14	is	O
15	a	O
16	positive	O
17	posttranscriptional	O
18	regulator	O
19	of	O
20	viral	O
21	structural	O
22	gene	O
23	expression	O
24	and	O
25	essential	O
26	for	O
27	virus	O
28	replication	O
29	.	O

1	The	O
2	ARF	B
3	promoter	I
4	was	O
5	also	O
6	found	O
7	to	O
8	be	O
9	highly	O
10	responsive	O
11	to	O
12	E2F1	B
13	expression	O
14	,	O
15	in	O
16	keeping	O
17	with	O
18	previous	O
19	results	O
20	at	O
21	the	O
22	RNA	O
23	level	O
24	.	O

1	In	O
2	adulthood	O
3	these	O
4	rats	O
5	were	O
6	hyperactive	O
7	and	O
8	learned	O
9	the	O
10	active	O
11	avoidance	O
12	response	O
13	later	O
14	than	O
15	the	O
16	controls	O
17	.	O

1	Familial	O
2	autoimmune	O
3	hepatitis	O
4	and	O
5	C4	B
6	deficiency	O

1	Therefore	O
2	,	O
3	use	O
4	of	O
5	presaturation	O
6	is	O
7	recommended	O
8	for	O
9	myocardial	O
10	motion	O
11	studies	O
12	using	O
13	cine	O
14	PC	O
15	velocity	O
16	data	O
17	.	O

1	Here	O
2	we	O
3	report	O
4	on	O
5	the	O
6	isolation	O
7	of	O
8	ICK2	B
9	,	O
10	and	O
11	show	O
12	that	O
13	it	O
14	interacts	O
15	with	O
16	Cdc2aAt	B
17	,	O
18	but	O
19	not	O
20	with	O
21	a	O
22	second	O
23	CDK	B
24	from	I
25	Arabidopsis	I
26	,	O
27	Cdc2bAt	B
28	.	O

1	The	O
2	topology	O
3	and	O
4	chain	O
5	folding	O
6	of	O
7	the	O
8	beta	O
9	subunits	O
10	in	O
11	the	O
12	artifactual	O
13	beta	O
14	60	O
15	capsid	O
16	are	O
17	similar	O
18	to	O
19	the	O
20	native	B
21	alpha	I
22	3	I
23	beta	I
24	60	I
25	enzyme	I
26	.	O

1	All	O
2	8	O
3	(	O
4	100	O
5	%)	O
6	patients	O
7	with	O
8	fulminant	O
9	hepatic	O
10	failure	O
11	who	O
12	received	O
13	grafts	O
14	survived	O
15	,	O
16	including	O
17	3	O
18	who	O
19	received	O
20	ABO	O
21	-	O
22	incompatible	O
23	grafts	O
24	,	O
25	though	O
26	2	O
27	of	O
28	these	O
29	subsequently	O
30	required	O
31	retransplantation	O
32	.	O

1	There	O
2	are	O
3	regions	O
4	with	O
5	long	O
6	runs	O
7	of	O
8	up	O
9	to	O
10	45	O
11	%	O
12	C	O
13	or	O
14	35	O
15	%	O
16	G	O
17	residues	O
18	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	studies	O
6	demonstrate	O
7	that	O
8	the	O
9	rat	O
10	HDL	O
11	receptor	O
12	SR	B
13	-	I
14	BI	I
15	promoter	O
16	contains	O
17	two	O
18	sterol	O
19	response	O
20	elements	O
21	(	O
22	pSRE	O
23	and	O
24	dSRE	O
25	)	O
26	through	O
27	which	O
28	SREBP	B
29	-	I
30	1a	I
31	can	O
32	bind	O
33	and	O
34	activate	O
35	transcription	O
36	of	O
37	this	O
38	gene	O
39	.	O

1	Among	O
2	the	O
3	remaining	O
4	22	O
5	sites	O
6	,	O
7	six	O
8	are	O
9	in	O
10	the	O
11	promoters	O
12	of	O
13	known	O
14	alpha	O
15	-	O
16	specific	O
17	genes	O
18	and	O
19	two	O
20	other	O
21	sites	O
22	have	O
23	an	O
24	alpha2	B
25	-	O
26	Mcm1	B
27	-	O
28	dependent	O
29	role	O
30	in	O
31	determining	O
32	the	O
33	direction	O
34	of	O
35	mating	O
36	type	O
37	switching	O
38	.	O

1	Stimulation	O
2	of	O
3	[	O
4	3H	O
5	]	O
6	PA	O
7	production	O
8	upon	O
9	CD3	B
10	cross	O
11	-	O
12	linking	O
13	was	O
14	77	O
15	%	O
16	lower	O
17	in	O
18	permeabilized	O
19	CD45	B
20	-	I
21	cells	O
22	than	O
23	in	O
24	CD45	B
25	+	I
26	cells	O
27	,	O
28	consistent	O
29	with	O
30	the	O
31	reduced	O
32	activity	O
33	of	O
34	p59fyn	B
35	in	O
36	CD45	B
37	-	I
38	cells	O
39	.	O

1	The	O
2	respiratory	O
3	rate	O
4	was	O
5	13	O
6	+/-	O
7	1	O
8	breaths	O
9	/	O
10	min	O
11	with	O
12	52	O
13	+/-	O
14	4	O
15	%	O
16	of	O
17	the	O
18	respiratory	O
19	cycle	O
20	spent	O
21	in	O
22	inspiration	O
23	;	O
24	end	O
25	-	O
26	tidal	O
27	CO2	O
28	pressure	O
29	increased	O
30	by	O
31	3	O
32	.	O
33	3	O
34	+/-	O
35	1	O
36	.	O
37	0	O
38	Torr	O
39	during	O
40	runs	O
41	at	O
42	SIP	O
43	.	O

1	The	O
2	3	O
3	'	O
4	UTR	O
5	has	O
6	several	O
7	stable	O
8	hairpins	O
9	that	O
10	are	O
11	flanked	O
12	by	O
13	single	O
14	-	O
15	stranded	O
16	(	O
17	A	O
18	/	O
19	U	O
20	)	O
21	UGC	O
22	sequences	O
23	.	O

1	Just	O
2	before	O
3	inserting	O
4	on	O
5	the	O
6	anterior	O
7	margin	O
8	and	O
9	apex	O
10	of	O
11	the	O
12	iliac	O
13	crest	O
14	it	O
15	widens	O
16	,	O
17	assuming	O
18	the	O
19	aspect	O
20	of	O
21	a	O
22	small	O
23	cone	O
24	.	O

1	In	O
2	metabolic	O
3	acidosis	O
4	there	O
5	was	O
6	a	O
7	marked	O
8	stimulation	O
9	when	O
10	clamped	O
11	at	O
12	-	O
13	10	O
14	to	O
15	-	O
16	100	O
17	mV	O
18	.	O

1	An	O
2	epidemiological	O
3	survey	O
4	of	O
5	rheumatic	O
6	valve	O
7	disease	O
8	and	O
9	rheumatic	O
10	fever	O
11	in	O
12	primary	O
13	and	O
14	secondary	O
15	school	O
16	students	O
17	in	O
18	Jiangxi	O
19	Province	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	investigate	O
5	the	O
6	incidence	O
7	and	O
8	presentation	O
9	of	O
10	acute	O
11	pernicious	O
12	or	O
13	fulminating	O
14	beriberi	O
15	in	O
16	a	O
17	general	O
18	district	O
19	hospital	O
20	.	O

1	As	O
2	hGM	B
3	-	I
4	CSF	I
5	receptor	I
6	(	O
7	hGMR	B
8	)	O
9	does	O
10	not	O
11	contain	O
12	a	O
13	consensus	O
14	sequence	O
15	for	O
16	binding	O
17	of	O
18	PI	B
19	3	I
20	-	I
21	kinase	I
22	,	O
23	hGMR	B
24	must	O
25	use	O
26	a	O
27	distinct	O
28	mechanism	O
29	for	O
30	its	O
31	association	O
32	with	O
33	and	O
34	activation	O
35	of	O
36	PI	B
37	3	I
38	-	I
39	kinase	I
40	.	O

1	TPA	O
2	and	O
3	TGF	B
4	-	I
5	beta	I
6	1	I
7	did	O
8	not	O
9	markedly	O
10	affect	O
11	the	O
12	activities	O
13	of	O
14	the	O
15	72	O
16	-	O
17	kDa	O
18	enzyme	O
19	.	O

1	These	O
2	results	O
3	demonstrate	O
4	Ras	B
5	-	O
6	and	O
7	Raf	B
8	-	O
9	independent	O
10	ERK	B
11	MAPK	O
12	activation	O
13	maintains	O
14	cell	O
15	viability	O
16	following	O
17	heat	O
18	shock	O
19	.	O

1	The	O
2	mean	O
3	values	O
4	of	O
5	protease	O
6	activity	O
7	were	O
8	significantly	O
9	higher	O
10	in	O
11	the	O
12	test	O
13	groups	O
14	than	O
15	in	O
16	the	O
17	control	O
18	group	O
19	at	O
20	baseline	O
21	.	O

1	Its	O
2	clinical	O
3	and	O
4	histopathologic	O
5	characteristics	O
6	.	O

1	A	O
2	triple	O
3	Ser	O
4	-->	O
5	Ala	O
6	mutant	O
7	form	O
8	of	O
9	yeast	O
10	eIF	B
11	-	I
12	2	I
13	alpha	I
14	was	O
15	found	O
16	to	O
17	be	O
18	no	O
19	longer	O
20	phosphorylated	O
21	by	O
22	either	O
23	of	O
24	the	O
25	yeast	O
26	(	O
27	or	O
28	mammalian	O
29	)	O
30	casein	B
31	kinase	I
32	activities	O
33	in	O
34	vitro	O
35	.	O

1	Behavioral	O
2	and	O
3	electrographic	O
4	expression	O
5	of	O
6	natural	O
7	sleep	O
8	and	O
9	wakefulness	O
10	in	O
11	reptiles	O

1	Molecular	O
2	cloning	O
3	of	O
4	mouse	B
5	thioredoxin	I
6	reductases	I
7	.	O

1	Three	O
2	radiologists	O
3	without	O
4	knowledge	O
5	of	O
6	patients	O
7	'	O
8	data	O
9	and	O
10	treatment	O
11	analyzed	O
12	30	O
13	angiograms	O
14	with	O
15	and	O
16	30	O
17	examinations	O
18	without	O
19	PGF	O
20	.	O

1	Lymphocytes	O
2	from	O
3	all	O
4	3	O
5	species	O
6	yielded	O
7	maximum	O
8	responses	O
9	with	O
10	a	O
11	48	O
12	-	O
13	hour	O
14	prelabel	O
15	and	O
16	12	O
17	-	O
18	to	O
19	-	O
20	16	O
21	hour	O
22	postlabel	O
23	incubation	O
24	period	O
25	at	O
26	41	O
27	C	O
28	and	O
29	1	O
30	:	O
31	20	O
32	blood	O
33	dilution	O
34	.	O

1	The	O
2	virus	O
3	encodes	O
4	a	O
5	40	O
6	-	O
7	kDa	O
8	protein	O
9	,	O
10	tax	B
11	,	O
12	that	O
13	is	O
14	important	O
15	for	O
16	the	O
17	immortalization	O
18	of	O
19	T	O
20	cells	O
21	.	O

1	Hprp3p	B
2	is	O
3	a	O
4	77	O
5	kDa	O
6	protein	O
7	,	O
8	which	O
9	is	O
10	homologous	O
11	to	O
12	the	O
13	Saccharomyces	B
14	cerevisiae	I
15	splicing	I
16	factor	I
17	Prp3p	I
18	.	O

1	32Pi	O
2	labeling	O
3	or	O
4	isoelectric	O
5	focusing	O
6	analysis	O
7	of	O
8	eIF	B
9	-	I
10	2	I
11	alpha	I
12	from	O
13	conditional	O
14	casein	B
15	kinase	I
16	II	I
17	mutants	I
18	indicated	O
19	that	O
20	phosphorylation	O
21	of	O
22	eIF	B
23	-	I
24	2	I
25	alpha	I
26	is	O
27	abolished	O
28	or	O
29	dephosphorylated	O
30	forms	O
31	of	O
32	eIF	B
33	-	I
34	2	I
35	alpha	I
36	are	O
37	detected	O
38	when	O
39	these	O
40	strains	O
41	are	O
42	grown	O
43	at	O
44	the	O
45	restrictive	O
46	growth	O
47	conditions	O
48	.	O

1	In	O
2	cases	O
3	of	O
4	1	O
5	degrees	O
6	HPT	O
7	,	O
8	the	O
9	plasma	O
10	1	O
11	,	O
12	25	O
13	-(	O
14	OH	O
15	)	O
16	2D	O
17	level	O
18	rose	O
19	significantly	O
20	in	O
21	all	O
22	cases	O
23	(	O
24	P	O
25	less	O
26	than	O
27	0	O
28	.	O
29	05	O
30	),	O
31	although	O
32	the	O
33	pattern	O
34	of	O
35	the	O
36	increase	O
37	was	O
38	not	O
39	uniform	O
40	.	O

1	On	O
2	the	O
3	role	O
4	of	O
5	transferrin	B
6	in	O
7	the	O
8	uptake	O
9	of	O
10	gallium	O
11	by	O
12	tumor	O
13	cells	O
14	.	O

1	Assembly	O
2	of	O
3	a	O
4	complex	O
5	between	O
6	FAK	B
7	and	O
8	Src	B
9	kinases	I
10	may	O
11	serve	O
12	to	O
13	regulate	O
14	the	O
15	subcellular	O
16	localization	O
17	and	O
18	the	O
19	enzymatic	O
20	activity	O
21	of	O
22	members	O
23	of	O
24	the	O
25	Src	B
26	family	I
27	of	O
28	kinases	O
29	.	O

1	Uroflowmetry	O
2	can	O
3	detect	O
4	dysuria	O
5	,	O
6	which	O
7	may	O
8	be	O
9	poorly	O
10	perceived	O
11	or	O
12	even	O
13	unknown	O
14	to	O
15	the	O
16	subjects	O
17	themselves	O
18	.	O

1	1993	O
2	.	O

1	We	O
2	previously	O
3	demonstrated	O
4	that	O
5	acute	O
6	expression	O
7	of	O
8	the	O
9	bovine	O
10	papillomavirus	O
11	type	O
12	1	O
13	(	O
14	BPV1	O
15	)	O
16	E2	B
17	protein	I
18	in	O
19	HeLa	O
20	and	O
21	HT	O
22	-	O
23	3	O
24	cervical	O
25	carcinoma	O
26	cell	O
27	lines	O
28	greatly	O
29	reduced	O
30	cellular	O
31	proliferation	O
32	by	O
33	imposing	O
34	a	O
35	specific	O
36	G1	O
37	/	O
38	S	O
39	phase	O
40	growth	O
41	arrest	O
42	.	O

1	The	O
2	changes	O
3	after	O
4	treatment	O
5	were	O
6	observed	O
7	chiefly	O
8	by	O
9	electromyography	O
10	while	O
11	sensory	O
12	and	O
13	motor	O
14	improvement	O
15	were	O
16	also	O
17	recorded	O
18	as	O
19	auxiliary	O
20	indicators	O
21	.	O

1	Additional	O
2	information	O
3	including	O
4	echocardiographic	O
5	sequences	O
6	,	O
7	perioperative	O
8	video	O
9	sequences	O
10	,	O
11	x	O
12	-	O
13	ray	O
14	analysis	O
15	,	O
16	angiograms	O
17	,	O
18	etc	O
19	.	O
20	is	O
21	represented	O
22	in	O
23	the	O
24	program	O
25	.	O

1	Cat	B
2	-	I
3	1	I
4	is	O
5	identical	O
6	to	O
7	the	O
8	recently	O
9	identified	O
10	binding	O
11	partner	O
12	for	O
13	the	O
14	beta	B
15	-	I
16	adrenergic	I
17	receptor	I
18	kinase	I
19	(	O
20	betaARK	B
21	or	O
22	GRK	B
23	-	I
24	2	I
25	),	O
26	which	O
27	was	O
28	shown	O
29	to	O
30	have	O
31	Arf	B
32	-	O
33	GAP	B
34	activity	O
35	.	O

1	Information	O
2	about	O
3	immunologic	O
4	drug	O
5	interactions	O
6	is	O
7	needed	O
8	by	O
9	pharmacists	O
10	to	O
11	make	O
12	rational	O
13	drug	O
14	-	O
15	use	O
16	decisions	O
17	.	O

1	The	O
2	interaction	O
3	between	O
4	piroxicam	O
5	and	O
6	poloxamer	O
7	was	O
8	studied	O
9	by	O
10	x	O
11	-	O
12	ray	O
13	diffractometry	O
14	(	O
15	XRD	O
16	),	O
17	infrared	O
18	(	O
19	IR	O
20	)	O
21	spectroscopy	O
22	and	O
23	differential	O
24	thermal	O
25	analysis	O
26	(	O
27	DTA	O
28	)	O
29	with	O
30	a	O
31	solid	O
32	dispersion	O
33	,	O
34	coprecipitate	O
35	,	O
36	or	O
37	physical	O
38	mixture	O
39	.	O

1	This	O
2	generalization	O
3	of	O
4	MFP	O
5	involves	O
6	defining	O
7	an	O
8	appropriate	O
9	high	O
10	-	O
11	resolution	O
12	cost	O
13	function	O
14	,	O
15	parametrizing	O
16	the	O
17	search	O
18	space	O
19	of	O
20	the	O
21	environment	O
22	and	O
23	source	O
24	,	O
25	constructing	O
26	solutions	O
27	of	O
28	the	O
29	wave	O
30	equation	O
31	,	O
32	and	O
33	utilizing	O
34	a	O
35	nonlinear	O
36	optimization	O
37	method	O
38	to	O
39	search	O
40	the	O
41	parameter	O
42	landscape	O
43	for	O
44	the	O
45	global	O
46	minimum	O
47	of	O
48	the	O
49	cost	O
50	function	O
51	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	report	O
7	a	O
8	detailed	O
9	study	O
10	of	O
11	the	O
12	structure	O
13	and	O
14	the	O
15	functional	O
16	role	O
17	of	O
18	the	O
19	MalT	B
20	binding	I
21	sites	I
22	located	O
23	in	O
24	the	O
25	adjacent	O
26	and	O
27	divergent	O
28	pulAp	B
29	and	O
30	pulCp	B
31	promoters	I
32	.	O

1	Six	O
2	distinct	O
3	Ets	B
4	mRNAs	I
5	were	O
6	identified	O
7	:	O
8	Ets2	B
9	,	O
10	Fli1	B
11	,	O
12	GABPalpha	B
13	,	O
14	SAP1	B
15	,	O
16	Elk1	B
17	,	O
18	and	O
19	PE1	B
20	.	O

1	The	O
2	alpha	O
3	7A	O
4	form	O
5	RNA	O
6	contains	O
7	an	O
8	additional	O
9	113	O
10	nucleotides	O
11	compared	O
12	to	O
13	the	O
14	B	O
15	form	O
16	,	O
17	and	O
18	a	O
19	common	O
20	coding	O
21	region	O
22	in	O
23	the	O
24	A	O
25	and	O
26	B	O
27	form	O
28	RNAs	O
29	is	O
30	used	O
31	in	O
32	alternate	O
33	reading	O
34	frames	O
35	.	O

1	In	O
2	the	O
3	cell	O
4	-	O
5	free	O
6	import	O
7	assay	O
8	,	O
9	beta	B
10	-	I
11	catenin	I
12	rapidly	O
13	migrates	O
14	into	O
15	the	O
16	nucleus	O
17	without	O
18	the	O
19	exogenous	O
20	addition	O
21	of	O
22	cytosol	O
23	,	O
24	Ran	B
25	,	O
26	or	O
27	ATP	O
28	/	O
29	GTP	O
30	.	O

1	The	O
2	clinical	O
3	efficacy	O
4	rates	O
5	evaluated	O
6	in	O
7	151	O
8	cases	O
9	(	O
10	KS	O
11	-	O
12	R1	O
13	group	O
14	in	O
15	77	O
16	cases	O
17	,	O
18	oral	O
19	group	O
20	in	O
21	74	O
22	cases	O
23	)	O
24	on	O
25	standard	O
26	criteria	O
27	of	O
28	committee	O
29	members	O
30	were	O
31	88	O
32	.	O
33	3	O
34	%	O
35	for	O
36	the	O
37	KS	O
38	-	O
39	R1	O
40	group	O
41	and	O
42	86	O
43	.	O
44	5	O
45	%	O
46	for	O
47	the	O
48	oral	O
49	group	O
50	,	O
51	respectively	O
52	.	O

1	The	O
2	YccA	B
3	protein	I
4	was	O
5	found	O
6	to	O
7	be	O
8	degraded	O
9	in	O
10	an	O
11	FtsH	B
12	-	O
13	dependent	O
14	manner	O
15	in	O
16	vivo	O
17	and	O
18	in	O
19	vitro	O
20	,	O
21	whereas	O
22	the	O
23	YccA11	B
24	mutant	I
25	protein	I
26	,	O
27	lacking	O
28	eight	O
29	amino	O
30	acid	O
31	residues	O
32	within	O
33	the	O
34	amino	O
35	-	O
36	terminal	O
37	cytoplasmic	O
38	domain	O
39	,	O
40	was	O
41	refractory	O
42	to	O
43	the	O
44	degradation	O
45	.	O

1	This	O
2	conclusion	O
3	is	O
4	based	O
5	on	O
6	the	O
7	observations	O
8	of	O
9	the	O
10	immunologic	O
11	changes	O
12	that	O
13	characterize	O
14	the	O
15	acute	O
16	stages	O
17	of	O
18	illness	O
19	as	O
20	well	O
21	as	O
22	on	O
23	the	O
24	demonstrated	O
25	association	O
26	with	O
27	toxin	O
28	-	O
29	producing	O
30	bacteria	O
31	in	O
32	the	O
33	pharynx	O
34	and	O
35	gastrointestinal	O
36	tract	O
37	.	O

1	The	O
2	protein	O
3	is	O
4	composed	O
5	of	O
6	a	O
7	central	O
8	alpha	O
9	-	O
10	helical	O
11	portion	O
12	with	O
13	globular	O
14	domains	O
15	at	O
16	both	O
17	NH2	O
18	and	O
19	COOH	O
20	termini	O
21	,	O
22	and	O
23	the	O
24	epitope	O
25	to	O
26	the	O
27	monoclonal	O
28	antibody	O
29	resides	O
30	in	O
31	the	O
32	central	O
33	alpha	O
34	-	O
35	helical	O
36	stalk	O
37	.	O

1	This	O
2	makes	O
3	these	O
4	compounds	O
5	attractive	O
6	as	O
7	vehicles	O
8	for	O
9	these	O
10	and	O
11	other	O
12	gases	O
13	in	O
14	-	O
15	vivo	O
16	and	O
17	in	O
18	-	O
19	vitro	O
20	.	O

1	In	O
2	the	O
3	local	O
4	geomagnetic	O
5	field	O
6	,	O
7	the	O
8	animals	O
9	preferred	O
10	the	O
11	SE	O
12	-	O
13	sector	O
14	.	O

1	A	O
2	role	O
3	for	O
4	glycogen	B
5	synthase	I
6	kinase	I
7	-	I
8	3	I
9	in	O
10	the	O
11	control	O
12	of	O
13	gene	O
14	expression	O
15	.	O

1	There	O
2	were	O
3	no	O
4	interfering	O
5	peaks	O
6	in	O
7	the	O
8	quantitation	O
9	of	O
10	sulbactam	O
11	.	O

1	PLUS	O
2	-	O
3	3	O
4	is	O
5	a	O
6	new	O
7	Swedish	O
8	protocol	O
9	of	O
10	natural	O
11	speech	O
12	in	O
13	3	O
14	-	O
15	year	O
16	-	O
17	old	O
18	children	O
19	.	O

1	Persistence	O
2	of	O
3	toxaphene	O
4	in	O
5	treated	O
6	lakes	O
7	.	O

1	Feline	O
2	leukemia	O
3	viruses	O
4	(	O
5	FeLVs	O
6	),	O
7	which	O
8	are	O
9	replication	O
10	-	O
11	competent	O
12	oncoretroviruses	O
13	of	O
14	the	O
15	domestic	O
16	cat	O
17	species	O
18	,	O
19	are	O
20	contagiously	O
21	transmitted	O
22	in	O
23	natural	O
24	environments	O
25	.	O

1	A	O
2	novel	O
3	,	O
4	testis	B
5	-	I
6	specific	I
7	mRNA	I
8	transcript	I
9	encoding	O
10	an	O
11	NH2	B
12	-	I
13	terminal	I
14	truncated	I
15	nitric	I
16	-	I
17	oxide	I
18	synthase	I
19	.	O
20	mRNA	O
21	diversity	O
22	represents	O
23	a	O
24	major	O
25	theme	O
26	of	O
27	neuronal	B
28	nitric	I
29	-	I
30	oxide	I
31	synthase	I
32	(	O
33	nNOS	B
34	)	O
35	gene	O
36	expression	O
37	in	O
38	somatic	O
39	cells	O
40	/	O
41	tissues	O
42	.	O

1	Among	O
2	six	O
3	different	O
4	library	O
5	isolates	O
6	containing	O
7	6	B
8	.	I
9	5	I
10	-	I
11	to	I
12	7	I
13	-	I
14	kb	I
15	IAP	I
16	units	I
17	,	O
18	some	O
19	restriction	O
20	sites	O
21	were	O
22	highly	O
23	conserved	O
24	whereas	O
25	others	O
26	varied	O
27	in	O
28	both	O
29	occurrence	O
30	and	O
31	position	O
32	.	O

1	After	O
2	tilting	O
3	,	O
4	systolic	O
5	blood	O
6	pressure	O
7	fell	O
8	an	O
9	average	O
10	of	O
11	17	O
12	%	O
13	in	O
14	patients	O
15	who	O
16	cramped	O
17	infrequently	O
18	(	O
19	p	O
20	=	O
21	0	O
22	.	O
23	0031	O
24	)	O
25	but	O
26	only	O
27	10	O
28	%	O
29	in	O
30	frequently	O
31	cramping	O
32	patients	O
33	.	O

1	A	O
2	sequence	O
3	comparison	O
4	reveals	O
5	two	O
6	CCAAT	B
7	/	I
8	enhancer	I
9	binding	I
10	protein	I
11	(	O
12	C	B
13	/	I
14	EBP	I
15	)	O
16	consensus	O
17	sequences	O
18	,	O
19	basic	O
20	DNA	O
21	binding	O
22	region	O
23	and	O
24	leucine	O
25	zippers	O
26	1	O
27	and	O
28	2	O
29	(	O
30	bZIP1	O
31	and	O
32	bZIP2	O
33	),	O
34	within	O
35	this	O
36	region	O
37	.	O

1	The	O
2	remaining	O
3	80	O
4	patients	O
5	underwent	O
6	recordings	O
7	of	O
8	ECG	O
9	,	O
10	beat	O
11	-	O
12	to	O
13	-	O
14	beat	O
15	arterial	O
16	oxygen	O
17	saturation	O
18	(	O
19	SaO2	O
20	),	O
21	and	O
22	respiration	O
23	during	O
24	both	O
25	spontaneous	O
26	and	O
27	controlled	O
28	breathing	O
29	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	study	O
5	demonstrates	O
6	that	O
7	transvaginal	O
8	ultrasonography	O
9	has	O
10	an	O
11	efficiency	O
12	of	O
13	88	O
14	%	O
15	in	O
16	differentiating	O
17	endometriomas	O
18	from	O
19	other	O
20	ovarian	O
21	masses	O
22	with	O
23	a	O
24	specificity	O
25	of	O
26	90	O
27	%.	O

1	The	O
2	available	O
3	data	O
4	suggest	O
5	that	O
6	the	O
7	NF	B
8	kappa	I
9	B2	I
10	nucleoprotein	I
11	complex	I
12	may	O
13	cooperate	O
14	with	O
15	DNA	O
16	-	O
17	bound	O
18	STAT6	B
19	to	O
20	achieve	O
21	IL	B
22	-	I
23	4	I
24	-	O
25	dependent	O
26	activation	O
27	of	O
28	the	O
29	human	B
30	IgE	I
31	germline	I
32	gene	I
33	.	O

1	In	O
2	the	O
3	lattice	O
4	,	O
5	23	O
6	%	O
7	of	O
8	the	O
9	sites	O
10	are	O
11	occupied	O
12	,	O
13	95	O
14	%	O
15	of	O
16	the	O
17	atoms	O
18	are	O
19	in	O
20	the	O
21	lowest	O
22	energy	O
23	magnetic	O
24	sublevel	O
25	,	O
26	and	O
27	37	O
28	%	O
29	are	O
30	in	O
31	the	O
32	lowest	O
33	3D	O
34	vibrational	O
35	state	O
36	.	O

1	The	O
2	major	O
3	phenotypes	O
4	resulting	O
5	from	O
6	Fab1p	B
7	kinase	I
8	inactivation	O
9	include	O
10	temperature	O
11	-	O
12	sensitive	O
13	growth	O
14	,	O
15	vacuolar	O
16	acidification	O
17	defects	O
18	,	O
19	and	O
20	dramatic	O
21	increases	O
22	in	O
23	vacuolar	O
24	size	O
25	.	O

1	All	O
2	other	O
3	ejaculate	O
4	parameters	O
5	(	O
6	density	O
7	,	O
8	motility	O
9	,	O
10	swelling	O
11	test	O
12	,	O
13	penetration	O
14	test	O
15	)	O
16	remained	O
17	unchanged	O
18	,	O
19	and	O
20	there	O
21	was	O
22	only	O
23	one	O
24	post	O
25	-	O
26	therapeutic	O
27	pregnancy	O
28	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	RNA	O
5	transcripts	O
6	encoded	O
7	by	O
8	the	O
9	murine	O
10	p105	B
11	NF	I
12	-	I
13	kappa	I
14	B	I
15	gene	O
16	generates	O
17	I	B
18	kappa	I
19	B	I
20	gamma	I
21	isoforms	I
22	with	O
23	different	O
24	inhibitory	O
25	activities	O
26	.	O

1	One	O
2	of	O
3	these	O
4	is	O
5	located	O
6	in	O
7	the	O
8	5	O
9	'-	O
10	untranslated	O
11	region	O
12	,	O
13	and	O
14	may	O
15	encode	O
16	regulatory	O
17	sequences	O
18	.	O

1	Routine	O
2	blood	O
3	examination	O
4	showed	O
5	leukocytosis	O
6	,	O
7	thrombocytopenia	O
8	,	O
9	positive	O
10	CRP	B
11	,	O
12	and	O
13	elevated	O
14	myocardial	O
15	enzymes	O
16	.	O

1	In	O
2	case	O
3	of	O
4	a	O
5	pathologically	O
6	convoluted	O
7	internal	O
8	carotid	O
9	the	O
10	common	O
11	carotid	O
12	artery	O
13	was	O
14	resected	O
15	with	O
16	an	O
17	end	O
18	-	O
19	to	O
20	-	O
21	end	O
22	anastomosis	O
23	.	O

1	Cattaneo	O
2	,	O
3	and	O
4	J	O
5	.	O

1	Six	O
2	patients	O
3	with	O
4	glomerulonephritis	O
5	in	O
6	association	O
7	with	O
8	a	O
9	ventriculovascular	O
10	shunt	O
11	were	O
12	treated	O
13	with	O
14	three	O
15	basic	O
16	modes	O
17	of	O
18	therapy	O
19	.	O

1	It	O
2	is	O
3	,	O
4	however	O
5	,	O
6	extremely	O
7	homologous	O
8	to	O
9	a	O
10	third	O
11	'	O
12	non	O
13	-	O
14	classical	O
15	'	O
16	gene	O
17	,	O
18	HLA	B
19	-	I
20	5	I
21	.	I
22	4	I
23	,	O
24	and	O
25	to	O
26	the	O
27	chimpanzee	O
28	gene	O
29	,	O
30	Ch28	B
31	.	O

1	Sustained	O
2	activation	O
3	of	O
4	p21	B
5	expression	O
6	is	O
7	proposed	O
8	to	O
9	be	O
10	a	O
11	distinguishing	O
12	feature	O
13	of	O
14	the	O
15	activity	O
16	of	O
17	NGF	B
18	that	O
19	contributes	O
20	to	O
21	PC12	O
22	growth	O
23	arrest	O
24	during	O
25	differentiation	O

1	Amiodarone	O
2	,	O
3	seldom	O
4	used	O
5	as	O
6	first	O
7	-	O
8	line	O
9	treatment	O
10	,	O
11	appears	O
12	to	O
13	be	O
14	the	O
15	most	O
16	effective	O
17	drug	O
18	.	O

1	The	O
2	subjects	O
3	of	O
4	the	O
5	study	O
6	were	O
7	10	O
8	normal	O
9	subjects	O
10	and	O
11	64	O
12	patients	O
13	with	O
14	gastroduodenal	O
15	disease	O
16	.	O

1	Mutations	O
2	at	O
3	three	O
4	sites	O
5	have	O
6	larger	O
7	effects	O
8	in	O
9	muscle	O
10	than	O
11	nonmuscle	O
12	cells	O
13	;	O
14	an	O
15	A	O
16	/	O
17	T	O
18	-	O
19	rich	O
20	site	O
21	mutation	O
22	has	O
23	a	O
24	pronounced	O
25	effect	O
26	in	O
27	both	O
28	striated	O
29	muscle	O
30	types	O
31	,	O
32	mutations	O
33	at	O
34	the	O
35	MEF1	B
36	(	I
37	Right	I
38	E	I
39	-	I
40	box	I
41	)	I
42	site	I
43	are	O
44	relatively	O
45	specific	O
46	to	O
47	expression	O
48	in	O
49	skeletal	O
50	muscle	O
51	,	O
52	and	O
53	mutations	O
54	at	O
55	the	O
56	CArG	O
57	site	O
58	are	O
59	relatively	O
60	specific	O
61	to	O
62	expression	O
63	in	O
64	cardiac	O
65	muscle	O
66	.	O

1	In	O
2	part	O
3	as	O
4	a	O
5	result	O
6	of	O
7	its	O
8	inability	O
9	to	O
10	sustain	O
11	radiative	O
12	loses	O
13	,	O
14	the	O
15	BB	O
16	resonator	O
17	has	O
18	extremely	O
19	low	O
20	RF	O
21	power	O
22	requirements	O
23	.	O

1	Luteinizing	B
2	hormone	I
3	-	I
4	releasing	I
5	hormone	I
6	analog	O
7	therapy	O
8	of	O
9	uterine	O
10	fibroid	O
11	:	O
12	analysis	O
13	of	O
14	results	O
15	obtained	O
16	with	O
17	buserelin	O
18	administered	O
19	intranasally	O
20	and	O
21	goserelin	O
22	administered	O
23	subcutaneously	O
24	as	O
25	a	O
26	monthly	O
27	depot	O
28	.	O

1	In	O
2	Arabidopsis	O
3	,	O
4	the	O
5	induction	O
6	of	O
7	a	O
8	dehydration	O
9	-	O
10	responsive	O
11	gene	O
12	,	O
13	rd22	B
14	,	O
15	is	O
16	mediated	O
17	by	O
18	abscisic	O
19	acid	O
20	(	O
21	ABA	O
22	)	O
23	and	O
24	requires	O
25	protein	O
26	biosynthesis	O
27	for	O
28	ABA	O
29	-	O
30	dependent	O
31	gene	O
32	expression	O
33	.	O

1	The	O
2	same	O
3	IL	B
4	-	I
5	4	I
6	-	O
7	inducible	O
8	reporter	O
9	gene	O
10	is	O
11	also	O
12	synergistically	O
13	activated	O
14	by	O
15	the	O
16	endogenous	B
17	Stat6	I
18	and	O
19	NF	B
20	-	I
21	kappaB	I
22	proteins	I
23	in	O
24	IL	B
25	-	I
26	4	I
27	-	O
28	stimulated	O
29	I	O
30	.	O
31	29mu	O
32	B	O
33	lymphoma	O
34	cells	O
35	.	O

1	The	O
2	5	O
3	'-	O
4	flanking	O
5	region	O
6	,	O
7	from	O
8	nucleotide	O
9	-	O
10	837	O
11	to	O
12	-	O
13	336	O
14	,	O
15	contains	O
16	TATA	O
17	and	O
18	inverted	O
19	CAAT	O
20	boxes	O
21	as	O
22	well	O
23	as	O
24	GATA	B
25	-	I
26	1	I
27	/	O
28	SP1	B
29	erythroid	O
30	-	O
31	specific	O
32	cis	O
33	-	O
34	acting	O
35	regulatory	O
36	elements	O
37	.	O

1	HuEpo	B
2	-	I
3	R	I
4	Ab	I
5	inhibited	O
6	Epo	B
7	-	O
8	induced	O
9	parental	O
10	UT	O
11	-	O
12	7	O
13	cell	O
14	growth	O
15	,	O
16	but	O
17	not	O
18	that	O
19	of	O
20	cells	O
21	of	O
22	clone	O
23	12	O
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	muEpo	B
29	-	I
30	R	I
31	is	O
32	able	O
33	to	O
34	induce	O
35	human	O
36	UT	O
37	-	O
38	7	O
39	cell	O
40	proliferation	O
41	.	O

1	In	O
2	ischemic	O
3	and	O
4	hypoxic	O
5	hypoxia	O
6	,	O
7	a	O
8	strong	O
9	correlation	O
10	was	O
11	found	O
12	between	O
13	cyt	O
14	a	O
15	,	O
16	a3	O
17	oxidation	O
18	level	O
19	and	O
20	VO2	O
21	in	O
22	both	O
23	ischemic	O
24	and	O
25	hypoxic	O
26	hypoxia	O
27	(	O
28	r2	O
29	=.	O
30	90	O
31	and	O
32	.	O
33	87	O
34	,	O
35	respectively	O
36	).	O

1	The	O
2	levels	O
3	of	O
4	galactosyltransferase	B
5	activity	O
6	in	O
7	sera	O
8	from	O
9	normal	O
10	children	O
11	and	O
12	patients	O
13	with	O
14	cystic	O
15	fibrosis	O
16	.	O

1	Expression	O
2	of	O
3	activated	O
4	Cdc42	B
5	results	O
6	in	O
7	the	O
8	translocation	O
9	of	O
10	PKClambda	B
11	from	O
12	the	O
13	nucleus	O
14	into	O
15	the	O
16	cytosol	O
17	,	O
18	and	O
19	Cdc42	B
20	and	O
21	PKClambda	B
22	colocalize	O
23	at	O
24	the	O
25	plasma	O
26	membrane	O
27	and	O
28	in	O
29	the	O
30	cytoplasm	O
31	.	O

1	The	O
2	gene	O
3	encoding	O
4	IFN	B
5	-	I
6	gamma	I
7	was	O
8	previously	O
9	found	O
10	to	O
11	contain	O
12	an	O
13	intronic	O
14	enhancer	O
15	element	O
16	that	O
17	was	O
18	not	O
19	tissue	O
20	-	O
21	specific	O
22	in	O
23	its	O
24	activity	O
25	,	O
26	despite	O
27	the	O
28	restricted	O
29	expression	O
30	of	O
31	the	O
32	intact	O
33	IFN	B
34	-	I
35	gamma	I
36	-	I
37	encoding	I
38	gene	I
39	.	O

1	The	O
2	mean	O
3	jitter	O
4	and	O
5	the	O
6	fiber	O
7	density	O
8	did	O
9	not	O
10	change	O
11	significantly	O
12	from	O
13	day	O
14	0	O
15	(	O
16	30	O
17	.	O
18	1	O
19	+/-	O
20	3	O
21	.	O
22	6	O
23	microseconds	O
24	;	O
25	1	O
26	.	O
27	4	O
28	+/-	O
29	0	O
30	.	O
31	07	O
32	)	O
33	to	O
34	day	O
35	30	O
36	(	O
37	34	O
38	.	O
39	5	O
40	+/-	O
41	2	O
42	.	O
43	7	O
44	microseconds	O
45	;	O
46	1	O
47	.	O
48	6	O
49	+/-	O
50	0	O
51	.	O
52	13	O
53	).	O

1	In	O
2	mice	O
3	,	O
4	three	O
5	major	O
6	families	O
7	of	O
8	L1	O
9	elements	O
10	,	O
11	termed	O
12	"	O
13	A	O
14	,"	O
15	"	O
16	F	O
17	,"	O
18	and	O
19	"	O
20	V	O
21	,"	O
22	have	O
23	been	O
24	defined	O
25	on	O
26	the	O
27	basis	O
28	of	O
29	the	O
30	sequence	O
31	found	O
32	at	O
33	the	O
34	5	O
35	'	O
36	terminus	O
37	.	O

1	Comparison	O
2	with	O
3	the	O
4	bovine	O
5	gene	O
6	showed	O
7	that	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	hATP1	B
16	gene	I
17	has	O
18	an	O
19	unconserved	O
20	guanine	O
21	-	O
22	cytosine	O
23	(	O
24	GC	O
25	)	O
26	rich	O
27	region	O
28	,	O
29	including	O
30	several	O
31	binding	O
32	motifs	O
33	of	O
34	transcriptional	O
35	factors	O
36	,	O
37	such	O
38	as	O
39	Sp1	B
40	,	O
41	AP	B
42	-	I
43	2	I
44	,	O
45	and	O
46	GCF	B
47	.	O

1	By	O
2	comparing	O
3	the	O
4	abundances	O
5	of	O
6	many	O
7	yeast	O
8	transcripts	O
9	in	O
10	isogenic	O
11	wild	O
12	-	O
13	type	O
14	and	O
15	paf1	B
16	mutant	I
17	strains	O
18	,	O
19	we	O
20	have	O
21	identified	O
22	genes	O
23	whose	O
24	expression	O
25	is	O
26	affected	O
27	by	O
28	PAF1	B
29	.	O

1	The	O
2	findings	O
3	are	O
4	discussed	O
5	in	O
6	the	O
7	context	O
8	of	O
9	known	O
10	properties	O
11	of	O
12	cortical	O
13	-	O
14	bar	O
15	detectors	O
16	.	O

1	Effects	O
2	of	O
3	estrogen	O
4	and	O
5	glucocorticoids	O
6	on	O
7	the	O
8	adrenal	O
9	development	O
10	of	O
11	the	O
12	fetus	O
13	.	O

1	A	O
2	new	O
3	semi	O
4	-	O
5	automatic	O
6	method	O
7	for	O
8	quantifying	O
9	regional	O
10	cerebral	O
11	uptake	O
12	of	O
13	99m	O
14	technetium	O
15	-	O
16	hexamethylpropylene	O
17	amine	O
18	oxime	O
19	(	O
20	99mTc	O
21	-	O
22	HMPAO	O
23	)	O
24	was	O
25	used	O
26	to	O
27	assess	O
28	single	O
29	photon	O
30	emission	O
31	tomograms	O
32	from	O
33	5	O
34	normal	O
35	subjects	O
36	,	O
37	14	O
38	patients	O
39	with	O
40	Alzheimer	O
41	'	O
42	s	O
43	disease	O
44	,	O
45	14	O
46	patients	O
47	with	O
48	dementia	O
49	of	O
50	frontal	O
51	lobe	O
52	type	O
53	and	O
54	4	O
55	patients	O
56	with	O
57	dementia	O
58	with	O
59	motor	O
60	neurone	O
61	disease	O
62	.	O

1	Patients	O
2	receiving	O
3	VPA	O
4	showed	O
5	differences	O
6	in	O
7	attention	O
8	,	O
9	visuomotor	O
10	performance	O
11	,	O
12	verbal	O
13	span	O
14	and	O
15	sensory	O
16	discrimination	O
17	tasks	O
18	at	O
19	T1	O
20	,	O
21	in	O
22	visuomotor	O
23	performance	O
24	at	O
25	T2	O
26	and	O
27	in	O
28	spatial	O
29	span	O
30	at	O
31	T3	O
32	,	O
33	whereas	O
34	no	O
35	differences	O
36	were	O
37	detected	O
38	at	O
39	T4	O
40	.	O

1	The	O
2	U17	B
3	/	O
4	U16	B
5	and	O
6	the	O
7	U16	B
8	+	I
9	gene	I
10	products	I
11	transactivated	O
12	the	O
13	HIV	B
14	LTR	I
15	.	O

1	It	O
2	is	O
3	clear	O
4	that	O
5	subclinical	O
6	and	O
7	silent	O
8	CD	O
9	exist	O
10	in	O
11	a	O
12	large	O
13	subgroup	O
14	of	O
15	the	O
16	celiac	O
17	population	O
18	.	O

1	LCBF	O
2	in	O
3	normal	O
4	and	O
5	hypoxic	O
6	puppies	O
7	was	O
8	correlated	O
9	with	O
10	local	O
11	cerebral	O
12	glucose	O
13	utilization	O
14	(	O
15	LCGU	O
16	)	O
17	obtained	O
18	under	O
19	the	O
20	same	O
21	experimental	O
22	conditions	O
23	(	O
24	Duffy	O
25	et	O
26	al	O
27	,	O
28	1982	O
29	).	O

1	Acute	O
2	inhalation	O
3	toxicity	O
4	of	O
5	T	O
6	-	O
7	2	O
8	mycotoxin	O
9	in	O
10	mice	O
11	.	O

1	Effect	O
2	of	O
3	phenformin	O
4	on	O
5	gluconeogenesis	O
6	in	O
7	perfused	O
8	rat	O
9	liver	O
10	.	O

1	Disruption	O
2	of	O
3	microtubules	O
4	did	O
5	not	O
6	affect	O
7	the	O
8	fidelity	O
9	or	O
10	kinetics	O
11	of	O
12	vacuolar	O
13	protein	O
14	sorting	O
15	,	O
16	indicating	O
17	that	O
18	Vps1p	B
19	function	O
20	is	O
21	not	O
22	dependent	O
23	on	O
24	microtubules	O
25	.	O

1	Lysosomal	O
2	enzymes	O
3	that	O
4	degrade	O
5	cartilage	O
6	are	O
7	released	O
8	.	O

1	Diagnosis	O
2	of	O
3	prostatic	O
4	carcinoma	O
5	:	O
6	the	O
7	yield	O
8	of	O
9	serum	B
10	prostate	I
11	specific	I
12	antigen	I
13	,	O
14	digital	O
15	rectal	O
16	examination	O
17	and	O
18	transrectal	O
19	ultrasonography	O
20	.	O

1	The	O
2	effects	O
3	on	O
4	reflex	O
5	latencies	O
6	but	O
7	not	O
8	on	O
9	paCO2	O
10	or	O
11	pHa	O
12	were	O
13	blocked	O
14	by	O
15	naloxone	O
16	(	O
17	2	O
18	mg	O
19	/	O
20	kg	O
21	),	O
22	and	O
23	were	O
24	not	O
25	present	O
26	in	O
27	morphine	O
28	-	O
29	tolerant	O
30	animals	O
31	.	O

1	We	O
2	have	O
3	screened	O
4	the	O
5	elastin	B
6	gene	I
7	for	O
8	mutations	O
9	responsible	O
10	for	O
11	supravalvular	O
12	aortic	O
13	stenosis	O
14	(	O
15	SVAS	O
16	)	O
17	in	O
18	two	O
19	large	O
20	,	O
21	independently	O
22	collected	O
23	families	O
24	with	O
25	isolated	O
26	(	O
27	nonsyndromic	O
28	)	O
29	SVAS	O
30	.	O

1	In	O
2	previous	O
3	work	O
4	(	O
5	E	O
6	.	O

1	Topics	O
2	reviewed	O
3	here	O
4	include	O
5	:	O
6	data	O
7	supporting	O
8	the	O
9	association	O
10	of	O
11	myositis	O
12	with	O
13	cancer	O
14	and	O
15	the	O
16	appropriate	O
17	evaluations	O
18	for	O
19	malignancy	O
20	in	O
21	a	O
22	myositis	O
23	patient	O
24	;	O
25	an	O
26	approach	O
27	to	O
28	the	O
29	assessment	O
30	of	O
31	patients	O
32	with	O
33	dermatomyositis	O
34	sine	O
35	myositis	O
36	;	O
37	the	O
38	usefulness	O
39	of	O
40	the	O
41	clinicopathological	O
42	and	O
43	serological	O
44	classifications	O
45	;	O
46	a	O
47	discussion	O
48	of	O
49	whether	O
50	childhood	O
51	and	O
52	adult	O
53	myositis	O
54	are	O
55	the	O
56	same	O
57	or	O
58	different	O
59	entities	O
60	;	O
61	a	O
62	review	O
63	of	O
64	those	O
65	prognostic	O
66	factors	O
67	to	O
68	consider	O
69	in	O
70	the	O
71	clinical	O
72	management	O
73	of	O
74	myositis	O
75	patients	O
76	;	O
77	current	O
78	approaches	O
79	and	O
80	their	O
81	limitations	O
82	for	O
83	assessing	O
84	disease	O
85	activity	O
86	and	O
87	damage	O
88	.	O

1	This	O
2	binary	O
3	repeat	O
4	contains	O
5	repetitive	O
6	DNA	O
7	elements	O
8	that	O
9	include	O
10	LINES	O
11	,	O
12	SINES	O
13	,	O
14	medium	O
15	reiteration	O
16	frequency	O
17	repeats	O
18	,	O
19	and	O
20	a	O
21	transposon	O
22	-	O
23	like	O
24	element	O
25	.	O

1	The	O
2	responsiveness	O
3	of	O
4	visual	O
5	cortex	O
6	(	O
7	VC	O
8	)	O
9	and	O
10	superior	O
11	colliculus	O
12	(	O
13	SC	O
14	)	O
15	was	O
16	simultaneously	O
17	compared	O
18	following	O
19	conditioning	O
20	"	O
21	ON	O
22	"	O
23	or	O
24	"	O
25	OFF	O
26	"	O
27	stimulation	O
28	,	O
29	in	O
30	the	O
31	rabbit	O
32	.	O

1	In	O
2	the	O
3	budding	O
4	yeast	O
5	,	O
6	Saccharomyces	O
7	cerevisiae	O
8	,	O
9	replicators	O
10	can	O
11	function	O
12	outside	O
13	the	O
14	chromosome	O
15	as	O
16	autonomously	O
17	replicating	O
18	sequence	O
19	(	O
20	ARS	O
21	)	O
22	elements	O
23	;	O
24	however	O
25	,	O
26	within	O
27	chromosome	O
28	III	O
29	,	O
30	certain	O
31	ARSs	O
32	near	O
33	the	O
34	transcriptionally	O
35	silent	O
36	HML	B
37	locus	I
38	show	O
39	no	O
40	replication	O
41	origin	O
42	activity	O
43	.	O

1	During	O
2	a	O
3	disease	O
4	remission	O
5	there	O
6	was	O
7	an	O
8	increase	O
9	in	O
10	GAG	O
11	secretion	O
12	with	O
13	urine	O
14	,	O
15	linked	O
16	with	O
17	hyperheparinuria	O
18	(	O
19	13	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	,	O
25	P	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	).	O

1	2000	O
2	update	O
3	of	O
4	recommendations	O
5	for	O
6	the	O
7	use	O
8	of	O
9	hematopoietic	B
10	colony	I
11	-	I
12	stimulating	I
13	factors	I
14	:	O
15	evidence	O
16	-	O
17	based	O
18	,	O
19	clinical	O
20	practice	O
21	guidelines	O
22	.	O

1	Immunolocalization	O
2	of	O
3	Sop1p	B
4	revealed	O
5	a	O
6	cytoplasmic	O
7	distribution	O
8	and	O
9	cell	O
10	fractionation	O
11	studies	O
12	showed	O
13	that	O
14	a	O
15	significant	O
16	fraction	O
17	of	O
18	Sop1p	B
19	was	O
20	recovered	O
21	in	O
22	a	O
23	sedimentable	O
24	fraction	O
25	of	O
26	the	O
27	cytosolic	O
28	material	O
29	.	O

1	IFI	B
2	16	I
3	mRNA	I
4	was	O
5	found	O
6	to	O
7	be	O
8	constitutively	O
9	expressed	O
10	in	O
11	lymphoid	O
12	cells	O
13	and	O
14	in	O
15	cell	O
16	lines	O
17	of	O
18	both	O
19	the	O
20	T	O
21	and	O
22	B	O
23	lineages	O
24	.	O

1	The	O
2	gene	O
3	encodes	O
4	an	O
5	ATP	B
6	-	I
7	binding	I
8	cassette	I
9	,	O
10	ABC	B
11	transporter	I
12	.	O

1	The	O
2	antilog	O
3	transformation	O
4	of	O
5	pH	O
6	did	O
7	not	O
8	improve	O
9	the	O
10	results	O
11	.	O

1	These	O
2	factors	O
3	belong	O
4	to	O
5	a	O
6	set	O
7	of	O
8	genetically	O
9	distinct	O
10	molecules	O
11	,	O
12	including	O
13	AP	B
14	-	I
15	4	I
16	and	O
17	MLTF	B
18	,	O
19	that	O
20	bind	O
21	to	O
22	the	O
23	CACCTGTC	O
24	motif	O
25	or	O
26	related	O
27	sequences	O
28	.	O

1	In	O
2	such	O
3	a	O
4	manner	O
5	,	O
6	activated	O
7	PKR	B
8	inhibits	O
9	cell	O
10	growth	O
11	and	O
12	induces	O
13	apoptosis	O
14	,	O
15	whereas	O
16	disruption	O
17	of	O
18	normal	O
19	PKR	B
20	signaling	O
21	results	O
22	in	O
23	unregulated	O
24	cell	O
25	growth	O
26	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	,	O
5	using	O
6	the	O
7	Ltp4	B
8	-	O
9	specific	O
10	probe	O
11	,	O
12	indicated	O
13	that	O
14	Xanthomonas	O
15	campestris	O
16	pv	O
17	.	O
18	translucens	O
19	induced	O
20	an	O
21	increase	O
22	over	O
23	basal	O
24	levels	O
25	of	O
26	Ltp4	B
27	mRNA	I
28	,	O
29	while	O
30	Pseudomonas	O
31	syringae	O
32	pv	O
33	.	O
34	japonica	O
35	caused	O
36	a	O
37	decrease	O
38	.	O

1	Voluntary	O
2	wheel	O
3	running	O
4	did	O
5	not	O
6	significantly	O
7	increase	O
8	estimated	O
9	alanine	O
10	or	O
11	pyruvate	O
12	Gneo	O
13	or	O
14	absolute	O
15	glycerol	O
16	Ra	O
17	.	O

1	Another	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	exonic	O
8	splicing	O
9	suppressor	O
10	1	O
11	(	O
12	ESS1	O
13	),	O
14	represses	O
15	use	O
16	of	O
17	the	O
18	nt	O
19	3225	O
20	3	O
21	'	O
22	splice	O
23	site	O
24	.	O

1	An	O
2	aromatic	O
3	stacking	O
4	interaction	O
5	between	O
6	subunits	O
7	helps	O
8	mediate	O
9	DNA	O
10	sequence	O
11	specificity	O
12	:	O
13	operator	O
14	site	O
15	discrimination	O
16	by	O
17	phage	B
18	lambda	I
19	cI	I
20	repressor	I
21	.	O

1	For	O
2	pressure	O
3	greater	O
4	than	O
5	121	O
6	atm	O
7	abs	O
8	,	O
9	an	O
10	increased	O
11	excitability	O
12	of	O
13	the	O
14	tadpoles	O
15	made	O
16	it	O
17	difficult	O
18	to	O
19	distinguish	O
20	the	O
21	righting	O
22	reflex	O
23	from	O
24	involuntary	O
25	movements	O
26	.	O

1	However	O
2	,	O
3	the	O
4	increase	O
5	in	O
6	biliary	O
7	excretion	O
8	did	O
9	not	O
10	compensate	O
11	for	O
12	the	O
13	reduced	O
14	elimination	O
15	of	O
16	bretylium	O
17	and	O
18	hexylsalicylic	O
19	acid	O
20	via	O
21	the	O
22	kidney	O
23	.	O

1	Five	O
2	-	O
3	year	O
4	prospective	O
5	study	O
6	of	O
7	peripheral	O
8	white	O
9	blood	O
10	cells	O
11	in	O
12	infectious	O
13	mononucleosis	O
14	.	O

1	Furthermore	O
2	,	O
3	bone	O
4	marrow	O
5	-	O
6	derived	O
7	macrophages	O
8	from	O
9	LAT	B
10	-	O
11	deficient	O
12	mice	O
13	displayed	O
14	reduced	O
15	phagocytic	O
16	efficiency	O
17	in	O
18	comparison	O
19	to	O
20	the	O
21	macrophages	O
22	from	O
23	wild	O
24	-	O
25	type	O
26	mice	O
27	.	O

1	Selected	O
2	topics	O
3	in	O
4	pediatric	O
5	ultrasonography	O
6	--	O
7	1992	O
8	.	O

1	DNA	O
2	sequencing	O
3	of	O
4	a	O
5	17	O
6	-	O
7	kb	O
8	segment	O
9	encompassing	O
10	a	O
11	gammaherpesvirus	O
12	divergent	O
13	locus	O
14	(	O
15	DL	O
16	-	O
17	B	O
18	)	O
19	between	O
20	ORF11	O
21	and	O
22	ORF17	O
23	revealed	O
24	the	O
25	presence	O
26	of	O
27	nine	O
28	viral	O
29	ORFs	O
30	with	O
31	predicted	O
32	gene	O
33	products	O
34	related	O
35	to	O
36	cellular	O
37	proteins	O
38	.	O

1	Although	O
2	Micrococcus	B
3	luteus	I
4	UV	I
5	endonuclease	I
6	has	O
7	been	O
8	reported	O
9	to	O
10	be	O
11	an	O
12	18	O
13	-	O
14	kDa	O
15	enzyme	O
16	with	O
17	possible	O
18	homology	O
19	to	O
20	the	O
21	16	B
22	-	I
23	kDa	I
24	endonuclease	I
25	V	I
26	from	I
27	bacteriophage	I
28	T4	I
29	(	O
30	Gordon	O
31	,	O
32	L	O
33	.	O

1	In	O
2	these	O
3	cells	O
4	,	O
5	ras	B
6	-	O
7	induced	O
8	transition	O
9	is	O
10	accompanied	O
11	by	O
12	a	O
13	strong	O
14	induction	O
15	of	O
16	AP	B
17	-	I
18	1	I
19	-	O
20	binding	O
21	activity	O
22	along	O
23	with	O
24	increased	O
25	expression	O
26	of	O
27	CD44	B
28	mRNA	I
29	and	O
30	protein	O
31	.	O

1	Together	O
2	with	O
3	a	O
4	considerably	O
5	shortened	O
6	and	O
7	interrupted	O
8	aromatic	O
9	aa	O
10	stretch	O
11	in	O
12	this	O
13	region	O
14	,	O
15	these	O
16	differences	O
17	are	O
18	discussed	O
19	in	O
20	terms	O
21	of	O
22	the	O
23	peculiar	O
24	affinity	O
25	of	O
26	cyanobacterial	B
27	cytochrome	I
28	oxidases	I
29	for	O
30	acidic	O
31	c	B
32	-	I
33	type	I
34	cytochromes	I
35	.	O

1	Students	O
2	,	O
3	parents	O
4	,	O
5	teachers	O
6	and	O
7	hearing	O
8	disorders	O

1	Reconstitution	O
2	of	O
3	Raf	B
4	-	I
5	1	I
6	activity	O
7	was	O
8	observed	O
9	only	O
10	with	O
11	kinase	O
12	active	O
13	Jak1	B
14	in	O
15	both	O
16	cell	O
17	lines	O
18	.	O

1	Recent	O
2	target	O
3	BP	O
4	goals	O
5	promulgated	O
6	by	O
7	the	O
8	Sixth	O
9	Report	O
10	from	O
11	the	O
12	Joint	O
13	National	O
14	Committee	O
15	(	O
16	JNC	O
17	VI	O
18	)	O
19	are	O
20	based	O
21	on	O
22	the	O
23	premise	O
24	that	O
25	the	O
26	intensity	O
27	of	O
28	treatment	O
29	directly	O
30	corresponds	O
31	to	O
32	the	O
33	magnitude	O
34	of	O
35	pretreatment	O
36	risk	O
37	.	O

1	BACKGROUND	O
2	:	O
3	Mitosis	O
4	is	O
5	regulated	O
6	by	O
7	MPF	B
8	(	O
9	maturation	B
10	promoting	I
11	factor	I
12	),	O
13	the	O
14	active	O
15	form	O
16	of	O
17	Cdc2	B
18	/	I
19	28	I
20	-	O
21	cyclin	B
22	B	I
23	complexes	O
24	.	O

1	In	O
2	order	O
3	to	O
4	examine	O
5	the	O
6	potential	O
7	role	O
8	of	O
9	transcriptional	O
10	silencing	O
11	during	O
12	productive	O
13	HSV	O
14	-	O
15	1	O
16	infection	O
17	,	O
18	recombinant	O
19	viruses	O
20	were	O
21	generated	O
22	in	O
23	which	O
24	wild	B
25	-	I
26	type	I
27	or	I
28	mutant	I
29	ICP34	I
30	.	I
31	5	I
32	promoters	I
33	controlling	O
34	the	O
35	expression	O
36	of	O
37	a	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	I
41	gene	I
42	were	O
43	inserted	O
44	into	O
45	the	O
46	thymidine	B
47	kinase	I
48	gene	I
49	of	O
50	the	O
51	viral	O
52	genome	O
53	.	O

1	Double	O
2	mutant	O
3	analysis	O
4	suggests	O
5	that	O
6	Rad54p	B
7	and	O
8	Mus81p	B
9	act	O
10	in	O
11	one	O
12	pathway	O
13	for	O
14	the	O
15	repair	O
16	of	O
17	,	O
18	or	O
19	tolerance	O
20	to	O
21	,	O
22	UV	O
23	-	O
24	induced	O
25	DNA	O
26	damage	O
27	.	O

1	Similarly	O
2	approximately	O
3	300	O
4	bp	O
5	of	O
6	sequence	O
7	downstream	O
8	of	O
9	the	O
10	translation	O
11	terminator	O
12	TGA	O
13	of	O
14	the	O
15	beta	B
16	-	I
17	tubulin	I
18	2	I
19	(	O
20	BTU2	B
21	)	O
22	gene	O
23	could	O
24	substitute	O
25	for	O
26	the	O
27	3	O
28	'	O
29	region	O
30	of	O
31	the	O
32	H4	B
33	-	I
34	I	I
35	gene	I
36	.	O

1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Percentage	O
6	change	O
7	in	O
8	the	O
9	apnea	O
10	-	O
11	hypopnea	O
12	index	O
13	(	O
14	AHI	O
15	;	O
16	apnea	O
17	events	O
18	+	O
19	hypopnea	O
20	events	O
21	per	O
22	hour	O
23	of	O
24	sleep	O
25	)	O
26	and	O
27	odds	O
28	of	O
29	developing	O
30	moderate	O
31	-	O
32	to	O
33	-	O
34	severe	O
35	SDB	O
36	(	O
37	defined	O
38	by	O
39	an	O
40	AHI	O
41	>	O
42	or	O
43	=	O
44	15	O
45	events	O
46	per	O
47	hour	O
48	of	O
49	sleep	O
50	),	O
51	with	O
52	respect	O
53	to	O
54	change	O
55	in	O
56	weight	O
57	.	O

1	By	O
2	150	O
3	minutes	O
4	after	O
5	Cr2O3	O
6	inhalation	O
7	,	O
8	FEV1	O
9	.	O
10	0	O
11	had	O
12	decreased	O
13	by	O
14	32	O
15	%.	O

1	In	O
2	addition	O
3	,	O
4	carp	B
5	JAK1	I
6	shows	O
7	higher	O
8	sequence	O
9	homology	O
10	to	O
11	mammalian	B
12	JAK1	I
13	in	O
14	both	O
15	the	O
16	kinase	O
17	-	O
18	like	O
19	(	O
20	JH2	B
21	)	O
22	and	O
23	kinase	O
24	(	O
25	JH1	B
26	)	O
27	domains	O
28	(	O
29	approximately	O
30	70	O
31	%	O
32	identity	O
33	).	O

1	High	O
2	fibrinogen	B
3	levels	O
4	could	O
5	thus	O
6	be	O
7	a	O
8	risk	O
9	for	O
10	perioperative	O
11	thrombosis	O
12	.	O

1	This	O
2	region	O
3	includes	O
4	verA	B
5	,	O
6	a	O
7	structural	O
8	gene	O
9	previously	O
10	shown	O
11	to	O
12	be	O
13	required	O
14	for	O
15	ST	O
16	biosynthesis	O
17	,	O
18	and	O
19	24	O
20	additional	O
21	closely	O
22	spaced	O
23	transcripts	O
24	ranging	O
25	in	O
26	size	O
27	from	O
28	0	O
29	.	O
30	6	O
31	to	O
32	7	O
33	.	O
34	2	O
35	kb	O
36	that	O
37	are	O
38	coordinately	O
39	induced	O
40	only	O
41	under	O
42	ST	O
43	-	O
44	producing	O
45	conditions	O
46	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	MBF	O
6	on	O
7	incisors	O
8	and	O
9	its	O
10	direction	O
11	in	O
12	three	O
13	dimensions	O
14	for	O
15	different	O
16	jaw	O
17	openings	O
18	in	O
19	ten	O
20	subjects	O
21	.	O

1	The	O
2	initial	O
3	phase	O
4	of	O
5	increased	O
6	vascular	O
7	permeability	O
8	in	O
9	the	O
10	peritoneal	O
11	cavity	O
12	and	O
13	LTB4	O
14	production	O
15	was	O
16	dose	O
17	dependently	O
18	inhibited	O
19	by	O
20	the	O
21	5	O
22	-	O
23	LO	O
24	inhibitors	O
25	phenidone	O
26	,	O
27	BW	O
28	A4C	O
29	,	O
30	A63162	O
31	,	O
32	and	O
33	ICI	O
34	207	O
35	968	O
36	but	O
37	not	O
38	by	O
39	dexamethasone	O
40	or	O
41	colchicine	O
42	.	O

1	Environmental	O
2	factors	O
3	were	O
4	more	O
5	important	O
6	in	O
7	the	O
8	older	O
9	cohorts	O
10	(	O
11	perhaps	O
12	because	O
13	of	O
14	less	O
15	reliable	O
16	recall	O
17	).	O

1	Once	O
2	NGF	B
3	administration	O
4	is	O
5	proven	O
6	effective	O
7	it	O
8	will	O
9	be	O
10	possible	O
11	to	O
12	develop	O
13	alternative	O
14	ways	O
15	of	O
16	NGF	B
17	administration	O
18	.	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	the	O
7	zinc	B
8	finger	I
9	protein	I
10	Gis1	I
11	acts	O
12	as	O
13	a	O
14	dosage	O
15	-	O
16	dependent	O
17	suppressor	O
18	of	O
19	the	O
20	rim15Delta	B
21	defect	O
22	in	O
23	nutrient	O
24	limitation	O
25	-	O
26	induced	O
27	transcriptional	O
28	derepression	O
29	of	O
30	SSA3	B
31	.	O

1	Recovery	O
2	of	O
3	carbimazole	O
4	-	O
5	induced	O
6	agranulocytosis	O
7	following	O
8	recombinant	B
9	granulocyte	I
10	-	I
11	macrophage	I
12	colony	I
13	stimulating	I
14	factor	I
15	(	O
16	rhGM	B
17	-	I
18	CSF	I
19	)	O
20	administration	O
21	.	O

1	They	O
2	were	O
3	almost	O
4	regularly	O
5	excited	O
6	by	O
7	pressure	O
8	to	O
9	the	O
10	ipsilateral	O
11	cornea	O
12	or	O
13	to	O
14	both	O
15	corneas	O
16	at	O
17	a	O
18	strength	O
19	well	O
20	above	O
21	the	O
22	human	O
23	corneal	O
24	pain	O
25	threshold	O
26	.	O

1	271	O
2	:	O
3	31290	O
4	-	O
5	31295	O
6	,	O
7	1996	O
8	).	O

1	More	O
2	generally	O
3	,	O
4	Ets1	B
5	and	O
6	Ets2	B
7	could	O
8	regulate	O
9	transcription	O
10	of	O
11	cellular	O
12	genes	O
13	.	O

1	From	O
2	our	O
3	ultrastructural	O
4	and	O
5	biochemical	O
6	studies	O
7	,	O
8	it	O
9	is	O
10	evident	O
11	that	O
12	Type	O
13	II	O
14	pneumocytes	O
15	are	O
16	an	O
17	early	O
18	target	O
19	of	O
20	radiation	O
21	and	O
22	the	O
23	release	O
24	of	O
25	surfactant	O
26	into	O
27	the	O
28	alveolus	O
29	shortly	O
30	after	O
31	exposure	O
32	persists	O
33	for	O
34	days	O
35	and	O
36	weeks	O
37	.	O

1	A	O
2	new	O
3	,	O
4	flexible	O
5	fiberoptic	O
6	ventriculoscope	O
7	for	O
8	observation	O
9	of	O
10	the	O
11	ventricles	O
12	and	O
13	major	O
14	cisterns	O
15	is	O
16	reported	O
17	.	O

1	The	O
2	experiment	O
3	included	O
4	6	O
5	male	O
6	and	O
7	4	O
8	female	O
9	healthy	O
10	subjects	O
11	who	O
12	,	O
13	during	O
14	a	O
15	24	O
16	-	O
17	hour	O
18	stay	O
19	in	O
20	the	O
21	respiration	O
22	chambers	O
23	,	O
24	performed	O
25	,	O
26	in	O
27	the	O
28	morning	O
29	and	O
30	afternoon	O
31	,	O
32	15	O
33	min	O
34	cycling	O
35	with	O
36	the	O
37	total	O
38	work	O
39	of	O
40	6	O
41	,	O
42	750	O
43	kg	O
44	m	O
45	.	O

1	The	O
2	so	O
3	-	O
4	called	O
5	"	B
6	SH3	I
7	"	I
8	segment	I
9	of	O
10	the	O
11	linker	O
12	domain	O
13	,	O
14	in	O
15	contrast	O
16	,	O
17	shows	O
18	species	O
19	-	O
20	specific	O
21	sequence	O
22	identity	O
23	in	O
24	all	O
25	but	O
26	one	O
27	amino	O
28	acid	O
29	residues	O
30	in	O
31	both	O
32	factors	O
33	,	O
34	in	O
35	cattle	O
36	,	O
37	human	O
38	,	O
39	and	O
40	mouse	O
41	.	O

1	Comparison	O
2	of	O
3	frequencies	O
4	of	O
5	atrial	O
6	fibrillation	O
7	after	O
8	coronary	O
9	artery	O
10	bypass	O
11	grafting	O
12	with	O
13	and	O
14	without	O
15	the	O
16	use	O
17	of	O
18	cardiopulmonary	O
19	bypass	O
20	.	O

1	Post	O
2	-	O
3	operative	O
4	functional	O
5	outcome	O
6	is	O
7	related	O
8	to	O
9	pre	O
10	-	O
11	operative	O
12	functional	O
13	status	O
14	.	O

1	The	O
2	pathogenesis	O
3	of	O
4	Dupuytren	O
5	'	O
6	s	O
7	contracture	O

1	New	O
2	and	O
3	successful	O
4	steps	O
5	have	O
6	been	O
7	made	O
8	in	O
9	immunodiagnostics	O
10	,	O
11	immunotherapy	O
12	,	O
13	and	O
14	immunoprophylaxis	O
15	of	O
16	immunologically	O
17	conditioned	O
18	infertility	O
19	.	O

1	This	O
2	sequence	O
3	is	O
4	almost	O
5	identical	O
6	with	O
7	that	O
8	of	O
9	human	B
10	luteinizing	I
11	hormone	I
12	(	O
13	Sairam	O
14	,	O
15	M	O
16	.	O

1	Most	O
2	recently	O
3	,	O
4	the	O
5	use	O
6	of	O
7	the	O
8	product	O
9	of	O
10	brain	O
11	weight	O
12	and	O
13	clearance	O
14	has	O
15	been	O
16	proposed	O
17	.	O

1	Methyllevamisole	O
2	was	O
3	used	O
4	as	O
5	the	O
6	internal	O
7	standard	O
8	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	the	O
7	structures	O
8	of	O
9	the	O
10	b	O
11	-	O
12	Zip	O
13	domain	O
14	are	O
15	well	O
16	conserved	O
17	among	O
18	these	O
19	Maf	B
20	-	I
21	related	I
22	proteins	I
23	.	O

1	I	O
2	.	O

1	NSCL	B
2	-	I
3	1	I
4	is	O
5	expressed	O
6	in	O
7	a	O
8	larger	O
9	number	O
10	of	O
11	these	O
12	cell	O
13	lines	O
14	.	O

1	In	O
2	order	O
3	to	O
4	gain	O
5	deeper	O
6	insight	O
7	into	O
8	the	O
9	role	O
10	of	O
11	the	O
12	amino	O
13	-	O
14	terminal	O
15	domain	O
16	of	O
17	the	O
18	p24	B
19	(	O
20	CA	B
21	)	O
22	protein	O
23	during	O
24	viral	O
25	replication	O
26	,	O
27	eight	O
28	highly	O
29	conserved	O
30	proline	O
31	residues	O
32	known	O
33	to	O
34	promote	O
35	turns	O
36	and	O
37	to	O
38	terminate	O
39	alpha	O
40	-	O
41	helices	O
42	within	O
43	the	O
44	p24	B
45	tertiary	O
46	structure	O
47	were	O
48	replaced	O
49	by	O
50	a	O
51	leucine	O
52	residue	O
53	(	O
54	P	O
55	-	O
56	position	O
57	-	O
58	L	O
59	).	O

1	The	O
2	corresponding	O
3	inhibition	O
4	of	O
5	acid	B
6	phosphatase	I
7	activity	O
8	in	O
9	control	O
10	male	O
11	and	O
12	female	O
13	guinea	O
14	pigs	O
15	was	O
16	15	O
17	.	O
18	91	O
19	%	O
20	and	O
21	20	O
22	.	O
23	33	O
24	%	O
25	respectively	O
26	.	O

1	Vivid	O
2	visual	O
3	hallucinations	O
4	without	O
5	other	O
6	psychopathology	O
7	have	O
8	been	O
9	reported	O
10	for	O
11	several	O
12	hundred	O
13	years	O
14	.	O

1	We	O
2	conclude	O
3	that	O
4	solidification	O
5	could	O
6	occur	O
7	in	O
8	all	O
9	feeds	O
10	containing	O
11	casein	B
12	and	O
13	that	O
14	alternative	O
15	feeds	O
16	should	O
17	be	O
18	considered	O
19	in	O
20	patients	O
21	with	O
22	increased	O
23	gastric	O
24	acidity	O
25	.	O

1	The	O
2	5	O
3	'	O
4	end	O
5	of	O
6	the	O
7	coding	O
8	region	O
9	was	O
10	located	O
11	precisely	O
12	by	O
13	comparing	O
14	the	O
15	deduced	O
16	amino	O
17	acid	O
18	sequence	O
19	to	O
20	the	O
21	actual	O
22	N	O
23	-	O
24	terminal	O
25	amino	O
26	acid	O
27	sequence	O
28	of	O
29	IHF	B
30	.	O

1	Signal	O
2	transduction	O
3	via	O
4	modulation	O
5	of	O
6	phosphorylation	O
7	after	O
8	selective	O
9	inhibition	O
10	of	O
11	protein	B
12	phosphatase	I
13	(	I
14	PP	I
15	)	I
16	1	I
17	and	O
18	/	O
19	or	O
20	PP2A	B
21	appears	O
22	to	O
23	play	O
24	a	O
25	role	O
26	in	O
27	okadaic	O
28	acid	O
29	(	O
30	OA	O
31	)-	O
32	mediated	O
33	effects	O
34	.	O

1	ATP	O
2	-	O
3	dependent	O
4	assembly	O
5	of	O
6	a	O
7	ternary	O
8	complex	O
9	consisting	O
10	of	O
11	a	O
12	DNA	O
13	mismatch	O
14	and	O
15	the	O
16	yeast	O
17	MSH2	B
18	-	O
19	MSH6	B
20	and	O
21	MLH1	B
22	-	O
23	PMS1	B
24	protein	O
25	complexes	O
26	.	O

1	We	O
2	conclude	O
3	that	O
4	at	O
5	steady	O
6	state	O
7	the	O
8	timing	O
9	of	O
10	a	O
11	light	O
12	meal	O
13	is	O
14	unlikely	O
15	to	O
16	alter	O
17	in	O
18	any	O
19	clinically	O
20	important	O
21	manner	O
22	the	O
23	pharmacokinetics	O
24	of	O
25	nifedipine	O
26	released	O
27	from	O
28	'	O
29	biphasic	O
30	'	O
31	tablets	O
32	.	O

1	In	O
2	a	O
3	randomized	O
4	study	O
5	on	O
6	150	O
7	patients	O
8	(	O
9	ASA	O
10	1	O
11	)	O
12	undergoing	O
13	induction	O
14	of	O
15	anaesthesia	O
16	,	O
17	the	O
18	effects	O
19	of	O
20	Fentanyl	O
21	(	O
22	0	O
23	.	O
24	1	O
25	mg	O
26	),	O
27	the	O
28	combination	O
29	of	O
30	Fentanyl	O
31	(	O
32	0	O
33	.	O
34	1	O
35	mg	O
36	)	O
37	and	O
38	Droperidol	O
39	(	O
40	5	O
41	mg	O
42	)	O
43	(	O
44	Innovar	O
45	,	O
46	Thalamonal	O
47	)	O
48	and	O
49	Atropine	O
50	(	O
51	0	O
52	.	O
53	01	O
54	mg	O
55	/	O
56	kg	O
57	b	O
58	.	O
59	w	O
60	.)	O
61	alone	O
62	on	O
63	cardiocirculatory	O
64	parameters	O
65	were	O
66	studied	O
67	.	O

1	Phenazone	O
2	potentiates	O
3	the	O
4	local	O
5	anaesthetic	O
6	effect	O
7	of	O
8	lidocaine	O
9	in	O
10	mice	O
11	.	O

1	Inclusion	O
2	of	O
3	the	O
4	extended	O
5	N	O
6	terminus	O
7	into	O
8	the	O
9	originally	O
10	reported	O
11	protein	O
12	resulted	O
13	in	O
14	a	O
15	striking	O
16	similarity	O
17	to	O
18	the	O
19	lymphoid	B
20	factor	I
21	Lef	I
22	-	I
23	1	I
24	.	O

1	Hypomagnesemia	O
2	was	O
3	due	O
4	to	O
5	magnesium	O
6	wasting	O
7	by	O
8	the	O
9	kidney	O
10	.	O

1	Year	O
2	one	O
3	of	O
4	the	O
5	first	O
6	general	O
7	practitioner	O
8	medical	O
9	unit	O
10	in	O
11	the	O
12	greater	O
13	Glasgow	O
14	area	O
15	.	O

1	We	O
2	suggest	O
3	that	O
4	MotA	B
5	and	O
6	AsiA	B
7	may	O
8	function	O
9	like	O
10	certain	O
11	eukaryotic	B
12	TAFs	I
13	(	O
14	TATA	B
15	binding	I
16	protein	I
17	(	I
18	TBP	I
19	)	I
20	associated	I
21	factors	I
22	)	O
23	whose	O
24	binding	O
25	to	O
26	TBP	B
27	results	O
28	in	O
29	transcription	O
30	from	O
31	new	O
32	core	O
33	promoter	O
34	sequences	O
35	.	O

1	These	O
2	motifs	O
3	include	O
4	a	O
5	Chi	O
6	motif	O
7	and	O
8	a	O
9	Chi	O
10	-	O
11	like	O
12	element	O
13	previously	O
14	found	O
15	in	O
16	the	O
17	recombination	O
18	hotspot	O
19	region	O
20	of	O
21	the	O
22	Bcl	B
23	-	I
24	2	I
25	proto	I
26	-	I
27	oncogene	I
28	and	O
29	close	O
30	to	O
31	chromosomal	O
32	breakpoints	O
33	in	O
34	T	O
35	-	O
36	ALL	O
37	lines	O
38	.	O

1	There	O
2	were	O
3	122	O
4	cases	O
5	of	O
6	tuberculosis	O
7	over	O
8	an	O
9	average	O
10	10	O
11	.	O
12	3	O
13	yr	O
14	of	O
15	follow	O
16	-	O
17	up	O
18	(	O
19	crude	O
20	annual	O
21	incidence	O
22	,	O
23	76	O
24	.	O
25	2	O
26	/	O
27	100	O
28	,	O
29	000	O
30	).	O

1	Blood	O
2	platelets	O
3	,	O
4	coagulation	O
5	factors	O
6	and	O
7	morphologic	O
8	organ	O
9	changes	O
10	following	O
11	scalding	O
12	shock	O
13	in	O
14	rhesus	O
15	monkeys	O

1	Approximately	O
2	50	O
3	%	O
4	of	O
5	the	O
6	residues	O
7	are	O
8	conserved	O
9	among	O
10	all	O
11	three	O
12	sequences	O
13	,	O
14	yet	O
15	all	O
16	three	O
17	viruses	O
18	have	O
19	retained	O
20	response	O
21	elements	O
22	for	O
23	glucocorticoids	O
24	,	O
25	two	O
26	positionally	O
27	conserved	O
28	CCAAT	O
29	boxes	O
30	,	O
31	and	O
32	positionally	O
33	conserved	O
34	TATA	O
35	boxes	O
36	.	O

1	Tryptic	O
2	cleavage	O
3	and	O
4	peptide	O
5	sequence	O
6	analysis	O
7	demonstrated	O
8	that	O
9	the	O
10	98	O
11	-	O
12	kD	O
13	protein	O
14	is	O
15	identical	O
16	to	O
17	a	O
18	recently	O
19	cloned	O
20	protein	O
21	,	O
22	special	B
23	A	I
24	-	I
25	T	I
26	-	I
27	rich	I
28	binding	I
29	protein	I
30	1	I
31	(	O
32	SATB1	B
33	),	O
34	that	O
35	binds	O
36	selectively	O
37	to	O
38	nuclear	O
39	matrix	O
40	/	O
41	scaffold	O
42	-	O
43	associated	O
44	regions	O
45	of	O
46	DNA	O
47	(	O
48	MARs	O
49	/	O
50	SARs	O
51	).	O

1	Output	O
2	of	O
3	99mTcO	O
4	-	O
5	4	O
6	by	O
7	the	O
8	parotid	O
9	gland	O
10	closely	O
11	mimicked	O
12	fluctuations	O
13	in	O
14	parotid	O
15	saliva	O
16	flow	O
17	rate	O
18	.	O

1	Successive	O
2	abdominal	O
3	scintillation	O
4	with	O
5	131	O
6	-	O
7	I	O
8	-	O
9	tagged	O
10	BSP	O
11	--	O
12	description	O
13	of	O
14	the	O
15	thyroid	O
16	gland	O
17	,	O
18	kidney	O
19	and	O
20	spleen	O
21	(	O
22	comparison	O
23	with	O
24	131	O
25	-	O
26	I	O
27	-	O
28	RB	O
29	)	O

1	The	O
2	calcium	O
3	requirement	O
4	for	O
5	hypothermic	O
6	storage	O
7	of	O
8	the	O
9	cardiac	O
10	explant	O
11	.	O

1	For	O
2	SMX	O
3	at	O
4	pH	O
5	7	O
6	.	O
7	0	O
8	,	O
9	a	O
10	1	O
11	:	O
12	1	O
13	complex	O
14	is	O
15	formed	O
16	,	O
17	but	O
18	at	O
19	pH	O
20	7	O
21	.	O
22	5	O
23	HPCD	O
24	has	O
25	little	O
26	effect	O
27	on	O
28	the	O
29	solubility	O
30	of	O
31	the	O
32	highly	O
33	ionized	O
34	SMX	O
35	,	O
36	presumably	O
37	since	O
38	only	O
39	un	O
40	-	O
41	ionized	O
42	molecules	O
43	can	O
44	form	O
45	inclusion	O
46	complexes	O
47	with	O
48	the	O
49	HPCD	O
50	.	O

1	The	O
2	average	O
3	annual	O
4	cost	O
5	per	O
6	head	O
7	of	O
8	population	O
9	was	O
10	US	O
11	+	O
12	0	O
13	X	O
14	46	O
15	.	O

1	Quantitation	O
2	of	O
3	exocrine	B
4	IgA	I
5	in	O
6	human	O
7	serum	O
8	in	O
9	health	O
10	and	O
11	disease	O
12	.	O

1	To	O
2	test	O
3	the	O
4	hypothesis	O
5	that	O
6	progestin	O
7	-	O
8	mediated	O
9	increases	O
10	in	O
11	resting	O
12	core	O
13	temperature	O
14	and	O
15	the	O
16	core	O
17	temperature	O
18	threshold	O
19	for	O
20	sweating	O
21	onset	O
22	are	O
23	counteracted	O
24	by	O
25	estrogen	O
26	,	O
27	we	O
28	studied	O
29	eight	O
30	women	O
31	(	O
32	24	O
33	+/-	O
34	2	O
35	yr	O
36	)	O
37	at	O
38	27	O
39	degrees	O
40	C	O
41	rest	O
42	,	O
43	during	O
44	20	O
45	min	O
46	of	O
47	passive	O
48	heating	O
49	(	O
50	35	O
51	degrees	O
52	C	O
53	),	O
54	and	O
55	during	O
56	40	O
57	min	O
58	of	O
59	exercise	O
60	at	O
61	35	O
62	degrees	O
63	C	O
64	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	provide	O
6	evidence	O
7	that	O
8	B	B
9	-	I
10	Myb	I
11	is	O
12	a	O
13	direct	O
14	physiological	O
15	target	O
16	for	O
17	cyclin	B
18	A	I
19	/	O
20	Cdk2	B
21	.	O

1	There	O
2	is	O
3	no	O
4	correlation	O
5	between	O
6	C2	O
7	-	O
8	C3	O
9	disk	O
10	morphology	O
11	and	O
12	the	O
13	diskographically	O
14	provoked	O
15	response	O
16	.	O

1	Cytochrome	B
2	b	I
3	in	O
4	human	B
5	complex	I
6	II	I
7	(	O
8	succinate	B
9	-	I
10	ubiquinone	I
11	oxidoreductase	I
12	):	O
13	cDNA	O
14	cloning	O
15	of	O
16	the	O
17	components	O
18	in	O
19	liver	O
20	mitochondria	O
21	and	O
22	chromosome	O
23	assignment	O
24	of	O
25	the	O
26	genes	O
27	for	O
28	the	O
29	large	O
30	(	O
31	SDHC	B
32	)	O
33	and	O
34	small	O
35	(	O
36	SDHD	B
37	)	O
38	subunits	O
39	to	O
40	1q21	O
41	and	O
42	11q23	O
43	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	human	B
16	nidogen	I
17	gene	I
18	.	O

1	Transcriptional	O
2	activation	O
3	by	O
4	the	O
5	HIV	B
6	-	I
7	1	I
8	Tat	I
9	protein	I
10	requires	O
11	specific	O
12	residues	O
13	in	O
14	the	O
15	hexanucleotide	O
16	loop	O
17	and	O
18	trinucleotide	O
19	bulge	O
20	of	O
21	the	O
22	TAR	B
23	RNA	O
24	stem	O
25	-	O
26	loop	O
27	structure	O
28	found	O
29	in	O
30	the	O
31	5	O
32	'-	O
33	untranslated	O
34	leader	O
35	of	O
36	all	O
37	viral	O
38	transcripts	O
39	.	O

1	Substitutions	O
2	of	O
3	region	O
4	I	O
5	with	O
6	synthetic	O
7	sequences	O
8	showed	O
9	that	O
10	no	O
11	specific	O
12	sequence	O
13	but	O
14	rather	O
15	repeats	O
16	of	O
17	three	O
18	or	O
19	more	O
20	consecutive	O
21	adenines	O
22	or	O
23	thymines	O
24	,	O
25	without	O
26	interruption	O
27	by	O
28	guanine	O
29	or	O
30	cytosine	O
31	,	O
32	are	O
33	required	O
34	for	O
35	the	O
36	ARS	O
37	activity	O
38	.	O

1	Acid	O
2	instilled	O
3	on	O
4	the	O
5	larynx	O
6	of	O
7	maturing	O
8	rabbits	O
9	resulted	O
10	in	O
11	significant	O
12	obstructive	O
13	,	O
14	central	O
15	,	O
16	and	O
17	mixed	O
18	apnea	O
19	.	O

1	Regulation	O
2	of	O
3	Gax	B
4	homeobox	I
5	gene	I
6	transcription	O
7	by	O
8	a	O
9	combination	O
10	of	O
11	positive	O
12	factors	O
13	including	O
14	myocyte	B
15	-	I
16	specific	I
17	enhancer	I
18	factor	I
19	2	I
20	.	O

1	When	O
2	BFDS	O
3	was	O
4	taken	O
5	as	O
6	the	O
7	reference	O
8	,	O
9	W	O
10	/	O
11	A	O
12	Z	O
13	scores	O
14	showed	O
15	consistent	O
16	positive	O
17	increments	O
18	,	O
19	from	O
20	birth	O
21	in	O
22	girls	O
23	and	O
24	1	O
25	mo	O
26	in	O
27	boys	O
28	.	O

1	Binding	O
2	site	O
3	selection	O
4	using	O
5	in	O
6	vitro	O
7	-	O
8	synthesized	O
9	proteins	O
10	reveals	O
11	that	O
12	the	O
13	ROR	B
14	alpha	I
15	1	I
16	and	O
17	ROR	B
18	alpha	I
19	2	I
20	isoforms	I
21	bind	O
22	DNA	O
23	as	O
24	monomers	O
25	to	O
26	hormone	O
27	response	O
28	elements	O
29	composed	O
30	of	O
31	a	O
32	6	O
33	-	O
34	bp	O
35	AT	O
36	-	O
37	rich	O
38	sequence	O
39	preceding	O
40	a	O
41	half	O
42	-	O
43	site	O
44	core	O
45	motif	O
46	PuGGTCA	O
47	(	O
48	RORE	B
49	).	O

1	Serine	O
2	phosphorylation	O
3	of	O
4	STAT3	B
5	was	O
6	only	O
7	apparent	O
8	after	O
9	somatostatin	B
10	treatment	O
11	and	O
12	was	O
13	abolished	O
14	by	O
15	pertussis	B
16	toxin	I
17	or	O
18	PD	O
19	98059	O
20	,	O
21	together	O
22	with	O
23	the	O
24	associated	O
25	increases	O
26	in	O
27	proliferation	O
28	.	O

1	Fluid	O
2	(	O
3	AVLF	O
4	)	O
5	31	O
6	.	O

1	Furthermore	O
2	,	O
3	the	O
4	identification	O
5	of	O
6	a	O
7	Dr1	B
8	-	I
9	like	I
10	protein	I
11	in	O
12	A	O
13	.	O
14	thaliana	O
15	strongly	O
16	argues	O
17	for	O
18	the	O
19	ubiquity	O
20	of	O
21	this	O
22	protein	O
23	among	O
24	eukaryotic	O
25	genera	O
26	and	O
27	for	O
28	a	O
29	conserved	O
30	mechanism	O
31	to	O
32	regulate	O
33	transcription	O
34	initiation	O
35	that	O
36	involves	O
37	Dr1	B
38	.	O

1	The	O
2	sequence	O
3	contains	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	1744	O
10	nt	O
11	in	O
12	the	O
13	virus	O
14	-	O
15	sense	O
16	strand	O
17	,	O
18	a	O
19	3	O
20	'	O
21	untranslated	O
22	region	O
23	of	O
24	1360	O
25	nt	O
26	and	O
27	a	O
28	3	O
29	'	O
30	poly	O
31	(	O
32	A	O
33	)	O
34	tail	O
35	.	O

1	Therefore	O
2	,	O
3	it	O
4	was	O
5	concluded	O
6	that	O
7	thrombotic	O
8	tendency	O
9	certainly	O
10	existed	O
11	in	O
12	patients	O
13	with	O
14	MS	O
15	compared	O
16	to	O
17	those	O
18	with	O
19	non	O
20	RHD	O
21	and	O
22	that	O
23	it	O
24	was	O
25	one	O
26	of	O
27	the	O
28	causes	O
29	of	O
30	the	O
31	significantly	O
32	high	O
33	incidence	O
34	of	O
35	thromboembolism	O
36	in	O
37	comparison	O
38	with	O
39	non	O
40	RHD	O
41	.	O

1	Specific	O
2	requirements	O
3	for	O
4	branched	O
5	-	O
6	chain	O
7	amino	O
8	acids	O
9	,	O
10	glutamine	O
11	,	O
12	and	O
13	arginine	O
14	are	O
15	evaluated	O
16	.	O

1	CONCLUSIONS	O
2	:	O
3	Physiologic	O
4	pacing	O
5	provides	O
6	little	O
7	benefit	O
8	over	O
9	ventricular	O
10	pacing	O
11	for	O
12	the	O
13	prevention	O
14	of	O
15	stroke	O
16	or	O
17	death	O
18	due	O
19	to	O
20	cardiovascular	O
21	causes	O
22	.	O

1	The	O
2	high	O
3	degree	O
4	of	O
5	sequence	O
6	identity	O
7	(	O
8	96	O
9	%)	O
10	between	O
11	hydrolase	B
12	B	I
13	and	I
14	C	I
15	,	O
16	particularly	O
17	in	O
18	the	O
19	3	O
20	'	O
21	untranslated	O
22	region	O
23	,	O
24	suggests	O
25	that	O
26	the	O
27	genes	O
28	encoding	O
29	these	O
30	two	O
31	carboxylesterases	B
32	evolved	O
33	by	O
34	duplication	O
35	and	O
36	divergence	O
37	of	O
38	a	O
39	common	O
40	ancestral	O
41	gene	O
42	.	O

1	It	O
2	is	O
3	largely	O
4	predicted	O
5	by	O
6	lupus	O
7	anticoagulant	O
8	(	O
9	estimated	O
10	by	O
11	activated	O
12	partial	O
13	thromboplastin	B
14	time	O
15	)	O
16	and	O
17	/	O
18	or	O
19	antibody	O
20	to	O
21	cardiolipin	O
22	.	O

1	Information	O
2	on	O
3	conserved	O
4	noncoding	O
5	sequences	O
6	will	O
7	help	O
8	in	O
9	studies	O
10	on	O
11	the	O
12	regulation	O
13	of	O
14	the	O
15	pro	B
16	alpha	I
17	1	I
18	(	I
19	II	I
20	)	I
21	collagen	I
22	gene	I
23	.	O

1	i	O
2	.	O

1	Exercise	O
2	training	O
3	has	O
4	become	O
5	increasingly	O
6	important	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	heart	O
12	failure	O
13	patients	O
14	.	O

1	Histochemical	O
2	localization	O
3	of	O
4	GUS	B
5	revealed	O
6	promoter	O
7	function	O
8	in	O
9	leaf	O
10	epidermis	O
11	,	O
12	mesophyll	O
13	and	O
14	vascular	O
15	bundles	O
16	,	O
17	in	O
18	the	O
19	cortex	O
20	and	O
21	vascular	O
22	cylinder	O
23	of	O
24	the	O
25	root	O
26	.	O

1	Recombinant	O
2	expression	O
3	of	O
4	a	O
5	chimeric	O
6	EGFR	B
7	/	O
8	ErbB	B
9	-	I
10	3	I
11	receptor	I
12	in	O
13	NIH	O
14	3T3	O
15	fibroblasts	O
16	allowed	O
17	us	O
18	to	O
19	investigate	O
20	cytoplasmic	O
21	events	O
22	associated	O
23	with	O
24	ErbB	B
25	-	I
26	3	I
27	signal	O
28	transduction	O
29	upon	O
30	ligand	O
31	activation	O
32	.	O

1	CONCLUSION	O
2	:	O
3	TNF	B
4	alpha	I
5	,	O
6	TGF	B
7	beta	I
8	,	O
9	PDGF	B
10	and	O
11	IL	B
12	-	I
13	1beta	I
14	increased	O
15	LDLr	B
16	gene	I
17	expression	O
18	by	O
19	increasing	O
20	sterol	O
21	-	O
22	independent	O
23	and	O
24	mitogenesis	O
25	-	O
26	independent	O
27	gene	O
28	transcription	O
29	.	O

1	Transient	O
2	expression	O
3	of	O
4	VSF	B
5	-	I
6	1	I
7	in	O
8	protoplasts	O
9	stimulated	O
10	vs	B
11	-	I
12	1	I
13	dependent	O
14	activation	O
15	of	O
16	the	O
17	-	B
18	76	I
19	/	I
20	grp1	I
21	.	I
22	8	I
23	minimal	I
24	promoter	I
25	.	O

1	This	O
2	motif	O
3	,	O
4	first	O
5	described	O
6	for	O
7	the	O
8	Drosophila	B
9	homeobox	I
10	activator	I
11	DEAF	I
12	-	I
13	1	I
14	,	O
15	identifies	O
16	an	O
17	emerging	O
18	group	O
19	of	O
20	metazoan	O
21	transcriptional	O
22	modulators	O
23	.	O

1	Ariga	O
2	,	O
3	Biochem	O
4	.	O

1	Arm	O
2	function	O
3	tests	O
4	.	O

1	In	O
2	patients	O
3	,	O
4	the	O
5	effect	O
6	of	O
7	CCK	B
8	-	O
9	PZ	B
10	on	O
11	the	O
12	movement	O
13	of	O
14	the	O
15	terminal	O
16	part	O
17	of	O
18	the	O
19	bile	O
20	duct	O
21	was	O
22	measured	O
23	with	O
24	a	O
25	pressure	O
26	sensor	O
27	using	O
28	a	O
29	duodenofiberscope	O
30	.	O

1	The	O
2	5	O
3	'	O
4	external	O
5	transcribed	O
6	spacer	O
7	(	O
8	ETS	O
9	)	O
10	region	O
11	of	O
12	the	O
13	pre	O
14	-	O
15	rRNA	O
16	in	O
17	Saccharomyces	O
18	cerevisiae	O
19	contains	O
20	a	O
21	sequence	O
22	with	O
23	10	O
24	bp	O
25	of	O
26	perfect	O
27	complementarity	O
28	to	O
29	the	O
30	U3	B
31	snoRNA	I
32	.	O

1	We	O
2	previously	O
3	described	O
4	the	O
5	purification	O
6	of	O
7	an	O
8	83	B
9	-	I
10	kDa	I
11	phosphatidic	I
12	acid	I
13	phosphatase	I
14	(	O
15	PAP	B
16	)	O
17	from	O
18	the	O
19	porcine	O
20	thymus	O
21	membranes	O
22	(	O
23	Kanoh	O
24	,	O
25	H	O
26	.,	O
27	Imai	O
28	,	O
29	S	O
30	.-	O
31	i	O
32	.,	O
33	Yamada	O
34	,	O
35	K	O
36	.	O
37	and	O
38	Sakane	O
39	,	O
40	F	O
41	.(	O
42	1992	O
43	)	O
44	J	O
45	.	O

1	CPT	O
2	-	O
3	11	O
4	was	O
5	administered	O
6	as	O
7	a	O
8	30	O
9	-	O
10	minute	O
11	i	O
12	.	O
13	v	O
14	.	O
15	infusion	O
16	at	O
17	a	O
18	dose	O
19	of	O
20	350	O
21	mg	O
22	/	O
23	m2	O
24	diluted	O
25	in	O
26	250	O
27	ml	O
28	normal	O
29	saline	O
30	every	O
31	3	O
32	weeks	O
33	.	O

1	However	O
2	,	O
3	the	O
4	serum	B
5	TNF	I
6	-	I
7	a	I
8	concentration	O
9	decreased	O
10	significantly	O
11	in	O
12	patients	O
13	receiving	O
14	pentoxifylline	O
15	(	O
16	basal	O
17	623	O
18	+/-	O
19	366	O
20	pg	O
21	/	O
22	ml	O
23	;	O
24	6th	O
25	month	O
26	562	O
27	+/-	O
28	358	O
29	pg	O
30	/	O
31	ml	O
32	,	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	),	O
39	but	O
40	not	O
41	in	O
42	the	O
43	control	O
44	group	O
45	.	O

1	Transfection	O
2	analyses	O
3	indicate	O
4	that	O
5	mutation	O
6	of	O
7	any	O
8	one	O
9	of	O
10	these	O
11	TGACCT	O
12	motifs	O
13	or	O
14	truncation	O
15	of	O
16	the	O
17	entire	O
18	HD	B
19	PPRE	O
20	into	O
21	a	O
22	separate	O
23	DR1	O
24	and	O
25	DR2	O
26	element	O
27	significantly	O
28	reduced	O
29	the	O
30	transcriptional	O
31	response	O
32	of	O
33	HD	B
34	PPRE	O
35	to	O
36	peroxisome	O
37	proliferators	O
38	.	O

1	Although	O
2	Pho85	B
3	is	O
4	not	O
5	essential	O
6	for	O
7	viability	O
8	,	O
9	Pcl1	B
10	,	I
11	2	I
12	-	O
13	Pho85	B
14	kinase	O
15	complexes	O
16	become	O
17	essential	O
18	for	O
19	Start	O
20	in	O
21	the	O
22	absence	O
23	of	O
24	Cln1	B
25	,	I
26	2	I
27	-	O
28	Cdc28	B
29	kinases	O
30	.	O

1	During	O
2	early	O
3	neurogenesis	O
4	,	O
5	Vnd	B
6	protein	I
7	is	O
8	restricted	O
9	to	O
10	ventral	O
11	column	O
12	neuroectoderm	O
13	and	O
14	neuroblasts	O
15	;	O
16	later	O
17	it	O
18	is	O
19	detected	O
20	in	O
21	a	O
22	complex	O
23	pattern	O
24	of	O
25	neurons	O
26	.	O

1	AMDA	O
2	white	O
3	paper	O
4	identifies	O
5	ways	O
6	to	O
7	improve	O
8	pharmaceutical	O
9	care	O
10	in	O
11	SNFs	O
12	.	O

1	Similarities	O
2	between	O
3	the	O
4	hIGFBP	B
5	-	I
6	1	I
7	and	O
8	phosphoenolpyruvate	B
9	kinase	I
10	(	O
11	PEPCK	B
12	)	O
13	promoters	O
14	,	O
15	including	O
16	regions	O
17	conferring	O
18	insulin	B
19	,	O
20	glucocorticoid	O
21	,	O
22	and	O
23	cyclic	O
24	adenosine	O
25	-	O
26	monophosphate	O
27	responses	O
28	,	O
29	are	O
30	consistent	O
31	with	O
32	our	O
33	previous	O
34	hypothesis	O
35	that	O
36	IGFBP	B
37	-	I
38	1	I
39	is	O
40	involved	O
41	in	O
42	regulation	O
43	of	O
44	glucose	O
45	metabolism	O
46	.	O

1	Mean	O
2	growth	O
3	changes	O
4	in	O
5	this	O
6	Class	O
7	II	O
8	sample	O
9	were	O
10	comparable	O
11	to	O
12	those	O
13	previously	O
14	reported	O
15	for	O
16	male	O
17	subjects	O
18	with	O
19	Class	O
20	I	O
21	malocclusions	O
22	over	O
23	the	O
24	same	O
25	age	O
26	period	O
27	,	O
28	suggesting	O
29	a	O
30	similarity	O
31	in	O
32	postpubertal	O
33	development	O
34	between	O
35	these	O
36	two	O
37	groups	O
38	.	O

1	The	O
2	high	O
3	degree	O
4	of	O
5	conservation	O
6	between	O
7	NQO2	B
8	and	O
9	NQO1	B
10	gene	I
11	organization	O
12	and	O
13	sequence	O
14	confirmed	O
15	that	O
16	NQO2	B
17	gene	I
18	encodes	O
19	for	O
20	a	O
21	second	O
22	member	O
23	of	O
24	the	O
25	NQO	B
26	gene	I
27	family	I
28	in	O
29	human	O
30	.	O

1	Primary	O
2	adrenal	O
3	hypersensitivity	O
4	to	O
5	ACTH	B
6	drive	O
7	in	O
8	obesity	O
9	has	O
10	also	O
11	been	O
12	suggested	O
13	.	O

1	Capnography	O
2	curves	O
3	of	O
4	40	O
5	HVS	O
6	patients	O
7	,	O
8	40	O
9	non	O
10	-	O
11	HVS	O
12	patients	O
13	with	O
14	psycho	O
15	-	O
16	somatic	O
17	complaints	O
18	and	O
19	26	O
20	healthy	O
21	controls	O
22	were	O
23	analyzed	O
24	.	O

1	Herpes	O
2	virus	O
3	infection	O
4	was	O
5	characterized	O
6	by	O
7	inversion	O
8	of	O
9	the	O
10	T4	O
11	/	O
12	T8	O
13	ratio	O
14	below	O
15	1	O
16	.	O
17	0	O
18	(	O
19	sensitivity	O
20	90	O
21	%,	O
22	specificity	O
23	88	O
24	%),	O
25	caused	O
26	by	O
27	proliferation	O
28	of	O
29	the	O
30	T8	O
31	subpopulation	O
32	,	O
33	which	O
34	--	O
35	compared	O
36	with	O
37	the	O
38	findings	O
39	in	O
40	patients	O
41	with	O
42	rejection	O
43	crises	O
44	--	O
45	was	O
46	significantly	O
47	raised	O
48	(	O
49	P	O
50	less	O
51	than	O
52	0	O
53	.	O
54	001	O
55	).	O

1	Eucaryotic	O
2	transcription	O
3	factors	O
4	that	O
5	stimulate	O
6	RNA	B
7	polymerase	I
8	II	I
9	by	O
10	increasing	O
11	the	O
12	efficiency	O
13	of	O
14	elongation	O
15	of	O
16	specifically	O
17	or	O
18	randomly	O
19	initiated	O
20	RNA	O
21	chains	O
22	have	O
23	been	O
24	isolated	O
25	and	O
26	characterized	O
27	.	O

1	Menstrual	O
2	-	O
3	cycle	O
4	phase	O
5	did	O
6	not	O
7	significantly	O
8	affect	O
9	personality	O
10	variables	O
11	in	O
12	either	O
13	group	O
14	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	previously	O
6	identified	O
7	and	O
8	characterized	O
9	attenuator	B
10	1	I
11	situated	O
12	93	O
13	nucleotides	O
14	downstream	O
15	from	O
16	the	O
17	major	O
18	late	O
19	transcription	O
20	start	O
21	site	O
22	,	O
23	a	O
24	second	O
25	attenuator	O
26	,	O
27	attenuator	B
28	2	I
29	,	O
30	situated	O
31	55	O
32	nucleotides	O
33	downstream	O
34	from	O
35	it	O
36	,	O
37	has	O
38	been	O
39	identified	O
40	.	O

1	Shoulder	O
2	forearm	O
3	support	O
4	for	O
5	the	O
6	subluxed	O
7	shoulder	O
8	.	O

1	The	O
2	second	O
3	complex	O
4	,	O
5	when	O
6	purified	O
7	,	O
8	contained	O
9	four	O
10	protein	O
11	components	O
12	including	O
13	the	O
14	36	O
15	-	O
16	kDa	O
17	protein	O
18	.	O

1	Abbreviations	O
2	:	O
3	CAS	B
4	,	O
5	CRK	B
6	-	I
7	associated	I
8	substrate	I
9	;	O
10	CH	B
11	,	O
12	calponin	B
13	-	I
14	homology	I
15	domain	I
16	;	O
17	CSK	B
18	,	O
19	C	B
20	-	I
21	terminal	I
22	SRC	I
23	kinase	I
24	;	O
25	E6	B
26	,	O
27	Papillomavirus	B
28	E6	I
29	protein	I
30	;	O
31	FAK	B
32	,	O
33	focal	B
34	adhesion	I
35	kinase	I
36	;	O
37	GIT	B
38	,	O
39	GRK	B
40	interacter	I
41	;	O
42	GPCR	B
43	,	O
44	heterotrimeric	B
45	-	I
46	G	I
47	-	I
48	protein	I
49	-	I
50	coupled	I
51	receptor	I
52	;	O
53	GRK	B
54	,	O
55	G	B
56	-	I
57	protein	I
58	-	I
59	coupled	I
60	-	I
61	receptor	I
62	kinase	I
63	;	O
64	MAPK	B
65	,	O
66	mitogen	B
67	-	I
68	activated	I
69	protein	I
70	kinase	I
71	(	O
72	ERK	B
73	,	O
74	p38	B
75	,	O
76	JNK	B
77	);	O
78	PAK	B
79	,	O
80	p21	B
81	-	I
82	activated	I
83	kinase	I
84	;	O
85	PBS	B
86	,	O
87	paxillin	B
88	-	I
89	binding	I
90	subdomain	I
91	;	O
92	PIX	B
93	,	O
94	PAK	B
95	-	I
96	interacting	I
97	exchange	I
98	factor	I
99	;	O
100	PKL	B
101	,	O
102	paxillin	B
103	kinase	I
104	linker	I
105	;	O
106	POR1	B
107	,	O
108	partner	B
109	of	I
110	Rac	I
111	;	O
112	PS	O
113	,	O
114	phosphoserine	O
115	;	O
116	PT	O
117	,	O
118	phosphothreonine	O
119	;	O
120	PY	O
121	,	O
122	phosphotyrosine	O
123	;	O
124	RTK	B
125	,	O
126	growth	B
127	factor	I
128	receptor	I
129	tyrosine	I
130	kinase	I
131	;	O
132	SH	B
133	,	O
134	SRC	B
135	-	I
136	homology	I
137	domain	I
138	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	mammalian	B
5	translation	I
6	initiation	I
7	factor	I
8	5	I
9	(	O
10	eIF5	B
11	):	O
12	role	O
13	of	O
14	interaction	O
15	between	O
16	the	O
17	beta	O
18	subunit	O
19	of	O
20	eIF2	B
21	and	O
22	eIF5	B
23	in	O
24	eIF5	B
25	function	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	vivo	O
31	.	O

1	AIMS	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	role	O
7	of	O
8	environmental	O
9	intra	O
10	-	O
11	uterine	O
12	factors	O
13	in	O
14	determining	O
15	the	O
16	birthweights	O
17	of	O
18	twins	O
19	with	O
20	increased	O
21	susceptibility	O
22	to	O
23	diabetes	O
24	and	O
25	discordant	O
26	for	O
27	abnormal	O
28	responses	O
29	to	O
30	the	O
31	oral	O
32	glucose	O
33	tolerance	O
34	test	O
35	(	O
36	OGTT	O
37	)	O
38	and	O
39	verify	O
40	the	O
41	possible	O
42	association	O
43	of	O
44	within	O
45	-	O
46	pair	O
47	birthweight	O
48	differences	O
49	and	O
50	metabolic	O
51	abnormalities	O
52	in	O
53	adult	O
54	life	O
55	.	O

1	These	O
2	indications	O
3	of	O
4	deregulated	O
5	signalling	O
6	in	O
7	the	O
8	absence	O
9	of	O
10	tyrosine	O
11	118	O
12	were	O
13	substantiated	O
14	by	O
15	sustained	O
16	activation	O
17	of	O
18	STAT3	B
19	.	O

1	MDBP	B
2	from	O
3	HeLa	O
4	and	O
5	Raji	O
6	cells	O
7	formed	O
8	DNA	O
9	-	O
10	protein	O
11	complexes	O
12	with	O
13	X	O
14	-	O
15	box	O
16	oligonucleotides	O
17	that	O
18	coelectrophoresed	O
19	with	O
20	those	O
21	containing	O
22	standard	O
23	MDBP	B
24	sites	I
25	.	O

1	On	O
2	parents	O

1	All	O
2	the	O
3	women	O
4	received	O
5	13	O
6	.	O
7	5	O
8	mg	O
9	plain	O
10	bupivacaine	O
11	via	O
12	subarachnoid	O
13	injection	O
14	at	O
15	the	O
16	L2	O
17	-	O
18	3	O
19	interspace	O
20	.	O

1	The	O
2	integration	O
3	at	O
4	the	O
5	VIP	B
6	CyRE	I
7	of	O
8	the	O
9	Jak	B
10	-	O
11	Stat	B
12	and	O
13	AP	B
14	-	I
15	1	I
16	signaling	O
17	pathways	O
18	with	O
19	other	O
20	pre	O
21	-	O
22	existing	O
23	proteins	O
24	provides	O
25	a	O
26	cellular	O
27	mechanism	O
28	for	O
29	cell	O
30	-	O
31	and	O
32	cytokine	O
33	-	O
34	specific	O
35	signaling	O
36	.	O

1	This	O
2	result	O
3	suggested	O
4	that	O
5	mutant	O
6	I299	O
7	has	O
8	diminished	O
9	cap	O
10	-	O
11	binding	O
12	activity	O
13	.	O

1	Human	O
2	T	O
3	-	O
4	cell	O
5	leukemia	O
6	virus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	encodes	O
15	a	O
16	40	O
17	-	O
18	kDa	O
19	nuclear	O
20	protein	O
21	,	O
22	Tax	B
23	,	O
24	which	O
25	stimulates	O
26	transcription	O
27	from	O
28	three	O
29	21	O
30	-	O
31	base	O
32	pair	O
33	(	O
34	bp	O
35	)	O
36	repeats	O
37	in	O
38	its	O
39	U3	O
40	region	O
41	.	O

1	GTPase	B
2	activating	O
3	specificity	O
4	of	O
5	RGS12	B
6	and	O
7	binding	O
8	specificity	O
9	of	O
10	an	O
11	alternatively	O
12	spliced	O
13	PDZ	B
14	(	O
15	PSD	B
16	-	I
17	95	I
18	/	O
19	Dlg	B
20	/	O
21	ZO	B
22	-	I
23	1	I
24	)	O
25	domain	O
26	.	O

1	The	O
2	optimal	O
3	sequence	O
4	for	O
5	interaction	O
6	with	O
7	mu	B
8	2	I
9	and	O
10	with	O
11	AP	B
12	-	I
13	2	I
14	has	O
15	tyrosine	O
16	as	O
17	an	O
18	anchor	O
19	and	O
20	prefers	O
21	arginine	O
22	at	O
23	position	O
24	Y	O
25	+	O
26	2	O
27	and	O
28	leucine	O
29	at	O
30	position	O
31	Y	O
32	+	O
33	3	O
34	.	O

1	Mutations	O
2	of	O
3	the	O
4	RET	B
5	gene	I
6	,	O
7	encoding	O
8	a	O
9	receptor	B
10	tyrosine	I
11	kinase	I
12	,	O
13	have	O
14	been	O
15	associated	O
16	with	O
17	the	O
18	inherited	O
19	cancer	O
20	syndromes	O
21	MEN	O
22	2A	O
23	and	O
24	MEN	O
25	2B	O
26	.	O

1	Coexpression	O
2	of	O
3	mouse	O
4	PKR	B
5	(	I
6	1	I
7	-	I
8	515	I
9	)	I
10	WT	I
11	as	O
12	a	O
13	Gal4	B
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	fusion	O
19	with	O
20	either	O
21	the	O
22	catalytic	O
23	-	O
24	deficient	O
25	human	O
26	PKR	B
27	(	I
28	1	I
29	-	I
30	551	I
31	)	I
32	K296R	O
33	mutant	O
34	,	O
35	the	O
36	RNA	O
37	-	O
38	binding	O
39	-	O
40	deficient	O
41	human	O
42	PKR	B
43	(	I
44	1	I
45	-	I
46	551	I
47	)	I
48	K64E	I
49	/	I
50	K296R	I
51	double	O
52	mutant	O
53	,	O
54	or	O
55	wild	O
56	-	O
57	type	O
58	mouse	O
59	PKR	B
60	(	I
61	1	I
62	-	I
63	515	I
64	)	I
65	WT	I
66	as	O
67	full	O
68	-	O
69	length	O
70	PKR	B
71	-	O
72	Gal4	B
73	activation	O
74	domain	O
75	fusions	O
76	resulted	O
77	in	O
78	activation	O
79	of	O
80	the	O
81	HIS3	B
82	and	O
83	lacZ	B
84	reporters	O
85	.	O

1	The	O
2	elm1	B
3	kinase	I
4	functions	O
5	in	O
6	a	O
7	mitotic	O
8	signaling	O
9	network	O
10	in	O
11	budding	O
12	yeast	O
13	.	O

1	Eight	O
2	patients	O
3	received	O
4	1	O
5	.	O
6	5	O
7	mg	O
8	of	O
9	adefovir	O
10	dipivoxil	O
11	per	O
12	kg	O
13	of	O
14	body	O
15	weight	O
16	,	O
17	and	O
18	six	O
19	patients	O
20	received	O
21	3	O
22	.	O
23	0	O
24	mg	O
25	of	O
26	adefovir	O
27	dipivoxil	O
28	per	O
29	kg	O
30	.	O

1	These	O
2	data	O
3	establish	O
4	Smd1p	B
5	as	O
6	a	O
7	required	O
8	component	O
9	of	O
10	the	O
11	cellular	O
12	splicing	O
13	apparatus	O
14	and	O
15	a	O
16	factor	O
17	in	O
18	snRNA	O
19	maturation	O
20	and	O
21	stability	O
22	.	O

1	Second	O
2	,	O
3	when	O
4	the	O
5	NBF1	B
6	+	I
7	R	I
8	protein	I
9	,	O
10	the	O
11	NBF2	B
12	protein	I
13	,	O
14	and	O
15	a	O
16	mixture	O
17	of	O
18	the	O
19	two	O
20	proteins	O
21	were	O
22	folded	O
23	separately	O
24	and	O
25	analyzed	O
26	by	O
27	molecular	O
28	sieve	O
29	chomatography	O
30	,	O
31	the	O
32	mixture	O
33	was	O
34	found	O
35	to	O
36	elute	O
37	prior	O
38	to	O
39	either	O
40	NBF1	B
41	+	I
42	R	I
43	or	O
44	NBF2	B
45	.	O

1	Activation	O
2	mediated	O
3	by	O
4	Cat8p	B
5	was	O
6	no	O
7	longer	O
8	detectable	O
9	in	O
10	a	O
11	cat1	B
12	mutant	I
13	.	O

1	These	O
2	results	O
3	provide	O
4	evidence	O
5	of	O
6	a	O
7	bypass	O
8	of	O
9	p53	B
10	-	O
11	induced	O
12	Waf1	B
13	/	O
14	Cip1	B
15	-	O
16	mediated	O
17	cell	O
18	cycle	O
19	regulatory	O
20	pathways	O
21	by	O
22	a	O
23	member	O
24	of	O
25	the	O
26	myb	B
27	oncogene	I
28	family	I
29	.	O

1	The	O
2	catalytic	O
3	site	O
4	has	O
5	an	O
6	S1	O
7	pocket	O
8	lined	O
9	with	O
10	conserved	O
11	hydrophobic	O
12	residues	O
13	to	O
14	accommodate	O
15	the	O
16	pyroglutamyl	O
17	residue	O
18	.	O

1	The	O
2	study	O
3	goals	O
4	were	O
5	to	O
6	isolate	O
7	a	O
8	full	O
9	-	O
10	length	O
11	clone	O
12	encoding	O
13	CO	B
14	-	I
15	Ag	I
16	from	O
17	a	O
18	bovine	O
19	corneal	O
20	cDNA	O
21	library	O
22	and	O
23	to	O
24	express	O
25	this	O
26	clone	O
27	in	O
28	Escherichia	O
29	coli	O
30	(	O
31	E	O
32	.	O
33	coli	O
34	).	O

1	A	O
2	cytosolic	O
3	variant	O
4	of	O
5	the	O
6	protein	O
7	underwent	O
8	efficient	O
9	transphosphorylation	O
10	,	O
11	yet	O
12	failed	O
13	to	O
14	activate	O
15	appreciably	O
16	either	O
17	p70	B
18	(	O
19	S6k	B
20	)	O
21	or	O
22	MAP	B
23	kinase	I
24	following	O
25	treatment	O
26	with	O
27	FK1012	O
28	.	O

1	Study	O
2	of	O
3	antinuclear	O
4	autoantibodies	O
5	by	O
6	immunofluorescence	O
7	technic	O
8	in	O
9	collagen	B
10	diseases	O

1	Plasma	O
2	lecithin	B
3	/	I
4	cholesterol	I
5	acyltransferase	I
6	(	O
7	LCAT	B
8	)	O
9	activity	O
10	in	O
11	multiple	O
12	-	O
13	organ	O
14	donors	O
15	:	O
16	a	O
17	predictor	O
18	of	O
19	allograft	O
20	viability	O
21	in	O
22	clinical	O
23	liver	O
24	transplantation	O
25	.	O

1	The	O
2	bactericidal	O
3	activity	O
4	of	O
5	six	O
6	new	O
7	rifamycin	O
8	derivatives	O
9	--	O
10	rifabutin	O
11	(	O
12	RBU	O
13	),	O
14	FCE	O
15	22250	O
16	(	O
17	F22	O
18	),	O
19	rifapentine	O
20	(	O
21	RPE	O
22	),	O
23	CGP	O
24	29861	O
25	(	O
26	C29	O
27	),	O
28	CGP	O
29	7040	O
30	(	O
31	C70	O
32	)	O
33	and	O
34	CGP	O
35	27557	O
36	(	O
37	C27	O
38	)	O
39	and	O
40	rifampicin	O
41	(	O
42	RMP	O
43	)--	O
44	have	O
45	been	O
46	measured	O
47	against	O
48	log	O
49	phase	O
50	and	O
51	,	O
52	as	O
53	a	O
54	better	O
55	test	O
56	of	O
57	sterilising	O
58	activity	O
59	,	O
60	against	O
61	stationary	O
62	phase	O
63	cultures	O
64	of	O
65	Mycobacterium	O
66	tuberculosis	O
67	,	O
68	H37Rv	O
69	.	O

1	While	O
2	mutations	O
3	in	O
4	K	B
5	-	I
6	Rev	I
7	that	O
8	inactivate	O
9	any	O
10	one	O
11	of	O
12	these	O
13	properties	O
14	also	O
15	blocked	O
16	K	B
17	-	I
18	Rev	I
19	-	O
20	dependent	O
21	nuclear	O
22	RNA	O
23	export	O
24	,	O
25	several	O
26	K	B
27	-	I
28	Rev	I
29	mutants	I
30	were	O
31	comparable	O
32	to	O
33	wild	O
34	type	O
35	when	O
36	assayed	O
37	for	O
38	any	O
39	of	O
40	these	O
41	individual	O
42	activities	O
43	yet	O
44	nevertheless	O
45	defective	O
46	for	O
47	RNA	O
48	export	O
49	.	O

1	We	O
2	conclude	O
3	from	O
4	this	O
5	study	O
6	that	O
7	Arix	B
8	and	O
9	NBPhox	B
10	exhibit	O
11	indistinguishable	O
12	and	O
13	independent	O
14	transcriptional	O
15	regulatory	O
16	properties	O
17	on	O
18	the	O
19	DBH	B
20	promoter	I
21	.	O

1	As	O
2	an	O
3	extension	O
4	of	O
5	our	O
6	structural	O
7	characterization	O
8	of	O
9	the	O
10	exon	O
11	-	O
12	intron	O
13	organization	O
14	of	O
15	the	O
16	mouse	B
17	Pkr	I
18	gene	I
19	,	O
20	we	O
21	now	O
22	have	O
23	isolated	O
24	and	O
25	characterized	O
26	the	O
27	mouse	B
28	Pkr	I
29	promoter	I
30	region	I
31	required	O
32	for	O
33	IFN	B
34	-	O
35	inducible	O
36	transcription	O
37	.	O

1	The	O
2	in	O
3	vitro	O
4	antibacterial	O
5	potency	O
6	is	O
7	greatest	O
8	when	O
9	the	O
10	1	O
11	-	O
12	substituent	O
13	is	O
14	2	O
15	,	O
16	4	O
17	-	O
18	difluorophenyl	O
19	and	O
20	the	O
21	7	O
22	-	O
23	substituent	O
24	is	O
25	a	O
26	3	O
27	-	O
28	amino	O
29	-	O
30	1	O
31	-	O
32	pyrrolidinyl	O
33	group	O
34	.	O

1	Evolutionary	O
2	relationships	O
3	among	O
4	putative	O
5	RNA	B
6	-	I
7	dependent	I
8	RNA	I
9	polymerases	I
10	encoded	O
11	by	O
12	a	O
13	mitochondrial	O
14	virus	O
15	-	O
16	like	O
17	RNA	O
18	in	O
19	the	O
20	Dutch	O
21	elm	O
22	disease	O
23	fungus	O
24	,	O
25	Ophiostoma	O
26	novo	O
27	-	O
28	ulmi	O
29	,	O
30	by	O
31	other	O
32	viruses	O
33	and	O
34	virus	O
35	-	O
36	like	O
37	RNAs	O
38	and	O
39	by	O
40	the	O
41	Arabidopsis	O
42	mitochondrial	O
43	genome	O
44	.	O

1	The	O
2	RNase	B
3	MRP	I
4	RNA	I
5	gene	I
6	was	O
7	deleted	O
8	by	O
9	insertional	O
10	replacement	O
11	and	O
12	found	O
13	to	O
14	be	O
15	essential	O
16	for	O
17	cellular	O
18	viability	O
19	,	O
20	indicating	O
21	a	O
22	critical	O
23	nuclear	O
24	role	O
25	for	O
26	RNase	B
27	MRP	I
28	.	O

1	This	O
2	region	O
3	of	O
4	hsp90	B
5	mediates	O
6	ATP	O
7	-	O
8	independent	O
9	chaperone	O
10	activity	O
11	,	O
12	overlaps	O
13	the	O
14	hsp90	B
15	dimerization	I
16	domain	I
17	,	O
18	and	O
19	includes	O
20	structural	O
21	elements	O
22	important	O
23	for	O
24	steroid	B
25	receptor	I
26	interaction	O
27	.	O

1	Antihistamines	O
2	in	O
3	asthma	O
4	.	O

1	As	O
2	hypothesized	O
3	,	O
4	believers	O
5	showed	O
6	relatively	O
7	higher	O
8	right	O
9	hemispheric	O
10	activation	O
11	and	O
12	reduced	O
13	hemispheric	O
14	asymmetry	O
15	of	O
16	functional	O
17	complexity	O
18	.	O

1	The	O
2	bioavailability	O
3	of	O
4	etodolac	O
5	from	O
6	capsules	O
7	exposed	O
8	to	O
9	stressed	O
10	conditions	O
11	was	O
12	compared	O
13	in	O
14	both	O
15	dogs	O
16	and	O
17	humans	O
18	to	O
19	capsules	O
20	stored	O
21	at	O
22	RT	O
23	conditions	O
24	.	O

1	To	O
2	study	O
3	a	O
4	possible	O
5	functional	O
6	role	O
7	of	O
8	this	O
9	putative	O
10	chicken	O
11	ICS	B
12	,	O
13	an	O
14	oligonucleotide	O
15	spanning	O
16	the	O
17	upstream	O
18	sequences	O
19	of	O
20	the	O
21	BF	B
22	-	I
23	IV	I
24	gene	I
25	(-	O
26	174	O
27	/-	O
28	194	O
29	)	O
30	was	O
31	cloned	O
32	singly	O
33	or	O
34	in	O
35	multiple	O
36	copies	O
37	before	O
38	the	O
39	herpes	O
40	TK	B
41	promoter	I
42	controlling	O
43	the	O
44	chloramphenicol	B
45	acetyl	I
46	transferase	I
47	(	O
48	CAT	B
49	)	O
50	gene	O
51	(	O
52	pBLCAT2	B
53	).	O

1	Salazopyrine	O
2	desensitization	O

1	Sex	O
2	of	O
3	calf	O
4	(	O
5	variate	O
6	2	O
7	)	O
8	was	O
9	associated	O
10	most	O
11	closely	O
12	with	O
13	width	O
14	of	O
15	muzzle	O
16	and	O
17	head	O
18	.	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	routinely	O
5	collected	O
6	data	O
7	provided	O
8	quantitative	O
9	estimates	O
10	of	O
11	changes	O
12	in	O
13	CBZ	O
14	Cl	O
15	/	O
16	F	O
17	due	O
18	to	O
19	comedication	O
20	and	O
21	an	O
22	age	O
23	-	O
24	related	O
25	decrease	O
26	in	O
27	Cl	O
28	/	O
29	F	O
30	The	O
31	derived	O
32	regression	O
33	equations	O
34	reasonably	O
35	predicted	O
36	concentrations	O
37	in	O
38	a	O
39	separate	O
40	validation	O
41	set	O
42	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	rat	B
5	SH2	I
6	-	I
7	containing	I
8	inositol	I
9	phosphatase	I
10	2	I
11	(	O
12	SHIP2	B
13	)	O
14	and	O
15	its	O
16	role	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	insulin	B
22	signaling	O
23	.	O

1	Homograft	O
2	response	O
3	and	O
4	hemagglutinin	B
5	production	O
6	by	O
7	sensitized	O
8	thymectomized	O
9	irradiated	O
10	adult	O
11	mice	O
12	.	O

1	Thus	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	an	O
7	activation	O
8	target	O
9	of	O
10	a	O
11	human	O
12	activator	O
13	,	O
14	Oct	B
15	-	I
16	1	I
17	,	O
18	within	O
19	its	O
20	cognate	O
21	basal	O
22	transcription	O
23	complex	O
24	.	O

1	Large	B
2	T	I
3	antigen	I
4	was	O
5	coimmunoprecipitated	O
6	by	O
7	antibodies	O
8	to	O
9	epitope	O
10	-	O
11	tagged	O
12	TBP	B
13	,	O
14	endogenous	O
15	TBP	B
16	,	O
17	hTAF	B
18	(	I
19	II	I
20	)	I
21	100	I
22	,	O
23	hTAF	B
24	(	I
25	II	I
26	)	I
27	130	I
28	,	O
29	and	O
30	hTAF	B
31	(	I
32	II	I
33	)	I
34	250	I
35	,	O
36	under	O
37	conditions	O
38	where	O
39	holo	B
40	-	I
41	TFIID	I
42	would	O
43	be	O
44	precipitated	O
45	.	O

1	Harel	O
2	,	O
3	E	O
4	.	O
5	M	O
6	.	O

1	Furthermore	O
2	,	O
3	this	O
4	study	O
5	looks	O
6	at	O
7	the	O
8	impact	O
9	of	O
10	synthesis	O
11	conditions	O
12	on	O
13	block	O
14	length	O
15	and	O
16	crystallinity	O
17	,	O
18	and	O
19	the	O
20	impact	O
21	of	O
22	the	O
23	blocking	O
24	on	O
25	both	O
26	,	O
27	crystallinity	O
28	and	O
29	solubility	O
30	of	O
31	the	O
32	polymers	O
33	.	O

1	Sterols	O
2	in	O
3	pollen	O
4	.	O

1	Caution	O
2	should	O
3	be	O
4	exercised	O
5	in	O
6	the	O
7	use	O
8	of	O
9	these	O
10	dyes	O
11	for	O
12	lymphograms	O
13	.	O

1	Retrospective	O
2	analyses	O
3	of	O
4	this	O
5	death	O
6	revealed	O
7	a	O
8	significant	O
9	decrease	O
10	of	O
11	the	O
12	left	O
13	ventricular	O
14	(	O
15	LV	O
16	)	O
17	end	O
18	-	O
19	diastolic	O
20	volume	O
21	index	O
22	(	O
23	EDVI	O
24	)	O
25	of	O
26	21	O
27	ml	O
28	/	O
29	m2	O
30	(	O
31	36	O
32	%	O
33	of	O
34	normal	O
35	).	O

1	This	O
2	sequence	O
3	also	O
4	confers	O
5	VDR	B
6	and	O
7	vitamin	O
8	D	O
9	responsiveness	O
10	to	O
11	a	O
12	heterologous	O
13	promoter	O
14	.	O

1	Urological	O
2	complications	O
3	are	O
4	frequent	O
5	during	O
6	and	O
7	after	O
8	the	O
9	treatment	O
10	of	O
11	gynecological	O
12	malignancy	O
13	.	O

1	However	O
2	,	O
3	in	O
4	contrast	O
5	with	O
6	previous	O
7	in	O
8	vitro	O
9	cell	O
10	-	O
11	free	O
12	integration	O
13	studies	O
14	,	O
15	alteration	O
16	of	O
17	the	O
18	highly	O
19	conserved	O
20	CA	O
21	dinucleotide	O
22	resulted	O
23	in	O
24	a	O
25	mutant	O
26	which	O
27	still	O
28	retained	O
29	40	O
30	%	O
31	of	O
32	wild	O
33	-	O
34	type	O
35	integration	O
36	activity	O
37	.	O

1	Salivary	O
2	sodium	O
3	,	O
4	calcium	O
5	,	O
6	and	O
7	magnesium	O
8	concentrations	O
9	were	O
10	significantly	O
11	higher	O
12	in	O
13	the	O
14	SLE	O
15	patients	O
16	with	O
17	systemic	O
18	lupus	O
19	erythematosus	O
20	,	O
21	whereas	O
22	potassium	O
23	and	O
24	total	O
25	protein	O
26	concentrations	O
27	and	O
28	amylase	B
29	activity	O
30	did	O
31	not	O
32	differ	O
33	significantly	O
34	from	O
35	the	O
36	controls	O
37	.	O

1	Likewise	O
2	,	O
3	at	O
4	150	O
5	degrees	O
6	C	O
7	with	O
8	2	O
9	%	O
10	APS	O
11	the	O
12	surface	O
13	density	O
14	of	O
15	NH2	O
16	groups	O
17	reached	O
18	a	O
19	maximum	O
20	at	O
21	24	O
22	hr	O
23	and	O
24	remained	O
25	relatively	O
26	constant	O
27	up	O
28	to	O
29	96	O
30	hr	O
31	.	O

1	These	O
2	studies	O
3	serve	O
4	as	O
5	the	O
6	basis	O
7	for	O
8	the	O
9	further	O
10	characterization	O
11	of	O
12	the	O
13	regulatory	O
14	mechanism	O
15	of	O
16	aromatase	B
17	expression	O
18	in	O
19	human	O
20	breast	O
21	cancer	O
22	and	O
23	ASCs	O
24	.	O

1	Aggravating	O
2	process	O
3	induced	O
4	by	O
5	indomethacin	O
6	on	O
7	chronic	O
8	gastric	O
9	lesion	O
10	in	O
11	rat	O
12	.	O

1	Overall	O
2	prevalences	O
3	of	O
4	antibody	O
5	were	O
6	70	O
7	per	O
8	cent	O
9	in	O
10	cattle	O
11	,	O
12	67	O
13	per	O
14	cent	O
15	in	O
16	sheep	O
17	and	O
18	76	O
19	per	O
20	cent	O
21	in	O
22	goats	O
23	as	O
24	assessed	O
25	by	O
26	an	O
27	immunodiffusion	O
28	test	O
29	.	O

1	Landsberg	O
2	(	O
3	La	O
4	-	O
5	O	O
6	)	O
7	and	O
8	cv	O
9	.	O

1	4	O
2	.	O

1	A	O
2	causal	O
3	analysis	O
4	of	O
5	secondary	O
6	variables	O
7	showed	O
8	that	O
9	the	O
10	formation	O
11	of	O
12	FB	O
13	memories	O
14	was	O
15	primarily	O
16	associated	O
17	with	O
18	the	O
19	level	O
20	of	O
21	importance	O
22	attached	O
23	to	O
24	the	O
25	event	O
26	and	O
27	level	O
28	of	O
29	affective	O
30	response	O
31	to	O
32	the	O
33	news	O
34	.	O

1	Canadian	O
2	survey	O
3	reveals	O
4	widespread	O
5	dissatisfaction	O
6	among	O
7	physicians	O
8	.	O

1	Patients	O
2	with	O
3	an	O
4	enzymatic	O
5	activity	O
6	below	O
7	X	O
8	--	O
9	1	O
10	manifested	O
11	a	O
12	decrease	O
13	of	O
14	the	O
15	content	O
16	of	O
17	IgA	B
18	,	O
19	IgG	B
20	,	O
21	IgM	B
22	,	O
23	T	O
24	and	O
25	B	O
26	lymphocytes	O
27	,	O
28	and	O
29	of	O
30	phagocytic	O
31	activity	O
32	of	O
33	neutrophils	O
34	as	O
35	compared	O
36	to	O
37	patients	O
38	exhibiting	O
39	a	O
40	high	O
41	enzymatic	O
42	activity	O
43	.	O

1	This	O
2	sequence	O
3	is	O
4	very	O
5	similar	O
6	to	O
7	the	O
8	insulin	B
9	response	I
10	sequence	I
11	found	O
12	in	O
13	the	O
14	regulatory	O
15	region	O
16	of	O
17	other	O
18	genes	O
19	negatively	O
20	regulated	O
21	by	O
22	insulin	B
23	such	O
24	as	O
25	those	O
26	encoding	O
27	phosphoenolpyruvate	B
28	carboxykinase	I
29	,	O
30	tyrosine	B
31	aminotransferase	I
32	,	O
33	and	O
34	insulin	B
35	-	I
36	like	I
37	growth	I
38	factor	I
39	-	I
40	binding	I
41	protein	I
42	1	I
43	.	O

1	Ti	O
2	exhibited	O
3	a	O
4	feather	O
5	-	O
6	like	O
7	morphology	O
8	.	O

1	In	O
2	the	O
3	Arithmetic	O
4	subtest	O
5	one	O
6	of	O
7	the	O
8	items	O
9	would	O
10	not	O
11	meet	O
12	the	O
13	difficulty	O
14	grading	O
15	shown	O
16	while	O
17	the	O
18	last	O
19	two	O
20	items	O
21	offer	O
22	very	O
23	little	O
24	possibility	O
25	of	O
26	success	O
27	for	O
28	all	O
29	subjects	O
30	.(	O
31	ABSTRACT	O
32	TRUNCATED	O
33	AT	O
34	250	O
35	WORDS	O
36	)	O

1	Low	O
2	molecular	O
3	weight	O
4	heparins	O
5	have	O
6	stimulated	O
7	much	O
8	interest	O
9	because	O
10	of	O
11	their	O
12	supposedly	O
13	more	O
14	selective	O
15	action	O
16	on	O
17	Xa	B
18	factor	I
19	.	O

1	Some	O
2	research	O
3	studies	O
4	have	O
5	related	O
6	this	O
7	kind	O
8	of	O
9	tumors	O
10	with	O
11	prolonged	O
12	ingestion	O
13	of	O
14	H2	O
15	inhibitors	O
16	and	O
17	others	O
18	antacid	O
19	.	O

1	Under	O
2	these	O
3	conditions	O
4	,	O
5	transfections	O
6	with	O
7	cDNAs	O
8	of	O
9	the	O
10	NF	B
11	-	I
12	kappa	I
13	B	I
14	p50	I
15	and	O
16	serum	B
17	response	I
18	factor	I
19	(	O
20	SRF	B
21	)	O
22	produced	O
23	a	O
24	factor	O
25	(	O
26	s	O
27	)	O
28	that	O
29	mediated	O
30	Tax	B
31	binding	O
32	to	O
33	the	O
34	NF	B
35	-	I
36	kappa	I
37	B	I
38	site	I
39	and	O
40	the	O
41	CArG	O
42	box	O
43	respectively	O
44	.	O

1	Triumph	O
2	of	O
3	Leninist	O
4	national	O
5	policy	O

1	Kinetics	O
2	of	O
3	the	O
4	inhibition	O
5	indicated	O
6	that	O
7	this	O
8	polymerase	O
9	domain	O
10	can	O
11	inhibit	O
12	viral	O
13	replication	O
14	only	O
15	during	O
16	the	O
17	preinitiation	O
18	stage	O
19	.	O

1	The	O
2	mature	O
3	protein	O
4	also	O
5	contains	O
6	a	O
7	cysteine	O
8	-	O
9	rich	O
10	,	O
11	highly	O
12	hydrophilic	O
13	region	O
14	homologous	O
15	to	O
16	the	O
17	ovomucoid	B
18	serine	I
19	protease	I
20	inhibitors	I
21	(	O
22	residues	O
23	76	O
24	-	O
25	132	O
26	).	O

1	Similar	O
2	observations	O
3	have	O
4	been	O
5	made	O
6	previously	O
7	for	O
8	other	O
9	genes	O
10	.	O

1	Phagocytosis	O
2	of	O
3	tubercle	O
4	bacilli	O
5	by	O
6	macrophages	O
7	.	O

1	Bupropion	O
2	to	O
3	aid	O
4	smoking	O
5	cessation	O
6	.	O

1	Mn2	O
2	+	O
3	increased	O
4	both	O
5	the	O
6	junction	O
7	binding	O
8	and	O
9	cleaving	O
10	activities	O
11	of	O
12	the	O
13	mutant	O
14	proteins	O
15	.	O

1	BRCA1	B
2	protein	I
3	contains	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	zinc	O
9	finger	O
10	motif	O
11	and	O
12	a	O
13	carboxy	O
14	-	O
15	terminal	O
16	acidic	O
17	region	O
18	.	O

1	Inhibition	O
2	of	O
3	histalog	O
4	-	O
5	stimulated	O
6	gastric	O
7	secretion	O
8	by	O
9	40	O
10	749	O
11	RP	O
12	,	O
13	a	O
14	new	O
15	long	O
16	-	O
17	acting	O
18	gastric	O
19	antisecretory	O
20	agent	O
21	.	O

1	We	O
2	also	O
3	recovered	O
4	mutations	O
5	in	O
6	the	O
7	60A	B
8	gene	I
9	which	O
10	encodes	O
11	another	O
12	TGF	B
13	-	I
14	beta	I
15	-	I
16	related	I
17	factor	I
18	in	O
19	Drosophila	O
20	.	O

1	UK	O
2	'	O
3	s	O
4	biotechnology	O
5	lacking	O
6	specialists	O
7	.	O

1	The	O
2	T	O
3	-	O
4	box	O
5	motif	O
6	is	O
7	present	O
8	in	O
9	a	O
10	family	O
11	of	O
12	genes	O
13	whose	O
14	structural	O
15	features	O
16	and	O
17	expression	O
18	patterns	O
19	support	O
20	their	O
21	involvement	O
22	in	O
23	developmental	O
24	gene	O
25	regulation	O
26	.	O

1	Temperature	O
2	dependence	O
3	of	O
4	the	O
5	sublattice	O
6	spontaneous	O
7	magnetization	O
8	of	O
9	YBa2Cu3O6	O
10	.	O

1	In	O
2	lean	O
3	mice	O
4	,	O
5	the	O
6	fat	O
7	/	O
8	water	O
9	intensity	O
10	ratio	O
11	was	O
12	about	O
13	1	O
14	:	O
15	4	O
16	,	O
17	about	O
18	half	O
19	that	O
20	in	O
21	normal	O
22	mice	O
23	.	O

1	The	O
2	beta	O
3	chain	O
4	contains	O
5	five	O
6	potential	O
7	N	O
8	-	O
9	linked	O
10	glycosylation	O
11	sites	O
12	,	O
13	and	O
14	endoglycosidase	B
15	digestion	O
16	suggested	O
17	that	O
18	the	O
19	beta	O
20	chain	O
21	contained	O
22	multiple	O
23	complex	O
24	carbohydrate	O
25	side	O
26	chains	O
27	.	O

1	Tumours	O
2	of	O
3	the	O
4	cavum	O
5	oris	O
6	and	O
7	oropharynx	O
8	of	O
9	T1	O
10	-	O
11	stage	O
12	are	O
13	possible	O
14	only	O
15	in	O
16	1	O
17	of	O
18	3	O
19	cases	O
20	.	O

1	However	O
2	,	O
3	the	O
4	few	O
5	studies	O
6	that	O
7	address	O
8	antimicrobial	O
9	prophylaxis	O
10	in	O
11	bone	O
12	marrow	O
13	transplantation	O
14	have	O
15	not	O
16	always	O
17	shown	O
18	a	O
19	survival	O
20	benefit	O
21	.	O

1	The	O
2	activated	O
3	glucocorticoid	B
4	receptor	I
5	forms	O
6	a	O
7	complex	O
8	with	O
9	Stat5	B
10	and	O
11	enhances	O
12	Stat5	B
13	-	O
14	mediated	O
15	transcriptional	O
16	induction	O
17	.	O

1	Purified	O
2	spleen	O
3	GAP	B
4	accelerated	O
5	hydrolysis	O
6	of	O
7	GTP	O
8	bound	O
9	to	O
10	recombinant	B
11	ARF1	I
12	,	O
13	ARF3	B
14	,	O
15	ARF5	B
16	,	O
17	and	O
18	ARF6	B
19	;	O
20	no	O
21	effect	O
22	of	O
23	NH2	O
24	-	O
25	terminal	O
26	myristoylation	O
27	was	O
28	observed	O
29	.	O

1	2	O
2	.--	O
3	concepts	O
4	of	O
5	higher	O
6	nervous	O
7	function	O
8	in	O
9	the	O
10	USSR	O
11	.	O

1	Thus	O
2	,	O
3	VF	O
4	resistant	O
5	to	O
6	defibrillation	O
7	is	O
8	not	O
9	necessarily	O
10	associated	O
11	with	O
12	both	O
13	toxic	O
14	plasma	O
15	drug	O
16	level	O
17	and	O
18	remarkably	O
19	decreased	O
20	conduction	O
21	.	O

1	All	O
2	four	O
3	domains	O
4	were	O
5	linked	O
6	via	O
7	proline	O
8	-	O
9	threonine	O
10	-	O
11	rich	O
12	peptides	O
13	.	O

1	The	O
2	effect	O
3	of	O
4	maternal	O
5	ingestion	O
6	of	O
7	the	O
8	reduced	O
9	energy	O
10	sweetener	O
11	erythritol	O
12	was	O
13	investigated	O
14	in	O
15	KBL	O
16	:	O
17	JW	O
18	strain	O
19	pregnant	O
20	rabbits	O
21	.	O

1	Ultrasonography	O
2	provides	O
3	excellent	O
4	intraoperative	O
5	evaluation	O
6	of	O
7	spinal	O
8	cord	O
9	injury	O
10	.	O

1	The	O
2	alpha	O
3	T3	O
4	-	O
5	1	O
6	cell	O
7	line	O
8	,	O
9	a	O
10	GnRH	B
11	-	O
12	responsive	O
13	gonadotroph	O
14	cell	O
15	line	O
16	developed	O
17	by	O
18	targeted	O
19	oncogenesis	O
20	in	O
21	transgenic	O
22	mice	O
23	,	O
24	was	O
25	used	O
26	to	O
27	study	O
28	regulation	O
29	of	O
30	the	O
31	glycoprotein	B
32	hormone	I
33	alpha	I
34	-	I
35	subunit	I
36	by	O
37	activin	B
38	.	O

1	Induction	O
2	in	O
3	AP	B
4	-	I
5	1	I
6	DNA	O
7	binding	O
8	correlates	O
9	with	O
10	a	O
11	concomitant	O
12	GH	B
13	trans	O
14	-	O
15	activation	O
16	of	O
17	c	B
18	-	I
19	jun	I
20	and	O
21	c	B
22	-	I
23	fos	I
24	genes	I
25	described	O
26	previously	O
27	.	O

1	Our	O
2	data	O
3	,	O
4	however	O
5	,	O
6	did	O
7	not	O
8	suggest	O
9	the	O
10	existence	O
11	of	O
12	a	O
13	conversion	O
14	factor	O
15	for	O
16	LDF	O
17	signal	O
18	to	O
19	absolute	O
20	flow	O
21	values	O
22	from	O
23	experiment	O
24	to	O
25	experiment	O
26	.	O

1	Serodiagnosis	O
2	of	O
3	ectromelia	O
4	in	O
5	laboratory	O
6	mice	O

1	At	O
2	the	O
3	genomic	O
4	level	O
5	,	O
6	the	O
7	sequences	O
8	of	O
9	two	O
10	members	O
11	of	O
12	this	O
13	family	O
14	are	O
15	known	O
16	in	O
17	the	O
18	rat	O
19	Rattus	O
20	norvegicus	O
21	:	O
22	the	O
23	VCSA1	B
24	gene	I
25	,	O
26	encoding	O
27	the	O
28	prohormone	B
29	-	I
30	like	I
31	polypeptide	I
32	SMR1	I
33	,	O
34	and	O
35	the	O
36	VCSB1	B
37	gene	I
38	,	O
39	encoding	O
40	a	O
41	salivary	O
42	Pro	O
43	-	O
44	rich	O
45	polypeptide	O
46	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	expression	O
5	of	O
6	human	B
7	UDP	I
8	-	I
9	d	I
10	-	I
11	Xylose	I
12	:	I
13	proteoglycan	I
14	core	I
15	protein	I
16	beta	I
17	-	I
18	d	I
19	-	I
20	xylosyltransferase	I
21	and	O
22	its	O
23	first	O
24	isoform	B
25	XT	I
26	-	I
27	II	I
28	.	O

1	Our	O
2	data	O
3	show	O
4	that	O
5	multiple	O
6	MLSN1	B
7	transcripts	I
8	,	O
9	both	O
10	constitutively	O
11	expressed	O
12	and	O
13	inducible	O
14	,	O
15	are	O
16	present	O
17	in	O
18	cultured	O
19	pigmented	O
20	melanoma	O
21	cells	O
22	,	O
23	and	O
24	suggest	O
25	that	O
26	MLSN1	B
27	expression	O
28	can	O
29	be	O
30	regulated	O
31	at	O
32	the	O
33	level	O
34	of	O
35	both	O
36	transcription	O
37	and	O
38	mRNA	O
39	processing	O
40	.	O

1	Although	O
2	differences	O
3	were	O
4	not	O
5	significant	O
6	,	O
7	infants	O
8	in	O
9	the	O
10	experimental	O
11	group	O
12	had	O
13	more	O
14	changes	O
15	in	O
16	the	O
17	intermittent	O
18	mandatory	O
19	ventilation	O
20	(	O
21	IMV	O
22	)	O
23	settings	O
24	during	O
25	transport	O
26	,	O
27	and	O
28	more	O
29	such	O
30	infants	O
31	arrived	O
32	at	O
33	the	O
34	receiving	O
35	hospital	O
36	with	O
37	acceptable	O
38	pH	O
39	and	O
40	PCO2	O
41	values	O
42	.	O

1	Using	O
2	a	O
3	3	O
4	'-	O
5	rapid	O
6	amplification	O
7	of	O
8	cDNA	O
9	ends	O
10	strategy	O
11	,	O
12	we	O
13	have	O
14	cloned	O
15	cDNAs	O
16	representing	O
17	the	O
18	3	O
19	'-	O
20	termini	O
21	of	O
22	both	O
23	the	O
24	native	O
25	and	O
26	mutant	O
27	transcripts	O
28	from	O
29	both	O
30	P388	O
31	/	O
32	ADR	O
33	/	O
34	3	O
35	and	O
36	P388	O
37	/	O
38	ADR	O
39	/	O
40	7	O
41	cells	O
42	.	O

1	During	O
2	skeletal	O
3	muscle	O
4	development	O
5	,	O
6	different	O
7	types	O
8	of	O
9	muscle	O
10	fibers	O
11	are	O
12	generated	O
13	,	O
14	which	O
15	express	O
16	different	O
17	combinations	O
18	of	O
19	muscle	O
20	-	O
21	specific	O
22	gene	O
23	products	O
24	.	O

1	Compensatory	O
2	renal	O
3	hypertrophy	O
4	in	O
5	parabiotic	O
6	rats	O
7	.	O

1	Number	O
2	of	O
3	patients	O
4	infected	O
5	with	O
6	nontuberculous	O
7	mycobacteria	O
8	(	O
9	NTM	O
10	)	O
11	is	O
12	increasing	O
13	world	O
14	-	O
15	wide	O
16	in	O
17	recent	O
18	years	O
19	.	O

1	COGLAB	O
2	includes	O
3	measures	O
4	of	O
5	preattentional	O
6	,	O
7	attentional	O
8	,	O
9	conceptual	O
10	,	O
11	and	O
12	psychomotor	O
13	performance	O
14	.	O

1	One	O
2	is	O
3	to	O
4	act	O
5	within	O
6	the	O
7	visceral	O
8	endoderm	O
9	to	O
10	promote	O
11	proper	O
12	streak	O
13	morphogenesis	O
14	.	O

1	Children	O
2	'	O
3	s	O
4	temperament	O
5	and	O
6	maternal	O
7	socialization	O
8	at	O
9	Time	O
10	1	O
11	(	O
12	n	O
13	=	O
14	103	O
15	,	O
16	aged	O
17	2	O
18	-	O
19	3	O
20	years	O
21	)	O
22	were	O
23	considered	O
24	predictors	O
25	of	O
26	future	O
27	conscience	O
28	,	O
29	assessed	O
30	using	O
31	new	O
32	observational	O
33	and	O
34	narrative	O
35	measures	O
36	.	O

1	Variables	O
2	evaluated	O
3	were	O
4	number	O
5	of	O
6	weekly	O
7	anginal	O
8	events	O
9	,	O
10	data	O
11	from	O
12	ergometric	O
13	exercise	O
14	testing	O
15	with	O
16	simultaneous	O
17	electrocardiographic	O
18	registration	O
19	,	O
20	semiquantitative	O
21	evaluation	O
22	of	O
23	Tc	O
24	-	O
25	99m	O
26	2	O
27	-	O
28	methoxy	O
29	isobutyl	O
30	isonitrile	O
31	(	O
32	MIBI	O
33	)	O
34	scans	O
35	and	O
36	rheologic	O
37	variables	O
38	.	O

1	An	O
2	exaggerated	O
3	tissue	O
4	response	O
5	adjacent	O
6	to	O
7	the	O
8	cyanoacrylate	O
9	site	O
10	suggested	O
11	a	O
12	potential	O
13	toxic	O
14	chemical	O
15	or	O
16	thermal	O
17	reaction	O
18	,	O
19	or	O
20	both	O
21	,	O
22	to	O
23	the	O
24	tissue	O
25	adhesive	O
26	,	O
27	but	O
28	there	O
29	was	O
30	no	O
31	evidence	O
32	of	O
33	any	O
34	distant	O
35	ocular	O
36	effects	O
37	.	O

1	One	O
2	of	O
3	its	O
4	lysine	O
5	residues	O
6	is	O
7	modified	O
8	by	O
9	spermidine	O
10	to	O
11	form	O
12	hypusine	O
13	,	O
14	a	O
15	posttranslational	O
16	modification	O
17	unique	O
18	to	O
19	eIF	B
20	-	I
21	5A	I
22	.	O

1	Fifty	O
2	-	O
3	eight	O
4	RMI	O
5	'	O
6	s	O
7	occurred	O
8	in	O
9	the	O
10	placebo	O
11	group	O
12	as	O
13	compared	O
14	to	O
15	only	O
16	twenty	O
17	in	O
18	the	O
19	AC	O
20	group	O
21	(	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	).	O

1	In	O
2	18	O
3	%	O
4	lymphography	O
5	was	O
6	clearly	O
7	positive	O
8	and	O
9	CT	O
10	negative	O
11	.	O

1	Receptors	O
2	for	O
3	interleukin	B
4	(	I
5	IL	I
6	)-	I
7	10	I
8	and	O
9	IL	B
10	-	I
11	6	I
12	-	I
13	type	I
14	cytokines	I
15	use	O
16	similar	O
17	signaling	O
18	mechanisms	O
19	for	O
20	inducing	O
21	transcription	O
22	through	O
23	IL	B
24	-	I
25	6	I
26	response	O
27	elements	O
28	.	O

1	We	O
2	show	O
3	that	O
4	IL	B
5	-	I
6	6	I
7	activates	O
8	JRE	B
9	-	I
10	IL6	I
11	through	O
12	an	O
13	H7	O
14	-	O
15	sensitive	O
16	pathway	O
17	that	O
18	does	O
19	not	O
20	involve	O
21	protein	B
22	kinase	I
23	C	I
24	,	O
25	cyclic	B
26	AMP	I
27	-	I
28	dependent	I
29	kinase	I
30	,	O
31	Ca	B
32	(	I
33	2	I
34	+)-	I
35	or	I
36	calmodulin	I
37	-	I
38	dependent	I
39	kinases	I
40	,	O
41	Ras	B
42	,	O
43	Raf	B
44	-	I
45	1	I
46	,	O
47	or	O
48	NF	B
49	-	I
50	IL6	I
51	(	O
52	C	B
53	/	I
54	EBP	I
55	beta	I
56	).	O

1	Furthermore	O
2	,	O
3	no	O
4	Shine	O
5	-	O
6	Dalgarno	O
7	sequences	O
8	are	O
9	present	O
10	upstream	O
11	of	O
12	the	O
13	presumed	O
14	translational	O
15	start	O
16	codons	O
17	.	O

1	Patients	O
2	with	O
3	detectable	O
4	serum	O
5	TNF	B
6	levels	O
7	had	O
8	significantly	O
9	lower	O
10	serum	O
11	T3	O
12	concentrations	O
13	compared	O
14	to	O
15	those	O
16	with	O
17	undetectable	O
18	levels	O
19	[	O
20	1	O
21	.	O
22	072	O
23	+/-	O
24	0	O
25	.	O
26	588	O
27	vs	O
28	.	O

1	Adduction	O
2	of	O
3	the	O
4	human	B
5	N	I
6	-	I
7	ras	I
8	codon	I
9	61	I
10	sequence	I
11	with	O
12	(-)-(	O
13	7S	O
14	,	O
15	8R	O
16	,	O
17	9R	O
18	,	O
19	10S	O
20	)-	O
21	7	O
22	,	O
23	8	O
24	-	O
25	dihydroxy	O
26	-	O
27	9	O
28	,	O
29	10	O
30	-	O
31	epoxy	O
32	-	O
33	7	O
34	,	O
35	8	O
36	,	O
37	9	O
38	,	O
39	10	O
40	-	O
41	tetrahydrobenzo	O
42	[	O
43	a	O
44	]	O
45	pyrene	O
46	:	O
47	structural	O
48	refinement	O
49	of	O
50	the	O
51	intercalated	O
52	SRSR	O
53	(	O
54	61	O
55	,	O
56	2	O
57	)	O
58	(-)-(	O
59	7S	O
60	,	O
61	8R	O
62	,	O
63	9S	O
64	,	O
65	10R	O
66	)-	O
67	N6	O
68	-[	O
69	10	O
70	-(	O
71	7	O
72	,	O
73	8	O
74	,	O
75	9	O
76	,	O
77	10	O
78	-	O
79	tetrahydrobenzo	O
80	[	O
81	a	O
82	]	O
83	pyrenyl	O
84	)]-	O
85	2	O
86	'-	O
87	deoxyadenosyl	O
88	adduct	O
89	from	O
90	1H	O
91	NMR	O
92	.	O

1	Studies	O
2	suggest	O
3	that	O
4	the	O
5	DGOR	O
6	without	O
7	acid	O
8	reflux	O
9	may	O
10	result	O
11	in	O
12	symptoms	O
13	but	O
14	unless	O
15	acid	O
16	reflux	O
17	is	O
18	present	O
19	simultaneously	O
20	,	O
21	it	O
22	does	O
23	not	O
24	cause	O
25	oesophagitis	O
26	.	O

1	Papers	O
2	of	O
3	the	O
4	Society	O
5	for	O
6	Clinical	O
7	Vascular	O
8	Surgery	O
9	.	O

1	TPBF	B
2	has	O
3	two	O
4	potential	O
5	coiled	O
6	-	O
7	coil	O
8	regions	O
9	,	O
10	a	O
11	basic	O
12	region	O
13	,	O
14	a	O
15	proline	O
16	-	O
17	rich	O
18	region	O
19	,	O
20	a	O
21	histidine	O
22	-	O
23	rich	O
24	N	O
25	terminus	O
26	,	O
27	and	O
28	a	O
29	nuclear	O
30	targeting	O
31	sequence	O
32	.	O

1	Whether	O
2	or	O
3	not	O
4	there	O
5	are	O
6	sequences	O
7	conferring	O
8	cAMP	O
9	responsiveness	O
10	which	O
11	are	O
12	common	O
13	both	O
14	to	O
15	P	B
16	-	I
17	450scc	I
18	and	O
19	the	O
20	other	O
21	steroidogenic	O
22	P	B
23	-	I
24	450	I
25	genes	I
26	remains	O
27	to	O
28	be	O
29	established	O
30	.	O

1	We	O
2	have	O
3	found	O
4	a	O
5	satisfactory	O
6	reproducibility	O
7	in	O
8	vitro	O
9	(	O
10	T1	O
11	:	O
12	1	O
13	.	O
14	9	O
15	%;	O
16	T2	O
17	:	O
18	6	O
19	.	O
20	2	O
21	%),	O
22	while	O
23	the	O
24	reproducibility	O
25	was	O
26	less	O
27	satisfactory	O
28	in	O
29	vivo	O
30	(	O
31	T1	O
32	:	O
33	16	O
34	.	O
35	4	O
36	%;	O
37	T2	O
38	:	O
39	13	O
40	.	O
41	4	O
42	%).	O

1	Transcription	O
2	of	O
3	the	O
4	metH	B
5	gene	I
6	in	I
7	Salmonella	I
8	typhimurium	I
9	and	I
10	Escherichia	I
11	coli	I
12	is	O
13	positively	O
14	regulated	O
15	by	O
16	the	O
17	metR	B
18	gene	I
19	product	I
20	,	O
21	a	O
22	DNA	O
23	binding	O
24	protein	O
25	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	deduced	O
6	amino	O
7	acid	O
8	sequence	O
9	of	O
10	a	O
11	second	O
12	family	O
13	(	O
14	ART5	B
15	)	O
16	of	O
17	transferases	O
18	,	O
19	cloned	O
20	from	O
21	murine	O
22	lymphoma	O
23	cells	O
24	and	O
25	expressed	O
26	in	O
27	high	O
28	abundance	O
29	in	O
30	testis	O
31	,	O
32	displays	O
33	a	O
34	hydrophobic	O
35	amino	O
36	terminus	O
37	,	O
38	consistent	O
39	with	O
40	a	O
41	signal	O
42	sequence	O
43	,	O
44	but	O
45	lacks	O
46	a	O
47	hydrophobic	O
48	signal	O
49	sequence	O
50	at	O
51	its	O
52	carboxyl	O
53	terminus	O
54	,	O
55	suggesting	O
56	that	O
57	the	O
58	protein	O
59	is	O
60	destined	O
61	for	O
62	export	O
63	.	O

1	Botulinum	B
2	toxin	I
3	:	O
4	preferred	O
5	treatment	O
6	for	O
7	hemifacial	O
8	spasm	O
9	.	O

1	A	O
2	215	O
3	-	O
4	base	O
5	-	O
6	pair	O
7	(	O
8	bp	O
9	)	O
10	region	O
11	of	O
12	the	O
13	mouse	B
14	MOPC	I
15	41	I
16	kappa	I
17	light	I
18	-	I
19	chain	I
20	immunoglobulin	I
21	gene	I
22	enhancer	I
23	has	O
24	been	O
25	analyzed	O
26	for	O
27	specific	O
28	binding	O
29	of	O
30	lymphoid	O
31	and	O
32	nonlymphoid	O
33	nuclear	O
34	factors	O
35	.	O

1	These	O
2	human	O
3	IFN	B
4	-	I
5	beta	I
6	-	O
7	transformed	O
8	cell	O
9	populations	O
10	have	O
11	acquired	O
12	a	O
13	low	O
14	,	O
15	constitutive	O
16	production	O
17	of	O
18	human	B
19	IFN	I
20	,	O
21	while	O
22	replicating	O
23	at	O
24	a	O
25	rate	O
26	similar	O
27	to	O
28	that	O
29	of	O
30	untransformed	O
31	cells	O
32	and	O
33	of	O
34	cells	O
35	transformed	O
36	with	O
37	the	O
38	control	O
39	vector	O
40	carrying	O
41	a	O
42	human	B
43	IFN	I
44	-	I
45	beta	I
46	sequence	I
47	encoding	O
48	an	O
49	inactive	O
50	,	O
51	mutated	O
52	protein	O
53	.	O

1	Jean	O
2	Klig	O
3	reviews	O
4	recent	O
5	literature	O
6	about	O
7	lower	O
8	respiratory	O
9	tract	O
10	infection	O
11	in	O
12	children	O
13	.	O

1	To	O
2	define	O
3	transcriptional	O
4	control	O
5	elements	O
6	responsible	O
7	for	O
8	muscle	O
9	-	O
10	specific	O
11	expression	O
12	of	O
13	the	O
14	human	B
15	myoglobin	I
16	gene	I
17	,	O
18	we	O
19	performed	O
20	mutational	O
21	analysis	O
22	of	O
23	upstream	O
24	sequences	O
25	(	O
26	nucleotide	O
27	positions	O
28	-	O
29	373	O
30	to	O
31	+	O
32	7	O
33	relative	O
34	to	O
35	the	O
36	transcriptional	O
37	start	O
38	site	O
39	)	O
40	linked	O
41	to	O
42	a	O
43	firefly	B
44	luciferase	I
45	gene	I
46	.	O

1	Also	O
2	like	O
3	the	O
4	thrombin	B
5	receptor	I
6	,	O
7	PAR2	B
8	can	O
9	be	O
10	activated	O
11	by	O
12	the	O
13	hexapeptide	O
14	corresponding	O
15	to	O
16	its	O
17	tethered	O
18	ligand	O
19	sequence	O
20	independent	O
21	of	O
22	receptor	O
23	cleavage	O
24	.	O

1	Eight	O
2	patients	O
3	with	O
4	ARC	O
5	and	O
6	renal	O
7	failure	O
8	were	O
9	recently	O
10	evaluated	O
11	.	O

1	Determination	O
2	of	O
3	diquat	O
4	in	O
5	biological	O
6	materials	O
7	by	O
8	electron	O
9	spin	O
10	resonance	O
11	spectroscopy	O
12	.	O

1	Peripheral	O
2	polyneuropathy	O
3	associated	O
4	with	O
5	multiple	O
6	myeloma	O
7	.	O

1	Their	O
2	afterglows	O
3	are	O
4	brighter	O
5	than	O
6	supernovae	O
7	and	O
8	therefore	O
9	are	O
10	called	O
11	hypernovae	O
12	.	O

1	Under	O
2	resting	O
3	conditions	O
4	,	O
5	activity	O
6	levels	O
7	of	O
8	cardiac	O
9	vagal	O
10	and	O
11	sympathetic	O
12	outflows	O
13	are	O
14	not	O
15	related	O
16	across	O
17	young	O
18	,	O
19	healthy	O
20	human	O
21	subjects	O
22	and	O
23	peripheral	O
24	interaction	O
25	is	O
26	not	O
27	manifest	O
28	between	O
29	the	O
30	autonomic	O
31	divisions	O
32	.	O

1	Twenty	O
2	-	O
3	eight	O
4	(	O
5	7	O
6	.	O
7	0	O
8	%)	O
9	infants	O
10	without	O
11	periventricular	O
12	hemorrhage	O
13	were	O
14	revealed	O
15	as	O
16	having	O
17	spastic	O
18	cerebral	O
19	palsy	O
20	by	O
21	neurodevelopmental	O
22	evaluation	O
23	in	O
24	later	O
25	infancy	O
26	.	O

1	This	O
2	finding	O
3	suggested	O
4	that	O
5	the	O
6	PI3K	B
7	-	O
8	Akt	B
9	activation	O
10	pathway	O
11	plays	O
12	some	O
13	role	O
14	in	O
15	the	O
16	antiapoptotic	O
17	effect	O
18	of	O
19	EPO	B
20	.	O

1	Actins	B
2	show	O
3	two	O
4	different	O
5	forms	O
6	of	O
7	N	O
8	-	O
9	terminal	O
10	processing	O
11	dependent	O
12	on	O
13	their	O
14	N	O
15	-	O
16	terminal	O
17	sequence	O
18	.	O

1	In	O
2	addition	O
3	,	O
4	CaMig1	B
5	formed	O
6	specific	O
7	complexes	O
8	with	O
9	the	O
10	URS1	O
11	region	O
12	of	O
13	the	O
14	S	B
15	.	I
16	cerevisiae	I
17	FBP1	I
18	gene	I
19	.	O

1	Neural	O
2	-	O
3	specific	O
4	expression	O
5	,	O
6	genomic	O
7	structure	O
8	,	O
9	and	O
10	chromosomal	O
11	localization	O
12	of	O
13	the	O
14	gene	O
15	encoding	O
16	the	O
17	zinc	B
18	-	I
19	finger	I
20	transcription	I
21	factor	I
22	NGFI	I
23	-	I
24	C	I
25	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	indicated	O
5	that	O
6	the	O
7	transcription	O
8	initiation	O
9	site	O
10	mapped	O
11	to	O
12	a	O
13	position	O
14	on	O
15	gene	B
16	IV	I
17	that	O
18	was	O
19	analogous	O
20	to	O
21	that	O
22	reported	O
23	for	O
24	the	O
25	structurally	O
26	similar	O
27	P	B
28	-	I
29	450e	I
30	gene	I
31	.	O

1	The	O
2	FMN	O
3	moiety	O
4	but	O
5	not	O
6	the	O
7	[	O
8	3Fe	O
9	-	O
10	4S	O
11	]	O
12	cluster	O
13	of	O
14	the	O
15	subunit	O
16	appears	O
17	to	O
18	participate	O
19	in	O
20	this	O
21	reaction	O
22	.	O

1	These	O
2	primers	O
3	yielded	O
4	a	O
5	PCR	O
6	product	O
7	of	O
8	a	O
9	characteristic	O
10	length	O
11	within	O
12	most	O
13	Xanthomonas	O
14	species	O
15	and	O
16	pathovars	O
17	tested	O
18	.	O

1	This	O
2	proposed	O
3	method	O
4	is	O
5	similar	O
6	in	O
7	principle	O
8	to	O
9	the	O
10	sets	O
11	technique	O
12	but	O
13	is	O
14	shown	O
15	to	O
16	have	O
17	much	O
18	better	O
19	expected	O
20	time	O
21	to	O
22	alarm	O
23	properties	O
24	.	O

1	Defective	O
2	provirus	O
3	genomes	O
4	of	O
5	human	O
6	T	O
7	-	O
8	cell	O
9	leukemia	O
10	virus	O
11	type	O
12	I	O
13	are	O
14	frequently	O
15	detected	O
16	in	O
17	lymphocytes	O
18	from	O
19	infected	O
20	individuals	O
21	and	O
22	in	O
23	infected	O
24	cell	O
25	lines	O
26	.	O

1	Histiocytic	O
2	panniculitis	O
3	was	O
4	observed	O
5	in	O
6	biopsy	O
7	specimens	O
8	with	O
9	cytophagocytosis	O
10	.	O

1	In	O
2	all	O
3	cells	O
4	,	O
5	the	O
6	accumulation	O
7	of	O
8	high	O
9	Dsg	B
10	protein	I
11	levels	O
12	required	O
13	calcium	O
14	and	O
15	was	O
16	not	O
17	observed	O
18	in	O
19	low	O
20	calcium	O
21	(	O
22	0	O
23	.	O
24	05	O
25	-	O
26	0	O
27	.	O
28	07	O
29	mM	O
30	)	O
31	media	O
32	.	O

1	Degenerate	O
2	primers	O
3	homologous	O
4	to	O
5	highly	O
6	conserved	O
7	regions	O
8	of	O
9	known	O
10	CYP3A	B
11	sequences	I
12	were	O
13	used	O
14	for	O
15	initial	O
16	RT	O
17	-	O
18	PCRs	O
19	.	O

1	Oncogenic	O
2	capacity	O
3	of	O
4	the	O
5	E2F1	B
6	gene	I
7	.	O

1	Upstream	O
2	from	O
3	the	O
4	transcription	O
5	start	O
6	point	O
7	(	O
8	tsp	O
9	),	O
10	a	O
11	nucleotide	O
12	sequence	O
13	highly	O
14	homologous	O
15	to	O
16	the	O
17	consensus	B
18	sequence	I
19	motif	I
20	for	I
21	the	I
22	sigma	I
23	35	I
24	-	I
25	recognized	I
26	promoters	I
27	was	O
28	found	O
29	.	O

1	Sequencing	O
2	of	O
3	the	O
4	facB	B
5	gene	I
6	revealed	O
7	that	O
8	it	O
9	encodes	O
10	a	O
11	protein	O
12	that	O
13	contains	O
14	an	O
15	N	O
16	-	O
17	terminal	O
18	GAL4	B
19	-	O
20	like	O
21	Zn	O
22	(	O
23	II	O
24	)	O
25	2Cys6	O
26	(	O
27	or	O
28	C6	O
29	zinc	O
30	)	O
31	binuclear	O
32	cluster	O
33	for	O
34	DNA	O
35	binding	O
36	,	O
37	leucine	O
38	zipper	O
39	-	O
40	like	O
41	heptad	O
42	repeat	O
43	motifs	O
44	and	O
45	central	O
46	and	O
47	C	O
48	-	O
49	terminal	O
50	acidic	O
51	alpha	O
52	-	O
53	helical	O
54	regions	O
55	,	O
56	consistent	O
57	with	O
58	a	O
59	function	O
60	as	O
61	a	O
62	DNA	O
63	-	O
64	binding	O
65	transcriptional	O
66	activator	O
67	.	O

1	We	O
2	found	O
3	14	O
4	protein	O
5	binding	O
6	sites	O
7	that	O
8	were	O
9	occupied	O
10	in	O
11	vivo	O
12	.	O

1	We	O
2	have	O
3	elucidated	O
4	the	O
5	exon	O
6	-	O
7	intron	O
8	organization	O
9	of	O
10	the	O
11	entire	O
12	human	O
13	CD58	B
14	gene	I
15	,	O
16	including	O
17	approximately	O
18	2	O
19	.	O
20	5	O
21	kilobases	O
22	(	O
23	kb	O
24	)	O
25	of	O
26	5	O
27	'-	O
28	flanking	O
29	DNA	O
30	.	O

1	In	O
2	cells	O
3	limited	O
4	for	O
5	His	O
6	,	O
7	increased	O
8	expression	O
9	of	O
10	arg	B
11	-	I
12	2	I
13	and	O
14	cpc	B
15	-	I
16	1	I
17	,	O
18	and	O
19	decreased	O
20	expression	O
21	of	O
22	cox	B
23	-	I
24	5	I
25	,	O
26	also	O
27	had	O
28	translational	O
29	and	O
30	transcriptional	O
31	components	O
32	.	O

1	Organ	O
2	transplantation	O
3	in	O
4	Denmark	O
5	.	O

1	In	O
2	an	O
3	attempt	O
4	to	O
5	investigate	O
6	whether	O
7	the	O
8	intergenic	O
9	region	O
10	between	O
11	the	O
12	oleosin	B
13	and	O
14	a	O
15	second	O
16	open	O
17	reading	O
18	frame	O
19	(	O
20	ORFII	O
21	)	O
22	in	O
23	Brassica	O
24	napus	O
25	(	O
26	L	O
27	.)	O
28	is	O
29	a	O
30	divergent	O
31	promoter	O
32	,	O
33	and	O
34	also	O
35	to	O
36	characterize	O
37	the	O
38	ORFII	B
39	,	O
40	cDNA	B
41	clones	I
42	homologous	I
43	to	I
44	ORFII	I
45	were	O
46	isolated	O
47	from	O
48	a	O
49	leaf	O
50	cDNA	O
51	library	O
52	.	O

1	The	O
2	congenital	O
3	forms	O
4	(	O
5	7	O
6	cases	O
7	)	O
8	all	O
9	occurred	O
10	in	O
11	female	O
12	infants	O
13	and	O
14	involved	O
15	the	O
16	mucosa	O
17	overlying	O
18	either	O
19	the	O
20	anterior	O
21	ridge	O
22	of	O
23	the	O
24	maxilla	O
25	or	O
26	the	O
27	mandible	O
28	.	O

1	The	O
2	full	O
3	-	O
4	length	O
5	N	B
6	gene	I
7	,	O
8	encoded	O
9	by	O
10	open	O
11	reading	O
12	frame	O
13	7	O
14	,	O
15	was	O
16	cloned	O
17	from	O
18	the	O
19	Canadian	O
20	PRRS	O
21	virus	O
22	,	O
23	PA	O
24	-	O
25	8	O
26	.	O

1	Determination	O
2	of	O
3	transaminases	O
4	with	O
5	an	O
6	autoanalyzer	O

1	As	O
2	a	O
3	sequence	O
4	-	O
5	specific	O
6	DNA	O
7	binding	O
8	transcription	O
9	factor	O
10	,	O
11	p53	B
12	specifically	O
13	binds	O
14	to	O
15	a	O
16	20	O
17	-	O
18	bp	O
19	consensus	O
20	motif	O
21	5	O
22	'-	O
23	PuPuPuC	O
24	(	O
25	A	O
26	/	O
27	T	O
28	)	O
29	(	O
30	T	O
31	/	O
32	A	O
33	)	O
34	GPyPyPyPuPuPuC	O
35	(	O
36	A	O
37	/	O
38	T	O
39	)(	O
40	T	O
41	/	O
42	A	O
43	)	O
44	GPyPyPy	O
45	-	O
46	3	O
47	'.	O

1	Sparfloxacin	O
2	and	O
3	clinafloxacin	O
4	were	O
5	evaluated	O
6	against	O
7	Enterococcus	O
8	faecium	O
9	SF2149	O
10	and	O
11	Enterococcus	O
12	faecalis	O
13	WH245	O
14	,	O
15	respectively	O
16	.	O

1	False	O
2	positive	O
3	PET	O
4	FDG	O
5	corresponded	O
6	to	O
7	lung	O
8	infection	O
9	,	O
10	degenerative	O
11	bone	O
12	disease	O
13	,	O
14	and	O
15	reconstruction	O
16	artifact	O
17	.	O

1	Though	O
2	the	O
3	BACTEC	O
4	9000	O
5	MB	O
6	system	O
7	is	O
8	recommended	O
9	for	O
10	respiratory	O
11	specimens	O
12	,	O
13	we	O
14	demonstrated	O
15	that	O
16	it	O
17	can	O
18	be	O
19	successfully	O
20	used	O
21	also	O
22	for	O
23	recovery	O
24	of	O
25	mycobacteria	O
26	from	O
27	clinical	O
28	specimens	O
29	from	O
30	various	O
31	extrapulmonary	O
32	sites	O
33	.	O

1	BACKGROUND	O
2	:	O
3	Chemicals	O
4	vary	O
5	considerably	O
6	in	O
7	their	O
8	intrinsic	O
9	ability	O
10	to	O
11	cause	O
12	allergic	O
13	contact	O
14	dermatitis	O
15	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	BOX	O
9	DNA	O
10	enhances	O
11	transcription	O
12	from	O
13	the	O
14	thymidine	B
15	kinase	I
16	(	O
17	TK	B
18	)	O
19	promoter	O
20	in	O
21	various	O
22	EC	O
23	cells	O
24	.	O

1	This	O
2	0	O
3	.	O
4	74	O
5	kb	O
6	cDNA	O
7	contains	O
8	an	O
9	open	O
10	reading	O
11	frame	O
12	(	O
13	ORF	O
14	)	O
15	of	O
16	477	O
17	bp	O
18	encoding	O
19	a	O
20	polypeptide	O
21	of	O
22	159	O
23	amino	O
24	acids	O
25	(	O
26	aa	O
27	)	O
28	which	O
29	differs	O
30	at	O
31	only	O
32	one	O
33	position	O
34	(	O
35	position	O
36	65	O
37	)	O
38	from	O
39	the	O
40	human	B
41	U1	I
42	-	I
43	C	I
44	protein	I
45	.	O

1	Studies	O
2	on	O
3	the	O
4	organic	O
5	matrix	O
6	of	O
7	human	O
8	ear	O
9	ossicles	O

1	The	O
2	effects	O
3	of	O
4	contrast	O
5	media	O
6	on	O
7	coagulation	B
8	factor	I
9	XII	I
10	.	O

1	Reactivities	O
2	to	O
3	horse	B
4	anti	I
5	-	I
6	lymphocyte	I
7	globulin	I
8	.	O

1	A	O
2	sheep	O
3	testicular	O
4	cDNA	O
5	library	O
6	constructed	O
7	in	O
8	pcDNA1	O
9	vector	O
10	was	O
11	screened	O
12	with	O
13	a	O
14	probe	O
15	generated	O
16	by	O
17	polymerase	O
18	chain	O
19	reaction	O
20	(	O
21	PCR	O
22	)	O
23	and	O
24	corresponding	O
25	to	O
26	a	O
27	1	O
28	.	O
29	6	O
30	kb	O
31	fragment	O
32	of	O
33	the	O
34	rat	B
35	luteinizing	I
36	hormone	I
37	receptor	I
38	cDNA	I
39	.	O

1	NuA4	B
2	has	O
3	an	O
4	apparent	O
5	molecular	O
6	mass	O
7	of	O
8	1	O
9	.	O
10	3	O
11	MDa	O
12	.	O

1	Human	O
2	SRF	B
3	-	I
4	related	I
5	proteins	I
6	:	O
7	DNA	O
8	-	O
9	binding	O
10	properties	O
11	and	O
12	potential	O
13	regulatory	O
14	targets	O
15	.	O

1	Resultant	O
2	activation	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	N	I
8	-	I
9	terminal	I
10	kinase	I
11	/	O
12	stress	B
13	-	I
14	activated	I
15	protein	I
16	kinase	I
17	(	O
18	JNK	B
19	/	O
20	SAPK	B
21	).	O

1	The	O
2	latter	O
3	domain	O
4	appears	O
5	to	O
6	be	O
7	involved	O
8	in	O
9	targeting	O
10	Num1p	B
11	to	O
12	the	O
13	mother	O
14	cell	O
15	cortex	O
16	.	O

1	This	O
2	machine	O
3	drift	O
4	,	O
5	which	O
6	was	O
7	not	O
8	associated	O
9	with	O
10	a	O
11	rise	O
12	in	O
13	water	O
14	phantom	O
15	temperature	O
16	and	O
17	did	O
18	not	O
19	consistently	O
20	correlate	O
21	with	O
22	estimated	O
23	x	O
24	-	O
25	ray	O
26	tube	O
27	heat	O
28	,	O
29	could	O
30	result	O
31	in	O
32	a	O
33	significant	O
34	overestimation	O
35	of	O
36	regional	O
37	cerebral	O
38	blood	O
39	flow	O
40	(	O
41	rCBF	O
42	)	O
43	for	O
44	a	O
45	xenon	O
46	/	O
47	CT	O
48	rCBF	O
49	protocol	O
50	involving	O
51	5	O
52	-	O
53	7	O
54	sequential	O
55	scans	O
56	obtained	O
57	at	O
58	1	O
59	-	O
60	min	O
61	interscan	O
62	intervals	O
63	.	O

1	These	O
2	studies	O
3	show	O
4	that	O
5	UCRBP	B
6	binds	O
7	to	O
8	various	O
9	target	O
10	motifs	O
11	that	O
12	are	O
13	distinct	O
14	from	O
15	the	O
16	UCR	O
17	motif	O
18	:	O
19	the	O
20	adeno	B
21	-	I
22	associated	I
23	virus	I
24	P5	I
25	promoter	I
26	and	O
27	elements	O
28	in	O
29	the	O
30	immunoglobulin	B
31	light	I
32	-	I
33	and	I
34	heavy	I
35	-	I
36	chain	I
37	genes	O
38	,	O
39	as	O
40	well	O
41	as	O
42	elements	O
43	in	O
44	ribosomal	B
45	protein	I
46	genes	I
47	.	O

1	Twenty	O
2	-	O
3	three	O
4	sequence	O
5	-	O
6	tagged	O
7	sites	O
8	(	O
9	STSs	O
10	)	O
11	were	O
12	mapped	O
13	within	O
14	the	O
15	contig	O
16	,	O
17	a	O
18	density	O
19	of	O
20	approximately	O
21	1	O
22	per	O
23	200	O
24	kb	O
25	.	O

1	Liu	O
2	,	O
3	B	O
4	.	O

1	The	O
2	interaction	O
3	of	O
4	caffeine	O
5	,	O
6	theophylline	O
7	and	O
8	theobromine	O
9	with	O
10	monoamine	B
11	oxidase	I
12	inhibitors	O
13	.	O

1	However	O
2	,	O
3	we	O
4	identified	O
5	a	O
6	gene	O
7	between	O
8	the	O
9	MDV2	B
10	UL54	I
11	and	O
12	UL55	B
13	genes	I
14	with	O
15	homology	O
16	to	O
17	the	O
18	first	B
19	ORF	I
20	(	I
21	ORF	I
22	-	I
23	1	I
24	)	I
25	of	I
26	equine	I
27	herpesvirus	I
28	type	I
29	1	I
30	and	O
31	corresponding	O
32	gene	O
33	identified	O
34	in	O
35	pseudorabies	O
36	virus	O
37	.	O

1	Remarkably	O
2	,	O
3	U21	B
4	contains	O
5	a	O
6	long	O
7	stretch	O
8	(	O
9	13	O
10	nt	O
11	.)	O
12	of	O
13	complementarity	O
14	to	O
15	a	O
16	highly	O
17	conserved	O
18	sequence	O
19	in	O
20	28S	B
21	rRNA	I
22	.	O

1	This	O
2	effect	O
3	and	O
4	the	O
5	fact	O
6	that	O
7	all	O
8	three	O
9	doses	O
10	were	O
11	toxic	O
12	to	O
13	the	O
14	dams	O
15	dictated	O
16	that	O
17	a	O
18	second	O
19	experiment	O
20	be	O
21	carried	O
22	out	O
23	at	O
24	lower	O
25	doses	O
26	.	O

1	On	O
2	admission	O
3	to	O
4	our	O
5	department	O
6	in	O
7	September	O
8	,	O
9	1987	O
10	,	O
11	the	O
12	patient	O
13	was	O
14	alert	O
15	and	O
16	had	O
17	spastic	O
18	paraparesis	O
19	,	O
20	the	O
21	impairment	O
22	of	O
23	all	O
24	sensory	O
25	modalities	O
26	below	O
27	the	O
28	level	O
29	of	O
30	Th	O
31	10	O
32	and	O
33	urinary	O
34	disturbance	O
35	.	O

1	Although	O
2	we	O
3	predicted	O
4	that	O
5	overexpression	O
6	of	O
7	the	O
8	COOH	O
9	-	O
10	terminal	O
11	domains	O
12	,	O
13	which	O
14	were	O
15	thought	O
16	to	O
17	be	O
18	involved	O
19	in	O
20	the	O
21	regulation	O
22	of	O
23	SREBP	B
24	processing	O
25	,	O
26	would	O
27	result	O
28	in	O
29	disruption	O
30	of	O
31	the	O
32	SREBP	B
33	-	O
34	dependent	O
35	transcriptional	O
36	regulation	O
37	of	O
38	several	O
39	genes	O
40	,	O
41	the	O
42	mRNA	O
43	levels	O
44	for	O
45	3	B
46	-	I
47	hydroxy	I
48	-	I
49	3	I
50	-	I
51	methylglutaryl	I
52	coenzyme	I
53	A	I
54	(	I
55	HMG	I
56	CoA	I
57	)	I
58	synthase	I
59	in	O
60	these	O
61	two	O
62	cell	O
63	lines	O
64	were	O
65	regulated	O
66	in	O
67	a	O
68	sterol	O
69	-	O
70	dependent	O
71	manner	O
72	.	O

1	Like	O
2	the	O
3	Tob	B
4	protein	I
5	,	O
6	Tob2	B
7	inhibited	O
8	cell	O
9	cycle	O
10	progression	O
11	from	O
12	the	O
13	G0	O
14	/	O
15	G1	O
16	to	O
17	S	O
18	phases	O
19	.	O

1	Clinically	O
2	meaningful	O
3	decreases	O
4	due	O
5	to	O
6	alkalinization	O
7	alone	O
8	within	O
9	30	O
10	minutes	O
11	are	O
12	unlikely	O
13	.	O

1	Poliomyelitis	O
2	from	O
3	a	O
4	vaccine	O
5	.	O

1	The	O
2	role	O
3	of	O
4	pharmacological	O
5	profiling	O
6	in	O
7	safety	O
8	assessment	O
9	.	O

1	Clinical	O
2	and	O
3	haematological	O
4	signs	O
5	are	O
6	not	O
7	specific	O
8	in	O
9	this	O
10	setting	O
11	,	O
12	and	O
13	the	O
14	diagnosis	O
15	relies	O
16	on	O
17	histological	O
18	features	O
19	,	O
20	mainly	O
21	bone	O
22	marrow	O
23	examination	O
24	.	O

1	K	O
2	.	O

1	Compound	O
2	1	O
3	is	O
4	either	O
5	21	O
6	-	O
7	O	O
8	-	O
9	angeloyl	O
10	,	O
11	22	O
12	-	O
13	O	O
14	-	O
15	tigloyl	O
16	R1	O
17	-	O
18	barrigenol	O
19	,	O
20	or	O
21	21	O
22	-	O
23	O	O
24	-	O
25	tigloyl	O
26	,	O
27	22	O
28	-	O
29	O	O
30	-	O
31	angeloyl	O
32	R1	O
33	-	O
34	barrigenol	O
35	.	O

1	The	O
2	sequence	O
3	and	O
4	isolated	O
5	cDNAs	O
6	will	O
7	provide	O
8	useful	O
9	reagents	O
10	for	O
11	studying	O
12	the	O
13	expression	O
14	of	O
15	Brca1	B
16	in	O
17	the	O
18	mouse	O
19	,	O
20	and	O
21	for	O
22	testing	O
23	the	O
24	importance	O
25	of	O
26	the	O
27	evolutionarily	O
28	conserved	O
29	domains	O
30	.	O

1	The	O
2	CRE	O
3	,	O
4	5	O
5	'-	O
6	TGACGTCA	O
7	-	O
8	3	O
9	',	O
10	has	O
11	been	O
12	described	O
13	as	O
14	the	O
15	consensus	O
16	sequence	O
17	for	O
18	the	O
19	cis	O
20	-	O
21	element	O
22	that	O
23	directs	O
24	cAMP	O
25	-	O
26	regulated	O
27	gene	O
28	expression	O
29	.	O

1	Plasmids	O
2	were	O
3	constructed	O
4	with	O
5	the	O
6	mouse	O
7	promoter	O
8	region	O
9	linked	O
10	to	O
11	the	O
12	reporter	B
13	gene	I
14	chloramphenicol	I
15	acetyltransferase	I
16	(	O
17	CAT	B
18	),	O
19	and	O
20	transiently	O
21	and	O
22	stably	O
23	transfected	O
24	in	O
25	the	O
26	INS	O
27	-	O
28	1	O
29	cells	O
30	.	O

1	These	O
2	sequence	O
3	analyses	O
4	suggest	O
5	that	O
6	xIRS	B
7	-	I
8	u	I
9	is	O
10	a	O
11	novel	O
12	member	O
13	of	O
14	the	O
15	IRS	B
16	family	I
17	rather	O
18	than	O
19	a	O
20	Xenopus	O
21	homolog	O
22	of	O
23	an	O
24	existing	O
25	member	O
26	.	O

1	The	O
2	rCBF	O
3	and	O
4	vasomotion	O
5	were	O
6	recorded	O
7	by	O
8	laser	O
9	-	O
10	doppler	O
11	fluxmetry	O
12	.	O

1	Slowly	O
2	adapting	O
3	type	O
4	I	O
5	mechanoreceptor	O
6	discharge	O
7	as	O
8	a	O
9	function	O
10	of	O
11	dynamic	O
12	force	O
13	versus	O
14	dynamic	O
15	displacement	O
16	of	O
17	glabrous	O
18	skin	O
19	of	O
20	raccoon	O
21	and	O
22	squirrel	O
23	monkey	O
24	hand	O
25	.	O

1	The	O
2	obtained	O
3	results	O
4	were	O
5	compared	O
6	with	O
7	control	O
8	group	O
9	(	O
10	10	O
11	female	O
12	volunteers	O
13	).	O

1	However	O
2	,	O
3	parallax	O
4	measurements	O
5	showed	O
6	that	O
7	at	O
8	150K	O
9	,	O
10	collapse	O
11	of	O
12	Epon	O
13	sections	O
14	does	O
15	not	O
16	take	O
17	place	O
18	.	O

1	Analysis	O
2	of	O
3	the	O
4	protein	O
5	sequences	O
6	of	O
7	these	O
8	two	O
9	replicases	B
10	,	O
11	together	O
12	with	O
13	previously	O
14	characterized	O
15	H	B
16	.	I
17	pylori	I
18	plasmid	I
19	replication	I
20	proteins	I
21	,	O
22	supports	O
23	the	O
24	formation	O
25	of	O
26	a	O
27	distinct	O
28	class	O
29	of	O
30	H	B
31	.	I
32	pylori	I
33	plasmid	I
34	proteins	I
35	.	O

1	After	O
2	PTCA	O
3	,	O
4	ejection	O
5	fraction	O
6	increased	O
7	from	O
8	54	O
9	+/-	O
10	8	O
11	%	O
12	to	O
13	59	O
14	+/-	O
15	8	O
16	%	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	05	O
24	)	O
25	and	O
26	regional	O
27	function	O
28	improved	O
29	significantly	O
30	(	O
31	maximal	O
32	standard	O
33	deviation	O
34	before	O
35	PTCA	O
36	:	O
37	2	O
38	.	O
39	8	O
40	+/-	O
41	0	O
42	.	O
43	8	O
44	;	O
45	after	O
46	PTCA	O
47	:	O
48	1	O
49	.	O
50	9	O
51	+/-	O
52	0	O
53	.	O
54	9	O
55	-	O
56	segments	O
57	below	O
58	the	O
59	first	O
60	standard	O
61	deviation	O
62	before	O
63	PTCA	O
64	:	O
65	31	O
66	+/-	O
67	16	O
68	;	O
69	after	O
70	PTCA	O
71	:	O
72	19	O
73	+/-	O
74	17	O
75	).	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	and	O
12	compare	O
13	interleukin	B
14	-	I
15	6	I
16	(	O
17	IL	B
18	-	I
19	6	I
20	)	O
21	levels	O
22	in	O
23	gingival	O
24	crevicular	O
25	fluid	O
26	(	O
27	GCF	O
28	)	O
29	and	O
30	clinical	O
31	periodontal	O
32	findings	O
33	in	O
34	patients	O
35	with	O
36	rheumatoid	O
37	arthritis	O
38	(	O
39	RA	O
40	)	O
41	and	O
42	adult	O
43	periodontitis	O
44	(	O
45	AP	O
46	).	O

1	The	O
2	addition	O
3	of	O
4	diatrizoate	O
5	to	O
6	the	O
7	IPRK	O
8	led	O
9	to	O
10	a	O
11	dose	O
12	-	O
13	dependent	O
14	biphasic	O
15	change	O
16	in	O
17	RPF	O
18	and	O
19	GFR	O
20	characterized	O
21	by	O
22	an	O
23	initial	O
24	transient	O
25	increase	O
26	followed	O
27	by	O
28	a	O
29	marked	O
30	and	O
31	sustained	O
32	decrease	O
33	.	O

1	The	O
2	E1	B
3	nuclear	I
4	transport	I
5	motif	I
6	is	O
7	highly	O
8	conserved	O
9	in	O
10	the	O
11	animal	O
12	and	O
13	human	O
14	papillomaviruses	O
15	and	O
16	is	O
17	encoded	O
18	in	O
19	a	O
20	similar	O
21	region	O
22	in	O
23	the	O
24	related	O
25	E1	B
26	genes	I
27	.	O

1	To	O
2	determine	O
3	if	O
4	CYC2	B
5	is	O
6	found	O
7	in	O
8	a	O
9	complex	O
10	with	O
11	previously	O
12	identified	O
13	trypanosome	B
14	cdc2	I
15	-	I
16	related	I
17	kinases	I
18	(	O
19	CRKs	B
20	),	O
21	the	O
22	CYC2	B
23	gene	I
24	was	O
25	fused	O
26	to	O
27	the	O
28	TY	B
29	epitope	I
30	tag	O
31	,	O
32	integrated	O
33	into	O
34	the	O
35	trypanosome	O
36	genome	O
37	,	O
38	and	O
39	expressed	O
40	under	O
41	inducible	O
42	control	O
43	.	O

1	The	O
2	Hagen	O
3	-	O
4	Poiseuille	O
5	equation	O
6	is	O
7	used	O
8	to	O
9	assess	O
10	the	O
11	effects	O
12	of	O
13	attached	O
14	parasites	O
15	in	O
16	the	O
17	foregut	O
18	of	O
19	Leishmania	O
20	-	O
21	infected	O
22	sandflies	O
23	on	O
24	blood	O
25	flow	O
26	.	O

1	Lack	O
2	of	O
3	controlled	O
4	prospective	O
5	studies	O
6	of	O
7	sleep	O
8	electroencephalograms	O
9	(	O
10	EEG	O
11	),	O
12	and	O
13	the	O
14	use	O
15	of	O
16	medication	O
17	,	O
18	in	O
19	children	O
20	with	O
21	developmental	O
22	dysphasia	O
23	,	O
24	may	O
25	deny	O
26	appropriate	O
27	treatment	O
28	strategies	O
29	to	O
30	children	O
31	with	O
32	severe	O
33	developmental	O
34	speech	O
35	and	O
36	language	O
37	disorders	O
38	.	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	cyclic	O
6	variations	O
7	in	O
8	heme	O
9	turnover	O
10	are	O
11	related	O
12	to	O
13	changes	O
14	in	O
15	erythrocyte	O
16	characteristics	O
17	during	O
18	the	O
19	progesterone	O
20	phase	O
21	.	O

1	1	O
2	)	O
3	CFDN	O
4	,	O
5	AMPC	O
6	and	O
7	MNZ	O
8	showed	O
9	a	O
10	potent	O
11	antimicrobial	O
12	activity	O
13	against	O
14	H	O
15	.	O
16	pylori	O
17	,	O
18	and	O
19	especially	O
20	,	O
21	AMPC	O
22	showed	O
23	a	O
24	marked	O
25	bactericidal	O
26	activity	O
27	in	O
28	a	O
29	short	O
30	time	O
31	.	O

1	The	O
2	susceptibility	O
3	of	O
4	the	O
5	PPNG	O
6	strains	O
7	to	O
8	clinically	O
9	relevant	O
10	antibiotics	O
11	varied	O
12	with	O
13	the	O
14	plasmid	O
15	pattern	O
16	;	O
17	this	O
18	stresses	O
19	the	O
20	necessity	O
21	of	O
22	permanent	O
23	surveillance	O
24	of	O
25	gonococcal	O
26	infections	O
27	and	O
28	of	O
29	regular	O
30	evaluation	O
31	of	O
32	the	O
33	recommendations	O
34	for	O
35	antimicrobial	O
36	treatment	O
37	.	O

1	Its	O
2	expression	O
3	pattern	O
4	is	O
5	representative	O
6	of	O
7	many	O
8	B	O
9	cell	O
10	-	O
11	specific	O
12	proteins	O
13	,	O
14	which	O
15	are	O
16	essential	O
17	for	O
18	B	O
19	cell	O
20	development	O
21	and	O
22	activation	O
23	but	O
24	are	O
25	down	O
26	-	O
27	regulated	O
28	after	O
29	B	O
30	cells	O
31	become	O
32	terminally	O
33	differentiated	O
34	plasma	O
35	cells	O
36	.	O

1	Laboratory	O
2	studies	O
3	using	O
4	Ca45	O
5	labeled	O
6	teeth	O
7	and	O
8	biologically	O
9	stained	O
10	teeth	O
11	confirmed	O
12	that	O
13	the	O
14	dentifrice	O
15	did	O
16	not	O
17	decalcify	O
18	enamel	O
19	or	O
20	bleach	O
21	teeth	O
22	.	O

1	Collectively	O
2	,	O
3	these	O
4	experiments	O
5	demonstrate	O
6	that	O
7	CFTR	B
8	'	I
9	s	I
10	NBF1	I
11	+	I
12	R	I
13	region	I
14	and	O
15	its	O
16	NBF2	B
17	domain	I
18	,	O
19	after	O
20	folding	O
21	separately	O
22	as	O
23	distinct	O
24	units	O
25	,	O
26	have	O
27	a	O
28	strong	O
29	propensity	O
30	to	O
31	interact	O
32	and	O
33	that	O
34	this	O
35	interaction	O
36	is	O
37	stable	O
38	in	O
39	the	O
40	absence	O
41	of	O
42	added	O
43	nucleotides	O
44	or	O
45	exogenously	O
46	induced	O
47	phosphorylation	O
48	.	O

1	Mean	O
2	corpuscular	B
3	hemoglobin	I
4	concentrations	O
5	remained	O
6	normal	O
7	for	O
8	48	O
9	h	O
10	and	O
11	then	O
12	decreased	O
13	in	O
14	both	O
15	groups	O
16	,	O
17	the	O
18	CO2	O
19	group	O
20	showing	O
21	the	O
22	larger	O
23	decrease	O
24	.	O

1	Appropriate	O
2	restriction	O
3	sites	O
4	allow	O
5	one	O
6	to	O
7	insert	O
8	virtually	O
9	any	O
10	desired	O
11	cDNA	O
12	fragment	O
13	directly	O
14	behind	O
15	the	O
16	epitope	O
17	-	O
18	specific	O
19	sequence	O
20	and	O
21	before	O
22	a	O
23	long	O
24	poly	O
25	(	O
26	A	O
27	)	O
28	tail	O
29	.	O

1	Although	O
2	basal	O
3	vessels	O
4	may	O
5	constrict	O
6	distal	O
7	parenchymal	O
8	vessels	O
9	tend	O
10	to	O
11	dilate	O
12	after	O
13	SAH	O
14	.	O

1	We	O
2	analyzed	O
3	the	O
4	modular	O
5	organization	O
6	of	O
7	DNA	B
8	polymerase	I
9	beta	I
10	and	O
11	found	O
12	that	O
13	residues	O
14	making	O
15	contact	O
16	with	O
17	DNA	O
18	phosphates	O
19	were	O
20	localized	O
21	to	O
22	five	O
23	modules	O
24	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	cynomolgus	O
6	monkeys	O
7	are	O
8	either	O
9	less	O
10	sensitive	O
11	or	O
12	respond	O
13	differently	O
14	than	O
15	rhesus	O
16	monkeys	O
17	to	O
18	some	O
19	of	O
20	the	O
21	pharmacological	O
22	effects	O
23	of	O
24	norcocaine	O
25	.	O

1	With	O
2	steady	O
3	illumination	O
4	,	O
5	outer	O
6	retinal	O
7	(	O
8	photoreceptor	O
9	)	O
10	QO2	O
11	decreased	O
12	to	O
13	1	O
14	.	O
15	4	O
16	+/-	O
17	0	O
18	.	O
19	9	O
20	ml	O
21	O2	O
22	/(	O
23	100	O
24	g	O
25	.	O
26	min	O
27	),	O
28	but	O
29	inner	O
30	retinal	O
31	QO2	O
32	remained	O
33	unchanged	O
34	at	O
35	3	O
36	.	O
37	7	O
38	+/-	O
39	1	O
40	.	O
41	5	O
42	ml	O
43	O2	O
44	/(	O
45	100	O
46	g	O
47	.	O
48	min	O
49	)	O
50	(	O
51	5	O
52	cats	O
53	).	O

1	The	O
2	rci	B
3	gene	I
4	was	O
5	fused	O
6	with	O
7	lacZ	B
8	and	O
9	its	O
10	gene	O
11	product	O
12	was	O
13	identified	O
14	by	O
15	Western	O
16	blot	O
17	analysis	O
18	.	O

1	A	O
2	striking	O
3	finding	O
4	in	O
5	all	O
6	of	O
7	the	O
8	studies	O
9	was	O
10	a	O
11	positive	O
12	correlation	O
13	between	O
14	PI	O
15	ACTH	B
16	and	O
17	MSH	B
18	contents	O
19	.	O

1	During	O
2	activity	O
3	III	O
4	,	O
5	one	O
6	patient	O
7	developed	O
8	angina	O
9	.	O

1	Oligonucleotide	O
2	-	O
3	directed	O
4	mutagenesis	O
5	was	O
6	used	O
7	to	O
8	create	O
9	an	O
10	NdeI	B
11	restriction	I
12	site	I
13	at	O
14	the	O
15	natural	O
16	ATG	O
17	of	O
18	the	O
19	yeast	O
20	R	O
21	.	O

1	The	O
2	Fyn	B
3	NH2	I
4	terminus	I
5	was	O
6	necessary	O
7	but	O
8	not	O
9	sufficient	O
10	for	O
11	interaction	O
12	with	O
13	zeta	O
14	and	O
15	both	O
16	Fyn	B
17	kinase	I
18	and	O
19	SH2	B
20	domains	I
21	were	O
22	required	O
23	,	O
24	directing	O
25	phosphorylation	O
26	of	O
27	zeta	B
28	ITAM	I
29	tyrosines	O
30	and	O
31	binding	O
32	to	O
33	zeta	B
34	ITAM	I
35	phosphotyrosines	O
36	.	O

1	In	O
2	line	O
3	with	O
4	the	O
5	small	O
6	values	O
7	for	O
8	QS	O
9	/	O
10	QC	O
11	,	O
12	our	O
13	results	O
14	further	O
15	indicate	O
16	that	O
17	even	O
18	large	O
19	,	O
20	well	O
21	-	O
22	perfused	O
23	,	O
24	occluded	O
25	air	O
26	spaces	O
27	in	O
28	the	O
29	lung	O
30	will	O
31	hardly	O
32	affect	O
33	the	O
34	recovered	O
35	ventilation	O
36	/	O
37	perfusion	O
38	distribution	O
39	obtained	O
40	from	O
41	inert	O
42	gas	O
43	data	O
44	when	O
45	CDCSF6	O
46	exceeds	O
47	0	O
48	.	O
49	1	O
50	ml	O
51	.	O
52	min	O
53	-	O
54	1	O
55	.	O
56	mmHg	O
57	-	O
58	1	O
59	.	O

1	Thyroid	O
2	function	O
3	tests	O
4	were	O
5	performed	O
6	on	O
7	300	O
8	admissions	O
9	,	O
10	leaving	O
11	707	O
12	untested	O
13	.	O

1	Determination	O
2	of	O
3	potassium	O
4	iodide	O
5	in	O
6	Polish	O
7	edible	O
8	salt	O

1	Interestingly	O
2	,	O
3	EGF	B
4	,	O
5	but	O
6	not	O
7	insulin	B
8	,	O
9	stimulated	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	c	B
14	-	I
15	cbl	I
16	and	O
17	its	O
18	association	O
19	with	O
20	Crk	B
21	-	I
22	II	I
23	.	O

1	This	O
2	model	O
3	is	O
4	further	O
5	supported	O
6	by	O
7	binding	O
8	of	O
9	the	O
10	Fos	B
11	-	O
12	Jun	B
13	complex	O
14	at	O
15	an	O
16	AP	B
17	-	I
18	1	I
19	site	I
20	in	O
21	the	O
22	type	B
23	alpha	I
24	I	I
25	collagen	I
26	promoter	I
27	that	O
28	is	O
29	contiguous	O
30	with	O
31	,	O
32	but	O
33	not	O
34	overlapping	O
35	,	O
36	the	O
37	VDRE	O
38	.	O

1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	Cdk2	B
7	-	O
8	phosphorylated	O
9	MARCKS	B
10	was	O
11	digested	O
12	with	O
13	lysyl	B
14	endoprotease	I
15	and	O
16	analysed	O
17	by	O
18	electrospray	O
19	MS	O
20	.	O

1	However	O
2	,	O
3	in	O
4	a	O
5	multivariate	O
6	analysis	O
7	considering	O
8	age	O
9	,	O
10	gender	O
11	,	O
12	and	O
13	a	O
14	previous	O
15	history	O
16	of	O
17	cardiovascular	O
18	diseases	O
19	,	O
20	female	O
21	gender	O
22	was	O
23	not	O
24	independently	O
25	associated	O
26	with	O
27	death	O
28	.	O

1	As	O
2	a	O
3	consequence	O
4	of	O
5	dark	O
6	rearing	O
7	,	O
8	the	O
9	numerical	O
10	density	O
11	of	O
12	cortical	O
13	neurons	O
14	in	O
15	area	O
16	17	O
17	amounted	O
18	to	O
19	about	O
20	double	O
21	of	O
22	the	O
23	value	O
24	observed	O
25	in	O
26	normally	O
27	reared	O
28	kittens	O
29	and	O
30	was	O
31	also	O
32	significantly	O
33	higher	O
34	in	O
35	area	O
36	18	O
37	.	O

1	Pharmacological	O
2	and	O
3	pharmacokinetic	O
4	characteristics	O
5	of	O
6	the	O
7	non	O
8	-	O
9	ionic	O
10	monomeric	O
11	X	O
12	-	O
13	ray	O
14	contrast	O
15	agent	O
16	iopromide	O
17	(	O
18	Ultravist	O
19	,	O
20	CAS	O
21	73334	O
22	-	O
23	07	O
24	-	O
25	3	O
26	)	O
27	were	O
28	evaluated	O
29	in	O
30	preclinical	O
31	studies	O
32	.	O

1	Recurrent	O
2	acute	O
3	rhinosinusitis	O
4	was	O
5	common	O
6	in	O
7	both	O
8	groups	O
9	of	O
10	patients	O
11	,	O
12	but	O
13	the	O
14	development	O
15	of	O
16	chronic	O
17	rhinosinusitis	O
18	was	O
19	only	O
20	found	O
21	in	O
22	patients	O
23	with	O
24	CVID	O
25	,	O
26	indicating	O
27	the	O
28	more	O
29	severe	O
30	nature	O
31	of	O
32	this	O
33	condition	O
34	compared	O
35	with	O
36	selective	O
37	IgA	B
38	deficiency	O
39	.	O

1	The	O
2	median	O
3	post	O
4	-	O
5	treatment	O
6	,	O
7	pre	O
8	-	O
9	operative	O
10	serum	B
11	PSA	I
12	was	O
13	0	O
14	.	O
15	4	O
16	ng	O
17	/	O
18	ml	O
19	.	O

1	A	O
2	quantitative	O
3	analysis	O
4	of	O
5	the	O
6	diffraction	O
7	intensity	O
8	as	O
9	function	O
10	of	O
11	the	O
12	accumulated	O
13	electron	O
14	dose	O
15	suggests	O
16	the	O
17	possibility	O
18	of	O
19	recording	O
20	up	O
21	to	O
22	250	O
23	diffraction	O
24	patterns	O
25	with	O
26	3	O
27	.	O
28	5	O
29	A	O
30	resolution	O
31	from	O
32	a	O
33	single	O
34	crotoxin	O
35	complex	O
36	crystal	O
37	128	O
38	A	O
39	thick	O
40	.	O

1	A	O
2	significant	O
3	direct	O
4	relationship	O
5	was	O
6	observed	O
7	between	O
8	the	O
9	percent	O
10	area	O
11	density	O
12	of	O
13	smooth	O
14	muscle	O
15	and	O
16	the	O
17	percent	O
18	change	O
19	in	O
20	peak	O
21	urinary	O
22	flow	O
23	rate	O
24	.	O

1	By	O
2	deletion	O
3	analysis	O
4	of	O
5	the	O
6	MLS1	B
7	control	O
8	region	O
9	,	O
10	we	O
11	identified	O
12	two	O
13	sites	O
14	,	O
15	UAS1	O
16	and	O
17	UAS2	O
18	,	O
19	as	O
20	important	O
21	for	O
22	efficient	O
23	derepression	O
24	of	O
25	the	O
26	gene	O
27	.	O

1	Mining	O
2	the	O
3	diagnostic	O
4	iron	O
5	ore	O
6	.	O

1	Furthermore	O
2	,	O
3	the	O
4	3	O
5	'-	O
6	untranslated	O
7	regions	O
8	of	O
9	pmGT10	B
10	display	O
11	a	O
12	marked	O
13	degree	O
14	of	O
15	homology	O
16	to	O
17	the	O
18	3	O
19	'	O
20	region	O
21	of	O
22	the	O
23	rat	B
24	Yb1	I
25	gene	I
26	,	O
27	while	O
28	this	O
29	region	O
30	of	O
31	pmGT2	B
32	displays	O
33	marked	O
34	homology	O
35	to	O
36	the	O
37	corresponding	O
38	region	O
39	of	O
40	the	O
41	rat	B
42	Yb2	I
43	gene	I
44	.	O

1	Leukemia	O
2	in	O
3	twins	O
4	:	O
5	world	O
6	-	O
7	wide	O
8	review	O
9	of	O
10	clinical	O
11	cases	O
12	.	O

1	Erythrocyte	B
2	delta	I
3	-	I
4	aminolevulinic	I
5	acid	I
6	dehydratase	I
7	(	O
8	ALAD	B
9	)	O
10	activity	O
11	,	O
12	erythrocyte	O
13	zinc	O
14	protoporphyrin	O
15	(	O
16	ZPP	O
17	)/	O
18	heme	O
19	ratio	O
20	,	O
21	and	O
22	urinary	O
23	coproporphyrin	O
24	(	O
25	UC	O
26	)	O
27	concentration	O
28	have	O
29	been	O
30	employed	O
31	as	O
32	biological	O
33	indicators	O
34	of	O
35	moderate	O
36	-	O
37	to	O
38	high	O
39	-	O
40	level	O
41	lead	O
42	exposure	O
43	,	O
44	corresponding	O
45	to	O
46	blood	O
47	levels	O
48	in	O
49	excess	O
50	of	O
51	50	O
52	micrograms	O
53	/	O
54	dl	O
55	,	O
56	in	O
57	human	O
58	subjects	O
59	.	O

1	220	O
2	,	O
3	263	O
4	-	O
5	273	O
6	).	O

1	They	O
2	also	O
3	occur	O
4	in	O
5	similar	O
6	locations	O
7	in	O
8	the	O
9	promoters	O
10	of	O
11	several	O
12	other	O
13	ribosomal	B
14	protein	I
15	genes	I
16	.	O

1	Two	O
2	related	O
3	cDNAs	O
4	were	O
5	isolated	O
6	that	O
7	encode	O
8	proteins	O
9	that	O
10	recognize	O
11	the	O
12	XMyoDa	B
13	TATA	I
14	motif	I
15	.	O

1	At	O
2	both	O
3	water	O
4	temperatures	O
5	,	O
6	VO2	O
7	increased	O
8	linearly	O
9	with	O
10	increasing	O
11	swimming	O
12	velocity	O
13	.	O

1	Sex	O
2	selection	O
3	via	O
4	albumin	B
5	columns	O
6	:	O
7	20	O
8	years	O
9	of	O
10	results	O
11	.	O

1	Expression	O
2	was	O
3	cell	O
4	cycle	O
5	controlled	O
6	,	O
7	with	O
8	steady	O
9	-	O
10	state	O
11	RNA	O
12	levels	O
13	significantly	O
14	higher	O
15	in	O
16	growth	O
17	-	O
18	arrested	O
19	than	O
20	in	O
21	growth	O
22	-	O
23	stimulated	O
24	cells	O
25	.	O

1	The	O
2	Dax	B
3	-	I
4	1	I
5	gene	I
6	encodes	O
7	a	O
8	protein	O
9	that	O
10	is	O
11	structurally	O
12	related	O
13	to	O
14	members	O
15	of	O
16	the	O
17	orphan	B
18	nuclear	I
19	receptor	I
20	superfamily	I
21	.	O

1	The	O
2	construct	O
3	was	O
4	introduced	O
5	into	O
6	BW2001	O
7	(	O
8	xth	O
9	-	O
10	11	O
11	,	O
12	nfo	O
13	-	O
14	2	O
15	)	O
16	strain	O
17	cells	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O

1	Tobramycin	O
2	-	O
3	loaded	O
4	SLN	O
5	administered	O
6	i	O
7	.	O
8	v	O
9	.	O
10	showed	O
11	a	O
12	prolonged	O
13	circulation	O
14	time	O
15	compared	O
16	to	O
17	the	O
18	i	O
19	.	O
20	v	O
21	.	O
22	administered	O
23	tobramycin	O
24	solution	O
25	.	O

1	Acute	O
2	appearance	O
3	of	O
4	hemiparesis	O
5	or	O
6	hemiplegia	O
7	with	O
8	initial	O
9	marked	O
10	spasticity	O
11	was	O
12	observed	O
13	in	O
14	8	O
15	stroke	O
16	patients	O
17	.	O

1	(	O
2	LH	B
3	P	O
4	<	O
5	0	O
6	.	O
7	05	O
8	,	O
9	LH	B
10	/	O
11	FSH	B
12	P	O
13	<	O
14	0	O
15	.	O
16	01	O
17	).	O

1	However	O
2	,	O
3	the	O
4	BCH	O
5	group	O
6	showed	O
7	inferior	O
8	gross	O
9	motor	O
10	performance	O
11	on	O
12	the	O
13	Bruininks	O
14	-	O
15	Oseretsky	O
16	Test	O
17	of	O
18	Motor	O
19	Proficiency	O
20	(	O
21	Bruininks	O
22	1978	O
23	).	O

1	In	O
2	both	O
3	experiments	O
4	,	O
5	average	O
6	daily	O
7	gain	O
8	and	O
9	gain	O
10	-	O
11	to	O
12	-	O
13	feed	O
14	ratio	O
15	were	O
16	similar	O
17	for	O
18	TR	O
19	and	O
20	CR	O
21	.	O

1	Lower	O
2	extremity	O
3	weight	O
4	bearing	O
5	under	O
6	various	O
7	standing	O
8	conditions	O
9	in	O
10	independently	O
11	ambulatory	O
12	patients	O
13	with	O
14	hemiparesis	O
15	.	O

1	The	O
2	pJR	O
3	vectors	O
4	differ	O
5	among	O
6	them	O
7	in	O
8	:	O
9	(	O
10	a	O
11	)	O
12	the	O
13	selectable	O
14	marker	O
15	(	O
16	Saccharomyces	O
17	cerevisiae	O
18	LEU	B
19	2	I
20	gene	I
21	,	O
22	which	O
23	complements	O
24	S	B
25	.	I
26	pombe	I
27	leu1	I
28	-	I
29	gene	I
30	and	O
31	S	O
32	.	O
33	pombe	O
34	ura4	B
35	+	I
36	and	O
37	his3	B
38	+	I
39	genes	I
40	);	O
41	(	O
42	b	O
43	)	O
44	the	O
45	thiamine	O
46	-	O
47	repressible	O
48	nmt1	B
49	promoter	I
50	(	O
51	3X	O
52	,	O
53	41X	O
54	and	O
55	81X	O
56	with	O
57	extremely	O
58	high	O
59	,	O
60	moderate	O
61	or	O
62	low	O
63	transcription	O
64	efficiency	O
65	,	O
66	respectively	O
67	);	O
68	and	O
69	(	O
70	c	O
71	)	O
72	the	O
73	multiple	O
74	cloning	O
75	site	O
76	(	O
77	two	O
78	multiple	O
79	cloning	O
80	sites	O
81	,	O
82	with	O
83	12	O
84	restriction	O
85	sites	O
86	each	O
87	).	O

1	The	O
2	test	O
3	for	O
4	alpha	B
5	-	I
6	naphthyl	I
7	esterase	I
8	and	O
9	quantitation	O
10	of	O
11	macrophages	O
12	(	O
13	absolute	O
14	number	O
15	)	O
16	per	O
17	infiltration	O
18	area	O
19	unit	O
20	adjacent	O
21	to	O
22	the	O
23	abscess	O
24	suggest	O
25	a	O
26	direct	O
27	correlation	O
28	between	O
29	the	O
30	absolute	O
31	number	O
32	of	O
33	macrophages	O
34	and	O
35	the	O
36	width	O
37	of	O
38	the	O
39	capsule	O
40	.	O

1	Less	O
2	antibacterial	O
3	activity	O
4	was	O
5	shown	O
6	toward	O
7	the	O
8	Gram	O
9	-	O
10	negative	O
11	bacilli	O
12	,	O
13	i	O
14	.	O
15	e	O
16	.,	O
17	Pseudomonas	O
18	,	O
19	Klebsiella	O
20	-	O
21	Enterobacter	O
22	,	O
23	Shigella	O
24	,	O
25	Escherichia	O
26	coli	O
27	,	O
28	Serratia	O
29	marcescens	O
30	and	O
31	Proteus	O
32	.	O

1	The	O
2	grandfather	O
3	and	O
4	the	O
5	granddaughter	O
6	both	O
7	had	O
8	microtia	O
9	and	O
10	meatal	O
11	atresia	O
12	,	O
13	whereas	O
14	the	O
15	daughter	O
16	had	O
17	a	O
18	normal	O
19	outer	O
20	ear	O
21	except	O
22	for	O
23	a	O
24	narrow	O
25	meatus	O
26	and	O
27	auricular	O
28	appendages	O
29	.	O

1	Air	O
2	ion	O
3	action	O
4	on	O
5	bacteria	O
6	.	O

1	Preliminary	O
2	use	O
3	of	O
4	the	O
5	Nottingham	O
6	Eczema	O
7	Severity	O
8	Score	O
9	would	O
10	support	O
11	further	O
12	development	O
13	as	O
14	a	O
15	research	O
16	tool	O
17	for	O
18	a	O
19	simple	O
20	assessment	O
21	of	O
22	disease	O
23	severity	O
24	that	O
25	could	O
26	be	O
27	used	O
28	in	O
29	epidemiological	O
30	studies	O
31	.	O

1	The	O
2	hypertension	O
3	with	O
4	elevated	O
5	PRA	O
6	,	O
7	however	O
8	,	O
9	was	O
10	resistant	O
11	to	O
12	the	O
13	angiotensin	B
14	II	I
15	(	O
16	AII	B
17	)	O
18	analog	O
19	[	O
20	Sar1	O
21	,	O
22	Ile8	O
23	]	O
24	ALL	O
25	.	O

1	The	O
2	favourable	O
3	effect	O
4	of	O
5	thymic	O
6	shielding	O
7	was	O
8	also	O
9	reflected	O
10	in	O
11	a	O
12	significant	O
13	increase	O
14	of	O
15	LD50	O
16	/	O
17	30	O
18	,	O
19	and	O
20	the	O
21	dose	O
22	reduction	O
23	factor	O
24	was	O
25	equal	O
26	to	O
27	2	O
28	.	O

1	High	O
2	values	O
3	of	O
4	both	O
5	retinol	O
6	and	O
7	beta	O
8	-	O
9	carotene	O
10	were	O
11	found	O
12	in	O
13	full	O
14	fat	O
15	cheeses	O
16	and	O
17	whipping	O
18	cream	O
19	:	O
20	from	O
21	179	O
22	.	O
23	0	O
24	(	O
25	cheese	O
26	,	O
27	Edam	O
28	-	O
29	type	O
30	)	O
31	to	O
32	318	O
33	.	O
34	7	O
35	micrograms	O
36	/	O
37	100	O
38	g	O
39	(	O
40	whipping	O
41	cream	O
42	)	O
43	and	O
44	from	O
45	86	O
46	.	O
47	7	O
48	(	O
49	cheese	O
50	,	O
51	Edam	O
52	-	O
53	type	O
54	)	O
55	to	O
56	186	O
57	.	O
58	5	O
59	micrograms	O
60	/	O
61	100	O
62	g	O
63	(	O
64	whipping	O
65	cream	O
66	)	O
67	for	O
68	all	O
69	-	O
70	trans	O
71	retinol	O
72	and	O
73	total	O
74	beta	O
75	-	O
76	carotene	O
77	,	O
78	respectively	O
79	.	O

1	We	O
2	further	O
3	show	O
4	that	O
5	proteolytic	O
6	targeting	O
7	by	O
8	calpain	B
9	II	I
10	and	O
11	the	O
12	proteasome	O
13	involves	O
14	different	O
15	structural	O
16	elements	O
17	of	O
18	YY1	B
19	.	O

1	Overexpression	O
2	of	O
3	either	O
4	DAP	B
5	-	I
6	1	I
7	or	O
8	sentrin	B
9	causes	O
10	apoptosis	O
11	of	O
12	TNF	B
13	-	O
14	sensitive	O
15	L929	O
16	fibroblast	O
17	cell	O
18	line	O
19	,	O
20	as	O
21	well	O
22	as	O
23	TNF	B
24	-	O
25	resistant	O
26	osteosarcoma	O
27	cell	O
28	line	O
29	,	O
30	U2OS	O
31	.	O

1	CONCLUSION	O
2	:	O
3	Although	O
4	quantitative	O
5	and	O
6	qualitative	O
7	criteria	O
8	for	O
9	diagnosing	O
10	fatty	O
11	liver	O
12	on	O
13	helical	O
14	CT	O
15	can	O
16	be	O
17	determined	O
18	,	O
19	they	O
20	are	O
21	protocol	O
22	-	O
23	specific	O
24	.	O

1	Effects	O
2	of	O
3	early	O
4	monocular	O
5	deprivation	O
6	on	O
7	development	O
8	of	O
9	cortico	O
10	-	O
11	geniculate	O
12	projections	O
13	in	O
14	the	O
15	cat	O
16	.	O

1	81	O
2	milk	O
3	samples	O
4	collected	O
5	from	O
6	35	O
7	donors	O
8	3	O
9	days	O
10	to	O
11	7	O
12	months	O
13	after	O
14	delivery	O
15	were	O
16	examined	O
17	for	O
18	the	O
19	occurrence	O
20	of	O
21	cytomegalovirus	O
22	(	O
23	CMV	O
24	).	O

1	The	O
2	site	O
3	-	O
4	specific	O
5	DNA	O
6	inversion	O
7	system	O
8	Cin	B
9	encoded	O
10	by	O
11	the	O
12	bacteriophage	O
13	P1	O
14	consists	O
15	of	O
16	a	O
17	recombinase	B
18	,	O
19	two	O
20	inverted	O
21	crossing	O
22	-	O
23	over	O
24	sites	O
25	and	O
26	a	O
27	recombinational	O
28	enhancer	O
29	.	O

1	In	O
2	contrast	O
3	,	O
4	when	O
5	the	O
6	isoform	O
7	containing	O
8	the	O
9	C	O
10	epsilon4	O
11	domain	O
12	joined	O
13	directly	O
14	to	O
15	the	O
16	M2	O
17	exon	O
18	(	O
19	IgE	B
20	grande	I
21	)	O
22	is	O
23	expressed	O
24	in	O
25	the	O
26	J558L	O
27	cell	O
28	line	O
29	,	O
30	it	O
31	is	O
32	degraded	O
33	intracellularly	O
34	,	O
35	suggesting	O
36	a	O
37	cell	O
38	line	O
39	-	O
40	dependent	O
41	regulation	O
42	of	O
43	secretion	O
44	.	O

1	Platelet	O
2	aggregation	O
3	in	O
4	response	O
5	to	O
6	10	O
7	micrograms	O
8	collagen	B
9	/	O
10	ml	O
11	was	O
12	decreased	O
13	in	O
14	parallel	O
15	after	O
16	treatment	O
17	with	O
18	ASA	O
19	.	O

1	The	O
2	significance	O
3	of	O
4	structural	O
5	integrity	O
6	of	O
7	lymphoid	O
8	tissue	O
9	for	O
10	antibody	O
11	production	O
12	in	O
13	culture	O
14	in	O
15	vivo	O

1	The	O
2	levels	O
3	of	O
4	NPY	B
5	-	O
6	ir	O
7	in	O
8	the	O
9	rat	O
10	vas	O
11	deferens	O
12	were	O
13	not	O
14	affected	O
15	by	O
16	either	O
17	surgical	O
18	or	O
19	pharmacological	O
20	treatment	O
21	.	O

1	Using	O
2	appropriate	O
3	synthetic	O
4	HSE	O
5	oligonucleotides	O
6	,	O
7	three	O
8	types	O
9	of	O
10	clones	O
11	with	O
12	potential	O
13	HSE	O
14	binding	O
15	domains	O
16	were	O
17	isolated	O
18	from	O
19	a	O
20	tomato	O
21	lambda	O
22	gt11	O
23	expression	O
24	library	O
25	by	O
26	DNA	O
27	-	O
28	ligand	O
29	screening	O
30	.	O

1	Homology	O
2	was	O
3	also	O
4	detected	O
5	between	O
6	the	O
7	putative	O
8	transit	O
9	peptide	O
10	sequence	O
11	of	O
12	cysteine	B
13	synthase	I
14	C	I
15	and	O
16	other	O
17	mitochondrion	O
18	-	O
19	targeting	O
20	leader	O
21	sequences	O
22	.	O

1	An	O
2	approximately	O
3	2	B
4	-	I
5	kilobase	I
6	B2	I
7	transcript	I
8	was	O
9	expressed	O
10	in	O
11	all	O
12	alfalfa	O
13	organs	O
14	tested	O
15	.	O

1	Gonadotropin	B
2	levels	O
3	in	O
4	mothers	O
5	who	O
6	have	O
7	had	O
8	two	O
9	sets	O
10	of	O
11	DZ	O
12	twins	O
13	.	O

1	This	O
2	test	O
3	should	O
4	provide	O
5	another	O
6	practical	O
7	means	O
8	to	O
9	study	O
10	leprosy	O
11	.	O

1	Recently	O
2	,	O
3	an	O
4	electrical	O
5	-	O
6	mechanical	O
7	analog	O
8	model	O
9	of	O
10	heat	O
11	flow	O
12	within	O
13	the	O
14	brain	O
15	has	O
16	been	O
17	developed	O
18	from	O
19	which	O
20	an	O
21	expression	O
22	for	O
23	CBF	O
24	has	O
25	been	O
26	derived	O
27	:	O
28	CBF	O
29	=	O
30	Cb	O
31	/(	O
32	tau	O
33	rho	O
34	c	O
35	)	O
36	where	O
37	tau	O
38	is	O
39	the	O
40	thermal	O
41	decay	O
42	constant	O
43	,	O
44	rho	O
45	is	O
46	the	O
47	density	O
48	of	O
49	blood	O
50	,	O
51	and	O
52	c	O
53	is	O
54	its	O
55	specific	O
56	heat	O
57	.	O

1	The	O
2	complement	B
3	C3a	I
4	anaphylatoxin	I
5	receptor	I
6	(	O
7	C3aR	B
8	)	O
9	is	O
10	a	O
11	seven	B
12	-	I
13	transmembrane	I
14	G	I
15	-	I
16	protein	I
17	coupled	I
18	chemoattractant	I
19	receptor	I
20	that	O
21	on	O
22	binding	O
23	the	O
24	C3a	B
25	peptide	I
26	ligand	I
27	mediates	O
28	numerous	O
29	cellular	O
30	responses	O
31	,	O
32	including	O
33	histamine	O
34	release	O
35	from	O
36	mast	O
37	cells	O
38	.	O
39	smooth	O
40	muscle	O
41	contraction	O
42	,	O
43	and	O
44	the	O
45	directed	O
46	migration	O
47	of	O
48	eosinophils	O
49	.	O

1	Optimal	O
2	activation	O
3	of	O
4	T	O
5	cells	O
6	requires	O
7	at	O
8	least	O
9	two	O
10	signals	O
11	.	O

1	A	O
2	transcript	O
3	of	O
4	about	O
5	2	O
6	kb	O
7	is	O
8	expected	O
9	for	O
10	each	O
11	PPO	B
12	.	O

1	Moreover	O
2	,	O
3	the	O
4	mass	O
5	estimated	O
6	with	O
7	the	O
8	QCM	O
9	response	O
10	through	O
11	the	O
12	Sauerbrey	O
13	equation	O
14	and	O
15	the	O
16	mass	O
17	which	O
18	can	O
19	be	O
20	measured	O
21	thanks	O
22	to	O
23	other	O
24	analytical	O
25	techniques	O
26	,	O
27	in	O
28	our	O
29	case	O
30	an	O
31	enzymatic	O
32	assay	O
33	,	O
34	are	O
35	different	O
36	:	O
37	the	O
38	deposited	O
39	mass	O
40	is	O
41	generally	O
42	overestimated	O
43	by	O
44	the	O
45	QCM	O
46	.	O

1	Morphologic	O
2	variables	O
3	included	O
4	cancer	O
5	volume	O
6	,	O
7	histologic	O
8	grade	O
9	,	O
10	capsular	O
11	penetration	O
12	,	O
13	seminal	O
14	vesicle	O
15	invasion	O
16	,	O
17	and	O
18	lymph	O
19	node	O
20	metastasis	O
21	.	O

1	Breast	O
2	-	O
3	fed	O
4	newborn	O
5	infants	O
6	synthesize	O
7	n	O
8	-	O
9	6	O
10	long	O
11	-	O
12	chain	O
13	polyunsaturated	O
14	fatty	O
15	acids	O
16	already	O
17	during	O
18	the	O
19	first	O
20	week	O
21	of	O
22	life	O
23	,	O
24	but	O
25	the	O
26	contribution	O
27	of	O
28	endogenous	O
29	synthesis	O
30	to	O
31	the	O
32	total	O
33	plasma	O
34	long	O
35	-	O
36	chain	O
37	polyunsaturated	O
38	pool	O
39	is	O
40	small	O
41	.	O

1	We	O
2	have	O
3	previously	O
4	isolated	O
5	a	O
6	cDNA	O
7	for	O
8	a	O
9	transcription	O
10	factor	O
11	referred	O
12	to	O
13	as	O
14	Zfhep	B
15	(	O
16	zinc	B
17	finger	I
18	homeodomain	I
19	enhancer	I
20	-	I
21	binding	I
22	protein	I
23	)	O
24	containing	O
25	two	O
26	separate	O
27	zinc	O
28	finger	O
29	domains	O
30	,	O
31	ZD1	B
32	and	O
33	ZD2	B
34	,	O
35	each	O
36	of	O
37	which	O
38	binds	O
39	DNA	O
40	,	O
41	and	O
42	a	O
43	homeodomain	O
44	.	O

1	Aspirin	O
2	intolerance	O
3	:	O
4	unaltered	O
5	susceptibility	O
6	of	O
7	platelet	B
8	cyclo	I
9	-	I
10	oxygenase	I
11	to	O
12	inhibition	O
13	by	O
14	aspirin	O
15	in	O
16	vitro	O
17	.	O

1	The	O
2	SCH9	B
3	protein	I
4	kinase	I
5	mRNA	I
6	contains	O
7	a	O
8	long	O
9	5	O
10	'	O
11	leader	O
12	with	O
13	a	O
14	small	O
15	open	O
16	reading	O
17	frame	O
18	.	O

1	The	O
2	PSD2	B
3	gene	I
4	was	O
5	heterologously	O
6	expressed	O
7	by	O
8	infection	O
9	of	O
10	Sf	O
11	-	O
12	9	O
13	insect	O
14	cells	O
15	with	O
16	recombinant	O
17	baculovirus	O
18	,	O
19	resulting	O
20	in	O
21	a	O
22	10	O
23	-	O
24	fold	O
25	increase	O
26	in	O
27	PSD	B
28	activity	O
29	.	O

1	Potentiation	O
2	of	O
3	the	O
4	thrombolytic	O
5	efficacy	O
6	of	O
7	single	B
8	-	I
9	chain	I
10	urokinase	I
11	(	O
12	Pro	B
13	-	I
14	urokinase	I
15	)	O
16	by	O
17	heparin	O
18	.	O

1	Since	O
2	myoglobin	B
3	is	O
4	co	O
5	-	O
6	extracted	O
7	with	O
8	the	O
9	hemoglobin	B
10	,	O
11	the	O
12	2	O
13	heme	O
14	pigments	O
15	are	O
16	separated	O
17	in	O
18	one	O
19	portion	O
20	of	O
21	the	O
22	extract	O
23	by	O
24	precipitating	O
25	the	O
26	hemoglobin	B
27	in	O
28	an	O
29	85	O
30	%	O
31	(	O
32	NH4	O
33	)	O
34	2SO4	O
35	solution	O
36	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	signaling	O
6	triggered	O
7	by	O
8	surface	O
9	Ig	B
10	engagement	O
11	in	O
12	B	O
13	lymphocytes	O
14	,	O
15	CD38	B
16	ligation	O
17	did	O
18	not	O
19	appear	O
20	to	O
21	induce	O
22	tyrosine	O
23	phosphorylation	O
24	of	O
25	the	O
26	src	B
27	-	I
28	like	I
29	protein	I
30	tyrosine	I
31	kinases	I
32	lyn	I
33	,	O
34	fyn	B
35	,	O
36	and	O
37	btk	B
38	,	O
39	or	O
40	of	O
41	vav	B
42	-	I
43	and	I
44	ras	I
45	-	I
46	GTPase	I
47	-	I
48	activating	I
49	protein	I
50	,	O
51	nor	O
52	did	O
53	it	O
54	induce	O
55	detectable	O
56	changes	O
57	in	O
58	cytosolic	O
59	CA2	O
60	+	O
61	concentrations	O
62	.	O

1	The	O
2	spermicide	O
3	nonoxynol	O
4	-	O
5	9	O
6	is	O
7	a	O
8	member	O
9	of	O
10	a	O
11	homologous	O
12	series	O
13	of	O
14	alkylphenol	O
15	-	O
16	ethoxylates	O
17	(	O
18	polyethoxyethanols	O
19	)	O
20	of	O
21	general	O
22	formula	O
23	C9H19	O
24	-	O
25	C6H6	O
26	-	O
27	O	O
28	-(	O
29	CH2CH2O	O
30	)	O
31	n	O
32	-	O
33	1	O
34	CH2CH2OH	O
35	.	O

1	CREST	O
2	syndrome	O
3	;	O
4	a	O
5	changing	O
6	clinical	O
7	significance	O

1	Respiratory	O
2	adaptation	O
3	to	O
4	chronic	O
5	hypoxia	O
6	in	O
7	newborn	O
8	rats	O
9	.	O

1	ORF	O
2	M1	O
3	has	O
4	striking	O
5	homology	O
6	to	O
7	poxvirus	O
8	serpins	B
9	,	O
10	while	O
11	ORF	O
12	M11	O
13	encodes	O
14	a	O
15	potential	O
16	homolog	O
17	of	O
18	Bcl	B
19	-	I
20	2	I
21	-	I
22	like	I
23	molecules	I
24	encoded	O
25	by	O
26	other	O
27	gammaherpesviruses	O
28	(	O
29	gene	B
30	16	I
31	of	O
32	HVS	O
33	and	O
34	KSHV	O
35	and	O
36	the	O
37	BHRF1	B
38	gene	I
39	of	O
40	EBV	O
41	).	O

1	63	O
2	.	O
3	3	O
4	micromol	O
5	/	O
6	1	O
7	,	O
8	p	O
9	<	O
10	0	O
11	.	O
12	01	O
13	)	O
14	and	O
15	area	O
16	under	O
17	the	O
18	plasma	O
19	concentration	O
20	-	O
21	time	O
22	curve	O
23	extrapolated	O
24	to	O
25	infinity	O
26	AUC	O
27	9	O
28	(	O
29	0	O
30	-	O
31	infinity	O
32	)(	O
33	518	O
34	.	O
35	7	O
36	vs	O
37	.	O

1	The	O
2	DNA	O
3	sequence	O
4	conferring	O
5	AP	B
6	-	I
7	1	I
8	activity	O
9	was	O
10	located	O
11	in	O
12	the	O
13	proximal	O
14	promoter	O
15	region	O
16	.	O

1	In	O
2	addition	O
3	,	O
4	narZ	B
5	expression	O
6	was	O
7	induced	O
8	approximately	O
9	20	O
10	-	O
11	fold	O
12	intracellularly	O
13	in	O
14	Madin	O
15	-	O
16	Darby	O
17	canine	O
18	kidney	O
19	epithelial	O
20	cells	O
21	and	O
22	16	O
23	-	O
24	fold	O
25	in	O
26	intracellular	O
27	salts	O
28	medium	O
29	,	O
30	which	O
31	is	O
32	believed	O
33	to	O
34	mimic	O
35	the	O
36	intracellular	O
37	milieu	O
38	.	O

1	The	O
2	examination	O
3	was	O
4	focused	O
5	on	O
6	assessment	O
7	of	O
8	different	O
9	types	O
10	of	O
11	drusen	O
12	,	O
13	on	O
14	evaluation	O
15	of	O
16	the	O
17	development	O
18	and	O
19	incidence	O
20	of	O
21	risk	O
22	factors	O
23	leading	O
24	to	O
25	complications	O
26	and	O
27	loss	O
28	of	O
29	central	O
30	vision	O
31	.	O

1	We	O
2	generated	O
3	transformed	O
4	B	O
5	lymphoblast	O
6	cell	O
7	lines	O
8	from	O
9	controls	O
10	,	O
11	from	O
12	four	O
13	patients	O
14	with	O
15	p47	B
16	-	O
17	phox	B
18	-	O
19	deficient	O
20	chronic	O
21	granulomatous	O
22	disease	O
23	,	O
24	and	O
25	from	O
26	three	O
27	parents	O
28	.	O

1	In	O
2	conclusion	O
3	,	O
4	changes	O
5	in	O
6	carotid	O
7	sinus	O
8	stimulation	O
9	alters	O
10	blood	O
11	flow	O
12	to	O
13	the	O
14	hindlimb	O
15	through	O
16	changes	O
17	in	O
18	both	O
19	Pcrit	O
20	and	O
21	Ra	O
22	.	O

1	Stereotactic	O
2	radiofrequency	O
3	lesioning	O
4	of	O
5	the	O
6	hamartoma	O
7	resulted	O
8	in	O
9	seizure	O
10	remission	O
11	without	O
12	complications	O
13	20	O
14	months	O
15	after	O
16	surgery	O
17	.	O

1	These	O
2	IgG	B
3	antibodies	I
4	in	O
5	the	O
6	babies	O
7	diminished	O
8	rapidly	O
9	after	O
10	delivery	O
11	,	O
12	and	O
13	were	O
14	detectable	O
15	only	O
16	in	O
17	3	O
18	cases	O
19	at	O
20	2	O
21	,	O
22	3	O
23	,	O
24	and	O
25	5	O
26	months	O
27	of	O
28	ages	O
29	out	O
30	of	O
31	38	O
32	babies	O
33	up	O
34	to	O
35	21	O
36	months	O
37	.	O

1	The	O
2	histologic	O
3	grade	O
4	for	O
5	the	O
6	same	O
7	anatomic	O
8	site	O
9	varied	O
10	among	O
11	hearts	O
12	and	O
13	among	O
14	different	O
15	anatomic	O
16	sites	O
17	in	O
18	the	O
19	same	O
20	heart	O
21	.	O

1	When	O
2	cells	O
3	were	O
4	microinjected	O
5	with	O
6	TFOs	O
7	designed	O
8	to	O
9	bind	O
10	to	O
11	a	O
12	30	O
13	-	O
14	bp	O
15	polypurine	O
16	site	O
17	situated	O
18	between	O
19	the	O
20	two	O
21	TK	B
22	genes	I
23	,	O
24	recombination	O
25	was	O
26	observed	O
27	at	O
28	frequencies	O
29	in	O
30	the	O
31	range	O
32	of	O
33	1	O
34	%,	O
35	2	O
36	,	O
37	500	O
38	-	O
39	fold	O
40	above	O
41	the	O
42	background	O
43	.	O

1	OKA	O
2	and	O
3	calyculin	O
4	A	O
5	do	O
6	not	O
7	decrease	O
8	OCFRE	B
9	DNA	O
10	-	O
11	protein	O
12	interactions	O
13	,	O
14	suggesting	O
15	that	O
16	important	O
17	protein	O
18	-	O
19	protein	O
20	interactions	O
21	are	O
22	phosphatase	O
23	regulated	O
24	.	O

1	In	O
2	general	O
3	,	O
4	the	O
5	values	O
6	obtained	O
7	by	O
8	the	O
9	two	O
10	methods	O
11	were	O
12	in	O
13	agreement	O
14	for	O
15	each	O
16	species	O
17	of	O
18	epidermal	B
19	growth	I
20	factor	I
21	and	O
22	followed	O
23	the	O
24	order	O
25	:	O
26	wild	O
27	type	O
28	greater	O
29	than	O
30	Glu24	O
31	----	O
32	Gly	O
33	greater	O
34	than	O
35	Asp27	O
36	----	O
37	Gly	O
38	much	O
39	greater	O
40	than	O
41	Pro7	O
42	----	O
43	Thr	O
44	greater	O
45	than	O
46	Tyr29	O
47	----	O
48	Gly	O
49	greater	O
50	than	O
51	Leu47	O
52	----	O
53	His	O
54	.	O

1	Liver	O
2	microsomes	O
3	of	O
4	the	O
5	shag	O
6	showed	O
7	smaller	O
8	than	O
9	8	O
10	%	O
11	of	O
12	the	O
13	epoxide	B
14	hydrase	I
15	activity	O
16	and	O
17	smaller	O
18	than	O
19	14	O
20	%	O
21	of	O
22	the	O
23	hydroxylating	O
24	capacity	O
25	of	O
26	liver	O
27	microsomes	O
28	from	O
29	the	O
30	rat	O
31	.	O

1	The	O
2	gene	O
3	includes	O
4	three	O
5	exons	O
6	and	O
7	two	O
8	introns	O
9	within	O
10	1	O
11	.	O
12	6	O
13	kilobases	O
14	of	O
15	DNA	O
16	,	O
17	and	O
18	the	O
19	entire	O
20	open	O
21	reading	O
22	frame	O
23	for	O
24	glycoprotein	B
25	IX	I
26	is	O
27	included	O
28	within	O
29	the	O
30	third	O
31	exon	O
32	.	O

1	We	O
2	have	O
3	recently	O
4	discovered	O
5	that	O
6	CCAAAT	B
7	/	I
8	enhancer	I
9	-	I
10	binding	I
11	protein	I
12	-	I
13	beta	I
14	(	O
15	C	B
16	/	I
17	EBP	I
18	-	I
19	beta	I
20	)	O
21	induces	O
22	gene	O
23	transcription	O
24	through	O
25	a	O
26	novel	O
27	IFN	B
28	response	I
29	element	I
30	called	O
31	the	O
32	gamma	B
33	-	I
34	IFN	I
35	-	I
36	activated	I
37	transcriptional	I
38	element	I

1	This	O
2	DNA	O
3	motif	O
4	represents	O
5	a	O
6	novel	O
7	protein	O
8	-	O
9	binding	O
10	sequence	O
11	.	O

1	Clinical	O
2	and	O
3	angiographic	O
4	examinations	O
5	in	O
6	occlusion	O
7	disease	O
8	of	O
9	the	O
10	great	O
11	intestinal	O
12	arteries	O

1	(	O
2	total	O
3	soluble	O
4	solids	O
5	)	O
6	and	O
7	organoleptic	O
8	characteristics	O
9	under	O
10	the	O
11	influence	O
12	of	O
13	different	O
14	treatments	O
15	.	O

1	Tracheal	O
2	transsection	O
3	combined	O
4	with	O
5	hilar	O
6	ligation	O
7	(	O
8	TL	O
9	&	O
10	PL	O
11	)	O
12	effected	O
13	a	O
14	reduction	O
15	of	O
16	19	O
17	.	O
18	9	O
19	%	O
20	(	O
21	n	O
22	.	O
23	s	O
24	.).	O

1	A	O
2	region	O
3	approximately	O
4	100	O
5	bp	O
6	upstream	O
7	from	O
8	the	O
9	transcription	O
10	start	O
11	point	O
12	of	O
13	virB	B
14	was	O
15	identified	O
16	as	O
17	being	O
18	necessary	O
19	for	O
20	full	O
21	activation	O
22	of	O
23	this	O
24	promoter	O
25	by	O
26	VirF	B
27	.	O

1	Approximately	O
2	60	O
3	%	O
4	of	O
5	cell	O
6	bodies	O
7	of	O
8	primary	O
9	neurons	O
10	innervating	O
11	the	O
12	intra	O
13	and	O
14	perioral	O
15	structures	O
16	through	O
17	the	O
18	inferior	O
19	alveolar	O
20	,	O
21	lingual	O
22	,	O
23	mental	O
24	,	O
25	and	O
26	buccal	O
27	nerves	O
28	were	O
29	in	O
30	the	O
31	range	O
32	between	O
33	300	O
34	and	O
35	600	O
36	micron	O
37	2	O
38	in	O
39	cross	O
40	-	O
41	sectional	O
42	area	O
43	:	O
44	mean	O
45	+/-	O
46	SD	O
47	509	O
48	+/-	O
49	243	O
50	micron	O
51	2	O
52	,	O
53	420	O
54	+/-	O
55	181	O
56	micron	O
57	2	O
58	,	O
59	469	O
60	+/-	O
61	200	O
62	micron	O
63	2	O
64	,	O
65	and	O
66	444	O
67	+/-	O
68	186	O
69	micron	O
70	2	O
71	,	O
72	respectively	O
73	.	O

1	This	O
2	phenomenon	O
3	may	O
4	be	O
5	regarded	O
6	as	O
7	a	O
8	variant	O
9	of	O
10	selective	O
11	individual	O
12	cell	O
13	death	O
14	,	O
15	currently	O
16	referred	O
17	to	O
18	as	O
19	apoptosis	O
20	,	O
21	which	O
22	has	O
23	not	O
24	been	O
25	previously	O
26	reported	O
27	in	O
28	a	O
29	case	O
30	of	O
31	embryonal	O
32	rhabdomyosarcoma	O
33	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	a	O
6	class	O
7	of	O
8	proline	O
9	-	O
10	rich	O
11	activator	O
12	proteins	O
13	and	O
14	RNA	B
15	polymerase	I
16	II	I
17	possess	O
18	a	O
19	common	O
20	structural	O
21	and	O
22	functional	O
23	component	O
24	which	O
25	can	O
26	interact	O
27	with	O
28	the	O
29	same	O
30	target	O
31	in	O
32	the	O
33	general	O
34	transcription	O
35	machinery	O
36	.	O

1	The	O
2	transcription	O
3	and	O
4	alternative	O
5	splicing	O
6	of	O
7	human	B
8	ORL1	I
9	and	O
10	GAIP	B
11	are	O
12	cell	O
13	-	O
14	type	O
15	specific	O
16	.	O

1	Early	O
2	infection	O
3	was	O
4	detected	O
5	in	O
6	one	O
7	of	O
8	50	O
9	control	O
10	women	O
11	who	O
12	gave	O
13	birth	O
14	to	O
15	a	O
16	healthy	O
17	infant	O
18	.	O

1	The	O
2	structural	O
3	gene	O
4	for	O
5	hydrogenase	B
6	encodes	O
7	a	O
8	protein	O
9	product	O
10	of	O
11	molecular	O
12	mass	O
13	45820	O
14	Da	O
15	.	O

1	We	O
2	report	O
3	two	O
4	patients	O
5	receiving	O
6	maintenance	O
7	valproate	O
8	,	O
9	one	O
10	with	O
11	resolving	O
12	acute	O
13	hepatitis	O
14	C	O
15	and	O
16	the	O
17	other	O
18	with	O
19	chronic	O
20	persistent	O
21	hepatitis	O
22	C	O
23	,	O
24	with	O
25	incidental	O
26	microvesicular	O
27	steatosis	O
28	demonstrated	O
29	on	O
30	oil	O
31	-	O
32	red	O
33	O	O
34	stains	O
35	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	Rat7p	B
9	/	O
10	Nup159p	B
11	is	O
12	anchored	O
13	within	O
14	the	O
15	NPC	O
16	through	O
17	its	O
18	coiled	O
19	-	O
20	coil	O
21	region	O
22	and	O
23	adjacent	O
24	sequences	O
25	.	O

1	Different	O
2	sequence	O
3	elements	O
4	of	O
5	both	O
6	the	O
7	retroviral	O
8	vectors	O
9	and	O
10	the	O
11	c	B
12	-	I
13	myc	I
14	gene	I
15	recombined	O
16	during	O
17	genesis	O
18	of	O
19	highly	O
20	oncogenic	O
21	retroviruses	O
22	CMII	O
23	,	O
24	MC29	O
25	,	O
26	or	O
27	MH2	O
28	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	identify	O
6	the	O
7	USH1C	B
8	disease	I
9	gene	I
10	we	O
11	have	O
12	isolated	O
13	the	O
14	region	O
15	between	O
16	these	O
17	markers	O
18	in	O
19	yeast	O
20	artificial	O
21	chromosomes	O
22	(	O
23	YACs	O
24	)	O
25	using	O
26	a	O
27	combination	O
28	of	O
29	STS	O
30	content	O
31	mapping	O
32	and	O
33	Alu	B
34	-	O
35	PCR	O
36	hybridization	O
37	.	O

1	In	O
2	PAV	O
3	-	O
4	3	O
5	,	O
6	the	O
7	E1A	B
8	region	I
9	is	O
10	located	O
11	between	O
12	1	O
13	.	O
14	5	O
15	and	O
16	3	O
17	.	O
18	8	O
19	map	O
20	units	O
21	.	O

1	Type	O
2	I	O
3	cysts	O
4	(	O
5	with	O
6	a	O
7	high	O
8	K	O
9	+/	O
10	Na	O
11	+	O
12	ratio	O
13	)	O
14	tend	O
15	to	O
16	have	O
17	higher	O
18	total	O
19	PSA	B
20	than	O
21	Type	O
22	II	O
23	cysts	O
24	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	the	O
6	ubiquitous	O
7	expression	O
8	of	O
9	2	O
10	.	O
11	9	O
12	kb	O
13	and	O
14	3	O
15	.	O

1	Chronic	O
2	administration	O
3	of	O
4	sodium	O
5	cyanate	O
6	decreases	O
7	O2	O
8	extraction	O
9	ratio	O
10	in	O
11	dogs	O
12	.	O

1	Our	O
2	results	O
3	show	O
4	that	O
5	the	O
6	temperature	B
7	-	I
8	sensitive	I
9	rad54	I
10	-	I
11	3	I
12	allele	I
13	blocks	O
14	mitotic	O
15	recombination	O
16	between	O
17	tandemly	O
18	repeated	O
19	DYZ3	B
20	satellite	I
21	sequences	I
22	and	O
23	significantly	O
24	stabilizes	O
25	a	O
26	human	B
27	DYZ5	I
28	satellite	O
29	-	O
30	containing	O
31	YAC	O
32	clone	O
33	.	O

1	In	O
2	support	O
3	of	O
4	this	O
5	interpretation	O
6	we	O
7	demonstrate	O
8	that	O
9	MQ9b	B
10	binds	O
11	strongly	O
12	5	O
13	of	O
14	17	O
15	motif	O
16	-	O
17	positive	O
18	,	O
19	pathogen	O
20	-	O
21	derived	O
22	synthetic	O
23	peptides	O
24	.	O

1	Six	O
2	patients	O
3	with	O
4	human	O
5	T	O
6	-	O
7	cell	O
8	lymphotropic	O
9	virus	O
10	type	O
11	I	O
12	(	O
13	HTLV	O
14	-	O
15	I	O
16	)-	O
17	associated	O
18	myelopathy	O
19	(	O
20	HAM	O
21	)	O
22	were	O
23	studied	O
24	by	O
25	electrophysiologic	O
26	methods	O
27	.	O

1	Reverse	O
2	transcription	O
3	-	O
4	PCR	O
5	was	O
6	then	O
7	used	O
8	to	O
9	clone	O
10	from	O
11	human	O
12	poly	O
13	(	O
14	A	O
15	)+	O
16	RNA	O
17	the	O
18	cDNA	O
19	corresponding	O
20	to	O
21	the	O
22	expressed	O
23	homolog	O
24	of	O
25	psi	B
26	ARF	I
27	4	I
28	,	O
29	referred	O
30	to	O
31	as	O
32	human	B
33	ARF	I
34	4	I
35	.	O

1	We	O
2	have	O
3	partially	O
4	sequenced	O
5	the	O
6	RAP74	B
7	protein	I
8	from	O
9	purified	O
10	HeLa	O
11	cells	O
12	,	O
13	cloned	O
14	its	O
15	complementary	O
16	DNA	O
17	and	O
18	shown	O
19	that	O
20	its	O
21	translation	O
22	product	O
23	can	O
24	interact	O
25	with	O
26	RAP30	B
27	in	O
28	vitro	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vivo	O
34	.	O

1	Characterization	O
2	of	O
3	fus1	B
4	of	O
5	Schizosaccharomyces	O
6	pombe	O
7	:	O
8	a	O
9	developmentally	O
10	controlled	O
11	function	O
12	needed	O
13	for	O
14	conjugation	O
15	.	O

1	Kinetic	O
2	coupling	O
3	and	O
4	requirement	O
5	for	O
6	ATP	O
7	hydrolysis	O
8	.	O

1	The	O
2	method	O
3	requires	O
4	a	O
5	reversed	O
6	-	O
7	phase	O
8	column	O
9	and	O
10	a	O
11	paired	O
12	-	O
13	ion	O
14	technique	O
15	to	O
16	separate	O
17	docusate	O
18	sodium	O
19	from	O
20	other	O
21	components	O
22	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	We	O
6	prospectively	O
7	compared	O
8	the	O
9	automated	O
10	measurements	O
11	of	O
12	left	O
13	ventricular	O
14	ejection	O
15	fraction	O
16	(	O
17	LVEF	O
18	)	O
19	and	O
20	volumes	O
21	from	O
22	rest	O
23	-	O
24	injected	O
25	gated	O
26	Technetium	O
27	99m	O
28	(	O
29	Tc99m	O
30	)	O
31	perfusion	O
32	SPECT	O
33	with	O
34	equilibrium	O
35	radionuclide	O
36	angiocardiography	O
37	(	O
38	ERNA	O
39	)	O
40	in	O
41	62	O
42	patients	O
43	and	O
44	the	O
45	assessment	O
46	of	O
47	regional	O
48	function	O
49	with	O
50	echocardiography	O
51	in	O
52	22	O
53	patients	O
54	.	O

1	Similarly	O
2	,	O
3	maternal	B
4	serum	I
5	somatomedin	I
6	A	I
7	was	O
8	significantly	O
9	reduced	O
10	in	O
11	rats	O
12	nursing	O
13	large	O
14	litters	O
15	.	O

1	In	O
2	NASCIS	O
3	III	O
4	,	O
5	a	O
6	randomization	O
7	imbalance	O
8	occurred	O
9	that	O
10	allocated	O
11	a	O
12	disproportionate	O
13	number	O
14	of	O
15	patients	O
16	with	O
17	no	O
18	motor	O
19	deficit	O
20	(	O
21	and	O
22	therefore	O
23	no	O
24	chance	O
25	for	O
26	recovery	O
27	)	O
28	to	O
29	the	O
30	lower	O
31	dose	O
32	control	O
33	group	O
34	.	O

1	REM	O
2	sleep	O
3	deprivation	O
4	was	O
5	performed	O
6	using	O
7	the	O
8	platform	O
9	technique	O
10	.	O

1	Desmethylferrochloroquine	O
2	1a	O
3	and	O
4	didesmethylferrochloroquine	O
5	2	O
6	would	O
7	be	O
8	more	O
9	potent	O
10	against	O
11	schizontocides	O
12	than	O
13	CQ	O
14	in	O
15	vitro	O
16	against	O
17	two	O
18	strains	O
19	(	O
20	HB3	O
21	and	O
22	Dd2	O
23	)	O
24	of	O
25	Plasmodium	O
26	falciparum	O
27	.	O

1	However	O
2	,	O
3	a	O
4	surprisingly	O
5	high	O
6	degree	O
7	of	O
8	conservation	O
9	of	O
10	intron	O
11	sequences	O
12	was	O
13	observed	O
14	between	O
15	both	O
16	species	O
17	.	O

1	The	O
2	plateau	O
3	MO2	O
4	value	O
5	was	O
6	that	O
7	predicted	O
8	by	O
9	allometric	O
10	relation	O
11	.	O

1	272	O
2	,	O
3	1904	O
4	].	O

1	The	O
2	results	O
3	imply	O
4	that	O
5	kindling	O
6	does	O
7	not	O
8	produce	O
9	its	O
10	facilitating	O
11	effect	O
12	on	O
13	acquisition	O
14	of	O
15	HPC	O
16	SS	O
17	by	O
18	removing	O
19	a	O
20	disruptive	O
21	effect	O
22	of	O
23	the	O
24	stimulation	O
25	.	O

1	The	O
2	smaller	O
3	uptake	O
4	rate	O
5	and	O
6	faster	O
7	clearance	O
8	rate	O
9	resulted	O
10	in	O
11	the	O
12	lower	O
13	BCF	O
14	for	O
15	SWA	O
16	killifish	O
17	.	O

1	Dimerization	O
2	of	O
3	Myf	B
4	-	I
5	5	I
6	with	O
7	the	O
8	ubiquitously	O
9	expressed	O
10	bHLH	O
11	protein	O
12	E12	B
13	not	O
14	only	O
15	increases	O
16	the	O
17	affinity	O
18	for	O
19	DNA	O
20	but	O
21	also	O
22	stimulates	O
23	transactivation	O
24	independently	O
25	of	O
26	DNA	O
27	binding	O
28	.	O

1	The	O
2	objectives	O
3	of	O
4	the	O
5	present	O
6	study	O
7	were	O
8	to	O
9	evaluate	O
10	the	O
11	effects	O
12	of	O
13	adding	O
14	Equex	O
15	to	O
16	a	O
17	TRIS	O
18	-	O
19	extender	O
20	,	O
21	diluting	O
22	the	O
23	semen	O
24	in	O
25	1	O
26	or	O
27	2	O
28	steps	O
29	,	O
30	freezing	O
31	according	O
32	to	O
33	2	O
34	methods	O
35	,	O
36	thawing	O
37	at	O
38	2	O
39	rates	O
40	,	O
41	and	O
42	the	O
43	interactions	O
44	between	O
45	these	O
46	treatments	O
47	,	O
48	on	O
49	the	O
50	post	O
51	-	O
52	thaw	O
53	survival	O
54	of	O
55	dog	O
56	spermatozoa	O
57	at	O
58	38	O
59	degrees	O
60	C	O
61	.	O

1	Mouse	B
2	mast	I
3	cell	I
4	protease	I
5	9	I
6	,	O
7	a	O
8	novel	O
9	member	O
10	of	O
11	the	O
12	chromosome	O
13	14	O
14	family	O
15	of	O
16	serine	B
17	proteases	I
18	that	O
19	is	O
20	selectively	O
21	expressed	O
22	in	O
23	uterine	O
24	mast	O
25	cells	O
26	.	O

1	Resources	O
2	for	O
3	helping	O
4	patients	O
5	to	O
6	quit	O
7	smoking	O
8	.	O

1	They	O
2	also	O
3	discuss	O
4	the	O
5	existing	O
6	nomenclature	O
7	.	O

1	Micro	O
2	high	O
3	-	O
4	performance	O
5	liquid	O
6	chromatographic	O
7	system	O
8	with	O
9	micro	O
10	precolumn	O
11	and	O
12	dual	O
13	electrochemical	O
14	detector	O
15	for	O
16	direct	O
17	injection	O
18	analysis	O
19	of	O
20	catecholamines	O
21	in	O
22	body	O
23	fluids	O
24	.	O

1	PARTICIPANTS	O
2	:	O
3	Convenience	O
4	sample	O
5	of	O
6	ambulatory	O
7	outpatients	O
8	with	O
9	hereditary	O
10	motor	O
11	and	O
12	sensory	O
13	neuropathy	O
14	,	O
15	type	O
16	I	O
17	(	O
18	n	O
19	=	O
20	9	O
21	),	O
22	myotonic	O
23	muscular	O
24	dystrophy	O
25	(	O
26	n	O
27	=	O
28	10	O
29	),	O
30	and	O
31	able	O
32	-	O
33	bodied	O
34	controls	O
35	(	O
36	n	O
37	=	O
38	11	O
39	).	O

1	Deletion	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	essential	O
7	domain	O
8	of	O
9	this	O
10	promoter	O
11	,	O
12	termed	O
13	the	O
14	ORF5	B
15	/	I
16	deltaX	I
17	transcript	I
18	promoter	I
19	,	O
20	mapped	O
21	to	O
22	nucleotides	O
23	1525	O
24	-	O
25	1625	O
26	.	O

1	IL	B
2	-	I
3	1	I
4	and	O
5	TNF	B
6	increase	O
7	AND	B
8	-	I
9	34	I
10	transcript	I
11	levels	O
12	in	O
13	thymic	O
14	cortical	O
15	reticular	O
16	,	O
17	thymic	O
18	nurse	O
19	,	O
20	and	O
21	fibroblast	O
22	cell	O
23	lines	O
24	.	O

1	Serum	O
2	prostatic	B
3	acid	I
4	phosphatase	I
5	levels	O
6	showed	O
7	a	O
8	significantly	O
9	weaker	O
10	correlation	O
11	with	O
12	cancer	O
13	volume	O
14	(	O
15	r	O
16	equals	O
17	0	O
18	.	O
19	51	O
20	)	O
21	and	O
22	every	O
23	other	O
24	pathological	O
25	parameter	O
26	.	O

1	However	O
2	,	O
3	addition	O
4	of	O
5	core	B
6	DNA	I
7	polymerase	I
8	III	I
9	to	O
10	preinitiation	O
11	complex	O
12	,	O
13	fully	O
14	reconstituting	O
15	holoenzyme	O
16	resulted	O
17	in	O
18	replacement	O
19	of	O
20	gamma	O
21	by	O
22	alpha	O
23	at	O
24	the	O
25	primer	O
26	terminus	O
27	.	O

1	This	O
2	region	O
3	,	O
4	however	O
5	,	O
6	contains	O
7	a	O
8	CCAATC	O
9	box	O
10	in	O
11	the	O
12	reverse	O
13	complement	O
14	and	O
15	several	O
16	GC	O
17	boxes	O
18	that	O
19	are	O
20	recognition	O
21	sites	O
22	for	O
23	SP1	B
24	.	O

1	All	O
2	numbers	O
3	refer	O
4	to	O
5	nucleotide	O
6	positions	O
7	on	O
8	the	O
9	wild	O
10	-	O
11	type	O
12	HIV	O
13	-	O
14	1	O
15	transcript	O
16	.	O

1	An	O
2	intralobar	O
3	change	O
4	in	O
5	temperature	O
6	above	O
7	or	O
8	below	O
9	36	O
10	degrees	O
11	C	O
12	decreases	O
13	only	O
14	the	O
15	lobar	O
16	bronchial	O
17	blood	O
18	flow	O
19	and	O
20	does	O
21	not	O
22	influence	O
23	blood	O
24	flow	O
25	to	O
26	other	O
27	nearby	O
28	tissues	O
29	including	O
30	those	O
31	vascularized	O
32	by	O
33	the	O
34	bronchial	O
35	circulation	O
36	.	O

1	Molecular	O
2	analysis	O
3	of	O
4	a	O
5	novel	O
6	schizosaccharomyces	O
7	pombe	O
8	gene	O
9	containing	O
10	two	O
11	RNP	O
12	consensus	O
13	-	O
14	sequence	O
15	RNA	O
16	-	O
17	binding	O
18	domains	O
19	.	O

1	Pyk2	B
2	phosphorylation	O
3	increased	O
4	upon	O
5	adherence	O
6	of	O
7	FLG	O
8	29	O
9	.	O
10	1	O
11	cells	O
12	to	O
13	fibronectin	B
14	and	O
15	to	O
16	ST2	O
17	stromal	O
18	cells	O
19	.	O

1	A	O
2	partial	O
3	cDNA	O
4	sequence	O
5	indicated	O
6	that	O
7	the	O
8	T	B
9	lymphocyte	I
10	early	I
11	-	I
12	activation	I
13	gene	I
14	(	O
15	Tea	B
16	)	O
17	encodes	O
18	a	O
19	protein	O
20	related	O
21	to	O
22	the	O
23	dual	O
24	-	O
25	function	O
26	ecotropic	B
27	retrovirus	I
28	receptor	I
29	/	O
30	cationic	B
31	amino	I
32	acid	I
33	transporter	I
34	(	O
35	ecoR	B
36	/	O
37	CAT1	B
38	),	O
39	and	O
40	RNA	O
41	blots	O
42	suggested	O
43	highest	O
44	Tea	B
45	expression	O
46	in	O
47	T	O
48	lymphocytes	O
49	and	O
50	liver	O
51	(	O
52	MacLeod	O
53	,	O
54	C	O
55	.	O
56	L	O
57	.,	O
58	Finley	O
59	,	O
60	K	O
61	.,	O
62	Kakuda	O
63	,	O
64	D	O
65	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	messenger	O
6	RNAs	O
7	encoding	O
8	trans	O
9	-	O
10	sialidases	O
11	containing	O
12	the	O
13	repeats	O
14	are	O
15	not	O
16	present	O
17	in	O
18	epimastigotes	O
19	but	O
20	are	O
21	abundant	O
22	in	O
23	trypomastigotes	O
24	.	O

1	We	O
2	report	O
3	an	O
4	example	O
5	of	O
6	an	O
7	MDV	O
8	-	O
9	transformed	O
10	T	O
11	-	O
12	lymphoblastoid	O
13	cell	O
14	line	O
15	(	O
16	T9	O
17	)	O
18	expressing	O
19	high	O
20	levels	O
21	of	O
22	a	O
23	truncated	B
24	C	I
25	-	I
26	MYB	I
27	protein	I
28	as	O
29	a	O
30	result	O
31	of	O
32	RAV	O
33	integration	O
34	within	O
35	one	O
36	c	B
37	-	I
38	myb	I
39	allele	I
40	.	O

1	All	O
2	clinical	O
3	isolates	O
4	were	O
5	concomitantly	O
6	tested	O
7	by	O
8	disk	O
9	diffusion	O
10	and	O
11	agar	O
12	dilution	O
13	procedures	O
14	as	O
15	outlined	O
16	by	O
17	the	O
18	National	O
19	Committee	O
20	for	O
21	Clinical	O
22	Laboratory	O
23	Standards	O
24	.	O

1	Mapping	O
2	features	O
3	of	O
4	HIV	B
5	-	I
6	1	I
7	integrase	I
8	near	O
9	selected	O
10	sites	O
11	on	O
12	viral	O
13	and	O
14	target	O
15	DNA	O
16	molecules	O
17	in	O
18	an	O
19	active	O
20	enzyme	O
21	-	O
22	DNA	O
23	complex	O
24	by	O
25	photo	O
26	-	O
27	cross	O
28	-	O
29	linking	O
30	.	O

1	These	O
2	sorting	B
3	nexins	I
4	also	O
5	associated	O
6	with	O
7	the	O
8	long	O
9	isoform	O
10	of	O
11	the	O
12	leptin	B
13	receptor	I
14	but	O
15	not	O
16	with	O
17	the	O
18	short	O
19	and	O
20	medium	O
21	isoforms	O
22	.	O

1	The	O
2	microcirculatory	O
3	dynamics	O
4	of	O
5	prostaglandin	O
6	E1	O
7	and	O
8	/	O
9	or	O
10	nicardipine	O
11	and	O
12	their	O
13	different	O
14	reactions	O
15	in	O
16	the	O
17	hyper	O
18	-	O
19	and	O
20	hypodynamic	O
21	state	O
22	of	O
23	septic	O
24	shock	O
25	in	O
26	a	O
27	rat	O
28	model	O

1	RNA	O
2	of	O
3	GBV	O
4	-	O
5	C	O
6	was	O
7	detected	O
8	in	O
9	14	O
10	(	O
11	18	O
12	%)	O
13	patients	O
14	before	O
15	BMT	O
16	.	O

1	Further	O
2	studies	O
3	on	O
4	a	O
5	"	O
6	new	O
7	"	O
8	human	O
9	isoprecipitin	B
10	system	O
11	(	O
12	Australia	O
13	antigen	O
14	).	O

1	A	O
2	genetic	O
3	system	O
4	was	O
5	devised	O
6	to	O
7	select	O
8	for	O
9	pi	B
10	protein	I
11	mutants	I
12	which	O
13	discriminate	O
14	between	O
15	IR	O
16	and	O
17	DR	O
18	(	O
19	York	O
20	et	O
21	al	O
22	.,	O
23	Gene	O
24	(	O
25	Amst	O
26	.)	O
27	116	O
28	,	O
29	7	O
30	-	O
31	12	O
32	,	O
33	1992	O
34	;	O
35	York	O
36	and	O
37	Filutowicz	O
38	,	O
39	J	O
40	.	O

1	The	O
2	mHIF	B
3	-	I
4	1	I
5	alpha	I
6	structural	I
7	gene	I
8	is	O
9	composed	O
10	of	O
11	15	O
12	exons	O
13	.	O

1	Our	O
2	study	O
3	shows	O
4	that	O
5	the	O
6	area	O
7	of	O
8	Alcoy	O
9	is	O
10	a	O
11	medium	O
12	MS	O
13	risk	O
14	region	O
15	according	O
16	to	O
17	the	O
18	thesis	O
19	of	O
20	Kurzke	O
21	,	O
22	although	O
23	high	O
24	MS	O
25	areas	O
26	may	O
27	be	O
28	found	O
29	,	O
30	thus	O
31	confirming	O
32	that	O
33	MS	O
34	distribution	O
35	in	O
36	southern	O
37	Europe	O
38	is	O
39	not	O
40	uniform	O
41	.	O

1	The	O
2	metabolism	O
3	and	O
4	pharmacology	O
5	of	O
6	5	O
7	-	O
8	fluorouracil	O
9	.	O

1	When	O
2	the	O
3	coronary	O
4	sinus	O
5	pressure	O
6	reached	O
7	15	O
8	torr	O
9	,	O
10	there	O
11	was	O
12	a	O
13	significant	O
14	decrease	O
15	in	O
16	cardiac	O
17	index	O
18	(	O
19	3	O
20	.	O
21	60	O
22	+/-	O
23	0	O
24	.	O
25	5	O
26	to	O
27	2	O
28	.	O
29	70	O
30	+/-	O
31	0	O
32	.	O
33	6	O
34	L	O
35	/	O
36	min	O
37	/	O
38	m2	O
39	,	O
40	p	O
41	less	O
42	than	O
43	0	O
44	.	O
45	001	O
46	),	O
47	coronary	O
48	blood	O
49	flow	O
50	(	O
51	13	O
52	.	O
53	7	O
54	+/-	O
55	3	O
56	.	O
57	1	O
58	to	O
59	7	O
60	.	O
61	0	O
62	+/-	O
63	2	O
64	.	O
65	1	O
66	ml	O
67	/	O
68	min	O
69	,	O
70	p	O
71	less	O
72	than	O
73	0	O
74	.	O
75	001	O
76	),	O
77	rate	O
78	of	O
79	rise	O
80	of	O
81	left	O
82	ventricular	O
83	pressure	O
84	(	O
85	1	O
86	,	O
87	567	O
88	+/-	O
89	275	O
90	to	O
91	1	O
92	,	O
93	331	O
94	+/-	O
95	314	O
96	,	O
97	p	O
98	less	O
99	than	O
100	0	O
101	.	O
102	05	O
103	),	O
104	and	O
105	an	O
106	increase	O
107	in	O
108	coronary	O
109	arteriovenous	O
110	difference	O
111	(	O
112	62	O
113	.	O
114	8	O
115	%	O
116	+/-	O
117	9	O
118	.	O
119	3	O
120	%	O
121	to	O
122	70	O
123	.	O
124	5	O
125	%	O
126	+/-	O
127	5	O
128	.	O
129	4	O
130	%	O
131	saturation	O
132	,	O
133	p	O
134	less	O
135	than	O
136	0	O
137	.	O
138	03	O
139	).	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	sequenced	O
6	the	O
7	gene	O
8	encoding	O
9	the	O
10	human	B
11	U1	I
12	-	I
13	70K	I
14	snRNP	I
15	protein	I
16	.	O

1	Airway	O
2	pressure	O
3	and	O
4	air	O
5	flow	O
6	were	O
7	measured	O
8	at	O
9	the	O
10	endotracheal	O
11	tube	O
12	in	O
13	13	O
14	children	O
15	on	O
16	a	O
17	variety	O
18	of	O
19	ventilators	O
20	.	O

1	We	O
2	describe	O
3	here	O
4	17	O
5	dominant	B
6	GCN2	I
7	mutations	I
8	that	O
9	lead	O
10	to	O
11	derepression	O
12	of	O
13	GCN4	B
14	expression	O
15	in	O
16	the	O
17	absence	O
18	of	O
19	amino	O
20	acid	O
21	starvation	O
22	.	O

1	TH	B
2	-	O
3	SH3	B
4	binding	O
5	in	O
6	vitro	O
7	is	O
8	abolished	O
9	by	O
10	specific	O
11	,	O
12	single	O
13	amino	O
14	acid	O
15	substitutions	O
16	within	O
17	the	O
18	Btk	B
19	TH	I
20	domain	I
21	or	O
22	the	O
23	Fyn	B
24	SH3	I
25	domain	I
26	.	O

1	An	O
2	amino	O
3	-	O
4	acid	O
5	sequence	O
6	comparison	O
7	revealed	O
8	that	O
9	Bacillus	B
10	YM55	I
11	-	I
12	1	I
13	aspartase	I
14	shared	O
15	71	O
16	%	O
17	homology	O
18	with	O
19	Bacillus	B
20	subtilis	I
21	aspartase	I
22	and	O
23	49	O
24	%	O
25	with	O
26	Escherichia	O
27	coli	O
28	and	O
29	Pseudomonas	B
30	fluorescens	I
31	aspartases	I
32	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	MHC	B
6	class	I
7	II	I
8	,	O
9	purified	B
10	soluble	I
11	D10	I
12	TCR	I
13	bound	O
14	to	O
15	Staphylococcus	B
16	aureus	I
17	enterotoxin	I
18	C2	I
19	with	O
20	an	O
21	association	O
22	rate	O
23	of	O
24	1	O
25	.	O
26	69	O
27	+/-	O
28	0	O
29	.	O
30	12	O
31	x	O
32	10	O
33	(	O
34	4	O
35	)	O
36	M	O
37	(-	O
38	1	O
39	)	O
40	sec	O
41	(-	O
42	1	O
43	)	O
44	and	O
45	a	O
46	dissociation	O
47	rate	O
48	of	O
49	1	O
50	.	O
51	9	O
52	+/-	O
53	0	O
54	.	O
55	47	O
56	x	O
57	10	O
58	(-	O
59	2	O
60	)	O
61	sec	O
62	(-	O
63	1	O
64	),	O
65	giving	O
66	a	O
67	dissociation	O
68	constant	O
69	of	O
70	1	O
71	.	O
72	1	O
73	microM	O
74	.	O

1	In	O
2	both	O
3	cases	O
4	,	O
5	at	O
6	the	O
7	end	O
8	of	O
9	exposure	O
10	the	O
11	same	O
12	level	O
13	of	O
14	blood	B
15	carboxyhemoglobin	I
16	(	O
17	COHb	B
18	)	O
19	(	O
20	about	O
21	50	O
22	%)	O
23	was	O
24	reached	O
25	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	revealed	O
6	that	O
7	two	O
8	clusters	O
9	of	O
10	basic	O
11	amino	O
12	acids	O
13	within	O
14	a	O
15	conserved	O
16	basic	O
17	region	O
18	and	O
19	two	O
20	amphipathic	O
21	helices	O
22	within	O
23	the	O
24	adjacent	O
25	HLH	O
26	domain	O
27	are	O
28	essential	O
29	for	O
30	sequence	O
31	-	O
32	specific	O
33	DNA	O
34	binding	O
35	and	O
36	hetero	O
37	-	O
38	oligomerization	O
39	,	O
40	respectively	O
41	.	O

1	Mean	O
2	(+/-	O
3	SE	O
4	)	O
5	measurements	O
6	of	O
7	clearance	O
8	(	O
9	24	O
10	.	O
11	5	O
12	+/-	O
13	2	O
14	.	O
15	06	O
16	v	O
17	26	O
18	.	O
19	5	O
20	+/-	O
21	2	O
22	.	O
23	05	O
24	mL	O
25	/	O
26	min	O
27	/	O
28	m2	O
29	),	O
30	half	O
31	-	O
32	life	O
33	(	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	0	O
39	.	O
40	5	O
41	v	O
42	6	O
43	.	O
44	4	O
45	+/-	O
46	0	O
47	.	O
48	5	O
49	hours	O
50	),	O
51	and	O
52	volume	O
53	of	O
54	distribution	O
55	(	O
56	12	O
57	.	O
58	4	O
59	+/-	O
60	1	O
61	.	O
62	1	O
63	v	O
64	13	O
65	.	O
66	7	O
67	+/-	O
68	1	O
69	.	O
70	6	O
71	L	O
72	/	O
73	m2	O
74	)	O
75	were	O
76	not	O
77	significantly	O
78	different	O
79	in	O
80	patients	O
81	with	O
82	jaundice	O
83	when	O
84	compared	O
85	with	O
86	controls	O
87	.	O

1	Overexpression	O
2	of	O
3	the	O
4	bZip	O
5	interaction	O
6	domain	O
7	of	O
8	CBP	B
9	specifically	O
10	abolishes	O
11	the	O
12	positive	O
13	cross	O
14	talk	O
15	between	O
16	TR	B
17	and	O
18	p45	B
19	/	O
20	NF	B
21	-	I
22	E2	I
23	.	O

1	Immunophenotyping	O
2	in	O
3	four	O
4	cases	O
5	,	O
6	demonstrated	O
7	non	O
8	-	O
9	B	O
10	,	O
11	non	O
12	-	O
13	T	O
14	cell	O
15	origin	O
16	in	O
17	three	O
18	and	O
19	pre	O
20	-	O
21	B	O
22	cell	O
23	origin	O
24	in	O
25	one	O
26	.	O

1	The	O
2	results	O
3	from	O
4	the	O
5	first	O
6	five	O
7	years	O
8	of	O
9	follow	O
10	up	O
11	in	O
12	1972	O
13	showed	O
14	a	O
15	4	O
16	.	O
17	7	O
18	-	O
19	fold	O
20	excess	O
21	mortality	O
22	for	O
23	ischaemic	O
24	and	O
25	other	O
26	heart	O
27	diseases	O
28	(	O
29	ICD	O
30	A83	O
31	-	O
32	A84	O
33	)	O
34	compared	O
35	with	O
36	a	O
37	comparable	O
38	reference	O
39	cohort	O
40	of	O
41	paper	O
42	mill	O
43	workers	O
44	.	O

1	Cytokine	O
2	-	O
3	induced	O
4	NF	B
5	-	I
6	kappa	I
7	B	I
8	DNA	O
9	binding	O
10	activity	O
11	,	O
12	RelA	B
13	nuclear	O
14	translocation	O
15	,	O
16	I	B
17	kappa	I
18	B	I
19	alpha	I
20	degradation	O
21	,	O
22	I	B
23	kappa	I
24	B	I
25	serine	O
26	32	O
27	phosphorylation	O
28	,	O
29	and	O
30	I	B
31	kappa	I
32	B	I
33	kinase	I
34	(	O
35	IKK	B
36	)	O
37	activity	O
38	were	O
39	blocked	O
40	by	O
41	curcumin	O
42	treatment	O
43	.	O

1	Influence	O
2	of	O
3	metoprolol	O
4	treatment	O
5	on	O
6	sympatho	O
7	-	O
8	adrenal	O
9	activation	O
10	of	O
11	fibrinolysis	O
12	.	O

1	Only	O
2	17	O
3	%	O
4	of	O
5	all	O
6	patients	O
7	admitted	O
8	it	O
9	at	O
10	all	O
11	times	O
12	.	O

1	More	O
2	recently	O
3	,	O
4	however	O
5	,	O
6	a	O
7	number	O
8	of	O
9	developments	O
10	such	O
11	as	O
12	the	O
13	successful	O
14	use	O
15	of	O
16	the	O
17	inhaled	O
18	steroid	O
19	budesonide	O
20	and	O
21	oral	O
22	dexamethasone	O
23	have	O
24	reinforced	O
25	the	O
26	argument	O
27	for	O
28	using	O
29	steroids	O
30	.	O

1	The	O
2	purified	O
3	recombinant	O
4	enzyme	O
5	catalyzed	O
6	specific	O
7	phosphoryl	O
8	transfer	O
9	from	O
10	ATP	O
11	to	O
12	UMP	O
13	and	O
14	CMP	O
15	.	O

1	Ligand	O
2	-	O
3	independent	O
4	activation	O
5	of	O
6	platelet	B
7	-	I
8	derived	I
9	growth	I
10	factor	I
11	receptor	I
12	is	O
13	a	O
14	necessary	O
15	intermediate	O
16	in	O
17	lysophosphatidic	O
18	,	O
19	acid	O
20	-	O
21	stimulated	O
22	mitogenic	O
23	activity	O
24	in	O
25	L	O
26	cells	O
27	.	O

1	Five	O
2	cell	O
3	strains	O
4	of	O
5	human	O
6	dermal	O
7	fibroblasts	O
8	were	O
9	each	O
10	treated	O
11	with	O
12	three	O
13	samples	O
14	of	O
15	burn	O
16	blister	O
17	fluid	O
18	and	O
19	the	O
20	effect	O
21	compared	O
22	with	O
23	the	O
24	rate	O
25	of	O
26	contraction	O
27	of	O
28	free	O
29	floating	O
30	fibroblast	O
31	populated	O
32	collagen	B
33	lattices	O
34	(	O
35	FPCL	O
36	).	O

1	Strikingly	O
2	,	O
3	stoichiometric	O
4	association	O
5	of	O
6	p107	B
7	or	O
8	p130	B
9	with	O
10	either	O
11	cyclin	B
12	E	I
13	-	O
14	cdk2	B
15	or	O
16	cyclin	B
17	A	I
18	-	O
19	cdk2	B
20	negated	O
21	the	O
22	activities	O
23	of	O
24	these	O
25	kinases	O
26	.	O

1	However	O
2	,	O
3	for	O
4	the	O
5	evaluable	O
6	cases	O
7	,	O
8	the	O
9	performances	O
10	of	O
11	the	O
12	CD3500	O
13	and	O
14	the	O
15	STKS	O
16	were	O
17	broadly	O
18	similar	O
19	and	O
20	generally	O
21	correlated	O
22	well	O
23	with	O
24	the	O
25	manual	O
26	reference	O
27	procedure	O
28	.	O

1	These	O
2	data	O
3	locate	O
4	the	O
5	aniridia	B
6	gene	I
7	(	O
8	AN2	B
9	)	O
10	and	O
11	a	O
12	recurrent	O
13	T	B
14	-	I
15	cell	I
16	leukemia	I
17	breakpoint	I
18	(	O
19	TCL2	B
20	)	O
21	in	O
22	the	O
23	marker	O
24	sequence	O
25	,	O
26	on	O
27	opposite	O
28	sides	O
29	of	O
30	MIC1	B
31	.	O

1	L	O
2	-	O
3	735	O
4	,	O
5	524	O
6	free	O
7	base	O
8	or	O
9	sulfate	O
10	salt	O
11	was	O
12	administered	O
13	orally	O
14	as	O
15	suspension	O
16	,	O
17	solution	O
18	or	O
19	in	O
20	solid	O
21	dosage	O
22	forms	O
23	to	O
24	fasted	O
25	or	O
26	fed	O
27	Beagle	O
28	dogs	O
29	.	O

1	Our	O
2	findings	O
3	demonstrate	O
4	a	O
5	dose	O
6	-	O
7	dependent	O
8	blockade	O
9	of	O
10	the	O
11	mechanical	O
12	sensitivity	O
13	caused	O
14	by	O
15	a	O
16	mild	O
17	thermal	O
18	injury	O
19	by	O
20	both	O
21	GBP	O
22	and	O
23	IBG	O
24	.	O

1	The	O
2	patient	O
3	was	O
4	treated	O
5	with	O
6	benzathine	O
7	penicillin	O
8	,	O
9	2	O
10	,	O
11	400	O
12	,	O
13	000	O
14	U	O
15	weekly	O
16	for	O
17	three	O
18	weeks	O
19	.	O

1	Group	O
2	I	O
3	consisted	O
4	of	O
5	six	O
6	noncholestatic	O
7	patients	O
8	;	O
9	group	O
10	II	O
11	consisted	O
12	of	O
13	nine	O
14	mildly	O
15	cholestatic	O
16	patients	O
17	with	O
18	mild	O
19	hepatic	O
20	impairment	O
21	(	O
22	conjugated	O
23	bilirubin	O
24	,	O
25	47	O
26	mumol	O
27	liter	O
28	-	O
29	1	O
30	;	O
31	alkaline	B
32	phosphatase	I
33	,	O
34	280	O
35	IU	O
36	liter	O
37	-	O
38	1	O
39	;	O
40	gamma	B
41	-	I
42	glutamyltranspeptidase	I
43	,	O
44	190	O
45	IU	O
46	liter	O
47	-	O
48	1	O
49	);	O
50	group	O
51	III	O
52	consisted	O
53	of	O
54	six	O
55	benign	O
56	intrahepatic	O
57	cholestatic	O
58	patients	O
59	with	O
60	high	O
61	isolated	O
62	conjugated	O
63	hyperbilirubinemia	O
64	(	O
65	98	O
66	.	O
67	1	O
68	mumol	O
69	liter	O
70	-	O
71	1	O
72	).	O

1	The	O
2	segmental	O
3	and	O
4	regional	O
5	projections	O
6	of	O
7	the	O
8	sciatic	O
9	,	O
10	tibial	O
11	and	O
12	common	O
13	peroneal	O
14	nerves	O
15	to	O
16	the	O
17	substantia	O
18	gelatinosa	O
19	of	O
20	the	O
21	spinal	O
22	cord	O
23	in	O
24	rats	O
25	--	O
26	an	O
27	experimental	O
28	study	O
29	by	O
30	means	O
31	of	O
32	an	O
33	acid	B
34	phosphatase	I
35	(	O
36	ACP	B
37	)	O
38	method	O
39	.	O

1	The	O
2	fragments	O
3	of	O
4	each	O
5	region	O
6	were	O
7	amplified	O
8	by	O
9	polymerase	O
10	chain	O
11	reaction	O
12	and	O
13	analyzed	O
14	by	O
15	gel	O
16	electrophoresis	O
17	to	O
18	detect	O
19	single	O
20	-	O
21	strand	O
22	conformation	O
23	polymorphism	O
24	.	O

1	Northern	O
2	blotting	O
3	analysis	O
4	indicates	O
5	that	O
6	expression	O
7	of	O
8	the	O
9	genes	O
10	corresponding	O
11	to	O
12	these	O
13	clones	O
14	is	O
15	confined	O
16	to	O
17	pollen	O
18	tissue	O
19	.	O

1	This	O
2	may	O
3	explain	O
4	in	O
5	part	O
6	a	O
7	secular	O
8	trend	O
9	towards	O
10	reduced	O
11	birthweight	O
12	for	O
13	gestation	O
14	in	O
15	preterm	O
16	infants	O
17	.	O

1	There	O
2	is	O
3	a	O
4	cysteine	O
5	clustering	O
6	region	O
7	in	O
8	an	O
9	N	O
10	-	O
11	terminal	O
12	region	O
13	of	O
14	the	O
15	c	B
16	-	I
17	raf	I
18	(-	I
19	1	I
20	)	I
21	product	I
22	deduced	O
23	from	O
24	the	O
25	nucleotide	O
26	sequence	O
27	,	O
28	and	O
29	this	O
30	cysteine	O
31	clustering	O
32	region	O
33	was	O
34	found	O
35	to	O
36	be	O
37	highly	O
38	homologous	O
39	to	O
40	that	O
41	present	O
42	in	O
43	an	O
44	N	O
45	-	O
46	terminal	O
47	region	O
48	of	O
49	protein	B
50	kinase	I
51	C	I
52	,	O
53	although	O
54	,	O
55	in	O
56	the	O
57	latter	O
58	cysteine	O
59	clusters	O
60	are	O
61	present	O
62	in	O
63	duplicate	O
64	.	O

1	We	O
2	have	O
3	tested	O
4	this	O
5	possibility	O
6	by	O
7	constructing	O
8	a	O
9	consecutive	O
10	series	O
11	of	O
12	cysteine	O
13	substitutions	O
14	in	O
15	the	O
16	Neu	B
17	juxtamembrane	I
18	domain	I
19	in	O
20	order	O
21	to	O
22	force	O
23	dimerization	O
24	along	O
25	a	O
26	series	O
27	of	O
28	interreceptor	O
29	faces	O
30	.	O

1	The	O
2	spontaneous	O
3	mutation	O
4	blocking	O
5	pca	B
6	gene	I
7	expression	O
8	was	O
9	located	O
10	in	O
11	the	O
12	promoter	O
13	for	O
14	the	O
15	pca	B
16	operon	I
17	.	O

1	Uses	O
2	of	O
3	orthoclone	O
4	OKT3	B
5	for	O
6	prophylaxis	O
7	of	O
8	rejection	O
9	and	O
10	induction	O
11	in	O
12	initial	O
13	nonfunction	O
14	in	O
15	kidney	O
16	transplantation	O
17	.	O

1	Palindromic	O
2	rheumatism	O

1	Although	O
2	the	O
3	gene	O
4	is	O
5	substantially	O
6	smaller	O
7	than	O
8	the	O
9	human	O
10	genes	O
11	for	O
12	other	O
13	mitochondrial	O
14	enzymes	O
15	,	O
16	its	O
17	intron	O
18	/	O
19	exon	O
20	organization	O
21	is	O
22	very	O
23	similar	O
24	,	O
25	especially	O
26	to	O
27	that	O
28	of	O
29	P450scc	B
30	.	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	RAD30	I
5	gene	I
6	,	O
7	a	O
8	homologue	B
9	of	I
10	Escherichia	I
11	coli	I
12	dinB	I
13	and	O
14	umuC	B
15	,	O
16	is	O
17	DNA	O
18	damage	O
19	inducible	O
20	and	O
21	functions	O
22	in	O
23	a	O
24	novel	O
25	error	O
26	-	O
27	free	O
28	postreplication	O
29	repair	O
30	mechanism	O
31	.	O

1	A	O
2	reduction	O
3	in	O
4	blood	O
5	pressure	O
6	was	O
7	only	O
8	observed	O
9	at	O
10	the	O
11	end	O
12	of	O
13	the	O
14	study	O
15	,	O
16	from	O
17	142	O
18	+/-	O
19	17	O
20	/	O
21	86	O
22	.	O
23	6	O
24	+/-	O
25	9	O
26	.	O
27	1	O
28	to	O
29	139	O
30	+/-	O
31	13	O
32	/	O
33	82	O
34	.	O
35	9	O
36	+/-	O
37	8	O
38	.	O
39	9	O
40	mmHg	O
41	(	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	05	O
48	for	O
49	DBP	O
50	).	O

1	Expression	O
2	plasmids	O
3	harboring	O
4	full	O
5	-	O
6	length	O
7	or	O
8	kinase	O
9	domain	O
10	of	O
11	PKC	B
12	alpha	I
13	and	O
14	PKC	B
15	delta	I
16	(	O
17	PKC	B
18	alpha	I
19	K	I
20	and	O
21	PKC	B
22	delta	I
23	K	I
24	)	O
25	were	O
26	constructed	O
27	.	O

1	Tonsillectomy	O
2	is	O
3	an	O
4	effective	O
5	means	O
6	of	O
7	prophylaxis	O
8	for	O
9	upper	O
10	respiratory	O
11	infection	O
12	in	O
13	habitual	O
14	angina	O
15	patients	O
16	.	O

1	A	O
2	724	O
3	-	O
4	bp	O
5	segment	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	consisting	O
13	of	O
14	the	O
15	proximal	O
16	E	O
17	-	O
18	box	O
19	flanked	O
20	upstream	O
21	by	O
22	a	O
23	mammalian	O
24	-	O
25	specific	O
26	352	O
27	-	O
28	bp	O
29	region	O
30	was	O
31	sufficient	O
32	for	O
33	maximal	O
34	transcriptional	O
35	activation	O
36	in	O
37	postconfluent	O
38	BC3H1	O
39	myoblasts	O
40	.	O

1	Finding	O
2	of	O
3	Rhodnius	O
4	prolixus	O
5	Stal	O
6	,	O
7	1859	O
8	,	O
9	in	O
10	babassu	O
11	palm	O
12	trees	O

1	Pathways	O
2	linking	O
3	the	O
4	olfactory	O
5	bulbs	O
6	with	O
7	the	O
8	medial	O
9	preoptic	O
10	anterior	O
11	hypothalamus	O
12	are	O
13	important	O
14	for	O
15	intermale	O
16	aggression	O
17	in	O
18	mice	O
19	.	O

1	The	O
2	Harleco	O
3	apparatus	O
4	is	O
5	a	O
6	simple	O
7	,	O
8	useful	O
9	,	O
10	cost	O
11	-	O
12	effective	O
13	adjunct	O
14	to	O
15	the	O
16	diagnosis	O
17	and	O
18	treatment	O
19	of	O
20	this	O
21	life	O
22	-	O
23	threatening	O
24	condition	O
25	.	O

1	These	O
2	viruses	O
3	depend	O
4	on	O
5	the	O
6	host	O
7	cell	O
8	machinery	O
9	for	O
10	their	O
11	existence	O
12	,	O
13	and	O
14	interference	O
15	with	O
16	these	O
17	processes	O
18	typically	O
19	interferes	O
20	with	O
21	other	O
22	important	O
23	host	O
24	physiology	O
25	.	O

1	Visual	O
2	averaged	O
3	evoked	O
4	responses	O
5	and	O
6	platelet	B
7	monoamine	I
8	oxidase	I
9	in	O
10	patients	O
11	suffering	O
12	from	O
13	alcoholism	O
14	.	O

1	Multistep	O
2	transformation	O
3	by	O
4	defined	O
5	fragments	O
6	of	O
7	herpes	O
8	simplex	O
9	virus	O
10	type	O
11	2	O
12	DNA	O
13	:	O
14	oncogenic	O
15	region	O
16	and	O
17	its	O
18	gene	O
19	product	O
20	.	O

1	The	O
2	isolation	O
3	of	O
4	this	O
5	gene	O
6	was	O
7	based	O
8	on	O
9	the	O
10	identification	O
11	of	O
12	the	O
13	Y	O
14	-	O
15	231	O
16	cosmid	O
17	that	O
18	contains	O
19	CpG	O
20	rich	O
21	sequences	O
22	(	O
23	HTF	O
24	islands	O
25	)	O
26	in	O
27	its	O
28	human	O
29	insert	O
30	.	O

1	As	O
2	determined	O
3	in	O
4	a	O
5	modified	O
6	yeast	O
7	two	O
8	-	O
9	hybrid	O
10	system	O
11	,	O
12	mIRS3	B
13	bound	O
14	strongly	O
15	to	O
16	the	O
17	p85	B
18	subunit	I
19	of	O
20	phosphatidylinositol	B
21	3	I
22	-	I
23	kinase	I
24	.	O

1	PRDII	B
2	-	I
3	BF1	I
4	-	I
5	derived	I
6	cDNAs	I
7	did	O
8	not	O
9	result	O
10	in	O
11	stimulation	O
12	of	O
13	either	O
14	basal	O
15	or	O
16	tat	B
17	-	O
18	induced	O
19	activated	O
20	gene	O
21	expression	O
22	.	O

1	Each	O
2	trial	O
3	consisted	O
4	of	O
5	light	O
6	and	O
7	buzzer	O
8	for	O
9	five	O
10	seconds	O
11	as	O
12	conditioned	O
13	stimuli	O
14	and	O
15	electric	O
16	shock	O
17	for	O
18	five	O
19	seconds	O
20	as	O
21	an	O
22	unconditioned	O
23	stimulus	O
24	.	O

1	The	O
2	CDC7	B
3	gene	I
4	has	O
5	two	O
6	in	O
7	-	O
8	frame	O
9	AUG	O
10	codons	O
11	as	O
12	possible	O
13	translation	O
14	start	O
15	sites	O
16	,	O
17	which	O
18	would	O
19	produce	O
20	58	O
21	-	O
22	and	O
23	56	O
24	-	O
25	kDa	O
26	proteins	O
27	,	O
28	respectively	O
29	.	O

1	Transformed	O
2	cell	O
3	lines	O
4	expressing	O
5	solely	O
6	E1a	B
7	or	O
8	E1a	B
9	and	O
10	E1b	B
11	gene	I
12	products	I
13	derived	O
14	from	O
15	these	O
16	viruses	O
17	display	O
18	enhanced	O
19	anchorage	O
20	-	O
21	independent	O
22	growth	O
23	at	O
24	37	O
25	degrees	O
26	C	O
27	versus	O
28	32	O
29	degrees	O
30	C	O
31	and	O
32	display	O
33	a	O
34	cytoskeletal	O
35	architecture	O
36	resembling	O
37	untransformed	O
38	fibroblastic	O
39	CREF	O
40	cells	O
41	.	O

1	The	O
2	transcriptional	O
3	activities	O
4	of	O
5	the	O
6	full	O
7	-	O
8	length	O
9	promoter	O
10	(-	O
11	295	O
12	to	O
13	+	O
14	85	O
15	)	O
16	and	O
17	of	O
18	three	O
19	deletion	O
20	constructs	O
21	(-	O
22	197	O
23	,	O
24	-	O
25	154	O
26	and	O
27	-	O
28	74	O
29	to	O
30	+	O
31	85	O
32	)	O
33	were	O
34	significantly	O
35	down	O
36	-	O
37	regulated	O
38	in	O
39	resistant	O
40	cells	O
41	.	O

1	Gas6	B
2	contains	O
3	an	O
4	NH2	O
5	-	O
6	terminal	O
7	Gla	O
8	domain	O
9	followed	O
10	by	O
11	four	O
12	epidermal	B
13	growth	I
14	factor	I
15	-	I
16	like	I
17	repeats	I
18	and	O
19	tandem	O
20	globular	O
21	(	O
22	G	O
23	)	O
24	domains	O
25	.	O

1	The	O
2	cardiac	B
3	myosin	I
4	light	I
5	chain	I
6	-	I
7	2	I
8	(	O
9	MLC	B
10	-	I
11	2	I
12	)	O
13	gene	O
14	promoter	O
15	contains	O
16	several	O
17	positive	O
18	and	O
19	negative	O
20	cis	O
21	-	O
22	acting	O
23	sequences	O
24	that	O
25	are	O
26	involved	O
27	in	O
28	the	O
29	regulation	O
30	of	O
31	its	O
32	expression	O
33	.	O

1	We	O
2	concluded	O
3	that	O
4	Ga	O
5	-	O
6	fbg	O
7	scintigraphy	O
8	is	O
9	a	O
10	very	O
11	simple	O
12	method	O
13	and	O
14	sufficiently	O
15	useful	O
16	for	O
17	detecting	O
18	active	O
19	left	O
20	ventricular	O
21	thrombi	O
22	and	O
23	for	O
24	monitoring	O
25	the	O
26	effect	O
27	of	O
28	anticoagulant	O
29	therapy	O
30	.	O

1	In	O
2	terms	O
3	of	O
4	sequence	O
5	repetitions	O
6	,	O
7	seven	O
8	tandemly	O
9	repeated	O
10	copies	O
11	of	O
12	the	O
13	hexanucleotide	O
14	ATTGTT	O
15	and	O
16	three	O
17	flanking	O
18	regions	O
19	of	O
20	dyad	O
21	symmetry	O
22	were	O
23	detected	O
24	,	O
25	all	O
26	in	O
27	ORF	O
28	T3C	O
29	.	O

1	METHODS	O
2	:	O
3	Twenty	O
4	-	O
5	two	O
6	patients	O
7	were	O
8	grouped	O
9	according	O
10	to	O
11	their	O
12	etiology	O
13	based	O
14	on	O
15	the	O
16	study	O
17	of	O
18	antiadrenal	O
19	antibodies	O
20	at	O
21	diagnosis	O
22	of	O
23	the	O
24	disease	O
25	:	O
26	7	O
27	were	O
28	positive	O
29	(	O
30	autoimmune	O
31	etiology	O
32	or	O
33	EAA	O
34	),	O
35	11	O
36	were	O
37	negative	O
38	(	O
39	tuberculous	O
40	etiology	O
41	or	O
42	EAT	O
43	)	O
44	and	O
45	in	O
46	four	O
47	serologic	O
48	study	O
49	was	O
50	not	O
51	available	O
52	(	O
53	undetermined	O
54	etiology	O
55	or	O
56	EAI	O
57	).	O

1	Prostacyclin	O
2	formation	O
3	,	O
4	reflected	O
5	by	O
6	the	O
7	excretion	O
8	rate	O
9	of	O
10	its	O
11	stable	O
12	metabolite	O
13	6	O
14	-	O
15	keto	O
16	-	O
17	prostaglandin	O
18	F1	O
19	alpha	O
20	,	O
21	was	O
22	measured	O
23	by	O
24	means	O
25	of	O
26	radioimmunoassay	O
27	in	O
28	4	O
29	-	O
30	hour	O
31	urine	O
32	specimens	O
33	obtained	O
34	during	O
35	a	O
36	smoking	O
37	-	O
38	free	O
39	period	O
40	and	O
41	after	O
42	participants	O
43	had	O
44	inhaled	O
45	smoke	O
46	from	O
47	four	O
48	high	O
49	-	O
50	nicotine	O
51	cigarettes	O
52	.	O

1	Other	O
2	parameters	O
3	of	O
4	iron	O
5	metabolism	O
6	,	O
7	including	O
8	ferritin	B
9	,	O
10	were	O
11	not	O
12	found	O
13	to	O
14	contribute	O
15	to	O
16	the	O
17	risk	O
18	.	O

1	These	O
2	tumors	O
3	were	O
4	classified	O
5	into	O
6	three	O
7	broad	O
8	groups	O
9	:	O
10	I	O
11	,	O
12	cystadenoma	O
13	;	O
14	II	O
15	,	O
16	cystadenocarcinoma	O
17	;	O
18	and	O
19	III	O
20	,	O
21	adenocarcinoma	O
22	with	O
23	mucin	B
24	production	O
25	or	O
26	an	O
27	associated	O
28	cyst	O
29	.	O

1	An	O
2	automated	O
3	method	O
4	for	O
5	the	O
6	quantitative	O
7	analysis	O
8	of	O
9	the	O
10	polyamines	O
11	putrescine	O
12	,	O
13	spermidine	O
14	and	O
15	spermine	O
16	in	O
17	cerebrospinal	O
18	fluid	O
19	(	O
20	CSF	O
21	)	O
22	was	O
23	used	O
24	to	O
25	analyze	O
26	CSF	O
27	samples	O
28	from	O
29	37	O
30	patients	O
31	with	O
32	central	O
33	nervous	O
34	system	O
35	(	O
36	CNS	O
37	)	O
38	tumors	O
39	and	O
40	from	O
41	13	O
42	patients	O
43	without	O
44	tumors	O
45	.	O

1	The	O
2	end	O
3	-	O
4	stage	O
5	or	O
6	involutional	O
7	phase	O
8	of	O
9	proliferative	O
10	diabetic	O
11	retinopathy	O
12	may	O
13	result	O
14	in	O
15	stabilization	O
16	of	O
17	vision	O
18	for	O
19	long	O
20	periods	O
21	of	O
22	time	O
23	.	O

1	Furthermore	O
2	,	O
3	an	O
4	upstream	O
5	element	O
6	,	O
7	collagen	O
8	element	O
9	I	O
10	(-	O
11	370	O
12	/-	O
13	344	O
14	),	O
15	which	O
16	shares	O
17	homology	O
18	with	O
19	the	O
20	LAP	B
21	binding	O
22	cis	O
23	-	O
24	element	O
25	of	O
26	the	O
27	albumin	B
28	promoter	I
29	(	O
30	9	O
31	of	O
32	13	O
33	bp	O
34	)	O
35	is	O
36	described	O
37	.	O

1	Mucoepidermoid	O
2	and	O
3	acinous	O
4	cell	O
5	carcinomas	O
6	of	O
7	salivary	O
8	tissues	O
9	.	O

1	A	O
2	comparative	O
3	study	O
4	by	O
5	holographic	O
6	interferometry	O
7	of	O
8	ten	O
9	porcine	O
10	bioprosthetic	O
11	valves	O
12	(	O
13	seven	O
14	Carpentier	O
15	-	O
16	Edwards	O
17	SAV	O
18	,	O
19	two	O
20	BioImplant	O
21	and	O
22	one	O
23	Valcor	O
24	)	O
25	with	O
26	five	O
27	human	O
28	aortic	O
29	valves	O
30	before	O
31	and	O
32	after	O
33	glutaraldehyde	O
34	treatment	O
35	is	O
36	presented	O
37	.	O

1	Investigation	O
2	of	O
3	the	O
4	control	O
5	of	O
6	coronavirus	O
7	subgenomic	O
8	mRNA	O
9	transcription	O
10	by	O
11	using	O
12	T7	O
13	-	O
14	generated	O
15	negative	O
16	-	O
17	sense	O
18	RNA	O
19	transcripts	O
20	.	O

1	We	O
2	isolated	O
3	several	O
4	overlapping	O
5	A	O
6	-	O
7	phage	O
8	and	O
9	cosmid	O
10	clones	O
11	that	O
12	cover	O
13	more	O
14	than	O
15	100	O
16	kb	O
17	of	O
18	human	O
19	DNA	O
20	and	O
21	contained	O
22	the	O
23	entire	O
24	VDR	B
25	gene	I
26	.	O

1	The	O
2	subjects	O
3	from	O
4	the	O
5	two	O
6	regions	O
7	with	O
8	a	O
9	higher	O
10	pollution	O
11	level	O
12	had	O
13	lower	O
14	FVC	O
15	and	O
16	FEV1	O
17	values	O
18	than	O
19	those	O
20	from	O
21	the	O
22	Viskovo	O
23	region	O
24	.	O

1	Oxfendazole	O
2	,	O
3	which	O
4	was	O
5	active	O
6	for	O
7	the	O
8	shortest	O
9	time	O
10	(	O
11	about	O
12	65	O
13	days	O
14	)	O
15	from	O
16	the	O
17	start	O
18	of	O
19	grazing	O
20	(	O
21	May	O
22	1	O
23	),	O
24	produced	O
25	a	O
26	78	O
27	.	O
28	1	O
29	per	O
30	cent	O
31	reduction	O
32	in	O
33	Ostertagia	O
34	species	O
35	and	O
36	an	O
37	84	O
38	.	O
39	4	O
40	per	O
41	cent	O
42	reduction	O
43	in	O
44	D	O
45	viviparus	O
46	.	O

1	Phosphoamino	O
2	acid	O
3	analysis	O
4	of	O
5	radiolabeled	O
6	ASGPR	B
7	subunits	I
8	identified	O
9	Ser	O
10	(	O
11	P	O
12	)	O
13	as	O
14	the	O
15	predominant	O
16	(	O
17	approximately	O
18	95	O
19	%)	O
20	and	O
21	Thr	O
22	(	O
23	P	O
24	)	O
25	as	O
26	a	O
27	minor	O
28	(	O
29	approximately	O
30	5	O
31	%)	O
32	phosphoamino	O
33	acid	O
34	in	O
35	each	O
36	polypeptide	O
37	and	O
38	confirmed	O
39	the	O
40	presence	O
41	of	O
42	Tyr	O
43	(	O
44	P	O
45	)	O
46	(	O
47	approximately	O
48	1	O
49	%)	O
50	in	O
51	RHL1	B
52	.	O

1	The	O
2	ability	O
3	to	O
4	maintain	O
5	expression	O
6	of	O
7	FAS1	B
8	in	O
9	nmt1	B
10	-	O
11	451Dino2	B
12	Delta	O
13	cells	O
14	suggests	O
15	the	O
16	existence	O
17	of	O
18	another	O
19	transcription	O
20	factor	O
21	,	O
22	or	O
23	factors	O
24	,	O
25	whose	O
26	expression	O
27	/	O
28	activity	O
29	is	O
30	inversely	O
31	related	O
32	to	O
33	overall	O
34	levels	O
35	of	O
36	cellular	O
37	protein	O
38	N	O
39	-	O
40	myristoy	O
41	-	O
42	lation	O
43	.	O

1	Cardiac	O
2	taurine	O
3	levels	O
4	and	O
5	sarcolemmal	O
6	calcium	O
7	binding	O
8	activity	O
9	in	O
10	furazolidone	O
11	-	O
12	induced	O
13	cardiomyopathy	O
14	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	B
5	negative	I
6	Smad2	I
7	significantly	O
8	reduces	O
9	the	O
10	level	O
11	of	O
12	luciferase	B
13	reporter	I
14	activity	O
15	induced	O
16	by	O
17	nodal	O
18	treatment	O
19	.	O

1	This	O
2	study	O
3	assesses	O
4	the	O
5	feasibility	O
6	and	O
7	toxicity	O
8	of	O
9	adoptive	O
10	immunotherapy	O
11	with	O
12	tumor	O
13	infiltrating	O
14	lymphocytes	O
15	and	O
16	recombinant	B
17	interleukin	I
18	-	I
19	2	I
20	in	O
21	29	O
22	patients	O
23	who	O
24	underwent	O
25	resection	O
26	for	O
27	stage	O
28	III	O
29	non	O
30	-	O
31	small	O
32	-	O
33	cell	O
34	lung	O
35	cancer	O
36	.	O

1	Gentamicin	O
2	given	O
3	by	O
4	DPI	O
5	and	O
6	SVN	O
7	significantly	O
8	decreased	O
9	the	O
10	sputum	O
11	Psa	O
12	density	O
13	(	O
14	p	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	by	O
21	almost	O
22	one	O
23	order	O
24	of	O
25	magnitude	O
26	.	O

1	Courses	O
2	were	O
3	repeated	O
4	every	O
5	four	O
6	weeks	O
7	.	O

1	Differential	O
2	association	O
3	of	O
4	products	O
5	of	O
6	alternative	O
7	transcripts	O
8	of	O
9	the	O
10	candidate	O
11	tumor	B
12	suppressor	I
13	ING1	I
14	with	O
15	the	O
16	mSin3	B
17	/	O
18	HDAC1	B
19	transcriptional	O
20	corepressor	O
21	complex	O
22	.	O

1	Recombinant	B
2	Ffh	I
3	has	O
4	a	O
5	melting	O
6	point	O
7	of	O
8	tm	O
9	=	O
10	89	O
11	degreesC	O
12	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	chloroplast	O
7	(	O
8	cp	O
9	)	O
10	DNA	O
11	from	O
12	maize	O
13	(	O
14	Zea	O
15	mays	O
16	)	O
17	has	O
18	been	O
19	completed	O
20	.	O

1	The	O
2	non	O
3	-	O
4	homologous	O
5	sequences	O
6	in	O
7	the	O
8	5	O
9	'	O
10	untranslated	O
11	regions	O
12	might	O
13	be	O
14	acquired	O
15	at	O
16	or	O
17	after	O
18	transcription	O
19	during	O
20	retrotransposition	O
21	of	O
22	the	O
23	ATLN	O
24	elements	O
25	.	O

1	All	O
2	carcasses	O
3	resulted	O
4	in	O
5	contamination	O
6	with	O
7	aerobic	O
8	mesophilic	O
9	bacteria	O
10	in	O
11	the	O
12	range	O
13	from	O
14	6	O
15	x	O
16	10	O
17	(	O
18	3	O
19	)	O
20	to	O
21	1	O
22	.	O
23	2	O
24	x	O
25	10	O
26	(	O
27	6	O
28	)	O
29	CFU	O
30	/	O
31	ml	O
32	liquid	O
33	washed	O
34	,	O
35	and	O
36	94	O
37	%	O
38	them	O
39	with	O
40	sporulate	O
41	bacteria	O
42	,	O
43	the	O
44	threshold	O
45	being	O
46	under	O
47	100	O
48	CFU	O
49	/	O
50	ml	O
51	(	O
52	Figure	O
53	1	O
54	).	O

1	From	O
2	an	O
3	RNK	O
4	-	O
5	16	O
6	lambda	O
7	-	O
8	gt11	O
9	library	O
10	,	O
11	we	O
12	have	O
13	isolated	O
14	and	O
15	sequenced	O
16	a	O
17	novel	O
18	cDNA	O
19	rat	B
20	NK	I
21	cell	I
22	protease	I
23	1	I
24	(	O
25	RNKP	B
26	-	I
27	1	I
28	)	O
29	that	O
30	has	O
31	characteristics	O
32	unique	O
33	to	O
34	serine	B
35	proteases	I
36	.	O

1	86	O
2	:	O
3	3199	O
4	-	O
5	3203	O
6	)	O
7	or	O
8	G1	O
9	to	O
10	S	O
11	phase	O
12	(	O
13	Reilly	O
14	,	O
15	C	O
16	.	O

1	In	O
2	ferrets	O
3	naturally	O
4	infected	O
5	with	O
6	H	O
7	.	O
8	mustelae	O
9	,	O
10	a	O
11	single	O
12	dose	O
13	(	O
14	50	O
15	mg	O
16	/	O
17	kg	O
18	,	O
19	per	O
20	os	O
21	)	O
22	of	O
23	fluorofamide	O
24	completely	O
25	inhibited	O
26	bacterial	B
27	urease	I
28	.	O

1	PURPOSE	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	evaluate	O
11	the	O
12	bony	O
13	anchorage	O
14	of	O
15	a	O
16	new	O
17	implant	O
18	(	O
19	orderly	O
20	wired	O
21	surface	O
22	effect	O
23	with	O
24	alloy	O
25	Ti	O
26	Al	O
27	Va	O
28	and	O
29	ordered	O
30	pores	O
31	of	O
32	488	O
33	mu	O
34	).	O

1	In	O
2	ciliates	O
3	,	O
4	both	O
5	mechanisms	O
6	are	O
7	readily	O
8	observed	O
9	.	O

1	The	O
2	results	O
3	supported	O
4	the	O
5	therapeutic	O
6	principle	O
7	of	O
8	TCM	O
9	:	O
10	Treating	O
11	patients	O
12	according	O
13	to	O
14	their	O
15	pathophysiological	O
16	patterns	O
17	.	O

1	With	O
2	chemical	O
3	shift	O
4	imaging	O
5	,	O
6	the	O
7	signal	O
8	intensity	O
9	decreased	O
10	on	O
11	the	O
12	out	O
13	-	O
14	of	O
15	-	O
16	phase	O
17	images	O
18	in	O
19	six	O
20	of	O
21	seven	O
22	(	O
23	86	O
24	%)	O
25	patients	O
26	with	O
27	APA	O
28	and	O
29	in	O
30	eight	O
31	of	O
32	nine	O
33	(	O
34	89	O
35	%)	O
36	patients	O
37	with	O
38	BAH	O
39	.	O

1	Genoa	O
2	,	O
3	Italy	O
4	,	O
5	24	O
6	-	O
7	28	O
8	August	O
9	1997	O
10	.	O

1	To	O
2	characterize	O
3	the	O
4	O7	B
5	-	I
6	LPS	I
7	region	I
8	,	O
9	the	O
10	recombinant	O
11	cosmids	O
12	pJHCV31	O
13	and	O
14	pJHCV32	O
15	were	O
16	mutagenized	O
17	by	O
18	transposon	O
19	mutagenesis	O
20	with	O
21	Tn3HoHo1	B
22	,	O
23	which	O
24	carries	O
25	a	O
26	promoterless	O
27	lac	B
28	operon	I
29	and	O
30	can	O
31	therefore	O
32	generate	O
33	lacZ	B
34	transcriptional	O
35	fusions	O
36	with	O
37	target	O
38	DNA	O
39	sequences	O
40	.	O

1	Comparison	O
2	of	O
3	patients	O
4	receiving	O
5	phenytoin	O
6	and	O
7	those	O
8	who	O
9	were	O
10	not	O
11	showed	O
12	significantly	O
13	lower	O
14	serum	O
15	folate	O
16	in	O
17	the	O
18	sub	O
19	-	O
20	group	O
21	receiving	O
22	phenytoin	O
23	,	O
24	but	O
25	there	O
26	was	O
27	no	O
28	significant	O
29	difference	O
30	between	O
31	the	O
32	sub	O
33	-	O
34	groups	O
35	with	O
36	respect	O
37	to	O
38	vitamin	O
39	B12	O
40	or	O
41	behaviour	O
42	problem	O
43	rating	O
44	.	O

1	18F	O
2	and	O
3	85Sr	O
4	scintimetry	O
5	in	O
6	the	O
7	study	O
8	of	O
9	primary	O
10	arthropathies	O
11	.	O

1	Improving	O
2	the	O
3	evidence	O
4	base	O
5	for	O
6	anaesthesia	O
7	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	indicate	O
7	that	O
8	thrombin	B
9	-	O
10	stimulated	O
11	vascular	O
12	smooth	O
13	muscle	O
14	proliferation	O
15	is	O
16	delayed	O
17	and	O
18	requires	O
19	the	O
20	de	O
21	novo	O
22	expression	O
23	of	O
24	one	O
25	or	O
26	more	O
27	autocrine	O
28	mitogens	O
29	.	O

1	The	O
2	5	O
3	'	O
4	region	O
5	shows	O
6	strong	O
7	sequence	O
8	similarity	O
9	to	O
10	Escherichia	O
11	coli	O
12	consensus	O
13	promoters	O
14	and	O
15	ribosome	O
16	-	O
17	binding	O
18	sequences	O
19	and	O
20	allows	O
21	high	O
22	levels	O
23	of	O
24	expression	O
25	in	O
26	E	O
27	.	O
28	coli	O
29	.	O

1	The	O
2	number	O
3	of	O
4	fecal	O
5	pellets	O
6	ingested	O
7	peaked	O
8	at	O
9	5	O
10	to	O
11	6	O
12	weeks	O
13	old	O
14	(	O
15	13	O
16	pellets	O
17	/	O
18	day	O
19	)	O
20	and	O
21	gradually	O
22	decreased	O
23	,	O
24	thereafter	O
25	(	O
26	2	O
27	.	O
28	1	O
29	pellets	O
30	at	O
31	78	O
32	weeks	O
33	old	O
34	,	O
35	1	O
36	.	O
37	5	O
38	pellets	O
39	at	O
40	104	O
41	weeks	O
42	old	O
43	).	O

1	Urinary	O
2	LTE4	O
3	increased	O
4	after	O
5	both	O
6	challenges	O
7	the	O
8	rise	O
9	being	O
10	higher	O
11	following	O
12	oral	O
13	as	O
14	compared	O
15	to	O
16	inhalation	O
17	provocation	O
18	(	O
19	p	O
20	=	O
21	0	O
22	.	O
23	0001	O
24	).	O

1	PPD	B
2	-	O
3	specific	O
4	IgG	B
5	subclass	O
6	responses	O
7	were	O
8	evident	O
9	to	O
10	all	O
11	four	O
12	IgG	B
13	subclasses	O
14	.	O

1	In	O
2	addition	O
3	,	O
4	these	O
5	cells	O
6	contained	O
7	one	O
8	,	O
9	two	O
10	,	O
11	or	O
12	multiple	O
13	nuclei	O
14	indicative	O
15	of	O
16	a	O
17	G2	O
18	/	O
19	M	O
20	delay	O
21	in	O
22	nuclear	O
23	division	O
24	and	O
25	also	O
26	a	O
27	defect	O
28	in	O
29	cytokinesis	O
30	and	O
31	/	O
32	or	O
33	cell	O
34	separation	O
35	.	O

1	These	O
2	data	O
3	further	O
4	define	O
5	a	O
6	role	O
7	for	O
8	TRADD	B
9	and	O
10	TRAF2	B
11	in	O
12	JNK	B
13	activation	O
14	and	O
15	confirm	O
16	that	O
17	LMP1	B
18	utilizes	O
19	signalling	O
20	mechanisms	O
21	used	O
22	by	O
23	the	O
24	TNF	B
25	receptor	I
26	/	O
27	CD40	B
28	family	O
29	to	O
30	elicit	O
31	its	O
32	pleiotropic	O
33	activities	O
34	.	O

1	Our	O
2	data	O
3	suggest	O
4	that	O
5	,	O
6	at	O
7	least	O
8	at	O
9	high	O
10	temperature	O
11	,	O
12	a	O
13	critical	O
14	minimal	O
15	level	O
16	of	O
17	Ypt	B
18	protein	I
19	prenylation	O
20	is	O
21	required	O
22	for	O
23	maintaining	O
24	vesicle	O
25	polarization	O
26	.	O

1	MK	O
2	-	O
3	927	O
4	:	O
5	a	O
6	topically	O
7	active	O
8	ocular	O
9	hypotensive	O
10	carbonic	B
11	anhydrase	I
12	inhibitor	O
13	.	O

1	In	O
2	Experiment	O
3	2	O
4	,	O
5	we	O
6	again	O
7	used	O
8	classification	O
9	,	O
10	but	O
11	the	O
12	fixed	O
13	standard	O
14	75	O
15	was	O
16	not	O
17	at	O
18	the	O
19	center	O
20	of	O
21	the	O
22	range	O
23	of	O
24	target	O
25	numbers	O
26	(	O
27	20	O
28	,	O
29	21	O
30	,	O
31	...	O

1	Neither	O
2	the	O
3	p42	B
4	/	I
5	44	I
6	nor	O
7	the	O
8	JNK	B
9	pathway	O
10	was	O
11	involved	O
12	in	O
13	the	O
14	action	O
15	of	O
16	IL	B
17	-	I
18	1beta	I
19	.	O

1	CONCLUSIONS	O
2	:	O
3	This	O
4	randomized	O
5	study	O
6	shows	O
7	that	O
8	Vivostat	O
9	fibrin	B
10	sealant	O
11	is	O
12	effective	O
13	in	O
14	preventing	O
15	air	O
16	leakage	O
17	after	O
18	small	O
19	lung	O
20	resections	O
21	in	O
22	pigs	O
23	,	O
24	even	O
25	at	O
26	high	O
27	inspiratory	O
28	pressures	O
29	.	O

1	No	O
2	hypotension	O
3	was	O
4	noted	O
5	in	O
6	patients	O
7	with	O
8	toxemia	O
9	and	O
10	only	O
11	2	O
12	ran	O
13	a	O
14	fever	O
15	above	O
16	37	O
17	.	O
18	5	O
19	degrees	O
20	C	O
21	.	O

1	Depending	O
2	on	O
3	treatment	O
4	exposures	O
5	,	O
6	this	O
7	at	O
8	-	O
9	risk	O
10	population	O
11	may	O
12	experience	O
13	life	O
14	-	O
15	threatening	O
16	late	O
17	effects	O
18	,	O
19	such	O
20	as	O
21	cirrhosis	O
22	secondary	O
23	to	O
24	hepatitis	O
25	C	O
26	or	O
27	late	O
28	-	O
29	onset	O
30	anthracycline	O
31	-	O
32	induced	O
33	cardiomyopathy	O
34	,	O
35	or	O
36	life	O
37	-	O
38	changing	O
39	late	O
40	effects	O
41	,	O
42	such	O
43	as	O
44	cognitive	O
45	dysfunction	O
46	.	O

1	The	O
2	highest	O
3	decrease	O
4	in	O
5	mutagenic	O
6	activity	O
7	was	O
8	observed	O
9	when	O
10	enzymatic	O
11	bleaching	O
12	was	O
13	used	O
14	together	O
15	with	O
16	chlorine	O
17	.	O

1	In	O
2	a	O
3	maxicell	O
4	system	O
5	a	O
6	protein	O
7	with	O
8	an	O
9	approximate	O
10	molecular	O
11	weight	O
12	of	O
13	36	O
14	,	O
15	000	O
16	was	O
17	synthesized	O
18	.	O

1	The	O
2	uncomplicated	O
3	cases	O
4	of	O
5	typhoid	O
6	fever	O
7	were	O
8	found	O
9	to	O
10	have	O
11	an	O
12	intact	O
13	CMIR	O
14	as	O
15	compared	O
16	to	O
17	the	O
18	complicated	O
19	cases	O
20	.	O

1	RESULTS	O
2	:	O
3	The	O
4	binding	O
5	of	O
6	99mTc	O
7	d	O
8	,	O
9	1	O
10	-	O
11	HMPAO	O
12	to	O
13	human	O
14	placenta	O
15	ranged	O
16	from	O
17	2	O
18	.	O
19	95	O
20	%	O
21	+/-	O
22	1	O
23	.	O
24	5	O
25	%	O
26	to	O
27	5	O
28	.	O
29	82	O
30	%	O
31	+/-	O
32	0	O
33	.	O
34	3	O
35	%	O
36	per	O
37	1	O
38	ml	O
39	standard	O
40	solution	O
41	.	O

1	With	O
2	the	O
3	modified	O
4	fingertip	O
5	-	O
6	to	O
7	-	O
8	floor	O
9	(	O
10	MFTF	O
11	)	O
12	method	O
13	,	O
14	patients	O
15	stand	O
16	on	O
17	a	O
18	stool	O
19	and	O
20	forward	O
21	bend	O
22	so	O
23	that	O
24	measurements	O
25	can	O
26	be	O
27	taken	O
28	on	O
29	patients	O
30	who	O
31	are	O
32	able	O
33	to	O
34	touch	O
35	the	O
36	floor	O
37	or	O
38	reach	O
39	beyond	O
40	the	O
41	level	O
42	of	O
43	the	O
44	floor	O
45	.	O

1	Complementary	O
2	DNAs	O
3	encompassing	O
4	the	O
5	coat	B
6	protein	I
7	coding	O
8	and	O
9	adjacent	O
10	regions	O
11	of	O
12	Agropyron	O
13	mosaic	O
14	virus	O
15	(	O
16	AgMV	O
17	)	O
18	and	O
19	Hordeum	O
20	mosaic	O
21	virus	O
22	(	O
23	HoMV	O
24	)	O
25	were	O
26	cloned	O
27	and	O
28	sequenced	O
29	.	O

1	The	O
2	synergistic	O
3	effect	O
4	due	O
5	to	O
6	the	O
7	5	O
8	'-	O
9	3	O
10	'	O
11	cooperation	O
12	was	O
13	at	O
14	least	O
15	fourfold	O
16	greater	O
17	than	O
18	the	O
19	sum	O
20	of	O
21	the	O
22	contributions	O
23	of	O
24	the	O
25	individual	O
26	UTRs	O
27	.	O

1	Fast	O
2	goal	O
3	-	O
4	directed	O
5	voluntary	O
6	movements	O
7	of	O
8	the	O
9	human	O
10	upper	O
11	extremity	O
12	are	O
13	known	O
14	to	O
15	be	O
16	associated	O
17	with	O
18	three	O
19	distinct	O
20	bursts	O
21	of	O
22	EMG	O
23	activity	O
24	in	O
25	antagonistic	O
26	muscles	O
27	.	O

1	Prostaglandins	O
2	and	O
3	gallstones	O

1	Of	O
2	the	O
3	153	O
4	patients	O
5	studied	O
6	,	O
7	CK	B
8	-	I
9	MB	I
10	results	O
11	were	O
12	positive	O
13	in	O
14	91	O
15	(	O
16	59	O
17	%)	O
18	patients	O
19	;	O
20	ECG	O
21	revealed	O
22	AMI	O
23	in	O
24	72	O
25	(	O
26	47	O
27	%)	O
28	patients	O
29	.	O

1	The	O
2	homology	O
3	to	O
4	v	B
5	-	I
6	mil	I
7	starts	O
8	within	O
9	the	O
10	coding	O
11	sequence	O
12	of	O
13	exon	O
14	1	O
15	and	O
16	ends	O
17	within	O
18	the	O
19	3	O
20	'	O
21	untranslated	O
22	region	O
23	of	O
24	exon	O
25	11	O
26	,	O
27	12	O
28	nucleotides	O
29	downstream	O
30	from	O
31	the	O
32	nonsense	O
33	codon	O
34	terminating	O
35	the	O
36	large	O
37	open	O
38	reading	O
39	frame	O
40	shared	O
41	between	O
42	c	B
43	-	I
44	mil	I
45	and	O
46	v	B
47	-	I
48	mil	I
49	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	CDC25B	B
5	may	O
6	therefore	O
7	contribute	O
8	to	O
9	the	O
10	control	O
11	of	O
12	cell	O
13	proliferation	O
14	.	O

1	Both	O
2	genes	O
3	comprise	O
4	three	O
5	exons	O
6	,	O
7	two	O
8	introns	O
9	and	O
10	an	O
11	unusually	O
12	long	O
13	3	O
14	'-	O
15	untranslated	O
16	region	O
17	(	O
18	3	O
19	.	O
20	2	O
21	kilobase	O
22	pairs	O
23	),	O
24	specificying	O
25	a	O
26	mRNA	O
27	of	O
28	approximately	O
29	4	O
30	.	O
31	1	O
32	kilobases	O
33	.	O

1	Elledge	O
2	,	O
3	P	O
4	.	O

1	Bacteriol	O
2	.	O

1	Examination	O
2	of	O
3	nuclear	O
4	magnetic	O
5	resonance	O
6	(	O
7	NMR	O
8	)	O
9	spectra	O
10	of	O
11	a	O
12	series	O
13	of	O
14	N	B
15	-	I
16	terminally	I
17	truncated	I
18	MIP	I
19	-	I
20	1	I
21	beta	I
22	variants	I
23	reveals	O
24	that	O
25	these	O
26	proteins	O
27	possess	O
28	a	O
29	range	O
30	of	O
31	ability	O
32	to	O
33	dimerize	O
34	.	O

1	Use	O
2	of	O
3	the	O
4	immunofluorescence	O
5	method	O
6	for	O
7	identification	O
8	of	O
9	enteroviruses	O
10	in	O
11	cell	O
12	cultures	O

1	Five	O
2	of	O
3	these	O
4	eight	O
5	patients	O
6	in	O
7	group	O
8	II	O
9	also	O
10	received	O
11	8	O
12	-	O
13	in	O
14	-	O
15	1	O
16	chemotherapy	O
17	.	O

1	In	O
2	the	O
3	Oct	B
4	-	I
5	1	I
6	crystal	O
7	,	O
8	the	O
9	POU	B
10	-	I
11	specific	I
12	domain	I
13	recognizes	O
14	a	O
15	GCAT	O
16	half	O
17	-	O
18	site	O
19	,	O
20	while	O
21	the	O
22	corresponding	O
23	sequence	O
24	recognized	O
25	by	O
26	the	O
27	Pit	B
28	-	I
29	1	I
30	POU	I
31	-	O
32	specific	O
33	domain	O
34	,	O
35	GTAT	O
36	,	O
37	is	O
38	on	O
39	the	O
40	opposing	O
41	strand	O
42	.	O

1	The	O
2	protein	O
3	coding	O
4	region	O
5	,	O
6	1	O
7	,	O
8	696	O
9	bps	O
10	long	O
11	,	O
12	is	O
13	divided	O
14	by	O
15	an	O
16	intron	O
17	into	O
18	two	O
19	exons	O
20	.	O

1	We	O
2	characterized	O
3	the	O
4	structure	O
5	of	O
6	this	O
7	leader	O
8	mRNA	O
9	by	O
10	using	O
11	the	O
12	program	O
13	Mfold	O
14	and	O
15	a	O
16	combination	O
17	of	O
18	nested	O
19	and	O
20	internal	O
21	deletions	O
22	transcriptionally	O
23	fused	O
24	to	O
25	a	O
26	promoterless	O
27	lac	B
28	operon	I
29	.	O

1	Moreover	O
2	,	O
3	glucan	B
4	synthase	I
5	activity	O
6	,	O
7	which	O
8	is	O
9	activated	O
10	by	O
11	Rho1p	B
12	,	O
13	was	O
14	significantly	O
15	reduced	O
16	in	O
17	the	O
18	deltabem4	B
19	mutant	I
20	.	O

1	Increased	O
2	granulocyte	B
3	-	I
4	colony	I
5	stimulating	I
6	factor	I
7	(	O
8	G	B
9	-	I
10	CSF	I
11	)	O
12	levels	O
13	in	O
14	neonates	O
15	with	O
16	perinatal	O
17	complications	O
18	.	O

1	Pentane	O
2	and	O
3	ethane	O
4	,	O
5	which	O
6	arise	O
7	during	O
8	lipid	O
9	peroxidation	O
10	in	O
11	vivo	O
12	,	O
13	were	O
14	measured	O
15	by	O
16	gas	O
17	chromatography	O
18	in	O
19	breath	O
20	samples	O
21	of	O
22	rats	O
23	fed	O
24	for	O
25	8	O
26	weeks	O
27	a	O
28	vitamin	O
29	E	O
30	-	O
31	deficient	O
32	diet	O
33	to	O
34	which	O
35	had	O
36	been	O
37	added	O
38	0	O
39	,	O
40	11	O
41	,	O
42	or	O
43	40	O
44	IU	O
45	vitamin	O
46	E	O
47	acetate	O
48	per	O
49	kg	O
50	.	O

1	The	O
2	identity	O
3	between	O
4	hnRNPs	B
5	H	I
6	and	O
7	H	B
8	'	I
9	is	O
10	96	O
11	%,	O
12	between	O
13	H	B
14	and	O
15	F	B
16	78	O
17	%,	O
18	and	O
19	between	O
20	H	B
21	'	I
22	and	O
23	F	B
24	75	O
25	%,	O
26	respectively	O
27	.	O

1	Analysis	O
2	of	O
3	an	O
4	autopsy	O
5	population	O
6	.	O

1	Women	O
2	'	O
3	s	O
4	opportunities	O
5	for	O
6	paid	O
7	work	O
8	outside	O
9	the	O
10	home	O
11	are	O
12	constrained	O
13	by	O
14	their	O
15	role	O
16	as	O
17	primary	O
18	carer	O
19	within	O
20	the	O
21	family	O
22	,	O
23	writes	O
24	Trudy	O
25	Wynne	O
26	.	O

1	Martin	O
2	Luther	O
3	and	O
4	his	O
5	physicians	O
6	.	O

1	Another	O
2	group	O
3	of	O
4	HIPP	O
5	-	O
6	and	O
7	HCX	O
8	-	O
9	lesioned	O
10	animals	O
11	trained	O
12	on	O
13	the	O
14	tasks	O
15	after	O
16	the	O
17	lesion	O
18	showed	O
19	reduced	O
20	impairments	O
21	of	O
22	the	O
23	type	O
24	described	O
25	above	O
26	,	O
27	suggesting	O
28	that	O
29	extrahippocampal	O
30	structures	O
31	trained	O
32	after	O
33	the	O
34	lesion	O
35	can	O
36	assume	O
37	the	O
38	role	O
39	of	O
40	the	O
41	hippocampus	O
42	to	O
43	some	O
44	degree	O
45	.	O

1	After	O
2	28	O
3	days	O
4	of	O
5	haloperidol	O
6	treatment	O
7	,	O
8	similar	O
9	changes	O
10	were	O
11	observed	O
12	for	O
13	delta	O
14	,	O
15	together	O
16	with	O
17	an	O
18	increase	O
19	of	O
20	alpha	O
21	1	O
22	,	O
23	and	O
24	a	O
25	decrease	O
26	of	O
27	fast	O
28	beta	O
29	.	O

1	A	O
2	13	O
3	base	O
4	-	O
5	pair	O
6	oligonucleotide	O
7	spanning	O
8	nucleotides	O
9	+	O
10	80	O
11	to	O
12	+	O
13	92	O
14	of	O
15	the	O
16	5	B
17	S	I
18	RNA	I
19	gene	I
20	retained	O
21	specific	O
22	and	O
23	high	O
24	-	O
25	affinity	O
26	binding	O
27	,	O
28	although	O
29	the	O
30	latter	O
31	was	O
32	reduced	O
33	sixfold	O
34	relative	O
35	to	O
36	longer	O
37	DNA	O
38	fragments	O
39	.	O

1	To	O
2	address	O
3	these	O
4	questions	O
5	,	O
6	a	O
7	recombinant	O
8	FRAP	B
9	/	O
10	mTOR	B
11	protein	O
12	and	O
13	a	O
14	FRAP	B
15	/	O
16	mTOR	B
17	immunoprecipitate	O
18	were	O
19	utilized	O
20	in	O
21	in	O
22	vitro	O
23	kinase	O
24	assays	O
25	to	O
26	phosphorylate	O
27	4E	B
28	-	I
29	BP1	I
30	.	O

1	The	O
2	TIMP	B
3	(-	O
4	59	O
5	/	O
6	-	O
7	53	O
8	)	O
9	AP1	B
10	site	O
11	is	O
12	a	O
13	promiscuous	O
14	motif	O
15	that	O
16	binds	O
17	c	B
18	-	I
19	Fos	I
20	/	O
21	c	B
22	-	I
23	Jun	I
24	AP1	I
25	translated	O
26	in	O
27	vitro	O
28	and	O
29	is	O
30	an	O
31	effective	O
32	competitor	O
33	for	O
34	binding	O
35	of	O
36	nuclear	B
37	AP1	I
38	factors	I
39	to	O
40	the	O
41	consensus	O
42	TRE	O
43	,	O
44	but	O
45	in	O
46	addition	O
47	it	O
48	binds	O
49	factors	O
50	that	O
51	do	O
52	not	O
53	associate	O
54	with	O
55	the	O
56	consensus	O
57	TRE	O
58	.	O

1	GH	B
2	failed	O
3	to	O
4	stimulate	O
5	phosphorylation	O
6	or	O
7	activation	O
8	of	O
9	Jun	B
10	N	I
11	-	I
12	terminal	I
13	kinase	I
14	under	O
15	the	O
16	conditions	O
17	used	O
18	.	O

1	Interdigitated	O
2	residues	O
3	within	O
4	a	O
5	small	O
6	region	O
7	of	O
8	VP16	B
9	interact	O
10	with	O
11	Oct	B
12	-	I
13	1	I
14	,	O
15	HCF	B
16	,	O
17	and	O
18	DNA	O
19	.	O

1	The	O
2	Nmd3	B
3	protein	I
4	sequence	I
5	does	O
6	not	O
7	contain	O
8	readily	O
9	recognizable	O
10	motifs	O
11	of	O
12	known	O
13	function	O
14	.	O

1	MutY	B
2	is	O
3	an	O
4	adenine	B
5	-	I
6	DNA	I
7	glycosylase	I
8	with	O
9	specificity	O
10	for	O
11	mismatches	O
12	involving	O
13	8	O
14	-	O
15	oxoguanine	O
16	(	O
17	oG	O
18	.	O
19	A	O
20	)	O
21	or	O
22	guanine	O
23	(	O
24	G	O
25	.	O
26	A	O
27	).	O

1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	multiple	O
6	oIGF	B
7	-	I
8	I	I
9	transcripts	I
10	in	O
11	a	O
12	broad	O
13	band	O
14	at	O
15	800	O
16	-	O
17	1	O
18	,	O
19	100	O
20	nucleotides	O
21	and	O
22	other	O
23	transcripts	O
24	of	O
25	higher	O
26	molecular	O
27	weight	O
28	in	O
29	liver	O
30	.	O

1	The	O
2	recombinant	O
3	protein	O
4	was	O
5	purified	O
6	to	O
7	homogeneity	O
8	by	O
9	(	O
10	NH4	O
11	)	O
12	2SO4	O
13	-	O
14	precipitation	O
15	and	O
16	affinity	O
17	chromatography	O
18	on	O
19	5	O
20	'	O
21	AMP	O
22	-	O
23	Sepharose	O
24	.	O

1	Five	O
2	different	O
3	subtypes	O
4	of	O
5	spondyloarthropathy	O
6	(	O
7	SpA	O
8	)	O
9	are	O
10	now	O
11	recognized	O
12	.	O

1	In	O
2	patients	O
3	with	O
4	limited	O
5	disease	O
6	,	O
7	the	O
8	survival	O
9	in	O
10	the	O
11	alternating	O
12	arm	O
13	was	O
14	significantly	O
15	superior	O
16	to	O
17	the	O
18	survival	O
19	in	O
20	the	O
21	CAV	O
22	arm	O
23	(	O
24	P	O
25	=	O
26	.	O
27	014	O
28	)	O
29	or	O
30	the	O
31	survival	O
32	in	O
33	the	O
34	PE	O
35	arm	O
36	(	O
37	P	O
38	=	O
39	.	O
40	023	O
41	).	O

1	100	O
2	of	O
3	the	O
4	patients	O
5	who	O
6	would	O
7	have	O
8	died	O
9	survive	O
10	.	O

1	When	O
2	statistically	O
3	analyzed	O
4	in	O
5	various	O
6	subgroupings	O
7	,	O
8	the	O
9	obtained	O
10	average	O
11	sedimentation	O
12	coefficients	O
13	and	O
14	polydispersity	O
15	profiles	O
16	supported	O
17	the	O
18	following	O
19	conclusions	O
20	:	O
21	(	O
22	a	O
23	)	O
24	loss	O
25	of	O
26	proteoglycan	O
27	aggregation	O
28	and	O
29	sedimentability	O
30	is	O
31	confirmed	O
32	to	O
33	be	O
34	a	O
35	primary	O
36	sign	O
37	of	O
38	cartilage	O
39	matrix	O
40	degradation	O
41	;	O
42	(	O
43	b	O
44	)	O
45	higher	O
46	S	O
47	values	O
48	for	O
49	proteoglycans	O
50	of	O
51	the	O
52	high	O
53	weight	O
54	(	O
55	HW	O
56	)-	O
57	bearing	O
58	areas	O
59	and	O
60	lower	O
61	values	O
62	for	O
63	those	O
64	of	O
65	the	O
66	low	O
67	weight	O
68	(	O
69	LW	O
70	)-	O
71	bearing	O
72	areas	O
73	were	O
74	a	O
75	typical	O
76	finding	O
77	in	O
78	normal	O
79	cartilage	O
80	samples	O
81	;	O
82	(	O
83	c	O
84	)	O
85	inversion	O
86	of	O
87	this	O
88	pattern	O
89	was	O
90	indicative	O
91	of	O
92	matrix	O
93	degradation	O
94	,	O
95	suggesting	O
96	that	O
97	the	O
98	HW	O
99	regions	O
100	are	O
101	more	O
102	affected	O
103	than	O
104	the	O
105	LW	O
106	-	O
107	bearing	O
108	areas	O
109	;	O
110	(	O
111	d	O
112	)	O
113	the	O
114	average	O
115	S	O
116	value	O
117	distribution	O
118	across	O
119	cartilage	O
120	thickness	O
121	tended	O
122	to	O
123	resemble	O
124	the	O
125	corresponding	O
126	proteoglycan	O
127	content	O
128	versus	O
129	distance	O
130	from	O
131	articular	O
132	surface	O
133	;	O
134	and	O
135	(	O
136	e	O
137	)	O
138	the	O
139	deepest	O
140	cartilage	O
141	layer	O
142	had	O
143	,	O
144	in	O
145	most	O
146	cases	O
147	,	O
148	the	O
149	smallest	O
150	amount	O
151	of	O
152	aggregates	O
153	while	O
154	the	O
155	highest	O
156	average	O
157	sedimentability	O
158	was	O
159	observed	O
160	at	O
161	the	O
162	middle	O
163	zone	O
164	of	O
165	the	O
166	normal	O
167	samples	O
168	.	O

1	Several	O
2	authors	O
3	have	O
4	recently	O
5	reported	O
6	interference	O
7	in	O
8	theophylline	O
9	analysis	O
10	by	O
11	paraxanthine	O
12	(	O
13	1	O
14	,	O
15	7	O
16	-	O
17	dimethylxanthine	O
18	),	O
19	an	O
20	important	O
21	metabolite	O
22	of	O
23	caffeine	O
24	.	O

1	2	O
2	.	O

1	Benign	O
2	intramural	O
3	tumors	O
4	of	O
5	the	O
6	esophagus	O

1	A	O
2	multicentre	O
3	study	O
4	involving	O
5	9	O
6	Italian	O
7	institutions	O
8	was	O
9	carried	O
10	out	O
11	to	O
12	compare	O
13	the	O
14	efficacy	O
15	and	O
16	safety	O
17	of	O
18	ranitidine	O
19	150	O
20	mg	O
21	b	O
22	.	O
23	i	O
24	.	O
25	d	O
26	.	O
27	and	O
28	ranitidine	O
29	300	O
30	mg	O
31	nocte	O
32	in	O
33	the	O
34	treatment	O
35	of	O
36	reflux	O
37	oesophagitis	O
38	.	O

1	All	O
2	loci	O
3	have	O
4	a	O
5	similar	O
6	organization	O
7	,	O
8	except	O
9	for	O
10	H1	B
11	.	I
12	8	I
13	that	O
14	harbors	O
15	two	O
16	TcP2beta	B
17	genes	I
18	arranged	O
19	in	O
20	tandem	O
21	and	O
22	separated	O
23	by	O
24	a	O
25	short	O
26	repetitive	O
27	sequence	O
28	,	O
29	named	O
30	SIRE	O
31	(	O
32	short	O
33	interspersed	O
34	repetitive	O
35	element	O
36	),	O
37	which	O
38	is	O
39	also	O
40	found	O
41	upstream	O
42	of	O
43	the	O
44	first	O
45	gene	O
46	of	O
47	the	O
48	tandem	O
49	and	O
50	downstream	O
51	of	O
52	the	O
53	second	O
54	.	O

1	During	O
2	the	O
3	conditioning	O
4	procedure	O
5	,	O
6	the	O
7	C	O
8	-	O
9	fiber	O
10	reflex	O
11	was	O
12	facilitated	O
13	(	O
14	wind	O
15	-	O
16	up	O
17	)	O
18	in	O
19	a	O
20	stimulus	O
21	-	O
22	dependent	O
23	fashion	O
24	in	O
25	intact	O
26	,	O
27	anesthetized	O
28	animals	O
29	during	O
30	the	O
31	application	O
32	of	O
33	the	O
34	first	O
35	seven	O
36	conditioning	O
37	stimuli	O
38	;	O
39	thereafter	O
40	,	O
41	the	O
42	magnitude	O
43	of	O
44	the	O
45	responses	O
46	reached	O
47	a	O
48	plateau	O
49	and	O
50	then	O
51	decreased	O
52	.	O

1	Decreased	O
2	levels	O
3	of	O
4	alpha2	B
5	-	I
6	antiplasmin	I
7	were	O
8	also	O
9	observed	O
10	in	O
11	the	O
12	mediastinum	O
13	(	O
14	0	O
15	.	O
16	50	O
17	versus	O
18	0	O
19	.	O
20	61	O
21	U	O
22	/	O
23	mL	O
24	;	O
25	p	O
26	<	O
27	0	O
28	.	O
29	05	O
30	).	O

1	Elimination	O
2	of	O
3	Haemophilus	O
4	influenzae	O
5	type	O
6	b	O
7	meningitis	O
8	after	O
9	introduction	O
10	of	O
11	vaccination	O

1	Feed	O
2	intake	O
3	and	O
4	BW	O
5	gains	O
6	were	O
7	decreased	O
8	(	O
9	P	O
10	<	O
11	0	O
12	.	O
13	05	O
14	)	O
15	by	O
16	dietary	O
17	treatments	O
18	containing	O
19	M	O
20	.	O

1	In	O
2	particular	O
3	,	O
4	the	O
5	highly	O
6	expressed	O
7	ADH1	B
8	gene	I
9	is	O
10	represented	O
11	in	O
12	this	O
13	database	O
14	by	O
15	no	O
16	less	O
17	than	O
18	20	O
19	EST	O
20	sequences	O
21	.	O

1	A	O
2	single	O
3	five	O
4	minute	O
5	period	O
6	of	O
7	rapid	O
8	atrial	O
9	pacing	O
10	fails	O
11	to	O
12	limit	O
13	infarct	O
14	size	O
15	in	O
16	the	O
17	in	O
18	situ	O
19	rabbit	O
20	heart	O
21	.	O

1	In	O
2	the	O
3	present	O
4	experiments	O
5	,	O
6	we	O
7	investigate	O
8	the	O
9	role	O
10	played	O
11	by	O
12	the	O
13	temporal	O
14	pattern	O
15	of	O
16	neural	O
17	activity	O
18	during	O
19	the	O
20	ontogeny	O
21	of	O
22	frequency	O
23	tuning	O
24	in	O
25	the	O
26	mouse	O
27	central	O
28	auditory	O
29	system	O
30	.	O

1	The	O
2	differential	O
3	diagnosis	O
4	of	O
5	both	O
6	affections	O
7	is	O
8	based	O
9	on	O
10	the	O
11	clinical	O
12	course	O
13	,	O
14	sialography	O
15	and	O
16	CT	O
17	examination	O
18	which	O
19	along	O
20	with	O
21	modern	O
22	ATB	O
23	treatment	O
24	significantly	O
25	modify	O
26	hitherto	O
27	used	O
28	surgical	O
29	therapy	O
30	.	O

1	The	O
2	ns2	B
3	gene	I
4	comprises	O
5	an	O
6	open	O
7	reading	O
8	frame	O
9	(	O
10	ORF	O
11	)	O
12	encoding	O
13	a	O
14	putative	O
15	nonstructural	O
16	(	O
17	ns	O
18	)	O
19	protein	O
20	of	O
21	279	O
22	amino	O
23	acids	O
24	with	O
25	a	O
26	predicted	O
27	molecular	O
28	mass	O
29	of	O
30	32	O
31	-	O
32	kDa	O
33	.	O

1	Patients	O
2	who	O
3	have	O
4	undergone	O
5	thyroidectomy	O
6	for	O
7	thyroid	O
8	carcinoma	O
9	are	O
10	frequently	O
11	subjected	O
12	to	O
13	periods	O
14	of	O
15	induced	O
16	severe	O
17	hypothyroidism	O
18	in	O
19	preparation	O
20	for	O
21	131I	O
22	whole	O
23	body	O
24	scanning	O
25	and	O
26	measurement	O
27	of	O
28	serum	O
29	TG	B
30	.	O

1	These	O
2	combined	O
3	observations	O
4	define	O
5	a	O
6	promoter	O
7	and	O
8	an	O
9	enhancer	O
10	for	O
11	the	O
12	chicken	B
13	L	I
14	-	I
15	CAM	I
16	gene	I
17	.	O

1	The	O
2	emerging	O
3	view	O
4	based	O
5	on	O
6	studies	O
7	in	O
8	yeast	O
9	is	O
10	that	O
11	each	O
12	class	O
13	of	O
14	snoRNPs	O
15	is	O
16	composed	O
17	of	O
18	a	O
19	unique	O
20	set	O
21	of	O
22	proteins	O
23	.	O

1	Methyl	O
2	mercury	O
3	intoxication	O
4	in	O
5	rat	O
6	kidneys	O
7	.	O

1	Increase	O
2	in	O
3	blood	O
4	NEFA	O
5	was	O
6	further	O
7	augmented	O
8	by	O
9	fat	O
10	plus	O
11	AA	O
12	supplementation	O
13	,	O
14	but	O
15	no	O
16	changes	O
17	in	O
18	concentrations	O
19	of	O
20	Lys	O
21	or	O
22	Met	O
23	in	O
24	blood	O
25	were	O
26	found	O
27	.	O

1	Methisergide	O
2	(	O
3	0	O
4	.	O
5	5	O
6	mg	O
7	/	O
8	kg	O
9	,	O
10	i	O
11	.	O
12	p	O
13	.),	O
14	a	O
15	blocker	O
16	of	O
17	serotonin	B
18	receptors	I
19	,	O
20	prevented	O
21	the	O
22	development	O
23	of	O
24	the	O
25	antinociceptive	O
26	effect	O
27	of	O
28	serotonin	O
29	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	an	O
6	analysis	O
7	of	O
8	the	O
9	dynamics	O
10	in	O
11	the	O
12	closing	O
13	phase	O
14	of	O
15	the	O
16	occluder	O
17	of	O
18	a	O
19	mechanical	O
20	monoleaflet	O
21	heart	O
22	valve	O
23	prosthesis	O
24	is	O
25	presented	O
26	.	O

1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	expression	O
7	of	O
8	a	O
9	tumour	O
10	derived	O
11	brk	B
12	cDNA	I
13	in	O
14	mouse	O
15	embryonic	O
16	fibroblasts	O
17	and	O
18	human	O
19	mammary	O
20	epithelial	O
21	cells	O
22	supports	O
23	anchorage	O
24	independent	O
25	growth	O
26	,	O
27	and	O
28	in	O
29	the	O
30	latter	O
31	potentiates	O
32	the	O
33	mitogenic	O
34	response	O
35	to	O
36	epidermal	B
37	growth	I
38	factor	I
39	.	O

1	Relatively	O
2	large	O
3	DNA	O
4	rearrangements	O
5	spanning	O
6	the	O
7	region	O
8	with	O
9	tandem	O
10	direct	O
11	repeats	O
12	encoding	O
13	the	O
14	carboxy	O
15	-	O
16	terminal	O
17	histone	B
18	H1	I
19	-	I
20	like	I
21	structure	O
22	of	O
23	AlgP	B
24	were	O
25	detected	O
26	in	O
27	several	O
28	strains	O
29	upon	O
30	conversion	O
31	from	O
32	the	O
33	mucoid	O
34	to	O
35	the	O
36	nonmucoid	O
37	phenotype	O
38	.	O

1	176	O
2	:	O
3	787	O
4	-	O
5	792	O
6	,	O
7	1992	O
8	;	O
9	M	O
10	.	O

1	A	O
2	genetic	O
3	and	O
4	molecular	O
5	analysis	O
6	of	O
7	non	O
8	-	O
9	inducible	O
10	qutA	B
11	mutants	I
12	showed	O
13	that	O
14	all	O
15	23	O
16	mutations	O
17	analysed	O
18	map	O
19	within	O
20	the	O
21	N	O
22	-	O
23	terminal	O
24	half	O
25	of	O
26	the	O
27	encoded	O
28	QUTA	B
29	protein	I
30	.	O

1	The	O
2	UV	O
3	absorption	O
4	spectrum	O
5	revealed	O
6	a	O
7	shoulder	O
8	at	O
9	250	O
10	nm	O
11	,	O
12	characteristic	O
13	of	O
14	CysS	O
15	-	O
16	Cd	O
17	(	O
18	II	O
19	)	O
20	ligand	O
21	-	O
22	to	O
23	-	O
24	metal	O
25	charge	O
26	-	O
27	transfer	O
28	transitions	O
29	,	O
30	and	O
31	the	O
32	difference	O
33	absorption	O
34	coefficient	O
35	after	O
36	acidification	O
37	(	O
38	delta	O
39	epsilon	O
40	248	O
41	,	O
42	24	O
43	mM	O
44	-	O
45	1	O
46	cm	O
47	-	O
48	1	O
49	)	O
50	indicated	O
51	the	O
52	presence	O
53	of	O
54	a	O
55	Cd	O
56	(	O
57	Cys	O
58	-	O
59	S	O
60	)	O
61	4	O
62	center	O
63	.	O

1	Since	O
2	proteins	O
3	containing	O
4	TPR	O
5	elements	O
6	are	O
7	typically	O
8	involved	O
9	in	O
10	multiple	O
11	protein	O
12	-	O
13	protein	O
14	interactions	O
15	,	O
16	we	O
17	suggest	O
18	that	O
19	the	O
20	102kD	O
21	protein	O
22	interacts	O
23	within	O
24	the	O
25	tri	O
26	-	O
27	snRNP	O
28	with	O
29	both	O
30	the	O
31	U5	B
32	and	O
33	U4	B
34	/	O
35	U6	B
36	snRNPs	O
37	,	O
38	thus	O
39	bridging	O
40	the	O
41	two	O
42	particles	O
43	.	O

1	Object	O
2	relations	O
3	,	O
4	affect	O
5	management	O
6	,	O
7	and	O
8	psychic	O
9	structure	O
10	formation	O
11	.	O

1	Identification	O
2	and	O
3	estimation	O
4	of	O
5	monosaccharides	O
6	and	O
7	disaccharides	O
8	in	O
9	urine	O
10	by	O
11	gas	O
12	-	O
13	liquid	O
14	chromatography	O
15	.	O

1	Prevalence	O
2	of	O
3	sleep	O
4	-	O
5	disordered	O
6	breathing	O
7	(	O
8	SDB	O
9	)	O
10	is	O
11	reported	O
12	to	O
13	increase	O
14	in	O
15	menopausal	O
16	women	O
17	.	O

1	Technetium	O
2	-	O
3	99m	O
4	methylene	O
5	diphosphonate	O
6	scintimammography	O
7	for	O
8	evaluation	O
9	of	O
10	palpable	O
11	breast	O
12	masses	O
13	.	O

1	Disruption	O
2	of	O
3	ARF2	B
4	causes	O
5	no	O
6	detectable	O
7	phenotype	O
8	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	show	O
6	that	O
7	the	O
8	expression	O
9	of	O
10	individual	O
11	members	O
12	of	O
13	one	O
14	subfamily	O
15	of	O
16	KRAB	B
17	zinc	I
18	finger	I
19	genes	I
20	is	O
21	restricted	O
22	to	O
23	specific	O
24	hematopoietic	O
25	cell	O
26	lineages	O
27	.	O

1	The	O
2	data	O
3	are	O
4	compatible	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	YLL031c	B
10	transfers	O
11	the	O
12	ethanolaminephosphate	O
13	to	O
14	the	O
15	inner	O
16	alpha1	O
17	-	O
18	2	O
19	-	O
20	linked	O
21	mannose	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	the	O
28	group	O
29	that	O
30	links	O
31	the	O
32	GPI	O
33	lipid	O
34	anchor	O
35	to	O
36	proteins	O
37	,	O
38	whereas	O
39	Mcd4p	B
40	and	O
41	Gpi7p	B
42	transfer	O
43	ethanolaminephosphate	O
44	onto	O
45	the	O
46	alpha1	O
47	-	O
48	4	O
49	-	O
50	and	O
51	alpha1	O
52	-	O
53	6	O
54	-	O
55	linked	O
56	mannoses	O
57	of	O
58	the	O
59	GPI	O
60	anchor	O
61	,	O
62	respectively	O
63	.	O

1	New	O
2	beta	O
3	-	O
4	blocking	O
5	drugs	O
6	have	O
7	been	O
8	introduced	O
9	which	O
10	may	O
11	prove	O
12	beneficial	O
13	in	O
14	certain	O
15	clinical	O
16	situations	O
17	since	O
18	they	O
19	exert	O
20	more	O
21	selective	O
22	blockade	O
23	of	O
24	the	O
25	cardiac	B
26	receptors	I
27	(	O
28	beta1	B
29	)	O
30	as	O
31	opposed	O
32	to	O
33	smooth	B
34	muscle	I
35	receptors	I
36	(	O
37	beta2	B
38	).	O

1	Host	O
2	lipids	O
3	in	O
4	tuberculous	O
5	infection	O
6	.	O

1	However	O
2	,	O
3	C3	B
4	toxin	I
5	alone	O
6	or	O
7	in	O
8	combination	O
9	with	O
10	growth	O
11	factors	O
12	did	O
13	not	O
14	stimulate	O
15	AP	B
16	-	I
17	1	I
18	:	O
19	Luc	B
20	activity	O
21	and	O
22	actually	O
23	antagonized	O
24	the	O
25	synergistic	O
26	activation	O
27	of	O
28	AP	B
29	-	I
30	1	I
31	:	O
32	Luc	B
33	observed	O
34	in	O
35	response	O
36	to	O
37	co	O
38	-	O
39	stimulation	O
40	with	O
41	growth	O
42	factors	O
43	and	O
44	Ro	O
45	-	O
46	31	O
47	-	O
48	8220	O
49	.	O

1	Waves	O
2	N1	O
3	,	O
4	P3	O
5	and	O
6	CNV	O
7	were	O
8	recorded	O
9	during	O
10	a	O
11	CNV	O
12	paradigm	O
13	in	O
14	a	O
15	simple	O
16	reaction	O
17	time	O
18	task	O
19	with	O
20	a	O
21	constant	O
22	interstimulus	O
23	interval	O
24	(	O
25	ISI	O
26	)	O
27	of	O
28	1	O
29	sec	O
30	.	O

1	Similarly	O
2	,	O
3	a	O
4	human	O
5	but	O
6	not	O
7	a	O
8	bovine	B
9	alpha	I
10	transgene	I
11	was	O
12	expressed	O
13	in	O
14	placenta	O
15	in	O
16	transgenic	O
17	mice	O
18	.	O

1	The	O
2	three	O
3	isoforms	O
4	purified	O
5	with	O
6	anti	B
7	-	I
8	FLAG	I
9	antibody	I
10	affinity	O
11	column	O
12	transferred	O
13	sulfate	O
14	to	O
15	heparan	O
16	sulfate	O
17	and	O
18	heparin	O
19	but	O
20	not	O
21	to	O
22	other	O
23	glycosaminoglycans	O
24	.	O

1	This	O
2	enhancer	O
3	activates	O
4	both	O
5	the	O
6	K19	B
7	and	O
8	TK	B
9	basal	I
10	promoters	I
11	in	O
12	HeLa	O
13	cells	O
14	.	O

1	However	O
2	,	O
3	there	O
4	has	O
5	not	O
6	been	O
7	any	O
8	evidence	O
9	of	O
10	A	O
11	.	O
12	salmonicida	O
13	infections	O
14	,	O
15	specifically	O
16	furunculosis	O
17	,	O
18	associated	O
19	with	O
20	the	O
21	fish	O
22	in	O
23	this	O
24	loch	O
25	.	O

1	Removal	O
2	of	O
3	the	O
4	GST	B
5	domain	I
6	from	O
7	GST	B
8	-	O
9	Tax	B
10	by	O
11	thrombin	B
12	restores	O
13	Tax	B
14	'	O
15	s	O
16	ability	O
17	to	O
18	assemble	O
19	a	O
20	ternary	O
21	Tax	B
22	-	O
23	CREB	B
24	-	O
25	21	O
26	-	O
27	bp	O
28	-	O
29	repeat	O
30	complex	O
31	.(	O
32	ABSTRACT	O
33	TRUNCATED	O
34	AT	O
35	400	O
36	WORDS	O
37	)	O

1	We	O
2	constructed	O
3	a	O
4	yeast	O
5	reporter	O
6	strain	O
7	containing	O
8	the	O
9	lacZ	B
10	gene	I
11	under	O
12	the	O
13	control	O
14	of	O
15	the	O
16	CYC1	B
17	promoter	I
18	associated	O
19	with	O
20	three	O
21	copies	O
22	of	O
23	TRE	B
24	-	I
25	1	I
26	.	O

1	The	O
2	color	O
3	-	O
4	word	O
5	interference	O
6	effect	O
7	previously	O
8	reported	O
9	with	O
10	normal	O
11	populations	O
12	when	O
13	given	O
14	the	O
15	Stroop	O
16	test	O
17	was	O
18	demonstrated	O
19	for	O
20	this	O
21	retarded	O
22	sample	O
23	using	O
24	a	O
25	special	O
26	format	O
27	.	O

1	Sources	O
2	of	O
3	noise	O
4	in	O
5	these	O
6	signals	O
7	were	O
8	evaluated	O
9	in	O
10	preparations	O
11	stained	O
12	with	O
13	the	O
14	potentiometric	O
15	probe	O
16	RH	O
17	-	O
18	414	O
19	.	O

1	Similarly	O
2	,	O
3	co	O
4	-	O
5	expression	O
6	of	O
7	a	O
8	dominant	O
9	-	O
10	negative	O
11	mutant	O
12	of	O
13	p38alpha	B
14	,	O
15	but	O
16	not	O
17	of	O
18	ERK1	B
19	,	O
20	ERK2	B
21	,	O
22	JNK1	B
23	,	O
24	or	O
25	JNK2	B
26	,	O
27	reduces	O
28	basal	O
29	and	O
30	cadmium	O
31	-	O
32	induced	O
33	pE1	B
34	-	I
35	luc	I
36	activity	O
37	.	O

1	Comprising	O
2	a	O
3	126	O
4	-	O
5	nucleotide	O
6	5	O
7	'	O
8	untranscribed	O
9	genomic	O
10	sequence	O
11	and	O
12	a	O
13	466	O
14	-	O
15	nucleotide	O
16	5	O
17	'	O
18	noncoding	O
19	cDNA	O
20	sequence	O
21	,	O
22	the	O
23	592	O
24	-	O
25	nucleotide	O
26	5	O
27	'	O
28	CpG	O
29	island	O
30	lacked	O
31	TATA	O
32	and	O
33	CAAT	O
34	boxes	O
35	but	O
36	displayed	O
37	a	O
38	high	O
39	G	O
40	+	O
41	C	O
42	content	O
43	,	O
44	was	O
45	enriched	O
46	for	O
47	CpG	O
48	dinucleotides	O
49	,	O
50	and	O
51	contained	O
52	a	O
53	potential	O
54	Sp1	B
55	-	I
56	binding	I
57	site	I
58	,	O
59	i	O
60	.	O
61	e	O
62	.,	O
63	features	O
64	compatible	O
65	with	O
66	a	O
67	housekeeping	O
68	gene	O
69	.	O

1	Seventeen	O
2	of	O
3	the	O
4	35	O
5	patients	O
6	were	O
7	randomly	O
8	chosen	O
9	to	O
10	receive	O
11	a	O
12	training	O
13	program	O
14	(	O
15	lasting	O
16	approximately	O
17	1	O
18	month	O
19	)	O
20	designed	O
21	to	O
22	establish	O
23	a	O
24	systematic	O
25	strategy	O
26	of	O
27	organizing	O
28	complex	O
29	visual	O
30	material	O
31	.	O

1	A	O
2	region	O
3	in	O
4	the	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	adenovirus	B
10	2	I
11	/	I
12	5	I
13	E1a	I
14	protein	I
15	is	O
16	required	O
17	for	O
18	association	O
19	with	O
20	a	O
21	cellular	O
22	phosphoprotein	O
23	and	O
24	important	O
25	for	O
26	the	O
27	negative	O
28	modulation	O
29	of	O
30	T24	O
31	-	O
32	ras	B
33	mediated	O
34	transformation	O
35	,	O
36	tumorigenesis	O
37	and	O
38	metastasis	O
39	.	O

1	The	O
2	cDNA	O
3	sequence	O
4	has	O
5	an	O
6	813	O
7	-	O
8	bp	O
9	open	O
10	reading	O
11	frame	O
12	(	O
13	ORF	O
14	)	O
15	whose	O
16	predicted	O
17	amino	O
18	acid	O
19	sequence	O
20	is	O
21	97	O
22	.	O
23	6	O
24	%	O
25	identical	O
26	to	O
27	the	O
28	272	O
29	carboxy	O
30	-	O
31	terminal	O
32	amino	O
33	acids	O
34	of	O
35	the	O
36	human	B
37	ets	I
38	-	I
39	1	I
40	protein	I
41	.	O

1	CDNA	O
2	cloning	O
3	of	O
4	chick	B
5	brain	I
6	alpha	I
7	-	I
8	amino	I
9	-	I
10	3	I
11	-	I
12	hydroxy	I
13	-	I
14	5	I
15	-	I
16	methyl	I
17	-	I
18	4	I
19	-	I
20	isoxazolepropionic	I
21	acid	I
22	receptors	I
23	reveals	O
24	conservation	O
25	of	O
26	structure	O
27	,	O
28	function	O
29	and	O
30	post	O
31	-	O
32	transcriptional	O
33	processes	O
34	with	O
35	mammalian	O
36	receptors	O
37	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	SRF	B
6	accessory	I
7	proteins	I
8	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	of	O
5	the	O
6	proximal	O
7	promoter	O
8	revealed	O
9	four	O
10	regions	O
11	of	O
12	protection	O
13	.	O

1	No	O
2	differences	O
3	in	O
4	total	O
5	cholesterol	O
6	levels	O
7	were	O
8	observed	O
9	between	O
10	mapuches	O
11	and	O
12	aymaras	O
13	.	O

1	Immunelectrophoretic	O
2	pattern	O
3	of	O
4	Wassermann	O
5	reagin	O
6	and	O
7	comparison	O
8	of	O
9	the	O
10	appearance	O
11	time	O
12	between	O
13	RPCF	B
14	and	O
15	FTA	B
16	antibodies	I

1	This	O
2	constitutes	O
3	evidence	O
4	for	O
5	an	O
6	in	O
7	vivo	O
8	role	O
9	of	O
10	SRC	B
11	-	I
12	1	I
13	in	O
14	dimerization	O
15	-	O
16	induced	O
17	activation	O
18	by	O
19	OR1	B
20	/	O
21	RXRalpha	B
22	.	O

1	Taste	O
2	reactivity	O
3	tests	O
4	were	O
5	used	O
6	to	O
7	examine	O
8	the	O
9	orofacial	O
10	responses	O
11	of	O
12	alcohol	O
13	preferring	O
14	(	O
15	P	O
16	)	O
17	rats	O
18	and	O
19	alcohol	O
20	nonpreferring	O
21	(	O
22	NP	O
23	)	O
24	rats	O
25	to	O
26	the	O
27	taste	O
28	of	O
29	alcohol	O
30	.	O

1	RT	O
2	-	O
3	PCR	O
4	was	O
5	performed	O
6	using	O
7	previously	O
8	reported	O
9	degenerate	O
10	oligonucleotide	O
11	primers	O
12	to	O
13	the	O
14	ligand	O
15	binding	O
16	domain	O
17	(	O
18	LBD	O
19	)	O
20	of	O
21	known	O
22	beta	B
23	integrin	I
24	subunits	I
25	and	O
26	Bge	B
27	cDNA	I
28	.	O

1	It	O
2	bound	O
3	to	O
4	vitamin	B
5	D	I
6	receptor	I
7	(	O
8	VDR	B
9	)	O
10	but	O
11	not	O
12	retinoic	B
13	acid	I
14	Xalpha	I
15	receptor	I
16	(	O
17	RXRalpha	B
18	)	O
19	in	O
20	the	O
21	human	O
22	T	O
23	cell	O
24	line	O
25	MT2	O
26	cells	O
27	.	O

1	However	O
2	,	O
3	a	O
4	clear	O
5	difference	O
6	exists	O
7	between	O
8	myoblasts	O
9	and	O
10	10T1	O
11	/	O
12	2	O
13	cells	O
14	(	O
15	and	O
16	other	O
17	non	O
18	-	O
19	muscle	O
20	cell	O
21	types	O
22	)	O
23	in	O
24	the	O
25	chromatin	O
26	structure	O
27	of	O
28	the	O
29	chromosomal	O
30	myoD	B
31	core	I
32	enhancer	I
33	,	O
34	suggesting	O
35	that	O
36	the	O
37	myoD	B
38	enhancer	I
39	is	O
40	repressed	O
41	by	O
42	epigenetic	O
43	mechanisms	O
44	in	O
45	10T1	O
46	/	O
47	2	O
48	cells	O
49	.	O

1	During	O
2	the	O
3	program	O
4	'	O
5	s	O
6	use	O
7	at	O
8	the	O
9	RSNA	O
10	meeting	O
11	,	O
12	the	O
13	program	O
14	selected	O
15	the	O
16	correct	O
17	diagnosis	O
18	in	O
19	the	O
20	top	O
21	five	O
22	22	O
23	%	O
24	of	O
25	the	O
26	time	O
27	.	O

1	No	O
2	specific	O
3	subgroup	O
4	of	O
5	clients	O
6	benefited	O
7	more	O
8	from	O
9	URD	O
10	,	O
11	although	O
12	a	O
13	prospective	O
14	study	O
15	employing	O
16	random	O
17	assignment	O
18	might	O
19	be	O
20	more	O
21	successful	O
22	in	O
23	identifying	O
24	such	O
25	a	O
26	group	O
27	.	O

1	The	O
2	role	O
3	of	O
4	ascorbic	O
5	acid	O
6	in	O
7	the	O
8	prevention	O
9	of	O
10	bladder	O
11	tumor	O
12	formation	O
13	.	O

1	Thus	O
2	,	O
3	the	O
4	pol	B
5	alpha	I
6	-	O
7	primase	B
8	complex	O
9	appears	O
10	to	O
11	act	O
12	processively	O
13	for	O
14	only	O
15	a	O
16	short	O
17	distance	O
18	.	O

1	DNA	O
2	-	O
3	protein	O
4	UV	O
5	cross	O
6	-	O
7	linking	O
8	studies	O
9	indicated	O
10	that	O
11	UHF	B
12	-	I
13	1	I
14	has	O
15	an	O
16	electrophoretic	O
17	mobility	O
18	on	O
19	sodium	O
20	dodecyl	O
21	sulfate	O
22	-	O
23	acrylamide	O
24	gels	O
25	of	O
26	approximately	O
27	85	O
28	kDa	O
29	and	O
30	suggested	O
31	that	O
32	additional	O
33	proteins	O
34	,	O
35	specific	O
36	to	O
37	each	O
38	promoter	O
39	,	O
40	bind	O
41	to	O
42	each	O
43	site	O
44	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	calcitonin	B
6	induced	O
7	a	O
8	beta	B
9	-	I
10	endorphin	I
11	increase	O
12	independent	O
13	of	O
14	enhanced	O
15	corticotrophin	B
16	-	O
17	cortisol	O
18	release	O
19	.	O

1	HRES	O
2	has	O
3	been	O
4	found	O
5	to	O
6	be	O
7	clinically	O
8	useful	O
9	in	O
10	assessing	O
11	histologic	O
12	damage	O
13	following	O
14	pneumatic	O
15	dilatation	O
16	and	O
17	in	O
18	localizing	O
19	the	O
20	LES	O
21	during	O
22	the	O
23	administration	O
24	of	O
25	intrasphincter	O
26	botulinum	B
27	toxin	I
28	injection	O
29	in	O
30	the	O
31	treatment	O
32	of	O
33	achalasia	O
34	.	O

1	The	O
2	human	O
3	immunodeficiency	O
4	virus	O
5	type	O
6	1	O
7	(	O
8	HIV	O
9	-	O
10	1	O
11	)	O
12	preferentially	O
13	infects	O
14	CD4	B
15	+	I
16	T	O
17	lymphocytes	O
18	and	O
19	may	O
20	exist	O
21	as	O
22	a	O
23	latent	O
24	provirus	O
25	within	O
26	these	O
27	cells	O
28	for	O
29	extended	O
30	periods	O
31	.	O

1	Three	O
2	mog	B
3	-	I
4	1	I
5	alleles	I
6	possess	O
7	premature	O
8	stop	O
9	codons	O
10	and	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	null	O
16	alleles	O
17	,	O
18	and	O
19	one	O
20	is	O
21	a	O
22	missense	O
23	mutation	O
24	and	O
25	is	O
26	likely	O
27	to	O
28	retain	O
29	residual	O
30	activity	O
31	.	O
32	mog	B
33	-	I
34	1	I
35	mRNA	I
36	is	O
37	expressed	O
38	in	O
39	both	O
40	germ	O
41	line	O
42	and	O
43	somatic	O
44	tissues	O
45	and	O
46	appears	O
47	to	O
48	be	O
49	ubiquitous	O
50	.	O

1	This	O
2	site	O
3	acts	O
4	as	O
5	a	O
6	negative	O
7	element	O
8	when	O
9	transferred	O
10	to	O
11	the	O
12	thymidine	B
13	kinase	I
14	promoter	I
15	,	O
16	but	O
17	does	O
18	not	O
19	confer	O
20	inducibility	O
21	.	O

1	The	O
2	uteroglobin	B
3	promoter	I
4	contains	O
5	a	O
6	noncanonical	O
7	estrogen	O
8	responsive	O
9	element	O
10	.	O

1	The	O
2	Mean	O
3	was	O
4	74	O
5	,	O
6	3	O
7	+/-	O
8	53	O
9	,	O
10	6	O
11	micrograms	O
12	J	O
13	/	O
14	g	O
15	Cr	O
16	,	O
17	the	O
18	Median	O
19	61	O
20	micrograms	O
21	J	O
22	/	O
23	g	O
24	Cr	O
25	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	negative	O
7	inotropic	O
8	action	O
9	of	O
10	nicorandil	O
11	is	O
12	caused	O
13	by	O
14	inhibition	O
15	of	O
16	Ca	O
17	influx	O
18	and	O
19	intracellular	O
20	mobilization	O
21	of	O
22	Ca	O
23	.	O

1	The	O
2	duration	O
3	of	O
4	reactive	O
5	hyperemia	O
6	decreased	O
7	with	O
8	aging	O
9	,	O
10	but	O
11	the	O
12	difference	O
13	between	O
14	males	O
15	and	O
16	females	O
17	was	O
18	not	O
19	significant	O
20	at	O
21	any	O
22	age	O
23	.	O

1	P	B
2	-	I
3	CIP1	I
4	,	O
5	a	O
6	novel	O
7	protein	O
8	that	O
9	interacts	O
10	with	O
11	the	O
12	cytosolic	O
13	domain	O
14	of	O
15	peptidylglycine	B
16	alpha	I
17	-	I
18	amidating	I
19	monooxygenase	I
20	,	O
21	is	O
22	associated	O
23	with	O
24	endosomes	O
25	.	O

1	However	O
2	,	O
3	rapamycin	O
4	inhibited	O
5	proliferation	O
6	of	O
7	Ba	O
8	/	O
9	F3	O
10	-	O
11	EpoRgp55	O
12	but	O
13	not	O
14	of	O
15	MEL	O
16	cells	O
17	despite	O
18	inhibition	O
19	of	O
20	p70	B
21	S6	I
22	kinase	I
23	activity	O
24	in	O
25	both	O
26	cells	O
27	.	O

1	Control	O
2	examination	O
3	was	O
4	performed	O
5	at	O
6	the	O
7	end	O
8	of	O
9	each	O
10	period	O
11	.	O

1	Here	O
2	we	O
3	report	O
4	that	O
5	Dbp5p	B
6	and	O
7	Rat7p	B
8	interact	O
9	through	O
10	their	O
11	Nterminal	O
12	domains	O
13	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	relationship	O
6	between	O
7	c	B
8	-	I
9	fos	I
10	and	O
11	Rb	B
12	,	O
13	a	O
14	eukaryotic	O
15	expression	O
16	plasmid	O
17	was	O
18	constructed	O
19	containing	O
20	the	O
21	c	B
22	-	I
23	fos	I
24	gene	I
25	under	O
26	control	O
27	of	O
28	the	O
29	SV40	B
30	promoter	I
31	complex	O
32	.	O

1	In	O
2	transformed	O
3	E	O
4	.	O
5	coli	O
6	,	O
7	constitutive	B
8	CAT	I
9	expression	O
10	is	O
11	maintained	O
12	when	O
13	as	O
14	little	O
15	as	O
16	0	O
17	.	O
18	3	O
19	kilobase	O
20	of	O
21	DNA	O
22	from	O
23	the	O
24	3	O
25	'	O
26	end	O
27	of	O
28	the	O
29	1	O
30	.	O
31	6	O
32	-	O
33	kilobase	O
34	segment	O
35	is	O
36	inserted	O
37	in	O
38	the	O
39	correct	O
40	orientation	O
41	in	O
42	front	O
43	of	O
44	the	O
45	CAT	B
46	gene	I
47	.	O

1	CONCLUSION	O
2	:	O
3	Twice	O
4	daily	O
5	treatment	O
6	with	O
7	inhaled	O
8	fluticasone	O
9	propionate	O
10	50	O
11	micrograms	O
12	or	O
13	100	O
14	micrograms	O
15	was	O
16	significantly	O
17	more	O
18	effective	O
19	than	O
20	theophylline	O
21	in	O
22	the	O
23	treatment	O
24	of	O
25	mild	O
26	-	O
27	to	O
28	-	O
29	moderate	O
30	asthma	O
31	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	the	O
6	use	O
7	of	O
8	endogenous	O
9	creatinine	O
10	clearance	O
11	to	O
12	estimate	O
13	the	O
14	glomerular	O
15	filtration	O
16	rate	O
17	(	O
18	GFR	O
19	)	O
20	requires	O
21	caution	O
22	and	O
23	the	O
24	recognition	O
25	of	O
26	the	O
27	limitations	O
28	of	O
29	the	O
30	method	O
31	,	O
32	and	O
33	that	O
34	simpler	O
35	techniques	O
36	(	O
37	serum	O
38	creatinine	O
39	or	O
40	estimated	O
41	endogenous	O
42	creatinine	O
43	clearance	O
44	)	O
45	are	O
46	preferable	O
47	in	O
48	routine	O
49	practice	O
50	.	O

1	However	O
2	,	O
3	the	O
4	requirement	O
5	of	O
6	rev3	B
7	for	O
8	the	O
9	production	O
10	of	O
11	G	O
12	.	O
13	C	O
14	-->	O
15	T	O
16	.	O
17	A	O
18	transversions	O
19	by	O
20	the	O
21	rad18	B
22	mutator	I
23	,	O
24	which	O
25	induces	O
26	only	O
27	these	O
28	substitutions	O
29	,	O
30	was	O
31	similar	O
32	to	O
33	that	O
34	for	O
35	rad6	B
36	-	O
37	mediated	O
38	G	O
39	.	O
40	C	O
41	-->	O
42	T	O
43	.	O
44	A	O
45	transversion	O
46	.	O

1	Rho	B
2	GDP	I
3	/	I
4	GTP	I
5	exchange	I
6	inhibitor	I
7	,	O
8	Rho	B
9	GDI	I
10	,	O
11	comigrated	O
12	with	O
13	Rac2	B
14	and	O
15	RhoA	B
16	,	O
17	but	O
18	not	O
19	Rac1	B
20	.	O

1	Fifteen	O
2	light	O
3	for	O
4	dates	O
5	infants	O
6	and	O
7	their	O
8	placentae	O
9	were	O
10	compared	O
11	to	O
12	15	O
13	well	O
14	-	O
15	grown	O
16	infants	O
17	and	O
18	their	O
19	placentae	O
20	.	O

1	The	O
2	cloned	O
3	alcR	B
4	gene	I
5	provided	O
6	in	O
7	trans	O
8	restored	O
9	these	O
10	siderophore	O
11	system	O
12	activities	O
13	to	O
14	the	O
15	mutants	O
16	.	O

1	The	O
2	'	O
3	Newcastle	O
4	'	O
5	model	O
6	,	O
7	which	O
8	is	O
9	based	O
10	on	O
11	Hotelling	O
12	'	O
13	s	O
14	T2	O
15	statistic	O
16	,	O
17	proved	O
18	to	O
19	be	O
20	more	O
21	sensitive	O
22	and	O
23	diagnosed	O
24	a	O
25	systematic	O
26	displacement	O
27	for	O
28	three	O
29	prostate	O
30	patients	O
31	.	O

1	A	O
2	more	O
3	complete	O
4	analysis	O
5	of	O
6	dose	O
7	response	O
8	,	O
9	time	O
10	and	O
11	mode	O
12	of	O
13	Ga	O
14	administration	O
15	(	O
16	preinjury	O
17	or	O
18	postinjury	O
19	),	O
20	and	O
21	availability	O
22	of	O
23	Ga	O
24	across	O
25	the	O
26	blood	O
27	-	O
28	brain	O
29	barrier	O
30	is	O
31	needed	O
32	to	O
33	further	O
34	evaluate	O
35	the	O
36	efficacy	O
37	of	O
38	this	O
39	compound	O
40	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	with	O
6	autonomic	O
7	nervous	O
8	system	O
9	activity	O
10	intact	O
11	,	O
12	carotid	O
13	chemoreceptor	O
14	reflex	O
15	activation	O
16	can	O
17	elicit	O
18	an	O
19	absolute	O
20	reflexly	O
21	mediated	O
22	reduction	O
23	in	O
24	coronary	O
25	blood	O
26	flow	O
27	in	O
28	the	O
29	normal	O
30	,	O
31	conscious	O
32	dog	O
33	,	O
34	despite	O
35	an	O
36	increase	O
37	in	O
38	arterial	O
39	pressure	O
40	.	O

1	Organisms	O
2	were	O
3	not	O
4	observed	O
5	in	O
6	the	O
7	5	O
8	bobcats	O
9	trapped	O
10	in	O
11	2	O
12	other	O
13	counties	O
14	.	O

1	The	O
2	only	O
3	abundant	O
4	viral	O
5	transcript	O
6	expressed	O
7	during	O
8	latency	O
9	is	O
10	the	O
11	latency	B
12	-	I
13	related	I
14	(	O
15	LR	B
16	)	O
17	RNA	O
18	.	O

1	The	O
2	effect	O
3	of	O
4	a	O
5	constant	O
6	magnetic	O
7	field	O
8	on	O
9	the	O
10	phagocytic	O
11	activity	O
12	of	O
13	Paramecia	O

1	Daily	O
2	and	O
3	seasonal	O
4	rhythmicity	O
5	in	O
6	the	O
7	methylation	O
8	of	O
9	pineal	O
10	indolic	O
11	compounds	O
12	in	O
13	adult	O
14	male	O
15	golden	O
16	hamsters	O
17	,	O
18	kept	O
19	under	O
20	natural	O
21	conditions	O
22	.	O

1	When	O
2	transfected	O
3	into	O
4	Drosophila	O
5	SL	O
6	-	O
7	2	O
8	cells	O
9	,	O
10	pCAT	O
11	plasmid	O
12	containing	O
13	2	O
14	,	O
15	090	O
16	bp	O
17	of	O
18	5	O
19	'-	O
20	flanking	O
21	region	O
22	shows	O
23	a	O
24	3	O
25	.	O
26	0	O
27	-	O
28	to	O
29	3	O
30	.	O
31	5	O
32	-	O
33	fold	O
34	increase	O
35	in	O
36	chloramphenicol	B
37	acetyltransferase	I
38	activity	O
39	after	O
40	induction	O
41	with	O
42	retinoic	O
43	acid	O
44	and	O
45	/	O
46	or	O
47	8	O
48	-	O
49	bromo	O
50	-	O
51	cAMP	O
52	.	O

1	Citrate	B
2	synthase	I
3	activity	O
4	was	O
5	increased	O
6	in	O
7	the	O
8	medial	O
9	head	O
10	(	O
11	81	O
12	%,	O
13	P	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	and	O
20	the	O
21	red	O
22	long	O
23	head	O
24	(	O
25	88	O
26	%,	O
27	P	O
28	<	O
29	0	O
30	.	O
31	001	O
32	)	O
33	of	O
34	the	O
35	triceps	O
36	brachii	O
37	muscle	O
38	in	O
39	R	O
40	rats	O
41	but	O
42	not	O
43	in	O
44	the	O
45	white	O
46	long	O
47	head	O
48	(	O
49	25	O
50	%,	O
51	P	O
52	=	O
53	0	O
54	.	O
55	06	O
56	).	O

1	Notably	O
2	,	O
3	these	O
4	residues	O
5	are	O
6	located	O
7	in	O
8	different	O
9	domains	O
10	.	O

1	The	O
2	TYAC	O
3	/	O
4	P1	O
5	resource	O
6	,	O
7	derivative	O
8	STSs	O
9	,	O
10	and	O
11	polymorphisms	O
12	constitute	O
13	an	O
14	enabling	O
15	resource	O
16	to	O
17	further	O
18	studies	O
19	of	O
20	telomere	O
21	structure	O
22	and	O
23	function	O
24	and	O
25	a	O
26	means	O
27	for	O
28	physical	O
29	and	O
30	genetic	O
31	map	O
32	integration	O
33	and	O
34	closure	O
35	.	O

1	The	O
2	former	O
3	procedure	O
4	is	O
5	economical	O
6	but	O
7	complicated	O
8	,	O
9	whereas	O
10	the	O
11	latter	O
12	is	O
13	simple	O
14	and	O
15	labour	O
16	-	O
17	saving	O
18	,	O
19	but	O
20	a	O
21	special	O
22	ultrafiltration	O
23	tube	O
24	is	O
25	required	O
26	.	O

1	Six	O
2	(	O
3	four	O
4	FAP	O
5	;	O
6	two	O
7	primary	O
8	amyloidosis	O
9	)	O
10	also	O
11	had	O
12	diffusely	O
13	positive	O
14	myocardial	O
15	uptakes	O
16	,	O
17	but	O
18	the	O
19	intensity	O
20	was	O
21	less	O
22	than	O
23	that	O
24	of	O
25	the	O
26	sternum	O
27	.	O

1	A	O
2	Chinese	O
3	(	O
4	HK	O
5	)	O
6	SF	O
7	-	O
8	36	O
9	survey	O
10	form	O
11	was	O
12	developed	O
13	by	O
14	an	O
15	iterative	O
16	translation	O
17	process	O
18	.	O

1	Pit	B
2	-	I
3	1	I
4	is	O
5	a	O
6	tissue	O
7	-	O
8	specific	O
9	POU	B
10	domain	I
11	factor	I
12	obligatory	O
13	for	O
14	the	O
15	appearance	O
16	of	O
17	three	O
18	cell	O
19	phenotypes	O
20	in	O
21	the	O
22	anterior	O
23	pituitary	O
24	gland	O
25	.	O

1	Basal	O
2	midexpiratory	O
3	lower	O
4	esophageal	O
5	sphincter	O
6	pressure	O
7	was	O
8	similar	O
9	in	O
10	the	O
11	study	O
12	group	O
13	(	O
14	mean	O
15	[	O
16	SD	O
17	]	O
18	20	O
19	.	O
20	1	O
21	[	O
22	9	O
23	.	O
24	1	O
25	]	O
26	mmHg	O
27	)	O
28	and	O
29	controls	O
30	(	O
31	17	O
32	.	O
33	6	O
34	[	O
35	6	O
36	.	O
37	0	O
38	]	O
39	mmHg	O
40	);	O
41	the	O
42	pressure	O
43	did	O
44	not	O
45	change	O
46	following	O
47	EVS	O
48	or	O
49	EVL	O
50	.	O

1	The	O
2	alternative	O
3	exon	O
4	introduces	O
5	the	O
6	novel	O
7	carboxyl	O
8	terminus	O
9	and	O
10	a	O
11	new	O
12	translation	O
13	stop	O
14	signal	O
15	,	O
16	while	O
17	simultaneously	O
18	converting	O
19	the	O
20	coding	O
21	sequence	O
22	for	O
23	40	O
24	carboxyl	O
25	-	O
26	terminal	O
27	residues	O
28	in	O
29	CeCAT	B
30	alpha	I
31	into	O
32	3	O
33	'-	O
34	untranslated	O
35	nucleotides	O
36	.	O

1	Furthermore	O
2	,	O
3	this	O
4	element	O
5	confers	O
6	p53	B
7	induction	O
8	to	O
9	the	O
10	otherwise	O
11	nonresponsive	O
12	adenovirus	O
13	major	O
14	late	O
15	promoter	O
16	.	O

1	SvO2	O
2	can	O
3	be	O
4	determined	O
5	in	O
6	vitro	O
7	and	O
8	in	O
9	vivo	O
10	.	O

1	Diagnosis	O
2	and	O
3	treatment	O
4	planning	O
5	in	O
6	Class	O
7	II	O
8	,	O
9	division	O
10	2	O

1	The	O
2	CVA16	B
3	.	I
4	4	I
5	proteolipid	I
6	transcript	I
7	is	O
8	the	O
9	most	O
10	prevalent	O
11	of	O
12	the	O
13	two	O
14	proteolipid	O
15	messages	O
16	in	O
17	expanding	O
18	ovules	O
19	harvested	O
20	10	O
21	d	O
22	post	O
23	-	O
24	anthesis	O
25	.	O

1	Varieties	O
2	of	O
3	envious	O
4	experience	O
5	.	O

1	"	O
2	Complex	O
3	partial	O
4	"	O
5	seizures	O
6	.	O

1	1	O
2	-(	O
3	1	O
4	-	O
5	Naphthyl	O
6	)	O
7	piperazine	O
8	(	O
9	1	O
10	-	O
11	NP	O
12	)	O
13	has	O
14	been	O
15	reported	O
16	to	O
17	have	O
18	serotonin	O
19	antagonist	O
20	properties	O
21	at	O
22	the	O
23	5	B
24	-	I
25	HT2	I
26	subtype	I
27	of	O
28	receptor	O
29	,	O
30	and	O
31	it	O
32	has	O
33	been	O
34	suggested	O
35	that	O
36	it	O
37	may	O
38	have	O
39	agonist	O
40	actions	O
41	at	O
42	the	O
43	5	B
44	-	I
45	HT1	I
46	site	I
47	.	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	B
6	PGS	I
7	-	I
8	2	I
9	gene	I
10	contains	O
11	a	O
12	CAAT	B
13	enhancer	I
14	-	I
15	binding	I
16	protein	I
17	consensus	I
18	site	I
19	(	I
20	CAAT	I
21	box	I
22	)	I
23	which	O
24	can	O
25	confer	O
26	hormone	O
27	inducibility	O
28	to	O
29	a	O
30	PGS	B
31	-	I
32	2	I
33	.	O
34	CAT	B
35	reporter	O
36	gene	O
37	,	O
38	as	O
39	well	O
40	as	O
41	a	O
42	putative	O
43	E	O
44	-	O
45	box	O
46	region	O
47	.	O

1	Macroscopic	O
2	researches	O
3	on	O
4	heart	O
5	vascularization	O
6	have	O
7	indicated	O
8	that	O
9	the	O
10	angioarchitecture	O
11	of	O
12	the	O
13	conducting	O
14	system	O
15	differs	O
16	from	O
17	that	O
18	of	O
19	the	O
20	normal	O
21	myocardium	O
22	.	O

1	In	O
2	the	O
3	chicken	O
4	liver	O
5	,	O
6	levels	O
7	of	O
8	chicken	B
9	MT	I
10	mRNA	I
11	were	O
12	rapidly	O
13	induced	O
14	by	O
15	metals	O
16	(	O
17	Cd2	O
18	+,	O
19	Zn2	O
20	+,	O
21	Cu2	O
22	+),	O
23	glucocorticoids	O
24	and	O
25	lipopolysaccharide	O
26	.	O

1	During	O
2	exercise	O
3	,	O
4	the	O
5	Pes	O
6	-	O
7	Ves	O
8	relation	O
9	was	O
10	shifted	O
11	toward	O
12	the	O
13	left	O
14	and	O
15	the	O
16	slope	O
17	[	O
18	end	O
19	-	O
20	systolic	O
21	elastance	O
22	(	O
23	Ees	O
24	)]	O
25	increased	O
26	from	O
27	7	O
28	.	O
29	7	O
30	+/-	O
31	2	O
32	.	O
33	8	O
34	to	O
35	12	O
36	.	O
37	7	O
38	+/-	O
39	4	O
40	.	O
41	2	O
42	(	O
43	SD	O
44	)	O
45	mmHg	O
46	/	O
47	ml	O
48	(	O
49	P	O
50	<	O
51	0	O
52	.	O
53	05	O
54	).	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	Anabaena	O
6	strain	O
7	7120	O
8	leuA	B
9	gene	O
10	did	O
11	not	O
12	complement	O
13	the	O
14	nifV	B
15	mutation	I
16	of	O
17	R229I	O
18	efficiently	O
19	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	developed	O
6	a	O
7	system	O
8	to	O
9	study	O
10	nuclear	O
11	targeting	O
12	in	O
13	plants	O
14	and	O
15	have	O
16	established	O
17	that	O
18	the	O
19	nuclear	O
20	transport	O
21	machinery	O
22	is	O
23	similar	O
24	in	O
25	monocots	O
26	and	O
27	dicots	O
28	.	O

1	The	O
2	inspiratory	O
3	oxygen	O
4	concentration	O
5	needed	O
6	(	O
7	FiO2	O
8	)	O
9	and	O
10	the	O
11	Horowitz	O
12	quotient	O
13	differed	O
14	in	O
15	a	O
16	highly	O
17	significant	O
18	manner	O
19	beginning	O
20	on	O
21	the	O
22	1st	O
23	day	O
24	after	O
25	trauma	O
26	.	O

1	Epidermal	B
2	growth	I
3	factor	I
4	receptor	I
5	transcriptionally	O
6	up	O
7	-	O
8	regulates	O
9	vascular	B
10	endothelial	I
11	growth	I
12	factor	I
13	expression	O
14	in	O
15	human	O
16	glioblastoma	O
17	cells	O
18	via	O
19	a	O
20	pathway	O
21	involving	O
22	phosphatidylinositol	B
23	3	I
24	'-	I
25	kinase	I
26	and	O
27	distinct	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	hypoxia	O
33	.	O

1	The	O
2	response	O
3	of	O
4	serum	B
5	GH	I
6	to	O
7	arginine	O
8	infusion	O
9	was	O
10	normal	O
11	,	O
12	while	O
13	that	O
14	to	O
15	insulin	B
16	-	O
17	induced	O
18	hypoglycemia	O
19	was	O
20	poor	O
21	.	O

1	However	O
2	,	O
3	when	O
4	,	O
5	where	O
6	and	O
7	how	O
8	the	O
9	DSPP	B
10	is	O
11	cleaved	O
12	into	O
13	DSP	B
14	and	O
15	DPP	B
16	is	O
17	not	O
18	clear	O
19	.	O

1	Coexisting	O
2	vertical	O
3	and	O
4	horizontal	O
5	one	O
6	and	O
7	a	O
8	half	O
9	syndromes	O
10	.	O

1	Upon	O
2	UV	O
3	damage	O
4	,	O
5	Crb2	B
6	is	O
7	transiently	O
8	modified	O
9	,	O
10	probably	O
11	phosphorylated	O
12	,	O
13	with	O
14	a	O
15	similar	O
16	timing	O
17	of	O
18	phosphorylation	O
19	in	O
20	Chk1	B
21	kinase	I
22	,	O
23	which	O
24	is	O
25	reported	O
26	to	O
27	restrain	O
28	Cdc2	B
29	activation	O
30	.	O

1	Thirty	O
2	of	O
3	the	O
4	clones	O
5	contained	O
6	a	O
7	complete	O
8	340	O
9	base	O
10	-	O
11	pair	O
12	dimer	O
13	unit	O
14	of	O
15	the	O
16	repeat	O
17	.	O

1	Moreover	O
2	,	O
3	Western	O
4	blots	O
5	demonstrated	O
6	at	O
7	least	O
8	six	O
9	types	O
10	of	O
11	Ypt	B
12	in	O
13	both	O
14	Cr	O
15	and	O
16	Vc	O
17	,	O
18	suggesting	O
19	that	O
20	these	O
21	Ypt	B
22	are	O
23	used	O
24	for	O
25	household	O
26	functions	O
27	responsible	O
28	for	O
29	vesicle	O
30	transport	O
31	rather	O
32	than	O
33	for	O
34	cellular	O
35	differentiation	O
36	.	O

1	Viral	O
2	infections	O
3	have	O
4	long	O
5	been	O
6	suspected	O
7	to	O
8	be	O
9	causative	O
10	agents	O
11	in	O
12	a	O
13	number	O
14	of	O
15	inner	O
16	ear	O
17	dysfunctions	O
18	.	O

1	Bilateral	O
2	Charnley	O
3	arthroplasty	O
4	as	O
5	a	O
6	single	O
7	procedure	O
8	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	Ski	B
6	is	O
7	a	O
8	component	O
9	of	O
10	the	O
11	HDAC	B
12	complex	I
13	and	O
14	that	O
15	Ski	B
16	is	O
17	required	O
18	for	O
19	the	O
20	transcriptional	O
21	repression	O
22	mediated	O
23	by	O
24	this	O
25	complex	O
26	.	O

1	Tetrad	O
2	analysis	O
3	and	O
4	mitotic	O
5	recombination	O
6	experiments	O
7	localized	O
8	the	O
9	PEP4	B
10	gene	I
11	proximal	O
12	to	O
13	GAL4	B
14	on	O
15	chromosome	O
16	XVI	O
17	.	O

1	Diet	O
2	and	O
3	atopic	O
4	eczema	O
5	.	O

1	BACKGROUND	O
2	:	O
3	It	O
4	is	O
5	generally	O
6	accepted	O
7	that	O
8	smoking	O
9	increases	O
10	blood	O
11	pressure	O
12	and	O
13	inhibits	O
14	muscle	O
15	sympathetic	O
16	nerve	O
17	activity	O
18	(	O
19	SNA	O
20	).	O

1	A	O
2	genomic	O
3	clone	O
4	was	O
5	isolated	O
6	that	O
7	contained	O
8	12	O
9	.	O
10	5	O
11	kb	O
12	of	O
13	the	O
14	5	O
15	'-	O
16	flanking	O
17	region	O
18	and	O
19	the	O
20	first	O
21	exon	O
22	of	O
23	the	O
24	p69	B
25	/	I
26	71	I
27	2	I
28	-	I
29	5A	I
30	synthetase	I
31	gene	I
32	.	O

1	Regionalization	O
2	of	O
3	drug	O
4	delivery	O
5	is	O
6	a	O
7	potential	O
8	method	O
9	to	O
10	avoid	O
11	this	O
12	problem	O
13	.	O

1	Growth	O
2	curves	O
3	indicated	O
4	that	O
5	proliferation	O
6	of	O
7	clone	O
8	CA9	O
9	in	O
10	the	O
11	presence	O
12	of	O
13	10	O
14	%	O
15	serum	O
16	was	O
17	reduced	O
18	by	O
19	60	O
20	%	O
21	compared	O
22	with	O
23	clone	O
24	ME10	O
25	.	O

1	The	O
2	centromeric	O
3	YAC	O
4	contig	O
5	,	O
6	which	O
7	consists	O
8	of	O
9	23	O
10	overlapping	O
11	YACs	O
12	and	O
13	orders	O
14	19	O
15	sequence	O
16	-	O
17	tagged	O
18	sites	O
19	(	O
20	STSs	O
21	),	O
22	covers	O
23	a	O
24	minimum	O
25	of	O
26	2	O
27	.	O
28	2	O
29	Mb	O
30	and	O
31	spans	O
32	the	O
33	Ewing	O
34	sarcoma	O
35	breakpoint	O
36	.	O
37	c	B
38	-	I
39	ets	I
40	1	I
41	and	O
42	Fli	B
43	-	I
44	1	I
45	,	O
46	two	O
47	members	O
48	of	O
49	the	O
50	ets	B
51	family	I
52	,	O
53	have	O
54	been	O
55	linked	O
56	within	O
57	400	O
58	kb	O
59	of	O
60	intervening	O
61	DNA	O
62	within	O
63	this	O
64	contig	O
65	,	O
66	which	O
67	also	O
68	comprises	O
69	a	O
70	polymorphic	O
71	microsatellite	O
72	,	O
73	D11S912	B
74	(	O
75	CA	O
76	)	O
77	n	O
78	,	O
79	which	O
80	we	O
81	have	O
82	localized	O
83	within	O
84	the	O
85	Fli	B
86	-	I
87	1	I
88	gene	I
89	.	O

1	A	O
2	significant	O
3	correlation	O
4	between	O
5	a	O
6	number	O
7	of	O
8	functional	O
9	parameters	O
10	of	O
11	gastric	O
12	secretion	O
13	,	O
14	incretion	O
15	and	O
16	histological	O
17	changes	O
18	of	O
19	gastric	O
20	mucosa	O
21	was	O
22	found	O
23	in	O
24	patients	O
25	with	O
26	chronic	O
27	gastritis	O
28	.	O

1	Although	O
2	the	O
3	effects	O
4	of	O
5	the	O
6	calcium	O
7	supplement	O
8	or	O
9	calcium	O
10	antagonist	O
11	alone	O
12	were	O
13	significant	O
14	,	O
15	such	O
16	hypotensive	O
17	responses	O
18	were	O
19	not	O
20	optimal	O
21	or	O
22	predictable	O
23	or	O
24	clearly	O
25	dose	O
26	-	O
27	dependent	O
28	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	loss	O
6	of	O
7	MAD2	B
8	staining	O
9	in	O
10	meiosis	O
11	was	O
12	not	O
13	correlated	O
14	with	O
15	initial	O
16	microtubule	O
17	attachment	O
18	but	O
19	was	O
20	correlated	O
21	with	O
22	a	O
23	measure	O
24	of	O
25	tension	O
26	:	O
27	the	O
28	distance	O
29	between	O
30	homologous	O
31	or	O
32	sister	O
33	kinetochores	O
34	(	O
35	in	O
36	meiosis	O
37	I	O
38	and	O
39	II	O
40	,	O
41	respectively	O
42	).	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	regions	O
6	of	O
7	both	O
8	pelA	B
9	and	O
10	pelB	B
11	were	O
12	translationally	O
13	fused	O
14	to	O
15	the	O
16	beta	B
17	-	I
18	glucuronidase	I
19	gene	I
20	and	O
21	introduced	O
22	into	O
23	F	O
24	.	O
25	solani	O
26	f	O
27	.	O
28	sp	O
29	.	O
30	pisi	O
31	,	O
32	and	O
33	beta	B
34	-	I
35	glucuronidase	I
36	activities	O
37	of	O
38	the	O
39	transformants	O
40	were	O
41	measured	O
42	.	O

1	TNF	B
2	-	I
3	alpha	I
4	exposure	O
5	markedly	O
6	increased	O
7	activity	O
8	of	O
9	several	O
10	RNA	O
11	-	O
12	binding	O
13	proteins	O
14	,	O
15	especially	O
16	a	O
17	novel	O
18	Mr	O
19	50	O
20	,	O
21	000	O
22	-	O
23	55	O
24	,	O
25	000	O
26	RNA	O
27	-	O
28	binding	O
29	protein	O
30	.	O

1	TcPO2	O
2	measurement	O
3	appears	O
4	to	O
5	be	O
6	a	O
7	reliable	O
8	technique	O
9	that	O
10	can	O
11	influence	O
12	ischaemic	O
13	ulcer	O
14	management	O
15	.	O

1	Duration	O
2	of	O
3	remission	O
4	in	O
5	advanced	O
6	gastric	O
7	cancer	O
8	patients	O
9	responding	O
10	to	O
11	sequential	O
12	dose	O
13	of	O
14	MTX	O
15	and	O
16	5	O
17	-	O
18	FU	O

1	Video	O
2	images	O
3	of	O
4	the	O
5	nostrils	O
6	were	O
7	captured	O
8	and	O
9	then	O
10	analyzed	O
11	for	O
12	area	O
13	,	O
14	perimeter	O
15	,	O
16	centroid	O
17	,	O
18	principal	O
19	axis	O
20	,	O
21	moments	O
22	about	O
23	the	O
24	major	O
25	and	O
26	minor	O
27	axes	O
28	(	O
29	I11	O
30	,	O
31	I22	O
32	),	O
33	anisometry	O
34	,	O
35	bulkiness	O
36	,	O
37	lateral	O
38	offset	O
39	,	O
40	internostril	O
41	angle	O
42	,	O
43	and	O
44	rotational	O
45	angle	O
46	.	O

1	The	O
2	euglobulin	B
3	clot	O
4	lysis	O
5	time	O
6	was	O
7	slightly	O
8	longer	O
9	in	O
10	the	O
11	smokers	O
12	than	O
13	in	O
14	the	O
15	non	O
16	-	O
17	smokers	O
18	in	O
19	all	O
20	three	O
21	experimental	O
22	situations	O
23	,	O
24	but	O
25	the	O
26	differences	O
27	were	O
28	not	O
29	significant	O
30	.	O

1	Up	O
2	to	O
3	95	O
4	%	O
5	of	O
6	the	O
7	total	O
8	UV	O
9	exposure	O
10	received	O
11	is	O
12	in	O
13	the	O
14	UV	O
15	-	O
16	A	O
17	waveband	O
18	(	O
19	320	O
20	-	O
21	400	O
22	nm	O
23	).	O

1	Following	O
2	seven	O
3	days	O
4	'	O
5	incubation	O
6	both	O
7	at	O
8	20	O
9	degrees	O
10	C	O
11	and	O
12	28	O
13	degrees	O
14	C	O
15	,	O
16	Ae	O
17	.	O
18	vexans	O
19	nip	O
20	.	O
21	was	O
22	capable	O
23	of	O
24	transmitting	O
25	the	O
26	virus	O
27	.	O

1	The	O
2	ventilation	O
3	did	O
4	not	O
5	increase	O
6	when	O
7	PACO2	O
8	was	O
9	increased	O
10	.	O

1	In	O
2	these	O
3	cases	O
4	,	O
5	asbestos	O
6	or	O
7	erionite	O
8	-	O
9	tissue	O
10	burden	O
11	followed	O
12	by	O
13	fibrosis	O
14	was	O
15	frequently	O
16	observed	O
17	.	O

1	A	O
2	one	O
3	-	O
4	week	O
5	ulcer	O
6	therapy	O
7	with	O
8	atropine	O
9	and	O
10	Vikalin	O
11	(	O
12	Roter	O
13	)	O
14	led	O
15	to	O
16	a	O
17	significant	O
18	(	O
19	p	O
20	less	O
21	than	O
22	0	O
23	.	O
24	01	O
25	)	O
26	reduction	O
27	of	O
28	the	O
29	nocturnal	O
30	proteolytic	O
31	activity	O
32	.	O

1	Most	O
2	of	O
3	the	O
4	phenomena	O
5	of	O
6	azotaemic	O
7	osteodystrophy	O
8	are	O
9	encountered	O
10	in	O
11	simple	O
12	vitamin	O
13	D	O
14	deficiency	O
15	;	O
16	as	O
17	in	O
18	that	O
19	condition	O
20	,	O
21	deficiency	O
22	of	O
23	1	O
24	,	O
25	25	O
26	-	O
27	dihydroxycholecalciferol	O
28	may	O
29	be	O
30	of	O
31	primary	O
32	significance	O
33	in	O
34	causing	O
35	secondary	O
36	hyperparathyroidism	O
37	in	O
38	renal	O
39	failure	O
40	.	O

1	Although	O
2	the	O
3	RAD23	B
4	equivalents	O
5	are	O
6	well	O
7	conserved	O
8	during	O
9	evolution	O
10	,	O
11	the	O
12	mammalian	O
13	genes	O
14	did	O
15	not	O
16	express	O
17	the	O
18	UV	O
19	-	O
20	inducible	O
21	phenotype	O
22	of	O
23	their	O
24	yeast	O
25	counterpart	O
26	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	Lrp	B
6	binds	O
7	a	O
8	central	O
9	palindromic	O
10	site	O
11	,	O
12	interacting	O
13	predominantly	O
14	with	O
15	the	O
16	major	O
17	groove	O
18	of	O
19	its	O
20	DNA	O
21	target	O
22	,	O
23	and	O
24	that	O
25	additional	O
26	dimers	O
27	bind	O
28	to	O
29	flanking	O
30	sites	O
31	to	O
32	form	O
33	a	O
34	nucleoprotein	O
35	activation	O
36	complex	O
37	.	O

1	To	O
2	test	O
3	the	O
4	feasibility	O
5	of	O
6	using	O
7	liposomes	O
8	to	O
9	deliver	O
10	therapeutic	O
11	agents	O
12	to	O
13	the	O
14	lungs	O
15	,	O
16	the	O
17	effect	O
18	of	O
19	liposome	O
20	-	O
21	encapsulated	O
22	superoxide	B
23	dismutase	I
24	(	O
25	SOD	B
26	)	O
27	or	O
28	catalase	B
29	on	O
30	pulmonary	O
31	oxygen	O
32	toxicity	O
33	was	O
34	studied	O
35	in	O
36	rats	O
37	.	O

1	The	O
2	dying	O
3	tTG	B
4	-	O
5	transfected	O
6	cells	O
7	exhibit	O
8	both	O
9	cytoplasmic	O
10	and	O
11	nuclear	O
12	changes	O
13	characteristic	O
14	of	O
15	cells	O
16	undergoing	O
17	apoptosis	O
18	.	O

1	The	O
2	sample	O
3	is	O
4	deproteinized	O
5	and	O
6	after	O
7	centrifugation	O
8	valproic	O
9	acid	O
10	in	O
11	the	O
12	supernatant	O
13	is	O
14	measured	O
15	in	O
16	the	O
17	free	O
18	form	O
19	by	O
20	direct	O
21	injection	O
22	into	O
23	the	O
24	gas	O
25	chromatograph	O
26	.	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	expression	O
6	vectors	O
7	for	O
8	CCAAT	B
9	/	I
10	enhancer	I
11	binding	I
12	protein	I
13	(	I
14	C	I
15	/	I
16	EBP	I
17	)	I
18	alpha	I
19	and	O
20	C	B
21	/	I
22	EBP	I
23	beta	I
24	trans	O
25	-	O
26	activated	O
27	the	O
28	rat	B
29	uncoupling	I
30	protein	I
31	gene	I
32	promoter	I
33	due	O
34	to	O
35	sequences	O
36	in	O
37	the	O
38	5	O
39	'	O
40	proximal	O
41	region	O
42	.	O

1	Endoscopic	O
2	examinations	O
3	,	O
4	peripheral	O
5	white	O
6	blood	O
7	cell	O
8	(	O
9	WBC	O
10	)	O
11	counts	O
12	,	O
13	and	O
14	assays	O
15	of	O
16	myeloperoxidase	B
17	activity	O
18	(	O
19	MPO	B
20	)	O
21	in	O
22	homogenates	O
23	of	O
24	colon	O
25	mucosa	O
26	were	O
27	performed	O
28	after	O
29	one	O
30	week	O
31	(	O
32	4	O
33	%	O
34	DSS	O
35	model	O
36	)	O
37	and	O
38	eight	O
39	weeks	O
40	(	O
41	1	O
42	%	O
43	DSS	O
44	model	O
45	).	O

1	This	O
2	utilization	O
3	of	O
4	an	O
5	intronic	O
6	polyadenylation	O
7	site	O
8	without	O
9	alternative	O
10	exon	O
11	usage	O
12	is	O
13	comparable	O
14	to	O
15	the	O
16	mechanism	O
17	whereby	O
18	both	O
19	secreted	O
20	and	O
21	membrane	O
22	-	O
23	bound	O
24	forms	O
25	of	O
26	the	O
27	immunoglobulin	B
28	mu	I
29	heavy	I
30	chain	I
31	are	O
32	made	O
33	from	O
34	a	O
35	single	O
36	genetic	O
37	locus	O
38	.	O

1	The	O
2	membrane	O
3	-	O
4	distal	O
5	cytoplasmic	O
6	region	O
7	of	O
8	human	B
9	granulocyte	I
10	colony	I
11	-	I
12	stimulating	I
13	factor	I
14	receptor	I
15	is	O
16	required	O
17	for	O
18	STAT3	B
19	but	O
20	not	O
21	STAT1	B
22	homodimer	I
23	formation	O
24	.	O

1	In	O
2	adult	O
3	tissues	O
4	,	O
5	it	O
6	was	O
7	less	O
8	restricted	O
9	,	O
10	indicating	O
11	that	O
12	RAFTK	B
13	expression	O
14	is	O
15	developmentally	O
16	up	O
17	-	O
18	regulated	O
19	.	O

1	A	O
2	motif	O
3	(	O
4	TGATGTCA	O
5	)	O
6	which	O
7	matches	O
8	a	O
9	CREB	B
10	site	I
11	and	O
12	is	O
13	similar	O
14	to	O
15	an	O
16	AP	B
17	-	I
18	1	I
19	site	I
20	is	O
21	embedded	O
22	within	O
23	ER2	B
24	.	O

1	When	O
2	RNA	O
3	encoding	O
4	the	O
5	tail	O
6	domain	O
7	of	O
8	desmoglein	B
9	was	O
10	coinjected	O
11	with	O
12	plakoglobin	B
13	RNA	I
14	,	O
15	both	O
16	the	O
17	dorsalizing	O
18	effect	O
19	and	O
20	nuclear	O
21	accumulation	O
22	of	O
23	plakoglobin	B
24	were	O
25	suppressed	O
26	.	O

1	Stress	O
2	effects	O
3	on	O
4	affiliation	O
5	preferences	O
6	among	O
7	subjects	O
8	possessing	O
9	the	O
10	type	O
11	A	O
12	coronary	O
13	-	O
14	prone	O
15	behavior	O
16	pattern	O
17	.	O

1	Twenty	O
2	-	O
3	one	O
4	percent	O
5	of	O
6	these	O
7	patients	O
8	had	O
9	neurologic	O
10	disease	O
11	that	O
12	appeared	O
13	to	O
14	be	O
15	responsible	O
16	for	O
17	the	O
18	tinnitus	O
19	.	O

1	Recurrent	O
2	G	O
3	-	O
4	to	O
5	-	O
6	A	O
7	substitution	O
8	in	O
9	a	O
10	single	O
11	codon	O
12	of	O
13	SREBP	B
14	cleavage	I
15	-	I
16	activating	I
17	protein	I
18	causes	O
19	sterol	O
20	resistance	O
21	in	O
22	three	O
23	mutant	O
24	Chinese	O
25	hamster	O
26	ovary	O
27	cell	O
28	lines	O
29	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	47	B
6	-	I
7	kilodalton	I
8	major	I
9	integral	I
10	membrane	I
11	immunogen	I
12	of	I
13	Treponema	I
14	pallidum	I
15	.	O

1	IGF	B
2	I	I
3	and	O
4	insulin	B
5	receptors	I
6	are	O
7	homologous	O
8	proteins	O
9	that	O
10	function	O
11	in	O
12	distinct	O
13	physiological	O
14	pathways	O
15	.	O

1	The	O
2	pseudolymphoma	O
3	syndrome	O
4	is	O
5	a	O
6	reversible	O
7	reactive	O
8	condition	O
9	consisting	O
10	of	O
11	fever	O
12	,	O
13	lymphadenopathy	O
14	and	O
15	generalized	O
16	rash	O
17	.	O

1	Neuregulin	B
2	stimulates	O
3	ErbB2	B
4	,	O
5	ErbB3	B
6	,	O
7	and	O
8	ErbB4	B
9	,	O
10	members	O
11	of	O
12	the	O
13	ErbB	B
14	family	I
15	of	O
16	receptor	B
17	tyrosine	I
18	kinases	I
19	.	O

1	The	O
2	ratio	O
3	of	O
4	radioactivity	O
5	in	O
6	tumour	O
7	compared	O
8	with	O
9	normal	O
10	tissue	O
11	(	O
12	T	O
13	:	O
14	N	O
15	ratio	O
16	)	O
17	was	O
18	determined	O
19	after	O
20	simultaneously	O
21	injecting	O
22	microspheres	O
23	into	O
24	the	O
25	portal	O
26	and	O
27	arterial	O
28	circulation	O
29	of	O
30	each	O
31	animal	O
32	.	O

1	This	O
2	promoter	O
3	segment	O
4	could	O
5	drive	O
6	expression	O
7	of	O
8	a	O
9	luciferase	B
10	reporter	I
11	gene	I
12	,	O
13	could	O
14	confer	O
15	correct	O
16	transcriptional	O
17	initiation	O
18	to	O
19	the	O
20	reporter	O
21	and	O
22	could	O
23	confer	O
24	the	O
25	EGF	B
26	-	O
27	responsiveness	O
28	previously	O
29	observed	O
30	in	O
31	the	O
32	native	O
33	gene	O
34	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	interaction	O
7	of	O
8	eIF4A	B
9	with	O
10	the	O
11	middle	O
12	region	O
13	of	O
14	eIF4GI	B
15	is	O
16	necessary	O
17	for	O
18	translation	O
19	,	O
20	whereas	O
21	the	O
22	interaction	O
23	of	O
24	eIF4A	B
25	with	O
26	the	O
27	C	O
28	-	O
29	terminal	O
30	region	O
31	plays	O
32	a	O
33	modulatory	O
34	role	O
35	.	O

1	Ultraviolet	O
2	light	O
3	-	O
4	induced	O
5	kinin	B
6	formation	O
7	in	O
8	human	O
9	skin	O
10	.	O

1	In	O
2	14	O
3	of	O
4	21	O
5	infant	O
6	hearts	O
7	(	O
8	66	O
9	%)	O
10	with	O
11	aortic	O
12	arch	O
13	interruption	O
14	between	O
15	the	O
16	left	O
17	common	O
18	carotid	O
19	and	O
20	left	O
21	subclavian	O
22	arteries	O
23	(	O
24	type	O
25	B	O
26	of	O
27	Celoria	O
28	and	O
29	Patton	O
30	),	O
31	the	O
32	right	O
33	subclavian	O
34	artery	O
35	(	O
36	SA	O
37	)	O
38	arose	O
39	anomalously	O
40	.	O

1	By	O
2	contrast	O
3	,	O
4	d	B
5	(	I
6	T2AG3T	I
7	)	I
8	and	O
9	d	B
10	(	I
11	T2G4T	I
12	)	I
13	form	O
14	only	O
15	the	O
16	G	O
17	-	O
18	quadruplex	O
19	monomer	O
20	structures	O
21	independent	O
22	of	O
23	K	O
24	cation	O
25	concentration	O
26	as	O
27	reported	O
28	previously	O
29	[	O
30	Sen	O
31	,	O
32	D	O
33	.,	O
34	&	O
35	Gilbert	O
36	,	O
37	W	O
38	.	O

1	Analysis	O
2	of	O
3	Bcl	B
4	-	I
5	2	I
6	/	O
7	Bcl	B
8	-	I
9	2	I
10	homodimerization	O
11	using	O
12	both	O
13	in	O
14	vitro	O
15	binding	O
16	assays	O
17	as	O
18	well	O
19	as	O
20	a	O
21	yeast	O
22	two	O
23	-	O
24	hybrid	O
25	method	O
26	provided	O
27	evidence	O
28	in	O
29	support	O
30	of	O
31	a	O
32	head	O
33	-	O
34	to	O
35	-	O
36	tail	O
37	model	O
38	for	O
39	Bcl	B
40	-	I
41	2	I
42	/	O
43	Bcl	B
44	-	I
45	2	I
46	homodimerization	O
47	and	O
48	revealed	O
49	that	O
50	sequences	O
51	within	O
52	the	O
53	NH2	O
54	-	O
55	terminal	O
56	A	O
57	domain	O
58	interact	O
59	with	O
60	a	O
61	structure	O
62	that	O
63	requires	O
64	the	O
65	presence	O
66	of	O
67	both	O
68	the	O
69	carboxyl	O
70	B	O
71	and	O
72	C	O
73	domains	O
74	in	O
75	combination	O
76	.	O

1	An	O
2	intact	O
3	5	O
4	.	O
5	7	O
6	-	O
7	kb	O
8	provirus	O
9	of	O
10	the	O
11	avian	O
12	erythroblastosis	O
13	virus	O
14	E26	O
15	has	O
16	been	O
17	molecularly	O
18	cloned	O
19	for	O
20	comparisons	O
21	with	O
22	avian	O
23	myeloblastosis	O
24	virus	O
25	(	O
26	AMV	O
27	)	O
28	and	O
29	other	O
30	avian	O
31	tumor	O
32	viruses	O
33	.	O

1	The	O
2	interferon	B
3	-	O
4	induced	O
5	RNA	B
6	-	I
7	dependent	I
8	protein	I
9	kinase	I
10	(	O
11	PKR	B
12	)	O
13	is	O
14	considered	O
15	to	O
16	play	O
17	an	O
18	important	O
19	role	O
20	in	O
21	the	O
22	cellular	O
23	defense	O
24	against	O
25	viral	O
26	infection	O
27	and	O
28	,	O
29	in	O
30	addition	O
31	,	O
32	has	O
33	been	O
34	suggested	O
35	to	O
36	be	O
37	a	O
38	tumor	O
39	suppressor	O
40	gene	O
41	because	O
42	of	O
43	its	O
44	growth	O
45	-	O
46	suppressive	O
47	properties	O
48	.	O

1	Vaccinia	O
2	virus	O
3	-	O
4	expressed	O
5	,	O
6	purified	O
7	full	B
8	-	I
9	length	I
10	HPV	I
11	-	I
12	16	I
13	and	I
14	BPV	I
15	-	I
16	1	I
17	E2	I
18	proteins	I
19	bound	O
20	a	O
21	consensus	O
22	E2	B
23	site	I
24	with	O
25	high	O
26	specific	O
27	affinities	O
28	(	O
29	Kd	O
30	=	O
31	approximately	O
32	10	O
33	(-	O
34	9	O
35	)	O
36	M	O
37	)	O
38	and	O
39	stimulated	O
40	in	O
41	vitro	O
42	transcription	O
43	up	O
44	to	O
45	six	O
46	-	O
47	to	O
48	eightfold	O
49	.	O

1	During	O
2	organogenesis	O
3	,	O
4	HFH	B
5	-	I
6	8	I
7	expression	O
8	is	O
9	found	O
10	in	O
11	the	O
12	splanchnic	O
13	mesoderm	O
14	in	O
15	close	O
16	apposition	O
17	of	O
18	the	O
19	gut	O
20	endoderm	O
21	,	O
22	suggesting	O
23	a	O
24	role	O
25	in	O
26	mesenchymal	O
27	-	O
28	epithelial	O
29	induction	O
30	of	O
31	lung	O
32	and	O
33	gut	O
34	morphogenesis	O
35	.	O

1	The	O
2	method	O
3	has	O
4	been	O
5	satisfactorily	O
6	applied	O
7	to	O
8	the	O
9	determination	O
10	of	O
11	paracetamol	O
12	in	O
13	pharmaceutical	O
14	formulations	O
15	and	O
16	biological	O
17	fluids	O
18	.	O

1	Anesthesia	O
2	was	O
3	maintained	O
4	with	O
5	isoflurane	O
6	(	O
7	ISO	O
8	)/	O
9	N2O	O
10	/	O
11	O2	O
12	inhalation	O
13	.	O

1	This	O
2	study	O
3	was	O
4	undertaken	O
5	to	O
6	assess	O
7	the	O
8	effects	O
9	of	O
10	hypothermia	O
11	and	O
12	chemical	O
13	cardioplegia	O
14	on	O
15	the	O
16	functional	O
17	recovery	O
18	of	O
19	hypertrophied	O
20	non	O
21	-	O
22	failing	O
23	rat	O
24	hearts	O
25	subjected	O
26	to	O
27	an	O
28	extended	O
29	period	O
30	of	O
31	global	O
32	ischaemia	O
33	.	O

1	E2F	B
2	-	I
3	1	I
4	is	O
5	a	O
6	transcription	O
7	factor	O
8	that	O
9	regulates	O
10	cell	O
11	cycle	O
12	progression	O
13	into	O
14	S	O
15	-	O
16	phase	O
17	.	O

1	The	O
2	human	B
3	T	I
4	cell	I
5	leukemia	I
6	/	I
7	lymphotropic	I
8	virus	I
9	type	I
10	1	I
11	Tax	I
12	protein	I
13	represses	O
14	MyoD	B
15	-	O
16	dependent	O
17	transcription	O
18	by	O
19	inhibiting	O
20	MyoD	B
21	-	O
22	binding	O
23	to	O
24	the	O
25	KIX	B
26	domain	I
27	of	O
28	p300	B
29	.	O

1	Here	O
2	we	O
3	localize	O
4	a	O
5	transferable	O
6	40	O
7	-	O
8	amino	O
9	acid	O
10	region	O
11	within	O
12	the	O
13	LBDs	B
14	of	O
15	RXR	B
16	,	O
17	RAR	B
18	,	O
19	TR	B
20	,	O
21	and	O
22	chicken	B
23	ovalbumin	I
24	upstream	I
25	promoter	I
26	transcription	I
27	factor	I
28	that	O
29	is	O
30	critical	O
31	for	O
32	determining	O
33	identity	O
34	in	O
35	the	O
36	heterodimeric	O
37	interaction	O
38	and	O
39	for	O
40	high	O
41	-	O
42	affinity	O
43	DNA	O
44	binding	O
45	.	O

1	We	O
2	have	O
3	been	O
4	able	O
5	to	O
6	map	O
7	specific	O
8	DNA	O
9	fragments	O
10	at	O
11	the	O
12	bases	O
13	of	O
14	chromatin	O
15	loops	O
16	with	O
17	the	O
18	help	O
19	of	O
20	a	O
21	novel	O
22	extraction	O
23	procedure	O
24	by	O
25	using	O
26	lithium	O
27	-	O
28	3	O
29	',	O
30	5	O
31	'-	O
32	diiodosalicylate	O
33	.	O

1	Incubation	O
2	of	O
3	the	O
4	purified	O
5	fusion	O
6	proteins	O
7	with	O
8	[	O
9	gamma	O
10	-	O
11	32P	O
12	]	O
13	ATP	O
14	in	O
15	an	O
16	in	O
17	vitro	O
18	assay	O
19	showed	O
20	that	O
21	both	O
22	proteins	O
23	were	O
24	capable	O
25	of	O
26	autophosphorylation	O
27	.	O

1	However	O
2	,	O
3	one	O
4	CAK	B
5	-	O
6	phosphorylated	O
7	phosphopeptide	O
8	comigrates	O
9	with	O
10	a	O
11	Cdc2	B
12	-	O
13	phosphorylated	O
14	phosphopeptide	O
15	previously	O
16	shown	O
17	to	O
18	be	O
19	mitosis	O
20	-	O
21	specific	O
22	,	O
23	suggesting	O
24	that	O
25	,	O
26	in	O
27	vitro	O
28	,	O
29	CAK	B
30	is	O
31	able	O
32	to	O
33	phosphorylate	O
34	at	O
35	least	O
36	one	O
37	site	O
38	that	O
39	is	O
40	also	O
41	phosphorylated	O
42	in	O
43	vivo	O
44	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	,	O
6	for	O
7	a	O
8	constant	O
9	amount	O
10	of	O
11	transfected	O
12	DNA	O
13	,	O
14	the	O
15	level	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	(	O
20	CAT	B
21	)	O
22	mRNA	O
23	is	O
24	increased	O
25	in	O
26	Vpr	B
27	-	O
28	expressing	O
29	cells	O
30	using	O
31	either	O
32	HIV	O
33	-	O
34	1	O
35	or	O
36	a	O
37	murine	O
38	leukemia	B
39	virus	I
40	(	I
41	MLV	I
42	)	I
43	SL3	I
44	-	I
45	3	I
46	LTR	I
47	-	O
48	CAT	B
49	reporter	O
50	construct	O
51	.	O

1	UDP	B
2	-	I
3	GlcNAc	I
4	:	O
5	alpha	B
6	-	I
7	6	I
8	-	I
9	D	I
10	-	I
11	mannoside	I
12	beta	I
13	-	I
14	1	I
15	,	I
16	2	I
17	-	I
18	N	I
19	-	I
20	acetylglucosaminyltransferase	I
21	II	I
22	(	O
23	GnT	B
24	II	I
25	;	O
26	EC	B
27	2	I
28	.	I
29	4	I
30	.	I
31	1	I
32	.	I
33	143	I
34	)	O
35	is	O
36	essential	O
37	for	O
38	the	O
39	normal	O
40	assembly	O
41	of	O
42	complex	O
43	Asn	O
44	-	O
45	linked	O
46	glycans	O
47	.	O

1	Corticosteroid	O
2	therapy	O
3	is	O
4	known	O
5	to	O
6	be	O
7	hazardous	O
8	in	O
9	patients	O
10	with	O
11	occult	O
12	infection	O
13	but	O
14	the	O
15	mechanism	O
16	by	O
17	which	O
18	the	O
19	host	O
20	parasite	O
21	relationship	O
22	is	O
23	altered	O
24	by	O
25	steroids	O
26	is	O
27	not	O
28	known	O
29	.	O
30	We	O
31	have	O
32	used	O
33	an	O
34	intestinal	O
35	protozoal	O
36	parasite	O
37	,	O
38	Giardia	O
39	muris	O
40	,	O
41	to	O
42	examine	O
43	the	O
44	effects	O
45	of	O
46	corticosteroids	O
47	on	O
48	the	O
49	number	O
50	of	O
51	parasites	O
52	in	O
53	the	O
54	intestine	O
55	in	O
56	the	O
57	course	O
58	of	O
59	a	O
60	primary	O
61	infection	O
62	.	O

1	An	O
2	immunologically	O
3	related	O
4	protein	O
5	was	O
6	detected	O
7	in	O
8	ribosome	O
9	and	O
10	membrane	O
11	fractions	O
12	of	O
13	mitochondria	O
14	from	O
15	Saccharomyces	O
16	cerevisiae	O
17	.	O

1	Genesis	O
2	of	O
3	foam	O
4	cells	O
5	:	O
6	study	O
7	in	O
8	rats	O
9	after	O
10	administration	O
11	of	O
12	Cloforex	O
13	.	O

1	Deletions	O
2	in	O
3	each	O
4	of	O
5	these	O
6	regions	O
7	abolish	O
8	membrane	O
9	localization	O
10	of	O
11	Tiam1	B
12	and	O
13	membrane	O
14	ruffling	O
15	,	O
16	suggesting	O
17	that	O
18	they	O
19	function	O
20	cooperatively	O
21	.	O

1	Stromelysin	B
2	-	I
3	1	I
4	,	O
5	matrix	B
6	metalloproteinase	I
7	-	I
8	3	I
9	(	O
10	MMP	B
11	-	I
12	3	I
13	),	O
14	is	O
15	an	O
16	important	O
17	endopeptidase	O
18	selectively	O
19	expressed	O
20	by	O
21	somatic	O
22	cells	O
23	in	O
24	organ	O
25	tissues	O
26	.	O

1	From	O
2	250	O
3	g	O
4	of	O
5	cells	O
6	,	O
7	we	O
8	isolated	O
9	1	O
10	mg	O
11	of	O
12	PDH	B
13	complex	I
14	with	O
15	a	O
16	specific	O
17	activity	O
18	of	O
19	12	O
20	.	O
21	6	O
22	U	O
23	/	O
24	mg	O
25	of	O
26	protein	O
27	.	O

1	Lastly	O
2	,	O
3	there	O
4	are	O
5	multiple	O
6	instances	O
7	in	O
8	which	O
9	short	O
10	oligonucleotide	O
11	direct	O
12	repeats	O
13	flank	O
14	a	O
15	region	O
16	absent	O
17	from	O
18	either	O
19	variola	O
20	or	O
21	vaccinia	O
22	virus	O
23	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	Swi4	B
6	and	O
7	Swi6	B
8	cell	O
9	viability	O
10	is	O
11	lost	O
12	,	O
13	but	O
14	can	O
15	be	O
16	regained	O
17	by	O
18	ectopic	O
19	expression	O
20	of	O
21	the	O
22	G1	B
23	cyclin	I
24	encoding	I
25	genes	I
26	,	O
27	CLN1	B
28	or	O
29	CLN2	B
30	.	O

1	Hops	O
2	,	O
3	and	O
4	L	O
5	.	O

1	What	O
2	'	O
3	s	O
4	new	O
5	in	O
6	gynecologic	O
7	and	O
8	obstetrical	O
9	surgery	O
10	.	O

1	Liposomal	O
2	Amphotericin	O
3	-	O
4	B	O
5	failed	O
6	in	O
7	6	O
8	/	O
9	7	O
10	patients	O
11	with	O
12	culture	O
13	-	O
14	proven	O
15	mycosis	O
16	who	O
17	died	O
18	from	O
19	infection	O
20	with	O
21	Aspergillus	O
22	(	O
23	n	O
24	=	O
25	2	O
26	)	O
27	and	O
28	Candida	O
29	(	O
30	n	O
31	=	O
32	4	O
33	),	O
34	respectively	O
35	.	O

1	Two	O
2	related	O
3	studies	O
4	conducted	O
5	over	O
6	a	O
7	five	O
8	week	O
9	period	O
10	measured	O
11	and	O
12	typed	O
13	HLA	B
14	-	I
15	DQA1	I
16	from	O
17	accumulated	O
18	DNA	O
19	on	O
20	autopsy	O
21	room	O
22	and	O
23	Forensic	O
24	DNA	O
25	Laboratory	O
26	structures	O
27	.	O

1	Prospects	O
2	for	O
3	controlled	O
4	-	O
5	delivery	O
6	systems	O
7	.	O

1	We	O
2	recently	O
3	found	O
4	that	O
5	17	O
6	beta	O
7	-	O
8	estradiol	O
9	(	O
10	E2	O
11	)	O
12	not	O
13	only	O
14	suppresses	O
15	bone	O
16	resorption	O
17	but	O
18	also	O
19	stimulates	O
20	bone	O
21	formation	O
22	in	O
23	the	O
24	cancellous	O
25	bone	O
26	of	O
27	female	O
28	rats	O
29	.	O

1	We	O
2	purified	O
3	a	O
4	Ca2	B
5	+/	I
6	calmodulin	I
7	(	I
8	CaM	I
9	)-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	O
14	CaM	B
15	kinase	I
16	)	O
17	from	O
18	the	O
19	yeast	O
20	Saccharomyces	O
21	cerevisiae	O
22	with	O
23	properties	O
24	similar	O
25	to	O
26	mammalian	B
27	type	I
28	II	I
29	CaM	I
30	kinases	I
31	.	O

1	Fenoldopam	O
2	,	O
3	a	O
4	dopamine	B
5	receptor	I
6	agonist	O
7	,	O
8	has	O
9	been	O
10	shown	O
11	,	O
12	in	O
13	animal	O
14	experiments	O
15	,	O
16	to	O
17	improve	O
18	renal	O
19	perfusion	O
20	.	O

1	Experience	O
2	with	O
3	the	O
4	restoration	O
5	of	O
6	agglutination	O
7	properties	O
8	of	O
9	non	O
10	-	O
11	agglutinating	O
12	dysenterial	O
13	cultures	O
14	with	O
15	the	O
16	use	O
17	of	O
18	Rzhaninov	O
19	'	O
20	s	O
21	method	O

1	During	O
2	the	O
3	observation	O
4	period	O
5	of	O
6	0	O
7	.	O
8	4	O
9	-	O
10	30	O
11	weeks	O
12	,	O
13	cardiac	O
14	white	O
15	spots	O
16	on	O
17	the	O
18	right	O
19	ventricle	O
20	of	O
21	BALB	O
22	/	O
23	c	O
24	mice	O
25	were	O
26	first	O
27	detected	O
28	at	O
29	three	O
30	weeks	O
31	(	O
32	6	O
33	of	O
34	20	O
35	mice	O
36	;	O
37	30	O
38	%),	O
39	and	O
40	the	O
41	maximal	O
42	incidence	O
43	of	O
44	cardiac	O
45	white	O
46	spots	O
47	was	O
48	obtained	O
49	at	O
50	nine	O
51	weeks	O
52	(	O
53	39	O
54	of	O
55	44	O
56	mice	O
57	;	O
58	88	O
59	%).	O

1	Despite	O
2	the	O
3	activation	O
4	of	O
5	these	O
6	intracellular	O
7	signaling	O
8	molecules	O
9	,	O
10	PDGF	B
11	beta	I
12	receptor	I
13	activation	O
14	elicited	O
15	no	O
16	detectable	O
17	effect	O
18	on	O
19	cell	O
20	proliferation	O
21	or	O
22	differentiation	O
23	.	O

1	The	O
2	genetic	O
3	basis	O
4	for	O
5	the	O
6	expression	O
7	of	O
8	a	O
9	latent	O
10	VH	B
11	allotype	I
12	in	O
13	the	O
14	rabbit	O
15	was	O
16	investigated	O
17	.	O

1	Amikacin	O
2	was	O
3	used	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	56	O
9	serious	O
10	gram	O
11	-	O
12	negative	O
13	infections	O
14	in	O
15	54	O
16	patients	O
17	of	O
18	whom	O
19	47	O
20	survived	O
21	.	O

1	Sputum	B
2	IL	I
3	-	I
4	8	I
5	and	O
6	MPO	B
7	were	O
8	significantly	O
9	increased	O
10	after	O
11	BPT	O
12	in	O
13	both	O
14	TDI	O
15	-	O
16	and	O
17	grain	O
18	dust	O
19	-	O
20	asthma	O
21	(	O
22	P	O
23	<	O
24	0	O
25	.	O
26	05	O
27	).	O

1	CM	B
2	-	I
3	ACO3	I
4	is	O
5	expressed	O
6	in	O
7	flowers	O
8	and	O
9	is	O
10	not	O
11	induced	O
12	by	O
13	any	O
14	of	O
15	the	O
16	stimuli	O
17	tested	O
18	.	O

1	The	O
2	retention	O
3	of	O
4	75SeHCAT	O
5	was	O
6	low	O
7	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Thr115	O
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	MyoD	B
16	function	O
17	under	O
18	conditions	O
19	of	O
20	high	O
21	mitogenesis	O
22	.	O

1	We	O
2	describe	O
3	a	O
4	case	O
5	of	O
6	a	O
7	perinephric	O
8	abscess	O
9	treated	O
10	with	O
11	amphotericin	O
12	B	O
13	and	O
14	nephrectomy	O
15	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	G	B
6	beta	I
7	gamma	I
8	-	O
9	stimulated	O
10	Shc	B
11	phosphorylation	O
12	represents	O
13	an	O
14	early	O
15	step	O
16	in	O
17	the	O
18	pathway	O
19	leading	O
20	to	O
21	p21ras	B
22	activation	O
23	,	O
24	similar	O
25	to	O
26	the	O
27	mechanism	O
28	utilized	O
29	by	O
30	growth	B
31	factor	I
32	tyrosine	I
33	kinase	I
34	receptors	I
35	.	O

1	We	O
2	could	O
3	demonstrate	O
4	the	O
5	involvement	O
6	of	O
7	cAMP	B
8	-	I
9	dependent	I
10	protein	I
11	kinase	I
12	(	O
13	PKA	B
14	)	O
15	in	O
16	the	O
17	phosphorylation	O
18	of	O
19	CDC25Mm	B
20	in	O
21	fibroblasts	O
22	overexpressing	O
23	this	O
24	RasGEF	B
25	as	O
26	well	O
27	as	O
28	in	O
29	mouse	O
30	brain	O
31	synaptosomal	O
32	membranes	O
33	.	O

1	The	O
2	pattern	O
3	and	O
4	timing	O
5	of	O
6	CARP	B
7	mRNA	I
8	expression	O
9	,	O
10	including	O
11	transient	O
12	expression	O
13	in	O
14	the	O
15	tongue	O
16	at	O
17	14	O
18	.	O
19	5	O
20	days	O
21	p	O
22	.	O
23	c	O
24	.,	O
25	coincides	O
26	with	O
27	that	O
28	of	O
29	Nkx2	B
30	.	I
31	5	I
32	/	O
33	Csx	B
34	(	O
35	a	O
36	putative	O
37	homolog	O
38	of	O
39	tinman	B
40	,	O
41	the	O
42	Drosophila	O
43	melanogaster	O
44	gene	O
45	responsible	O
46	for	O
47	cardiac	O
48	development	O
49	).	O

1	Renal	O
2	cell	O
3	carcinoma	O
4	in	O
5	children	O
6	:	O
7	a	O
8	single	O
9	institution	O
10	'	O
11	s	O
12	experience	O
13	.	O

1	Several	O
2	different	O
3	oncogenes	O
4	and	O
5	growth	O
6	factors	O
7	promote	O
8	G1	O
9	phase	O
10	progression	O
11	.	O

1	Isolation	O
2	of	O
3	Aeromonas	O
4	from	O
5	faeces	O
6	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	repressor	O
6	locus	O
7	,	O
8	c	O
9	,	O
10	of	O
11	the	O
12	Streptomyces	O
13	temperate	O
14	phage	O
15	,	O
16	phi	O
17	C31	O
18	,	O
19	was	O
20	shown	O
21	previously	O
22	to	O
23	contain	O
24	an	O
25	open	O
26	reading	O
27	frame	O
28	encoding	O
29	a	O
30	74	O
31	kDa	O
32	protein	O
33	.	O

1	Evaluation	O
2	of	O
3	thyroid	O
4	function	O
5	.	O

1	The	O
2	0	O
3	.	O
4	22	O
5	-	O
6	kb	O
7	NheI	B
8	/	O
9	BglII	B
10	promoter	O
11	exhibited	O
12	PMA	O
13	inducibility	O
14	in	O
15	myeloid	O
16	cells	O
17	and	O
18	contained	O
19	a	O
20	PMA	O
21	-	O
22	responsive	O
23	element	O
24	recognized	O
25	by	O
26	Sp1	B
27	and	O
28	EGR	B
29	-	I
30	1	I
31	transcription	I
32	factors	I
33	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	LIM	B
7	domain	I
8	homeobox	I
9	protein	I
10	isl	I
11	-	I
12	1	I
13	activates	O
14	the	O
15	rat	B
16	amylin	I
17	promoter	I
18	in	O
19	both	O
20	fibroblast	O
21	and	O
22	islet	O
23	cell	O
24	lines	O
25	.	O

1	The	O
2	present	O
3	investigation	O
4	conducted	O
5	in	O
6	a	O
7	population	O
8	of	O
9	258	O
10	dentally	O
11	aware	O
12	individuals	O
13	in	O
14	the	O
15	age	O
16	range	O
17	20	O
18	-	O
19	69	O
20	years	O
21	,	O
22	was	O
23	initiated	O
24	to	O
25	elucidate	O
26	the	O
27	relationship	O
28	between	O
29	tobacco	O
30	smoking	O
31	and	O
32	supragingival	O
33	calculus	O
34	,	O
35	taking	O
36	into	O
37	account	O
38	possible	O
39	confounding	O
40	factors	O
41	such	O
42	as	O
43	age	O
44	,	O
45	gender	O
46	,	O
47	oral	O
48	hygiene	O
49	and	O
50	gingival	O
51	inflammation	O
52	.	O

1	Secondary	O
2	pancreatic	O
3	involvement	O
4	of	O
5	mycosis	O
6	fungoides	O
7	detected	O
8	by	O
9	a	O
10	clinically	O
11	palpable	O
12	mass	O
13	.	O

1	Tobramycin	O
2	60	O
3	mg	O
4	did	O
5	not	O
6	show	O
7	any	O
8	remarkable	O
9	effect	O
10	,	O
11	but	O
12	dibecacin	O
13	100	O
14	mg	O
15	produced	O
16	a	O
17	slight	O
18	potentiating	O
19	effect	O
20	on	O
21	the	O
22	action	O
23	of	O
24	d	O
25	-	O
26	tubocurarine	O
27	.	O

1	Plots	O
2	of	O
3	RV	O
4	,	O
5	LV	O
6	+	O
7	S	O
8	and	O
9	2A	O
10	weight	O
11	vs	O
12	real	O
13	hematocrit	O
14	showed	O
15	sharp	O
16	upward	O
17	inflections	O
18	at	O
19	real	O
20	hematocrit	O
21	65	O
22	%,	O
23	suggesting	O
24	a	O
25	possible	O
26	role	O
27	of	O
28	increased	O
29	viscosity	O
30	in	O
31	CO	O
32	cardiomegaly	O
33	at	O
34	the	O
35	higher	O
36	hematocrit	O
37	.	O

1	Along	O
2	with	O
3	previously	O
4	mapped	O
5	genes	O
6	including	O
7	Ly	B
8	-	I
9	1	I
10	and	O
11	CD20	B
12	,	O
13	OSBP	B
14	defines	O
15	a	O
16	new	O
17	conserved	O
18	syntenic	O
19	group	O
20	on	O
21	the	O
22	long	O
23	arm	O
24	of	O
25	chromosome	O
26	11	O
27	in	O
28	the	O
29	human	O
30	and	O
31	the	O
32	proximal	O
33	end	O
34	of	O
35	chromosome	O
36	19	O
37	in	O
38	the	O
39	mouse	O
40	.	O

1	To	O
2	assess	O
3	the	O
4	ability	O
5	of	O
6	the	O
7	atria	O
8	to	O
9	maintain	O
10	elevated	O
11	plasma	O
12	concentrations	O
13	of	O
14	atrial	B
15	natriuretic	I
16	peptide	I
17	(	O
18	ANP	B
19	),	O
20	the	O
21	temporal	O
22	changes	O
23	in	O
24	plasma	B
25	ANP	I
26	concentrations	O
27	were	O
28	studied	O
29	in	O
30	seven	O
31	chloralose	O
32	-	O
33	anaesthetized	O
34	dogs	O
35	during	O
36	4	O
37	h	O
38	of	O
39	sustained	O
40	rapid	O
41	cardiac	O
42	pacing	O
43	.	O

1	MBI	O
2	and	O
3	MMBI	O
4	showed	O
5	similar	O
6	Cmax	O
7	values	O
8	,	O
9	but	O
10	the	O
11	former	O
12	disappeared	O
13	slower	O
14	in	O
15	the	O
16	serum	O
17	than	O
18	the	O
19	latter	O
20	and	O
21	resulted	O
22	in	O
23	its	O
24	larger	O
25	AUC	O
26	values	O
27	.	O

1	This	O
2	Mr	O
3	is	O
4	similar	O
5	to	O
6	those	O
7	of	O
8	the	O
9	purified	B
10	smg	I
11	p25A	I
12	GDI	I
13	estimated	O
14	by	O
15	sodium	O
16	dodecyl	O
17	sulfate	O
18	-	O
19	polyacrylamide	O
20	gel	O
21	electrophoresis	O
22	and	O
23	sucrose	O
24	density	O
25	gradient	O
26	ultracentrifugation	O
27	,	O
28	which	O
29	are	O
30	about	O
31	54	O
32	,	O
33	000	O
34	and	O
35	65	O
36	,	O
37	000	O
38	,	O
39	respectively	O
40	.	O

1	Since	O
2	each	O
3	transcript	O
4	appears	O
5	to	O
6	encode	O
7	the	O
8	same	O
9	protein	O
10	,	O
11	this	O
12	complexity	O
13	may	O
14	reflect	O
15	the	O
16	need	O
17	for	O
18	lineage	O
19	-	O
20	specific	O
21	or	O
22	differentiation	O
23	-	O
24	dependent	O
25	control	O
26	of	O
27	expression	O
28	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	CBF	B
6	-	I
7	A	I
8	is	O
9	a	O
10	novel	O
11	CArG	O
12	box	O
13	-,	O
14	ssDNA	B
15	-	I
16	and	I
17	RNA	I
18	-	I
19	binding	I
20	protein	I
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	repressive	O
27	transcriptional	O
28	factor	O
29	.	O

1	They	O
2	contrast	O
3	trends	O
4	in	O
5	fertility	O
6	,	O
7	life	O
8	expectancy	O
9	ratios	O
10	,	O
11	and	O
12	gender	O
13	differences	O
14	in	O
15	these	O
16	countries	O
17	with	O
18	the	O
19	Hispanic	O
20	population	O
21	of	O
22	the	O
23	United	O
24	States	O
25	.	O

1	Human	B
2	alpha	I
3	-	I
4	galactosidase	I
5	A	I
6	:	O
7	nucleotide	O
8	sequence	O
9	of	O
10	a	O
11	cDNA	O
12	clone	O
13	encoding	O
14	the	O
15	mature	O
16	enzyme	O
17	.	O

1	We	O
2	demonstrate	O
3	here	O
4	that	O
5	the	O
6	-	O
7	DEDDDL	O
8	sequence	O
9	stabilizes	O
10	GDP	O
11	binding	O
12	to	O
13	Ran	B
14	,	O
15	and	O
16	that	O
17	the	O
18	domain	O
19	is	O
20	required	O
21	for	O
22	high	O
23	affinity	O
24	interaction	O
25	with	O
26	a	O
27	Ran	B
28	-	I
29	binding	I
30	protein	I
31	,	O
32	HTF9A	B
33	/	O
34	RanBP1	B
35	.	O

1	Observation	O
2	of	O
3	dipolar	O
4	interactions	O
5	between	O
6	Pb0	O
7	defects	O
8	at	O
9	the	O
10	(	O
11	111	O
12	)	O
13	Si	O
14	/	O
15	SiO2	O
16	interface	O
17	.	O

1	Dopamine	B
2	receptor	I
3	blockade	O
4	and	O
5	the	O
6	neuroleptics	O
7	,	O
8	a	O
9	crystallographic	O
10	study	O
11	.	O

1	Thus	O
2	,	O
3	YMIP	B
4	is	O
5	a	O
6	functional	O
7	homolog	O
8	of	O
9	RMIP	B
10	and	O
11	represents	O
12	a	O
13	new	O
14	component	O
15	of	O
16	the	O
17	yeast	O
18	mitochondrial	O
19	import	O
20	machinery	O
21	.	O

1	RESULTS	O
2	:	O
3	The	O
4	main	O
5	effect	O
6	of	O
7	muscle	O
8	pain	O
9	,	O
10	compared	O
11	to	O
12	non	O
13	-	O
14	painful	O
15	stimulation	O
16	,	O
17	was	O
18	a	O
19	significant	O
20	and	O
21	long	O
22	-	O
23	lasting	O
24	increase	O
25	of	O
26	delta	O
27	(	O
28	1	O
29	-	O
30	3	O
31	Hz	O
32	)	O
33	power	O
34	and	O
35	an	O
36	alpha	O
37	-	O
38	1	O
39	(	O
40	9	O
41	-	O
42	11	O
43	Hz	O
44	)	O
45	power	O
46	increase	O
47	over	O
48	the	O
49	contralateral	O
50	parietal	O
51	locus	O
52	.	O

1	Like	O
2	humans	O
3	,	O
4	the	O
5	PITSLRE	B
6	PK	I
7	genes	I
8	in	I
9	chickens	I
10	must	O
11	be	O
12	closely	O
13	linked	O
14	,	O
15	based	O
16	on	O
17	fluorescent	O
18	in	O
19	situ	O
20	hybridization	O
21	(	O
22	FISH	O
23	)	O
24	localization	O
25	of	O
26	these	O
27	genes	O
28	to	O
29	a	O
30	single	O
31	chicken	O
32	microchromosome	O
33	.	O

1	Practical	O
2	interest	O
3	of	O
4	such	O
5	studies	O
6	is	O
7	limited	O
8	since	O
9	the	O
10	pharmacokinetic	O
11	parameters	O
12	are	O
13	systematically	O
14	evaluated	O
15	in	O
16	man	O
17	during	O
18	phase	O
19	I	O
20	trials	O
21	.	O

1	Sensory	O
2	kindling	O
3	:	O
4	implications	O
5	for	O
6	development	O
7	of	O
8	sensory	O
9	prostheses	O
10	.	O

1	In	O
2	addition	O
3	,	O
4	26	O
5	amino	O
6	acid	O
7	residues	O
8	,	O
9	K69	O
10	,	O
11	D88	O
12	,	O
13	E94	O
14	,	O
15	D134	O
16	,	O
17	R154	O
18	,	O
19	K169	O
20	,	O
21	H197	O
22	,	O
23	D233	O
24	,	O
25	G235	O
26	,	O
27	G236	O
28	,	O
29	G237	O
30	,	O
31	F238	O
32	,	O
33	E274	O
34	,	O
35	G276	O
36	,	O
37	R277	O
38	,	O
39	Y278	O
40	,	O
41	K294	O
42	,	O
43	Y323	O
44	,	O
45	Y331	O
46	,	O
47	D332	O
48	,	O
49	C360	O
50	,	O
51	D361	O
52	,	O
53	D364	O
54	,	O
55	G387	O
56	,	O
57	Y389	O
58	,	O
59	and	O
60	F397	O
61	(	O
62	mouse	O
63	ODC	B
64	numbering	O
65	),	O
66	all	O
67	of	O
68	which	O
69	are	O
70	implicated	O
71	in	O
72	the	O
73	formation	O
74	of	O
75	the	O
76	pyridoxal	O
77	phosphate	O
78	-	O
79	binding	O
80	domain	O
81	and	O
82	the	O
83	substrate	O
84	-	O
85	binding	O
86	domain	O
87	and	O
88	in	O
89	dimer	O
90	stabilization	O
91	with	O
92	the	O
93	eukaryotic	O
94	ODCs	B
95	,	O
96	were	O
97	also	O
98	conserved	O
99	in	O
100	S	O
101	.	O
102	ruminantium	O
103	LDC	B
104	.	O

1	Pulmonary	O
2	arterial	O
3	pressure	O
4	and	O
5	structure	O
6	in	O
7	the	O
8	patas	O
9	monkey	O
10	after	O
11	prolonged	O
12	administration	O
13	of	O
14	aminorex	O
15	fumarate	O
16	.	O

1	Liver	O
2	dysfunction	O
3	in	O
4	the	O
5	presence	O
6	of	O
7	different	O
8	adverse	O
9	reactions	O
10	presented	O
11	with	O
12	a	O
13	higher	O
14	activity	O
15	in	O
16	the	O
17	blood	O
18	serum	O
19	of	O
20	indicator	O
21	liver	O
22	enzymes	O
23	and	O
24	its	O
25	impaired	O
26	protein	O
27	-	O
28	forming	O
29	function	O
30	.	O

1	Working	O
2	session	O
3	report	O
4	:	O
5	in	O
6	vivo	O
7	-	O
8	in	O
9	vitro	O
10	screening	O
11	.	O

1	The	O
2	SH2	B
3	domain	I
4	-	I
5	containing	I
6	inositol	I
7	5	I
8	'-	I
9	phosphatase	I
10	(	O
11	SHIP	B
12	)	O
13	recruits	O
14	the	O
15	p85	B
16	subunit	I
17	of	O
18	phosphoinositide	B
19	3	I
20	-	I
21	kinase	I
22	during	O
23	FcgammaRIIb1	B
24	-	O
25	mediated	O
26	inhibition	O
27	of	O
28	B	B
29	cell	I
30	receptor	I
31	signaling	O
32	.	O

1	The	O
2	PRB	B
3	-	I
4	1b	I
5	gene	I
6	encodes	O
7	for	O
8	a	O
9	basic	O
10	-	O
11	type	O
12	component	O
13	of	O
14	the	O
15	pathogenesis	O
16	-	O
17	related	O
18	PR	B
19	-	I
20	1	I
21	protein	I
22	family	I
23	.	O

1	Both	O
2	classes	O
3	of	O
4	MHBst	B
5	proteins	I
6	were	O
7	found	O
8	to	O
9	form	O
10	dimers	O
11	;	O
12	an	O
13	which	O
14	is	O
15	involved	O
16	in	O
17	mediating	O
18	the	O
19	dimerization	O
20	.	O

1	Optimal	O
2	monitoring	O
3	of	O
4	ODA	O
5	remains	O
6	undefined	O
7	.	O

1	Genomic	O
2	organization	O
3	of	O
4	the	O
5	human	O
6	phosphodiesterase	B
7	PDE11A	I
8	gene	I
9	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	transcription	O
6	of	O
7	c	B
8	-	I
9	IAP2	I
10	promoter	I
11	was	O
12	strongly	O
13	up	O
14	-	O
15	regulated	O
16	when	O
17	CD40	B
18	or	O
19	Epstein	B
20	-	I
21	Barr	I
22	virus	I
23	latent	I
24	membrane	I
25	protein	I
26	1	I
27	was	O
28	overexpressed	O
29	.	O

1	We	O
2	found	O
3	sequences	O
4	related	O
5	to	O
6	this	O
7	insertion	O
8	in	O
9	wild	O
10	-	O
11	type	O
12	strains	O
13	of	O
14	N	O
15	.	O
16	crassa	O
17	and	O
18	other	O
19	Neurospora	O
20	species	O
21	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	identified	O
8	as	O
9	CACGTGACCCG	O
10	,	O
11	is	O
12	located	O
13	34	O
14	bp	O
15	upstream	O
16	from	O
17	the	O
18	transcription	O
19	initiation	O
20	site	O
21	,	O
22	and	O
23	contains	O
24	the	O
25	core	O
26	sequence	O
27	of	O
28	the	O
29	upstream	O
30	promoter	O
31	sequence	O
32	of	O
33	Ad2MLP	B
34	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	show	O
8	that	O
9	SRm160	B
10	/	I
11	300	I
12	is	O
13	required	O
14	for	O
15	a	O
16	purine	O
17	-	O
18	rich	O
19	ESE	B
20	to	O
21	promote	O
22	the	O
23	splicing	O
24	of	O
25	a	O
26	pre	O
27	-	O
28	mRNA	O
29	derived	O
30	from	O
31	the	O
32	Drosophila	B
33	doublesex	I
34	gene	I
35	.	O

1	The	O
2	bZP2	O
3	cDNA	O
4	(	O
5	115	O
6	-	O
7	1914	O
8	nt	O
9	,	O
10	1	O
11	.	O
12	8	O
13	kb	O
14	),	O
15	excluding	O
16	sequences	O
17	coding	O
18	for	O
19	N	O
20	-	O
21	terminal	O
22	signal	O
23	sequence	O
24	and	O
25	C	O
26	-	O
27	terminal	O
28	transmembranelike	O
29	domain	O
30	,	O
31	was	O
32	PCR	O
33	amplified	O
34	and	O
35	Sac1	B
36	-	O
37	Sal1	B
38	restricted	O
39	fragment	O
40	cloned	O
41	in	O
42	frame	O
43	downstream	O
44	of	O
45	the	O
46	T5	O
47	promoter	O
48	under	O
49	the	O
50	lac	B
51	operator	I
52	control	O
53	in	O
54	a	O
55	pQE	O
56	-	O
57	30	O
58	vector	O
59	.	O

1	The	O
2	data	O
3	indicates	O
4	the	O
5	presence	O
6	of	O
7	5	B
8	-	I
9	HT2	I
10	serotonergic	I
11	receptors	I
12	in	O
13	the	O
14	bronchial	O
15	artery	O
16	of	O
17	these	O
18	species	O
19	.	O

1	The	O
2	cellular	O
3	sequences	O
4	5	O
5	'	O
6	to	O
7	the	O
8	viral	O
9	integration	O
10	site	O
11	exhibited	O
12	85	O
13	to	O
14	97	O
15	%	O
16	identity	O
17	to	O
18	several	O
19	sequences	O
20	belonging	O
21	to	O
22	the	O
23	mouse	B
24	L1	I
25	family	I
26	of	O
27	long	O
28	interspersed	O
29	repetitive	O
30	sequences	O
31	.	O

1	The	O
2	purified	O
3	recombinant	O
4	protein	O
5	was	O
6	assayed	O
7	for	O
8	its	O
9	enzyme	O
10	activity	O
11	by	O
12	monitoring	O
13	transfer	O
14	of	O
15	[	O
16	3H	O
17	]	O
18	methyl	O
19	groups	O
20	from	O
21	the	O
22	substrate	O
23	DNA	O
24	to	O
25	the	O
26	MGMT	B
27	protein	I
28	;	O
29	the	O
30	activity	O
31	was	O
32	found	O
33	to	O
34	be	O
35	stable	O
36	at	O
37	90	O
38	degrees	O
39	C	O
40	for	O
41	at	O
42	least	O
43	30	O
44	min	O
45	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	a	O
5	new	O
6	human	O
7	lymphocyte	O
8	cell	O
9	surface	O
10	molecule	O
11	has	O
12	been	O
13	isolated	O
14	and	O
15	shown	O
16	to	O
17	identify	O
18	a	O
19	fourth	O
20	member	O
21	of	O
22	a	O
23	recently	O
24	discovered	O
25	family	O
26	of	O
27	adhesion	O
28	proteins	O
29	.	O

1	The	O
2	HOI	O
3	induced	O
4	a	O
5	nearly	O
6	fourfold	O
7	increase	O
8	in	O
9	ANF	B
10	in	O
11	the	O
12	elderly	O
13	,	O
14	whereas	O
15	that	O
16	for	O
17	the	O
18	young	O
19	was	O
20	threefold	O
21	.	O

1	To	O
2	further	O
3	understand	O
4	the	O
5	role	O
6	of	O
7	cis	O
8	-	O
9	acting	O
10	elements	O
11	in	O
12	these	O
13	regulatory	O
14	mechanisms	O
15	,	O
16	we	O
17	have	O
18	characterized	O
19	a	O
20	transcriptional	O
21	promoter	O
22	that	O
23	drives	O
24	germline	O
25	expression	O
26	of	O
27	TCR	B
28	beta	I
29	gene	I
30	segments	I
31	in	O
32	vivo	O
33	.	O

1	Thus	O
2	,	O
3	as	O
4	expected	O
5	,	O
6	trans	O
7	-	O
8	splicing	O
9	depends	O
10	on	O
11	the	O
12	integrity	O
13	of	O
14	U2	B
15	,	O
16	U4	B
17	,	O
18	and	O
19	U6	B
20	snRNAs	I
21	.	O

1	Two	O
2	activities	O
3	of	O
4	the	O
5	D	B
6	protein	I
7	of	O
8	the	O
9	miniF	O
10	plasmid	O
11	have	O
12	been	O
13	found	O
14	.	O

1	Analyses	O
2	of	O
3	additional	O
4	tumors	O
5	induced	O
6	in	O
7	mice	O
8	from	O
9	two	O
10	reciprocal	O
11	crosses	O
12	,	O
13	A	O
14	/	O
15	J	O
16	x	O
17	C3H	O
18	/	O
19	HeJ	O
20	F1	O
21	(	O
22	hereafter	O
23	called	O
24	AC3F1	O
25	)	O
26	and	O
27	C3H	O
28	/	O
29	HeJ	O
30	x	O
31	A	O
32	/	O
33	J	O
34	F1	O
35	(	O
36	hereafter	O
37	called	O
38	C3AF1	O
39	),	O
40	provided	O
41	evidence	O
42	for	O
43	the	O
44	inactivation	O
45	of	O
46	one	O
47	allele	O
48	of	O
49	the	O
50	putative	O
51	chromosome	O
52	4	O
53	tumor	O
54	suppressor	O
55	gene	O
56	by	O
57	parental	O
58	imprinting	O
59	.	O

1	Review	O
2	:	O
3	deterioration	O
4	of	O
5	glucose	O
6	tolerance	O
7	with	O
8	age	O
9	:	O
10	the	O
11	role	O
12	of	O
13	insulin	B
14	resistance	O
15	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	diagnostic	O
6	validity	O
7	of	O
8	NFPD	O
9	in	O
10	CP	O
11	/	O
12	NCA	O
13	patients	O
14	,	O
15	because	O
16	such	O
17	patients	O
18	had	O
19	a	O
20	family	O
21	history	O
22	of	O
23	panic	O
24	disorder	O
25	similar	O
26	to	O
27	patients	O
28	with	O
29	a	O
30	more	O
31	classical	O
32	panic	O
33	disorder	O
34	presentation	O
35	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	open	O
7	-	O
8	section	O
9	effect	O
10	decreases	O
11	the	O
12	torsional	O
13	stiffness	O
14	and	O
15	stress	O
16	concentration	O
17	effects	O
18	decrease	O
19	the	O
20	torsional	O
21	strength	O
22	of	O
23	a	O
24	long	O
25	bone	O
26	with	O
27	a	O
28	longitudinal	O
29	defect	O
30	.	O

1	The	O
2	asymmetric	O
3	methylation	O
4	was	O
5	associated	O
6	with	O
7	tissue	O
8	-	O
9	specific	O
10	disruption	O
11	of	O
12	H19	B
13	genomic	O
14	imprinting	O
15	in	O
16	fetal	O
17	brain	O
18	.	O

1	19	O
2	-	O
3	32	O
4	.	O

1	These	O
2	risk	O
3	factors	O
4	can	O
5	be	O
6	divided	O
7	into	O
8	2	O
9	groups	O
10	:	O
11	local	O
12	vessel	O
13	wall	O
14	-	O
15	related	O
16	factors	O
17	,	O
18	and	O
19	local	O
20	(	O
21	focal	O
22	action	O
23	)	O
24	systemic	O
25	factors	O
26	.	O

1	We	O
2	speculate	O
3	that	O
4	these	O
5	tumors	O
6	may	O
7	represent	O
8	congenital	O
9	hamartomatous	O
10	growths	O
11	.	O

1	The	O
2	epitope	O
3	-	O
4	protected	O
5	lysine	O
6	(	O
7	K	O
8	)	O
9	was	O
10	present	O
11	in	O
12	a	O
13	30	B
14	-	I
15	aa	I
16	TPO	I
17	fragment	I
18	that	O
19	,	O
20	by	O
21	N	O
22	-	O
23	terminal	O
24	sequencing	O
25	,	O
26	was	O
27	found	O
28	to	O
29	be	O
30	K713	O
31	.	O

1	The	O
2	arginyl	O
3	peptide	O
4	bonds	O
5	that	O
6	are	O
7	cleaved	O
8	in	O
9	the	O
10	conversion	O
11	of	O
12	human	B
13	factor	I
14	IX	I
15	to	O
16	factor	B
17	IXa	I
18	by	O
19	factor	B
20	XIa	I
21	were	O
22	identified	O
23	as	O
24	Arg145	O
25	-	O
26	Ala146	O
27	and	O
28	Arg180	O
29	-	O
30	Val181	O
31	.	O

1	Downregulation	O
2	of	O
3	FUS	B
4	expression	O
5	in	O
6	BCR	B
7	/	O
8	ABL	B
9	-	O
10	expressing	O
11	32Dcl3	O
12	cells	O
13	was	O
14	associated	O
15	with	O
16	suppression	O
17	of	O
18	growth	O
19	factor	O
20	-	O
21	independent	O
22	colony	O
23	formation	O
24	,	O
25	restoration	O
26	of	O
27	G	B
28	-	I
29	CSF	I
30	-	O
31	induced	O
32	granulocytic	O
33	differentiation	O
34	and	O
35	reduced	O
36	tumorigenic	O
37	potential	O
38	in	O
39	vivo	O
40	.	O

1	In	O
2	the	O
3	TLE	O
4	patients	O
5	the	O
6	NAA	O
7	:	O
8	Cr	O
9	ratios	O
10	were	O
11	reduced	O
12	in	O
13	the	O
14	seizure	O
15	focus	O
16	,	O
17	while	O
18	in	O
19	the	O
20	FLE	O
21	patients	O
22	they	O
23	were	O
24	not	O
25	always	O
26	reduced	O
27	in	O
28	the	O
29	seizure	O
30	focus	O
31	.	O

1	Independent	O
2	splicing	O
3	events	O
4	involve	O
5	three	O
6	previously	O
7	described	O
8	cassette	O
9	exons	O
10	,	O
11	which	O
12	are	O
13	predicted	O
14	to	O
15	encode	O
16	most	O
17	of	O
18	the	O
19	second	O
20	transmembrane	O
21	domain	O
22	.	O

1	Furthermore	O
2	,	O
3	RING1	B
4	overexpression	O
5	results	O
6	in	O
7	enhanced	O
8	expression	O
9	of	O
10	the	O
11	proto	O
12	-	O
13	oncogenes	O
14	c	B
15	-	I
16	jun	I
17	and	O
18	c	B
19	-	I
20	fos	I
21	.	O

1	The	O
2	divergence	O
3	in	O
4	primary	O
5	structure	O
6	between	O
7	the	O
8	sheep	O
9	CRF1	B
10	and	O
11	the	O
12	other	O
13	mammalian	B
14	CRF1s	I
15	is	O
16	primarily	O
17	localized	O
18	to	O
19	the	O
20	extracellular	O
21	amino	O
22	terminal	O
23	domain	O
24	of	O
25	the	O
26	receptor	O
27	(	O
28	18	O
29	of	O
30	22	O
31	divergent	O
32	residues	O
33	,	O
34	ovine	O
35	vs	O
36	human	B
37	CRF1	I
38	).	O

1	Differential	O
2	screening	O
3	of	O
4	mitochondrial	O
5	cDNA	O
6	libraries	O
7	from	O
8	male	O
9	-	O
10	fertile	O
11	and	O
12	cytoplasmic	O
13	male	O
14	-	O
15	sterile	O
16	sugar	O
17	-	O
18	beet	O
19	reveals	O
20	genome	O
21	rearrangements	O
22	at	O
23	atp6	B
24	and	O
25	atpA	B
26	loci	I
27	.	O

1	Slowed	O
2	lysosomal	B
3	enzyme	I
4	release	O
5	and	O
6	its	O
7	normalization	O
8	by	O
9	drugs	O
10	in	O
11	adjuvant	O
12	-	O
13	induced	O
14	polyarthritis	O
15	.	O

1	Oncostatin	B
2	M	I
3	stimulates	O
4	c	B
5	-	I
6	Fos	I
7	to	O
8	bind	O
9	a	O
10	transcriptionally	O
11	responsive	O
12	AP	B
13	-	I
14	1	I
15	element	I
16	within	O
17	the	O
18	tissue	B
19	inhibitor	I
20	of	I
21	metalloproteinase	I
22	-	I
23	1	I
24	promoter	I
25	.	O

1	Consistent	O
2	with	O
3	ErbB	B
4	-	I
5	2	I
6	being	O
7	a	O
8	shared	O
9	receptor	O
10	subunit	O
11	,	O
12	its	O
13	tyrosine	O
14	phosphorylation	O
15	was	O
16	increased	O
17	by	O
18	both	O
19	heterologous	O
20	ligands	O
21	and	O
22	it	O
23	mediated	O
24	a	O
25	trans	O
26	-	O
27	inhibitory	O
28	effect	O
29	of	O
30	NDF	B
31	on	O
32	EGF	B
33	binding	O
34	.	O

1	The	O
2	maps	O
3	of	O
4	Case	O
5	2	O
6	showed	O
7	that	O
8	a	O
9	maximum	O
10	first	O
11	appeared	O
12	on	O
13	the	O
14	upper	O
15	right	O
16	back	O
17	and	O
18	then	O
19	moved	O
20	down	O
21	the	O
22	right	O
23	side	O
24	of	O
25	the	O
26	posterior	O
27	thorax	O
28	.	O

1	An	O
2	abnormally	O
3	high	O
4	percentage	O
5	of	O
6	hypertensive	O
7	patients	O
8	(	O
9	approximately	O
10	30	O
11	%)	O
12	undergoing	O
13	cardiac	O
14	catheterization	O
15	because	O
16	of	O
17	anginal	O
18	pain	O
19	and	O
20	/	O
21	or	O
22	exercise	O
23	-	O
24	induced	O
25	ST	O
26	-	O
27	segment	O
28	depressions	O
29	has	O
30	angiographically	O
31	normal	O
32	coronary	O
33	arteries	O
34	.	O

1	The	O
2	concentrations	O
3	of	O
4	apo	B
5	A	I
6	-	I
7	I	I
8	and	O
9	apo	B
10	A	I
11	-	I
12	II	I
13	of	O
14	abstainers	O
15	decreased	O
16	significantly	O
17	compared	O
18	with	O
19	the	O
20	corresponding	O
21	changes	O
22	in	O
23	controls	O
24	.	O

1	In	O
2	the	O
3	work	O
4	reported	O
5	here	O
6	,	O
7	we	O
8	used	O
9	peptide	O
10	mapping	O
11	,	O
12	mass	O
13	spectrometry	O
14	,	O
15	and	O
16	site	O
17	-	O
18	directed	O
19	mutagenesis	O
20	to	O
21	identify	O
22	two	O
23	sets	O
24	of	O
25	pAP	B
26	phosphorylation	O
27	sites	O
28	.	O

1	Responsiveness	O
2	to	O
3	beta	O
4	-	O
5	2	O
6	agonist	O
7	therapy	O
8	was	O
9	retained	O
10	with	O
11	both	O
12	agents	O
13	(	O
14	p	O
15	less	O
16	than	O
17	0	O
18	.	O
19	05	O
20	).	O

1	However	O
2	,	O
3	no	O
4	genetic	O
5	alteration	O
6	was	O
7	detected	O
8	in	O
9	any	O
10	of	O
11	the	O
12	cancers	O
13	examined	O
14	.	O

1	To	O
2	measure	O
3	the	O
4	enhancer	O
5	activity	O
6	of	O
7	DR60	B
8	,	O
9	a	O
10	reporter	O
11	plasmid	O
12	was	O
13	constructed	O
14	that	O
15	contained	O
16	DR60	B
17	cloned	O
18	upstream	O
19	of	O
20	the	O
21	reporter	O
22	chloramphenicol	B
23	acetyltransferase	I
24	gene	I
25	under	O
26	the	O
27	control	O
28	of	O
29	the	O
30	delayed	O
31	-	O
32	early	O
33	39K	O
34	promoter	O
35	.	O

1	Results	O
2	for	O
3	men	O
4	who	O
5	drank	O
6	up	O
7	to	O
8	two	O
9	drinks	O
10	per	O
11	day	O
12	suggest	O
13	that	O
14	if	O
15	the	O
16	dependence	O
17	criteria	O
18	were	O
19	invalid	O
20	,	O
21	reductions	O
22	in	O
23	the	O
24	prevalence	O
25	of	O
26	specific	O
27	indicators	O
28	of	O
29	alcohol	O
30	dependence	O
31	would	O
32	range	O
33	from	O
34	0	O
35	.	O
36	3	O
37	%	O
38	to	O
39	5	O
40	.	O
41	2	O
42	%.	O

1	An	O
2	overexpression	O
3	of	O
4	the	O
5	betaAPP	B
6	gene	I
7	in	O
8	certain	O
9	areas	O
10	of	O
11	the	O
12	AD	O
13	brain	O
14	has	O
15	been	O
16	suggested	O
17	to	O
18	be	O
19	an	O
20	important	O
21	factor	O
22	in	O
23	the	O
24	neuropathology	O
25	of	O
26	AD	O
27	.	O

1	Twelve	O
2	genomic	O
3	fragments	O
4	containing	O
5	novel	O
6	response	O
7	elements	O
8	are	O
9	described	O
10	,	O
11	and	O
12	the	O
13	transcription	O
14	unit	O
15	associated	O
16	with	O
17	one	O
18	of	O
19	them	O
20	,	O
21	NN	B
22	-	I
23	84AG	I
24	,	O
25	was	O
26	characterized	O
27	in	O
28	detail	O
29	.	O

1	A	O
2	-	O
3	tracts	O
4	functioned	O
5	best	O
6	when	O
7	positioned	O
8	close	O
9	to	O
10	the	O
11	-	O
12	35	O
13	hexamer	O
14	rather	O
15	than	O
16	one	O
17	helical	O
18	turn	O
19	farther	O
20	upstream	O
21	,	O
22	similar	O
23	to	O
24	the	O
25	positioning	O
26	optimal	O
27	for	O
28	UP	O
29	element	O
30	function	O
31	.	O

1	These	O
2	results	O
3	may	O
4	suggest	O
5	involvement	O
6	of	O
7	peripheral	O
8	enkephalins	O
9	in	O
10	pain	O
11	modulation	O
12	in	O
13	patients	O
14	with	O
15	episodic	O
16	cluster	O
17	headache	O
18	.	O

1	Human	B
2	rIL	I
3	-	I
4	3	I
5	expressed	O
6	in	O
7	COS7	O
8	cells	O
9	has	O
10	multipotential	O
11	CSF	B
12	activity	O
13	in	O
14	semisolid	O
15	cultures	O
16	of	O
17	bone	O
18	marrow	O
19	cells	O
20	,	O
21	and	O
22	selectively	O
23	induced	O
24	the	O
25	proliferation	O
26	of	O
27	My	O
28	-	O
29	10	O
30	+	O
31	marrow	O
32	or	O
33	cord	O
34	blood	O
35	cells	O
36	in	O
37	liquid	O
38	cultures	O
39	.	O

1	Self	O
2	-	O
3	heating	O
4	after	O
5	deep	O
6	hypothermia	O
7	(	O
8	20	O
9	degrees	O
10	C	O
11	)	O
12	causes	O
13	a	O
14	considerable	O
15	increase	O
16	in	O
17	the	O
18	brain	O
19	tissues	O
20	glutaminase	B
21	activity	O
22	at	O
23	all	O
24	studied	O
25	incubation	O
26	temperatures	O
27	(	O
28	37	O
29	,	O
30	30	O
31	,	O
32	20	O
33	and	O
34	10	O
35	degrees	O
36	C	O
37	)	O
38	as	O
39	compared	O
40	to	O
41	control	O
42	rats	O
43	and	O
44	rats	O
45	under	O
46	hypothermia	O
47	.	O

1	Demyelinating	O
2	diseases	O
3	involving	O
4	the	O
5	grey	O
6	matter	O
7	were	O
8	very	O
9	rare	O
10	,	O
11	but	O
12	we	O
13	must	O
14	consider	O
15	the	O
16	presence	O
17	of	O
18	symmetrical	O
19	thalamic	O
20	involvement	O
21	in	O
22	patients	O
23	with	O
24	ADEM	O
25	.	O

1	Thus	O
2	,	O
3	blocks	O
4	in	O
5	the	O
6	RARalpha	B
7	-	O
8	specific	O
9	pathway	O
10	of	O
11	retinoid	O
12	-	O
13	induced	O
14	differentiation	O
15	may	O
16	be	O
17	bypassed	O
18	during	O
19	retinoid	O
20	induction	O
21	of	O
22	FR	B
23	-	I
24	beta	I
25	expression	O
26	.	O

1	In	O
2	all	O
3	sessions	O
4	under	O
5	IFN	B
6	,	O
7	the	O
8	latency	O
9	of	O
10	the	O
11	P100	O
12	component	O
13	of	O
14	the	O
15	VEP	O
16	was	O
17	shortened	O
18	as	O
19	compared	O
20	to	O
21	baseline	O
22	conditions	O
23	.	O

1	Although	O
2	previous	O
3	data	O
4	have	O
5	suggested	O
6	that	O
7	Rev	B
8	uses	O
9	the	O
10	same	O
11	export	O
12	pathway	O
13	as	O
14	uracil	O
15	-	O
16	rich	O
17	small	O
18	nuclear	O
19	RNAs	O
20	and	O
21	5S	B
22	ribosomal	I
23	RNA	I
24	,	O
25	the	O
26	CTE	O
27	seems	O
28	to	O
29	interact	O
30	with	O
31	evolutionarily	O
32	conserved	O
33	factors	O
34	that	O
35	are	O
36	essential	O
37	for	O
38	cellular	O
39	mRNA	O
40	export	O
41	.	O

1	Prior	O
2	to	O
3	meals	O
4	2	O
5	to	O
6	3	O
7	times	O
8	daily	O
9	,	O
10	1	O
11	-	O
12	2	O
13	tablespoons	O
14	of	O
15	Alzoon	O
16	are	O
17	recommended	O
18	.	O

1	There	O
2	were	O
3	3	O
4	/	O
5	32	O
6	(	O
7	9	O
8	.	O
9	4	O
10	per	O
11	cent	O
12	)	O
13	adverse	O
14	reactions	O
15	(	O
16	ADRs	O
17	),	O
18	and	O
19	one	O
20	case	O
21	each	O
22	of	O
23	nausea	O
24	,	O
25	dizziness	O
26	and	O
27	increased	O
28	menstrual	O
29	flow	O
30	.	O

1	GTRE	O
2	,	O
3	TRE	O
4	,	O
5	and	O
6	CRE	O
7	oligonucleotides	O
8	all	O
9	compete	O
10	more	O
11	efficiently	O
12	for	O
13	protein	O
14	binding	O
15	to	O
16	their	O
17	labeled	O
18	congeners	O
19	than	O
20	for	O
21	protein	O
22	binding	O
23	to	O
24	either	O
25	of	O
26	the	O
27	other	O
28	labeled	O
29	oligonucleotides	O
30	,	O
31	suggesting	O
32	that	O
33	the	O
34	GTRE	O
35	,	O
36	TRE	O
37	,	O
38	and	O
39	CRE	O
40	oligonucleotides	O
41	,	O
42	suggesting	O
43	that	O
44	the	O
45	GTRE	O
46	,	O
47	TRE	O
48	,	O
49	and	O
50	CRE	O
51	oligonucleotides	O
52	each	O
53	bind	O
54	unique	O
55	as	O
56	well	O
57	as	O
58	common	O
59	proteins	O
60	,	O
61	likely	O
62	to	O
63	be	O
64	members	O
65	of	O
66	the	O
67	Jun	B
68	/	O
69	Fos	B
70	and	O
71	cAMP	B
72	-	I
73	responsive	I
74	element	I
75	-	I
76	binding	I
77	protein	I
78	/	O
79	activating	B
80	transcription	I
81	factors	I
82	(	O
83	CREB	B
84	/	O
85	ATF	B
86	)	O
87	families	O
88	of	O
89	transcription	O
90	factors	O
91	,	O
92	in	O
93	chromaffin	O
94	cells	O
95	.	O

1	Expression	O
2	of	O
3	herpes	O
4	simplex	O
5	virus	O
6	beta	O
7	and	O
8	gamma	O
9	genes	O
10	integrated	O
11	in	O
12	mammalian	O
13	cells	O
14	and	O
15	their	O
16	induction	O
17	by	O
18	an	O
19	alpha	O
20	gene	O
21	product	O
22	.	O

1	Endostatin	O
2	treatment	O
3	for	O
4	10	O
5	minutes	O
6	or	O
7	24	O
8	hours	O
9	induced	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	Shb	B
14	and	O
15	formation	O
16	of	O
17	multiprotein	O
18	complexes	O
19	.	O

1	Also	O
2	,	O
3	HR21ap	B
4	as	O
5	well	O
6	as	O
7	HR21Xap	B
8	are	O
9	specific	O
10	in	O
11	their	O
12	inhibition	O
13	of	O
14	Sp1	B
15	binding	O
16	.	O

1	Ten	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	with	O
7	progressive	O
8	disease	O
9	had	O
10	mast	O
11	cells	O
12	greater	O
13	than	O
14	or	O
15	equal	O
16	to	O
17	0	O
18	.	O
19	5	O
20	%,	O
21	hyaluronan	O
22	greater	O
23	than	O
24	or	O
25	equal	O
26	to	O
27	50	O
28	micrograms	O
29	.	O
30	l	O
31	-	O
32	1	O
33	and	O
34	fibronectin	B
35	greater	O
36	than	O
37	or	O
38	equal	O
39	to	O
40	350	O
41	micrograms	O
42	.	O
43	l	O
44	-	O
45	1	O
46	compared	O
47	to	O
48	eight	O
49	out	O
50	of	O
51	41	O
52	patients	O
53	with	O
54	stable	O
55	or	O
56	regressive	O
57	disease	O
58	.(	O
59	ABSTRACT	O
60	TRUNCATED	O
61	AT	O
62	250	O
63	WORDS	O
64	)	O

1	The	O
2	present	O
3	investigation	O
4	has	O
5	revealed	O
6	that	O
7	the	O
8	distribution	O
9	of	O
10	the	O
11	main	O
12	fatty	O
13	acids	O
14	in	O
15	Leptospira	O
16	phospholipids	O
17	is	O
18	similar	O
19	to	O
20	their	O
21	distribution	O
22	in	O
23	Leptospira	O
24	neutral	O
25	lipids	O
26	with	O
27	the	O
28	exception	O
29	of	O
30	unsaturated	O
31	fatty	O
32	acid	O
33	with	O
34	14	O
35	carbon	O
36	atoms	O
37	,	O
38	occurring	O
39	mainly	O
40	in	O
41	phospholipids	O
42	.	O

1	The	O
2	effect	O
3	of	O
4	low	O
5	-	O
6	profile	O
7	serine	O
8	substitutions	O
9	in	O
10	the	O
11	V3	B
12	loop	O
13	of	O
14	HIV	O
15	-	O
16	1	O
17	gp120	B
18	IIIB	I
19	/	O
20	LAI	B
21	on	O
22	the	O
23	immunogenicity	O
24	of	O
25	the	O
26	envelope	B
27	protein	O
28	.	O

1	For	O
2	228	O
3	of	O
4	425	O
5	deaths	O
6	(	O
7	54	O
8	%)	O
9	occurring	O
10	among	O
11	26	O
12	100	O
13	people	O
14	of	O
15	known	O
16	age	O
17	in	O
18	the	O
19	Malumfashi	O
20	area	O
21	of	O
22	northern	O
23	Nigeria	O
24	,	O
25	data	O
26	were	O
27	collected	O
28	on	O
29	symptoms	O
30	present	O
31	prior	O
32	to	O
33	death	O
34	.	O

1	Levels	O
2	of	O
3	the	O
4	MEK	B
5	inhibitor	O
6	PD98059	O
7	that	O
8	block	O
9	EGF	B
10	-	O
11	induced	O
12	mitogenesis	O
13	and	O
14	MAP	B
15	kinase	I
16	phosphorylation	O
17	also	O
18	abrogate	O
19	EGF	B
20	-	O
21	induced	O
22	focal	O
23	adhesion	O
24	disassembly	O
25	and	O
26	cell	O
27	motility	O
28	.	O

1	The	O
2	architecture	O
3	of	O
4	microvasculature	O
5	in	O
6	these	O
7	two	O
8	regions	O
9	was	O
10	also	O
11	examined	O
12	by	O
13	scanning	O
14	electron	O
15	microscopy	O
16	,	O
17	using	O
18	the	O
19	resin	O
20	casting	O
21	method	O
22	.	O

1	We	O
2	have	O
3	mapped	O
4	the	O
5	human	B
6	STAG3	I
7	gene	I
8	to	O
9	the	O
10	7q22	O
11	region	O
12	of	O
13	chromosome	O
14	7	O
15	;	O
16	six	O
17	human	B
18	STAG3	I
19	-	I
20	related	I
21	genes	I
22	have	O
23	also	O
24	been	O
25	mapped	O
26	:	O
27	two	O
28	at	O
29	7q22	O
30	near	O
31	the	O
32	functional	O
33	gene	O
34	,	O
35	one	O
36	at	O
37	7q11	O
38	.	O
39	22	O
40	,	O
41	and	O
42	three	O
43	at	O
44	7q11	O
45	.	O
46	23	O
47	,	O
48	two	O
49	of	O
50	them	O
51	flanking	O
52	the	O
53	breakpoints	O
54	commonly	O
55	associated	O
56	with	O
57	the	O
58	Williams	B
59	-	I
60	Beuren	I
61	syndrome	I
62	(	I
63	WBS	I
64	)	I
65	deletion	I
66	.	O

1	The	O
2	ICBF	O
3	in	O
4	the	O
5	ischaemic	O
6	cortex	O
7	revealed	O
8	a	O
9	graded	O
10	reduction	O
11	from	O
12	the	O
13	ischaemic	O
14	centre	O
15	to	O
16	the	O
17	surrounding	O
18	tissues	O
19	.	O

1	Finally	O
2	,	O
3	over	O
4	a	O
5	similar	O
6	range	O
7	of	O
8	QO2	O
9	,	O
10	oxygen	O
11	extraction	O
12	was	O
13	greater	O
14	in	O
15	patients	O
16	with	O
17	ARDS	O
18	compared	O
19	to	O
20	patients	O
21	with	O
22	non	O
23	-	O
24	ARDS	O
25	respiratory	O
26	failure	O
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	67	O
34	and	O
35	slope	O
36	=	O
37	-	O
38	0	O
39	.	O
40	62	O
41	vs	O
42	r	O
43	=	O
44	-	O
45	0	O
46	.	O
47	45	O
48	and	O
49	slope	O
50	=	O
51	-	O
52	0	O
53	.	O
54	35	O
55	;	O
56	p	O
57	less	O
58	than	O
59	0	O
60	.	O
61	05	O
62	).	O

1	L3	O
2	-	O
3	L4	O
4	compressive	O
5	load	O
6	was	O
7	calculated	O
8	using	O
9	a	O
10	model	O
11	of	O
12	the	O
13	anatomy	O
14	of	O
15	the	O
16	trunk	O
17	musculoskeletal	O
18	system	O
19	.	O

1	To	O
2	discern	O
3	whether	O
4	these	O
5	disorders	O
6	of	O
7	GnRH	B
8	deficiency	O
9	are	O
10	associated	O
11	with	O
12	altered	O
13	melatonin	O
14	secretion	O
15	profiles	O
16	,	O
17	we	O
18	compared	O
19	untreated	O
20	young	O
21	males	O
22	IGD	O
23	(	O
24	n	O
25	=	O
26	7	O
27	)	O
28	and	O
29	DP	O
30	(	O
31	n	O
32	=	O
33	7	O
34	)	O
35	to	O
36	normal	O
37	pubertal	O
38	male	O
39	controls	O
40	(	O
41	n	O
42	=	O
43	6	O
44	).	O

1	A	O
2	degenerate	O
3	DNA	O
4	transposon	O
5	,	O
6	Pat	B
7	,	O
8	was	O
9	identified	O
10	in	O
11	the	O
12	genomes	O
13	of	O
14	various	O
15	wild	O
16	-	O
17	type	O
18	strains	O
19	of	O
20	the	O
21	filamentous	O
22	fungus	O
23	Podospora	O
24	anserina	O
25	.	O

1	Thus	O
2	,	O
3	two	O
4	very	O
5	different	O
6	regulatory	O
7	elements	O
8	are	O
9	used	O
10	to	O
11	mediate	O
12	estrogen	O
13	induction	O
14	of	O
15	related	O
16	genes	O
17	in	O
18	chickens	O
19	and	O
20	amphibians	O
21	.	O

1	The	O
2	protein	B
3	-	I
4	tyrosine	I
5	kinase	I
6	fer	I
7	associates	O
8	with	O
9	signaling	O
10	complexes	O
11	containing	O
12	insulin	B
13	receptor	I
14	substrate	I
15	-	I
16	1	I
17	and	O
18	phosphatidylinositol	B
19	3	I
20	-	I
21	kinase	I
22	.	O

1	Vocal	O
2	cord	O
3	abduction	O
4	rehabilitation	O
5	by	O
6	nervous	O
7	selective	O
8	anastomosis	O
9	.	O

1	Allergenic	O
2	activity	O
3	of	O
4	allergen	O
5	extract	O
6	Ambrosia	O
7	elatior	O
8	(	O
9	AE	O
10	)	O
11	was	O
12	tested	O
13	in	O
14	fifteen	O
15	volunteers	O
16	extremely	O
17	sensitive	O
18	to	O
19	the	O
20	allergen	O
21	.	O

1	The	O
2	dynamic	O
3	properties	O
4	of	O
5	this	O
6	protein	O
7	fragment	O
8	were	O
9	measured	O
10	and	O
11	analyzed	O
12	using	O
13	both	O
14	isotropic	O
15	and	O
16	anisotropic	O
17	models	O
18	of	O
19	molecular	O
20	motion	O
21	.	O

1	In	O
2	vivo	O
3	,	O
4	CARbeta	B
5	/	O
6	RXRalpha	B
7	activated	O
8	transcription	O
9	from	O
10	an	O
11	HD	B
12	-	O
13	PPRE	O
14	luciferase	B
15	reporter	I
16	construct	I
17	.	O

1	Specialist	O
2	in	O
3	family	O
4	practice	O
5	--	O
6	prototype	O
7	of	O
8	a	O
9	doctor	O
10	.	O

1	Serotonin	B
2	5	I
3	-	I
4	HT2	I
5	receptor	I
6	binding	O
7	on	O
8	blood	O
9	platelets	O
10	as	O
11	a	O
12	state	O
13	dependent	O
14	marker	O
15	in	O
16	major	O
17	affective	O
18	disorder	O
19	.	O

1	PFK	B
2	-	I
3	A	I
4	mRNA	O
5	was	O
6	more	O
7	abundantly	O
8	expressed	O
9	in	O
10	all	O
11	tissues	O
12	than	O
13	were	O
14	the	O
15	PFK	B
16	-	I
17	B	I
18	and	O
19	PFK	B
20	-	I
21	C	I
22	genes	I
23	.	O

1	More	O
2	specific	O
3	adverse	O
4	events	O
5	,	O
6	also	O
7	frequently	O
8	considered	O
9	as	O
10	dose	O
11	-	O
12	limiting	O
13	toxicities	O
14	,	O
15	include	O
16	hypotension	O
17	with	O
18	IL	B
19	-	I
20	1	I
21	,	O
22	severe	O
23	headache	O
24	or	O
25	skin	O
26	rash	O
27	with	O
28	IL	B
29	-	I
30	3	I
31	,	O
32	and	O
33	nasal	O
34	congestion	O
35	and	O
36	gastroduodenal	O
37	lesions	O
38	with	O
39	IL	B
40	-	I
41	4	I
42	.	O

1	Cells	O
2	respond	O
3	to	O
4	the	O
5	accumulation	O
6	of	O
7	unfolded	O
8	proteins	O
9	in	O
10	the	O
11	endoplasmic	O
12	reticulum	O
13	(	O
14	ER	O
15	)	O
16	by	O
17	increasing	O
18	the	O
19	transcription	O
20	of	O
21	the	O
22	genes	O
23	encoding	O
24	ER	B
25	-	I
26	resident	I
27	chaperone	I
28	proteins	I
29	.	O

1	Dose	O
2	of	O
3	20	O
4	ig	O
5	were	O
6	administered	O
7	within	O
8	a	O
9	scheme	O
10	from	O
11	0	O
12	.	O
13	1	O
14	to	O
15	6	O
16	months	O
17	in	O
18	order	O
19	to	O
20	study	O
21	its	O
22	immunogenicity	O
23	,	O
24	which	O
25	was	O
26	evaluated	O
27	at	O
28	2	O
29	,	O
30	7	O
31	,	O
32	and	O
33	12	O
34	months	O
35	after	O
36	the	O
37	first	O
38	dose	O
39	.	O

1	One	O
2	form	O
3	of	O
4	the	O
5	SBEI	B
6	gene	I
7	transcript	I
8	in	O
9	12	O
10	-	O
11	day	O
12	old	O
13	kernels	O
14	contained	O
15	the	O
16	exon	O
17	I	O
18	+	O
19	II	O
20	+	O
21	III	O
22	combination	O
23	at	O
24	the	O
25	5	O
26	'	O
27	end	O
28	,	O
29	whereas	O
30	other	O
31	forms	O
32	differed	O
33	by	O
34	inclusion	O
35	of	O
36	intron	O
37	1	O
38	or	O
39	exclusion	O
40	of	O
41	exon	O
42	II	O
43	sequences	O
44	.	O

1	Inactivation	O
2	of	O
3	the	O
4	Neurospora	B
5	crassa	I
6	mitochondrial	I
7	outer	I
8	membrane	I
9	protein	I
10	TOM70	I
11	by	O
12	repeat	O
13	-	O
14	induced	O
15	point	O
16	mutation	O
17	(	O
18	RIP	O
19	)	O
20	causes	O
21	defects	O
22	in	O
23	mitochondrial	O
24	protein	O
25	import	O
26	and	O
27	morphology	O
28	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	en	B
6	stripes	O
7	expand	O
8	anteriorly	O
9	in	O
10	slp	B
11	mutant	O
12	embryos	O
13	and	O
14	that	O
15	slp	B
16	activity	O
17	is	O
18	an	O
19	absolute	O
20	requirement	O
21	for	O
22	maintenance	O
23	of	O
24	wg	B
25	expression	O
26	at	O
27	the	O
28	same	O
29	time	O
30	that	O
31	wg	B
32	transcription	O
33	is	O
34	dependent	O
35	on	O
36	hh	B
37	.	O

1	The	O
2	antibody	O
3	titer	O
4	of	O
5	202	O
6	chickens	O
7	to	O
8	SA	O
9	-	O
10	11	O
11	rotavirus	O
12	was	O
13	determined	O
14	by	O
15	enzyme	O
16	-	O
17	linked	O
18	immunosorbent	O
19	blocking	O
20	assay	O
21	.	O

1	Regulation	O
2	of	O
3	pituitary	O
4	vasopressin	B
5	V1b	I
6	receptors	I
7	plays	O
8	a	O
9	critical	O
10	role	O
11	in	O
12	regulating	O
13	pituitary	B
14	adrenocorticotropic	I
15	hormone	I
16	(	O
17	ACTH	B
18	)	O
19	secretion	O
20	during	O
21	adaptation	O
22	to	O
23	stress	O
24	.	O

1	The	O
2	partial	O
3	categories	O
4	of	O
5	the	O
6	SIP	O
7	that	O
8	were	O
9	more	O
10	affected	O
11	were	O
12	work	O
13	,	O
14	recreation	O
15	and	O
16	pastimes	O
17	,	O
18	home	O
19	management	O
20	,	O
21	and	O
22	sleep	O
23	and	O
24	rest	O
25	.	O

1	202	O
2	-	O
3	8	O
4	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	amino	O
6	acid	O
7	sequence	O
8	of	O
9	the	O
10	T	O
11	.	O
12	thermophilus	O
13	enzyme	O
14	with	O
15	that	O
16	of	O
17	the	O
18	Escherichia	O
19	coli	O
20	enzyme	O
21	showed	O
22	(	O
23	i	O
24	)	O
25	a	O
26	37	O
27	%	O
28	overall	O
29	similarity	O
30	;	O
31	(	O
32	ii	O
33	)	O
34	the	O
35	conservation	O
36	of	O
37	the	O
38	Ser	O
39	residue	O
40	,	O
41	which	O
42	is	O
43	known	O
44	to	O
45	be	O
46	phosphorylated	O
47	in	O
48	the	O
49	E	O
50	.	O
51	coli	O
52	enzyme	O
53	,	O
54	and	O
55	of	O
56	the	O
57	surrounding	O
58	sequence	O
59	;	O
60	and	O
61	(	O
62	iii	O
63	)	O
64	the	O
65	presence	O
66	of	O
67	141	O
68	extra	O
69	residues	O
70	at	O
71	the	O
72	C	O
73	terminus	O
74	of	O
75	the	O
76	T	O
77	.	O
78	thermophilus	O
79	enzyme	O
80	.	O

1	The	O
2	maximum	O
3	deflections	O
4	of	O
5	phase	O
6	IV	O
7	for	O
8	Ar	O
9	and	O
10	N2	O
11	from	O
12	extrapolated	O
13	phase	O
14	III	O
15	slopes	O
16	were	O
17	smaller	O
18	in	O
19	the	O
20	prone	O
21	position	O
22	,	O
23	suggesting	O
24	more	O
25	uniform	O
26	tracer	O
27	gas	O
28	concentrations	O
29	across	O
30	the	O
31	lungs	O
32	.	O

1	The	O
2	[	O
3	18F	O
4	]	O
5	FMISO	O
6	TMRR	O
7	is	O
8	a	O
9	simple	O
10	and	O
11	clinically	O
12	useful	O
13	index	O
14	for	O
15	detecting	O
16	tumour	O
17	hypoxia	O
18	in	O
19	NPC	O
20	.	O

1	Recombinant	B
2	human	I
3	erythropoietin	I
4	(	O
5	epoetin	B
6	)	O
7	is	O
8	approved	O
9	to	O
10	be	O
11	administered	O
12	by	O
13	the	O
14	intravenous	O
15	(	O
16	i	O
17	.	O
18	v	O
19	.)	O
20	or	O
21	subcutaneous	O
22	(	O
23	SC	O
24	)	O
25	route	O
26	.	O

1	Coronary	O
2	arteries	O
3	--	O
4	old	O
5	and	O
6	new	O
7	.	O

1	The	O
2	JTc	O
3	delta	O
4	among	O
5	the	O
6	three	O
7	groups	O
8	did	O
9	not	O
10	differ	O
11	as	O
12	well	O
13	:	O
14	JTc	O
15	delta	O
16	of	O
17	the	O
18	VT	O
19	group	O
20	was	O
21	70	O
22	ms	O
23	+/-	O
24	30	O
25	ms	O
26	,	O
27	the	O
28	JTc	O
29	delta	O
30	of	O
31	the	O
32	PVC	O
33	group	O
34	was	O
35	60	O
36	msec	O
37	+/-	O
38	25	O
39	msec	O
40	,	O
41	and	O
42	the	O
43	JTc	O
44	delta	O
45	of	O
46	the	O
47	control	O
48	group	O
49	was	O
50	70	O
51	ms	O
52	+/-	O
53	30	O
54	ms	O
55	.	O

1	All	O
2	injections	O
3	of	O
4	CSF	B
5	were	O
6	given	O
7	after	O
8	the	O
9	initiation	O
10	of	O
11	neutropenia	O
12	and	O
13	continued	O
14	until	O
15	the	O
16	occurrence	O
17	of	O
18	an	O
19	absolute	O
20	neutrophil	O
21	recovery	O
22	.	O
23	rHu	B
24	GM	I
25	-	I
26	CSF	I
27	and	O
28	rHu	B
29	G	I
30	-	I
31	CSF	I
32	,	O
33	administered	O
34	once	O
35	daily	O
36	at	O
37	the	O
38	250	O
39	microg	O
40	m	O
41	(-	O
42	2	O
43	)	O
44	day	O
45	(-	O
46	1	O
47	)	O
48	and	O
49	5	O
50	microg	O
51	kg	O
52	(-	O
53	1	O
54	)	O
55	day	O
56	(-	O
57	1	O
58	)	O
59	level	O
60	,	O
61	were	O
62	effective	O
63	in	O
64	increasing	O
65	the	O
66	absolute	O
67	neutrophil	O
68	count	O
69	and	O
70	neutrophil	O
71	function	O
72	,	O
73	as	O
74	measured	O
75	by	O
76	an	O
77	automated	O
78	chemiluminescence	O
79	system	O
80	.	O

1	The	O
2	sub	O
3	-	O
4	acute	O
5	inhalation	O
6	toxicity	O
7	of	O
8	furfural	O
9	was	O
10	studied	O
11	in	O
12	Syrian	O
13	golden	O
14	hamsters	O
15	.	O

1	Short	O
2	therapy	O
3	with	O
4	omeprazole	O
5	20	O
6	mg	O
7	/	O
8	b	O
9	.	O
10	i	O
11	.	O
12	d	O
13	.,	O
14	clarithromycin	O
15	500	O
16	mg	O
17	/	O
18	b	O
19	.	O
20	i	O
21	.	O
22	d	O
23	.,	O
24	and	O
25	CBS	O
26	120	O
27	mg	O
28	/	O
29	q	O
30	.	O
31	i	O
32	.	O
33	d	O
34	.	O
35	is	O
36	a	O
37	safe	O
38	,	O
39	well	O
40	tolerated	O
41	combination	O
42	that	O
43	achieves	O
44	a	O
45	80	O
46	.	O
47	6	O
48	%	O
49	eradication	O
50	rate	O
51	of	O
52	H	O
53	.	O
54	pylori	O
55	and	O
56	duodenal	O
57	ulcer	O
58	healing	O
59	rates	O
60	as	O
61	good	O
62	as	O
63	those	O
64	achieved	O
65	by	O
66	omeprazole	O
67	20	O
68	mg	O
69	/	O
70	d	O
71	when	O
72	given	O
73	for	O
74	4	O
75	wk	O
76	.	O

1	In	O
2	addition	O
3	,	O
4	two	O
5	-	O
6	dimensional	O
7	nuclear	O
8	magnetic	O
9	resonance	O
10	studies	O
11	with	O
12	F17A	O
13	,	O
14	K13Q	O
15	,	O
16	F15Y	O
17	and	O
18	F27Y	O
19	revealed	O
20	that	O
21	the	O
22	mutants	O
23	have	O
24	the	O
25	same	O
26	overall	O
27	structure	O
28	as	O
29	the	O
30	wild	B
31	-	I
32	type	I
33	CspB	I
34	protein	I
35	.	O

1	Deletion	O
2	of	O
3	the	O
4	RVH	B
5	domain	I
6	resulted	O
7	in	O
8	loss	O
9	of	O
10	Ca	O
11	(	O
12	2	O
13	+)-	O
14	dependent	O
15	activation	O
16	.	O

1	Basal	O
2	FVR	O
3	was	O
4	reduced	O
5	by	O
6	approximately	O
7	18	O
8	%	O
9	by	O
10	ERT	O
11	and	O
12	HRT	O
13	,	O
14	but	O
15	FVR	O
16	responses	O
17	to	O
18	noradrenaline	O
19	,	O
20	angiotensin	B
21	II	I
22	,	O
23	acetylcholine	O
24	and	O
25	nitroprusside	O
26	were	O
27	unaffected	O
28	.	O

1	Histological	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	neuronal	O
7	loss	O
8	in	O
9	the	O
10	DHED	O
11	-	O
12	treated	O
13	group	O
14	was	O
15	notably	O
16	reduced	O
17	in	O
18	the	O
19	hippocampal	O
20	area	O
21	(	O
22	CA1	O
23	)	O
24	of	O
25	ischemic	O
26	rats	O
27	and	O
28	in	O
29	the	O
30	dentate	O
31	gyrus	O
32	and	O
33	hippocampal	O
34	area	O
35	(	O
36	CA1	O
37	and	O
38	CA3	O
39	)	O
40	of	O
41	EC	O
42	-	O
43	lesioned	O
44	rats	O
45	compared	O
46	with	O
47	the	O
48	nontreated	O
49	group	O
50	.	O

1	Judge	O
2	OKs	O
3	docs	O
4	'	O
5	bid	O
6	for	O
7	Chicago	O
8	hospital	O
9	.	O

1	Combined	O
2	intravenous	O
3	and	O
4	intra	O
5	-	O
6	arterial	O
7	recombinant	O
8	tissue	B
9	plasminogen	I
10	activator	I
11	in	O
12	acute	O
13	ischemic	O
14	stroke	O
15	.	O

1	Mae	O
2	West	O
3	and	O
4	the	O
5	doctor	O
6	shortage	O
7	.	O

1	Their	O
2	use	O
3	resulted	O
4	in	O
5	a	O
6	sensitivity	O
7	of	O
8	73	O
9	%	O
10	and	O
11	a	O
12	specificity	O
13	of	O
14	74	O
15	%	O
16	with	O
17	regard	O
18	to	O
19	predictability	O
20	of	O
21	ALT	B
22	levels	O
23	increasing	O
24	during	O
25	the	O
26	trial	O
27	.	O

1	The	O
2	up	O
3	-	O
4	regulation	O
5	of	O
6	E	B
7	-	I
8	selectin	I
9	,	O
10	one	O
11	of	O
12	the	O
13	adhesion	O
14	molecules	O
15	on	O
16	the	O
17	endothelium	O
18	,	O
19	is	O
20	an	O
21	important	O
22	event	O
23	in	O
24	the	O
25	mediation	O
26	of	O
27	the	O
28	inflammatory	O
29	response	O
30	.	O

1	Association	O
2	of	O
3	stress	O
4	during	O
5	delivery	O
6	with	O
7	increased	O
8	numbers	O
9	of	O
10	nucleated	O
11	cells	O
12	and	O
13	hematopoietic	O
14	progenitor	O
15	cells	O
16	in	O
17	umbilical	O
18	cord	O
19	blood	O
20	.	O

1	Model	O
2	predictions	O
3	were	O
4	in	O
5	accord	O
6	with	O
7	the	O
8	nine	O
9	-	O
10	year	O
11	survival	O
12	experience	O
13	of	O
14	women	O
15	in	O
16	the	O
17	HIP	O
18	trial	O
19	,	O
20	and	O
21	,	O
22	with	O
23	the	O
24	exception	O
25	of	O
26	women	O
27	40	O
28	-	O
29	44	O
30	years	O
31	old	O
32	,	O
33	with	O
34	HIP	O
35	data	O
36	on	O
37	18	O
38	-	O
39	year	O
40	survival	O
41	.	O

1	Nhp2p	B
2	is	O
3	a	O
4	highly	O
5	basic	O
6	protein	O
7	that	O
8	belongs	O
9	to	O
10	a	O
11	family	O
12	of	O
13	putative	O
14	RNA	O
15	-	O
16	binding	O
17	proteins	O
18	.	O

1	This	O
2	difference	O
3	may	O
4	result	O
5	from	O
6	the	O
7	lower	O
8	match	O
9	to	O
10	the	O
11	ARG	O
12	box	O
13	consensus	O
14	of	O
15	the	O
16	O	B
17	(	I
18	rocD	I
19	)	I
20	site	I
21	.	O

1	The	O
2	DNA	O
3	binding	O
4	and	O
5	multimerization	O
6	activities	O
7	of	O
8	c	B
9	-	I
10	Myb	I
11	appear	O
12	to	O
13	be	O
14	unaffected	O
15	by	O
16	the	O
17	S528A	O
18	substitution	O
19	,	O
20	suggesting	O
21	that	O
22	phosphorylation	O
23	of	O
24	serine	O
25	528	O
26	may	O
27	mediate	O
28	its	O
29	effect	O
30	on	O
31	the	O
32	transcription	O
33	transactivating	O
34	activity	O
35	of	O
36	c	B
37	-	I
38	Myb	I
39	by	O
40	regulating	O
41	interactions	O
42	with	O
43	other	O
44	proteins	O
45	.	O

1	Acute	O
2	experiments	O
3	on	O
4	nembutal	O
5	-	O
6	anesthetized	O
7	cats	O
8	(	O
9	50	O
10	mg	O
11	/	O
12	kg	O
13	)	O
14	were	O
15	employed	O
16	to	O
17	investigate	O
18	the	O
19	effect	O
20	of	O
21	1	O
22	T	O
23	pulsating	O
24	magnetic	O
25	field	O
26	(	O
27	PMF	O
28	)	O
29	on	O
30	neuromuscular	O
31	system	O
32	of	O
33	the	O
34	leg	O
35	.	O

1	The	O
2	pharmacological	O
3	effects	O
4	of	O
5	the	O
6	novel	O
7	compound	O
8	WEB	O
9	1881	O
10	FU	O
11	(	O
12	4	O
13	-	O
14	amino	O
15	-	O
16	methyl	O
17	-	O
18	1	O
19	-	O
20	benzyl	O
21	-	O
22	pyrrolidine	O
23	-	O
24	2	O
25	-	O
26	one	O
27	-	O
28	fumarate	O
29	)	O
30	were	O
31	investigated	O
32	.	O

1	II	O
2	.	O

1	The	O
2	effect	O
3	of	O
4	calcitonin	B
5	,	O
6	a	O
7	large	O
8	amount	O
9	of	O
10	calcium	O
11	given	O
12	orally	O
13	,	O
14	pentagastrin	O
15	and	O
16	glucagon	B
17	on	O
18	plasma	O
19	47Ca	O
20	radioactivity	O
21	curves	O
22	in	O
23	subjects	O
24	pretreated	O
25	with	O
26	47Ca	O
27	was	O
28	examined	O
29	.	O

1	A	O
2	736	O
3	-	O
4	bp	O
5	sequence	O
6	of	O
7	the	O
8	5	O
9	'	O
10	flanking	O
11	region	O
12	adjacent	O
13	to	O
14	the	O
15	cap	O
16	site	O
17	of	O
18	the	O
19	human	B
20	AFP	I
21	gene	I
22	shows	O
23	a	O
24	61	O
25	%	O
26	similarity	O
27	with	O
28	the	O
29	corresponding	O
30	region	O
31	of	O
32	the	O
33	mouse	B
34	AFP	I
35	gene	I
36	.	O

1	Grimelius	O
2	stain	O
3	was	O
4	positive	O
5	,	O
6	Masson	O
7	Fontana	O
8	stain	O
9	negative	O
10	.	O

1	Temporal	O
2	control	O
3	of	O
4	GUS	B
5	expression	O
6	was	O
7	found	O
8	to	O
9	involve	O
10	two	O
11	negative	O
12	regulatory	O
13	sequences	O
14	,	O
15	NRS1	O
16	(-	O
17	391	O
18	to	O
19	-	O
20	295	O
21	)	O
22	and	O
23	NRS2	O
24	(-	O
25	518	O
26	to	O
27	-	O
28	418	O
29	),	O
30	as	O
31	well	O
32	as	O
33	the	O
34	positive	O
35	domain	O
36	UAS1	O
37	.	O

1	Similar	O
2	mechanisms	O
3	leading	O
4	to	O
5	deregulation	O
6	of	O
7	Tcf	B
8	target	I
9	gene	I
10	activity	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	involved	O
16	in	O
17	melanoma	O
18	and	O
19	other	O
20	forms	O
21	of	O
22	cancer	O
23	.	O

1	In	O
2	the	O
3	first	O
4	,	O
5	homologous	O
6	sequences	O
7	were	O
8	deleted	O
9	from	O
10	a	O
11	mouse	O
12	enhancer	O
13	,	O
14	resulting	O
15	in	O
16	a	O
17	tissue	O
18	-	O
19	specific	O
20	loss	O
21	of	O
22	activity	O
23	when	O
24	assayed	O
25	in	O
26	transgenic	O
27	mice	O
28	.	O

1	Lipoprotein	B
2	lipase	I
3	(	O
4	LPL	B
5	),	O
6	a	O
7	key	O
8	enzyme	O
9	in	O
10	normal	O
11	lipoprotein	O
12	metabolism	O
13	,	O
14	has	O
15	a	O
16	complex	O
17	pattern	O
18	of	O
19	regulation	O
20	and	O
21	tissue	O
22	-	O
23	specific	O
24	expression	O
25	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	indicates	O
5	that	O
6	AHA2	B
7	mRNA	I
8	relative	O
9	to	O
10	total	O
11	cellular	O
12	RNA	O
13	is	O
14	expressed	O
15	at	O
16	significantly	O
17	higher	O
18	levels	O
19	in	O
20	root	O
21	tissue	O
22	as	O
23	compared	O
24	with	O
25	shoot	O
26	tissue	O
27	.	O

1	Splice	O
2	variations	O
3	in	O
4	genes	O
5	coding	O
6	for	O
7	the	O
8	transmembrane	B
9	FGF	I
10	receptor	I
11	(	O
12	FGFR	B
13	)	O
14	result	O
15	in	O
16	isoforms	O
17	that	O
18	vary	O
19	in	O
20	the	O
21	ectodomain	O
22	,	O
23	intracellular	O
24	juxtamembrane	O
25	domain	O
26	,	O
27	and	O
28	the	O
29	intracellular	O
30	kinase	O
31	domain	O
32	.	O

1	We	O
2	reviewed	O
3	the	O
4	records	O
5	of	O
6	151	O
7	patients	O
8	with	O
9	optic	O
10	neuritis	O
11	examined	O
12	over	O
13	an	O
14	eight	O
15	-	O
16	year	O
17	period	O
18	.	O

1	A	O
2	newly	O
3	synthesized	O
4	anti	O
5	-	O
6	inflammatory	O
7	agent	O
8	,	O
9	Y	O
10	-	O
11	8004	O
12	demonstrated	O
13	a	O
14	greater	O
15	inhibition	O
16	than	O
17	did	O
18	indomethacin	O
19	(	O
20	IM	O
21	).	O
22	on	O
23	inflammatory	O
24	response	O
25	such	O
26	as	O
27	ultraviolet	O
28	erythema	O
29	in	O
30	guinea	O
31	pigs	O
32	,	O
33	carrageenin	O
34	edema	O
35	,	O
36	evans	O
37	blue	O
38	and	O
39	carrageenin	O
40	-	O
41	induced	O
42	pleuritis	O
43	and	O
44	acetic	O
45	acid	O
46	-	O
47	induced	O
48	peritonitis	O
49	in	O
50	rats	O
51	.	O

1	A	O
2	mutation	O
3	linked	O
4	to	O
5	the	O
6	SOC1	B
7	gene	I
8	,	O
9	previously	O
10	defined	O
11	by	O
12	recessive	O
13	mutations	O
14	that	O
15	suppress	O
16	cbp1	B
17	ts	I
18	alleles	I
19	and	O
20	stabilize	O
21	many	O
22	mitochondrial	O
23	mRNAs	O
24	,	O
25	was	O
26	also	O
27	isolated	O
28	.	O

1	The	O
2	serum	O
3	levels	O
4	of	O
5	IgE	B
6	,	O
7	and	O
8	asIgE	B
9	and	O
10	IgG	B
11	-	I
12	4	I
13	against	O
14	14	O
15	common	O
16	food	O
17	allergens	O
18	were	O
19	determined	O
20	.	O

1	It	O
2	may	O
3	be	O
4	time	O
5	to	O
6	reevaluate	O
7	the	O
8	dichotomy	O
9	between	O
10	AD	O
11	and	O
12	VaD	O
13	.	O

1	Ultrasound	O
2	effect	O
3	on	O
4	the	O
5	cytochrome	B
6	oxidase	I
7	activity	O

1	Infarct	O
2	regional	O
3	ejection	O
4	fraction	O
5	improved	O
6	by	O
7	10	O
8	.	O
9	1	O
10	+/-	O
11	2	O
12	.	O
13	1	O
14	%	O
15	between	O
16	early	O
17	and	O
18	late	O
19	studies	O
20	when	O
21	the	O
22	infarct	O
23	-	O
24	related	O
25	artery	O
26	was	O
27	patent	O
28	and	O
29	by	O
30	4	O
31	.	O
32	8	O
33	+/-	O
34	1	O
35	.	O
36	4	O
37	%	O
38	if	O
39	it	O
40	was	O
41	occluded	O
42	(	O
43	p	O
44	=	O
45	0	O
46	.	O
47	048	O
48	);	O
49	changes	O
50	in	O
51	global	O
52	and	O
53	noninfarct	O
54	regional	O
55	ejection	O
56	fraction	O
57	were	O
58	similar	O
59	irrespective	O
60	of	O
61	perfusion	O
62	status	O
63	.	O

1	Joys	O
2	and	O
3	F	O
4	.	O

1	Chernoff	O
2	,	O
3	submitted	O
4	for	O
5	publication	O
6	).	O

1	Invited	O
2	editorial	O
3	on	O
4	"	O
5	Acute	O
6	and	O
7	chronic	O
8	effects	O
9	of	O
10	exercise	O
11	on	O
12	leptin	B
13	levels	O
14	in	O
15	humans	O
16	".	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	report	O
7	the	O
8	isolation	O
9	and	O
10	characterization	O
11	of	O
12	the	O
13	entire	O
14	rat	B
15	GSTA3	I
16	(	O
17	rGST	B
18	Yc1	I
19	)	O
20	subunit	O
21	gene	O
22	.	O

1	On	O
2	long	O
3	-	O
4	term	O
5	follow	O
6	-	O
7	up	O
8	,	O
9	there	O
10	was	O
11	no	O
12	significant	O
13	difference	O
14	in	O
15	the	O
16	incidence	O
17	of	O
18	hospitalizations	O
19	(	O
20	1	O
21	per	O
22	2	O
23	.	O
24	1	O
25	vs	O
26	.	O

1	O2	O
2	and	O
3	CO2	O
4	in	O
5	the	O
6	tracheostomy	O
7	tube	O
8	were	O
9	continuously	O
10	monitored	O
11	by	O
12	mass	O
13	spectrometry	O
14	using	O
15	a	O
16	special	O
17	sample	O
18	-	O
19	hold	O
20	phase	O
21	-	O
22	locked	O
23	sampling	O
24	technique	O
25	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	results	O
5	demonstrate	O
6	that	O
7	at	O
8	the	O
9	site	O
10	of	O
11	lumbar	O
12	disc	O
13	herniation	O
14	,	O
15	inflammatory	O
16	cytokines	O
17	such	O
18	as	O
19	interleukin	B
20	-	I
21	1	I
22	alpha	I
23	are	O
24	produced	O
25	,	O
26	which	O
27	increases	O
28	prostaglandin	O
29	E2	O
30	production	O
31	.	O

1	Overexpression	O
2	of	O
3	wild	B
4	-	I
5	type	I
6	p53	I
7	also	O
8	induces	O
9	apoptosis	O
10	in	O
11	an	O
12	LCL	O
13	.	O

1	Ask	O
2	AONE	O
3	'	O
4	s	O
5	experts	O
6	...	O
7	about	O
8	productivity	O
9	indicators	O
10	.	O

1	These	O
2	results	O
3	confirmed	O
4	that	O
5	cleavage	O
6	of	O
7	the	O
8	leader	O
9	peptide	O
10	is	O
11	the	O
12	last	O
13	step	O
14	in	O
15	nisin	B
16	maturation	O
17	and	O
18	is	O
19	necessary	O
20	to	O
21	generate	O
22	a	O
23	biologically	O
24	active	O
25	peptide	O
26	.	O

1	Finally	O
2	,	O
3	we	O
4	determined	O
5	that	O
6	the	O
7	P68	B
8	amino	O
9	terminus	O
10	was	O
11	both	O
12	necessary	O
13	and	O
14	sufficient	O
15	for	O
16	binding	O
17	dsRNA	O
18	as	O
19	we	O
20	were	O
21	able	O
22	to	O
23	transfer	O
24	dsRNA	O
25	-	O
26	binding	O
27	properties	O
28	to	O
29	a	O
30	reporter	O
31	gene	O
32	product	O
33	previously	O
34	unable	O
35	to	O
36	bind	O
37	RNA	O
38	.	O

1	PowerBLAST	O
2	analysis	O
3	identified	O
4	six	O
5	clusters	O
6	of	O
7	expressed	O
8	sequence	O
9	tags	O
10	(	O
11	ESTs	O
12	),	O
13	two	O
14	known	O
15	genes	O
16	(	O
17	BIR	B
18	,	O
19	SUR1	B
20	)	O
21	mapped	O
22	previously	O
23	to	O
24	this	O
25	region	O
26	,	O
27	and	O
28	a	O
29	previously	O
30	characterized	O
31	but	O
32	unmapped	O
33	gene	B
34	NEFA	I
35	(	O
36	DNA	B
37	binding	I
38	/	I
39	EF	I
40	hand	I
41	/	I
42	acidic	I
43	amino	I
44	-	I
45	acid	I
46	-	I
47	rich	I
48	).	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	sMtCK	B
6	genomic	I
7	upstream	I
8	sequences	I
9	reveals	O
10	a	O
11	typical	O
12	TATAA	O
13	box	O
14	within	O
15	the	O
16	80	O
17	base	O
18	pairs	O
19	(	O
20	bp	O
21	)	O
22	that	O
23	,	O
24	by	O
25	transfection	O
26	experiments	O
27	,	O
28	are	O
29	sufficient	O
30	to	O
31	promote	O
32	expression	O
33	of	O
34	chimeric	O
35	plasmids	O
36	with	O
37	the	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	I
41	.	O

1	The	O
2	introduction	O
3	of	O
4	an	O
5	acidic	O
6	residue	O
7	at	O
8	the	O
9	second	O
10	site	O
11	was	O
12	essential	O
13	for	O
14	suppression	O
15	of	O
16	the	O
17	Asn	O
18	-	O
19	285	O
20	mutation	O
21	because	O
22	Lys	O
23	-	O
24	220	O
25	and	O
26	Gln	O
27	-	O
28	220	O
29	second	O
30	-	O
31	site	O
32	mutants	O
33	of	O
34	the	O
35	Asn	O
36	-	O
37	285	O
38	mutant	O
39	showed	O
40	very	O
41	low	O
42	tetracycline	O
43	resistance	O
44	.(	O
45	ABSTRACT	O
46	TRUNCATED	O
47	AT	O
48	250	O
49	WORDS	O
50	)	O

1	The	O
2	IgG	B
3	subclass	O
4	profile	O
5	of	O
6	untreated	O
7	coeliac	O
8	disease	O
9	was	O
10	found	O
11	to	O
12	be	O
13	the	O
14	same	O
15	as	O
16	in	O
17	healthy	O
18	controls	O
19	(	O
20	IgG1	B
21	approximately	O
22	IgG2	B
23	>	O
24	IgG3	B
25	>	O
26	IgG4	B
27	),	O
28	with	O
29	only	O
30	the	O
31	magnitude	O
32	of	O
33	the	O
34	individual	O
35	subclass	O
36	responses	O
37	being	O
38	increased	O
39	in	O
40	coeliac	O
41	patients	O
42	.	O

1	However	O
2	,	O
3	the	O
4	truncated	O
5	deer	B
6	receptor	I
7	lacks	O
8	the	O
9	most	O
10	C	O
11	-	O
12	terminal	O
13	tyrosine	O
14	residue	O
15	in	O
16	the	O
17	intracellular	O
18	domain	O
19	which	O
20	is	O
21	believed	O
22	to	O
23	be	O
24	essential	O
25	for	O
26	activation	O
27	of	O
28	the	O
29	beta	B
30	-	I
31	casein	I
32	promoter	I
33	.	O

1	Moreover	O
2	,	O
3	LD50	O
4	in	O
5	mice	O
6	of	O
7	RP	O
8	-	O
9	170	O
10	(	O
11	4	O
12	.	O
13	3	O
14	g	O
15	/	O
16	kg	O
17	on	O
18	i	O
19	.	O
20	v	O
21	.)	O
22	was	O
23	increased	O
24	to	O
25	5	O
26	.	O
27	2	O
28	g	O
29	/	O
30	kg	O
31	by	O
32	oral	O
33	administration	O
34	.	O

1	When	O
2	expressed	O
3	in	O
4	and	O
5	purified	O
6	from	O
7	Escherichia	O
8	coli	O
9	,	O
10	both	O
11	full	B
12	-	I
13	length	I
14	Fpr3	I
15	and	O
16	its	O
17	isolated	O
18	COOH	O
19	-	O
20	terminal	O
21	domain	O
22	exhibit	O
23	readily	O
24	detectable	O
25	PPIase	B
26	activity	O
27	.	O

1	In	O
2	silicosis	O
3	,	O
4	significant	O
5	relationships	O
6	between	O
7	patients	O
8	and	O
9	sons	O
10	were	O
11	not	O
12	seen	O
13	with	O
14	respect	O
15	to	O
16	arterial	O
17	blood	O
18	gas	O
19	determinations	O
20	and	O
21	ventilatory	O
22	responses	O
23	except	O
24	for	O
25	Paco2	O
26	of	O
27	patients	O
28	and	O
29	hypercapnic	O
30	ventilatory	O
31	responses	O
32	of	O
33	sons	O
34	.	O

1	High	O
2	concentrations	O
3	of	O
4	tumor	O
5	-	O
6	associated	O
7	trypsin	B
8	inhibitor	O
9	in	O
10	hemodialyzed	O
11	patients	O
12	.	O

1	In	O
2	biopsies	O
3	CK	B
4	-	I
5	MB	I
6	fraction	O
7	of	O
8	total	O
9	myocardial	O
10	CPK	B
11	was	O
12	37	O
13	%,	O
14	the	O
15	total	B
16	-	I
17	CPK	I
18	activity	O
19	of	O
20	human	O
21	skeletal	O
22	muscles	O
23	still	O
24	shows	O
25	a	O
26	5	O
27	%	O
28	fraction	O
29	of	O
30	CK	B
31	-	I
32	MB	I
33	.	O

1	These	O
2	results	O
3	lead	O
4	us	O
5	to	O
6	hypothesize	O
7	that	O
8	a	O
9	single	O
10	multisubunit	B
11	TFIID	I
12	protein	I
13	supports	O
14	transcriptional	O
15	stimulation	O
16	by	O
17	diverse	O
18	activation	O
19	domains	O
20	and	O
21	from	O
22	a	O
23	TATA	O
24	-	O
25	less	O
26	promoter	O
27	.	O

1	The	O
2	regurgitation	O
3	of	O
4	large	O
5	vitreous	O
6	injections	O
7	.	O

1	We	O
2	report	O
3	the	O
4	preliminary	O
5	biochemical	O
6	characterization	O
7	of	O
8	the	O
9	T	B
10	antigens	I
11	encoded	O
12	by	O
13	three	O
14	SV40	O
15	mutants	O
16	,	O
17	5030	O
18	,	O
19	5031	O
20	,	O
21	and	O
22	5061	O
23	,	O
24	each	O
25	of	O
26	which	O
27	have	O
28	altered	O
29	residues	O
30	within	O
31	or	O
32	near	O
33	the	O
34	ATP	O
35	binding	O
36	pocket	O
37	.	O

1	Our	O
2	results	O
3	,	O
4	when	O
5	combined	O
6	with	O
7	previously	O
8	published	O
9	in	O
10	vitro	O
11	results	O
12	,	O
13	support	O
14	a	O
15	direct	O
16	role	O
17	for	O
18	Prp44p	B
19	in	O
20	unwinding	O
21	of	O
22	the	O
23	U4	B
24	/	O
25	U6	B
26	helix	O
27	.	O

1	The	O
2	Tullio	O
3	phenomenon	O
4	,	O
5	fistula	O
6	test	O
7	,	O
8	and	O
9	Hennebert	O
10	'	O
11	s	O
12	sign	O
13	:	O
14	clinical	O
15	significance	O
16	.	O

1	The	O
2	assembly	O
3	of	O
4	sequence	O
5	ready	O
6	,	O
7	high	O
8	-	O
9	resolution	O
10	physical	O
11	maps	O
12	and	O
13	construction	O
14	of	O
15	minimally	O
16	overlapping	O
17	contigs	O
18	for	O
19	the	O
20	human	O
21	as	O
22	well	O
23	as	O
24	model	O
25	genomes	O
26	requires	O
27	accurate	O
28	determination	O
29	of	O
30	the	O
31	extent	O
32	of	O
33	overlap	O
34	between	O
35	adjacent	O
36	clones	O
37	as	O
38	well	O
39	as	O
40	their	O
41	relative	O
42	orientation	O
43	.	O

1	According	O
2	to	O
3	out	O
4	field	O
5	research	O
6	,	O
7	the	O
8	tick	O
9	fauna	O
10	was	O
11	very	O
12	rich	O
13	throughout	O
14	that	O
15	area	O
16	,	O
17	and	O
18	it	O
19	was	O
20	permissible	O
21	enough	O
22	to	O
23	determine	O
24	ticks	O
25	as	O
26	the	O
27	vectors	O
28	,	O
29	based	O
30	on	O
31	arising	O
32	of	O
33	anti	B
34	-	I
35	SF	I
36	group	I
37	rickettsiae	I
38	(	O
39	SFGR	B
40	)	O
41	antibody	O
42	in	O
43	mice	O
44	inoculated	O
45	with	O
46	some	O
47	tick	O
48	emulsions	O
49	,	O
50	findings	O
51	of	O
52	rickettsiae	O
53	reactive	O
54	to	O
55	patient	O
56	sera	O
57	or	O
58	a	O
59	species	O
60	-	O
61	specific	O
62	monoclonal	O
63	antibody	O
64	to	O
65	JSFR	B
66	in	O
67	the	O
68	hemolymph	O
69	cells	O
70	of	O
71	some	O
72	ticks	O
73	,	O
74	and	O
75	electron	O
76	microscopical	O
77	observations	O
78	of	O
79	SFGR	B
80	in	O
81	various	O
82	internal	O
83	organs	O
84	including	O
85	the	O
86	salivary	O
87	gland	O
88	of	O
89	ticks	O
90	.	O

1	These	O
2	adverse	O
3	effects	O
4	usually	O
5	abate	O
6	with	O
7	time	O
8	.	O

1	In	O
2	contrast	O
3	,	O
4	rats	O
5	receiving	O
6	U74500A	O
7	(	O
8	2	O
9	mg	O
10	/	O
11	kg	O
12	i	O
13	.	O
14	v	O
15	.	O
16	infusion	O
17	commencing	O
18	30	O
19	min	O
20	prior	O
21	to	O
22	revascularisation	O
23	)	O
24	exhibited	O
25	enhanced	O
26	GMBF	O
27	throughout	O
28	reperfusion	O
29	[	O
30	PI	O
31	10	O
32	min	O
33	:	O
34	3	O
35	.	O
36	26	O
37	(	O
38	2	O
39	.	O
40	56	O
41	-	O
42	3	O
43	.	O
44	63	O
45	);	O
46	120	O
47	min	O
48	:	O
49	2	O
50	.	O
51	03	O
52	(	O
53	1	O
54	.	O
55	73	O
56	-	O
57	2	O
58	.	O
59	25	O
60	);	O
61	240	O
62	min	O
63	:	O
64	2	O
65	.	O
66	13	O
67	(	O
68	1	O
69	.	O
70	75	O
71	-	O
72	2	O
73	.	O
74	44	O
75	),	O
76	p	O
77	<	O
78	0	O
79	.	O
80	01	O
81	vs	O
82	.	O
83	controls	O
84	and	O
85	normals	O
86	]	O
87	with	O
88	complete	O
89	muscle	O
90	salvage	O
91	[	O
92	GMV	O
93	100	O
94	%	O
95	in	O
96	all	O
97	reperfused	O
98	muscles	O
99	,	O
100	p	O
101	<	O
102	0	O
103	.	O
104	01	O
105	vs	O
106	.	O
107	controls	O
108	,	O
109	not	O
110	significant	O
111	(	O
112	NS	O
113	)	O
114	vs	O
115	.	O
116	normals	O
117	and	O
118	6	O
119	h	O
120	ischaemia	O
121	].(	O
122	ABSTRACT	O
123	TRUNCATED	O
124	AT	O
125	250	O
126	WORDS	O
127	)	O

1	Moreover	O
2	,	O
3	moderate	O
4	overexpression	O
5	of	O
6	Chk1	B
7	suppresses	O
8	the	O
9	phenotypes	O
10	of	O
11	cut5	B
12	and	O
13	crb2	B
14	mutants	I
15	.	O

1	Fifty	O
2	min	O
3	after	O
4	release	O
5	from	O
6	stress	O
7	,	O
8	increases	O
9	in	O
10	plasma	O
11	corticosterone	O
12	levels	O
13	induced	O
14	by	O
15	stress	O
16	recovered	O
17	in	O
18	the	O
19	biting	O
20	group	O
21	but	O
22	remained	O
23	high	O
24	in	O
25	the	O
26	non	O
27	-	O
28	biting	O
29	group	O
30	.	O

1	Toward	O
2	this	O
3	end	O
4	,	O
5	we	O
6	prepared	O
7	synthetic	O
8	proteins	O
9	with	O
10	either	O
11	the	O
12	catalytic	O
13	domain	O
14	of	O
15	FAP	B
16	-	I
17	1	I
18	(	I
19	C	I
20	-	I
21	terminal	I
22	399	I
23	amino	I
24	acids	I
25	)	I
26	or	O
27	its	O
28	inactive	O
29	form	O
30	(	O
31	Cys2408	O
32	-->	O
33	Ser	O
34	)	O
35	fused	O
36	to	O
37	glutathione	B
38	-	I
39	S	I
40	-	I
41	transferase	I
42	(	O
43	GST	B
44	).	O

1	Basal	O
2	plasma	O
3	AVP	B
4	levels	O
5	and	O
6	AVP	B
7	release	O
8	after	O
9	postural	O
10	change	O
11	were	O
12	assessed	O
13	,	O
14	and	O
15	plasma	O
16	NPY	B
17	levels	O
18	were	O
19	measured	O
20	in	O
21	the	O
22	same	O
23	samples	O
24	.	O

1	The	O
2	full	O
3	protocol	O
4	was	O
5	completed	O
6	by	O
7	33	O
8	patients	O
9	(	O
10	45	O
11	%	O
12	of	O
13	original	O
14	cohort	O
15	).	O

1	Chimeras	O
2	containing	O
3	IE1	B
4	peptides	I
5	dramatically	O
6	activated	O
7	transcription	O
8	of	O
9	the	O
10	basal	O
11	promoter	O
12	only	O
13	when	O
14	lac	B
15	operator	I
16	sequences	I
17	were	O
18	present	O
19	.	O

1	This	O
2	repression	O
3	was	O
4	mediated	O
5	through	O
6	binding	O
7	to	O
8	the	O
9	E2	B
10	DNA	I
11	-	I
12	binding	I
13	site	I
14	immediately	O
15	upstream	O
16	of	O
17	the	O
18	P105	B
19	promoter	O
20	TATA	O
21	box	O
22	and	O
23	could	O
24	be	O
25	abrogated	O
26	by	O
27	preincubation	O
28	of	O
29	the	O
30	HPV	B
31	-	I
32	18	I
33	P105	I
34	promoter	I
35	template	O
36	with	O
37	the	O
38	nuclear	O
39	extract	O
40	allowing	O
41	the	O
42	formation	O
43	of	O
44	the	O
45	preinitiation	O
46	complex	O
47	.	O

1	LDL	B
2	cholesterol	I
3	decreased	O
4	from	O
5	4	O
6	.	O
7	74	O
8	+/-	O
9	0	O
10	.	O
11	87	O
12	to	O
13	3	O
14	.	O
15	78	O
16	+/-	O
17	0	O
18	.	O
19	78	O
20	mmol	O
21	/	O
22	l	O
23	after	O
24	8	O
25	weeks	O
26	on	O
27	simvastatin	O
28	(	O
29	P	O
30	<	O
31	0	O
32	.	O
33	001	O
34	),	O
35	and	O
36	apo	B
37	B	I
38	fell	O
39	from	O
40	142	O
41	+/-	O
42	31	O
43	to	O
44	112	O
45	+/-	O
46	22	O
47	mg	O
48	/	O
49	dl	O
50	(	O
51	P	O
52	<	O
53	0	O
54	.	O
55	001	O
56	).	O

1	Bacteriostatic	O
2	and	O
3	bacteriacidal	O
4	activity	O
5	of	O
6	hydroxy	O
7	-	O
8	9	O
9	ellipticine	O
10	in	O
11	vitro	O

1	Statistics	O
2	of	O
3	the	O
4	past	O
5	5	O
6	years	O

1	The	O
2	more	O
3	traditional	O
4	SERMS	O
5	,	O
6	clomiphene	O
7	citrate	O
8	and	O
9	tamoxifen	O
10	,	O
11	will	O
12	be	O
13	reviewed	O
14	along	O
15	with	O
16	such	O
17	modern	O
18	drugs	O
19	as	O
20	raloxifene	O
21	and	O
22	faslodex	O
23	,	O
24	with	O
25	emphasis	O
26	upon	O
27	their	O
28	actions	O
29	on	O
30	breast	O
31	,	O
32	uterus	O
33	,	O
34	bone	O
35	and	O
36	lipids	O
37	.	O

1	Then	O
2	,	O
3	pure	O
4	pancreatic	O
5	juice	O
6	was	O
7	infused	O
8	into	O
9	the	O
10	duodenum	O
11	.	O

1	The	O
2	corresponding	O
3	differences	O
4	in	O
5	FVIIa	B
6	and	O
7	PAI	B
8	-	I
9	1	I
10	were	O
11	not	O
12	statistically	O
13	significant	O
14	.	O

1	A	O
2	survey	O
3	is	O
4	given	O
5	of	O
6	the	O
7	pharmacological	O
8	backgrounds	O
9	that	O
10	are	O
11	relevant	O
12	for	O
13	the	O
14	drug	O
15	treatment	O
16	of	O
17	essential	O
18	hypertension	O
19	in	O
20	the	O
21	elderly	O
22	.	O

1	The	O
2	expression	O
3	analysis	O
4	of	O
5	the	O
6	KlHIS4	B
7	gene	I
8	under	O
9	phosphate	O
10	starvation	O
11	or	O
12	high	O
13	adenine	O
14	supply	O
15	shows	O
16	that	O
17	factors	O
18	,	O
19	such	O
20	as	O
21	Bas1	B
22	or	O
23	Bas2	B
24	,	O
25	involved	O
26	in	O
27	the	O
28	basal	O
29	control	O
30	may	O
31	also	O
32	operate	O
33	in	O
34	a	O
35	different	O
36	way	O
37	in	O
38	K	O
39	.	O
40	lactis	O
41	.	O

1	Clin	O
2	.	O

1	Fibrinogen	B
2	determination	O
3	using	O
4	the	O
5	KZM	O
6	-	O
7	1	O
8	meter	O

1	Microcirculatory	O
2	oxygenation	O
3	and	O
4	shunting	O
5	in	O
6	sepsis	O
7	and	O
8	shock	O
9	.	O

1	An	O
2	anchored	O
3	AFLP	O
4	-	O
5	and	O
6	retrotransposon	O
7	-	O
8	based	O
9	map	O
10	of	O
11	diploid	O
12	Avena	O
13	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	may	O
5	exacerbate	O
6	cryoblobulinemia	O
7	-	O
8	related	O
9	ischemic	O
10	manifestations	O
11	:	O
12	an	O
13	adverse	O
14	effect	O
15	potentially	O
16	related	O
17	to	O
18	its	O
19	anti	O
20	-	O
21	angiogenic	O
22	activity	O
23	.	O

1	A	O
2	synergistic	O
3	effect	O
4	on	O
5	HCK	B
6	promoter	I
7	activity	O
8	was	O
9	observed	O
10	at	O
11	high	O
12	concentrations	O
13	of	O
14	Sp1	B
15	.	O

1	Upon	O
2	differentiation	O
3	with	O
4	retinoic	O
5	acid	O
6	(	O
7	RA	O
8	),	O
9	transcription	O
10	of	O
11	the	O
12	Rex	B
13	-	I
14	1	I
15	gene	I
16	decreases	O
17	rapidly	O
18	.	O

1	However	O
2	,	O
3	when	O
4	domain	O
5	I	O
6	and	O
7	domain	O
8	II	O
9	were	O
10	linked	O
11	on	O
12	the	O
13	same	O
14	plasmid	O
15	,	O
16	high	O
17	levels	O
18	of	O
19	replication	O
20	were	O
21	observed	O
22	.	O

1	EMSA	O
2	competition	O
3	experiments	O
4	showed	O
5	that	O
6	mutations	O
7	within	O
8	the	O
9	direct	O
10	repeats	O
11	failed	O
12	to	O
13	compete	O
14	for	O
15	binding	O
16	of	O
17	the	O
18	nuclear	O
19	proteins	O
20	to	O
21	labeled	O
22	wild	O
23	type	O
24	oligonucleotide	O
25	.	O

1	Data	O
2	from	O
3	the	O
4	V	O
5	-	O
6	HeFT	O
7	II	O
8	show	O
9	that	O
10	at	O
11	2	O
12	-	O
13	year	O
14	follow	O
15	-	O
16	up	O
17	,	O
18	a	O
19	progressive	O
20	rise	O
21	of	O
22	plasma	O
23	norepinephrine	O
24	was	O
25	observed	O
26	in	O
27	both	O
28	treatment	O
29	arms	O
30	,	O
31	suggesting	O
32	that	O
33	disease	O
34	progresses	O
35	despite	O
36	treatment	O
37	with	O
38	either	O
39	an	O
40	angiotensin	B
41	-	I
42	converting	I
43	enzyme	I
44	inhibitor	O
45	,	O
46	enalapril	O
47	,	O
48	or	O
49	vasodilator	O
50	therapy	O
51	with	O
52	hydralazine	O
53	/	O
54	isosorbide	O
55	dinitrate	O
56	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	bulbospinal	O
7	micturition	O
8	reflex	O
9	evoked	O
10	by	O
11	bladder	O
12	filling	O
13	and	O
14	L	O
15	-	O
16	dopa	O
17	involves	O
18	a	O
19	descending	O
20	pathway	O
21	where	O
22	transmission	O
23	is	O
24	partly	O
25	mediated	O
26	by	O
27	spinal	B
28	alpha	I
29	1	I
30	-	I
31	adrenoceptors	I
32	.	O

1	As	O
2	well	O
3	,	O
4	further	O
5	deletion	O
6	of	O
7	the	O
8	promoter	O
9	region	O
10	to	O
11	nucleotide	O
12	-	O
13	110	O
14	,	O
15	which	O
16	contains	O
17	only	O
18	one	O
19	SF	B
20	-	I
21	1	I
22	binding	I
23	site	I
24	,	O
25	still	O
26	retained	O
27	the	O
28	ability	O
29	to	O
30	respond	O
31	to	O
32	exogenous	O
33	SF	B
34	-	I
35	1	I
36	.	O

1	To	O
2	study	O
3	retinoid	O
4	signalling	O
5	in	O
6	zebrafish	O
7	embryos	O
8	,	O
9	we	O
10	developed	O
11	a	O
12	novel	O
13	method	O
14	to	O
15	detect	O
16	endogenous	O
17	retinoids	O
18	in	O
19	situ	O
20	in	O
21	embryos	O
22	,	O
23	using	O
24	a	O
25	fusion	O
26	protein	O
27	of	O
28	the	O
29	ligand	O
30	inducible	O
31	transactivation	O
32	domain	O
33	of	O
34	a	O
35	retinoic	B
36	acid	I
37	receptor	I
38	and	O
39	a	O
40	heterologous	O
41	DNA	O
42	binding	O
43	domain	O
44	.	O

1	We	O
2	report	O
3	a	O
4	prevalence	O
5	study	O
6	of	O
7	the	O
8	best	O
9	visual	O
10	acuity	O
11	in	O
12	the	O
13	affected	O
14	eye	O
15	of	O
16	100	O
17	selected	O
18	patients	O
19	with	O
20	herpetic	O
21	keratitis	O
22	seen	O
23	during	O
24	a	O
25	two	O
26	-	O
27	year	O
28	period	O
29	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	this	O
5	100	O
6	-	O
7	bp	O
8	Col2a1	B
9	enhancer	I
10	revealed	O
11	several	O
12	sequence	O
13	motifs	O
14	similar	O
15	to	O
16	motifs	O
17	present	O
18	within	O
19	the	O
20	regulatory	O
21	region	O
22	of	O
23	the	O
24	link	B
25	protein	I
26	gene	I
27	,	O
28	another	O
29	cartilage	O
30	gene	O
31	.	O

1	Collectively	O
2	,	O
3	these	O
4	and	O
5	previously	O
6	published	O
7	data	O
8	suggest	O
9	a	O
10	model	O
11	where	O
12	NS1	B
13	recruits	O
14	eIF4GI	B
15	specifically	O
16	to	O
17	the	O
18	5	O
19	'	O
20	untranslated	O
21	region	O
22	(	O
23	5	O
24	'	O
25	UTR	O
26	)	O
27	of	O
28	the	O
29	viral	O
30	mRNA	O
31	,	O
32	allowing	O
33	for	O
34	the	O
35	preferential	O
36	translation	O
37	of	O
38	the	O
39	influenza	O
40	virus	O
41	messengers	O
42	.	O

1	These	O
2	studies	O
3	indicate	O
4	that	O
5	the	O
6	acidimetric	O
7	test	O
8	was	O
9	less	O
10	sensitive	O
11	than	O
12	the	O
13	chromogenic	O
14	cephalosporin	O
15	substrates	O
16	and	O
17	that	O
18	nitrocefin	O
19	and	O
20	S1	O
21	could	O
22	be	O
23	used	O
24	to	O
25	screen	O
26	for	O
27	beta	B
28	-	I
29	lactamase	I
30	production	O
31	in	O
32	these	O
33	tested	O
34	species	O
35	.	O

1	Methods	O
2	included	O
3	24	O
4	-	O
5	hour	O
6	dietary	O
7	recall	O
8	,	O
9	menu	O
10	weights	O
11	,	O
12	and	O
13	recipe	O
14	analysis	O
15	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	CSF1R	B
5	/	O
6	IRDelta960	B
7	was	O
8	as	O
9	effective	O
10	as	O
11	the	O
12	CSF1R	B
13	/	O
14	IR	B
15	in	O
16	mediating	O
17	CSF	B
18	-	I
19	1	I
20	protection	O
21	of	O
22	cells	O
23	from	O
24	staurosporine	O
25	-	O
26	induced	O
27	apoptosis	O
28	.	O

1	Eukaryotic	B
2	translation	I
3	initiation	I
4	factor	I
5	4GI	I
6	is	O
7	a	O
8	cellular	O
9	target	O
10	for	O
11	NS1	B
12	protein	I
13	,	O
14	a	O
15	translational	O
16	activator	O
17	of	O
18	influenza	O
19	virus	O
20	.	O

1	The	O
2	N	O
3	terminus	O
4	of	O
5	beta	O
6	(	O
7	95	O
8	kDa	O
9	)	O
10	corresponds	O
11	to	O
12	alpha	O
13	with	O
14	the	O
15	integrase	B
16	domain	I
17	attached	O
18	to	O
19	the	O
20	C	O
21	terminus	O
22	(	O
23	32	O
24	kDa	O
25	).	O

1	The	O
2	DAP5	B
3	/	O
4	p86	B
5	apoptotic	O
6	form	O
7	was	O
8	more	O
9	potent	O
10	than	O
11	DAP5	B
12	/	O
13	p97	B
14	in	O
15	these	O
16	functional	O
17	assays	O
18	.	O

1	Modifications	O
2	of	O
3	the	O
4	involuntary	O
5	postcontraction	O
6	in	O
7	diseased	O
8	people	O
9	.	O

1	Rearrangements	O
2	of	O
3	the	O
4	NFKB2	B
5	gene	I
6	are	O
7	associated	O
8	with	O
9	lymphoid	O
10	malignancies	O
11	,	O
12	but	O
13	the	O
14	functional	O
15	significance	O
16	of	O
17	these	O
18	alterations	O
19	is	O
20	not	O
21	known	O
22	.	O

1	Exon	O
2	A	O
3	is	O
4	located	O
5	approximately	O
6	7	O
7	kb	O
8	5	O
9	'	O
10	to	O
11	the	O
12	HSL	B
13	translation	I
14	start	I
15	site	I
16	.	O

1	The	O
2	cloned	O
3	alcR	B
4	gene	I
5	provided	O
6	in	O
7	trans	O
8	restored	O
9	these	O
10	siderophore	O
11	system	O
12	activities	O
13	to	O
14	the	O
15	mutants	O
16	.	O

1	Purified	B
2	P7	I
3	could	O
4	be	O
5	assembled	O
6	onto	O
7	particles	O
8	lacking	O
9	P7	B
10	and	O
11	particles	O
12	lacking	O
13	both	O
14	P2	B
15	(	O
16	RNA	B
17	polymerase	I
18	)	O
19	and	O
20	P7	B
21	.	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	activity	O
5	was	O
6	increased	O
7	up	O
8	to	O
9	15	O
10	times	O
11	above	O
12	the	O
13	upper	O
14	normal	O
15	limit	O
16	in	O
17	children	O
18	,	O
19	who	O
20	received	O
21	aminopyrine	O
22	for	O
23	two	O
24	weeks	O
25	or	O
26	longer	O
27	.	O

1	We	O
2	have	O
3	demonstrated	O
4	previously	O
5	that	O
6	two	O
7	binding	O
8	sites	O
9	in	O
10	the	O
11	-	B
12	184	I
13	HNF	I
14	-	I
15	3	I
16	beta	I
17	promoter	I
18	are	O
19	recognized	O
20	by	O
21	widely	O
22	distributed	O
23	factors	O
24	and	O
25	that	O
26	there	O
27	is	O
28	also	O
29	a	O
30	critical	O
31	autoregulatory	O
32	site	O
33	,	O
34	we	O
35	identified	O
36	a	O
37	binding	O
38	site	O
39	for	O
40	a	O
41	cell	O
42	-	O
43	specific	O
44	factor	O
45	,	O
46	LF	B
47	-	I
48	H3	I
49	beta	I
50	,	O
51	that	O
52	may	O
53	function	O
54	in	O
55	restricting	O
56	HNF	B
57	-	I
58	3	I
59	beta	I
60	gene	I
61	expression	O
62	to	O
63	hepatocytes	O
64	.	O

1	To	O
2	determine	O
3	whether	O
4	mononuclear	O
5	cell	O
6	secretory	O
7	products	O
8	contribute	O
9	to	O
10	the	O
11	changes	O
12	in	O
13	bone	O
14	turnover	O
15	that	O
16	characterize	O
17	the	O
18	development	O
19	of	O
20	postmenopausal	O
21	osteoporosis	O
22	,	O
23	we	O
24	evaluated	O
25	the	O
26	effects	O
27	of	O
28	oophorectomy	O
29	and	O
30	subsequent	O
31	estrogen	O
32	replacement	O
33	on	O
34	the	O
35	spontaneous	O
36	secretion	O
37	of	O
38	interleukin	B
39	1	I
40	(	O
41	IL	B
42	-	I
43	1	I
44	)	O
45	and	O
46	tumor	B
47	necrosis	I
48	factor	I
49	alpha	I
50	(	O
51	TNF	B
52	-	I
53	alpha	I
54	)	O
55	and	O
56	on	O
57	the	O
58	phytohemagglutinin	B
59	A	I
60	-	O
61	induced	O
62	secretion	O
63	of	O
64	granulocyte	B
65	-	I
66	macrophage	I
67	colony	I
68	-	I
69	stimulating	I
70	factor	I
71	(	O
72	GM	B
73	-	I
74	CSF	I
75	)	O
76	from	O
77	peripheral	O
78	blood	O
79	mononuclear	O
80	cells	O
81	.	O

1	To	O
2	test	O
3	whether	O
4	Sp1	B
5	and	O
6	zif268	B
7	/	O
8	egr	B
9	-	I
10	1	I
11	interact	O
12	with	O
13	this	O
14	motif	O
15	,	O
16	gel	O
17	retardation	O
18	assays	O
19	were	O
20	performed	O
21	.	O

1	The	O
2	two	O
3	contiguous	O
4	IGF2	B
5	(	O
6	human	B
7	insulin	I
8	-	I
9	like	I
10	growth	I
11	factor	I
12	II	I
13	)	O
14	and	O
15	H19	B
16	genes	I
17	are	O
18	reciprocally	O
19	imprinted	O
20	in	O
21	both	O
22	human	O
23	and	O
24	mouse	O
25	.	O

1	These	O
2	results	O
3	imply	O
4	that	O
5	the	O
6	GCN3	B
7	product	I
8	can	O
9	promote	O
10	either	O
11	repression	O
12	or	O
13	activation	O
14	of	O
15	GCN4	B
16	expression	O
17	depending	O
18	on	O
19	amino	O
20	acid	O
21	availability	O
22	.	O

1	SCL	O
2	prolonged	O
3	promptly	O
4	after	O
5	verapamil	O
6	,	O
7	and	O
8	sinus	O
9	arrest	O
10	developed	O
11	in	O
12	two	O
13	of	O
14	10	O
15	group	O
16	2	O
17	and	O
18	two	O
19	of	O
20	five	O
21	group	O
22	3	O
23	animals	O
24	.	O

1	These	O
2	changes	O
3	at	O
4	the	O
5	site	O
6	of	O
7	injection	O
8	consist	O
9	of	O
10	a	O
11	focal	O
12	abnormality	O
13	characterized	O
14	by	O
15	a	O
16	slight	O
17	increase	O
18	in	O
19	signal	O
20	intensity	O
21	on	O
22	T1	O
23	weighted	O
24	images	O
25	and	O
26	markedly	O
27	increased	O
28	signal	O
29	intensity	O
30	on	O
31	T2	O
32	weighted	O
33	images	O
34	.	O

1	Therefore	O
2	,	O
3	Mxi1	B
4	and	O
5	Mad	B
6	might	O
7	antagonize	O
8	Myc	B
9	function	O
10	and	O
11	are	O
12	candidate	O
13	tumor	O
14	suppressor	O
15	genes	O
16	.	O

1	Solving	O
2	an	O
3	age	O
4	old	O
5	problem	O
6	.	O

1	Finally	O
2	,	O
3	a	O
4	role	O
5	for	O
6	NF	B
7	-	I
8	kappaB	I
9	in	O
10	preventing	O
11	apoptosis	O
12	induced	O
13	by	O
14	ER	O
15	calcium	O
16	release	O
17	was	O
18	demonstrated	O
19	by	O
20	data	O
21	showing	O
22	that	O
23	sAPPalpha	B
24	prevents	O
25	thapsigargin	O
26	-	O
27	induced	O
28	apoptosis	O
29	,	O
30	an	O
31	effect	O
32	blocked	O
33	by	O
34	kappaB	B
35	decoy	O
36	DNA	O
37	.	O

1	Treatment	O
2	of	O
3	Graves	O
4	'	O
5	disease	O
6	.	O

1	(	O
2	Emeritus	O
3	)	O
4	John	O
5	Henri	O
6	Roosegaarde	O
7	Bisschop	O

1	Mutational	O
2	analysis	O
3	shows	O
4	that	O
5	both	O
6	an	O
7	AP	B
8	-	I
9	1	I
10	like	I
11	sequence	I
12	(-	O
13	294	O
14	/-	O
15	285	O
16	,	O
17	TGAATCATCA	O
18	)	O
19	and	O
20	an	O
21	A	O
22	/	O
23	T	O
24	-	O
25	rich	O
26	myocyte	B
27	enhancer	I
28	factor	I
29	(	I
30	MEF	I
31	)-	I
32	2	I
33	like	I
34	sequence	I
35	(-	O
36	310	O
37	/-	O
38	298	O
39	,	O
40	TTAAAAATAAAAA	O
41	)	O
42	in	O
43	the	O
44	33	O
45	-	O
46	bp	O
47	region	O
48	are	O
49	necessary	O
50	for	O
51	the	O
52	OP	B
53	-	I
54	1	I
55	effect	O
56	.	O

1	Potential	O
2	consensus	O
3	sequences	O
4	for	O
5	early	O
6	and	O
7	late	O
8	regulatory	O
9	elements	O
10	were	O
11	identified	O
12	.	O

1	Alanine	O
2	substitution	O
3	mutations	O
4	in	O
5	the	O
6	Zta	B
7	activation	I
8	domain	I
9	which	O
10	eliminate	O
11	the	O
12	ability	O
13	of	O
14	Zta	B
15	to	O
16	stimulate	O
17	the	O
18	D	B
19	-	I
20	A	I
21	complex	I
22	were	O
23	examined	O
24	.	O

1	We	O
2	also	O
3	compared	O
4	the	O
5	sequence	O
6	with	O
7	the	O
8	partly	O
9	homologous	O
10	products	O
11	of	O
12	the	O
13	S	O
14	.	O
15	cerevisiae	O
16	genes	O
17	TPS2	B
18	and	O
19	TSL1	B
20	which	O
21	code	O
22	for	O
23	the	O
24	larger	O
25	subunits	O
26	of	O
27	the	O
28	trehalose	B
29	synthase	I
30	complex	I
31	and	O
32	with	O
33	a	O
34	TSL1	B
35	homologue	I
36	,	O
37	TPS3	B
38	,	O
39	of	O
40	unknown	O
41	function	O
42	.	O

1	The	O
2	main	O
3	aim	O
4	of	O
5	the	O
6	contribution	O
7	,	O
8	which	O
9	opens	O
10	an	O
11	arena	O
12	for	O
13	discussion	O
14	on	O
15	the	O
16	Rivista	O
17	dell	O
18	'	O
19	Infermiere	O
20	is	O
21	to	O
22	critically	O
23	appraise	O
24	published	O
25	research	O
26	works	O
27	focusing	O
28	both	O
29	on	O
30	strengths	O
31	and	O
32	novelty	O
33	and	O
34	weaknesses	O
35	in	O
36	the	O
37	hypothesis	O
38	formulation	O
39	,	O
40	methods	O
41	and	O
42	instruments	O
43	used	O
44	,	O
45	discussion	O
46	of	O
47	results	O
48	.	O

1	Biol	O
2	.	O

1	The	O
2	deduced	O
3	protein	O
4	sequence	O
5	was	O
6	88	O
7	%	O
8	homologous	O
9	to	O
10	that	O
11	of	O
12	hNUC	B
13	I	I
14	,	O
15	isolated	O
16	from	O
17	human	O
18	osteosarcoma	O
19	cells	O
20	.	O

1	These	O
2	data	O
3	strongly	O
4	implicate	O
5	the	O
6	normal	O
7	product	O
8	of	O
9	the	O
10	int	B
11	-	I
12	2	I
13	gene	I
14	,	O
15	which	O
16	is	O
17	related	O
18	to	O
19	the	O
20	fibroblast	B
21	growth	I
22	factor	I
23	family	I
24	,	O
25	as	O
26	a	O
27	contributory	O
28	factor	O
29	in	O
30	virally	O
31	induced	O
32	mammary	O
33	tumors	O
34	.	O

1	A	O
2	correlation	O
3	coefficient	O
4	was	O
5	used	O
6	for	O
7	assessing	O
8	the	O
9	similarity	O
10	of	O
11	each	O
12	map	O
13	pattern	O
14	with	O
15	the	O
16	normal	O
17	mean	O
18	IQRST	O
19	map	O
20	.	O

1	These	O
2	results	O
3	illustrate	O
4	an	O
5	important	O
6	role	O
7	for	O
8	La	B
9	in	O
10	RNA	O
11	production	O
12	by	O
13	demonstrating	O
14	its	O
15	ability	O
16	to	O
17	clear	O
18	the	O
19	termination	O
20	sites	O
21	of	O
22	class	O
23	III	O
24	templates	O
25	,	O
26	thereby	O
27	promoting	O
28	efficient	O
29	use	O
30	of	O
31	transcription	O
32	complexes	O
33	by	O
34	pol	B
35	III	I
36	.	O

1	A	O
2	poor	O
3	correlation	O
4	was	O
5	also	O
6	observed	O
7	between	O
8	PbB	O
9	and	O
10	ALAD	B
11	activity	O
12	of	O
13	the	O
14	stearate	O
15	workers	O
16	.	O

1	Circulating	O
2	oxytocin	B
3	in	O
4	male	O
5	guinea	O
6	pigs	O
7	affected	O
8	by	O
9	the	O
10	female	O
11	cohabitation	O
12	and	O
13	reproductive	O
14	condition	O
15	.	O

1	A	O
2	G22V	B
3	mutant	I
4	of	O
5	M	B
6	-	I
7	Ras	I
8	was	O
9	constitutively	O
10	active	O
11	and	O
12	its	O
13	expression	O
14	in	O
15	an	O
16	interleukin	B
17	-	I
18	3	I
19	(	O
20	IL	B
21	-	I
22	3	I
23	)-	O
24	dependent	O
25	mast	O
26	cell	O
27	/	O
28	megakaryocyte	O
29	cell	O
30	line	O
31	resulted	O
32	in	O
33	increased	O
34	survival	O
35	in	O
36	the	O
37	absence	O
38	of	O
39	IL	B
40	-	I
41	3	I
42	,	O
43	increased	O
44	growth	O
45	in	O
46	IL	B
47	-	I
48	4	I
49	,	O
50	and	O
51	,	O
52	at	O
53	high	O
54	expression	O
55	levels	O
56	,	O
57	in	O
58	factor	O
59	-	O
60	independent	O
61	growth	O
62	.	O

1	Expression	O
2	of	O
3	constitutively	O
4	active	O
5	MEK1	B
6	,	O
7	the	O
8	kinase	O
9	that	O
10	activates	O
11	ERKs	B
12	,	O
13	or	O
14	overexpression	O
15	of	O
16	ERK2	B
17	,	O
18	but	O
19	not	O
20	JNK1	B
21	,	O
22	inhibited	O
23	Stat3	B
24	activation	O
25	.	O

1	ROS	B
2	x	O
3	SRC	B
4	(	O
5	R	B
6	)	O
7	contains	O
8	a	O
9	16	O
10	-	O
11	amino	O
12	-	O
13	acid	O
14	deletion	O
15	that	O
16	includes	O
17	the	O
18	3	O
19	'	O
20	half	O
21	of	O
22	the	O
23	transmembrane	O
24	domain	O
25	of	O
26	ros	B
27	.	O

1	Proteins	O
2	known	O
3	to	O
4	bind	O
5	the	O
6	PEPCK	B
7	CRE	O
8	include	O
9	the	O
10	CRE	B
11	-	I
12	binding	I
13	protein	I
14	(	O
15	CREB	B
16	)	O
17	and	O
18	members	O
19	of	O
20	the	O
21	CCAAT	B
22	/	I
23	enhancer	I
24	-	I
25	binding	I
26	protein	I
27	(	O
28	C	B
29	/	I
30	EBP	I
31	)	O
32	family	O
33	.	O

1	Most	O
2	smokers	O
3	would	O
4	prefer	O
5	to	O
6	quit	O
7	smoking	O
8	on	O
9	their	O
10	own	O
11	.	O

1	An	O
2	N	O
3	-	O
4	terminal	O
5	arm	O
6	from	O
7	each	O
8	subunit	O
9	wraps	O
10	around	O
11	the	O
12	dinucleotide	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	an	O
18	adjacent	O
19	subunit	O
20	,	O
21	covering	O
22	the	O
23	adenine	O
24	ring	O
25	of	O
26	NADP	O
27	.	O

1	Nine	O
2	DNA	O
3	fragments	O
4	that	O
5	were	O
6	specifically	O
7	recognized	O
8	and	O
9	bound	O
10	by	O
11	histidine	O
12	-	O
13	tagged	O
14	AdpA	B
15	were	O
16	isolated	O
17	by	O
18	cycles	O
19	of	O
20	a	O
21	gel	O
22	mobility	O
23	shift	O
24	-	O
25	PCR	O
26	method	O
27	.	O

1	The	O
2	mean	O
3	transfer	O
4	ratios	O
5	of	O
6	the	O
7	drug	O
8	into	O
9	the	O
10	genital	O
11	tissues	O
12	to	O
13	the	O
14	concentration	O
15	in	O
16	the	O
17	uterine	O
18	arterial	O
19	blood	O
20	were	O
21	such	O
22	that	O
23	the	O
24	transfer	O
25	ratio	O
26	into	O
27	the	O
28	portio	O
29	vaginalis	O
30	was	O
31	the	O
32	highest	O
33	,	O
34	followed	O
35	by	O
36	the	O
37	uterine	O
38	cervix	O
39	and	O
40	the	O
41	myometrium	O
42	,	O
43	and	O
44	that	O
45	into	O
46	the	O
47	oviduct	O
48	was	O
49	the	O
50	lowest	O
51	with	O
52	about	O
53	1	O
54	/	O
55	2	O
56	that	O
57	into	O
58	the	O
59	portio	O
60	vaginalis	O
61	.	O

1	Therefore	O
2	,	O
3	it	O
4	is	O
5	hoped	O
6	that	O
7	by	O
8	defining	O
9	the	O
10	transcriptional	O
11	control	O
12	of	O
13	the	O
14	L7	B
15	gene	I
16	insights	O
17	into	O
18	the	O
19	mechanisms	O
20	that	O
21	control	O
22	functional	O
23	fate	O
24	and	O
25	organization	O
26	in	O
27	the	O
28	nervous	O
29	system	O
30	can	O
31	be	O
32	gained	O
33	.	O

1	The	O
2	gene	B
3	lac	I
4	-	I
5	1	I
6	,	O
7	encoding	O
8	the	O
9	enzyme	O
10	laccase	B
11	,	O
12	is	O
13	the	O
14	best	O
15	characterized	O
16	of	O
17	a	O
18	number	O
19	of	O
20	genes	O
21	in	O
22	the	O
23	chestnut	O
24	blight	O
25	fungus	O
26	,	O
27	Cryphonectria	O
28	parasitica	O
29	,	O
30	that	O
31	are	O
32	repressed	O
33	by	O
34	hypoviruses	O
35	,	O
36	a	O
37	group	O
38	of	O
39	virulence	O
40	-	O
41	attenuating	O
42	mycoviruses	O
43	.	O
44	lac	B
45	-	I
46	1	I
47	has	O
48	also	O
49	been	O
50	shown	O
51	to	O
52	be	O
53	transcriptionally	O
54	activated	O
55	by	O
56	low	O
57	concentrations	O
58	of	O
59	the	O
60	translational	O
61	inhibitor	O
62	cycloheximide	O
63	(	O
64	CHX	O
65	)	O
66	and	O
67	by	O
68	the	O
69	immunosuppressant	O
70	cyclosporin	O
71	A	O
72	.	O

1	Ganciclovir	O
2	and	O
3	foscarnet	O
4	efficacy	O
5	in	O
6	AIDS	O
7	-	O
8	related	O
9	CMV	O
10	polyradiculopathy	O
11	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	Xenopus	B
5	U7	I
6	gene	I
7	contains	O
8	two	O
9	adjacent	O
10	octamer	O
11	-	O
12	binding	O
13	motifs	O
14	located	O
15	only	O
16	12	O
17	and	O
18	24	O
19	bp	O
20	upstream	O
21	from	O
22	the	O
23	PSE	B
24	,	O
25	instead	O
26	of	O
27	the	O
28	usual	O
29	location	O
30	around	O
31	150	O
32	-	O
33	200	O
34	bp	O
35	upstream	O
36	.	O

1	The	O
2	major	O
3	RNase	B
4	E	I
5	cleavage	O
6	product	O
7	(	O
8	denoted	O
9	pSok	B
10	-	I
11	6	I
12	)	O
13	is	O
14	rapidly	O
15	degraded	O
16	by	O
17	polynucleotide	B
18	phosphorylase	I
19	(	O
20	PNPase	B
21	).	O

1	CCAAT	B
2	/	I
3	enhancer	I
4	-	I
5	binding	I
6	protein	I
7	isoforms	I
8	beta	I
9	and	I
10	delta	I
11	are	O
12	expressed	O
13	in	O
14	mammary	O
15	epithelial	O
16	cells	O
17	and	O
18	bind	O
19	to	O
20	multiple	O
21	sites	O
22	in	O
23	the	O
24	beta	B
25	-	I
26	casein	I
27	gene	I
28	promoter	I
29	.	O

1	Regulation	O
2	of	O
3	urokinase	B
4	plasminogen	I
5	activator	I
6	gene	I
7	transcription	O
8	in	O
9	the	O
10	RAW264	O
11	murine	O
12	macrophage	O
13	cell	O
14	line	O
15	by	O
16	macrophage	B
17	colony	I
18	-	I
19	stimulating	I
20	factor	I
21	(	O
22	CSF	B
23	-	I
24	1	I
25	)	O
26	is	O
27	dependent	O
28	upon	O
29	the	O
30	level	O
31	of	O
32	cell	O
33	-	O
34	surface	O
35	receptor	O
36	.	O

1	Interferon	B
2	beta	I
3	therapy	O
4	was	O
5	discontinued	O
6	for	O
7	4	O
8	weeks	O
9	.	O

1	The	O
2	pigment	O
3	intensity	O
4	of	O
5	both	O
6	melanized	O
7	colonies	O
8	and	O
9	appressoria	O
10	of	O
11	CAL	O
12	transformants	O
13	was	O
14	weaker	O
15	than	O
16	that	O
17	of	O
18	the	O
19	wild	O
20	type	O
21	.	O

1	A	O
2	low	O
3	aspirin	B
4	esterase	I
5	activity	O
6	may	O
7	be	O
8	a	O
9	contributory	O
10	factor	O
11	in	O
12	precipitating	O
13	these	O
14	aspirin	O
15	sensitive	O
16	reactions	O
17	.	O

1	After	O
2	screening	O
3	the	O
4	Berkeley	O
5	Drosophila	O
6	Genome	O
7	Project	O
8	database	O
9	with	O
10	sequences	O
11	from	O
12	a	O
13	recently	O
14	characterized	O
15	Leu	B
16	-	I
17	rich	I
18	repeats	I
19	-	I
20	containing	I
21	G	I
22	protein	I
23	-	I
24	coupled	I
25	receptor	I
26	(	O
27	LGR	B
28	)	O
29	from	O
30	Drosophila	O
31	(	O
32	DLGR	B
33	-	I
34	1	I
35	),	O
36	we	O
37	identified	O
38	a	O
39	second	O
40	gene	O
41	for	O
42	a	O
43	different	O
44	LGR	B
45	(	O
46	DLGR	B
47	-	I
48	2	I
49	)	O
50	and	O
51	cloned	O
52	its	O
53	cDNA	O
54	.	O

1	Increased	O
2	p53	B
3	activity	O
4	induced	O
5	by	O
6	OP	O
7	is	O
8	not	O
9	due	O
10	to	O
11	elevated	O
12	p53	B
13	mRNA	I
14	nor	O
15	to	O
16	protein	O
17	levels	O
18	.	O

1	Sequence	O
2	comparison	O
3	between	O
4	the	O
5	translated	O
6	ORF	O
7	and	O
8	a	O
9	protein	O
10	database	O
11	reveal	O
12	between	O
13	26	O
14	.	O
15	5	O
16	and	O
17	23	O
18	.	O
19	4	O
20	%	O
21	aa	O
22	sequence	O
23	homology	O
24	to	O
25	bacterial	B
26	transmembrane	I
27	(	I
28	TM	I
29	)	I
30	proteins	I
31	including	O
32	those	O
33	mediating	O
34	chloramphenicol	O
35	(	O
36	Cm	O
37	)	O
38	and	O
39	tetracycline	O
40	(	O
41	Tc	O
42	)	O
43	resistance	O
44	and	O
45	an	O
46	arabinose	O
47	-	O
48	proton	O
49	symport	O
50	protein	O
51	.	O

1	Malaria	O
2	,	O
3	anaemia	O
4	,	O
5	and	O
6	HIV	O
7	-	O
8	1	O
9	transmission	O
10	in	O
11	central	O
12	Africa	O
13	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	phenotype	O
7	of	O
8	XLP	O
9	may	O
10	result	O
11	from	O
12	perturbed	O
13	signaling	O
14	not	O
15	only	O
16	through	O
17	SLAM	B
18	,	O
19	but	O
20	also	O
21	other	O
22	cell	O
23	surface	O
24	molecules	O
25	that	O
26	utilize	O
27	SAP	B
28	as	O
29	a	O
30	signaling	O
31	adaptor	O
32	protein	O
33	.	O

1	The	O
2	structural	O
3	similarity	O
4	between	O
5	Vav	B
6	and	O
7	other	O
8	guanine	B
9	nucleotide	I
10	exchange	I
11	factors	I
12	for	O
13	small	B
14	GTP	I
15	-	I
16	binding	I
17	proteins	I
18	,	O
19	together	O
20	with	O
21	the	O
22	recent	O
23	identification	O
24	of	O
25	biochemical	O
26	routes	O
27	specific	O
28	for	O
29	members	O
30	of	O
31	the	O
32	Ras	B
33	and	O
34	Rho	B
35	family	I
36	of	O
37	GTPases	B
38	,	O
39	prompted	O
40	us	O
41	to	O
42	explore	O
43	whether	O
44	MAPK	B
45	or	O
46	JNK	B
47	are	O
48	downstream	O
49	components	O
50	of	O
51	the	O
52	Vav	B
53	signaling	O
54	pathways	O
55	.	O

1	To	O
2	isolate	O
3	this	O
4	gene	O
5	,	O
6	a	O
7	P	O
8	-	O
9	1	O
10	artificial	O
11	chromosome	O
12	(	O
13	PAC	O
14	)	O
15	library	O
16	was	O
17	screened	O
18	with	O
19	a	O
20	full	B
21	length	I
22	UGT2B7	I
23	probe	O
24	and	O
25	a	O
26	clone	O
27	of	O
28	approximately	O
29	100	O
30	kb	O
31	in	O
32	length	O
33	was	O
34	isolated	O
35	.	O

1	The	O
2	bronchial	O
3	epithelia	O
4	of	O
5	all	O
6	smoke	O
7	-	O
8	exposed	O
9	animals	O
10	were	O
11	hyperplastic	O
12	,	O
13	and	O
14	their	O
15	ultrastructure	O
16	showed	O
17	invaginations	O
18	,	O
19	tilt	O
20	of	O
21	nuclear	O
22	axes	O
23	,	O
24	an	O
25	increase	O
26	in	O
27	the	O
28	number	O
29	and	O
30	size	O
31	of	O
32	lysosomes	O
33	and	O
34	multivesiculated	O
35	bodies	O
36	,	O
37	and	O
38	increased	O
39	numbers	O
40	of	O
41	enlarged	O
42	intramitochondrial	O
43	granules	O
44	.	O

1	The	O
2	absolute	O
3	configuration	O
4	at	O
5	C	O
6	-	O
7	2	O
8	in	O
9	monocrotalic	O
10	acid	O
11	.	O

1	Interleukin	B
2	-	I
3	12	I
4	(	O
5	IL	B
6	-	I
7	12	I
8	)	O
9	is	O
10	a	O
11	cytokine	O
12	produced	O
13	by	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	(	O
19	PBMC	O
20	)	O
21	that	O
22	causes	O
23	interferon	B
24	-	I
25	gamma	I
26	(	O
27	IFN	B
28	-	I
29	gamma	I
30	)	O
31	production	O
32	and	O
33	enhancement	O
34	of	O
35	cell	O
36	-	O
37	mediated	O
38	cytotoxicity	O
39	.	O

1	Transforming	B
2	growth	I
3	factor	I
4	(	I
5	TGF	I
6	)-	I
7	beta1	I
8	induces	O
9	extracellular	O
10	matrix	O
11	deposition	O
12	and	O
13	proliferation	O
14	of	O
15	mesenchymal	O
16	cells	O
17	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	residue	O
6	266	O
7	serves	O
8	as	O
9	a	O
10	"	O
11	protein	O
12	sensor	O
13	"	O
14	of	O
15	altered	O
16	minor	O
17	groove	O
18	interactions	O
19	and	O
20	identifies	O
21	which	O
22	base	O
23	pair	O
24	interactions	O
25	are	O
26	altered	O
27	by	O
28	these	O
29	lesions	O
30	.	O

1	Dopamine	B
2	beta	I
3	-	I
4	hydroxylase	I
5	(	O
6	DBH	B
7	)	O
8	catalyzes	O
9	the	O
10	conversion	O
11	of	O
12	dopamine	O
13	to	O
14	noradrenaline	O
15	and	O
16	is	O
17	selectively	O
18	expressed	O
19	in	O
20	noradrenergic	O
21	and	O
22	adrenergic	O
23	neurons	O
24	and	O
25	neuroendocrine	O
26	cells	O
27	.	O

1	Circulating	O
2	platelets	O
3	may	O
4	be	O
5	activated	O
6	by	O
7	exposed	O
8	triple	O
9	-	O
10	helical	O
11	collagen	B
12	in	O
13	atherosclerotic	O
14	lesions	O
15	in	O
16	Mg	O
17	-	O
18	deficient	O
19	ruminants	O
20	.	O

1	Sp1	B
2	binds	O
3	two	O
4	sites	O
5	in	O
6	the	O
7	CD11c	B
8	promoter	I
9	in	O
10	vivo	O
11	specifically	O
12	in	O
13	myeloid	O
14	cells	O
15	and	O
16	cooperates	O
17	with	O
18	AP1	B
19	to	O
20	activate	O
21	transcription	O
22	.	O

1	Activation	O
2	of	O
3	the	O
4	SH2	B
5	-	I
6	containing	I
7	protein	I
8	tyrosine	I
9	phosphatase	I
10	,	O
11	SH	B
12	-	I
13	PTP2	I
14	,	O
15	by	O
16	phosphotyrosine	O
17	-	O
18	containing	O
19	peptides	O
20	derived	O
21	from	O
22	insulin	B
23	receptor	I
24	substrate	I
25	-	I
26	1	I
27	.	O

1	Promoter	O
2	analysis	O
3	demonstrated	O
4	that	O
5	the	O
6	sequence	O
7	identical	O
8	to	O
9	consensus	O
10	cAMP	O
11	-	O
12	responsive	O
13	element	O
14	(	O
15	CRE	O
16	)	O
17	located	O
18	at	O
19	-	O
20	481	O
21	of	O
22	the	O
23	SMemb	B
24	promoter	I
25	was	O
26	critical	O
27	for	O
28	Hex	B
29	responsiveness	O
30	.	O

1	The	O
2	rate	O
3	of	O
4	resectability	O
5	is	O
6	low	O
7	and	O
8	5	O
9	-	O
10	year	O
11	survival	O
12	is	O
13	very	O
14	poor	O
15	.	O

1	A	O
2	large	O
3	increase	O
4	of	O
5	serum	O
6	ketones	O
7	occurred	O
8	under	O
9	all	O
10	conditions	O
11	,	O
12	and	O
13	the	O
14	exercise	O
15	respiratory	O
16	quotient	O
17	suggested	O
18	some	O
19	increase	O
20	of	O
21	fat	O
22	utilization	O
23	,	O
24	WW	O
25	(	O
26	0	O
27	.	O
28	85	O
29	)	O
30	through	O
31	CW	O
32	(	O
33	0	O
34	.	O
35	84	O
36	)	O
37	to	O
38	CC	O
39	(	O
40	0	O
41	.	O
42	83	O
43	).	O

1	Validation	O
2	of	O
3	automated	O
4	systems	O
5	--	O
6	system	O
7	definition	O
8	.	O

1	Here	O
2	,	O
3	a	O
4	case	O
5	of	O
6	Sjogren	O
7	'	O
8	s	O
9	syndrome	O
10	is	O
11	presented	O
12	that	O
13	was	O
14	initially	O
15	diagnosed	O
16	because	O
17	of	O
18	dental	O
19	complaints	O
20	,	O
21	and	O
22	long	O
23	-	O
24	term	O
25	treatment	O
26	of	O
27	Sjogren	O
28	'	O
29	s	O
30	patients	O
31	is	O
32	discussed	O
33	.	O

1	This	O
2	protein	O
3	can	O
4	bind	O
5	to	O
6	a	O
7	region	O
8	of	O
9	the	O
10	promoter	O
11	of	O
12	an	O
13	Arabidopsis	B
14	light	I
15	-	I
16	harvesting	I
17	chlorophyll	I
18	a	I
19	/	I
20	b	I
21	protein	I
22	gene	I
23	,	O
24	Lhcb1	B
25	*	I
26	3	I
27	,	O
28	which	O
29	is	O
30	necessary	O
31	for	O
32	its	O
33	regulation	O
34	by	O
35	phytochrome	B
36	.	O

1	When	O
2	voltage	O
3	-	O
4	operated	O
5	Ca2	O
6	+	O
7	channels	O
8	(	O
9	VOC	O
10	)	O
11	were	O
12	blocked	O
13	by	O
14	nifedipine	O
15	,	O
16	midazolam	O
17	,	O
18	in	O
19	concentrations	O
20	more	O
21	than	O
22	1	O
23	microM	O
24	,	O
25	attenuated	O
26	both	O
27	phasic	O
28	and	O
29	tonic	O
30	responses	O
31	.	O

1	Following	O
2	the	O
3	results	O
4	of	O
5	toxicological	O
6	experiments	O
7	in	O
8	the	O
9	target	O
10	animals	O
11	"	O
12	Toxicological	O
13	Drinking	O
14	Water	O
15	Standards	O
16	for	O
17	Animals	O
18	"	O
19	can	O
20	be	O
21	established	O
22	.	O

1	Specific	O
2	class	B
3	I	I
4	and	I
5	II	I
6	histone	I
7	deacetylases	I
8	(	O
9	HDACs	B
10	)	O
11	interact	O
12	in	O
13	vivo	O
14	with	O
15	BCoR	B
16	,	O
17	suggesting	O
18	that	O
19	BCoR	B
20	may	O
21	functionally	O
22	link	O
23	these	O
24	two	O
25	classes	O
26	of	O
27	HDACs	B
28	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	We	O
6	report	O
7	our	O
8	experience	O
9	with	O
10	seven	O
11	children	O
12	with	O
13	active	O
14	small	O
15	bowel	O
16	Crohn	O
17	'	O
18	s	O
19	disease	O
20	given	O
21	a	O
22	casein	B
23	-	O
24	based	O
25	,	O
26	polymeric	O
27	feed	O
28	rich	O
29	in	O
30	TGF	B
31	-	I
32	beta	I
33	2	I
34	(	O
35	Specific	O
36	Polymeric	O
37	Diet	O
38	;	O
39	Nestle	O
40	-	O
41	Clintec	O
42	;	O
43	Vevey	O
44	,	O
45	Switzerland	O
46	)	O
47	as	O
48	complete	O
49	nutrition	O
50	for	O
51	8	O
52	weeks	O
53	.	O

1	Recombination	O
2	and	O
3	transcription	O
4	of	O
5	the	O
6	endogenous	B
7	Ig	I
8	heavy	I
9	chain	I
10	locus	I
11	is	O
12	effected	O
13	by	O
14	the	O
15	Ig	B
16	heavy	I
17	chain	I
18	intronic	I
19	enhancer	I
20	core	I
21	region	I
22	in	O
23	the	O
24	absence	O
25	of	O
26	the	O
27	matrix	O
28	attachment	O
29	regions	O
30	.	O

1	A	O
2	hypothesis	O
3	.	O

1	Single	O
2	tooth	O
3	replacement	O
4	with	O
5	the	O
6	aid	O
7	of	O
8	the	O
9	ITI	O
10	(	O
11	International	O
12	Team	O
13	fur	O
14	Implantologie	O
15	)	O
16	type	O
17	F	O
18	hollow	O
19	-	O
20	cylinder	O
21	implant	O

1	The	O
2	association	O
3	of	O
4	clopamide	O
5	and	O
6	hydergine	O
7	(	O
8	Brinedine	O
9	)	O
10	in	O
11	the	O
12	treatment	O
13	of	O
14	the	O
15	vasculo	O
16	-	O
17	renal	O
18	syndromes	O
19	of	O
20	pregnancy	O

1	A	O
2	possible	O
3	decrease	O
4	in	O
5	theophylline	O
6	'	O
7	s	O
8	volume	O
9	of	O
10	distribution	O
11	at	O
12	4	O
13	days	O
14	,	O
15	but	O
16	not	O
17	immediately	O
18	,	O
19	after	O
20	administration	O
21	of	O
22	chloroquine	O
23	was	O
24	suggested	O
25	,	O
26	although	O
27	this	O
28	just	O
29	failed	O
30	to	O
31	achieve	O
32	statistical	O
33	significance	O
34	(	O
35	p	O
36	=	O
37	0	O
38	.	O
39	055	O
40	).	O

1	In	O
2	MCCP	O
3	functions	O
4	of	O
5	the	O
6	source	O
7	emission	O
8	,	O
9	surface	O
10	reflection	O
11	,	O
12	photoacceptor	O
13	sensitivity	O
14	are	O
15	approximated	O
16	by	O
17	the	O
18	normal	O
19	distribution	O
20	curves	O
21	.	O

1	A	O
2	cDNA	O
3	cloning	O
4	vector	O
5	that	O
6	permits	O
7	expression	O
8	of	O
9	cDNA	O
10	inserts	O
11	in	O
12	mammalian	O
13	cells	O
14	.	O

1	In	O
2	vitro	O
3	interaction	O
4	studies	O
5	,	O
6	using	O
7	proteins	O
8	fused	O
9	to	O
10	glutathione	B
11	-	I
12	S	I
13	-	I
14	transferase	I
15	,	O
16	showed	O
17	that	O
18	RBP	B
19	-	I
20	J	I
21	kappa	I
22	and	O
23	Su	B
24	(	I
25	H	I
26	)	I
27	bind	O
28	directly	O
29	to	O
30	the	O
31	RAM23	B
32	regions	I
33	of	O
34	mouse	B
35	Notch1	I
36	and	O
37	Drosophila	B
38	Notch	I
39	,	O
40	respectively	O
41	.	O

1	Complete	O
2	sequences	O
3	were	O
4	obtained	O
5	for	O
6	the	O
7	three	O
8	large	O
9	thrombic	O
10	peptides	O
11	,	O
12	and	O
13	these	O
14	were	O
15	aligned	O
16	by	O
17	using	O
18	peptides	O
19	from	O
20	the	O
21	V8	B
22	protease	I
23	digest	O
24	.	O

1	The	O
2	seventh	O
3	cysteine	O
4	residue	O
5	of	O
6	CTSE	B
7	is	O
8	located	O
9	within	O
10	the	O
11	activation	O
12	peptide	O
13	region	O
14	of	O
15	the	O
16	proenzyme	O
17	.	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	MIP	O
6	,	O
7	MMIF	O
8	,	O
9	FIC	O
10	,	O
11	Wimax	O
12	,	O
13	P0	O
14	.	O
15	1	O
16	and	O
17	minute	O
18	ventilation	O
19	(	O
20	Vr	O
21	)	O
22	were	O
23	significantly	O
24	increased	O
25	after	O
26	administration	O
27	of	O
28	methylphenidatum	O
29	and	O
30	aminophylline	O
31	.	O

1	In	O
2	the	O
3	context	O
4	of	O
5	the	O
6	ADH2	B
7	upstream	I
8	regulatory	I
9	region	I
10	,	O
11	including	O
12	UAS1	O
13	,	O
14	working	O
15	in	O
16	concert	O
17	with	O
18	the	O
19	ADH2	B
20	basal	I
21	promoter	I
22	elements	I
23	,	O
24	UAS2	O
25	-	O
26	dependent	O
27	gene	O
28	activation	O
29	was	O
30	dependent	O
31	on	O
32	orientation	O
33	,	O
34	copy	O
35	number	O
36	,	O
37	and	O
38	helix	O
39	phase	O
40	.	O

1	Plasma	O
2	was	O
3	tested	O
4	before	O
5	and	O
6	after	O
7	(	O
8	14	O
9	+/-	O
10	7	O
11	.	O
12	5	O
13	[	O
14	SD	O
15	]	O
16	days	O
17	)	O
18	surgery	O
19	for	O
20	IgG	B
21	antibodies	I
22	to	O
23	the	O
24	complex	O
25	of	O
26	heparin	B
27	/	I
28	platelet	I
29	factor	I
30	4	I
31	,	O
32	using	O
33	a	O
34	standardized	O
35	,	O
36	validated	O
37	enzyme	O
38	-	O
39	linked	O
40	immunosorbent	O
41	assay	O
42	(	O
43	ELISA	O
44	).	O

1	Gel	O
2	retardation	O
3	assays	O
4	detected	O
5	ZiaR	B
6	-	O
7	dependent	O
8	complexes	O
9	forming	O
10	with	O
11	the	O
12	zia	B
13	operator	I
14	-	I
15	promoter	I
16	and	O
17	ZiaR	B
18	-	O
19	DNA	O
20	binding	O
21	was	O
22	enhanced	O
23	by	O
24	treatment	O
25	with	O
26	a	O
27	metal	O
28	-	O
29	chelator	O
30	in	O
31	vitro	O
32	.	O

1	The	O
2	effects	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	were	O
8	further	O
9	dissected	O
10	by	O
11	showing	O
12	that	O
13	c	B
14	-	I
15	myc	I
16	can	O
17	inhibit	O
18	differentiation	O
19	independently	O
20	of	O
21	Id	B
22	,	O
23	a	O
24	negative	O
25	regulator	O
26	of	O
27	muscle	O
28	differentiation	O
29	.	O

1	Increases	O
2	in	O
3	the	O
4	perfusate	O
5	PCO2	O
6	but	O
7	not	O
8	in	O
9	the	O
10	perfusate	O
11	H	O
12	+	O
13	were	O
14	highly	O
15	correlated	O
16	with	O
17	decreases	O
18	in	O
19	both	O
20	myocardial	O
21	contractility	O
22	and	O
23	oxygen	O
24	consumption	O
25	(	O
26	r2	O
27	=	O
28	.	O
29	88	O
30	).	O

1	At	O
2	rest	O
3	AFF	O
4	was	O
5	significantly	O
6	higher	O
7	in	O
8	UT	O
9	(	O
10	29	O
11	%)	O
12	as	O
13	compared	O
14	to	O
15	AT	O
16	(	O
17	25	O
18	%)	O
19	and	O
20	UEA	O
21	(	O
22	25	O
23	%).	O

1	Six	O
2	tandem	O
3	repeats	O
4	of	O
5	the	O
6	P	B
7	element	I
8	linked	O
9	to	O
10	the	O
11	SV40	B
12	promoter	I
13	responded	O
14	to	O
15	phorbol	O
16	12	O
17	-	O
18	myristate	O
19	13	O
20	-	O
21	acetate	O
22	,	O
23	while	O
24	that	O
25	of	O
26	other	O
27	elements	O
28	did	O
29	not	O
30	.	O

1	Frequent	O
2	loss	O
3	of	O
4	heterozygosity	O
5	(	O
6	LOH	O
7	)	O
8	of	O
9	>	O
10	30	O
11	%	O
12	of	O
13	the	O
14	informative	O
15	cases	O
16	was	O
17	observed	O
18	on	O
19	chromosomes	O
20	3p	O
21	(	O
22	41	O
23	.	O
24	1	O
25	%),	O
26	5q	O
27	(	O
28	52	O
29	.	O
30	6	O
31	%),	O
32	6p	O
33	(	O
34	30	O
35	.	O
36	4	O
37	%),	O
38	8p	O
39	(	O
40	33	O
41	.	O
42	3	O
43	%),	O
44	9p	O
45	(	O
46	35	O
47	.	O
48	7	O
49	%),	O
50	9q	O
51	(	O
52	30	O
53	.	O
54	8	O
55	%),	O
56	11p	O
57	(	O
58	32	O
59	.	O
60	4	O
61	%),	O
62	13q	O
63	(	O
64	52	O
65	.	O
66	7	O
67	%),	O
68	17p	O
69	(	O
70	55	O
71	.	O
72	2	O
73	%),	O
74	17q	O
75	(	O
76	33	O
77	.	O
78	3	O
79	%),	O
80	18q	O
81	(	O
82	45	O
83	.	O
84	7	O
85	%),	O
86	and	O
87	19q	O
88	(	O
89	30	O
90	.	O
91	4	O
92	%).	O

1	We	O
2	show	O
3	that	O
4	in	O
5	contrast	O
6	to	O
7	SRC1	B
8	,	O
9	direct	O
10	binding	O
11	of	O
12	CBP	B
13	to	O
14	the	O
15	estrogen	B
16	receptor	I
17	is	O
18	weak	O
19	,	O
20	suggesting	O
21	that	O
22	SRC1	B
23	functions	O
24	primarily	O
25	as	O
26	an	O
27	adaptor	O
28	to	O
29	recruit	O
30	CBP	B
31	and	O
32	p300	B
33	.	O

1	Characterization	O
2	of	O
3	the	O
4	promoter	O
5	for	O
6	the	O
7	human	B
8	85	I
9	kDa	I
10	cytosolic	I
11	phospholipase	I
12	A2	I
13	gene	I
14	.	O

1	Only	O
2	the	O
3	3	O
4	.	O
5	0	O
6	-	O
7	kb	O
8	transcript	O
9	was	O
10	detected	O
11	in	O
12	adult	O
13	tissues	O
14	,	O
15	where	O
16	its	O
17	expression	O
18	was	O
19	restricted	O
20	almost	O
21	exclusively	O
22	to	O
23	the	O
24	central	O
25	nervous	O
26	system	O
27	.	O

1	Enhanced	O
2	hepatic	O
3	portal	O
4	blood	O
5	flow	O
6	induced	O
7	by	O
8	prostaglandin	O
9	E1	O
10	following	O
11	liver	O
12	transplantation	O
13	in	O
14	pigs	O
15	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	wild	O
6	-	O
7	type	O
8	strain	O
9	containing	O
10	a	O
11	temperature	B
12	-	I
13	sensitive	I
14	threonyl	I
15	-	I
16	tRNA	I
17	synthetase	I
18	mutation	I
19	showed	O
20	increased	O
21	thr	B
22	operon	I
23	expression	O
24	at	O
25	the	O
26	non	O
27	-	O
28	permissive	O
29	temperature	O
30	,	O
31	whereas	O
32	none	O
33	of	O
34	the	O
35	mutants	O
36	showed	O
37	any	O
38	change	O
39	.	O

1	Open	O
2	reading	O
3	frames	O
4	in	O
5	a	O
6	4556	O
7	nucleotide	O
8	sequence	O
9	within	O
10	MDV	B
11	-	I
12	1	I
13	BamHI	I
14	-	I
15	D	I
16	DNA	I
17	fragment	I
18	:	O
19	evidence	O
20	for	O
21	splicing	O
22	of	O
23	mRNA	O
24	from	O
25	a	O
26	new	O
27	viral	O
28	glycoprotein	O
29	gene	O
30	.	O

1	The	O
2	relations	O
3	among	O
4	various	O
5	negative	O
6	emotional	O
7	and	O
8	behavioral	O
9	characteristics	O
10	(	O
11	e	O
12	.	O
13	g	O
14	.,	O
15	aggression	O
16	,	O
17	anxiety	O
18	,	O
19	undercompliance	O
20	,	O
21	depressive	O
22	mood	O
23	)	O
24	and	O
25	adjustment	O
26	were	O
27	examined	O
28	through	O
29	use	O
30	of	O
31	data	O
32	from	O
33	the	O
34	31	O
35	-	O
36	year	O
37	-	O
38	old	O
39	New	O
40	York	O
41	Longitudinal	O
42	Study	O
43	.	O

1	This	O
2	computerized	O
3	list	O
4	was	O
5	linked	O
6	to	O
7	the	O
8	central	O
9	files	O
10	of	O
11	the	O
12	Massachusetts	O
13	Cancer	O
14	Registry	O
15	and	O
16	cases	O
17	diagnosed	O
18	between	O
19	1982	O
20	and	O
21	1988	O
22	were	O
23	identified	O
24	.	O

1	The	O
2	equivalent	O
3	of	O
4	the	O
5	third	O
6	ligand	O
7	,	O
8	H	O
9	-	O
10	87	O
11	,	O
12	is	O
13	T	O
14	-	O
15	47	O
16	in	O
17	the	O
18	PSTAIRE	O
19	sequence	O
20	motif	O
21	.	O

1	The	O
2	lack	O
3	of	O
4	change	O
5	in	O
6	the	O
7	ratio	O
8	of	O
9	the	O
10	two	O
11	spliced	O
12	products	O
13	expressed	O
14	from	O
15	either	O
16	the	O
17	normal	O
18	or	O
19	the	O
20	5	B
21	'-	I
22	rearranged	I
23	myb	I
24	further	O
25	indicates	O
26	that	O
27	the	O
28	insertion	O
29	of	O
30	the	O
31	unique	O
32	121	O
33	amino	O
34	acids	O
35	in	O
36	the	O
37	larger	O
38	myb	B
39	transcripts	I
40	is	O
41	not	O
42	a	O
43	consequence	O
44	of	O
45	tumor	O
46	-	O
47	specific	O
48	activation	O
49	of	O
50	the	O
51	mouse	B
52	myb	I
53	oncogene	I
54	.	O

1	The	O
2	sequence	O
3	of	O
4	four	O
5	clones	O
6	was	O
7	sufficient	O
8	to	O
9	construct	O
10	a	O
11	3018	B
12	-	I
13	bp	I
14	BAL	I
15	cDNA	I
16	structure	O
17	.	O

1	Alveolar	O
2	lymphocytes	O
3	were	O
4	surprisingly	O
5	increased	O
6	in	O
7	most	O
8	patients	O
9	with	O
10	AIDS	O
11	(	O
12	mean	O
13	26	O
14	.	O
15	1	O
16	+/-	O
17	21	O
18	.	O
19	9	O
20	%;	O
21	range	O
22	1	O
23	-	O
24	76	O
25	%)	O
26	and	O
27	CGL	O
28	(	O
29	mean	O
30	26	O
31	.	O
32	6	O
33	+/-	O
34	22	O
35	.	O
36	6	O
37	%;	O
38	range	O
39	3	O
40	-	O
41	76	O
42	%)	O
43	with	O
44	criteria	O
45	of	O
46	activation	O
47	contrasting	O
48	with	O
49	the	O
50	blood	O
51	lymphopenia	O
52	.	O

1	The	O
2	pathogenesis	O
3	of	O
4	Limited	O
5	Joint	O
6	Mobility	O
7	(	O
8	LJM	O
9	)	O
10	in	O
11	diabetes	O
12	is	O
13	unknown	O
14	,	O
15	but	O
16	the	O
17	abnormality	O
18	is	O
19	said	O
20	to	O
21	be	O
22	associated	O
23	with	O
24	an	O
25	increased	O
26	incidence	O
27	of	O
28	microangiopathy	O
29	.	O

1	Clinical	O
2	use	O
3	of	O
4	absorbable	O
5	polyglycolic	O
6	acid	O
7	suture	O
8	in	O
9	Blalock	O
10	-	O
11	Taussig	O
12	'	O
13	s	O
14	operation	O

1	EM	O
2	analysis	O
3	demonstrated	O
4	that	O
5	only	O
6	one	O
7	Rep	B
8	-	I
9	DNA	I
10	complex	I
11	was	O
12	formed	O
13	on	O
14	ch	O
15	-	O
16	19	O
17	target	O
18	DNA	O
19	.	O

1	G	O
2	-	O
3	DNA	O
4	is	O
5	a	O
6	four	O
7	-	O
8	stranded	O
9	DNA	O
10	structure	O
11	with	O
12	diverse	O
13	putative	O
14	biological	O
15	roles	O
16	.	O

1	This	O
2	in	O
3	turn	O
4	will	O
5	further	O
6	enhance	O
7	the	O
8	role	O
9	of	O
10	meta	O
11	-	O
12	analysis	O
13	in	O
14	helping	O
15	clinicians	O
16	and	O
17	policy	O
18	makers	O
19	answer	O
20	clinical	O
21	questions	O
22	.	O

1	The	O
2	predicted	O
3	molecular	O
4	weight	O
5	of	O
6	the	O
7	polyprotein	O
8	encoded	O
9	by	O
10	ORF1	O
11	is	O
12	33	O
13	kilodaltons	O
14	(	O
15	kDa	O
16	).	O

1	TSA	O
2	treatment	O
3	,	O
4	however	O
5	,	O
6	did	O
7	not	O
8	detectably	O
9	alter	O
10	enhancer	O
11	factor	O
12	binding	O
13	or	O
14	the	O
15	positioning	O
16	of	O
17	nuc	B
18	-	I
19	1	I
20	on	O
21	the	O
22	majority	O
23	of	O
24	the	O
25	chromatin	O
26	templates	O
27	indicating	O
28	that	O
29	protein	O
30	acetylation	O
31	and	O
32	chromatin	O
33	remodeling	O
34	may	O
35	be	O
36	limiting	O
37	steps	O
38	that	O
39	occur	O
40	only	O
41	on	O
42	transcriptionally	O
43	competent	O
44	templates	O
45	,	O
46	or	O
47	that	O
48	remodeling	O
49	of	O
50	nuc	B
51	-	I
52	1	I
53	requires	O
54	additional	O
55	factors	O
56	.	O

1	We	O
2	demonstrate	O
3	that	O
4	Ddc1p	B
5	interacts	O
6	physically	O
7	in	O
8	vivo	O
9	with	O
10	Mec3p	B
11	,	O
12	and	O
13	this	O
14	interaction	O
15	requires	O
16	Rad17p	B
17	.	O

1	"	O
2	In	O
3	vitro	O
4	"	O
5	study	O
6	of	O
7	dentin	O
8	adhesion	O
9	to	O
10	adhesives	O
11	made	O
12	from	O
13	urethane	O
14	molecules	O
15	with	O
16	free	O
17	groups	O
18	of	O
19	isocyanate	O

1	METHODS	O
2	:	O
3	A	O
4	total	O
5	of	O
6	15	O
7	pigs	O
8	were	O
9	randomised	O
10	to	O
11	ligation	O
12	of	O
13	left	O
14	marginal	O
15	arteries	O
16	(	O
17	infarction	O
18	group	O
19	,	O
20	n	O
21	=	O
22	5	O
23	),	O
24	to	O
25	TMLR	O
26	of	O
27	the	O
28	left	O
29	lateral	O
30	wall	O
31	using	O
32	a	O
33	holmium	O
34	:	O
35	yttrium	O
36	-	O
37	aluminium	O
38	garnet	O
39	(	O
40	Ho	O
41	:	O
42	YAG	O
43	)	O
44	laser	O
45	(	O
46	laser	O
47	group	O
48	,	O
49	n	O
50	=	O
51	5	O
52	),	O
53	and	O
54	to	O
55	both	O
56	(	O
57	laser	O
58	-	O
59	infarction	O
60	group	O
61	,	O
62	n	O
63	=	O
64	5	O
65	).	O

1	A	O
2	chicken	B
3	paxillin	I
4	cDNA	I
5	was	O
6	also	O
7	cloned	O
8	and	O
9	is	O
10	predicted	O
11	to	O
12	encode	O
13	a	O
14	protein	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	human	B
21	paxil	I
22	-	I
23	lin	I
24	.	O

1	Erythromycin	O
2	and	O
3	clindamycin	O
4	resistance	O
5	in	O
6	Corynebacterium	O
7	diphtheriae	O
8	from	O
9	skin	O
10	lesions	O
11	.	O

1	Other	O
2	uncertainties	O
3	in	O
4	the	O
5	dosimetry	O
6	at	O
7	Y	O
8	-	O
9	12	O
10	and	O
11	Vinca	O
12	are	O
13	unaltered	O
14	.	O

1	Badcock	O
2	and	O
3	Westheimer	O
4	(	O
5	Spatial	O
6	Vision	O
7	1	O
8	(	O
9	1	O
10	),	O
11	3	O
12	-	O
13	11	O
14	,	O
15	1985	O
16	)	O
17	showed	O
18	that	O
19	a	O
20	thin	O
21	vertical	O
22	line	O
23	induces	O
24	nearby	O
25	zones	O
26	of	O
27	attraction	O
28	and	O
29	repulsion	O
30	;	O
31	this	O
32	study	O
33	extends	O
34	those	O
35	results	O
36	by	O
37	more	O
38	closely	O
39	examining	O
40	the	O
41	horizontal	O
42	and	O
43	vertical	O
44	extents	O
45	of	O
46	the	O
47	repulsion	O
48	zone	O
49	and	O
50	by	O
51	using	O
52	an	O
53	illusory	O
54	contour	O
55	to	O
56	induce	O
57	repulsion	O
58	.	O

1	We	O
2	have	O
3	inactivated	O
4	Krox	B
5	-	I
6	20	I
7	by	O
8	homologous	O
9	recombination	O
10	in	O
11	ES	O
12	cells	O
13	and	O
14	demonstrated	O
15	that	O
16	the	O
17	mutation	O
18	leads	O
19	to	O
20	the	O
21	deletion	O
22	of	O
23	r3	O
24	and	O
25	r5	O
26	.	O

1	RESULTS	O
2	:	O
3	Soluble	O
4	CD23	B
5	levels	O
6	were	O
7	significantly	O
8	higher	O
9	in	O
10	women	O
11	with	O
12	endometriosis	O
13	before	O
14	treatment	O
15	than	O
16	in	O
17	ten	O
18	normal	O
19	controls	O
20	.	O

1	Antibodies	O
2	raised	O
3	against	O
4	GST	B
5	mSH2	I
6	-	I
7	B	I
8	identified	O
9	a	O
10	cellular	O
11	protein	O
12	of	O
13	92	O
14	kDa	O
15	that	O
16	was	O
17	not	O
18	found	O
19	to	O
20	be	O
21	phosphorylated	O
22	on	O
23	Tyr	O
24	.	O

1	HTLV	O
2	-	O
3	1	O
4	gene	O
5	expression	O
6	by	O
7	defective	O
8	proviruses	O
9	in	O
10	an	O
11	infected	O
12	T	O
13	-	O
14	cell	O
15	line	O
16	.	O

1	This	O
2	distribution	O
3	implies	O
4	that	O
5	the	O
6	polycistronic	O
7	precursor	O
8	is	O
9	imported	O
10	into	O
11	the	O
12	nucleolus	O
13	for	O
14	processing	O
15	to	O
16	the	O
17	mature	O
18	snoRNAs	O
19	,	O
20	and	O
21	that	O
22	the	O
23	import	O
24	or	O
25	processing	O
26	pathway	O
27	involves	O
28	coiled	O
29	bodies	O
30	.	O

1	Determination	O
2	of	O
3	three	O
4	-	O
5	dimensional	O
6	imaging	O
7	properties	O
8	of	O
9	a	O
10	light	O
11	microscope	O
12	system	O
13	.	O

1	Serum	O
2	ferritin	B
3	concentration	O
4	and	O
5	bone	O
6	marrow	O
7	iron	O
8	stores	O
9	.	O

1	Individual	O
2	alcohol	O
3	reaction	O
4	profiles	O
5	.	O

1	Analysis	O
2	of	O
3	electrically	O
4	evoked	O
5	response	O
6	(	O
7	EER	O
8	)	O
9	in	O
10	relation	O
11	to	O
12	the	O
13	central	O
14	visual	O
15	pathway	O
16	of	O
17	the	O
18	cat	O
19	(	O
20	1	O
21	).	O

1	Where	O
2	UMDNJ	O
3	is	O
4	headed	O
5	.	O

1	The	O
2	fission	B
3	yeast	I
4	dsk1	I
5	+	I
6	gene	I
7	,	O
8	a	O
9	multicopy	O
10	suppressor	O
11	for	O
12	cold	O
13	-	O
14	sensitive	O
15	dis1	B
16	mutants	I
17	,	O
18	encodes	O
19	a	O
20	novel	O
21	61	O
22	-	O
23	kd	O
24	protein	O
25	kinase	O
26	.	O

1	Local	O
2	graft	O
3	irradiation	O
4	as	O
5	an	O
6	adjunct	O
7	to	O
8	pharmacologic	O
9	immunosuppression	O
10	.	O

1	YAC	O
2	and	O
3	cosmid	O
4	contigs	O
5	spanning	O
6	the	O
7	BRCA1	B
8	region	I
9	were	O
10	used	O
11	to	O
12	select	O
13	cDNA	O
14	clones	O
15	from	O
16	pools	O
17	of	O
18	cDNAs	O
19	derived	O
20	from	O
21	human	O
22	placenta	O
23	,	O
24	HeLa	O
25	cells	O
26	,	O
27	activated	O
28	T	O
29	cells	O
30	,	O
31	and	O
32	fetal	O
33	head	O
34	.	O

1	High	O
2	-	O
3	level	O
4	expression	O
5	in	O
6	Escherichia	O
7	coli	O
8	of	O
9	selenocysteine	O
10	-	O
11	containing	O
12	rat	B
13	thioredoxin	I
14	reductase	I
15	utilizing	O
16	gene	O
17	fusions	O
18	with	O
19	engineered	O
20	bacterial	O
21	-	O
22	type	O
23	SECIS	O
24	elements	O
25	and	O
26	co	O
27	-	O
28	expression	O
29	with	O
30	the	O
31	selA	B
32	,	O
33	selB	B
34	and	O
35	selC	B
36	genes	I
37	.	O

1	Inherent	O
2	hematology	O
3	of	O
4	old	O
5	age	O

1	Removal	O
2	of	O
3	beta	B
4	2	I
5	-	I
6	microglobulin	I
7	by	O
8	hemodialysis	O
9	and	O
10	hemofiltration	O
11	:	O
12	a	O
13	four	O
14	year	O
15	follow	O
16	up	O
17	.	O

1	Characteristics	O
2	of	O
3	anesthesia	O
4	and	O
5	resuscitation	O
6	in	O
7	emergency	O
8	lung	O
9	surgery	O

1	The	O
2	TATA	B
3	box	I
4	-	I
5	binding	I
6	protein	I
7	(	O
8	TBP	B
9	)	O
10	plays	O
11	an	O
12	essential	O
13	role	O
14	in	O
15	transcription	O
16	by	O
17	all	O
18	three	O
19	eukaryotic	O
20	nuclear	B
21	RNA	I
22	polymerases	I
23	,	O
24	polymerases	B
25	(	I
26	Pol	I
27	)	I
28	I	I
29	,	I
30	II	I
31	,	I
32	and	I
33	III	I
34	.	O

1	Thus	O
2	,	O
3	the	O
4	positive	O
5	effect	O
6	of	O
7	NS1	B
8	on	O
9	the	O
10	steady	O
11	-	O
12	state	O
13	levels	O
14	of	O
15	P4	B
16	transcripts	I
17	depends	O
18	on	O
19	the	O
20	amplification	O
21	of	O
22	gene	O
23	copy	O
24	number	O
25	and	O
26	the	O
27	integrity	O
28	of	O
29	the	O
30	terminal	O
31	repeats	O
32	.	O

1	Oncogenic	B
2	Raf	I
3	-	I
4	1	I
5	activates	O
6	p70	B
7	S6	I
8	kinase	I
9	via	O
10	a	O
11	mitogen	B
12	-	I
13	activated	I
14	protein	I
15	kinase	I
16	-	O
17	independent	O
18	pathway	O
19	.	O

1	Lesion	O
2	diameters	O
3	of	O
4	greater	O
5	than	O
6	20	O
7	mm	O
8	and	O
9	the	O
10	large	O
11	sessile	O
12	-	O
13	type	O
14	configurations	O
15	were	O
16	factors	O
17	that	O
18	were	O
19	associated	O
20	with	O
21	incomplete	O
22	removal	O
23	.	O

1	To	O
2	identify	O
3	structural	O
4	features	O
5	of	O
6	residues	O
7	flanking	O
8	the	O
9	c	O
10	-	O
11	region	O
12	that	O
13	influence	O
14	the	O
15	fidelity	O
16	and	O
17	efficiency	O
18	of	O
19	signal	O
20	peptidase	O
21	cleavage	O
22	as	O
23	well	O
24	as	O
25	co	O
26	-	O
27	translational	O
28	translocation	O
29	,	O
30	we	O
31	introduced	O
32	six	O
33	amino	O
34	acid	O
35	substitutions	O
36	into	O
37	the	O
38	COOH	O
39	terminus	O
40	of	O
41	the	O
42	hydrophobic	O
43	core	O
44	and	O
45	seven	O
46	substitutions	O
47	at	O
48	the	O
49	NH2	O
50	terminus	O
51	of	O
52	the	O
53	mature	O
54	region	O
55	(	O
56	the	O
57	+	O
58	1	O
59	position	O
60	)	O
61	of	O
62	a	O
63	model	O
64	eukaryotic	B
65	preprotein	I
66	-	I
67	human	I
68	pre	I
69	(	I
70	delta	I
71	pro	I
72	)	I
73	apoA	I
74	-	I
75	II	I
76	.	O

1	Two	O
2	new	O
3	glucosidase	B
4	inhibitors	O
5	(	O
6	BAY	O
7	m	O
8	1099	O
9	and	O
10	BAY	O
11	o	O
12	1248	O
13	)	O
14	were	O
15	studied	O
16	in	O
17	volunteers	O
18	and	O
19	type	O
20	II	O
21	diabetics	O
22	under	O
23	various	O
24	conditions	O
25	.	O

1	In	O
2	a	O
3	similar	O
4	experiment	O
5	,	O
6	simultaneous	O
7	nitrofurazone	O
8	administration	O
9	and	O
10	S	O
11	.	O
12	enteritidis	O
13	challenge	O
14	resulted	O
15	in	O
16	no	O
17	significant	O
18	differences	O
19	in	O
20	S	O
21	.	O
22	enteritidis	O
23	isolation	O
24	frequency	O
25	.	O

1	M	O
2	.	O

1	[	B
2	Ala85	I
3	]	I
4	Dk	I
5	(	I
6	69	I
7	-	I
8	85	I
9	)	I
10	retains	O
11	full	O
12	biological	O
13	activity	O
14	.	O

1	These	O
2	changes	O
3	in	O
4	virus	O
5	entry	O
6	features	O
7	may	O
8	result	O
9	in	O
10	coronaviruses	O
11	with	O
12	novel	O
13	pathogenic	O
14	properties	O
15	.	O

1	Similar	O
2	synergistic	O
3	activation	O
4	was	O
5	observed	O
6	in	O
7	the	O
8	IL	B
9	-	I
10	8	I
11	promoter	I
12	,	O
13	which	O
14	also	O
15	contains	O
16	both	O
17	NF	B
18	-	I
19	IL6	I
20	and	O
21	NF	B
22	-	I
23	kappa	I
24	B	I
25	binding	I
26	sites	I
27	.	O

1	The	O
2	experiment	O
3	results	O
4	showed	O
5	:	O
6	(	O
7	i	O
8	)	O
9	not	O
10	only	O
11	1O2	O
12	,	O
13	but	O
14	also	O
15	free	O
16	radicals	O
17	(	O
18	O2	O
19	-.	O
20	.	O
21	OH	O
22	and	O
23	YHPD	O
24	-.)	O
25	can	O
26	be	O
27	formed	O
28	by	O
29	the	O
30	aid	O
31	of	O
32	YHPD	O
33	;	O
34	and	O
35	(	O
36	ii	O
37	)	O
38	as	O
39	to	O
40	the	O
41	ability	O
42	of	O
43	producing	O
44	1O2	O
45	,	O
46	YHPD	O
47	less	O
48	than	O
49	BHPD	O
50	,	O
51	while	O
52	for	O
53	generating	O
54	O2	O
55	-.	O
56	and	O
57	.	O
58	OH	O
59	,	O
60	YHPD	O
61	greater	O
62	than	O
63	BHPD	O
64	.	O

1	To	O
2	lower	O
3	the	O
4	current	O
5	high	O
6	incidence	O
7	of	O
8	NANB	O
9	-	O
10	induced	O
11	PTH	O
12	,	O
13	in	O
14	1986	O
15	,	O
16	the	O
17	American	O
18	Association	O
19	of	O
20	Blood	O
21	Banks	O
22	(	O
23	AABB	O
24	)	O
25	recommended	O
26	testing	O
27	for	O
28	these	O
29	PTH	O
30	-	O
31	associated	O
32	"	O
33	surrogate	O
34	"	O
35	markers	O
36	on	O
37	all	O
38	donated	O
39	units	O
40	of	O
41	blood	O
42	.	O

1	The	O
2	cloning	O
3	of	O
4	PTR2	B
5	represents	O
6	the	O
7	first	O
8	example	O
9	of	O
10	the	O
11	molecular	O
12	genetic	O
13	characterization	O
14	of	O
15	a	O
16	eucaryotic	O
17	peptide	O
18	transport	O
19	gene	O
20	.	O

1	Expression	O
2	of	O
3	this	O
4	cDNA	O
5	in	O
6	vitro	O
7	yields	O
8	a	O
9	peptide	O
10	which	O
11	comigrates	O
12	with	O
13	natural	B
14	eIF	I
15	-	I
16	2B	I
17	alpha	I
18	in	O
19	SDS	O
20	/	O
21	polyacrylamide	O
22	gels	O
23	.	O

1	The	O
2	sequence	O
3	upstream	O
4	of	O
5	the	O
6	rhlA	B
7	promoter	I
8	contains	O
9	two	O
10	inverted	O
11	repeats	O
12	which	O
13	define	O
14	putative	O
15	binding	O
16	sites	O
17	for	O
18	the	O
19	RhlR	B
20	regulator	I
21	.	O

1	A	O
2	stretch	O
3	of	O
4	16	O
5	nucleotides	O
6	just	O
7	upstream	O
8	of	O
9	the	O
10	IL	B
11	-	I
12	4RE	I
13	contributed	O
14	to	O
15	IL	B
16	-	I
17	4	I
18	inducibility	O
19	and	O
20	formed	O
21	nucleoprotein	O
22	complexes	O
23	with	O
24	constitutive	O
25	factors	O
26	.	O

1	The	O
2	second	O
3	primary	O
4	mutant	O
5	contained	O
6	a	O
7	proline	O
8	-	O
9	to	O
10	-	O
11	leucine	O
12	change	O
13	at	O
14	position	O
15	243	O
16	(	O
17	P243L	O
18	).	O

1	Cross	O
2	-	O
3	talking	O
4	among	O
5	Drosophila	O
6	nuclear	O
7	receptors	O
8	at	O
9	the	O
10	promiscuous	O
11	response	O
12	element	O
13	of	O
14	the	O
15	ng	B
16	-	I
17	1	I
18	and	O
19	ng	B
20	-	I
21	2	I
22	intermolt	I
23	genes	I
24	.	O

1	Intraoperatively	O
2	the	O
3	complement	B
4	factor	I
5	C3c	I
6	decreased	O
7	by	O
8	20	O
9	%,	O
10	while	O
11	alpha	B
12	1	I
13	-	I
14	antitrypsin	I
15	showed	O
16	postoperatively	O
17	an	O
18	increase	O
19	by	O
20	30	O
21	%.	O

1	We	O
2	report	O
3	the	O
4	identification	O
5	and	O
6	characterization	O
7	of	O
8	myr	B
9	4	I
10	(	O
11	myosin	B
12	from	I
13	rat	I
14	),	O
15	the	O
16	first	O
17	mammalian	B
18	myosin	I
19	I	I
20	that	O
21	is	O
22	not	O
23	closely	O
24	related	O
25	to	O
26	brush	O
27	border	O
28	myosin	B
29	I	I
30	.	O

1	A	O
2	polypeptide	O
3	chain	O
4	of	O
5	34	O
6	residues	O
7	of	O
8	the	O
9	deduced	O
10	yeast	O
11	amino	O
12	acid	O
13	sequence	O
14	closely	O
15	resembles	O
16	a	O
17	peptide	O
18	sequence	O
19	at	O
20	the	O
21	ADP	O
22	binding	O
23	site	O
24	of	O
25	bovine	B
26	muscle	I
27	pyruvate	I
28	kinase	I
29	.	O

1	Rss1p	B
2	encodes	O
3	a	O
4	novel	O
5	essential	O
6	protein	O
7	of	O
8	538	O
9	amino	O
10	acids	O
11	,	O
12	which	O
13	contains	O
14	an	O
15	extended	O
16	predicted	O
17	coiled	O
18	-	O
19	coil	O
20	domain	O
21	and	O
22	is	O
23	located	O
24	both	O
25	at	O
26	nuclear	O
27	pore	O
28	complexes	O
29	(	O
30	NPCs	O
31	)	O
32	and	O
33	in	O
34	the	O
35	cytoplasm	O
36	.	O

1	The	O
2	Pro	O
3	-	O
4	258	O
5	-->	O
6	Leu	O
7	(	O
8	P258L	O
9	)	O
10	mutation	O
11	caused	O
12	constitutive	O
13	receptor	O
14	signaling	O
15	that	O
16	was	O
17	equivalent	O
18	to	O
19	about	O
20	45	O
21	%	O
22	of	O
23	the	O
24	maximum	O
25	level	O
26	observed	O
27	in	O
28	wild	O
29	-	O
30	type	O
31	cells	O
32	stimulated	O
33	with	O
34	alpha	B
35	-	I
36	factor	I
37	.	O

1	Finally	O
2	,	O
3	Cas	B
4	existed	O
5	mainly	O
6	in	O
7	cytosol	O
8	and	O
9	membrane	O
10	cytoskeleton	O
11	fractions	O
12	in	O
13	the	O
14	resting	O
15	state	O
16	,	O
17	and	O
18	remained	O
19	unchanged	O
20	during	O
21	platelet	O
22	aggregation	O
23	,	O
24	when	O
25	FAK	B
26	translocated	O
27	to	O
28	the	O
29	cytoskeletal	O
30	fraction	O
31	.	O

1	The	O
2	results	O
3	also	O
4	showed	O
5	that	O
6	although	O
7	oyster	O
8	shell	O
9	supplementation	O
10	generally	O
11	increased	O
12	alkaline	B
13	phosphatase	I
14	activity	O
15	,	O
16	bone	O
17	mineralization	O
18	was	O
19	relatively	O
20	uninfluenced	O
21	as	O
22	judged	O
23	by	O
24	the	O
25	low	O
26	coefficients	O
27	of	O
28	variation	O
29	(	O
30	CV	O
31	)	O
32	of	O
33	3	O
34	.	O
35	14	O
36	-	O
37	3	O
38	.	O
39	51	O
40	%	O
41	and	O
42	3	O
43	.	O
44	39	O
45	-	O
46	4	O
47	.	O
48	82	O
49	%	O
50	for	O
51	calcium	O
52	and	O
53	phosphorus	O
54	content	O
55	in	O
56	the	O
57	femur	O
58	and	O
59	tibia	O
60	respectively	O
61	.	O

1	The	O
2	variations	O
3	were	O
4	caused	O
5	by	O
6	opposite	O
7	shifts	O
8	in	O
9	TSH	B
10	frequency	O
11	distribution	O
12	in	O
13	mothers	O
14	and	O
15	neonates	O
16	.	O

1	Similar	O
2	observations	O
3	were	O
4	made	O
5	with	O
6	unilateral	O
7	pneumothorax	O
8	of	O
9	15	O
10	cmH2O	O
11	for	O
12	30	O
13	min	O
14	.	O

1	The	O
2	structure	O
3	of	O
4	the	O
5	free	O
6	SH2	B
7	domain	I
8	has	O
9	been	O
10	compared	O
11	to	O
12	that	O
13	of	O
14	the	O
15	SH2	B
16	complexed	O
17	with	O
18	a	O
19	doubly	O
20	phosphorylated	O
21	peptide	O
22	derived	O
23	from	O
24	polyomavirus	B
25	middle	I
26	T	I
27	antigen	I
28	(	O
29	MT	B
30	).	O

1	Suppressive	O
2	therapy	O
3	for	O
4	thyroid	O
5	nodules	O
6	.	O

1	On	O
2	the	O
3	other	O
4	side	O
5	,	O
6	when	O
7	the	O
8	aortic	O
9	ring	O
10	was	O
11	perfused	O
12	with	O
13	L	O
14	-	O
15	NNA	O
16	(	O
17	NO	O
18	-	O
19	synthesis	O
20	inhibitor	O
21	)	O
22	or	O
23	methylene	O
24	blue	O
25	(	O
26	soluble	O
27	cGMPase	B
28	inhibitor	O
29	),	O
30	the	O
31	changes	O
32	could	O
33	be	O
34	attenuated	O
35	.	O

1	Lauciello	O
2	describes	O
3	a	O
4	technique	O
5	for	O
6	the	O
7	placement	O
8	of	O
9	functionally	O
10	generated	O
11	amalgam	O
12	stops	O
13	as	O
14	restorations	O
15	within	O
16	mandibular	O
17	acrylic	O
18	teeth	O
19	.	O

1	Promoter	O
2	activity	O
3	was	O
4	high	O
5	in	O
6	cell	O
7	lines	O
8	that	O
9	expressed	O
10	high	O
11	levels	O
12	of	O
13	endogenous	O
14	D3	B
15	mRNA	I
16	,	O
17	as	O
18	indicated	O
19	by	O
20	Northern	O
21	blot	O
22	analyses	O
23	,	O
24	and	O
25	was	O
26	significantly	O
27	reduced	O
28	when	O
29	the	O
30	promoter	O
31	was	O
32	truncated	O
33	to	O
34	-	O
35	122	O
36	bp	O
37	.	O

1	One	O
2	complex	O
3	most	O
4	likely	O
5	contained	O
6	Sp1	B
7	,	O
8	and	O
9	another	O
10	complex	O
11	showed	O
12	S	O
13	-	O
14	phase	O
15	-	O
16	specific	O
17	binding	O
18	,	O
19	suggesting	O
20	a	O
21	direct	O
22	role	O
23	in	O
24	the	O
25	cell	O
26	-	O
27	cycle	O
28	-	O
29	dependent	O
30	R1	B
31	gene	I
32	expression	O
33	.	O

1	Blood	O
2	flow	O
3	velocity	O
4	waveforms	O
5	were	O
6	recorded	O
7	by	O
8	pulsed	O
9	Doppler	O
10	examination	O
11	of	O
12	the	O
13	fetal	O
14	internal	O
15	carotid	O
16	and	O
17	middle	O
18	cerebral	O
19	arteries	O
20	using	O
21	the	O
22	established	O
23	transabdominal	O
24	route	O
25	as	O
26	well	O
27	as	O
28	a	O
29	new	O
30	transvaginal	O
31	approach	O
32	.	O

1	An	O
2	RME1	B
3	-	O
4	independent	O
5	pathway	O
6	for	O
7	sporulation	O
8	control	O
9	in	O
10	Saccharomyces	O
11	cerevisiae	O
12	acts	O
13	through	O
14	IME1	B
15	transcript	I
16	accumulation	O
17	.	O

1	CONCLUSIONS	O
2	:	O
3	Free	O
4	protein	B
5	S	I
6	deficiency	O
7	is	O
8	common	O
9	among	O
10	hospitalized	O
11	patients	O
12	,	O
13	even	O
14	in	O
15	the	O
16	absence	O
17	of	O
18	a	O
19	recognized	O
20	predisposing	O
21	condition	O
22	.	O

1	One	O
2	member	O
3	of	O
4	this	O
5	multigene	O
6	family	O
7	,	O
8	GATA	B
9	-	I
10	3	I
11	,	O
12	is	O
13	most	O
14	abundantly	O
15	expressed	O
16	in	O
17	T	O
18	lymphocytes	O
19	,	O
20	a	O
21	cellular	O
22	target	O
23	for	O
24	human	O
25	immunodeficiency	O
26	virus	O
27	type	O
28	1	O
29	(	O
30	HIV	O
31	-	O
32	1	O
33	)	O
34	infection	O
35	and	O
36	replication	O
37	.	O

1	A	O
2	"	O
3	Level	O
4	A	O
5	"	O
6	in	O
7	vitro	O
8	/	O
9	in	O
10	vivo	O
11	correlation	O
12	was	O
13	established	O
14	for	O
15	a	O
16	sustained	O
17	release	O
18	theophylline	O
19	(	O
20	CAS	O
21	58	O
22	-	O
23	55	O
24	-	O
25	9	O
26	)	O
27	preparation	O
28	(	O
29	Bronchoretard	O
30	)	O
31	under	O
32	investigation	O
33	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	the	O
5	amino	O
6	-	O
7	terminal	O
8	17	O
9	%	O
10	of	O
11	apoB	B
12	(	O
13	apoB17	B
14	)	O
15	was	O
16	fused	O
17	to	O
18	a	O
19	cDNA	O
20	coding	O
21	for	O
22	the	O
23	last	O
24	37	O
25	amino	O
26	acids	O
27	of	O
28	decay	B
29	-	I
30	accelerating	I
31	factor	I
32	(	O
33	DAF	B
34	),	O
35	which	O
36	contains	O
37	the	O
38	signal	O
39	for	O
40	glycosylphosphatidylinositol	O
41	anchor	O
42	attachment	O
43	.	O

1	In	O
2	contrast	O
3	,	O
4	both	O
5	Sp1	B
6	and	O
7	ETS	B
8	proteins	I
9	are	O
10	required	O
11	to	O
12	bring	O
13	about	O
14	full	O
15	promoter	O
16	activity	O
17	in	O
18	the	O
19	Surf	B
20	-	I
21	1	I
22	direction	O
23	.	O

1	During	O
2	the	O
3	period	O
4	from	O
5	May	O
6	to	O
7	August	O
8	,	O
9	1978	O
10	,	O
11	an	O
12	epidemic	O
13	of	O
14	hand	O
15	,	O
16	foot	O
17	and	O
18	mouth	O
19	disease	O
20	(	O
21	HFMD	O
22	)	O
23	occurred	O
24	in	O
25	Gifu	O
26	prefecture	O
27	.	O

1	Effect	O
2	of	O
3	heparin	O
4	on	O
5	the	O
6	inactivation	O
7	of	O
8	serum	B
9	lipoprotein	I
10	lipase	I
11	by	O
12	the	O
13	liver	O
14	in	O
15	unanesthetized	O
16	dogs	O
17	.	O

1	We	O
2	compared	O
3	the	O
4	parameters	O
5	pleural	B
6	adenosine	I
7	deaminase	I
8	(	O
9	PADA	B
10	,	O
11	determined	O
12	in	O
13	405	O
14	patients	O
15	),	O
16	the	O
17	PADA	B
18	/	O
19	serum	B
20	ADA	I
21	ratio	O
22	(	O
23	P	B
24	/	O
25	SADA	B
26	;	O
27	276	O
28	cases	O
29	),	O
30	pleural	B
31	lysozyme	I
32	(	O
33	PLYS	B
34	,	O
35	276	O
36	cases	O
37	),	O
38	the	O
39	PLYS	B
40	/	O
41	serum	B
42	LYS	I
43	ratio	O
44	(	O
45	P	B
46	/	O
47	SLYS	B
48	;	O
49	276	O
50	cases	O
51	),	O
52	and	O
53	pleural	B
54	interferon	I
55	gamma	I
56	(	O
57	IFN	B
58	,	O
59	145	O
60	cases	O
61	)	O
62	regarding	O
63	their	O
64	ability	O
65	to	O
66	differentiate	O
67	tuberculous	O
68	pleural	O
69	effusions	O
70	from	O
71	others	O
72	.	O

1	A	O
2	human	B
3	Raf	I
4	-	I
5	responsive	I
6	zinc	I
7	-	I
8	finger	I
9	protein	I
10	that	O
11	binds	O
12	to	O
13	divergent	O
14	sequences	O
15	.	O

1	A	O
2	polypeptide	O
3	encoded	O
4	by	O
5	the	O
6	NTS	O
7	16	O
8	open	O
9	reading	O
10	frame	O
11	has	O
12	sequence	O
13	similarity	O
14	to	O
15	the	O
16	catalytic	O
17	domain	O
18	of	O
19	several	O
20	receptor	B
21	protein	I
22	kinases	I
23	from	I
24	plants	I
25	including	O
26	the	O
27	S	B
28	-	I
29	receptor	I
30	kinases	I
31	implicated	O
32	in	O
33	the	O
34	rejection	O
35	of	O
36	self	O
37	-	O
38	pollen	O
39	in	O
40	Brassica	O
41	species	O
42	and	O
43	the	O
44	Pto	B
45	gene	I
46	product	I
47	of	I
48	tomato	I
49	which	O
50	confers	O
51	resistance	O
52	to	O
53	a	O
54	bacterial	O
55	pathogen	O
56	.	O

1	Carbohydrates	O
2	and	O
3	glycoconjugates	O
4	biophysical	O
5	methods	O
6	.	O

1	This	O
2	study	O
3	reports	O
4	the	O
5	isolation	O
6	of	O
7	a	O
8	P	O
9	.	O
10	hybrida	O
11	gene	O
12	,	O
13	jaf13	B
14	,	O
15	encoding	O
16	a	O
17	basic	B
18	helix	I
19	-	I
20	loop	I
21	-	I
22	helix	I
23	protein	I
24	that	O
25	,	O
26	on	O
27	the	O
28	basis	O
29	of	O
30	sequence	O
31	homology	O
32	and	O
33	intron	O
34	/	O
35	exon	O
36	structure	O
37	,	O
38	represents	O
39	the	O
40	P	O
41	.	O
42	hybrida	O
43	orthologue	O
44	of	O
45	the	O
46	Z	B
47	.	I
48	mays	I
49	r	I
50	genes	I
51	.	O

1	Plasma	O
2	ion	O
3	changes	O
4	in	O
5	venous	O
6	blood	O
7	incubated	O
8	with	O
9	beta	B
10	receptor	I
11	blockers	O
12	and	O
13	subjected	O
14	to	O
15	tonometry	O
16	in	O
17	vitro	O
18	.	O

1	Stems	O
2	contain	O
3	distinctly	O
4	less	O
5	P	B
6	protein	I
7	mRNA	I
8	and	O
9	the	O
10	relative	O
11	level	O
12	in	O
13	roots	O
14	is	O
15	very	O
16	low	O
17	but	O
18	still	O
19	clearly	O
20	detectable	O
21	.	O

1	In	O
2	transient	O
3	cotransfections	O
4	E1A	B
5	could	O
6	induce	O
7	the	O
8	activity	O
9	of	O
10	the	O
11	p53	B
12	promoter	I
13	to	O
14	a	O
15	high	O
16	level	O
17	;	O
18	12S	B
19	E1A	I
20	was	O
21	threefold	O
22	as	O
23	efficient	O
24	as	O
25	13S	B
26	E1A	I
27	in	O
28	this	O
29	activity	O
30	,	O
31	and	O
32	YY1	B
33	bound	O
34	to	O
35	the	O
36	composite	O
37	element	O
38	was	O
39	shown	O
40	to	O
41	mediate	O
42	55	O
43	%	O
44	of	O
45	this	O
46	induction	O
47	.	O

1	Platelet	B
2	activating	I
3	factor	I
4	was	O
5	given	O
6	in	O
7	six	O
8	doses	O
9	at	O
10	15	O
11	minute	O
12	intervals	O
13	and	O
14	airway	O
15	response	O
16	measured	O
17	as	O
18	change	O
19	in	O
20	partial	O
21	expiratory	O
22	flow	O
23	at	O
24	30	O
25	%	O
26	of	O
27	vital	O
28	capacity	O
29	(	O
30	Vp30	O
31	).	O

1	Karger	O
2	AG	O
3	,	O
4	Basel	O

1	Rainbow	O
2	trout	O
3	were	O
4	obtained	O
5	from	O
6	a	O
7	commercial	O
8	trout	O
9	farm	O
10	,	O
11	kept	O
12	in	O
13	running	O
14	water	O
15	and	O
16	feeding	O
17	in	O
18	experimental	O
19	pellets	O
20	for	O
21	4	O
22	to	O
23	8	O
24	weeks	O
25	.	O

1	Regulation	O
2	of	O
3	RhoA	B
4	is	O
5	required	O
6	to	O
7	maintain	O
8	adhesion	O
9	in	O
10	stationary	O
11	cells	O
12	,	O
13	but	O
14	is	O
15	also	O
16	critical	O
17	for	O
18	cell	O
19	spreading	O
20	and	O
21	migration	O
22	[	O
23	3	O
24	].	O

1	A	O
2	new	O
3	hypothesis	O
4	on	O
5	mechanisms	O
6	for	O
7	inhibiting	O
8	catalytic	O
9	subunits	O
10	by	O
11	gamma	O
12	-	O
13	subunits	O
14	and	O
15	activation	O
16	of	O
17	a	O
18	holoenzyme	O
19	by	O
20	transducin	B

1	The	O
2	cause	O
3	of	O
4	death	O
5	is	O
6	often	O
7	quite	O
8	apparent	O
9	from	O
10	the	O
11	pathological	O
12	and	O
13	toxicological	O
14	findings	O
15	;	O
16	however	O
17	,	O
18	the	O
19	manner	O
20	of	O
21	death	O
22	often	O
23	gives	O
24	the	O
25	examining	O
26	official	O
27	some	O
28	difficulty	O
29	.	O

1	Administration	O
2	of	O
3	growth	B
4	hormone	I
5	leads	O
6	to	O
7	faster	O
8	growth	O
9	,	O
10	but	O
11	also	O
12	faster	O
13	bone	O
14	maturation	O
15	.	O

1	These	O
2	data	O
3	support	O
4	a	O
5	possible	O
6	biological	O
7	significance	O
8	of	O
9	the	O
10	frameshift	O
11	to	O
12	occur	O
13	at	O
14	this	O
15	position	O
16	of	O
17	the	O
18	large	O
19	overlap	O
20	by	O
21	including	O
22	the	O
23	putative	O
24	RNA	O
25	template	O
26	-	O
27	binding	O
28	site	O
29	of	O
30	the	O
31	PLRV	B
32	replicase	I
33	in	O
34	the	O
35	ORF2a	B
36	/	I
37	ORF2b	I
38	transframe	I
39	protein	I
40	.	O

1	Composites	O
2	as	O
3	restoration	O
4	materials	O

1	GlcNAc	O
2	-	O
3	and	O
4	GlcNAc2	O
5	-	O
6	PP	O
7	-	O
8	Dolichol	O
9	biosynthesis	O
10	could	O
11	be	O
12	shown	O
13	with	O
14	isolated	O
15	S	O
16	.	O
17	cerevisiae	O
18	membranes	O
19	from	O
20	cells	O
21	harboring	O
22	the	O
23	recombinant	O
24	plasmid	O
25	and	O
26	grown	O
27	on	O
28	glucose	O
29	thus	O
30	suppressing	O
31	transcription	O
32	of	O
33	the	O
34	endogenous	O
35	gene	O
36	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	mRNA	B
5	capping	I
6	enzyme	I
7	identifies	O
8	amino	O
9	acids	O
10	involved	O
11	in	O
12	GTP	O
13	binding	O
14	,	O
15	enzyme	O
16	-	O
17	guanylate	O
18	formation	O
19	,	O
20	and	O
21	GMP	O
22	transfer	O
23	to	O
24	RNA	O
25	.	O

1	MSMS	O
2	Council	O
3	hears	O
4	new	O
5	public	O
6	health	O
7	director	O
8	.	O

1	In	O
2	contrast	O
3	,	O
4	cotransfection	O
5	of	O
6	TFIIB	B
7	and	O
8	IRF	B
9	-	I
10	1	I
11	into	O
12	NIH	O
13	3T3	O
14	cells	O
15	resulted	O
16	in	O
17	a	O
18	dose	O
19	-	O
20	dependent	O
21	repression	O
22	of	O
23	promoter	O
24	activation	O
25	which	O
26	occurred	O
27	in	O
28	a	O
29	TATA	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	Structural	O
2	features	O
3	of	O
4	the	O
5	minimal	O
6	DNA	O
7	binding	O
8	domain	O
9	(	O
10	M98	O
11	-	O
12	F219	O
13	)	O
14	of	O
15	human	B
16	nucleotide	I
17	excision	I
18	repair	I
19	protein	I
20	XPA	I
21	.	O

1	Testing	O
2	for	O
3	serum	B
4	IgM	I
5	binding	O
6	to	O
7	GM1	O
8	ganglioside	O
9	in	O
10	clinical	O
11	practice	O
12	.	O

1	Chaperones	O
2	/	O
3	HSPs	B
4	thus	O
5	play	O
6	important	O
7	roles	O
8	within	O
9	cell	O
10	cycle	O
11	processes	O
12	.	O

1	Pseudosubstrate	O
2	(	O
3	19	O
4	-	O
5	36	O
6	),	O
7	derived	O
8	from	O
9	the	O
10	C	O
11	-	O
12	terminus	O
13	of	O
14	Ca	B
15	-	I
16	dependent	I
17	PKC	I
18	isotypes	I
19	,	O
20	inhibited	O
21	beta	B
22	-	I
23	PKC	I
24	but	O
25	not	O
26	nPKC	B
27	activity	O
28	using	O
29	either	O
30	Histone	B
31	IIIS	I
32	or	O
33	peptide	O
34	(	O
35	19	O
36	-	O
37	31	O
38	)	O
39	as	O
40	substrate	O
41	.	O

1	We	O
2	have	O
3	determined	O
4	that	O
5	these	O
6	nicks	O
7	occur	O
8	in	O
9	both	O
10	the	O
11	wild	O
12	-	O
13	type	O
14	and	O
15	the	O
16	mutant	O
17	sites	O
18	.	O

1	Recessive	O
2	lethal	O
3	mutations	O
4	were	O
5	isolated	O
6	based	O
7	upon	O
8	failure	O
9	to	O
10	complement	O
11	the	O
12	recessive	O
13	lethality	O
14	of	O
15	Df	O
16	(	O
17	3L	O
18	)	O
19	RR2	O
20	,	O
21	a	O
22	deletion	O
23	of	O
24	the	O
25	DRE	O
26	region	O
27	that	O
28	removes	O
29	16	O
30	-	O
31	18	O
32	polytene	O
33	chromosome	O
34	bands	O
35	.	O

1	Handgrip	O
2	dynamometry	O
3	was	O
4	also	O
5	carried	O
6	out	O
7	in	O
8	249	O
9	of	O
10	the	O
11	patients	O
12	.	O

1	Horseradish	B
2	peroxidase	I
3	as	O
4	a	O
5	permeability	O
6	marker	O
7	in	O
8	injured	O
9	rat	O
10	caudal	O
11	and	O
12	iliac	O
13	arteries	O
14	.	O

1	Perfusion	O
2	washout	O
3	:	O
4	increasing	O
5	a	O
6	microvascular	O
7	free	O
8	flap	O
9	tolerance	O
10	to	O
11	ischemia	O
12	.	O

1	Transforming	B
2	growth	I
3	factor	I
4	-	I
5	beta1	I
6	(	O
7	TGF	B
8	-	I
9	beta1	I
10	)	O
11	can	O
12	act	O
13	as	O
14	a	O
15	tumor	O
16	suppressor	O
17	or	O
18	a	O
19	tumor	O
20	promoter	O
21	depending	O
22	on	O
23	the	O
24	characteristics	O
25	of	O
26	the	O
27	malignant	O
28	cell	O
29	.	O

1	In	O
2	Rat	O
3	1a	O
4	cells	O
5	,	O
6	m1R	B
7	stimulation	O
8	of	O
9	phospholipase	B
10	C	I
11	beta	I
12	and	O
13	the	O
14	marked	O
15	rise	O
16	in	O
17	intracellular	O
18	calcium	O
19	stimulated	O
20	cyclic	O
21	AMP	O
22	(	O
23	cAMP	O
24	)	O
25	synthesis	O
26	,	O
27	resulting	O
28	in	O
29	the	O
30	activation	O
31	of	O
32	protein	B
33	kinase	I
34	A	I
35	.	O

1	This	O
2	study	O
3	allows	O
4	us	O
5	to	O
6	draw	O
7	conclusions	O
8	about	O
9	the	O
10	identity	O
11	of	O
12	proteins	O
13	required	O
14	for	O
15	the	O
16	development	O
17	of	O
18	the	O
19	nervous	O
20	system	O
21	in	O
22	Drosophila	O
23	and	O
24	provides	O
25	an	O
26	example	O
27	of	O
28	a	O
29	molecular	O
30	approach	O
31	to	O
32	characterize	O
33	en	O
34	masse	O
35	transposon	O
36	-	O
37	tagged	O
38	mutations	O
39	identified	O
40	in	O
41	genetic	O
42	screens	O
43	.	O

1	One	O
2	possible	O
3	solution	O
4	is	O
5	a	O
6	thin	O
7	radial	O
8	forearm	O
9	free	O
10	flap	O
11	.	O

1	The	O
2	eluent	O
3	from	O
4	the	O
5	column	O
6	was	O
7	mixed	O
8	with	O
9	the	O
10	chemiluminescent	O
11	solution	O
12	containing	O
13	lucigenin	B
14	and	O
15	Triton	O
16	X	O
17	-	O
18	100	O
19	and	O
20	a	O
21	0	O
22	.	O
23	28	O
24	M	O
25	KOH	O
26	solution	O
27	by	O
28	pumps	O
29	and	O
30	monitored	O
31	by	O
32	a	O
33	chemiluminescence	O
34	detector	O
35	.	O

1	Because	O
2	of	O
3	a	O
4	rapid	O
5	development	O
6	of	O
7	the	O
8	connective	O
9	tissue	O
10	scars	O
11	,	O
12	however	O
13	,	O
14	at	O
15	the	O
16	place	O
17	of	O
18	the	O
19	destroyed	O
20	glandular	O
21	parenchyma	O
22	areas	O
23	,	O
24	there	O
25	is	O
26	no	O
27	normalization	O
28	of	O
29	the	O
30	organ	O
31	'	O
32	s	O
33	structure	O
34	and	O
35	function	O
36	by	O
37	the	O
38	42d	O
39	day	O
40	.	O

1	Ovulation	O
2	was	O
3	induced	O
4	in	O
5	8	O
6	(	O
7	56	O
8	.	O
9	7	O
10	%)	O
11	patients	O
12	who	O
13	conceived	O
14	.	O

1	Managing	O
2	dysphagia	O
3	in	O
4	a	O
5	chronic	O
6	care	O
7	setting	O
8	:	O
9	an	O
10	introduction	O
11	.	O

1	The	O
2	emerging	O
3	complexity	O
4	of	O
5	the	O
6	5	O
7	'	O
8	regulatory	O
9	region	O
10	of	O
11	the	O
12	GH	B
13	receptor	I
14	gene	I
15	was	O
16	emphasised	O
17	by	O
18	the	O
19	observation	O
20	that	O
21	probes	O
22	derived	O
23	from	O
24	exon	O
25	1B	O
26	and	O
27	the	O
28	distal	O
29	3	O
30	'	O
31	intron	O
32	boundary	O
33	do	O
34	not	O
35	hybridise	O
36	with	O
37	previously	O
38	cloned	O
39	genomic	O
40	sequences	O
41	that	O
42	span	O
43	the	O
44	liver	O
45	-	O
46	specific	O
47	P1	O
48	promoter	O
49	and	O
50	exon	O
51	2	O
52	.	O

1	The	O
2	mutations	O
3	did	O
4	not	O
5	affect	O
6	the	O
7	repression	O
8	of	O
9	CPA1	B
10	by	O
11	arginine	O
12	.	O

1	The	O
2	malate	B
3	synthase	I
4	gene	I
5	,	O
6	MLS1	B
7	,	O
8	of	O
9	the	O
10	yeast	O
11	Saccharomyces	O
12	cerevisiae	O
13	is	O
14	transcriptionally	O
15	regulated	O
16	by	O
17	the	O
18	carbon	O
19	source	O
20	in	O
21	the	O
22	growth	O
23	medium	O
24	.	O

1	Comparison	O
2	of	O
3	immunoassay	O
4	kits	O
5	for	O
6	detection	O
7	of	O
8	staphylococcal	B
9	enterotoxins	I
10	produced	O
11	by	O
12	Staphylococcus	O
13	aureus	O

1	Within	O
2	the	O
3	3	O
4	'	O
5	terminal	O
6	50	O
7	nucleotides	O
8	,	O
9	the	O
10	mouse	B
11	mt	I
12	12S	I
13	rRNA	I
14	contains	O
15	a	O
16	potential	O
17	10	O
18	bp	O
19	hairpin	O
20	structure	O
21	and	O
22	a	O
23	sequence	O
24	of	O
25	15	O
26	consecutive	O
27	nucleotides	O
28	common	O
29	to	O
30	the	O
31	RNA	O
32	of	O
33	the	O
34	small	O
35	ribosomal	O
36	subunit	O
37	in	O
38	all	O
39	systems	O
40	,	O
41	but	O
42	does	O
43	not	O
44	contain	O
45	the	O
46	mRNA	O
47	binding	O
48	site	O
49	(	O
50	ACCUCC	O
51	)	O
52	found	O
53	in	O
54	E	O
55	.	O
56	coli	O
57	and	O
58	corn	O
59	chloroplast	O
60	rRNAs	O
61	.	O

1	As	O
2	the	O
3	components	O
4	of	O
5	these	O
6	complexes	O
7	,	O
8	at	O
9	least	O
10	five	O
11	TRBPs	B
12	(	O
13	p30	B
14	,	O
15	p37	B
16	,	O
17	p46	B
18	,	O
19	p50	B
20	,	O
21	and	O
22	p56	B
23	)	O
24	showing	O
25	specific	O
26	binding	O
27	to	O
28	the	O
29	TAR	O
30	RNA	O
31	were	O
32	detected	O
33	in	O
34	the	O
35	uv	O
36	cross	O
37	-	O
38	linking	O
39	assay	O
40	.	O

1	This	O
2	mode	O
3	of	O
4	ternary	O
5	complex	O
6	formation	O
7	is	O
8	in	O
9	contrast	O
10	to	O
11	the	O
12	one	O
13	seen	O
14	in	O
15	the	O
16	promoter	O
17	of	O
18	the	O
19	c	B
20	-	I
21	fos	I
22	protooncogene	I
23	,	O
24	where	O
25	formation	O
26	of	O
27	the	O
28	ternary	O
29	complex	O
30	is	O
31	dependent	O
32	on	O
33	the	O
34	prior	O
35	assembly	O
36	of	O
37	the	O
38	serum	B
39	response	I
40	factor	I
41	-	I
42	DNA	I
43	binary	I
44	complex	I
45	.	O

1	Inducible	O
2	VT	O
3	was	O
4	suppressed	O
5	entirely	O
6	in	O
7	one	O
8	patient	O
9	.	O

1	A	O
2	noncatalytic	O
3	domain	O
4	conserved	O
5	among	O
6	cytoplasmic	B
7	protein	I
8	-	I
9	tyrosine	I
10	kinases	I
11	modifies	O
12	the	O
13	kinase	O
14	function	O
15	and	O
16	transforming	O
17	activity	O
18	of	O
19	Fujinami	B
20	sarcoma	I
21	virus	I
22	P130gag	I
23	-	O
24	fps	B
25	.	O

1	It	O
2	is	O
3	the	O
4	human	O
5	homolog	O
6	of	O
7	the	O
8	mouse	B
9	Mx	I
10	protein	I
11	involved	O
12	in	O
13	resistance	O
14	to	O
15	influenza	O
16	virus	O
17	.	O

1	This	O
2	open	O
3	reading	O
4	frame	O
5	was	O
6	confirmed	O
7	the	O
8	correct	O
9	one	O
10	by	O
11	direct	O
12	amino	O
13	-	O
14	terminal	O
15	sequence	O
16	analysis	O
17	of	O
18	the	O
19	overproduced	O
20	msgB	B
21	gene	I
22	product	I
23	.	O

1	The	O
2	QT	O
3	interval	O
4	was	O
5	related	O
6	to	O
7	various	O
8	components	O
9	of	O
10	the	O
11	insulin	B
12	resistance	O
13	syndrome	O
14	,	O
15	including	O
16	BP	O
17	and	O
18	insulin	B
19	sensitivity	O
20	.	O

1	Serotonin	B
2	receptors	I
3	in	O
4	suicide	O
5	victims	O
6	with	O
7	major	O
8	depression	O
9	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	molecular	O
6	lesions	O
7	of	O
8	nine	O
9	Scm	B
10	mutant	I
11	alleles	I
12	,	O
13	which	O
14	identify	O
15	functional	O
16	requirements	O
17	for	O
18	specific	O
19	domains	O
20	.	O

1	Thus	O
2	,	O
3	CHOP	B
4	not	O
5	only	O
6	is	O
7	a	O
8	negative	O
9	or	O
10	a	O
11	positive	O
12	regulator	O
13	of	O
14	C	B
15	/	I
16	EBP	I
17	target	O
18	genes	O
19	but	O
20	also	O
21	,	O
22	when	O
23	tethered	O
24	to	O
25	AP	B
26	-	I
27	1	I
28	factors	I
29	,	O
30	can	O
31	activate	O
32	AP	B
33	-	I
34	1	I
35	target	O
36	genes	O
37	.	O

1	The	O
2	ParaSight	O
3	-	O
4	F	O
5	test	O
6	alone	O
7	was	O
8	used	O
9	to	O
10	monitor	O
11	serum	O
12	antigen	O
13	levels	O
14	after	O
15	treatment	O
16	in	O
17	24	O
18	patients	O
19	.	O

1	Vimentin	B
2	positivity	O
3	was	O
4	noted	O
5	in	O
6	the	O
7	undifferentiated	O
8	and	O
9	fibroblastic	O
10	components	O
11	.	O

1	Eleven	O
2	biopsy	O
3	specimens	O
4	(	O
5	five	O
6	papules	O
7	and	O
8	six	O
9	dusky	O
10	or	O
11	crusted	O
12	lesions	O
13	)	O
14	from	O
15	four	O
16	patients	O
17	with	O
18	pityriasis	O
19	lichenoides	O
20	et	O
21	varioliformis	O
22	acuta	O
23	(	O
24	PLEVA	O
25	)	O
26	were	O
27	studied	O
28	by	O
29	direct	O
30	immunofluorescence	O
31	and	O
32	immunoperoxidase	B
33	technics	O
34	.	O

1	Cyclin	B
2	D1	I
3	promoter	I
4	activity	O
5	was	O
6	stimulated	O
7	by	O
8	overexpression	O
9	of	O
10	mitogen	B
11	-	I
12	activated	I
13	protein	I
14	kinase	I
15	(	O
16	p41MAPK	B
17	)	O
18	or	O
19	c	B
20	-	I
21	Ets	I
22	-	I
23	2	I
24	through	O
25	the	O
26	proximal	O
27	22	O
28	base	O
29	pairs	O
30	.	O

1	The	O
2	effects	O
3	of	O
4	mean	O
5	luminance	O
6	were	O
7	also	O
8	measured	O
9	and	O
10	a	O
11	general	O
12	expression	O
13	that	O
14	would	O
15	take	O
16	them	O
17	into	O
18	account	O
19	was	O
20	derived	O
21	.	O

1	Sequencing	O
2	the	O
3	gene	O
4	for	O
5	an	O
6	imipenem	O
7	-	O
8	cefoxitin	O
9	-	O
10	hydrolyzing	O
11	enzyme	O
12	(	O
13	CfiA	B
14	)	O
15	from	O
16	Bacteroides	O
17	fragilis	O
18	TAL2480	O
19	reveals	O
20	strong	O
21	similarity	O
22	between	O
23	CfiA	B
24	and	O
25	Bacillus	B
26	cereus	I
27	beta	I
28	-	I
29	lactamase	I
30	II	I
31	.	O

1	These	O
2	repressor	O
3	sites	O
4	are	O
5	pyrimidine	O
6	rich	O
7	and	O
8	bind	O
9	avidly	O
10	to	O
11	the	O
12	polypyrimidine	B
13	tract	I
14	binding	I
15	protein	I
16	(	O
17	PTB	B
18	)	O
19	in	O
20	HeLa	O
21	nuclear	O
22	extracts	O
23	as	O
24	determined	O
25	by	O
26	UV	O
27	crosslinking	O
28	/	O
29	competition	O
30	assays	O
31	.	O

1	A	O
2	full	B
3	-	I
4	length	I
5	PRL	I
6	receptor	I
7	(	O
8	PRLR	B
9	)	O
10	complementary	O
11	DNA	O
12	from	O
13	pigeons	O
14	was	O
15	obtained	O
16	by	O
17	screening	O
18	pigeon	O
19	crop	O
20	sac	O
21	libraries	O
22	and	O
23	by	O
24	reverse	O
25	transcription	O
26	coupled	O
27	with	O
28	polymerase	O
29	chain	O
30	reaction	O
31	.	O

1	Within	O
2	each	O
3	lobe	O
4	,	O
5	the	O
6	PA	O
7	dispersion	O
8	was	O
9	up	O
10	to	O
11	10	O
12	cmH2O	O
13	at	O
14	CFV	O
15	of	O
16	90	O
17	l	O
18	/	O
19	min	O
20	;	O
21	when	O
22	flow	O
23	decreased	O
24	,	O
25	PA	O
26	at	O
27	all	O
28	sites	O
29	decreased	O
30	,	O
31	as	O
32	did	O
33	the	O
34	intralobar	O
35	dispersion	O
36	.	O

1	y	O
2	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	requirements	O
6	of	O
7	the	O
8	CH	B
9	gene	I
10	switch	O
11	by	O
12	characterizing	O
13	two	O
14	rearranged	B
15	gamma	I
16	2b	I
17	genes	I
18	from	O
19	a	O
20	gamma	B
21	2b	I
22	producing	O
23	mouse	O
24	myeloma	O
25	(	O
26	MPC	O
27	-	O
28	11	O
29	).	O

1	Reaction	O
2	times	O
3	to	O
4	tachistoscopically	O
5	presented	O
6	stimuli	O
7	in	O
8	diabetics	O

1	T2	O
2	cancers	O
3	should	O
4	not	O
5	be	O
6	excluded	O
7	from	O
8	the	O
9	benefit	O
10	of	O
11	preoperative	O
12	irradiation	O
13	.	O

1	Variable	O
2	FHR	O
3	decelerations	O
4	or	O
5	bradycardias	O
6	were	O
7	encountered	O
8	on	O
9	95	O
10	nonstress	O
11	tests	O
12	(	O
13	18	O
14	.	O
15	8	O
16	%)	O
17	in	O
18	80	O
19	(	O
20	33	O
21	.	O
22	5	O
23	%)	O
24	postdate	O
25	patients	O
26	.	O

1	Fourteen	O
2	different	O
3	species	O
4	(	O
5	eight	O
6	Platyhelmintha	O
7	,	O
8	one	O
9	Nematoda	O
10	and	O
11	five	O
12	Crustacea	O
13	)	O
14	have	O
15	been	O
16	inventorized	O
17	.	O

1	The	O
2	requirement	O
3	of	O
4	different	O
5	essential	O
6	fatty	O
7	acids	O
8	in	O
9	patients	O
10	with	O
11	total	O
12	parenteral	O
13	nutrition	O
14	after	O
15	heavy	O
16	injury	O
17	is	O
18	of	O
19	special	O
20	interest	O
21	with	O
22	respect	O
23	to	O
24	the	O
25	development	O
26	and	O
27	prognosis	O
28	of	O
29	shock	O
30	,	O
31	sepsis	O
32	or	O
33	adult	O
34	respiratory	O
35	distress	O
36	syndrome	O
37	.	O

1	ORFK10	B
2	.	I
3	5	I
4	encodes	O
5	a	O
6	protein	O
7	,	O
8	latency	B
9	-	I
10	associated	I
11	nuclear	I
12	antigen	I
13	2	I
14	(	O
15	LANA2	B
16	),	O
17	which	O
18	is	O
19	expressed	O
20	in	O
21	KSHV	O
22	-	O
23	infected	O
24	hematopoietic	O
25	tissues	O
26	,	O
27	including	O
28	PEL	O
29	and	O
30	CD	O
31	but	O
32	not	O
33	KS	O
34	lesions	O
35	.	O

1	No	O
2	correlation	O
3	between	O
4	the	O
5	age	O
6	of	O
7	the	O
8	horses	O
9	and	O
10	the	O
11	antibody	O
12	level	O
13	could	O
14	be	O
15	found	O
16	.	O

1	The	O
2	effects	O
3	of	O
4	dominant	O
5	interfering	O
6	forms	O
7	of	O
8	the	O
9	JNK	B
10	/	O
11	p38	B
12	signaling	O
13	pathway	O
14	demonstrate	O
15	that	O
16	activation	O
17	of	O
18	these	O
19	kinases	O
20	is	O
21	critical	O
22	for	O
23	cytokine	O
24	-	O
25	induced	O
26	E	B
27	-	I
28	selectin	I
29	gene	I
30	expression	O
31	.	O

1	The	O
2	pilE	B
3	gene	I
4	product	I
5	of	I
6	Pseudomonas	I
7	aeruginosa	I
8	,	O
9	required	O
10	for	O
11	pilus	O
12	biogenesis	O
13	,	O
14	shares	O
15	amino	O
16	acid	O
17	sequence	O
18	identity	O
19	with	O
20	the	O
21	N	O
22	-	O
23	termini	O
24	of	O
25	type	B
26	4	I
27	prepilin	I
28	proteins	I
29	.	O

1	Lung	O
2	mesenchyme	O
3	serves	O
4	as	O
5	a	O
6	'	O
7	compleat	O
8	'	O
9	inducer	O
10	of	O
11	lung	O
12	morphogenesis	O
13	by	O
14	secreting	O
15	soluble	O
16	peptide	O
17	growth	O
18	factors	O
19	.	O

1	On	O
2	admission	O
3	to	O
4	the	O
5	ICU	O
6	,	O
7	117	O
8	patients	O
9	(	O
10	61	O
11	percent	O
12	)	O
13	had	O
14	hypomagnesemia	O
15	(	O
16	serum	O
17	Mg	O
18	less	O
19	than	O
20	1	O
21	.	O
22	5	O
23	mEq	O
24	/	O
25	dl	O
26	),	O
27	66	O
28	patients	O
29	(	O
30	34	O
31	percent	O
32	)	O
33	had	O
34	normomagnesemia	O
35	(	O
36	1	O
37	.	O
38	5	O
39	to	O
40	2	O
41	.	O
42	0	O
43	mEq	O
44	/	O
45	dl	O
46	),	O
47	and	O
48	ten	O
49	patients	O
50	(	O
51	5	O
52	percent	O
53	)	O
54	had	O
55	hypermagnesemia	O
56	(	O
57	greater	O
58	than	O
59	2	O
60	.	O
61	0	O
62	mEq	O
63	/	O
64	dl	O
65	).	O

1	Treatment	O
2	with	O
3	amphotericin	O
4	B	O
5	and	O
6	flucytosine	O
7	led	O
8	to	O
9	improvement	O
10	of	O
11	the	O
12	symptoms	O
13	but	O
14	did	O
15	not	O
16	eradicate	O
17	the	O
18	micro	O
19	-	O
20	organisms	O
21	from	O
22	the	O
23	cerebrospinal	O
24	fluid	O
25	(	O
26	CSF	O
27	).	O

1	Metabolism	O
2	of	O
3	calcium	O
4	and	O
5	vitamin	O
6	D3	O
7	in	O
8	patients	O
9	with	O
10	acute	O
11	tubulointerstitial	O
12	nephritis	O
13	:	O
14	a	O
15	study	O
16	of	O
17	41	O
18	patients	O
19	with	O
20	nephropathia	O
21	epidemica	O
22	.	O

1	These	O
2	characteristic	O
3	structural	O
4	features	O
5	were	O
6	used	O
7	to	O
8	create	O
9	the	O
10	abbreviation	O
11	AZF1	B
12	(	O
13	Asparagine	B
14	-	I
15	rich	I
16	Zinc	I
17	Finger	I
18	protein	I
19	).	O

1	A	O
2	five	O
3	-	O
4	phase	O
5	experiment	O
6	was	O
7	designed	O
8	to	O
9	investigate	O
10	(	O
11	a	O
12	)	O
13	whether	O
14	contingent	O
15	music	O
16	-	O
17	listening	O
18	would	O
19	act	O
20	as	O
21	a	O
22	reinforcer	O
23	to	O
24	increase	O
25	arithmetic	O
26	performance	O
27	of	O
28	EMR	O
29	children	O
30	and	O
31	(	O
32	b	O
33	)	O
34	whether	O
35	this	O
36	contingent	O
37	reinforcement	O
38	would	O
39	affect	O
40	preference	O
41	for	O
42	that	O
43	reinforcer	O
44	.	O

1	Excision	O
2	repair	O
3	at	O
4	the	O
5	level	O
6	of	O
7	the	O
8	nucleotide	O
9	in	O
10	the	O
11	Saccharomyces	B
12	cerevisiae	I
13	MFA2	I
14	gene	I
15	:	O
16	mapping	O
17	of	O
18	where	O
19	enhanced	O
20	repair	O
21	in	O
22	the	O
23	transcribed	O
24	strand	O
25	begins	O
26	or	O
27	ends	O
28	and	O
29	identification	O
30	of	O
31	only	O
32	a	O
33	partial	O
34	rad16	B
35	requisite	O
36	for	O
37	repairing	O
38	upstream	O
39	control	O
40	sequences	O
41	.	O

1	Kinetic	O
2	experiments	O
3	revealed	O
4	that	O
5	within	O
6	10	O
7	min	O
8	this	O
9	radiolabeled	O
10	precursor	O
11	protein	O
12	was	O
13	converted	O
14	in	O
15	HL	O
16	-	O
17	60	O
18	cells	O
19	into	O
20	an	O
21	Mr	O
22	approximately	O
23	150	O
24	,	O
25	000	O
26	chondroitin	O
27	sulfate	O
28	proteoglycan	O
29	intermediate	O
30	.	O

1	Metastasis	O
2	of	O
3	colon	O
4	carcinoma	O
5	to	O
6	the	O
7	lip	O
8	.	O

1	The	O
2	following	O
3	technique	O
4	describes	O
5	a	O
6	modification	O
7	to	O
8	a	O
9	bar	O
10	superstructure	O
11	that	O
12	provided	O
13	the	O
14	advantages	O
15	of	O
16	convenience	O
17	,	O
18	security	O
19	,	O
20	and	O
21	consistent	O
22	positioning	O
23	even	O
24	though	O
25	one	O
26	implant	O
27	was	O
28	lost	O
29	and	O
30	the	O
31	angulation	O
32	of	O
33	implants	O
34	limited	O
35	accuracy	O
36	.	O

1	Aberrant	O
2	protein	O
3	phosphorylation	O
4	at	O
5	tyrosine	O
6	is	O
7	responsible	O
8	for	O
9	the	O
10	growth	O
11	-	O
12	inhibitory	O
13	action	O
14	of	O
15	pp60v	B
16	-	I
17	src	I
18	expressed	O
19	in	O
20	the	O
21	yeast	O
22	Saccharomyces	O
23	cerevisiae	O
24	.	O

1	The	O
2	effective	O
3	and	O
4	low	O
5	toxic	O
6	dose	O
7	schedules	O
8	of	O
9	KW	O
10	-	O
11	2083	O
12	should	O
13	be	O
14	investigated	O
15	further	O
16	.	O

1	Response	O
2	durations	O
3	were	O
4	short	O
5	.	O

1	The	O
2	specific	O
3	electrical	O
4	resistance	O
5	of	O
6	the	O
7	cerebrospinal	O
8	fluid	O
9	was	O
10	measured	O
11	by	O
12	means	O
13	of	O
14	conductometry	O
15	in	O
16	14	O
17	cases	O
18	of	O
19	meningitis	O
20	purulenta	O
21	,	O
22	17	O
23	cases	O
24	of	O
25	meningitis	O
26	serosa	O
27	,	O
28	10	O
29	cases	O
30	of	O
31	encephalitis	O
32	and	O
33	in	O
34	32	O
35	control	O
36	subjects	O
37	.	O

1	Using	O
2	mutated	B
3	IL2R	I
4	alpha	I
5	promoter	I
6	constructs	I
7	in	O
8	transient	O
9	transfection	O
10	and	O
11	DNA	O
12	binding	O
13	assays	O
14	,	O
15	we	O
16	now	O
17	demonstrate	O
18	that	O
19	sequences	O
20	located	O
21	immediately	O
22	upstream	O
23	and	O
24	downstream	O
25	of	O
26	the	O
27	kappa	B
28	B	I
29	enhancer	I
30	also	O
31	contribute	O
32	to	O
33	the	O
34	regulation	O
35	of	O
36	IL2R	B
37	alpha	I
38	gene	I
39	expression	O
40	.	O

1	Four	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	showed	O
7	clinical	O
8	improvement	O
9	according	O
10	to	O
11	Ritchie	O
12	-	O
13	Index	O
14	,	O
15	pain	O
16	score	O
17	,	O
18	ESR	O
19	and	O
20	CRP	B
21	.	O

1	The	O
2	rates	O
3	of	O
4	total	O
5	energy	O
6	use	O
7	(	O
8	mean	O
9	+/-	O
10	SD	O
11	=	O
12	39	O
13	.	O
14	3	O
15	+/-	O
16	1	O
17	.	O
18	2	O
19	vs	O
20	35	O
21	.	O
22	7	O
23	+/-	O
24	1	O
25	.	O
26	3	O
27	kJ	O
28	X	O
29	min	O
30	-	O
31	1	O
32	;	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	)	O
40	were	O
41	significantly	O
42	higher	O
43	at	O
44	-	O
45	10	O
46	degrees	O
47	C	O
48	than	O
49	at	O
50	22	O
51	degrees	O
52	C	O
53	.	O

1	Significant	O
2	alterations	O
3	in	O
4	the	O
5	vasectomized	O
6	rats	O
7	from	O
8	sham	O
9	rats	O
10	included	O
11	:	O
12	testicular	O
13	and	O
14	epididymal	O
15	hypertrophy	O
16	,	O
17	formation	O
18	of	O
19	pathologic	O
20	vas	O
21	deferens	O
22	granulomas	O
23	,	O
24	decreased	O
25	total	O
26	serum	O
27	protein	O
28	,	O
29	lowered	O
30	alpha	B
31	-	I
32	globulin	I
33	levels	O
34	as	O
35	shown	O
36	by	O
37	serum	O
38	electrophoresis	O
39	,	O
40	and	O
41	increased	O
42	sperm	O
43	agglutinin	B
44	antibody	O
45	titers	O
46	.	O

1	Therefore	O
2	,	O
3	both	O
4	the	O
5	Chilean	O
6	and	O
7	the	O
8	Japanese	O
9	samples	O
10	collected	O
11	in	O
12	high	O
13	-	O
14	risk	O
15	areas	O
16	showed	O
17	higher	O
18	mutagenic	O
19	rates	O
20	than	O
21	the	O
22	Japanese	O
23	ones	O
24	in	O
25	a	O
26	low	O
27	-	O
28	risk	O
29	area	O
30	,	O
31	with	O
32	a	O
33	statistical	O
34	significance	O
35	(	O
36	p	O
37	<	O
38	0	O
39	.	O
40	001	O
41	),	O
42	chi	O
43	-	O
44	square	O
45	test	O
46	).	O

1	We	O
2	propose	O
3	that	O
4	Gly84	O
5	is	O
6	part	O
7	of	O
8	a	O
9	putative	O
10	"	O
11	oxyanion	O
12	hole	O
13	"	O
14	involved	O
15	in	O
16	the	O
17	stabilization	O
18	of	O
19	the	O
20	transition	O
21	state	O
22	similar	O
23	to	O
24	the	O
25	C	B
26	group	I
27	of	O
28	the	O
29	esterase	B
30	/	O
31	lipase	B
32	family	O
33	.	O

1	DR1	B
2	molecules	I
3	purified	O
4	from	O
5	human	O
6	lymphoblastoid	O
7	cell	O
8	lines	O
9	could	O
10	specifically	O
11	bind	O
12	to	O
13	these	O
14	peptide	O
15	sequences	O
16	expressed	O
17	on	O
18	the	O
19	phage	O
20	surface	O
21	.	O

1	Myelomatous	O
2	pleural	O
3	effusion	O
4	as	O
5	presentation	O
6	form	O
7	of	O
8	multiple	O
9	myeloma	O

1	In	O
2	two	O
3	further	O
4	cases	O
5	(	O
6	one	O
7	type	O
8	I	O
9	and	O
10	one	O
11	type	O
12	III	O
13	SMA	O
14	),	O
15	de	O
16	novo	O
17	deletions	O
18	of	O
19	only	O
20	one	O
21	copy	O
22	of	O
23	Ag1	B
24	-	I
25	CA	I
26	and	O
27	C212	B
28	were	O
29	found	O
30	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	release	O
6	of	O
7	interleukin	B
8	-	I
9	1	I
10	beta	I
11	(	O
12	IL	B
13	-	I
14	1	I
15	)	O
16	and	O
17	tumour	B
18	necrosis	I
19	factor	I
20	-	I
21	alpha	I
22	(	O
23	TNF	B
24	)	O
25	by	O
26	unstimulated	O
27	monocytes	O
28	and	O
29	monocytes	O
30	stimulated	O
31	with	O
32	lipopolysaccharide	O
33	(	O
34	LPS	O
35	)	O
36	isolated	O
37	from	O
38	the	O
39	peripheral	O
40	blood	O
41	of	O
42	two	O
43	patients	O
44	with	O
45	acute	O
46	poststreptococcal	O
47	glomerulonephritis	O
48	(	O
49	AGN	O
50	)	O
51	and	O
52	16	O
53	healthy	O
54	controls	O
55	.	O

1	In	O
2	this	O
3	respect	O
4	C	B
5	reactive	I
6	protein	I
7	concentrations	O
8	are	O
9	superior	O
10	to	O
11	white	O
12	cell	O
13	count	O
14	,	O
15	erythrocyte	O
16	sedimentation	O
17	rate	O
18	,	O
19	and	O
20	temperature	O
21	and	O
22	the	O
23	concentrations	O
24	of	O
25	antiproteases	O
26	.	O

1	Insulin	B
2	receptor	I
3	substrate	I
4	-	I
5	1	I
6	-	O
7	mediated	O
8	enhancement	O
9	of	O
10	growth	B
11	hormone	I
12	-	O
13	induced	O
14	mitogen	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	activation	O
20	.	O

1	Regional	O
2	insertional	O
3	mutagenesis	O
4	of	O
5	specific	O
6	genes	O
7	on	O
8	the	O
9	CIC5F11	B
10	/	O
11	CIC2B9	B
12	locus	O
13	of	O
14	Arabidopsis	O
15	thaliana	O
16	chromosome	O
17	5	O
18	using	O
19	the	O
20	Ac	B
21	/	O
22	Ds	B
23	transposon	O
24	in	O
25	combination	O
26	with	O
27	the	O
28	cDNA	O
29	scanning	O
30	method	O
31	.	O

1	Immunological	O
2	testing	O
3	was	O
4	performed	O
5	on	O
6	all	O
7	brewery	O
8	workers	O
9	and	O
10	some	O
11	control	O
12	volunteers	O
13	using	O
14	skin	O
15	prick	O
16	testing	O
17	with	O
18	hops	O
19	,	O
20	barley	O
21	,	O
22	and	O
23	yeast	O
24	antigens	O
25	as	O
26	well	O
27	as	O
28	other	O
29	nonoccupational	O
30	allergens	O
31	,	O
32	and	O
33	by	O
34	determining	O
35	total	O
36	serum	B
37	IgE	I
38	levels	O
39	.	O

1	A	O
2	potential	O
3	outcome	O
4	of	O
5	these	O
6	biochemical	O
7	effects	O
8	may	O
9	include	O
10	the	O
11	limited	O
12	responsiveness	O
13	of	O
14	infected	O
15	T	O
16	cells	O
17	to	O
18	antigenic	O
19	stimulation	O
20	observed	O
21	during	O
22	HIV	O
23	-	O
24	1	O
25	infection	O
26	.	O

1	Synovial	O
2	cysts	O
3	of	O
4	the	O
5	hip	O
6	joint	O

1	Two	O
2	hundred	O
3	forty	O
4	-	O
5	three	O
6	patients	O
7	have	O
8	received	O
9	WR	O
10	-	O
11	2721	O
12	in	O
13	Phase	O
14	I	O
15	-	O
16	II	O
17	studies	O
18	.	O

1	Fundamental	O
2	and	O
3	clinical	O
4	evaluation	O
5	of	O
6	equilibrium	O
7	dialysis	O
8	--	O
9	radioimmunoassay	O
10	system	O
11	for	O
12	measurement	O
13	of	O
14	serum	O
15	free	O
16	thyroxine	O

1	Therefore	O
2	,	O
3	the	O
4	results	O
5	indicate	O
6	that	O
7	repeated	O
8	exposure	O
9	to	O
10	amphetamine	O
11	or	O
12	apomorphine	O
13	overcomes	O
14	the	O
15	context	O
16	-	O
17	dependent	O
18	component	O
19	of	O
20	sensitization	O
21	of	O
22	amphetamine	O
23	-	O
24	or	O
25	apomorphine	O
26	-	O
27	induced	O
28	stereotyped	O
29	behavior	O
30	.	O

1	Sequence	O
2	comparison	O
3	indicates	O
4	that	O
5	exons	O
6	5	O
7	'/	O
8	L	O
9	and	O
10	L	O
11	/	O
12	N	O
13	in	O
14	PSG12	B
15	and	O
16	PSG12	B
17	psi	I
18	are	O
19	99	O
20	%	O
21	identical	O
22	,	O
23	except	O
24	that	O
25	the	O
26	L	O
27	/	O
28	N	O
29	exon	O
30	in	O
31	the	O
32	PSG12	B
33	psi	I
34	gene	I
35	contains	O
36	a	O
37	stop	O
38	codon	O
39	.	O

1	Vertebrate	B
2	synapsins	I
3	constitute	O
4	a	O
5	family	O
6	of	O
7	synaptic	O
8	proteins	O
9	that	O
10	participate	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	neurotransmitter	O
16	release	O
17	.	O

1	Max	B
2	:	O
3	functional	O
4	domains	O
5	and	O
6	interaction	O
7	with	O
8	c	B
9	-	I
10	Myc	I
11	.	O

1	Ventilatory	O
2	management	O
3	casebook	O
4	.	O

1	Possible	O
2	pathogenetic	O
3	mechanisms	O
4	of	O
5	hemopoietic	O
6	changes	O
7	in	O
8	response	O
9	to	O
10	space	O
11	flight	O
12	effects	O
13	are	O
14	described	O
15	.	O

1	The	O
2	effect	O
3	of	O
4	salmon	B
5	calcitonin	I
6	nasal	O
7	spray	O
8	in	O
9	women	O
10	with	O
11	established	O
12	osteoporosis	O
13	has	O
14	also	O
15	been	O
16	studied	O
17	.	O

1	When	O
2	10	O
3	fields	O
4	were	O
5	analysed	O
6	,	O
7	a	O
8	strong	O
9	relationship	O
10	was	O
11	found	O
12	between	O
13	the	O
14	presence	O
15	of	O
16	bacteria	O
17	on	O
18	Gram	O
19	staining	O
20	and	O
21	the	O
22	final	O
23	diagnosis	O
24	of	O
25	VAP	O
26	(	O
27	for	O
28	PSB	O
29	and	O
30	PTC	O
31	respectively	O
32	:	O
33	sensitivity	O
34	74	O
35	and	O
36	81	O
37	%,	O
38	specificity	O
39	94	O
40	and	O
41	100	O
42	%,	O
43	positive	O
44	predictive	O
45	value	O
46	91	O
47	and	O
48	100	O
49	%,	O
50	negative	O
51	predictive	O
52	value	O
53	82	O
54	and	O
55	88	O
56	%).	O

1	To	O
2	explore	O
3	the	O
4	function	O
5	of	O
6	human	O
7	SINA	B
8	-	I
9	homologous	I
10	(	I
11	Siah	I
12	)	I
13	proteins	I
14	,	O
15	expression	O
16	plasmids	O
17	encoding	O
18	Siah	B
19	-	I
20	1A	I
21	were	O
22	transiently	O
23	transfected	O
24	into	O
25	293	O
26	epithelial	O
27	cells	O
28	and	O
29	GM701	O
30	fibroblast	O
31	cells	O
32	,	O
33	resulting	O
34	in	O
35	growth	O
36	arrest	O
37	without	O
38	induction	O
39	of	O
40	apoptosis	O
41	.	O

1	The	O
2	enzyme	O
3	displays	O
4	optimal	O
5	activity	O
6	at	O
7	about	O
8	0	O
9	.	O
10	5	O
11	mM	O
12	pantoate	O
13	(	O
14	k	O
15	(	O
16	cat	O
17	)	O
18	0	O
19	.	O
20	63	O
21	s	O
22	(-	O
23	1	O
24	))	O
25	and	O
26	at	O
27	pH	O
28	7	O
29	.	O
30	8	O
31	.	O

1	Phylogenetic	O
2	position	O
3	of	O
4	the	O
5	Phacotaceae	O
6	within	O
7	the	O
8	Chlamydophyceaeas	O
9	revealed	O
10	by	O
11	analysis	O
12	of	O
13	18S	B
14	rDNA	I
15	and	O
16	rbcL	B
17	sequences	I
18	.	O

1	ASL	O
2	-	O
3	8123	O
4	demonstrated	O
5	weak	O
6	competitive	O
7	beta	B
8	-	I
9	adrenoreceptor	I
10	blocking	O
11	activity	O
12	in	O
13	isolated	O
14	guinea	O
15	pig	O
16	right	O
17	atria	O
18	with	O
19	a	O
20	pA2	O
21	of	O
22	3	O
23	.	O
24	73	O
25	+/-	O
26	0	O
27	.	O
28	07	O
29	;	O
30	no	O
31	agonist	O
32	-	O
33	like	O
34	activity	O
35	was	O
36	observed	O
37	in	O
38	this	O
39	tissue	O
40	at	O
41	concentrations	O
42	of	O
43	ASL	O
44	-	O
45	8123	O
46	from	O
47	3	O
48	X	O
49	10	O
50	(-	O
51	5	O
52	)	O
53	to	O
54	1	O
55	X	O
56	10	O
57	(-	O
58	2	O
59	)	O
60	M	O
61	.	O

1	Neuronal	O
2	mechanisms	O
3	underlying	O
4	stimulus	O
5	-	O
6	response	O
7	(	O
8	S	O
9	-	O
10	R	O
11	)	O
12	associations	O
13	in	O
14	S	O
15	-	O
16	R	O
17	compatibility	O
18	tasks	O
19	were	O
20	identified	O
21	in	O
22	2	O
23	experiments	O
24	with	O
25	monkeys	O
26	.	O

1	Members	O
2	of	O
3	the	O
4	C	B
5	/	I
6	EBP	I
7	family	I
8	of	O
9	basic	B
10	-	I
11	leucine	I
12	zipper	I
13	(	I
14	bZip	I
15	)	I
16	transcription	I
17	factors	I
18	form	O
19	heterodimers	O
20	and	O
21	bind	O
22	to	O
23	the	O
24	CAAT	O
25	box	O
26	and	O
27	other	O
28	sequence	O
29	-	O
30	related	O
31	enhancer	O
32	motifs	O
33	.	O

1	ISIS	O
2	5	O
3	possibilities	O
4	.	O

1	Measurements	O
2	were	O
3	compared	O
4	with	O
5	two	O
6	computerised	O
7	treatment	O
8	planning	O
9	systems	O
10	--	O
11	Theraplan	O
12	VO5B	O
13	and	O
14	ADAC	O
15	Pinnacle3	O
16	V4	O
17	.	O
18	0b	O
19	.	O

1	The	O
2	11	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	specifically	O
8	linked	O
9	to	O
10	Ewing	O
11	sarcoma	O
12	and	O
13	primitive	O
14	neuroectodermal	O
15	tumor	O
16	results	O
17	in	O
18	a	O
19	chimeric	O
20	molecule	O
21	fusing	O
22	the	O
23	amino	O
24	-	O
25	terminal	O
26	-	O
27	encoding	O
28	portion	O
29	of	O
30	the	O
31	EWS	B
32	gene	I
33	to	O
34	the	O
35	carboxyl	O
36	-	O
37	terminal	O
38	DNA	O
39	-	O
40	binding	O
41	domain	O
42	encoded	O
43	by	O
44	the	O
45	FLI1	B
46	gene	I
47	.	O

1	Comparison	O
2	of	O
3	data	O
4	obtained	O
5	with	O
6	the	O
7	results	O
8	of	O
9	chronic	O
10	treatment	O
11	with	O
12	the	O
13	opioid	O
14	antagonist	O
15	permits	O
16	to	O
17	conclude	O
18	that	O
19	the	O
20	chronic	O
21	blockade	O
22	increases	O
23	the	O
24	fatiguability	O
25	to	O
26	a	O
27	great	O
28	extent	O
29	than	O
30	chronic	O
31	activation	O
32	of	O
33	opioid	O
34	system	O
35	.	O

1	Unilateral	O
2	naris	O
3	occlusion	O
4	and	O
5	the	O
6	rat	O
7	accessory	O
8	olfactory	O
9	bulb	O
10	.	O

1	Type	O
2	I	O
3	position	O
4	-	O
5	vestibular	O
6	-	O
7	pause	O
8	(	O
9	PVP	O
10	I	O
11	)	O
12	and	O
13	vestibular	O
14	-	O
15	only	O
16	(	O
17	V	O
18	I	O
19	)	O
20	neurons	O
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	smaller	O
27	number	O
28	of	O
29	other	O
30	type	O
31	I	O
32	and	O
33	type	O
34	II	O
35	eye	O
36	-	O
37	plus	O
38	-	O
39	vestibular	O
40	neurons	O
41	were	O
42	studied	O
43	.	O

1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	DNA	O
7	binding	O
8	domain	O
9	of	O
10	ILF	B
11	has	O
12	strong	O
13	homology	O
14	to	O
15	the	O
16	recently	O
17	described	O
18	fork	B
19	head	I
20	DNA	I
21	binding	I
22	domain	I
23	found	O
24	in	O
25	the	O
26	Drosophila	B
27	homeotic	I
28	protein	I
29	fork	I
30	head	I
31	and	O
32	a	O
33	family	O
34	of	O
35	hepatocyte	B
36	nuclear	I
37	factors	I
38	,	O
39	HNF	B
40	-	I
41	3	I
42	.	O

1	Disruption	O
2	of	O
3	any	O
4	one	O
5	of	O
6	the	O
7	four	O
8	genes	O
9	encoding	O
10	the	O
11	newly	O
12	identified	O
13	SRP	B
14	proteins	I
15	results	O
16	in	O
17	slow	O
18	cell	O
19	growth	O
20	and	O
21	inefficient	O
22	protein	O
23	translocation	O
24	across	O
25	the	O
26	ER	O
27	membrane	O
28	.	O

1	Beta	O
2	blocking	O
3	agents	O
4	.	O

1	Sci	O
2	.	O

1	Agonist	O
2	-	O
3	induced	O
4	receptor	O
5	internalization	O
6	,	O
7	determined	O
8	as	O
9	the	O
10	percent	O
11	of	O
12	total	O
13	[	O
14	125I	O
15	]	O
16	Tyr0	B
17	-	I
18	oCRF	I
19	bound	O
20	located	O
21	in	O
22	the	O
23	acid	O
24	-	O
25	resistant	O
26	fraction	O
27	of	O
28	transfected	O
29	Cos	O
30	7	O
31	cells	O
32	,	O
33	increased	O
34	with	O
35	time	O
36	(	O
37	0	O
38	-	O
39	60	O
40	min	O
41	at	O
42	37	O
43	degrees	O
44	C	O
45	)	O
46	for	O
47	both	O
48	wild	O
49	-	O
50	type	O
51	and	O
52	variant	O
53	oCRF1	B
54	.	O

1	Plasma	B
2	renin	I
3	activity	O
4	does	O
5	not	O
6	predict	O
7	the	O
8	antihypertensive	O
9	efficacy	O
10	of	O
11	chlorthalidone	O
12	.	O

1	The	O
2	unphosphorylated	O
3	form	O
4	of	O
5	RNA	B
6	polymerase	I
7	II	I
8	is	O
9	designated	O
10	IIA	O
11	,	O
12	whereas	O
13	the	O
14	phosphorylated	O
15	form	O
16	is	O
17	designated	O
18	IIO	O
19	.	O

1	It	O
2	is	O
3	reported	O
4	that	O
5	,	O
6	at	O
7	present	O
8	,	O
9	most	O
10	of	O
11	the	O
12	MRSAs	O
13	spreading	O
14	in	O
15	Japan	O
16	are	O
17	acceleratedly	O
18	acquiring	O
19	resistance	O
20	to	O
21	many	O
22	drugs	O
23	,	O
24	and	O
25	especially	O
26	,	O
27	they	O
28	are	O
29	developing	O
30	high	O
31	resistance	O
32	against	O
33	beta	O
34	-	O
35	lactams	O
36	.	O

1	The	O
2	mortality	O
3	rate	O
4	and	O
5	histopathological	O
6	features	O
7	of	O
8	Nocardia	O
9	asteroides	O
10	and	O
11	Nocardia	O
12	brasiliensis	O
13	infections	O
14	in	O
15	congenitally	O
16	athymic	O
17	(	O
18	nude	O
19	)	O
20	mice	O
21	of	O
22	ICR	O
23	and	O
24	C3H	O
25	/	O
26	eB	O
27	origins	O
28	were	O
29	quite	O
30	different	O
31	from	O
32	what	O
33	we	O
34	found	O
35	for	O
36	Swiss	O
37	white	O
38	mice	O
39	and	O
40	other	O
41	inbred	O
42	mouse	O
43	strains	O
44	(	O
45	namely	O
46	,	O
47	C57	O
48	/	O
49	BL	O
50	/	O
51	6J	O
52	,	O
53	New	O
54	Zealand	O
55	Black	O
56	,	O
57	BALB	O
58	/	O
59	c	O
60	,	O
61	CBA	O
62	/	O
63	LAC	O
64	,	O
65	and	O
66	C3H	O
67	/	O
68	eB	O
69	).	O

1	Antimicrobial	O
2	Susceptibility	O
3	of	O
4	Klebsiella	O
5	pneumoniae	O
6	Producing	O
7	Extended	B
8	-	I
9	Spectrum	I
10	beta	I
11	-	I
12	lactamase	I
13	(	O
14	ESBL	B
15	)	O
16	Isolated	O
17	in	O
18	Hospitals	O
19	in	O
20	Brazil	O
21	.	O

1	The	O
2	distribution	O
3	of	O
4	patients	O
5	was	O
6	as	O
7	follows	O
8	:	O
9	group	O
10	1	O
11	--	O
12	complex	O
13	gamma	O
14	-	O
15	therapy	O
16	(	O
17	55	O
18	cases	O
19	),	O
20	group	O
21	2	O
22	--	O
23	complex	O
24	gamma	O
25	-	O
26	therapy	O
27	plus	O
28	iliac	O
29	lymphadenectomy	O
30	(	O
31	50	O
32	cases	O
33	)	O
34	and	O
35	group	O
36	3	O
37	--	O
38	complex	O
39	radiation	O
40	treatment	O
41	with	O
42	megavolt	O
43	bremsstrahlung	O
44	beam	O
45	from	O
46	the	O
47	luc	O
48	type	O
49	installation	O
50	and	O
51	iliac	O
52	lymphadenectomy	O
53	(	O
54	50	O
55	cases	O
56	).	O

1	M	B
2	-	I
3	Ras	I
4	interacted	O
5	poorly	O
6	in	O
7	a	O
8	yeast	O
9	two	O
10	-	O
11	hybrid	O
12	assay	O
13	with	O
14	multiple	O
15	Ras	B
16	effectors	O
17	,	O
18	including	O
19	c	B
20	-	I
21	Raf	I
22	-	I
23	1	I
24	,	O
25	A	B
26	-	I
27	Raf	I
28	,	O
29	B	B
30	-	I
31	Raf	I
32	,	O
33	phosphoinositol	B
34	-	I
35	3	I
36	kinase	I
37	delta	I
38	,	O
39	RalGDS	B
40	,	O
41	and	O
42	Rin1	B
43	.	O

1	Terminal	B
2	deoxynucleotidyl	I
3	transferase	I
4	-	O
5	mediated	O
6	nick	O
7	end	O
8	labeling	O
9	assays	O
10	revealed	O
11	that	O
12	hormonal	O
13	activation	O
14	of	O
15	the	O
16	PAX3	B
17	repressors	I
18	induced	O
19	extensive	O
20	apoptosis	O
21	that	O
22	correlated	O
23	with	O
24	down	O
25	-	O
26	regulation	O
27	of	O
28	BCL	B
29	-	I
30	X	I
31	(	I
32	L	I
33	)	I
34	expression	O
35	.	O

1	The	O
2	model	O
3	is	O
4	able	O
5	to	O
6	anticipate	O
7	why	O
8	the	O
9	effect	O
10	of	O
11	water	O
12	fluoridation	O
13	on	O
14	caries	O
15	prevalence	O
16	is	O
17	most	O
18	pronounced	O
19	when	O
20	caries	O
21	is	O
22	diagnosed	O
23	at	O
24	cavity	O
25	level	O
26	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	significant	O
6	reduction	O
7	in	O
8	blood	O
9	pressure	O
10	,	O
11	the	O
12	angiotensin	B
13	converting	I
14	enzyme	I
15	(	O
16	ACE	B
17	)	O
18	inhibitor	O
19	ramipril	O
20	caused	O
21	a	O
22	significant	O
23	regression	O
24	of	O
25	pathologic	O
26	left	O
27	ventricular	O
28	hypertrophy	O
29	demonstrated	O
30	by	O
31	magnetic	O
32	resonance	O
33	imaging	O
34	and	O
35	echocardiography	O
36	.	O

1	RESULTS	O
2	:	O
3	Auditory	O
4	thresholds	O
5	collected	O
6	during	O
7	audiometric	O
8	tests	O
9	increased	O
10	gradually	O
11	in	O
12	proportion	O
13	with	O
14	age	O
15	,	O
16	especially	O
17	in	O
18	the	O
19	hypertensive	O
20	group	O
21	(	O
22	p	O
23	<	O
24	0	O
25	.	O
26	05	O
27	).	O

1	Among	O
2	38	O
3	patients	O
4	with	O
5	inducible	O
6	reentrant	O
7	VTs	O
8	who	O
9	underwent	O
10	electrophysiologic	O
11	study	O
12	(	O
13	EPS	O
14	),	O
15	10	O
16	VTs	O
17	of	O
18	six	O
19	patients	O
20	were	O
21	selected	O
22	.	O

1	GGS1	B
2	is	O
3	the	O
4	same	O
5	gene	O
6	as	O
7	TPS1	B
8	which	O
9	was	O
10	identified	O
11	as	O
12	encoding	O
13	a	O
14	subunit	O
15	of	O
16	the	O
17	trehalose	B
18	-	I
19	6	I
20	-	I
21	phosphate	I
22	synthase	I
23	/	I
24	phosphatase	I
25	complex	I
26	and	O
27	it	O
28	is	O
29	allelic	O
30	to	O
31	the	O
32	fdp1	B
33	,	O
34	byp1	B
35	,	O
36	glc6	B
37	and	O
38	cif1	O
39	mutations	O
40	.	O

1	We	O
2	have	O
3	isolated	O
4	three	O
5	mutant	O
6	alleles	O
7	of	O
8	CDC4	B
9	(	O
10	cdc4	B
11	-	I
12	10	I
13	,	O
14	cdc4	B
15	-	I
16	11	I
17	,	O
18	and	O
19	cdc4	B
20	-	I
21	16	I
22	)	O
23	which	O
24	suppress	O
25	the	O
26	nuclear	O
27	division	O
28	defect	O
29	of	O
30	cdc20	B
31	-	I
32	1	I
33	cells	O
34	.	O

1	The	O
2	lacS	B
3	gene	I
4	was	O
5	cloned	O
6	in	O
7	an	O
8	E	O
9	.	O
10	coli	O
11	-	O
12	Streptococcus	O
13	shuttle	O
14	vector	O
15	and	O
16	was	O
17	expressed	O
18	both	O
19	in	O
20	a	O
21	lacS	B
22	deletion	O
23	derivative	O
24	of	O
25	S	O
26	.	O
27	thermophilus	O
28	and	O
29	in	O
30	a	O
31	pNZ63	O
32	-	O
33	cured	O
34	strain	O
35	,	O
36	L	O
37	.	O
38	lactis	O
39	NZ6091	O
40	.	O

1	Thus	O
2	,	O
3	elongin	B
4	C	I
5	is	O
6	found	O
7	to	O
8	oligomerize	O
9	in	O
10	solution	O
11	and	O
12	to	O
13	undergo	O
14	significant	O
15	structural	O
16	rearrangements	O
17	upon	O
18	binding	O
19	of	O
20	two	O
21	different	O
22	partner	O
23	proteins	O
24	.	O

1	A	O
2	similar	O
3	chimera	O
4	was	O
5	assembled	O
6	from	O
7	the	O
8	two	O
9	halves	O
10	of	O
11	the	O
12	molecule	O
13	expressed	O
14	separately	O
15	in	O
16	different	O
17	bacteria	O
18	and	O
19	refolded	O
20	together	O
21	.	O

1	Based	O
2	on	O
3	subcellular	O
4	fractionation	O
5	,	O
6	the	O
7	47	B
8	-	I
9	kDa	I
10	P	I
11	-	I
12	CIP2	I
13	protein	I
14	is	O
15	mostly	O
16	cytosolic	O
17	.	O

1	The	O
2	most	O
3	frequent	O
4	causes	O
5	of	O
6	the	O
7	meningitis	O
8	was	O
9	the	O
10	external	O
11	ventricular	O
12	drainage	O
13	(	O
14	14	O
15	.	O
16	8	O
17	%),	O
18	post	O
19	-	O
20	neurosurgical	O
21	(	O
22	0	O
23	.	O
24	8	O
25	%)	O
26	and	O
27	head	O
28	injury	O
29	(	O
30	0	O
31	.	O
32	0007	O
33	%).	O

1	255	O
2	-	O
3	61	O
4	.	O

1	Increased	O
2	PTHRP	B
3	production	O
4	by	O
5	a	O
6	tyrosine	B
7	kinase	I
8	oncogene	I
9	,	O
10	Tpr	B
11	-	I
12	Met	I
13	:	O
14	role	O
15	of	O
16	the	O
17	Ras	B
18	signaling	O
19	pathway	O
20	.	O

1	In	O
2	order	O
3	to	O
4	provide	O
5	adequate	O
6	local	O
7	control	O
8	without	O
9	compromising	O
10	cosmetic	O
11	outcome	O
12	,	O
13	the	O
14	amount	O
15	of	O
16	breast	O
17	tissue	O
18	that	O
19	must	O
20	be	O
21	excised	O
22	in	O
23	BCT	O
24	needs	O
25	to	O
26	be	O
27	individualized	O
28	.	O

1	Relaxation	O
2	of	O
3	catch	O
4	in	O
5	a	O
6	molluscan	O
7	smooth	O
8	muscle	O
9	.	O

1	Western	O
2	blot	O
3	analysis	O
4	showed	O
5	a	O
6	rapid	O
7	corresponding	O
8	increase	O
9	in	O
10	p21WAF1	B
11	/	O
12	CIP1	B
13	protein	O
14	,	O
15	whereas	O
16	protein	O
17	levels	O
18	of	O
19	another	O
20	member	O
21	of	O
22	the	O
23	cyclin	B
24	-	I
25	dependent	I
26	kinase	I
27	inhibitor	I
28	family	I
29	,	O
30	p27kip1	B
31	,	O
32	were	O
33	unchanged	O
34	.	O

1	The	O
2	antihypertensive	O
3	effect	O
4	of	O
5	Estulic	O
6	has	O
7	been	O
8	examined	O
9	over	O
10	a	O
11	12	O
12	-	O
13	month	O
14	period	O
15	in	O
16	101	O
17	hypertensive	O
18	patients	O
19	.	O

1	Most	O
2	apneic	O
3	events	O
4	occurred	O
5	during	O
6	Stages	O
7	I	O
8	and	O
9	II	O
10	,	O
11	and	O
12	REM	O
13	,	O
14	but	O
15	this	O
16	proportion	O
17	was	O
18	less	O
19	during	O
20	the	O
21	gamma	O
22	OH	O
23	study	O
24	(	O
25	77	O
26	.	O
27	9	O
28	+/-	O
29	8	O
30	.	O
31	9	O
32	%)	O
33	than	O
34	during	O
35	the	O
36	control	O
37	studies	O
38	(	O
39	92	O
40	.	O
41	3	O
42	+/-	O
43	1	O
44	.	O
45	9	O
46	and	O
47	95	O
48	.	O
49	9	O
50	+/-	O
51	2	O
52	.	O
53	2	O
54	%),	O
55	apneas	O
56	occurring	O
57	even	O
58	during	O
59	SWS	O
60	with	O
61	gamma	O
62	OH	O
63	.(	O
64	ABSTRACT	O
65	TRUNCATED	O
66	AT	O
67	250	O
68	WORDS	O
69	)	O

1	In	O
2	conclusion	O
3	,	O
4	we	O
5	observed	O
6	a	O
7	great	O
8	regeneration	O
9	ability	O
10	following	O
11	mechanical	O
12	injury	O
13	in	O
14	the	O
15	nasal	O
16	mucosa	O
17	.	O

1	The	O
2	predicted	O
3	protein	O
4	products	O
5	of	O
6	ORFs	B
7	N2417	I
8	and	O
9	N2403	B
10	present	O
11	similarities	O
12	with	O
13	domains	O
14	from	O
15	proteins	O
16	of	O
17	other	O
18	organisms	O
19	:	O
20	the	O
21	Candida	O
22	maltosa	O
23	cycloheximide	B
24	-	I
25	resistance	I
26	protein	I
27	,	O
28	the	O
29	human	O
30	interleukin	B
31	enhancer	I
32	-	I
33	binding	I
34	factor	I
35	(	O
36	ILF	B
37	-	I
38	2	I
39	).	O

1	The	O
2	patients	O
3	who	O
4	presented	O
5	with	O
6	mucocutaneous	O
7	disease	O
8	also	O
9	had	O
10	low	O
11	CD4	B
12	+	I
13	T	O
14	lymphocyte	O
15	counts	O
16	,	O
17	and	O
18	most	O
19	of	O
20	them	O
21	had	O
22	AIDS	O
23	defining	O
24	illnesses	O
25	.	O

1	The	O
2	cost	O
3	per	O
4	test	O
5	is	O
6	less	O
7	than	O
8	those	O
9	for	O
10	CC	O
11	,	O
12	kEIA	O
13	and	O
14	PACE2	O
15	.	O

1	Using	O
2	varying	O
3	conditions	O
4	,	O
5	three	O
6	distinct	O
7	complexes	O
8	were	O
9	shown	O
10	to	O
11	interact	O
12	specifically	O
13	with	O
14	the	O
15	NIP	B
16	region	I
17	,	O
18	although	O
19	only	O
20	one	O
21	correlates	O
22	with	O
23	repressor	O
24	activity	O
25	.	O

1	To	O
2	study	O
3	the	O
4	origin	O
5	of	O
6	different	O
7	fMLF	B
8	-	I
9	R	I
10	transcripts	I
11	,	O
12	the	O
13	genetic	O
14	linkage	O
15	of	O
16	chemotactic	O
17	receptor	O
18	genes	O
19	,	O
20	and	O
21	the	O
22	regulation	O
23	of	O
24	fMLF	B
25	-	I
26	R	I
27	gene	I
28	expression	O
29	,	O
30	we	O
31	determined	O
32	the	O
33	copy	O
34	number	O
35	,	O
36	chromosomal	O
37	location	O
38	,	O
39	structural	O
40	organization	O
41	,	O
42	and	O
43	5	O
44	'-	O
45	flanking	O
46	sequence	O
47	of	O
48	the	O
49	human	B
50	fMLF	I
51	-	I
52	R	I
53	gene	I
54	.	O

1	Seven	O
2	out	O
3	of	O
4	34	O
5	patients	O
6	died	O
7	,	O
8	giving	O
9	a	O
10	mortality	O
11	rate	O
12	of	O
13	21	O
14	%.	O

1	RESULTS	O
2	:	O
3	Abnormal	O
4	color	O
5	perception	O
6	was	O
7	found	O
8	in	O
9	32	O
10	%	O
11	of	O
12	the	O
13	epilepsy	O
14	patients	O
15	treated	O
16	with	O
17	vigabatrin	O
18	monotherapy	O
19	and	O
20	28	O
21	%	O
22	of	O
23	the	O
24	epilepsy	O
25	patients	O
26	treated	O
27	with	O
28	carbamazepine	O
29	monotherapy	O
30	.	O

1	In	O
2	addition	O
3	to	O
4	targeting	O
5	partially	O
6	assembled	O
7	Ti	B
8	alpha	I
9	-	I
10	beta	I
11	CD3	I
12	gamma	I
13	delta	I
14	epsilon	I
15	TCR	I
16	complexes	I
17	to	O
18	the	O
19	cell	O
20	surface	O
21	,	O
22	CD3	B
23	zeta	I
24	appears	O
25	to	O
26	be	O
27	essential	O
28	for	O
29	interleukin	B
30	-	I
31	2	I
32	production	O
33	after	O
34	TCR	B
35	stimulation	O
36	with	O
37	antigen	B
38	/	I
39	major	I
40	histocompatibility	I
41	complex	I
42	.	O

1	In	O
2	contrast	O
3	,	O
4	high	O
5	COUP	B
6	-	I
7	TFI	I
8	expression	O
9	impeded	O
10	the	O
11	neuronal	O
12	differentiation	O
13	of	O
14	P19	O
15	cells	O
16	induced	O
17	with	O
18	RA	O
19	,	O
20	resulting	O
21	in	O
22	cell	O
23	cultures	O
24	lacking	O
25	neurons	O
26	.	O

1	Anti	B
2	-	I
3	PTB	I
4	antibodies	I
5	did	O
6	not	O
7	inhibit	O
8	the	O
9	binding	O
10	of	O
11	PTB	B
12	to	O
13	RNA	O
14	because	O
15	they	O
16	were	O
17	able	O
18	to	O
19	supershift	O
20	RNA	B
21	-	I
22	PTB	I
23	complexes	I
24	.	O

1	The	O
2	MET4	B
3	gene	O
4	was	O
5	cloned	O
6	,	O
7	and	O
8	its	O
9	sequence	O
10	reveals	O
11	that	O
12	it	O
13	encodes	O
14	a	O
15	protein	O
16	related	O
17	to	O
18	the	O
19	family	O
20	of	O
21	the	O
22	bZIP	B
23	transcriptional	I
24	activators	I
25	.	O

1	Since	O
2	the	O
3	-	O
4	172	O
5	/-	O
6	148	O
7	element	O
8	also	O
9	conferred	O
10	estrogen	O
11	and	O
12	thyroid	O
13	hormone	O
14	responsiveness	O
15	,	O
16	it	O
17	can	O
18	be	O
19	considered	O
20	a	O
21	composite	O
22	hormone	O
23	response	O
24	element	O
25	.	O

1	LysR	B
2	proteins	I
3	have	O
4	been	O
5	shown	O
6	to	O
7	regulate	O
8	urease	B
9	in	I
10	Klebsiella	I
11	aerogenes	I
12	(	O
13	NAC	B
14	),	O
15	and	O
16	catalase	B
17	in	I
18	Escherichia	I
19	coli	I
20	(	O
21	OxyR	B
22	),	O
23	which	O
24	offers	O
25	the	O
26	intracellular	O
27	bacterium	O
28	protection	O
29	from	O
30	phagolysosome	O
31	damage	O
32	.	O

1	Thus	O
2	,	O
3	hGRbeta	B
4	potentially	O
5	functions	O
6	as	O
7	a	O
8	dominant	O
9	negative	O
10	inhibitor	O
11	of	O
12	hGRalpha	B
13	activity	O
14	.	O

1	The	O
2	Cut9	B
3	subunit	I
4	is	O
5	likely	O
6	to	O
7	be	O
8	a	O
9	target	O
10	for	O
11	regulating	O
12	APC	B
13	/	I
14	cyclosome	I
15	function	O
16	through	O
17	protein	O
18	-	O
19	protein	O
20	interactions	O
21	and	O
22	phosphorylation	O
23	.	O

1	Respondents	O
2	who	O
3	lived	O
4	with	O
5	a	O
6	spouse	O
7	/	O
8	partner	O
9	only	O
10	were	O
11	less	O
12	likely	O
13	to	O
14	have	O
15	an	O
16	unfavorable	O
17	BMI	O
18	status	O
19	than	O
20	people	O
21	in	O
22	the	O
23	other	O
24	two	O
25	groups	O
26	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	binding	O
7	of	O
8	CBF	B
9	/	O
10	NF	B
11	-	I
12	Y	I
13	to	O
14	the	O
15	inverted	O
16	CCAAT	O
17	box	O
18	is	O
19	responsible	O
20	for	O
21	transcriptional	O
22	activation	O
23	of	O
24	the	O
25	nTPH	B
26	gene	I
27	.	O

1	Serum	B
2	IgM	I
3	and	O
4	IgE	B
5	concentrations	O
6	,	O
7	allergen	B
8	-	I
9	specific	I
10	IgE	I
11	scores	O
12	,	O
13	and	O
14	the	O
15	tumor	O
16	E2R	B
17	status	O
18	were	O
19	combined	O
20	to	O
21	construct	O
22	a	O
23	three	O
24	-	O
25	level	O
26	risk	O
27	classification	O
28	that	O
29	was	O
30	more	O
31	prognostic	O
32	than	O
33	any	O
34	of	O
35	the	O
36	individual	O
37	components	O
38	.	O

1	Two	O
2	protease	O
3	-	O
4	resistant	O
5	fragments	O
6	spanning	O
7	the	O
8	N	O
9	-	O
10	and	O
11	C	O
12	-	O
13	terminal	O
14	halves	O
15	of	O
16	the	O
17	nuclease	O
18	were	O
19	identified	O
20	using	O
21	different	O
22	proteases	O
23	which	O
24	cleave	O
25	the	O
26	protein	O
27	in	O
28	the	O
29	same	O
30	region	O
31	.	O

1	However	O
2	,	O
3	essential	O
4	contrast	O
5	differences	O
6	existing	O
7	between	O
8	the	O
9	FSE	O
10	sequences	O
11	and	O
12	their	O
13	routine	O
14	asymmetric	O
15	dual	O
16	SE	O
17	counterpart	O
18	can	O
19	be	O
20	identified	O
21	.	O

1	The	O
2	husband	O
3	in	O
4	one	O
5	of	O
6	the	O
7	married	O
8	couples	O
9	was	O
10	treated	O
11	for	O
12	hepatitis	O
13	of	O
14	unidentified	O
15	etiology	O
16	in	O
17	an	O
18	Infectology	O
19	Department	O
20	four	O
21	years	O
22	ago	O
23	.	O

1	Normal	O
2	values	O
3	for	O
4	the	O
5	peripheral	O
6	blood	O
7	and	O
8	bone	O
9	marrow	O
10	of	O
11	the	O
12	grey	O
13	(	O
14	Armenian	O
15	)	O
16	hamster	O

1	Results	O
2	of	O
3	electron	O
4	therapy	O
5	of	O
6	tumors	O
7	in	O
8	different	O
9	sites	O

1	Diuretics	O
2	:	O
3	basic	O
4	clinical	O
5	pharmacology	O
6	and	O
7	therapeutic	O
8	use	O
9	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	B
5	-	I
6	negative	I
7	ras	I
8	gene	I
9	also	O
10	blocks	O
11	TIS10	B
12	/	O
13	PGS2	B
14	induction	O
15	by	O
16	v	B
17	-	I
18	src	I
19	.	O

1	FTF	B
2	is	O
3	also	O
4	abundantly	O
5	expressed	O
6	in	O
7	the	O
8	pancreas	O
9	and	O
10	may	O
11	exert	O
12	differentiation	O
13	functions	O
14	in	O
15	endodermal	O
16	sublineages	O
17	,	O
18	similar	O
19	to	O
20	SF	B
21	-	I
22	1	I
23	in	O
24	steroidogenic	O
25	tissues	O
26	.	O

1	Polysorbate	O
2	80	O
3	did	O
4	not	O
5	have	O
6	a	O
7	direct	O
8	stimulant	O
9	or	O
10	relaxant	O
11	effect	O
12	on	O
13	either	O
14	guinea	O
15	pig	O
16	ileum	O
17	or	O
18	rat	O
19	uterus	O
20	,	O
21	however	O
22	,	O
23	it	O
24	antagonised	O
25	the	O
26	contractions	O
27	induced	O
28	by	O
29	acetylcholine	O
30	,	O
31	histamine	O
32	,	O
33	barium	O
34	,	O
35	5	O
36	-	O
37	hydroxytryptamine	O
38	and	O
39	carbachol	O
40	in	O
41	a	O
42	dose	O
43	-	O
44	dependent	O
45	manner	O
46	.	O

1	ENV	B
2	also	O
3	was	O
4	secreted	O
5	from	O
6	P	O
7	.	O
8	pastoris	O
9	using	O
10	the	O
11	S	B
12	.	I
13	cerevisiae	I
14	alpha	I
15	-	I
16	factor	I
17	prepro	I
18	secretion	I
19	leader	I
20	and	O
21	the	O
22	S	B
23	.	I
24	cerevisiae	I
25	invertase	I
26	signal	I
27	sequence	I
28	.	O

1	In	O
2	contrast	O
3	,	O
4	no	O
5	change	O
6	was	O
7	detected	O
8	in	O
9	the	O
10	phenotype	O
11	of	O
12	'	O
13	unstressed	O
14	'	O
15	clones	O
16	,	O
17	with	O
18	respect	O
19	to	O
20	any	O
21	of	O
22	the	O
23	following	O
24	parameters	O
25	:	O
26	proliferation	O
27	rate	O
28	in	O
29	monolayer	O
30	,	O
31	serum	O
32	-	O
33	dependence	O
34	for	O
35	proliferation	O
36	or	O
37	survival	O
38	,	O
39	tumorigenicity	O
40	,	O
41	cellular	O
42	morphology	O
43	,	O
44	or	O
45	tissue	O
46	-	O
47	specific	O
48	differentiation	O
49	markers	O
50	.	O

1	Mnt	B
2	:	O
3	Max	B
4	complexes	O
5	also	O
6	efficiently	O
7	suppress	O
8	Myc	B
9	-	O
10	dependent	O
11	activation	O
12	from	O
13	the	O
14	same	O
15	promoter	O
16	.	O

1	Thromboelastography	O
2	is	O
3	a	O
4	test	O
5	that	O
6	could	O
7	potentially	O
8	correlate	O
9	with	O
10	the	O
11	degree	O
12	of	O
13	anticoagulation	O
14	produced	O
15	by	O
16	low	O
17	molecular	O
18	weight	O
19	heparin	O
20	.	O

1	In	O
2	the	O
3	latter	O
4	category	O
5	particular	O
6	emphasis	O
7	is	O
8	being	O
9	placed	O
10	on	O
11	new	O
12	anthracycline	O
13	analogues	O
14	of	O
15	doxorubicin	O
16	and	O
17	analogues	O
18	of	O
19	cisplatinum	O
20	diammine	O
21	dichloride	O
22	.	O

1	Since	O
2	the	O
3	stability	O
4	of	O
5	TF1	B
6	resides	O
7	in	O
8	its	O
9	primary	O
10	structure	O
11	,	O
12	we	O
13	cloned	O
14	a	O
15	gene	O
16	coding	O
17	for	O
18	TF1	B
19	,	O
20	and	O
21	the	O
22	primary	O
23	structure	O
24	of	O
25	the	O
26	beta	O
27	subunit	O
28	was	O
29	deduced	O
30	from	O
31	the	O
32	nucleotide	O
33	sequence	O
34	of	O
35	the	O
36	gene	O
37	to	O
38	compare	O
39	the	O
40	sequence	O
41	with	O
42	those	O
43	of	O
44	beta	O
45	'	O
46	s	O
47	of	O
48	three	O
49	major	O
50	categories	O
51	of	O
52	F1	B
53	'	O
54	s	O
55	;	O
56	prokaryotic	O
57	membranes	O
58	,	O
59	chloroplasts	O
60	,	O
61	and	O
62	mitochondria	O
63	.	O

1	The	O
2	RAP74	B
3	subunit	I
4	of	O
5	TFIIF	B
6	alone	O
7	contained	O
8	the	O
9	stimulatory	O
10	activity	O
11	and	O
12	the	O
13	minimal	O
14	region	O
15	sufficient	O
16	for	O
17	stimulation	O
18	corresponds	O
19	to	O
20	COOH	O
21	-	O
22	terminal	O
23	residues	O
24	358	O
25	-	O
26	517	O
27	.	O

1	Though	O
2	hepatomegaly	O
3	and	O
4	mild	O
5	elevation	O
6	of	O
7	enzymes	O
8	can	O
9	be	O
10	observed	O
11	in	O
12	a	O
13	significant	O
14	proportion	O
15	of	O
16	patients	O
17	,	O
18	involvement	O
19	of	O
20	liver	O
21	leading	O
22	to	O
23	acute	O
24	hepatitis	O
25	or	O
26	liver	O
27	cell	O
28	necrosis	O
29	is	O
30	a	O
31	relatively	O
32	uncommon	O
33	complication	O
34	in	O
35	P	O
36	.	O
37	falciparum	O
38	malaria	O
39	.	O

1	Within	O
2	a	O
3	135	O
4	-	O
5	bp	O
6	core	O
7	homology	O
8	region	O
9	,	O
10	the	O
11	human	B
12	HS12	I
13	enhancers	I
14	are	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	the	O
21	murine	O
22	homolog	O
23	and	O
24	include	O
25	several	O
26	motifs	O
27	previously	O
28	demonstrated	O
29	to	O
30	be	O
31	important	O
32	for	O
33	function	O
34	of	O
35	the	O
36	murine	O
37	enhancer	O
38	;	O
39	additional	O
40	segments	O
41	of	O
42	high	O
43	sequence	O
44	conservation	O
45	suggest	O
46	the	O
47	possibility	O
48	of	O
49	previously	O
50	unrecognized	O
51	functional	O
52	motifs	O
53	.	O

1	Sestamibi	O
2	scintigraphy	O
3	,	O
4	performed	O
5	in	O
6	70	O
7	patients	O
8	,	O
9	was	O
10	less	O
11	sensitive	O
12	than	O
13	ultrasonography	O
14	(	O
15	80	O
16	%).	O

1	Analysis	O
2	of	O
3	various	O
4	deletion	O
5	mutants	O
6	indicates	O
7	that	O
8	the	O
9	sequence	O
10	requirements	O
11	for	O
12	binding	O
13	by	O
14	QBP	B
15	in	O
16	vitro	O
17	are	O
18	indistinguishable	O
19	from	O
20	those	O
21	necessary	O
22	for	O
23	Q	O
24	activity	O
25	in	O
26	vivo	O
27	,	O
28	strongly	O
29	suggesting	O
30	that	O
31	QBP	B
32	is	O
33	required	O
34	for	O
35	the	O
36	function	O
37	of	O
38	this	O
39	TATA	O
40	-	O
41	independent	O
42	promoter	O
43	.	O

1	Cranio	O
2	-	O
3	caudal	O
4	differences	O
5	in	O
6	granulation	O
7	tissue	O
8	formation	O
9	:	O
10	an	O
11	experimental	O
12	study	O
13	in	O
14	the	O
15	rat	O
16	.	O

1	Recent	O
2	investigations	O
3	have	O
4	shown	O
5	that	O
6	Grenz	O
7	rays	O
8	can	O
9	suppress	O
10	the	O
11	allergic	O
12	contact	O
13	dermatitis	O
14	reaction	O
15	completely	O
16	and	O
17	that	O
18	Langerhans	O
19	cells	O
20	,	O
21	identified	O
22	by	O
23	OKT6	B
24	antibodies	I
25	and	O
26	electron	O
27	microscopy	O
28	,	O
29	disappear	O
30	from	O
31	the	O
32	epidermis	O
33	at	O
34	the	O
35	same	O
36	time	O
37	.	O

1	Ten	O
2	selenocysteine	O
3	residues	O
4	(	O
5	deduced	O
6	)	O
7	are	O
8	present	O
9	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	5	O
6	KE	O
7	X	O
8	3	O
9	/	O
10	W	O
11	may	O
12	be	O
13	the	O
14	optimal	O
15	regimen	O
16	to	O
17	augment	O
18	the	O
19	antitumor	O
20	immunity	O
21	of	O
22	RNL	O
23	.	O

1	Lymphocyte	O
2	subpopulations	O
3	,	O
4	serum	B
5	IgE	I
6	and	O
7	total	O
8	eosinophil	O
9	counts	O
10	in	O
11	patients	O
12	with	O
13	bronchial	O
14	asthma	O
15	.	O

1	This	O
2	suggests	O
3	that	O
4	while	O
5	underpredictions	O
6	of	O
7	pain	O
8	do	O
9	not	O
10	hurt	O
11	more	O
12	,	O
13	disruption	O
14	on	O
15	primary	O
16	tasks	O
17	and	O
18	physiological	O
19	impact	O
20	are	O
21	higher	O
22	.	O

1	Unlike	O
2	class	O
3	II	O
4	-	O
5	and	O
6	III	O
7	-	O
8	specific	O
9	TBP	B
10	-	O
11	TAF	B
12	complexes	O
13	,	O
14	the	O
15	corresponding	O
16	murine	O
17	and	O
18	human	O
19	class	O
20	I	O
21	-	O
22	specific	O
23	transcription	O
24	initiation	O
25	factor	O
26	TIF	B
27	-	I
28	IB	I
29	/	O
30	SL1	B
31	exhibits	O
32	a	O
33	pronounced	O
34	selectivity	O
35	for	O
36	its	O
37	homologous	O
38	promoter	O
39	.	O

1	The	O
2	increase	O
3	in	O
4	amplitudes	O
5	of	O
6	the	O
7	b	O
8	-	O
9	wave	O
10	during	O
11	the	O
12	adaptation	O
13	period	O
14	was	O
15	more	O
16	prominent	O
17	in	O
18	lead	O
19	-	O
20	exposed	O
21	subjects	O
22	than	O
23	in	O
24	controls	O
25	.	O

1	The	O
2	Stryker	O
3	frame	O
4	modification	O
5	to	O
6	the	O
7	standard	O
8	Dornier	O
9	HM3	O
10	lithotriptor	O
11	allows	O
12	for	O
13	improved	O
14	visualization	O
15	and	O
16	easier	O
17	localization	O
18	of	O
19	distal	O
20	ureteral	O
21	calculi	O
22	compared	O
23	to	O
24	the	O
25	standard	O
26	gantry	O
27	.	O

1	Genetic	O
2	and	O
3	molecular	O
4	data	O
5	indicate	O
6	that	O
7	wild	B
8	-	I
9	type	I
10	Pan	I
11	and	O
12	CiD	B
13	compete	O
14	for	O
15	binding	O
16	to	O
17	Arm	B
18	,	O
19	leading	O
20	to	O
21	a	O
22	compromised	O
23	transduction	O
24	of	O
25	the	O
26	Wg	B
27	signal	O
28	in	O
29	heterozygous	O
30	ciD	B
31	/+	I
32	animals	O
33	and	O
34	to	O
35	a	O
36	dramatic	O
37	enhancement	O
38	of	O
39	the	O
40	gain	O
41	-	O
42	of	O
43	-	O
44	function	O
45	activity	O
46	of	O
47	CiD	B
48	in	O
49	homozygous	O
50	mutants	O
51	.	O

1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	O
14	in	O
15	their	O
16	ability	O
17	to	O
18	bypass	O
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	SxlM4	B
26	being	O
27	the	O
28	strongest	O
29	and	O
30	SxlM1	B
31	the	O
32	weakest	O
33	.	O

1	These	O
2	characteristics	O
3	indicated	O
4	the	O
5	pronounced	O
6	activity	O
7	of	O
8	collagenous	O
9	fiber	O
10	synthesis	O
11	and	O
12	the	O
13	matrix	O
14	of	O
15	the	O
16	osteoid	O
17	tissue	O
18	.	O

1	Studying	O
2	intracellular	O
3	signaling	O
4	pathways	O
5	,	O
6	which	O
7	may	O
8	be	O
9	involved	O
10	in	O
11	malignant	O
12	transformation	O
13	of	O
14	Ret	B
15	-	I
16	9bp	I
17	expressing	O
18	NIH3T3	O
19	cells	O
20	,	O
21	we	O
22	could	O
23	demonstrate	O
24	Ret	B
25	-	I
26	9bp	I
27	dependent	O
28	phosphorylation	O
29	of	O
30	insulin	B
31	receptor	I
32	substrate	I
33	-	I
34	2	I
35	(	O
36	IRS	B
37	-	I
38	2	I
39	)	O
40	with	O
41	consecutive	O
42	activation	O
43	of	O
44	phosphatidylinositol	B
45	3	I
46	-	I
47	kinase	I
48	(	O
49	PI	B
50	3	I
51	-	I
52	kinase	I
53	)	O
54	and	O
55	protein	B
56	kinase	I
57	B	I
58	(	O
59	PKB	B
60	/	O
61	AKT	B
62	).	O

1	The	O
2	promoter	O
3	segment	O
4	was	O
5	inactive	O
6	when	O
7	introduced	O
8	into	O
9	the	O
10	rat	O
11	glioma	O
12	cell	O
13	line	O
14	C6B4	O
15	,	O
16	the	O
17	rat	O
18	submandibular	O
19	cell	O
20	line	O
21	RSMT	O
22	-	O
23	A5	O
24	,	O
25	and	O
26	the	O
27	rat	O
28	pancreatic	O
29	beta	O
30	cell	O
31	line	O
32	RIN	O
33	-	O
34	5AH	O
35	,	O
36	all	O
37	of	O
38	which	O
39	do	O
40	not	O
41	express	O
42	the	O
43	endogenous	O
44	alpha2c	B
45	-	I
46	AR	I
47	gene	I
48	.	O

1	Use	O
2	of	O
3	the	O
4	vena	O
5	cava	O
6	to	O
7	extend	O
8	the	O
9	right	O
10	renal	O
11	vein	O
12	for	O
13	cadaver	O
14	transplantation	O
15	is	O
16	controversial	O
17	.	O

1	The	O
2	plant	O
3	hormone	O
4	auxin	O
5	transcriptionally	O
6	activates	O
7	early	B
8	genes	I
9	.	O

1	High	B
2	-	I
3	mobility	I
4	-	I
5	group	I
6	protein	I
7	I	I
8	can	O
9	modulate	O
10	binding	O
11	of	O
12	transcription	O
13	factors	O
14	to	O
15	the	O
16	U5	B
17	region	I
18	of	O
19	the	O
20	human	B
21	immunodeficiency	I
22	virus	I
23	type	I
24	1	I
25	proviral	I
26	promoter	I
27	.	O

1	Two	O
2	disulphide	O
3	bridges	O
4	,	O
5	which	O
6	are	O
7	conserved	O
8	in	O
9	all	O
10	spermadhesin	O
11	molecules	O
12	and	O
13	many	O
14	CUB	O
15	domains	O
16	,	O
17	crosslink	O
18	loop	O
19	LA	O
20	and	O
21	strand	O
22	beta	O
23	4	O
24	and	O
25	loops	O
26	LE	O
27	and	O
28	LG	O
29	,	O
30	respectively	O
31	,	O
32	at	O
33	opposite	O
34	edges	O
35	of	O
36	the	O
37	same	O
38	face	O
39	of	O
40	the	O
41	domain	O
42	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	putative	O
6	RBP1	B
7	protein	I
8	contains	O
9	two	O
10	copies	O
11	of	O
12	an	O
13	RNA	O
14	recognition	O
15	motif	O
16	,	O
17	two	O
18	glutamine	O
19	stretches	O
20	,	O
21	an	O
22	asparagine	O
23	-	O
24	rich	O
25	region	O
26	,	O
27	a	O
28	methionine	O
29	-	O
30	rich	O
31	region	O
32	,	O
33	and	O
34	two	O
35	long	O
36	potential	O
37	alpha	O
38	-	O
39	helixes	O
40	.	O

1	Gel	O
2	-	O
3	shift	O
4	assays	O
5	identified	O
6	two	O
7	Sp1	B
8	binding	I
9	sites	I
10	within	O
11	this	O
12	element	O
13	.	O

1	Comparison	O
2	of	O
3	cDNA	O
4	sequences	O
5	revealed	O
6	that	O
7	the	O
8	two	O
9	mRNA	O
10	species	O
11	arise	O
12	as	O
13	a	O
14	result	O
15	of	O
16	alternate	O
17	use	O
18	of	O
19	poly	O
20	(	O
21	A	O
22	)-	O
23	addition	O
24	sites	O
25	.	O

1	The	O
2	mitochondrial	B
3	regulatory	I
4	region	I
5	(	O
6	mrr	B
7	)	O
8	located	O
9	between	O
10	the	O
11	tRNAPhe	B
12	and	O
13	tRNAPro	B
14	genes	I
15	of	O
16	mitochondrial	O
17	DNA	O
18	(	O
19	mtDNA	O
20	)	O
21	is	O
22	essential	O
23	for	O
24	regulation	O
25	of	O
26	replication	O
27	and	O
28	transcription	O
29	of	O
30	the	O
31	mitochondrial	O
32	genome	O
33	.	O

1	Results	O
2	of	O
3	a	O
4	controlled	O
5	study	O

1	Based	O
2	on	O
3	a	O
4	type	O
5	I	O
6	error	O
7	of	O
8	0	O
9	.	O
10	05	O
11	,	O
12	our	O
13	study	O
14	had	O
15	a	O
16	power	O
17	greater	O
18	than	O
19	or	O
20	equal	O
21	to	O
22	75	O
23	%	O
24	to	O
25	detect	O
26	group	O
27	differences	O
28	in	O
29	treatment	O
30	effect	O
31	of	O
32	greater	O
33	than	O
34	or	O
35	equal	O
36	to	O
37	15	O
38	%	O
39	to	O
40	20	O
41	%.	O

1	Moloney	O
2	murine	O
3	leukemia	O
4	virus	O
5	(	O
6	MMLV	O
7	)-	O
8	derived	O
9	pUCMoTiN	O
10	-	O
11	based	O
12	retroviral	O
13	vectors	O
14	were	O
15	engineered	O
16	to	O
17	allow	O
18	constitutive	O
19	and	O
20	Tat	B
21	(	O
22	trans	B
23	-	I
24	activator	I
25	of	I
26	transcription	I
27	)-	O
28	inducible	O
29	expression	O
30	of	O
31	five	O
32	hammerhead	O
33	ribozymes	O
34	targeted	O
35	against	O
36	highly	O
37	conserved	O
38	sequences	O
39	within	O
40	the	O
41	group	B
42	antigen	I
43	(	O
44	Gag	B
45	),	O
46	protease	B
47	(	O
48	Pro	B
49	),	O
50	reverse	B
51	transcriptase	I
52	(	O
53	RT	B
54	),	O
55	tat	B
56	,	O
57	and	O
58	envelope	B
59	(	O
60	Env	B
61	)	O
62	coding	O
63	regions	O
64	of	O
65	human	O
66	immunodeficiency	O
67	virus	O
68	type	O
69	-	O
70	1	O
71	(	O
72	HIV	O
73	-	O
74	1	O
75	)	O
76	RNA	O
77	.	O

1	Therefore	O
2	,	O
3	the	O
4	rbcL	B
5	-	O
6	rbcS	B
7	locus	O
8	seems	O
9	to	O
10	be	O
11	barely	O
12	expressed	O
13	under	O
14	a	O
15	standard	O
16	condition	O
17	for	O
18	photoautotrophic	O
19	growth	O
20	.	O

1	This	O
2	paper	O
3	brings	O
4	together	O
5	data	O
6	,	O
7	obtained	O
8	from	O
9	a	O
10	variety	O
11	of	O
12	sources	O
13	,	O
14	on	O
15	the	O
16	extent	O
17	of	O
18	prescription	O
19	and	O
20	use	O
21	of	O
22	psychotropic	O
23	drugs	O
24	in	O
25	the	O
26	late	O
27	1960s	O
28	and	O
29	early	O
30	1970s	O
31	.	O

1	Members	O
2	of	O
3	the	O
4	myocyte	B
5	-	I
6	specific	I
7	enhancer	I
8	-	I
9	binding	I
10	factor	I
11	2	I
12	(	O
13	MEF2	B
14	)	O
15	family	O
16	of	O
17	transcription	O
18	factors	O
19	bind	O
20	a	O
21	conserved	O
22	A	O
23	/	O
24	T	O
25	-	O
26	rich	O
27	sequence	O
28	in	O
29	the	O
30	control	O
31	regions	O
32	of	O
33	numerous	O
34	muscle	O
35	-	O
36	specific	O
37	genes	O
38	.	O

1	The	O
2	mMIWC1	B
3	promoter	I
4	was	O
5	identified	O
6	and	O
7	contained	O
8	TATA	O
9	,	O
10	CAAT	O
11	,	O
12	GATA	O
13	,	O
14	and	O
15	AP	B
16	-	I
17	2	I
18	elements	I
19	;	O
20	primer	O
21	extension	O
22	revealed	O
23	mMIWC	B
24	transcription	O
25	initiation	O
26	at	O
27	621	O
28	bp	O
29	upstream	O
30	from	O
31	the	O
32	mMIWC1	B
33	translational	O
34	initiation	O
35	site	O
36	.	O

1	Angiotensin	B
2	converting	I
3	enzyme	I
4	inhibitors	O
5	enhance	O
6	the	O
7	antihypertensive	O
8	efficacy	O
9	of	O
10	diuretics	O
11	and	O
12	blunt	O
13	or	O
14	prevent	O
15	adverse	O
16	metabolic	O
17	effects	O
18	.	O

1	Drug	O
2	effect	O
3	,	O
4	measured	O
5	as	O
6	postural	O
7	sway	O
8	,	O
9	was	O
10	also	O
11	similar	O
12	in	O
13	the	O
14	patients	O
15	with	O
16	cirrhosis	O
17	and	O
18	control	O
19	subjects	O
20	;	O
21	therefore	O
22	the	O
23	ratio	O
24	of	O
25	effect	O
26	area	O
27	under	O
28	the	O
29	curve	O
30	to	O
31	concentration	O
32	area	O
33	under	O
34	the	O
35	curve	O
36	,	O
37	a	O
38	measure	O
39	of	O
40	sensitivity	O
41	,	O
42	did	O
43	not	O
44	differ	O
45	significantly	O
46	between	O
47	the	O
48	patients	O
49	with	O
50	cirrhosis	O
51	and	O
52	the	O
53	control	O
54	subjects	O
55	.	O

1	Rolandic	O
2	spikes	O
3	and	O
4	cognitive	O
5	function	O
6	.	O

1	Two	O
2	studies	O
3	on	O
4	the	O
5	relationship	O
6	between	O
7	taking	O
8	a	O
9	commercial	O
10	coaching	O
11	course	O
12	and	O
13	performance	O
14	on	O
15	the	O
16	Medical	O
17	College	O
18	Admission	O
19	Test	O
20	(	O
21	MCAT	O
22	)	O
23	are	O
24	reported	O
25	.	O

1	Serum	O
2	IgG	B
3	was	O
4	initially	O
5	elevated	O
6	in	O
7	6	O
8	patients	O
9	.	O

1	The	O
2	measurement	O
3	of	O
4	the	O
5	areas	O
6	of	O
7	fibrin	B
8	,	O
9	of	O
10	tissue	O
11	and	O
12	fibrinolysis	O
13	,	O
14	at	O
15	the	O
16	above	O
17	mentioned	O
18	times	O
19	,	O
20	has	O
21	been	O
22	effected	O
23	at	O
24	standard	O
25	magnification	O
26	(	O
27	15	O
28	X	O
29	)	O
30	by	O
31	an	O
32	image	O
33	analyser	O
34	(	O
35	Videoplan	O
36	)	O
37	scale	O
38	1	O
39	:	O
40	8	O
41	.	O

1	Identification	O
2	of	O
3	a	O
4	consensus	O
5	cyclin	B
6	-	I
7	dependent	I
8	kinase	I
9	phosphorylation	I
10	site	I
11	unique	O
12	to	O
13	the	O
14	nuclear	O
15	form	O
16	of	O
17	human	B
18	deoxyuridine	I
19	triphosphate	I
20	nucleotidohydrolase	I
21	.	O

1	Co	O
2	-	O
3	administration	O
4	of	O
5	5FU	O
6	,	O
7	angiotensin	B
8	II	I
9	and	O
10	microspheres	O
11	via	O
12	the	O
13	hepatic	O
14	artery	O
15	may	O
16	reduce	O
17	drug	O
18	exposure	O
19	in	O
20	the	O
21	systemic	O
22	compartment	O
23	and	O
24	therefore	O
25	may	O
26	increase	O
27	the	O
28	therapeutic	O
29	ratio	O
30	of	O
31	5FU	O
32	administration	O
33	via	O
34	the	O
35	hepatic	O
36	artery	O
37	.	O

1	No	O
2	somatic	O
3	mutations	O
4	were	O
5	found	O
6	in	O
7	any	O
8	of	O
9	the	O
10	samples	O
11	,	O
12	suggesting	O
13	that	O
14	ING1	B
15	is	O
16	not	O
17	a	O
18	tumor	O
19	suppressor	O
20	gene	O
21	target	O
22	in	O
23	head	O
24	and	O
25	neck	O
26	cancer	O
27	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	T	O
6	.	O
7	C	O
8	.,	O
9	LDL	B
10	-	I
11	C	I
12	.,	O
13	HDL	B
14	-	I
15	C	I
16	.,	O
17	HDL2	B
18	-	I
19	C	I
20	.,	O
21	apo	B
22	B	I
23	,	O
24	apo	B
25	A	I
26	-	I
27	I	I
28	/	I
29	B	I
30	ratio	O
31	and	O
32	apo	B
33	A	I
34	-	I
35	II	I
36	/	I
37	B	I
38	ratio	O
39	are	O
40	predictive	O
41	risk	O
42	factors	O
43	of	O
44	the	O
45	coronary	O
46	heart	O
47	disease	O
48	.	O

1	In	O
2	order	O
3	to	O
4	infer	O
5	shape	O
6	from	O
7	contour	O
8	,	O
9	the	O
10	human	O
11	visual	O
12	system	O
13	must	O
14	selectively	O
15	integrate	O
16	fragments	O
17	projecting	O
18	from	O
19	a	O
20	common	O
21	object	O
22	while	O
23	keeping	O
24	fragments	O
25	from	O
26	different	O
27	objects	O
28	separate	O
29	.	O

1	Of	O
2	49	O
3	receptors	O
4	which	O
5	fired	O
6	in	O
7	phase	O
8	with	O
9	ventilation	O
10	,	O
11	13	O
12	behaved	O
13	like	O
14	mammalian	O
15	rapidly	O
16	adapting	O
17	pulmonary	O
18	stretch	O
19	receptors	O
20	,	O
21	19	O
22	like	O
23	mammalian	O
24	slowly	O
25	adapting	O
26	pulmonary	O
27	stretch	O
28	receptors	O
29	(	O
30	PSR	O
31	),	O
32	and	O
33	17	O
34	like	O
35	avian	O
36	intrapulmonary	O
37	CO2	O
38	-	O
39	sensitive	O
40	chemoreceptors	O
41	(	O
42	IPC	O
43	).	O

1	However	O
2	,	O
3	bilateral	O
4	diffuse	O
5	pulmonary	O
6	infiltrations	O
7	developed	O
8	21	O
9	days	O
10	later	O
11	.	O

1	Lars	O
2	has	O
3	AIDS	O
4	--	O
5	a	O
6	more	O
7	dignified	O
8	life	O
9	with	O
10	care	O
11	at	O
12	home	O
13	.	O

1	Specific	O
2	clotting	O
3	factor	O
4	assays	O
5	showed	O
6	an	O
7	isolated	O
8	deficiency	O
9	of	O
10	factor	B
11	X	I
12	ranging	O
13	from	O
14	7	O
15	to	O
16	12	O
17	per	O
18	cent	O
19	on	O
20	three	O
21	determinations	O
22	.	O

1	Most	O
2	of	O
3	the	O
4	patients	O
5	presented	O
6	with	O
7	Transient	O
8	Ischemic	O
9	Attacks	O
10	(	O
11	64	O
12	%)	O
13	or	O
14	Reversible	O
15	Ischemic	O
16	Neurologic	O
17	Deficits	O
18	(	O
19	19	O
20	%).	O

1	(	O
2	1994	O
3	,	O
4	Hum	O
5	.	O

1	Following	O
2	iv	O
3	injection	O
4	of	O
5	0	O
6	.	O
7	5	O
8	g	O
9	galactose	O
10	per	O
11	kg	O
12	body	O
13	weight	O
14	,	O
15	together	O
16	with	O
17	2	O
18	mu	O
19	Ci	O
20	generally	O
21	14C	O
22	-	O
23	labelled	O
24	galactose	O
25	,	O
26	14CO2	O
27	is	O
28	collected	O
29	in	O
30	regular	O
31	intervals	O
32	during	O
33	one	O
34	hour	O
35	.	O

1	Glycogen	O
2	synthesis	O
3	and	O
4	catabolism	O
5	,	O
6	gluconeogenesis	O
7	,	O
8	glycolysis	O
9	,	O
10	motility	O
11	,	O
12	cell	O
13	surface	O
14	properties	O
15	and	O
16	adherence	O
17	are	O
18	modulated	O
19	by	O
20	csrA	B
21	in	I
22	Escherichia	I
23	coli	I
24	,	O
25	while	O
26	the	O
27	production	O
28	of	O
29	several	O
30	secreted	O
31	virulence	O
32	factors	O
33	,	O
34	the	O
35	plant	O
36	hypersensitive	O
37	response	O
38	elicitor	O
39	HrpN	B
40	(	O
41	Ecc	B
42	)	O
43	and	O
44	,	O
45	potentially	O
46	,	O
47	other	O
48	secondary	O
49	metabolites	O
50	are	O
51	regulated	O
52	by	O
53	rsmA	B
54	in	I
55	Erwinia	I
56	carotovora	I
57	.	O

1	Bimodal	O
2	cochlear	O
3	response	O
4	curves	O
5	in	O
6	rodents	O
7	.	O

1	Biol	O
2	.	O

1	Although	O
2	the	O
3	molecular	O
4	mechanisms	O
5	involved	O
6	in	O
7	this	O
8	regulation	O
9	are	O
10	currently	O
11	being	O
12	elucidated	O
13	,	O
14	very	O
15	little	O
16	is	O
17	known	O
18	about	O
19	the	O
20	trans	O
21	-	O
22	acting	O
23	factors	O
24	that	O
25	allow	O
26	expression	O
27	of	O
28	the	O
29	nitrate	B
30	and	I
31	nitrite	I
32	reductase	I
33	genes	I
34	which	O
35	code	O
36	for	O
37	the	O
38	first	O
39	enzymes	O
40	in	O
41	the	O
42	pathway	O
43	.	O

1	A	O
2	polymorphic	O
3	dinucleotide	O
4	(	O
5	GT	O
6	/	O
7	CA	O
8	)	O
9	n	O
10	repeat	O
11	contained	O
12	in	O
13	the	O
14	NHE5	O
15	cosmid	O
16	was	O
17	identified	O
18	and	O
19	developed	O
20	into	O
21	a	O
22	microsatellite	O
23	PCR	O
24	marker	O
25	.	O

1	Linear	O
2	regression	O
3	analysis	O
4	was	O
5	performed	O
6	and	O
7	the	O
8	following	O
9	result	O
10	was	O
11	obtained	O
12	:	O
13	clearance	O
14	(	O
15	HMPAO	O
16	)	O
17	=	O
18	0	O
19	.	O
20	07	O
21	+	O
22	0	O
23	.	O
24	43	O
25	.	O
26	rCBF	O
27	with	O
28	a	O
29	high	O
30	significance	O
31	(	O
32	p	O
33	less	O
34	than	O
35	0	O
36	.	O
37	001	O
38	).	O

1	The	O
2	management	O
3	of	O
4	the	O
5	"	O
6	chronic	O
7	"	O
8	patient	O
9	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	patients	O
6	with	O
7	neuroinfection	O
8	,	O
9	Lyme	O
10	disease	O
11	,	O
12	Guillain	O
13	Barre	O
14	syndrome	O
15	,	O
16	demyelinization	O
17	,	O
18	partial	O
19	or	O
20	generalized	O
21	,	O
22	epilepsy	O
23	,	O
24	we	O
25	have	O
26	investigated	O
27	antiphospholipid	O
28	antibodies	O
29	of	O
30	IgG	B
31	and	O
32	IgM	B
33	subtypes	O
34	,	O
35	together	O
36	with	O
37	anticoagulant	O
38	factors	O
39	,	O
40	member	O
41	of	O
42	thrombocytes	O
43	,	O
44	sedimentation	O
45	rate	O
46	of	O
47	erythrocytes	O
48	.	O

1	Freezing	O
2	of	O
3	plasma	O
4	to	O
5	obtain	O
6	better	O
7	yield	O
8	of	O
9	factor	B
10	VIII	I
11	:	O
12	C	O
13	.	O

1	Metabolic	O
2	labeling	O
3	studies	O
4	in	O
5	S	O
6	.	O
7	cerevisiae	O
8	and	O
9	co	O
10	-	O
11	expression	O
12	of	O
13	nmt72p	B
14	with	O
15	several	O
16	protein	O
17	substrates	O
18	of	O
19	Nmt1p	B
20	in	O
21	Escherichia	O
22	coli	O
23	indicate	O
24	that	O
25	the	O
26	Leu99	O
27	-->	O
28	Pro	O
29	substitution	O
30	causes	O
31	a	O
32	reduction	O
33	in	O
34	the	O
35	acylation	O
36	of	O
37	some	O
38	but	O
39	not	O
40	all	O
41	protein	O
42	substrates	O
43	.	O

1	Both	O
2	groups	O
3	rejected	O
4	pops	O
5	with	O
6	added	O
7	SOA	O
8	,	O
9	decreasing	O
10	mouthing	O
11	times	O
12	as	O
13	SOA	O
14	concentration	O
15	increased	O
16	.	O

1	When	O
2	two	O
3	-	O
4	dimensional	O
5	polyacrylamide	O
6	gel	O
7	electrophoretic	O
8	patterns	O
9	of	O
10	[	O
11	35S	O
12	]	O
13	methionine	O
14	-	O
15	labeled	O
16	proteins	O
17	secreted	O
18	from	O
19	cells	O
20	infected	O
21	with	O
22	parental	O
23	and	O
24	recombinant	O
25	viruses	O
26	were	O
27	compared	O
28	,	O
29	a	O
30	spot	O
31	missing	O
32	from	O
33	the	O
34	latter	O
35	corresponded	O
36	in	O
37	molecular	O
38	weigh	O
39	and	O
40	isoelectric	O
41	point	O
42	with	O
43	that	O
44	predicted	O
45	from	O
46	the	O
47	N1L	B
48	ORF	I
49	.	O

1	The	O
2	results	O
3	obtained	O
4	were	O
5	as	O
6	follows	O
7	:	O
8	The	O
9	mitral	O
10	valve	O
11	orifice	O
12	area	O
13	(	O
14	MVA	O
15	)	O
16	was	O
17	significantly	O
18	smaller	O
19	in	O
20	patients	O
21	with	O
22	type	O
23	III	O
24	of	O
25	the	O
26	LVIT	O
27	flow	O
28	velocity	O
29	pattern	O
30	than	O
31	in	O
32	patients	O
33	with	O
34	type	O
35	I	O
36	(	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	Liver	O
2	injuries	O

1	This	O
2	report	O
3	describes	O
4	a	O
5	patient	O
6	with	O
7	a	O
8	previous	O
9	inferior	O
10	acute	O
11	myocardial	O
12	infarction	O
13	who	O
14	developed	O
15	right	O
16	ventricular	O
17	infarction	O
18	with	O
19	significant	O
20	anterior	O
21	lead	O
22	ST	O
23	segment	O
24	elevation	O
25	(	O
26	V1	O
27	-	O
28	V4	O
29	)	O
30	caused	O
31	by	O
32	the	O
33	loss	O
34	of	O
35	two	O
36	large	O
37	right	O
38	ventricular	O
39	branches	O
40	during	O
41	a	O
42	coronary	O
43	angioplasty	O
44	of	O
45	the	O
46	right	O
47	coronary	O
48	artery	O
49	.	O

1	Halothane	O
2	is	O
3	metabolized	O
4	by	O
5	an	O
6	oxidative	O
7	pathway	O
8	to	O
9	stable	O
10	,	O
11	nonvolatile	O
12	end	O
13	products	O
14	,	O
15	trifluoroacetic	O
16	acid	O
17	(	O
18	TFAA	O
19	)	O
20	and	O
21	bromide	O
22	(	O
23	Br	O
24	-),	O
25	and	O
26	by	O
27	reductive	O
28	pathways	O
29	to	O
30	Br	O
31	-	O
32	and	O
33	inorganic	O
34	fluoride	O
35	(	O
36	F	O
37	-).	O

1	The	O
2	tyrosine	O
3	-	O
4	phosphorylated	O
5	state	O
6	of	O
7	CAK	B
8	beta	I
9	was	O
10	not	O
11	reduced	O
12	on	O
13	trypsinization	O
14	,	O
15	nor	O
16	enhanced	O
17	in	O
18	response	O
19	to	O
20	plating	O
21	3Y1	O
22	cells	O
23	onto	O
24	fibronectin	B
25	.	O

1	The	O
2	SH3	B
3	domains	I
4	of	O
5	Grb2	B
6	bound	O
7	in	O
8	vitro	O
9	to	O
10	specific	O
11	proline	O
12	-	O
13	rich	O
14	motifs	O
15	in	O
16	the	O
17	HPK1	B
18	tail	O
19	and	O
20	functioned	O
21	synergistically	O
22	to	O
23	direct	O
24	the	O
25	stable	O
26	binding	O
27	of	O
28	Grb2	B
29	to	O
30	HPK1	B
31	in	O
32	transfected	O
33	Cos1	O
34	cells	O
35	.	O

1	The	O
2	real	O
3	challenge	O
4	for	O
5	the	O
6	future	O
7	will	O
8	be	O
9	the	O
10	management	O
11	of	O
12	patients	O
13	who	O
14	do	O
15	not	O
16	respond	O
17	to	O
18	first	O
19	-	O
20	line	O
21	treatment	O
22	.	O

1	Acute	O
2	pancreatitis	O
3	is	O
4	a	O
5	rather	O
6	common	O
7	abdominal	O
8	disorder	O
9	.	O

1	Neuromyelitis	O
2	optica	O
3	(	O
4	Devic	O
5	'	O
6	s	O
7	syndrome	O
8	):	O
9	not	O
10	always	O
11	multiple	O
12	sclerosis	O
13	.	O

1	Method	O
2	of	O
3	synthesis	O
4	of	O
5	the	O
6	rheumatoid	B
7	factor	I
8	in	O
9	clinico	O
10	-	O
11	immunological	O
12	studies	O

1	Disulfiram	O
2	and	O
3	the	O
4	drug	O
5	-	O
6	induced	O
7	effects	O
8	on	O
9	motility	O
10	.	O

1	A	O
2	convenient	O
3	measure	O
4	of	O
5	this	O
6	impairment	O
7	may	O
8	be	O
9	obtained	O
10	using	O
11	the	O
12	ratio	O
13	of	O
14	urine	O
15	volume	O
16	(	O
17	V	O
18	)	O
19	divided	O
20	by	O
21	lithium	O
22	clearance	O
23	(	O
24	CLi	O
25	).	O

1	It	O
2	is	O
3	mainly	O
4	transcribed	O
5	in	O
6	neural	O
7	structures	O
8	and	O
9	in	O
10	developing	O
11	organs	O
12	characterized	O
13	by	O
14	epithelial	O
15	-	O
16	mesenchymal	O
17	interactions	O
18	.	O

1	To	O
2	evaluate	O
3	the	O
4	effects	O
5	of	O
6	HRT	O
7	on	O
8	those	O
9	factors	O
10	in	O
11	end	O
12	-	O
13	stage	O
14	renal	O
15	disease	O
16	(	O
17	ESRD	O
18	)	O
19	patients	O
20	,	O
21	we	O
22	evaluated	O
23	the	O
24	changes	O
25	of	O
26	lipid	O
27	profile	O
28	,	O
29	coagulation	O
30	and	O
31	fibrinolysis	O
32	markers	O
33	,	O
34	and	O
35	plasma	O
36	homocysteine	O
37	levels	O
38	after	O
39	treatment	O
40	.	O

1	C	B
2	/	I
3	EBP	I
4	beta	I
5	V	I
6	>	O
7	A	O
8	selectively	O
9	binds	O
10	only	O
11	the	O
12	subset	O
13	of	O
14	C	B
15	/	I
16	EBP	I
17	sites	I
18	that	O
19	are	O
20	also	O
21	DBP	B
22	sites	I
23	,	O
24	both	O
25	as	O
26	oligonucleotides	O
27	and	O
28	within	O
29	the	O
30	natural	O
31	contexts	O
32	of	O
33	the	O
34	albumin	B
35	and	O
36	cholesterol	B
37	hydroxylase	I
38	promoters	I
39	.	O

1	This	O
2	sequence	O
3	similarity	O
4	raises	O
5	the	O
6	possibility	O
7	that	O
8	GCN1	B
9	interacts	O
10	with	O
11	ribosomes	O
12	or	O
13	tRNA	O
14	molecules	O
15	and	O
16	functions	O
17	in	O
18	conjunction	O
19	with	O
20	GCN2	B
21	in	O
22	monitoring	O
23	uncharged	O
24	tRNA	O
25	levels	O
26	during	O
27	the	O
28	process	O
29	of	O
30	translation	O
31	elongation	O
32	.	O

1	The	O
2	lowest	O
3	culture	O
4	failure	O
5	rate	O
6	of	O
7	0	O
8	.	O
9	2	O
10	per	O
11	cent	O
12	was	O
13	found	O
14	after	O
15	EAF	O
16	compared	O
17	with	O
18	0	O
19	.	O
20	9	O
21	per	O
22	cent	O
23	among	O
24	CVS	O
25	.	O

1	Removal	O
2	of	O
3	each	O
4	of	O
5	three	O
6	contiguous	O
7	segments	O
8	from	O
9	the	O
10	N	O
11	-	O
12	terminal	O
13	half	O
14	specifically	O
15	inhibits	O
16	the	O
17	formation	O
18	of	O
19	5	B
20	.	I
21	8Ss	I
22	rRNA	I
23	,	O
24	whereas	O
25	deleting	O
26	part	O
27	of	O
28	the	O
29	C	O
30	-	O
31	terminal	O
32	region	O
33	of	O
34	the	O
35	protein	O
36	only	O
37	blocks	O
38	the	O
39	production	O
40	of	O
41	18S	B
42	rRNA	I
43	.	O

1	These	O
2	observations	O
3	have	O
4	led	O
5	us	O
6	to	O
7	conclude	O
8	that	O
9	an	O
10	elevated	O
11	VIII	O
12	-	O
13	ratio	O
14	is	O
15	a	O
16	very	O
17	sensitive	O
18	indicator	O
19	of	O
20	intravascular	O
21	coagulation	O
22	.	O

1	Using	O
2	immunogold	O
3	electron	O
4	microscopy	O
5	,	O
6	we	O
7	found	O
8	that	O
9	p58	B
10	/	O
11	p45	B
12	and	O
13	p54	B
14	are	O
15	localized	O
16	on	O
17	both	O
18	sides	O
19	of	O
20	the	O
21	nuclear	O
22	pore	O
23	complex	O
24	,	O
25	like	O
26	p62	B
27	.	O

1	The	O
2	mobility	O
3	shift	O
4	of	O
5	both	O
6	of	O
7	these	O
8	proteins	O
9	is	O
10	abolished	O
11	by	O
12	treatment	O
13	with	O
14	inhibitors	O
15	of	O
16	PKC	B
17	or	O
18	mitogen	B
19	-	I
20	activated	I
21	protein	I
22	kinase	I
23	/	O
24	extracellular	B
25	signal	I
26	-	I
27	related	I
28	kinase	I
29	kinase	I
30	.	O

1	The	O
2	aim	O
3	of	O
4	the	O
5	study	O
6	was	O
7	to	O
8	correlate	O
9	the	O
10	responsiveness	O
11	to	O
12	bronchoprovocation	O
13	with	O
14	methacholine	O
15	in	O
16	subjects	O
17	a	O
18	with	O
19	allergic	O
20	rhinitis	O
21	during	O
22	and	O
23	out	O
24	of	O
25	the	O
26	pollen	O
27	season	O
28	with	O
29	total	O
30	serum	O
31	IgE	B
32	and	O
33	blood	O
34	eosinophils	O
35	.	O

1	An	O
2	evolutionary	O
3	comparison	O
4	of	O
5	amino	O
6	acid	O
7	sequences	O
8	of	O
9	34	O
10	HSP70	B
11	proteins	I
12	from	O
13	17	O
14	species	O
15	suggests	O
16	that	O
17	BiP	B
18	genes	I
19	share	O
20	a	O
21	common	O
22	ancestor	O
23	,	O
24	which	O
25	diverged	O
26	from	O
27	other	O
28	HSP70	B
29	genes	I
30	near	O
31	the	O
32	time	O
33	when	O
34	eukaryotes	O
35	first	O
36	appeared	O
37	.	O

1	Tctex	B
2	-	I
3	1	I
4	binding	O
5	required	O
6	the	O
7	first	O
8	19	O
9	amino	O
10	acids	O
11	of	O
12	Fyn	B
13	and	O
14	integrity	O
15	of	O
16	two	O
17	lysine	O
18	residues	O
19	within	O
20	this	O
21	sequence	O
22	that	O
23	were	O
24	previously	O
25	shown	O
26	to	O
27	be	O
28	important	O
29	for	O
30	Fyn	B
31	interactions	O
32	with	O
33	the	O
34	immunoreceptor	O
35	tyrosine	O
36	-	O
37	based	O
38	activation	O
39	motifs	O
40	(	O
41	ITAMs	O
42	)	O
43	of	O
44	lymphocyte	B
45	Ag	I
46	receptors	I
47	.	O

1	METHODS	O
2	:	O
3	Total	O
4	muscle	O
5	paralysis	O
6	was	O
7	induced	O
8	under	O
9	general	O
10	anesthesia	O
11	in	O
12	a	O
13	group	O
14	of	O
15	obese	O
16	persons	O
17	(	O
18	n	O
19	=	O
20	9	O
21	;	O
22	body	O
23	mass	O
24	index	O
25	,	O
26	32	O
27	+/-	O
28	3	O
29	kg	O
30	[-	O
31	2	O
32	])	O
33	and	O
34	in	O
35	a	O
36	group	O
37	of	O
38	nonobese	O
39	persons	O
40	(	O
41	n	O
42	=	O
43	9	O
44	;	O
45	body	O
46	mas	O
47	index	O
48	,	O
49	21	O
50	+/-	O
51	2	O
52	kg	O
53	[-	O
54	2	O
55	]).	O

1	Type	O
2	II	O
3	could	O
4	be	O
5	divided	O
6	further	O
7	into	O
8	two	O
9	forms	O
10	(	O
11	IIA	O
12	and	O
13	IIB	O
14	)	O
15	that	O
16	may	O
17	represent	O
18	two	O
19	underscribed	O
20	species	O
21	or	O
22	developmental	O
23	stages	O
24	of	O
25	the	O
26	same	O
27	species	O
28	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	CCCC	O
6	module	O
7	is	O
8	structurally	O
9	related	O
10	to	O
11	the	O
12	DNA	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	the	O
18	erythroid	B
19	transcription	I
20	factor	I
21	GATA	I
22	-	I
23	1	I
24	.	O

1	Resistance	O
2	pattern	O
3	of	O
4	Mycobacterium	O
5	tuberculosis	O
6	(	O
7	H	O
8	37	O
9	Rv	O
10	)	O
11	to	O
12	a	O
13	new	O
14	antibiotic	O
15	,	O
16	lividomycin	O

1	To	O
2	our	O
3	knowledge	O
4	this	O
5	is	O
6	the	O
7	first	O
8	case	O
9	in	O
10	which	O
11	a	O
12	probable	O
13	association	O
14	between	O
15	cholelithiasis	O
16	and	O
17	Wildervanck	O
18	'	O
19	s	O
20	syndrome	O
21	has	O
22	been	O
23	recorded	O
24	.	O

1	However	O
2	,	O
3	D8	B
4	binding	O
5	was	O
6	observed	O
7	by	O
8	nuclease	O
9	protection	O
10	with	O
11	lactotroph	B
12	-	I
13	as	I
14	well	I
15	as	I
16	somatotroph	I
17	-	I
18	like	I
19	cell	I
20	nuclear	I
21	protein	I
22	.	O

1	The	O
2	incidence	O
3	of	O
4	early	O
5	neonatal	O
6	convulsions	O
7	for	O
8	inborn	O
9	babies	O
10	was	O
11	3	O
12	.	O
13	0	O
14	/	O
15	1000	O
16	live	O
17	births	O
18	.	O

1	The	O
2	cryptococcal	B
3	antigen	I
4	test	O
5	was	O
6	positive	O
7	at	O
8	1	O
9	:	O
10	125	O
11	by	O
12	latex	O
13	agglutination	O
14	.	O

1	We	O
2	have	O
3	tested	O
4	this	O
5	proposal	O
6	by	O
7	carrying	O
8	out	O
9	circular	O
10	dichroism	O
11	(	O
12	CD	O
13	)	O
14	and	O
15	NMR	O
16	experiments	O
17	on	O
18	the	O
19	Skn	B
20	domain	I
21	and	O
22	five	O
23	truncated	O
24	proteins	O
25	.	O

1	We	O
2	now	O
3	describe	O
4	the	O
5	identification	O
6	of	O
7	DEK	B
8	as	O
9	this	O
10	43	B
11	-	I
12	kDa	I
13	pets	I
14	factor	I
15	.	O

1	The	O
2	sympathetic	O
3	neuroeffector	O
4	influence	O
5	on	O
6	the	O
7	myocardium	O
8	with	O
9	ATCI	O
10	depends	O
11	to	O
12	a	O
13	large	O
14	measure	O
15	on	O
16	the	O
17	intensity	O
18	of	O
19	the	O
20	neurotransmitter	O
21	biosynthesis	O
22	and	O
23	function	O
24	of	O
25	cardiomyocyte	O
26	adrenoreceptors	O
27	.	O

1	Moreover	O
2	,	O
3	this	O
4	enhancement	O
5	of	O
6	transcriptional	O
7	activation	O
8	by	O
9	COUP	B
10	-	I
11	TFI	I
12	requires	O
13	specifically	O
14	the	O
15	AF	O
16	-	O
17	1	O
18	transactivation	O
19	function	O
20	of	O
21	ER	B
22	and	O
23	can	O
24	be	O
25	observed	O
26	in	O
27	the	O
28	presence	O
29	of	O
30	E2	O
31	or	O
32	4	O
33	-	O
34	hydroxytamoxifen	O
35	but	O
36	not	O
37	ICI	O
38	164384	O
39	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	this	O
6	difference	O
7	is	O
8	due	O
9	to	O
10	the	O
11	presence	O
12	of	O
13	a	O
14	Mot3	B
15	binding	I
16	site	I
17	in	O
18	OpA	B
19	.	O

1	DNA	O
2	blot	O
3	hybridization	O
4	suggests	O
5	that	O
6	the	O
7	rat	O
8	genome	O
9	may	O
10	contain	O
11	more	O
12	than	O
13	one	O
14	gene	O
15	encoding	O
16	PtdIns	B
17	transfer	I
18	protein	I
19	.	O

1	Comparison	O
2	to	O
3	other	O
4	coxI	B
5	genes	I
6	revealed	O
7	a	O
8	966	O
9	-	O
10	bp	O
11	group	O
12	I	O
13	intron	O
14	,	O
15	which	O
16	,	O
17	based	O
18	on	O
19	homology	O
20	with	O
21	the	O
22	related	O
23	yeast	B
24	coxI	I
25	intron	I
26	aI4	I
27	,	O
28	potentially	O
29	encodes	O
30	a	O
31	279	O
32	-	O
33	amino	O
34	-	O
35	acid	O
36	site	O
37	-	O
38	specific	O
39	DNA	B
40	endonuclease	I
41	.	O

1	The	O
2	interindividual	O
3	variability	O
4	of	O
5	the	O
6	parameters	O
7	is	O
8	taken	O
9	into	O
10	consideration	O
11	by	O
12	interactively	O
13	determining	O
14	the	O
15	threshold	O
16	levels	O
17	.	O

1	An	O
2	industry	O
3	-	O
4	wide	O
5	retrospective	O
6	cohort	O
7	mortality	O
8	study	O
9	was	O
10	conducted	O
11	on	O
12	6	O
13	,	O
14	152	O
15	chemical	O
16	workers	O
17	(	O
18	2	O
19	,	O
20	460	O
21	exposed	O
22	and	O
23	3	O
24	,	O
25	692	O
26	nonexposed	O
27	)	O
28	engaged	O
29	in	O
30	chloromethyl	O
31	ether	O
32	manufacture	O
33	at	O
34	7	O
35	major	O
36	U	O
37	.	O
38	S	O
39	.	O
40	companies	O
41	between	O
42	1948	O
43	and	O
44	1980	O
45	.	O

1	As	O
2	expected	O
3	for	O
4	a	O
5	positive	O
6	SpHE	B
7	transcriptional	I
8	regulator	I
9	,	O
10	the	O
11	timing	O
12	of	O
13	SpEts4	B
14	gene	I
15	expression	O
16	precedes	O
17	the	O
18	transient	O
19	expression	O
20	of	O
21	SpHE	B
22	in	O
23	the	O
24	very	O
25	early	O
26	sea	O
27	urchin	O
28	blastula	O
29	.	O

1	In	O
2	men	O
3	with	O
4	BMI	O
5	<	O
6	30	O
7	,	O
8	the	O
9	OR	O
10	was	O
11	1	O
12	.	O
13	83	O
14	for	O
15	postprandial	O
16	TG	O
17	(	O
18	P	O
19	=	O
20	.	O
21	041	O
22	)	O
23	and	O
24	2	O
25	.	O
26	77	O
27	for	O
28	postprandial	O
29	RP	O
30	(	O
31	P	O
32	=	O
33	.	O
34	032	O
35	)	O
36	in	O
37	models	O
38	that	O
39	included	O
40	fasting	O
41	TG	O
42	,	O
43	LDL	B
44	-	I
45	C	I
46	,	O
47	and	O
48	hypertension	O
49	.	O

1	The	O
2	effects	O
3	of	O
4	loading	O
5	the	O
6	respiratory	O
7	pumps	O
8	on	O
9	the	O
10	oxygen	O
11	consumption	O
12	of	O
13	Callionymus	O
14	lyra	O
15	.	O

1	Analysis	O
2	of	O
3	the	O
4	E2F1	B
5	gene	I
6	promoter	I
7	showed	O
8	that	O
9	the	O
10	-	O
11	146	O
12	to	O
13	-	O
14	54	O
15	region	O
16	was	O
17	required	O
18	for	O
19	E2	B
20	-	O
21	responsiveness	O
22	in	O
23	transient	O
24	transfection	O
25	assays	O
26	,	O
27	and	O
28	subsequent	O
29	deletion	O
30	/	O
31	mutation	O
32	analysis	O
33	showed	O
34	that	O
35	a	O
36	single	O
37	upstream	O
38	GC	O
39	-	O
40	rich	O
41	and	O
42	two	O
43	downstream	O
44	CCAAT	O
45	-	O
46	binding	O
47	sites	O
48	were	O
49	required	O
50	for	O
51	transactivation	O
52	by	O
53	E2	B
54	.	O

1	The	O
2	appearance	O
3	of	O
4	dyskinetic	O
5	movement	O
6	disorders	O
7	in	O
8	humans	O
9	following	O
10	the	O
11	chronic	O
12	use	O
13	of	O
14	levodopa	O
15	or	O
16	amphetamine	O
17	may	O
18	be	O
19	a	O
20	manifestation	O
21	of	O
22	similarly	O
23	increased	O
24	dopamine	B
25	receptor	I
26	site	I
27	sensitivity	O
28	within	O
29	the	O
30	striatum	O
31	.	O

1	Thus	O
2	,	O
3	the	O
4	tri	O
5	-	O
6	snRNP	O
7	-	O
8	specific	O
9	27K	O
10	protein	O
11	could	O
12	potentially	O
13	be	O
14	involved	O
15	in	O
16	SR	B
17	protein	O
18	-	O
19	mediated	O
20	protein	O
21	/	O
22	protein	O
23	interactions	O
24	and	O
25	,	O
26	additionally	O
27	,	O
28	its	O
29	phosphorylation	O
30	state	O
31	could	O
32	modulate	O
33	pre	O
34	-	O
35	mRNA	O
36	splicing	O
37	.	O

1	In	O
2	about	O
3	770	O
4	bp	O
5	upstream	O
6	region	O
7	of	O
8	Spam1	B
9	that	O
10	has	O
11	been	O
12	cloned	O
13	and	O
14	sequenced	O
15	,	O
16	multiple	O
17	transcription	O
18	factor	O
19	binding	O
20	sites	O
21	including	O
22	a	O
23	CRE	O
24	(	O
25	cAMP	O
26	-	O
27	responsive	O
28	element	O
29	)	O
30	were	O
31	found	O
32	.	O

1	Possibly	O
2	,	O
3	the	O
4	scr1	B
5	-	I
6	1	I
7	mutation	I
8	does	O
9	not	O
10	affect	O
11	signal	O
12	recognition	O
13	or	O
14	translational	O
15	arrest	O
16	but	O
17	instead	O
18	results	O
19	in	O
20	maintenance	O
21	of	O
22	translational	O
23	arrest	O
24	of	O
25	AEP	B
26	synthesis	O
27	.	O

1	Ab	O
2	-	O
3	MLV	O
4	strains	O
5	expressing	O
6	P70	B
7	/	O
8	S2	B
9	failed	O
10	to	O
11	transform	O
12	NIH	O
13	3T3	O
14	cells	O
15	and	O
16	demonstrated	O
17	a	O
18	greatly	O
19	reduced	O
20	capacity	O
21	to	O
22	mediate	O
23	signaling	O
24	events	O
25	associated	O
26	with	O
27	the	O
28	Ras	B
29	-	O
30	dependent	O
31	mitogen	B
32	-	I
33	activated	I
34	protein	I
35	(	I
36	MAP	I
37	)	I
38	kinase	I
39	pathway	O
40	.	O

1	A	O
2	high	O
3	-	O
4	frequency	O
5	restriction	O
6	fragment	O
7	length	O
8	polymorphism	O
9	was	O
10	evident	O
11	in	O
12	the	O
13	DNA	O
14	from	O
15	29	O
16	unrelated	O
17	individuals	O
18	using	O
19	the	O
20	enzyme	O
21	BglII	B
22	.	O

1	Antileukoproteinase	B
2	(	O
3	ALP	B
4	)	O
5	is	O
6	a	O
7	low	O
8	mol	O
9	wt	O
10	mucosal	O
11	secretory	O
12	protein	O
13	which	O
14	,	O
15	in	O
16	human	O
17	tissues	O
18	,	O
19	inhibits	O
20	the	O
21	activities	O
22	of	O
23	the	O
24	neutral	O
25	serine	B
26	lysosomal	I
27	proteinases	I
28	elastase	I
29	and	O
30	cathepsin	B
31	-	I
32	G	I
33	.	O

1	The	O
2	extents	O
3	of	O
4	phosphorylation	O
5	of	O
6	Ser44	O
7	and	O
8	Ser64	O
9	were	O
10	1	O
11	:	O
12	1	O
13	,	O
14	whereas	O
15	those	O
16	of	O
17	the	O
18	four	O
19	minor	O
20	sites	O
21	all	O
22	together	O
23	were	O
24	<	O
25	30	O
26	%	O
27	of	O
28	the	O
29	major	O
30	one	O
31	.	O

1	Additionally	O
2	,	O
3	MIP	B
4	-	I
5	2A	I
6	antagonizes	O
7	cell	O
8	growth	O
9	regulatory	O
10	role	O
11	of	O
12	MBP	B
13	-	I
14	1	I
15	.	O

1	Human	B
2	thyroid	I
3	stimulator	I
4	(	O
5	HTS	B
6	)	O
7	in	O
8	thyroid	O
9	diseases	O

1	SETTING	O
2	:	O
3	A	O
4	division	O
5	of	O
6	a	O
7	large	O
8	tea	O
9	plantation	O
10	in	O
11	Kandy	O
12	.	O

1	Pure	O
2	T1	O
3	and	O
4	dual	O
5	-	O
6	T1	O
7	images	O
8	were	O
9	visually	O
10	evaluated	O
11	for	O
12	image	O
13	quality	O
14	(	O
15	IQ	O
16	)	O
17	on	O
18	a	O
19	five	O
20	-	O
21	point	O
22	scale	O
23	(	O
24	0	O
25	=	O
26	unacceptable	O
27	to	O
28	4	O
29	=	O
30	excellent	O
31	).	O

1	To	O
2	identify	O
3	the	O
4	precise	O
5	location	O
6	of	O
7	the	O
8	phosphorylation	O
9	site	O
10	on	O
11	the	O
12	64	O
13	-	O
14	kDa	O
15	protein	O
16	,	O
17	a	O
18	step	O
19	-	O
20	by	O
21	-	O
22	step	O
23	mutagenesis	O
24	procedures	O
25	was	O
26	followed	O
27	.	O

1	It	O
2	acts	O
3	on	O
4	Cdks	B
5	in	O
6	the	O
7	G1	O
8	and	O
9	S	O
10	phases	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	,	O
16	and	O
17	also	O
18	binds	O
19	to	O
20	proliferating	B
21	cell	I
22	nuclear	I
23	antigen	I
24	(	O
25	PCNA	B
26	),	O
27	blocking	O
28	DNA	O
29	replication	O
30	in	O
31	vitro	O
32	.	O

1	This	O
2	concept	O
3	is	O
4	supported	O
5	by	O
6	the	O
7	identification	O
8	of	O
9	RH	B
10	-	I
11	like	I
12	genes	I
13	in	O
14	non	O
15	human	O
16	primates	O
17	.	O

1	Glomerular	O
2	lesions	O
3	in	O
4	renal	O
5	allografts	O
6	.	O

1	Investigations	O
2	using	O
3	hippocampal	O
4	slices	O
5	maintained	O
6	in	O
7	vitro	O
8	have	O
9	demonstrated	O
10	that	O
11	bursts	O
12	of	O
13	oscillatory	O
14	field	O
15	potentials	O
16	in	O
17	the	O
18	gamma	O
19	frequency	O
20	range	O
21	(	O
22	30	O
23	-	O
24	80	O
25	Hz	O
26	)	O
27	are	O
28	followed	O
29	by	O
30	a	O
31	slower	O
32	oscillation	O
33	in	O
34	the	O
35	beta	O
36	1	O
37	range	O
38	(	O
39	12	O
40	-	O
41	20	O
42	Hz	O
43	).	O

1	Polarised	O
2	expression	O
3	of	O
4	human	O
5	intestinal	O
6	N	B
7	-	I
8	benzoyl	I
9	-	I
10	L	I
11	-	I
12	tyrosyl	I
13	-	I
14	p	I
15	-	I
16	aminobenzoic	I
17	acid	I
18	hydrolase	I
19	(	O
20	human	B
21	meprin	I
22	)	O
23	alpha	O
24	and	O
25	beta	O
26	subunits	O
27	in	O
28	Madin	O
29	-	O
30	Darby	O
31	canine	O
32	kidney	O
33	cells	O
34	.	O

1	The	O
2	neural	O
3	mechanism	O
4	of	O
5	parkinsonian	O
6	motor	O
7	symptoms	O
8	,	O
9	i	O
10	.	O
11	e	O
12	.,	O
13	rigidity	O
14	,	O
15	tremor	O
16	and	O
17	akinesia	O
18	,	O
19	which	O
20	are	O
21	the	O
22	result	O
23	of	O
24	nigrostriatal	O
25	dopamine	O
26	deficiency	O
27	,	O
28	is	O
29	interpreted	O
30	from	O
31	long	O
32	-	O
33	term	O
34	observations	O
35	on	O
36	the	O
37	effect	O
38	of	O
39	surgical	O
40	and	O
41	pharmacological	O
42	treatment	O
43	of	O
44	the	O
45	disease	O
46	in	O
47	relation	O
48	to	O
49	the	O
50	neuropathological	O
51	findings	O
52	within	O
53	the	O
54	substantia	O
55	nigra	O
56	zona	O
57	compacta	O
58	(	O
59	SNc	O
60	).	O

1	This	O
2	machinery	O
3	involves	O
4	a	O
5	secondary	O
6	structure	O
7	,	O
8	SECIS	O
9	element	O
10	,	O
11	in	O
12	the	O
13	selenoprotein	B
14	-	O
15	encoding	O
16	mRNA	O
17	,	O
18	directing	O
19	selenocysteine	O
20	insertion	O
21	at	O
22	the	O
23	position	O
24	of	O
25	an	O
26	opal	O
27	(	O
28	UGA	O
29	)	O
30	codon	O
31	,	O
32	normally	O
33	conferring	O
34	termination	O
35	of	O
36	translation	O
37	.	O

1	The	O
2	present	O
3	study	O
4	describes	O
5	the	O
6	cell	O
7	volume	O
8	dynamics	O
9	in	O
10	intact	O
11	rat	O
12	hearts	O
13	,	O
14	during	O
15	ischemia	O
16	and	O
17	after	O
18	reperfusion	O
19	.	O

1	Delta	O
2	-	O
3	aminolevulinic	O
4	acid	O
5	in	O
6	physiological	O
7	conditions	O
8	and	O
9	some	O
10	diseases	O
11	in	O
12	children	O

1	Argatroban	O
2	may	O
3	be	O
4	more	O
5	effective	O
6	under	O
7	low	O
8	HC	B
9	II	I
10	conditions	O
11	because	O
12	of	O
13	its	O
14	potent	O
15	inhibition	O
16	of	O
17	thrombin	B
18	activity	O
19	at	O
20	sites	O
21	of	O
22	vascular	O
23	wall	O
24	damage	O
25	.	O

1	Demonstration	O
2	of	O
3	the	O
4	agent	O
5	was	O
6	performed	O
7	from	O
8	the	O
9	6th	O
10	to	O
11	the	O
12	11th	O
13	day	O
14	p	O
15	.	O
16	i	O
17	.	O
18	by	O
19	direct	O
20	microscopic	O
21	methods	O
22	(	O
23	Stamp	O
24	and	O
25	auramine	O
26	staining	O
27	,	O
28	fluorescent	O
29	antibody	O
30	technique	O
31	);	O
32	the	O
33	Coxiella	O
34	content	O
35	was	O
36	determined	O
37	by	O
38	titration	O
39	in	O
40	embryonated	O
41	hen	O
42	'	O
43	s	O
44	eggs	O
45	.	O

1	These	O
2	HPV16	O
3	E6	B
4	/	O
5	E7	B
6	cDNAs	O
7	were	O
8	cloned	O
9	under	O
10	the	O
11	SV40	B
12	enhancer	I
13	/	I
14	promoter	I
15	and	O
16	the	O
17	MMTV	B
18	LTR	I
19	to	O
20	examine	O
21	the	O
22	activities	O
23	of	O
24	ras	B
25	-	O
26	collaborative	O
27	transformation	O
28	and	O
29	induction	O
30	of	O
31	cellular	O
32	DNA	O
33	synthesis	O
34	,	O
35	both	O
36	of	O
37	which	O
38	depend	O
39	on	O
40	the	O
41	E7	B
42	gene	I
43	product	O
44	.	O

1	The	O
2	transverse	O
3	magnetization	O
4	decays	O
5	mentioned	O
6	above	O
7	exhibited	O
8	two	O
9	components	O
10	,	O
11	a	O
12	T2	O
13	fast	O
14	(	O
15	T2f	O
16	)	O
17	and	O
18	a	O
19	T2	O
20	slow	O
21	(	O
22	T2s	O
23	)	O
24	component	O
25	.	O

1	Selective	O
2	macrophage	O
3	inhibition	O
4	abolishes	O
5	warfarin	O
6	-	O
7	induced	O
8	reduction	O
9	of	O
10	metastasis	O
11	.	O

1	The	O
2	individual	O
3	subunits	O
4	of	O
5	Ku	B
6	have	O
7	been	O
8	difficult	O
9	to	O
10	isolate	O
11	from	O
12	human	O
13	cells	O
14	without	O
15	denaturation	O
16	and	O
17	attempts	O
18	to	O
19	produce	O
20	functional	B
21	recombinant	I
22	Ku	I
23	have	O
24	been	O
25	largely	O
26	unsuccessful	O
27	.	O

1	PO2	O
2	measurements	O
3	using	O
4	a	O
5	double	O
6	barrelled	O
7	recess	O
8	type	O
9	microelectrodes	O
10	were	O
11	measured	O
12	in	O
13	the	O
14	optic	O
15	nerve	O
16	head	O
17	of	O
18	miniature	O
19	pigs	O
20	in	O
21	normoxia	O
22	and	O
23	hyperoxia	O
24	.	O

1	Lung	O
2	prostacyclin	O
3	production	O
4	may	O
5	be	O
6	related	O
7	to	O
8	flow	O
9	.	O

1	We	O
2	did	O
3	not	O
4	observe	O
5	any	O
6	changes	O
7	in	O
8	Bcl	B
9	-	I
10	2	I
11	or	O
12	Bcl	B
13	-	I
14	2	I
15	-	I
16	related	I
17	proteins	I
18	(	O
19	Bcl	B
20	-	I
21	x	I
22	,	O
23	Bax	B
24	,	O
25	and	O
26	Bad	B
27	)	O
28	in	O
29	control	O
30	or	O
31	KCREB	B
32	-	O
33	transfected	O
34	cells	O
35	before	O
36	or	O
37	after	O
38	treatment	O
39	with	O
40	Tg	O
41	.	O

1	A	O
2	putative	O
3	inhibitor	O
4	(	O
5	s	O
6	)	O
7	appears	O
8	to	O
9	co	O
10	-	O
11	elute	O
12	in	O
13	the	O
14	inactive	O
15	fraction	O
16	that	O
17	blocked	O
18	the	O
19	L	B
20	(	I
21	alpha	I
22	)	I
23	activity	O
24	.	O

1	Interestingly	O
2	,	O
3	addition	O
4	of	O
5	purified	O
6	CBP	B
7	to	O
8	the	O
9	nuclear	O
10	extracts	O
11	of	O
12	T47D	O
13	cells	O
14	markedly	O
15	stimulated	O
16	progesterone	O
17	-	O
18	and	O
19	PR	B
20	-	O
21	dependent	O
22	transcription	O
23	from	O
24	a	O
25	nucleosome	O
26	-	O
27	free	O
28	,	O
29	progesterone	O
30	response	O
31	element	O
32	(	O
33	PRE	O
34	)-	O
35	linked	O
36	reporter	O
37	DNA	O
38	template	O
39	.	O

1	SETTING	O
2	--	O
3	Women	O
4	,	O
5	Infants	O
6	,	O
7	and	O
8	Children	O
9	clinics	O
10	in	O
11	Minneapolis	O
12	,	O
13	Minn	O
14	.	O

1	A	O
2	DNA	O
3	motif	O
4	related	O
5	to	O
6	the	O
7	cAMP	O
8	-	O
9	responsive	O
10	element	O
11	and	O
12	an	O
13	exon	B
14	-	I
15	located	I
16	activator	I
17	protein	I
18	-	I
19	2	I
20	binding	I
21	site	I
22	in	O
23	the	O
24	human	B
25	tissue	I
26	-	I
27	type	I
28	plasminogen	I
29	activator	I
30	gene	I
31	promoter	I
32	cooperate	O
33	in	O
34	basal	O
35	expression	O
36	and	O
37	convey	O
38	activation	O
39	by	O
40	phorbol	O
41	ester	O
42	and	O
43	cAMP	O
44	.	O

1	C	O
2	.,	O
3	Sun	O
4	,	O
5	J	O
6	.,	O
7	Hsu	O
8	,	O
9	M	O
10	.-	O
11	Y	O
12	.,	O
13	Vallejo	O
14	-	O
15	Ramirez	O
16	,	O
17	J	O
18	.,	O
19	Inouye	O
20	,	O
21	S	O
22	.,	O
23	and	O
24	Inouye	O
25	,	O
26	M	O
27	.	O

1	We	O
2	propose	O
3	that	O
4	epigenetic	O
5	features	O
6	of	O
7	tissue	O
8	-	O
9	specific	O
10	control	O
11	and	O
12	of	O
13	the	O
14	control	O
15	of	O
16	allelic	O
17	expression	O
18	are	O
19	intricately	O
20	linked	O
21	.	O

1	Positron	O
2	emission	O
3	tomography	O
4	radioligands	O
5	for	O
6	dopamine	B
7	transporters	I
8	and	O
9	studies	O
10	in	O
11	human	O
12	and	O
13	nonhuman	O
14	primates	O
15	.	O

1	Hantaan	O
2	virus	O
3	.	O

1	The	O
2	marker	O
3	orders	O
4	from	O
5	the	O
6	genetic	O
7	and	O
8	RH	O
9	maps	O
10	were	O
11	consistent	O
12	.	O

1	Age	O
2	>/=	O
3	50	O
4	years	O
5	(	O
6	odds	O
7	ratio	O
8	[	O
9	OR	O
10	],	O
11	14	O
12	.	O
13	1	O
14	),	O
15	BMI	O
16	>/=	O
17	28	O
18	kg	O
19	/	O
20	m	O
21	(	O
22	2	O
23	)	O
24	(	O
25	OR	O
26	,	O
27	5	O
28	.	O
29	7	O
30	),	O
31	triglycerides	O
32	>/=	O
33	1	O
34	.	O
35	7	O
36	mmol	O
37	/	O
38	L	O
39	(	O
40	OR	O
41	,	O
42	5	O
43	),	O
44	and	O
45	alanine	B
46	aminotransferase	I
47	(	O
48	ALT	B
49	)	O
50	>/=	O
51	2N	O
52	(	O
53	OR	O
54	,	O
55	4	O
56	.	O
57	6	O
58	)	O
59	were	O
60	independently	O
61	associated	O
62	with	O
63	septal	O
64	fibrosis	O
65	.	O

1	Besides	O
2	,	O
3	it	O
4	was	O
5	considered	O
6	that	O
7	the	O
8	NPF	O
9	was	O
10	a	O
11	useful	O
12	tool	O
13	for	O
14	activation	O
15	of	O
16	velopharyngeal	O
17	activity	O
18	by	O
19	way	O
20	of	O
21	visual	O
22	feed	O
23	-	O
24	back	O
25	control	O
26	.	O

1	Neither	O
2	mutant	O
3	exhibited	O
4	derepression	O
5	of	O
6	the	O
7	silent	B
8	mating	I
9	type	I
10	loci	I
11	.	O

1	In	O
2	contrast	O
3	to	O
4	previously	O
5	characterized	O
6	proteophosphoglycans	O
7	,	O
8	the	O
9	ppg1	B
10	gene	O
11	product	O
12	is	O
13	predominantly	O
14	membrane	O
15	-	O
16	associated	O
17	and	O
18	it	O
19	is	O
20	expressed	O
21	on	O
22	the	O
23	promastigote	O
24	cell	O
25	surface	O
26	.	O

1	Responses	O
2	to	O
3	the	O
4	Plowright	O
5	Rinderpest	O
6	vaccine	O
7	by	O
8	43	O
9	calves	O
10	and	O
11	70	O
12	adult	O
13	cattle	O
14	in	O
15	Uganda	O
16	in	O
17	1990	O
18	,	O
19	through	O
20	the	O
21	production	O
22	of	O
23	IgG	B
24	antibodies	I
25	,	O
26	were	O
27	monitored	O
28	for	O
29	4	O
30	weeks	O
31	using	O
32	the	O
33	ELISA	O
34	assay	O
35	.	O

1	Gtx	B
2	mRNA	I
3	accumulates	O
4	in	O
5	parallel	O
6	with	O
7	the	O
8	RNAs	O
9	encoding	O
10	the	O
11	major	O
12	structural	O
13	proteins	O
14	of	O
15	myelin	O
16	,	O
17	myelin	B
18	basic	I
19	protein	I
20	(	O
21	MBP	B
22	),	O
23	and	O
24	proteolipid	B
25	protein	I
26	(	O
27	PLP	B
28	)	O
29	during	O
30	postnatal	O
31	brain	O
32	development	O
33	;	O
34	Gtx	B
35	mRNA	I
36	decreases	O
37	in	O
38	parallel	O
39	with	O
40	MBP	B
41	and	O
42	PLP	B
43	mRNAs	I
44	in	O
45	the	O
46	brains	O
47	of	O
48	myelin	O
49	-	O
50	deficient	O
51	rats	O
52	,	O
53	which	O
54	have	O
55	a	O
56	point	O
57	mutation	O
58	in	O
59	the	O
60	PLP	B
61	gene	I
62	.	O

1	Unlike	O
2	P135gag	B
3	-	O
4	myb	B
5	-	O
6	ets	B
7	and	O
8	the	O
9	Mr	O
10	75	O
11	,	O
12	000	O
13	translation	O
14	product	O
15	of	O
16	c	B
17	-	I
18	myb	I
19	(	O
20	P75c	B
21	-	I
22	myb	I
23	),	O
24	which	O
25	are	O
26	nuclear	O
27	proteins	O
28	,	O
29	P54c	B
30	-	I
31	ets	I
32	was	O
33	found	O
34	to	O
35	be	O
36	predominantly	O
37	cytoplasmic	O
38	.	O

1	Fregnac	O
2	,	O
3	M	O
4	.	O

1	The	O
2	aim	O
3	of	O
4	the	O
5	present	O
6	study	O
7	was	O
8	to	O
9	examine	O
10	the	O
11	antimicrobial	O
12	susceptibility	O
13	to	O
14	10	O
15	currently	O
16	used	O
17	antimicrobial	O
18	agents	O
19	of	O
20	50	O
21	strains	O
22	of	O
23	P	O
24	.	O
25	acnes	O
26	isolated	O
27	from	O
28	acne	O
29	lesions	O
30	and	O
31	identified	O
32	using	O
33	a	O
34	Rap	O
35	ID	O
36	ANA	O
37	II	O
38	panel	O
39	.	O

1	Interpersonal	O
2	style	O
3	differences	O
4	among	O
5	drug	O
6	abusers	O
7	were	O
8	explored	O
9	using	O
10	Ryan	O
11	'	O
12	s	O
13	(	O
14	1977	O
15	)	O
16	typological	O
17	system	O
18	of	O
19	FIRO	O
20	-	O
21	B	O
22	interpretation	O
23	.	O

1	Measurement	O
2	of	O
3	gastric	O
4	acid	O
5	secretion	O
6	by	O
7	conductivity	O
8	.	O

1	67	O
2	393	O
3	bp	O
4	of	O
5	contiguous	O
6	DNA	O
7	located	O
8	between	O
9	markers	O
10	cdc18	B
11	and	O
12	cdc14	B
13	on	O
14	the	O
15	right	O
16	arm	O
17	of	O
18	fission	O
19	yeast	O
20	chromosome	O
21	II	O
22	has	O
23	been	O
24	sequenced	O
25	as	O
26	part	O
27	of	O
28	the	O
29	European	O
30	Union	O
31	Schizosaccharomyces	O
32	pombe	O
33	genome	O
34	sequencing	O
35	project	O
36	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	the	O
6	expression	O
7	of	O
8	LIMK	B
9	-	I
10	1	I
11	mRNA	I
12	predominantly	O
13	in	O
14	the	O
15	brain	O
16	and	O
17	the	O
18	expression	O
19	of	O
20	LIMK	B
21	-	I
22	2	I
23	mRNA	I
24	in	O
25	various	O
26	tissues	O
27	in	O
28	the	O
29	rat	O
30	.	O

1	However	O
2	,	O
3	mandibular	O
4	position	O
5	(	O
6	S	O
7	-	O
8	N	O
9	-	O
10	B	O
11	and	O
12	S	O
13	-	O
14	N	O
15	-	O
16	Pog	O
17	)	O
18	was	O
19	found	O
20	to	O
21	be	O
22	significantly	O
23	more	O
24	retrusive	O
25	in	O
26	Class	O
27	II	O
28	when	O
29	compared	O
30	with	O
31	Class	O
32	I	O
33	subjects	O
34	.	O

1	The	O
2	mass	O
3	of	O
4	UO2	O
5	in	O
6	the	O
7	extrapulmonary	O
8	bronchi	O
9	and	O
10	first	O
11	bifurcation	O
12	decreased	O
13	more	O
14	slowly	O
15	over	O
16	0	O
17	--	O
18	8	O
19	d	O
20	after	O
21	inhalation	O
22	than	O
23	the	O
24	corresponding	O
25	mass	O
26	on	O
27	the	O
28	trachea	O
29	.	O

1	Ischemic	O
2	heart	O
3	disease	O
4	evaluated	O
5	by	O
6	exercise	O
7	stress	O
8	thallium	O
9	-	O
10	201	O
11	myocardial	O
12	scintigraphy	O
13	:	O
14	a	O
15	comparison	O
16	of	O
17	SPECT	O
18	and	O
19	bull	O
20	'	O
21	s	O
22	eye	O
23	display	O

1	Oligonucleotide	O
2	mutagenesis	O
3	of	O
4	these	O
5	binding	O
6	domains	O
7	indicated	O
8	their	O
9	importance	O
10	in	O
11	the	O
12	transcriptional	O
13	regulation	O
14	of	O
15	the	O
16	E3	B
17	promoter	I
18	in	O
19	yeast	O
20	cells	O
21	.	O

1	Advances	O
2	in	O
3	hemophilia	O
4	treatment	O
5	:	O
6	a	O
7	hepatitis	O
8	-	O
9	safe	O
10	factor	B
11	VIII	I
12	concentrate	O

1	Serum	O
2	lipids	O
3	and	O
4	lipoproteins	O
5	of	O
6	29	O
7	insulin	B
8	dependent	O
9	diabetic	O
10	children	O
11	have	O
12	been	O
13	determined	O
14	and	O
15	related	O
16	to	O
17	the	O
18	metabolic	O
19	status	O
20	of	O
21	the	O
22	patients	O
23	.	O

1	Structure	O
2	,	O
3	promoter	O
4	analysis	O
5	and	O
6	chromosomal	O
7	assignment	O
8	of	O
9	the	O
10	human	B
11	APEX	I
12	gene	I
13	.	O

1	We	O
2	have	O
3	thus	O
4	identified	O
5	the	O
6	first	O
7	mammalian	B
8	homolog	I
9	of	I
10	yeast	I
11	UPF1	I
12	,	O
13	a	O
14	protein	O
15	that	O
16	regulates	O
17	levels	O
18	of	O
19	nonsense	O
20	mRNA	O
21	,	O
22	and	O
23	we	O
24	tentatively	O
25	name	O
26	this	O
27	protein	O
28	human	B
29	HUPF1	I
30	(	O
31	for	O
32	human	B
33	homolog	I
34	of	I
35	UPF1	I
36	).	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	Pseudomonas	B
7	putida	I
8	PpG7	I
9	salicylate	I
10	hydroxylase	I
11	gene	I
12	(	O
13	nahG	B
14	)	O
15	and	O
16	its	O
17	3	O
18	'-	O
19	flanking	O
20	region	O
21	.	O

1	Induction	O
2	of	O
3	the	O
4	CINC	B
5	promoter	I
6	by	O
7	IL	B
8	-	I
9	17	I
10	in	O
11	IEC	O
12	-	O
13	6	O
14	cells	O
15	was	O
16	TNF	B
17	receptor	I
18	-	I
19	associated	I
20	factor	I
21	-	I
22	6	I
23	(	O
24	TRAF6	B
25	),	O
26	but	O
27	not	O
28	TRAF2	B
29	,	O
30	dependent	O
31	.	O

1	We	O
2	conclude	O
3	that	O
4	androgenic	O
5	hormones	O
6	reduce	O
7	HDL	B
8	-	I
9	cholesterol	I
10	concentrations	O
11	and	O
12	the	O
13	HDL2	B
14	-	I
15	cholesterol	I
16	subfraction	O
17	,	O
18	possibly	O
19	by	O
20	enhancing	O
21	hepatic	B
22	triglyceride	I
23	lipase	I
24	activity	O
25	.	O

1	CsA	O
2	alone	O
3	resulted	O
4	in	O
5	elevated	O
6	bone	O
7	turnover	O
8	.	O

1	Analysis	O
2	for	O
3	DNA	O
4	-	O
5	protein	O
6	interactions	O
7	by	O
8	in	O
9	vitro	O
10	DNase	B
11	-	I
12	I	I
13	footprinting	O
14	identified	O
15	a	O
16	broad	O
17	region	O
18	of	O
19	protection	O
20	extending	O
21	from	O
22	nt	O
23	-	O
24	12	O
25	to	O
26	+	O
27	38	O
28	.	O

1	Depletion	O
2	of	O
3	dopamine	O
4	in	O
5	the	O
6	nucleus	O
7	accumbens	O
8	led	O
9	to	O
10	a	O
11	dramatic	O
12	shift	O
13	in	O
14	behavior	O
15	in	O
16	which	O
17	there	O
18	was	O
19	a	O
20	significant	O
21	decrease	O
22	in	O
23	lever	O
24	pressing	O
25	but	O
26	a	O
27	significant	O
28	increase	O
29	in	O
30	consumption	O
31	of	O
32	lab	O
33	chow	O
34	.	O

1	Regulation	O
2	of	O
3	ASN1	B
4	and	O
5	ASN2	B
6	expression	O
7	was	O
8	studied	O
9	using	O
10	lacZ	B
11	fusions	I
12	and	O
13	both	O
14	genes	O
15	were	O
16	found	O
17	to	O
18	be	O
19	several	O
20	times	O
21	less	O
22	expressed	O
23	in	O
24	the	O
25	absence	O
26	of	O
27	the	O
28	transcription	O
29	activator	O
30	Gcn4p	B
31	.	O

1	Furthermore	O
2	,	O
3	loss	O
4	of	O
5	methylation	O
6	also	O
7	greatly	O
8	reduced	O
9	the	O
10	association	O
11	of	O
12	another	O
13	yeast	O
14	B	O
15	-	O
16	type	O
17	subunit	O
18	,	O
19	Rts1p	B
20	.	O

1	Sequence	O
2	analysis	O
3	suggests	O
4	that	O
5	TtrA	B
6	contains	O
7	a	O
8	molybdopterin	O
9	guanine	O
10	dinucleotide	O
11	cofactor	O
12	and	O
13	a	O
14	[	O
15	4Fe	O
16	-	O
17	4S	O
18	]	O
19	cluster	O
20	,	O
21	that	O
22	TtrB	B
23	binds	O
24	four	O
25	[	O
26	4Fe	O
27	-	O
28	4S	O
29	]	O
30	clusters	O
31	,	O
32	and	O
33	that	O
34	TtrC	B
35	is	O
36	an	O
37	integral	O
38	membrane	O
39	protein	O
40	containing	O
41	a	O
42	quinol	O
43	oxidation	O
44	site	O
45	.	O

1	Exploratory	O
2	-	O
3	motor	O
4	task	O
5	to	O
6	evaluate	O
7	right	O
8	frontal	O
9	lobe	O
10	damage	O
11	.	O

1	METHODS	O
2	:	O
3	Fifty	O
4	-	O
5	one	O
6	healthy	O
7	eyes	O
8	,	O
9	169	O
10	ocular	O
11	hypertensive	O
12	eyes	O
13	with	O
14	normal	O
15	visual	O
16	fields	O
17	,	O
18	and	O
19	132	O
20	glaucomatous	O
21	eyes	O
22	with	O
23	early	O
24	visual	O
25	field	O
26	defects	O
27	were	O
28	evaluated	O
29	with	O
30	qualitative	O
31	and	O
32	quantitative	O
33	measures	O
34	of	O
35	structural	O
36	damage	O
37	to	O
38	the	O
39	optic	O
40	nerve	O
41	and	O
42	nerve	O
43	fiber	O
44	layer	O
45	.	O

1	The	O
2	syndrome	O
3	of	O
4	resistance	O
5	to	O
6	thyroid	O
7	hormone	O
8	is	O
9	characterized	O
10	by	O
11	elevated	O
12	serum	O
13	free	O
14	thyroid	O
15	hormones	O
16	,	O
17	failure	O
18	to	O
19	suppress	O
20	pituitary	B
21	thyrotropin	I
22	secretion	O
23	,	O
24	and	O
25	variable	O
26	peripheral	O
27	refractoriness	O
28	to	O
29	hormone	O
30	action	O
31	.	O

1	By	O
2	electrophoresis	O
3	mobility	O
4	shift	O
5	assays	O
6	using	O
7	probes	O
8	corresponding	O
9	to	O
10	different	O
11	segments	O
12	of	O
13	the	O
14	putative	O
15	human	B
16	c	I
17	-	I
18	myb	I
19	intron	I
20	1	I
21	transcription	I
22	pause	I
23	region	I
24	and	O
25	nuclear	O
26	extracts	O
27	from	O
28	myeloid	O
29	leukemia	O
30	HL	O
31	60	O
32	and	O
33	fibroblast	O
34	WI	O
35	38	O
36	cells	O
37	,	O
38	we	O
39	detected	O
40	a	O
41	HL	O
42	-	O
43	60	O
44	-	O
45	specific	O
46	DNA	O
47	-	O
48	protein	O
49	complex	O
50	with	O
51	a	O
52	123	O
53	-	O
54	bp	O
55	fragment	O
56	containing	O
57	binding	O
58	sites	O
59	for	O
60	the	O
61	interferon	B
62	regulatory	I
63	factors	I
64	(	O
65	IRFs	B
66	)	O
67	nuclear	O
68	proteins	O
69	.	O

1	Cytohesin	B
2	-	I
3	1	I
4	,	O
5	a	O
6	protein	O
7	abundant	O
8	in	O
9	cells	O
10	of	O
11	the	O
12	immune	O
13	system	O
14	,	O
15	has	O
16	been	O
17	proposed	O
18	to	O
19	be	O
20	a	O
21	human	O
22	homolog	O
23	of	O
24	the	O
25	Saccharomyces	B
26	cerevisiae	I
27	Sec7	I
28	gene	I
29	product	I
30	,	O
31	which	O
32	is	O
33	crucial	O
34	in	O
35	protein	O
36	transport	O
37	.	O

1	Marked	O
2	hemolysis	O
3	significantly	O
4	increased	O
5	plasma	O
6	values	O
7	of	O
8	potassium	O
9	,	O
10	phosphorus	O
11	,	O
12	total	O
13	protein	O
14	,	O
15	and	O
16	aspartate	B
17	aminotransferase	I
18	.	O

1	In	O
2	budding	O
3	yeast	O
4	,	O
5	the	O
6	protein	O
7	Skp1p	B
8	,	O
9	the	O
10	cullin	B
11	-	I
12	family	I
13	member	I
14	Cdc53p	I
15	,	O
16	and	O
17	the	O
18	F	O
19	-	O
20	box	O
21	/	O
22	WD	O
23	-	O
24	repeat	O
25	protein	O
26	Cdc4p	B
27	form	O
28	the	O
29	SCFCdc4p	B
30	ubiquitin	I
31	ligase	I
32	complex	O
33	,	O
34	which	O
35	targets	O
36	the	O
37	cyclin	B
38	-	I
39	dependent	I
40	kinase	I
41	(	O
42	Cdk	B
43	)	O
44	inhibitor	O
45	Sic1p	B
46	for	O
47	proteolysis	O
48	[	O
49	3	O
50	]	O
51	[	O
52	4	O
53	]	O
54	[	O
55	5	O
56	]	O
57	[	O
58	6	O
59	]	O
60	[	O
61	7	O
62	]	O
63	[	O
64	8	O
65	].	O

1	Two	O
2	members	O
3	of	O
4	the	O
5	Cbl	B
6	family	I
7	have	O
8	since	O
9	been	O
10	defined	O
11	in	O
12	mammals	O
13	(	O
14	c	B
15	-	I
16	Cbl	I
17	and	O
18	Cbl	B
19	-	I
20	b	I
21	),	O
22	one	O
23	in	O
24	C	O
25	.	O
26	elegans	O
27	(	O
28	Sli	B
29	-	I
30	1	I
31	)	O
32	and	O
33	one	O
34	in	O
35	Drosophila	O
36	(	O
37	D	B
38	-	I
39	Cbl	I
40	).	O

1	To	O
2	assess	O
3	the	O
4	effects	O
5	of	O
6	alveolar	O
7	hypoxia	O
8	and	O
9	angiotensin	B
10	II	I
11	infusion	O
12	on	O
13	distribution	O
14	of	O
15	blood	O
16	flow	O
17	to	O
18	the	O
19	lung	O
20	we	O
21	performed	O
22	perfusion	O
23	lung	O
24	scans	O
25	on	O
26	anesthetized	O
27	mechanically	O
28	ventilated	O
29	lambs	O
30	.	O

1	To	O
2	achieve	O
3	complete	O
4	dissection	O
5	of	O
6	the	O
7	anterior	O
8	vitreous	O
9	,	O
10	we	O
11	remove	O
12	even	O
13	a	O
14	clear	O
15	lens	O
16	during	O
17	the	O
18	first	O
19	surgical	O
20	intervention	O
21	in	O
22	selected	O
23	cases	O
24	.	O

1	IL	B
2	-	I
3	2	I
4	is	O
5	accepted	O
6	as	O
7	a	O
8	standard	O
9	treatment	O
10	used	O
11	alone	O
12	,	O
13	or	O
14	in	O
15	combination	O
16	with	O
17	chemotherapy	O
18	or	O
19	biotherapy	O
20	in	O
21	the	O
22	management	O
23	of	O
24	metastatic	O
25	melanoma	O
26	and	O
27	metastatic	O
28	renal	O
29	cell	O
30	carcinoma	O
31	.	O

1	Similarly	O
2	,	O
3	we	O
4	examined	O
5	whether	O
6	the	O
7	ELK1	B
8	,	O
9	SAP1a	B
10	,	O
11	FLI1	B
12	,	O
13	EWS	B
14	-	O
15	FLI1	B
16	,	O
17	ETS1	B
18	,	O
19	ETS2	B
20	,	O
21	PEA3	B
22	and	O
23	PU	B
24	.	I
25	1	I
26	proteins	I
27	can	O
28	form	O
29	ternary	O
30	complexes	O
31	with	O
32	SRF	B
33	on	O
34	the	O
35	Egr1	B
36	SREI	I
37	and	I
38	II	I
39	.	O

1	Recombinant	B
2	human	I
3	serum	I
4	albumin	I
5	(	O
6	rHSA	B
7	)	O
8	produced	O
9	by	O
10	cultured	O
11	fermentation	O
12	has	O
13	been	O
14	prepared	O
15	in	O
16	the	O
17	form	O
18	of	O
19	microcapsules	O
20	nominally	O
21	3	O
22	-	O
23	5	O
24	microns	O
25	in	O
26	diameter	O
27	and	O
28	radiolabelled	O
29	with	O
30	technetium	O
31	-	O
32	99m	O
33	following	O
34	reduction	O
35	with	O
36	stannous	O
37	chloride	O
38	.	O

1	Overall	O
2	,	O
3	lesions	O
4	infiltrating	O
5	the	O
6	deep	O
7	lamina	O
8	propria	O
9	do	O
10	not	O
11	exhibit	O
12	a	O
13	reduced	O
14	frequency	O
15	of	O
16	occurrence	O
17	compared	O
18	to	O
19	lesions	O
20	infiltrating	O
21	the	O
22	skeletal	O
23	muscle	O
24	;	O
25	however	O
26	,	O
27	carcinomas	O
28	affecting	O
29	other	O
30	oral	O
31	sites	O
32	showed	O
33	a	O
34	reduced	O
35	frequency	O
36	of	O
37	deeply	O
38	infiltrating	O
39	lesions	O
40	in	O
41	comparison	O
42	to	O
43	more	O
44	superficial	O
45	lesions	O
46	.	O

1	With	O
2	respect	O
3	to	O
4	effective	O
5	diffusivity	O
6	of	O
7	platelets	O
8	(	O
9	De	O
10	)	O
11	and	O
12	the	O
13	surface	O
14	reactivity	O
15	constant	O
16	(	O
17	K	O
18	),	O
19	less	O
20	significant	O
21	differences	O
22	were	O
23	found	O
24	among	O
25	artificial	O
26	materials	O
27	.	O

1	The	O
2	comparison	O
3	of	O
4	the	O
5	expression	O
6	patterns	O
7	of	O
8	the	O
9	known	O
10	Kv4	B
11	family	I
12	members	I
13	shows	O
14	subtype	O
15	specificity	O
16	with	O
17	significant	O
18	overlaps	O
19	.	O

1	Inhibition	O
2	of	O
3	the	O
4	Mek	B
5	/	O
6	Erk	B
7	pathway	O
8	in	O
9	Rat1	O
10	/	O
11	ras	B
12	cells	O
13	,	O
14	using	O
15	the	O
16	Mek	B
17	inhibitor	O
18	,	O
19	PD98059	O
20	,	O
21	resulted	O
22	in	O
23	complete	O
24	cytoskeletal	O
25	recovery	O
26	,	O
27	indistinguishable	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	HR12	O
33	.	O

1	Glutathione	B
2	S	I
3	-	I
4	transferase	I
5	(	O
6	GST	B
7	)-	O
8	E2F	B
9	and	O
10	GST	B
11	-	O
12	DP	B
13	fusion	O
14	proteins	O
15	were	O
16	found	O
17	to	O
18	cooperate	O
19	in	O
20	binding	O
21	to	O
22	the	O
23	three	O
24	E2F	B
25	sites	I
26	in	O
27	the	O
28	DNA	B
29	polymerase	I
30	alpha	I
31	gene	I
32	promoter	I
33	in	O
34	vitro	O
35	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	the	O
5	cytoplasmic	O
6	tail	O
7	appears	O
8	to	O
9	generate	O
10	multiple	O
11	PECAM	B
12	-	I
13	1	I
14	isoforms	I
15	that	O
16	may	O
17	regulate	O
18	phosphorylation	O
19	,	O
20	cytoskeletal	O
21	association	O
22	,	O
23	and	O
24	affinity	O
25	modulation	O
26	of	O
27	the	O
28	mature	O
29	protein	O
30	.	O

1	An	O
2	increase	O
3	in	O
4	hypothalamic	O
5	expression	O
6	of	O
7	at	O
8	least	O
9	two	O
10	of	O
11	the	O
12	erbB	B
13	receptors	I
14	is	O
15	initiated	O
16	before	O
17	the	O
18	pubertal	O
19	augmentation	O
20	of	O
21	gonadal	O
22	steroid	O
23	secretion	O
24	and	O
25	is	O
26	completed	O
27	on	O
28	the	O
29	day	O
30	of	O
31	the	O
32	first	O
33	preovulatory	O
34	surge	O
35	of	O
36	gonadotropins	B
37	.	O

1	Morphofunctional	O
2	status	O
3	of	O
4	the	O
5	formed	O
6	elements	O
7	of	O
8	the	O
9	blood	O
10	in	O
11	rats	O
12	subjected	O
13	to	O
14	different	O
15	variants	O
16	of	O
17	combined	O
18	and	O
19	isolated	O
20	exposure	O
21	to	O
22	BR	O
23	-	O
24	1	O
25	benzene	O

1	Thus	O
2	,	O
3	hypoxia	O
4	-	O
5	inducible	O
6	nuclear	O
7	import	O
8	and	O
9	transactivation	O
10	by	O
11	recruitment	O
12	of	O
13	CBP	B
14	can	O
15	be	O
16	functionally	O
17	separated	O
18	from	O
19	one	O
20	another	O
21	and	O
22	play	O
23	critical	O
24	roles	O
25	in	O
26	signal	O
27	transduction	O
28	by	O
29	HIF	B
30	-	I
31	1alpha	I
32	.	O

1	The	O
2	availability	O
3	of	O
4	sequence	O
5	from	O
6	multiple	O
7	species	O
8	has	O
9	permitted	O
10	us	O
11	to	O
12	determine	O
13	that	O
14	the	O
15	UBE	O
16	site	O
17	has	O
18	close	O
19	similarity	O
20	to	O
21	motifs	O
22	that	O
23	bind	O
24	members	O
25	of	O
26	the	O
27	NF	B
28	-	I
29	1	I
30	family	I
31	of	I
32	transcription	I
33	factors	I
34	.	O

1	Further	O
2	analysis	O
3	of	O
4	this	O
5	DNA	O
6	fragment	O
7	showed	O
8	that	O
9	four	O
10	genes	O
11	are	O
12	present	O
13	encoding	O
14	proteins	O
15	of	O
16	16	O
17	,	O
18	18	O
19	.	O
20	5	O
21	,	O
22	21	O
23	and	O
24	89	O
25	kDal	O
26	.	O

1	Yang	O
2	and	O
3	H	O
4	.	O

1	Factors	O
2	that	O
3	showed	O
4	significant	O
5	correlation	O
6	to	O
7	elevated	O
8	CIC	O
9	'	O
10	s	O
11	in	O
12	the	O
13	highly	O
14	elevated	O
15	portion	O
16	of	O
17	our	O
18	CIC	O
19	population	O
20	were	O
21	poor	O
22	NIH	O
23	score	O
24	,	O
25	increased	O
26	patient	O
27	age	O
28	,	O
29	low	O
30	peak	O
31	expiratory	O
32	flow	O
33	rate	O
34	,	O
35	and	O
36	elevated	O
37	total	O
38	serum	B
39	IgG	I
40	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	a	O
5	6	O
6	.	O
7	3	O
8	-	O
9	kbp	O
10	genomic	O
11	EcoRI	B
12	-	O
13	fragment	O
14	of	O
15	Alcaligenes	O
16	eutrophus	O
17	,	O
18	which	O
19	was	O
20	recently	O
21	identified	O
22	by	O
23	using	O
24	a	O
25	dihydrolipoamide	B
26	dehydrogenase	I
27	-	O
28	specific	O
29	DNA	O
30	probe	O
31	(	O
32	A	O
33	.	O

1	The	O
2	avian	O
3	cellular	O
4	homolog	O
5	of	O
6	the	O
7	oncogene	B
8	jun	I
9	.	O

1	However	O
2	,	O
3	changing	O
4	the	O
5	half	O
6	-	O
7	site	O
8	to	O
9	the	O
10	consensus	O
11	sequence	O
12	AGGTCA	O
13	(	O
14	IRper	O
15	-	O
16	1	O
17	)	O
18	increased	O
19	binding	O
20	of	O
21	AaEcR	B
22	.	I
23	AaUSP	I
24	10	O
25	-	O
26	fold	O
27	over	O
28	IRhsp	O
29	-	O
30	1	O
31	and	O
32	,	O
33	at	O
34	the	O
35	same	O
36	time	O
37	,	O
38	reduced	O
39	the	O
40	stringency	O
41	of	O
42	the	O
43	spacer	O
44	length	O
45	requirement	O
46	,	O
47	with	O
48	IRper	O
49	-	O
50	0	O
51	to	O
52	IRper	O
53	-	O
54	5	O
55	showing	O
56	detectable	O
57	binding	O
58	.	O

1	Endorphins	B
2	at	O
3	the	O
4	approach	O
5	of	O
6	death	O
7	.	O

1	The	O
2	introns	O
3	are	O
4	1	O
5	.	O
6	6	O
7	-	O
8	1	O
9	.	O
10	9	O
11	kbp	O
12	long	O
13	.	O

1	A	O
2	soluble	O
3	62	O
4	-	O
5	kDa	O
6	protein	O
7	was	O
8	produced	O
9	without	O
10	the	O
11	proteolytic	O
12	processing	O
13	by	O
14	inserting	O
15	the	O
16	coding	O
17	sequence	O
18	of	O
19	amino	O
20	acids	O
21	112	O
22	to	O
23	660	O
24	of	O
25	ORF	O
26	-	O
27	2	O
28	in	O
29	a	O
30	baculovirus	O
31	expression	O
32	vector	O
33	and	O
34	using	O
35	the	O
36	corresponding	O
37	virus	O
38	to	O
39	infect	O
40	Sf9	O
41	cells	O
42	.	O

1	It	O
2	has	O
3	come	O
4	out	O
5	that	O
6	CAEC	O
7	is	O
8	between	O
9	CC	O
10	and	O
11	CIEC	O
12	and	O
13	that	O
14	attacks	O
15	of	O
16	biliary	O
17	fever	O
18	and	O
19	high	O
20	levels	O
21	of	O
22	alkaline	B
23	phosphatase	I
24	and	O
25	transaminases	O
26	in	O
27	the	O
28	serum	O
29	are	O
30	the	O
31	helpful	O
32	findings	O
33	for	O
34	preoperative	O
35	diagnosis	O
36	.	O

1	Like	O
2	scrotal	O
3	testes	O
4	,	O
5	undescended	O
6	testes	O
7	were	O
8	hypointense	O
9	to	O
10	fat	O
11	on	O
12	sequences	O
13	with	O
14	a	O
15	short	O
16	repetition	O
17	time	O
18	(	O
19	TR	O
20	)	O
21	and	O
22	echo	O
23	time	O
24	(	O
25	TE	O
26	)	O
27	in	O
28	all	O
29	cases	O
30	,	O
31	and	O
32	hyperintense	O
33	or	O
34	isointense	O
35	to	O
36	fat	O
37	on	O
38	long	O
39	TR	O
40	/	O
41	TE	O
42	sequences	O
43	in	O
44	all	O
45	but	O
46	two	O
47	cases	O
48	.	O

1	The	O
2	MVV	O
3	-	O
4	value	O
5	is	O
6	under	O
7	the	O
8	predicted	O
9	level	O
10	in	O
11	the	O
12	case	O
13	of	O
14	67	O
15	-	O
16	76	O
17	percent	O
18	.	O

1	A	O
2	multivariate	O
3	analysis	O
4	of	O
5	risk	O
6	factors	O
7	for	O
8	relapse	O
9	examined	O
10	age	O
11	,	O
12	WBC	O
13	at	O
14	diagnosis	O
15	,	O
16	blast	O
17	count	O
18	at	O
19	diagnosis	O
20	,	O
21	percentage	O
22	of	O
23	marrow	O
24	blasts	O
25	,	O
26	FAB	B
27	subtype	O
28	,	O
29	the	O
30	number	O
31	of	O
32	remission	O
33	induction	O
34	courses	O
35	to	O
36	achieve	O
37	a	O
38	remission	O
39	,	O
40	maintenance	O
41	therapy	O
42	,	O
43	consolidation	O
44	therapy	O
45	,	O
46	marrow	O
47	cell	O
48	dose	O
49	,	O
50	donor	O
51	-	O
52	recipient	O
53	sex	O
54	,	O
55	GVHD	O
56	prophylaxis	O
57	regimen	O
58	and	O
59	isolation	O
60	and	O
61	decontamination	O
62	in	O
63	laminar	O
64	airflow	O
65	rooms	O
66	.	O

1	Effect	O
2	of	O
3	indoramin	O
4	in	O
5	small	O
6	doses	O
7	on	O
8	the	O
9	central	O
10	vasomotor	O
11	loci	O
12	has	O
13	been	O
14	studied	O
15	in	O
16	chloralose	O
17	anesthetized	O
18	cats	O
19	by	O
20	localizing	O
21	it	O
22	to	O
23	the	O
24	central	O
25	sites	O
26	.	O

1	Patients	O
2	with	O
3	lesions	O
4	affecting	O
5	the	O
6	PRC	O
7	but	O
8	sparing	O
9	the	O
10	PHC	O
11	,	O
12	and	O
13	patients	O
14	with	O
15	lesions	O
16	affecting	O
17	both	O
18	PRC	O
19	and	O
20	PHC	O
21	,	O
22	performed	O
23	an	O
24	oculomotor	O
25	delayed	O
26	response	O
27	task	O
28	with	O
29	unpredictably	O
30	varied	O
31	memory	O
32	delays	O
33	of	O
34	up	O
35	to	O
36	30	O
37	s	O
38	.	O

1	In	O
2	order	O
3	to	O
4	define	O
5	potential	O
6	candidate	O
7	genes	O
8	for	O
9	inherited	O
10	disorders	O
11	characterized	O
12	by	O
13	aberrant	O
14	gene	O
15	expression	O
16	,	O
17	we	O
18	utilized	O
19	Kruppel	B
20	-	I
21	related	I
22	sequences	I
23	to	O
24	isolate	O
25	zinc	O
26	finger	O
27	-	O
28	containing	O
29	cDNAs	O
30	.	O

1	Biol	O
2	.	O

1	The	O
2	effects	O
3	of	O
4	antithrombotic	O
5	drugs	O
6	in	O
7	patients	O
8	with	O
9	left	O
10	ventricular	O
11	thrombi	O
12	:	O
13	assessment	O
14	with	O
15	indium	O
16	-	O
17	111	O
18	platelet	O
19	imaging	O
20	and	O
21	two	O
22	-	O
23	dimensional	O
24	echocardiography	O
25	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	the	O
6	structure	O
7	of	O
8	the	O
9	decorin	B
10	gene	I
11	promoter	I
12	is	O
13	different	O
14	from	O
15	that	O
16	of	O
17	any	O
18	other	O
19	proteoglycan	O
20	promoter	O
21	characterized	O
22	so	O
23	far	O
24	and	O
25	indicate	O
26	that	O
27	the	O
28	pur	O
29	/	O
30	pyr	O
31	segment	O
32	plays	O
33	a	O
34	role	O
35	in	O
36	the	O
37	regulation	O
38	of	O
39	gene	O
40	transcription	O
41	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	3874	O
6	bp	O
7	of	O
8	cloned	O
9	R	O
10	.	O
11	sphaeroides	O
12	chromosomal	O
13	DNA	O
14	,	O
15	including	O
16	the	O
17	three	O
18	structural	O
19	genes	O
20	fbcF	B
21	,	O
22	fbcB	B
23	and	O
24	fbcC	B
25	has	O
26	been	O
27	determined	O
28	.	O

1	The	O
2	addition	O
3	of	O
4	a	O
5	Paf	B
6	-	O
7	containing	O
8	extract	O
9	does	O
10	not	O
11	lead	O
12	to	O
13	significant	O
14	protein	O
15	binding	O
16	to	O
17	these	O
18	two	O
19	hly	B
20	target	I
21	sequences	I
22	in	O
23	the	O
24	absence	O
25	of	O
26	PrfA	B
27	but	O
28	converts	O
29	the	O
30	complex	O
31	(	O
32	CIII	O
33	)	O
34	consisting	O
35	of	O
36	PrfA	B
37	and	O
38	the	O
39	109	B
40	bp	I
41	hly	I
42	DNA	I
43	fragment	I
44	to	O
45	a	O
46	slower	O
47	migrating	O
48	PrfA	B
49	-	O
50	Paf	B
51	-	O
52	DNA	O
53	complex	O
54	(	O
55	CI	O
56	).	O

1	No	O
2	difference	O
3	in	O
4	the	O
5	clinical	O
6	acceptability	O
7	could	O
8	be	O
9	ascertained	O
10	between	O
11	the	O
12	two	O
13	groups	O
14	.	O

1	Two	O
2	new	O
3	flavone	O
4	glucosides	O
5	,	O
6	nevadensin	O
7	5	O
8	-	O
9	O	O
10	-	O
11	beta	O
12	-	O
13	D	O
14	-	O
15	glucoside	O
16	and	O
17	nevadensin	O
18	5	O
19	-	O
20	O	O
21	-	O
22	beta	O
23	-	O
24	D	O
25	-	O
26	glucosyl	O
27	(	O
28	1	O
29	-->	O
30	6	O
31	)	O
32	beta	O
33	-	O
34	D	O
35	-	O
36	glucoside	O
37	,	O
38	have	O
39	been	O
40	isolated	O
41	from	O
42	the	O
43	aerial	O
44	parts	O
45	of	O
46	Lysionotus	O
47	pauciflorus	O
48	.	O

1	The	O
2	novel	O
3	hematopoietic	B
4	growth	I
5	factor	I
6	FLT3	I
7	ligand	I
8	(	O
9	FL	B
10	)	O
11	is	O
12	the	O
13	cognate	O
14	ligand	O
15	for	O
16	the	O
17	FLT3	B
18	,	O
19	tyrosine	B
20	kinase	I
21	receptor	I
22	(	O
23	R	B
24	),	O
25	also	O
26	referred	O
27	to	O
28	as	O
29	FLK	B
30	-	I
31	2	I
32	and	O
33	STK	B
34	-	I
35	1	I
36	.	O

1	Two	O
2	new	O
3	artifacts	O
4	in	O
5	automated	O
6	coagulation	O
7	testing	O
8	.	O

1	Several	O
2	secondary	O
3	structure	O
4	elements	O
5	were	O
6	identified	O
7	.	O

1	Underestimations	O
2	by	O
3	as	O
4	much	O
5	as	O
6	35	O
7	%	O
8	may	O
9	occur	O
10	due	O
11	to	O
12	the	O
13	problems	O
14	in	O
15	the	O
16	existing	O
17	methodologies	O
18	.	O

1	Interdomain	O
2	signaling	O
3	in	O
4	a	O
5	two	O
6	-	O
7	domain	O
8	fragment	O
9	of	O
10	the	O
11	human	B
12	glucocorticoid	I
13	receptor	I
14	.	O

1	We	O
2	performed	O
3	dipole	O
4	estimation	O
5	of	O
6	spikes	O
7	and	O
8	SEP	O
9	components	O
10	in	O
11	identical	O
12	patients	O
13	.	O

1	Analysis	O
2	of	O
3	a	O
4	set	O
5	of	O
6	deletion	O
7	constructs	O
8	in	O
9	transient	O
10	transfection	O
11	assays	O
12	measuring	O
13	heterologous	O
14	reporter	O
15	gene	O
16	(	O
17	luciferase	B
18	)	O
19	activity	O
20	demonstrated	O
21	that	O
22	the	O
23	182	O
24	-	O
25	bp	O
26	5	O
27	'-	O
28	flanking	O
29	region	O
30	provides	O
31	full	O
32	promoter	O
33	activity	O
34	in	O
35	IL	B
36	-	I
37	2	I
38	-	O
39	stimulated	O
40	L2	O
41	cells	O
42	.	O

1	To	O
2	improve	O
3	test	O
4	efficiency	O
5	,	O
6	we	O
7	modified	O
8	our	O
9	previously	O
10	introduced	O
11	contrast	O
12	/	O
13	color	O
14	card	O
15	test	O
16	by	O
17	including	O
18	a	O
19	patterned	O
20	test	O
21	stimulus	O
22	and	O
23	reducing	O
24	the	O
25	number	O
26	of	O
27	stimuli	O
28	in	O
29	both	O
30	experimental	O
31	phases	O
32	.	O

1	3	O
2	.	O

1	Abstracts	O
2	.	O

1	Role	O
2	of	O
3	superoxide	B
4	dismutase	I
5	in	O
6	cellular	O
7	oxidative	O
8	processes	O
9	and	O
10	method	O
11	of	O
12	its	O
13	determination	O
14	in	O
15	biological	O
16	materials	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	identified	O
7	Sp1	B
8	and	O
9	Sp3	B
10	as	O
11	major	O
12	factors	O
13	binding	O
14	to	O
15	the	O
16	Sp1	B
17	sites	I
18	of	O
19	the	O
20	p21	B
21	/	O
22	WAF1	B
23	/	O
24	Cip1	B
25	promoter	O
26	in	O
27	MG63	O
28	cells	O
29	through	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assays	O
34	and	O
35	showed	O
36	that	O
37	TSA	O
38	treatment	O
39	did	O
40	not	O
41	change	O
42	their	O
43	binding	O
44	activities	O
45	.	O

1	In	O
2	the	O
3	mouse	O
4	,	O
5	CtBP1	B
6	is	O
7	expressed	O
8	from	O
9	embryo	O
10	to	O
11	adult	O
12	,	O
13	but	O
14	CtBP2	B
15	is	O
16	mainly	O
17	expressed	O
18	during	O
19	embryogenesis	O
20	.	O

1	The	O
2	kallistatin	B
3	gene	I
4	was	O
5	localized	O
6	by	O
7	in	O
8	situ	O
9	hybridization	O
10	to	O
11	human	O
12	chromosome	O
13	14q31	O
14	-	O
15	q32	O
16	.	O
17	1	O
18	,	O
19	close	O
20	to	O
21	the	O
22	serpin	B
23	genes	I
24	encoding	O
25	alpha	B
26	1	I
27	-	I
28	antichymotrypsin	I
29	,	O
30	protein	B
31	C	I
32	inhibitor	I
33	,	O
34	alpha	B
35	1	I
36	-	I
37	antitrypsin	I
38	,	O
39	and	O
40	corticosteroid	B
41	-	I
42	binding	I
43	globulin	I
44	.	O

1	The	O
2	MAP	B
3	kinase	I
4	cascade	O
5	is	O
6	highly	O
7	conserved	O
8	in	O
9	all	O
10	eukaryotes	O
11	and	O
12	involved	O
13	in	O
14	numerous	O
15	cellular	O
16	responses	O
17	.	O

1	These	O
2	observations	O
3	link	O
4	actin	B
5	plaque	O
6	assembly	O
7	to	O
8	increased	O
9	cell	O
10	substrate	O
11	adhesion	O
12	.	O

1	Family	O
2	environment	O
3	was	O
4	an	O
5	important	O
6	influence	O
7	on	O
8	interpersonal	O
9	relationships	O
10	,	O
11	substance	O
12	use	O
13	,	O
14	and	O
15	social	O
16	support	O
17	.	O

1	The	O
2	currently	O
3	proposed	O
4	extended	O
5	arch	O
6	repair	O
7	should	O
8	be	O
9	reserved	O
10	for	O
11	the	O
12	small	O
13	group	O
14	of	O
15	infants	O
16	with	O
17	transverse	O
18	aortic	O
19	arch	O
20	to	O
21	ascending	O
22	aorta	O
23	diameter	O
24	ratios	O
25	(	O
26	arch	O
27	indices	O
28	)	O
29	of	O
30	less	O
31	than	O
32	0	O
33	.	O
34	25	O
35	.	O

1	Examination	O
2	of	O
3	immediate	B
4	-	I
5	early	I
6	transcription	I
7	factor	I
8	expression	O
9	during	O
10	the	O
11	MDI	O
12	regimen	O
13	revealed	O
14	that	O
15	RA	O
16	mediated	O
17	an	O
18	elevated	O
19	,	O
20	prolonged	O
21	expression	O
22	of	O
23	c	B
24	-	I
25	Jun	I
26	mRNA	I
27	accompanied	O
28	by	O
29	diminished	O
30	expression	O
31	of	O
32	c	B
33	-	I
34	Fos	I
35	and	O
36	Jun	B
37	-	I
38	B	I
39	mRNAs	I
40	.	O

1	A	O
2	total	O
3	of	O
4	576	O
5	1	O
6	-	O
7	day	O
8	-	O
9	old	O
10	Ross	O
11	broiler	O
12	chicks	O
13	were	O
14	housed	O
15	in	O
16	six	O
17	treatment	O
18	groups	O
19	[	O
20	six	O
21	replicates	O
22	of	O
23	16	O
24	each	O
25	;	O
26	control	O
27	,	O
28	CLI	O
29	(	O
30	15	O
31	g	O
32	kg	O
33	(-	O
34	1	O
35	)	O
36	diet	O
37	),	O
38	50	O
39	parts	O
40	per	O
41	billion	O
42	(	O
43	ppb	O
44	)	O
45	AF	B
46	,	O
47	50	O
48	ppb	O
49	AF	B
50	plus	O
51	CLI	O
52	,	O
53	100	O
54	ppb	O
55	AF	B
56	,	O
57	100	O
58	ppb	O
59	AF	B
60	plus	O
61	CLI	O
62	]	O
63	for	O
64	42	O
65	days	O
66	.	O

1	Familial	O
2	glutathione	B
3	reductase	I
4	deficiency	O
5	and	O
6	disorder	O
7	of	O
8	glutathione	O
9	synthesis	O
10	in	O
11	the	O
12	erythrocyte	O

1	However	O
2	,	O
3	mean	O
4	food	O
5	intake	O
6	in	O
7	the	O
8	40	O
9	%	O
10	group	O
11	was	O
12	half	O
13	that	O
14	of	O
15	the	O
16	ACT	O
17	group	O
18	(	O
19	p	O
20	<	O
21	0	O
22	.	O
23	001	O
24	)	O
25	and	O
26	significantly	O
27	less	O
28	(	O
29	p	O
30	<	O
31	0	O
32	.	O
33	01	O
34	)	O
35	than	O
36	the	O
37	SEP	O
38	group	O
39	,	O
40	which	O
41	consumed	O
42	amounts	O
43	equivalent	O
44	to	O
45	65	O
46	%	O
47	of	O
48	daily	O
49	requirement	O
50	.	O

1	In	O
2	the	O
3	evening	O
4	,	O
5	the	O
6	amplitude	O
7	of	O
8	the	O
9	responses	O
10	to	O
11	both	O
12	O2	O
13	and	O
14	CO2	O
15	increased	O
16	but	O
17	the	O
18	increase	O
19	in	O
20	CO2	O
21	sensitivity	O
22	was	O
23	proportionally	O
24	more	O
25	important	O
26	.	O

1	It	O
2	contained	O
3	seven	O
4	extra	O
5	amino	O
6	acids	O
7	of	O
8	FVVLNLQ	O
9	;	O
10	this	O
11	short	O
12	stretch	O
13	of	O
14	extra	O
15	sequence	O
16	was	O
17	found	O
18	between	O
19	Gln	O
20	(	O
21	421	O
22	)	O
23	and	O
24	Phe	O
25	(	O
26	422	O
27	)	O
28	within	O
29	the	O
30	SET	B
31	(	O
32	Suvar3	B
33	-	I
34	9	I
35	,	O
36	Enhancer	B
37	-	I
38	of	I
39	-	I
40	zeste	I
41	,	O
42	Trithorax	B
43	)	O
44	interacting	O
45	domain	O
46	(	O
47	SID	O
48	)	O
49	of	O
50	rMTM	B
51	.	O

1	These	O
2	results	O
3	with	O
4	clozapine	O
5	illustrate	O
6	that	O
7	LI	O
8	is	O
9	sensitive	O
10	to	O
11	antipsychotics	O
12	which	O
13	differ	O
14	in	O
15	their	O
16	mode	O
17	of	O
18	action	O
19	and	O
20	furthermore	O
21	emphasize	O
22	the	O
23	value	O
24	of	O
25	LI	O
26	as	O
27	a	O
28	test	O
29	model	O
30	for	O
31	detecting	O
32	the	O
33	antipsychotic	O
34	potential	O
35	of	O
36	novel	O
37	drugs	O
38	.	O

1	Studies	O
2	of	O
3	lipoprotein	B
4	-	I
5	X	I
6	(	O
7	LP	B
8	-	I
9	X	I
10	)	O
11	and	O
12	bile	O
13	acids	O
14	in	O
15	familial	O
16	LCAT	B
17	deficiency	O
18	.	O

1	Quantitative	O
2	analysis	O
3	of	O
4	plasmid	O
5	loss	O
6	rates	O
7	in	O
8	cdc28	B
9	-	I
10	1N	I
11	strains	O
12	carrying	O
13	plasmids	O
14	with	O
15	multiple	O
16	replication	O
17	origins	O
18	suggests	O
19	that	O
20	a	O
21	defect	O
22	in	O
23	initiating	O
24	DNA	O
25	replication	O
26	probably	O
27	causes	O
28	this	O
29	plasmid	O
30	loss	O
31	phenotype	O
32	.	O

1	Studies	O
2	on	O
3	immunoglobulin	B
4	E	I
5	:	O
6	the	O
7	impact	O
8	of	O
9	a	O
10	sojourn	O
11	with	O
12	Professor	O
13	Dan	O
14	H	O
15	.	O

1	There	O
2	was	O
3	a	O
4	weak	O
5	significant	O
6	correlation	O
7	between	O
8	TGF	B
9	beta	I
10	1	I
11	levels	O
12	and	O
13	normal	O
14	cell	O
15	radiosensitivity	O
16	(	O
17	lymphocyte	O
18	SF2	O
19	).	O

1	The	O
2	relation	O
3	between	O
4	myocardial	B
5	beta	I
6	-	I
7	adrenergic	I
8	receptor	I
9	and	O
10	left	O
11	ventricular	O
12	(	O
13	LV	O
14	)	O
15	function	O
16	was	O
17	studied	O
18	in	O
19	10	O
20	patients	O
21	,	O
22	aged	O
23	41	O
24	to	O
25	61	O
26	years	O
27	(	O
28	average	O
29	51	O
30	),	O
31	with	O
32	LV	O
33	volume	O
34	overload	O
35	mainly	O
36	due	O
37	to	O
38	chronic	O
39	mitral	O
40	regurgitation	O
41	.	O

1	Of	O
2	419	O
3	persons	O
4	surveyed	O
5	,	O
6	207	O
7	(	O
8	49	O
9	.	O
10	4	O
11	%)	O
12	were	O
13	antigen	O
14	-	O
15	positive	O
16	with	O
17	the	O
18	Og4C3	B
19	assay	O
20	.	O

1	To	O
2	illustrate	O
3	its	O
4	performance	O
5	,	O
6	measurements	O
7	of	O
8	photoluminescence	O
9	in	O
10	GaAs	O
11	/	O
12	AlGaAs	O
13	heterostructures	O
14	are	O
15	presented	O
16	.	O

1	Mutational	O
2	analyses	O
3	have	O
4	demonstrated	O
5	the	O
6	importance	O
7	of	O
8	sequences	O
9	within	O
10	the	O
11	327	O
12	bp	O
13	segment	O
14	that	O
15	contain	O
16	a	O
17	putative	O
18	cyclic	B
19	AMP	I
20	responsive	I
21	element	I
22	binding	I
23	protein	I
24	(	O
25	CREB	B
26	)	O
27	binding	O
28	site	O
29	for	O
30	TGF	B
31	-	I
32	beta	I
33	1	I
34	and	O
35	PMA	O
36	responsiveness	O
37	and	O
38	putative	O
39	PU	B
40	-	I
41	1	I
42	and	O
43	Sp1	B
44	binding	I
45	sites	I
46	for	O
47	basal	O
48	promoter	O
49	activity	O
50	.	O

1	Action	O
2	of	O
3	strontium	O
4	-	O
5	90	O
6	and	O
7	metaphos	O
8	on	O
9	Cyprinus	O
10	carpio	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	contractile	O
6	action	O
7	of	O
8	arachidonic	O
9	acid	O
10	,	O
11	via	O
12	a	O
13	presumed	O
14	cyclooxygenase	B
15	product	O
16	that	O
17	mediated	O
18	the	O
19	contractions	O
20	caused	O
21	by	O
22	both	O
23	TF	B
24	and	O
25	EGF	B
26	,	O
27	was	O
28	not	O
29	blocked	O
30	by	O
31	any	O
32	of	O
33	the	O
34	signal	O
35	pathway	O
36	probe	O
37	inhibitors	O
38	.	O

1	Regional	O
2	CBF	O
3	was	O
4	determined	O
5	by	O
6	clearance	O
7	of	O
8	xenon	O
9	133	O
10	in	O
11	67	O
12	patients	O
13	undergoing	O
14	coronary	O
15	bypass	O
16	grafting	O
17	procedures	O
18	.	O

1	We	O
2	introduced	O
3	the	O
4	gel	O
5	technique	O
6	as	O
7	a	O
8	routine	O
9	assay	O
10	for	O
11	antibody	O
12	detection	O
13	and	O
14	identification	O
15	in	O
16	1993	O
17	.	O

1	BYV	O
2	,	O
3	citrus	O
4	tristeza	O
5	virus	O
6	(	O
7	CTV	O
8	),	O
9	beet	O
10	yellow	O
11	stunt	O
12	virus	O
13	(	O
14	BYSV	O
15	)	O
16	and	O
17	carnation	O
18	necrotic	O
19	fleck	O
20	virus	O
21	templates	O
22	produced	O
23	1	O
24	kb	O
25	amplification	O
26	products	O
27	,	O
28	which	O
29	were	O
30	shown	O
31	by	O
32	sequencing	O
33	to	O
34	represent	O
35	fragments	O
36	of	O
37	the	O
38	respective	O
39	HSP70	B
40	genes	I
41	.	O

1	Typical	O
2	configurations	O
3	of	O
4	psychosocial	O
5	stress	O
6	factors	O
7	of	O
8	psychiatrically	O
9	conspicuous	O
10	children	O
11	and	O
12	adolescents	O

1	The	O
2	dnaQ	B
3	-	O
4	lacZ	B
5	and	O
6	the	O
7	rnh	B
8	-	O
9	lacZ	B
10	fused	O
11	genes	O
12	were	O
13	constructed	O
14	and	O
15	hybrid	O
16	proteins	O
17	with	O
18	beta	B
19	-	I
20	galactosidase	I
21	activity	O
22	were	O
23	produced	O
24	.	O

1	Among	O
2	mucus	O
3	-	O
4	secreting	O
5	cells	O
6	,	O
7	the	O
8	gastric	O
9	gland	O
10	mucous	O
11	cells	O
12	,	O
13	Brunner	O
14	'	O
15	s	O
16	glands	O
17	,	O
18	accessory	O
19	glands	O
20	of	O
21	pancreaticobiliary	O
22	tract	O
23	,	O
24	and	O
25	pancreatic	O
26	ducts	O
27	exhibiting	O
28	gastric	O
29	metaplasia	O
30	are	O
31	unique	O
32	in	O
33	that	O
34	they	O
35	express	O
36	class	B
37	III	I
38	mucin	I
39	identified	O
40	by	O
41	paradoxical	O
42	Con	B
43	A	I
44	staining	O
45	composed	O
46	of	O
47	periodate	O
48	oxidation	O
49	,	O
50	sodium	O
51	borohydride	O
52	reduction	O
53	,	O
54	Con	B
55	A	I
56	,	O
57	and	O
58	horseradish	B
59	peroxidase	I
60	reaction	O
61	.	O

1	In	O
2	the	O
3	case	O
4	of	O
5	congenital	O
6	protein	B
7	C	I
8	deficiency	O
9	,	O
10	vitamin	O
11	K	O
12	antagonists	O
13	must	O
14	be	O
15	started	O
16	cautiously	O
17	due	O
18	to	O
19	the	O
20	risk	O
21	of	O
22	skin	O
23	necrosis	O
24	.	O

1	Antibodies	O
2	affinity	O
3	-	O
4	purified	O
5	using	O
6	the	O
7	bacterially	O
8	expressed	O
9	recombinant	O
10	protein	O
11	recognized	O
12	the	O
13	56K	B
14	autoantigen	I
15	in	O
16	a	O
17	HeLa	O
18	cell	O
19	extract	O
20	.	O
21	cDNA	O
22	sequencing	O
23	revealed	O
24	that	O
25	the	O
26	56K	B
27	cDNA	I
28	shares	O
29	a	O
30	high	O
31	degree	O
32	of	O
33	homology	O
34	in	O
35	both	O
36	nucleotide	O
37	(	O
38	87	O
39	%)	O
40	and	O
41	amino	O
42	acid	O
43	sequence	O
44	(	O
45	92	O
46	.	O
47	5	O
48	%)	O
49	with	O
50	bovine	B
51	annexin	I
52	XI	I
53	,	O
54	indicating	O
55	that	O
56	the	O
57	56K	B
58	cDNA	I
59	encodes	O
60	the	O
61	human	B
62	homologue	I
63	of	I
64	annexin	I
65	XI	I
66	,	O
67	a	O
68	member	O
69	of	O
70	the	O
71	Ca	B
72	(	I
73	2	I
74	+)-	I
75	dependent	I
76	phospholipid	I
77	binding	I
78	protein	I
79	family	I
80	.	O

1	To	O
2	study	O
3	the	O
4	regulation	O
5	of	O
6	its	O
7	expression	O
8	,	O
9	the	O
10	human	B
11	aldehyde	I
12	reductase	I
13	gene	I
14	and	O
15	promoter	O
16	were	O
17	cloned	O
18	and	O
19	characterized	O
20	.	O

1	DPA	O
2	attenuated	O
3	the	O
4	increase	O
5	of	O
6	the	O
7	intensity	O
8	of	O
9	the	O
10	ischemic	O
11	and	O
12	pressure	O
13	pain	O
14	components	O
15	with	O
16	increasing	O
17	ischemia	O
18	duration	O
19	,	O
20	but	O
21	only	O
22	the	O
23	effect	O
24	on	O
25	the	O
26	pressure	O
27	pain	O
28	component	O
29	was	O
30	significant	O
31	.	O

1	The	O
2	murine	B
3	facilitative	I
4	glucose	I
5	transporter	I
6	isoform	I
7	3	I
8	(	O
9	Glut	B
10	3	I
11	)	O
12	is	O
13	developmentally	O
14	regulated	O
15	and	O
16	is	O
17	predominantly	O
18	expressed	O
19	in	O
20	neurons	O
21	and	O
22	trophoblasts	O
23	.	O

1	The	O
2	American	O
3	Burkitt	O
4	Lymphoma	O
5	Registry	O
6	:	O
7	a	O
8	progress	O
9	report	O
10	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	Bazett	O
5	-	O
6	corrected	O
7	QT	O
8	(	O
9	QTc	O
10	)	O
11	interval	O
12	during	O
13	exercise	O
14	has	O
15	been	O
16	used	O
17	as	O
18	a	O
19	marker	O
20	for	O
21	ischemic	O
22	disease	O
23	,	O
24	arrhythmogenic	O
25	substrate	O
26	and	O
27	the	O
28	long	O
29	QT	O
30	syndrome	O
31	.	O

1	BACKGROUND	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	predictors	O
7	of	O
8	desipramine	O
9	-	O
10	refractory	O
11	depression	O
12	,	O
13	the	O
14	authors	O
15	examined	O
16	the	O
17	outcome	O
18	in	O
19	patients	O
20	with	O
21	major	O
22	depression	O
23	who	O
24	were	O
25	admitted	O
26	to	O
27	a	O
28	general	O
29	hospital	O
30	and	O
31	treated	O
32	with	O
33	desipramine	O
34	adjusted	O
35	to	O
36	an	O
37	adequate	O
38	blood	O
39	level	O
40	.	O

1	We	O
2	now	O
3	describe	O
4	a	O
5	second	O
6	RIM	B
7	protein	I
8	,	O
9	called	O
10	RIM2	B
11	,	O
12	that	O
13	is	O
14	highly	O
15	homologous	O
16	to	O
17	RIM1	B
18	and	O
19	also	O
20	expressed	O
21	primarily	O
22	in	O
23	brain	O
24	.	O

1	All	O
2	nuclear	O
3	receptors	O
4	have	O
5	several	O
6	well	O
7	-	O
8	characterized	O
9	structural	O
10	domains	O
11	,	O
12	including	O
13	a	O
14	conserved	O
15	DNA	O
16	-	O
17	binding	O
18	domain	O
19	,	O
20	and	O
21	a	O
22	ligand	O
23	binding	O
24	domain	O
25	at	O
26	the	O
27	carboxyl	O
28	terminus	O
29	of	O
30	the	O
31	receptor	O
32	.	O

1	Only	O
2	transcripts	O
3	specific	O
4	for	O
5	TSGF	B
6	-	I
7	2	I
8	are	O
9	detected	O
10	in	O
11	ovary	O
12	and	O
13	testes	O
14	tissues	O
15	of	O
16	adults	O
17	as	O
18	well	O
19	as	O
20	in	O
21	puparia	O
22	,	O
23	while	O
24	neither	O
25	gene	O
26	is	O
27	expressed	O
28	during	O
29	the	O
30	larval	O
31	developmental	O
32	stages	O
33	.	O

1	Subsequent	O
2	cloning	O
3	and	O
4	nucleotide	O
5	sequence	O
6	analysis	O
7	of	O
8	the	O
9	S	B
10	.	I
11	pombe	I
12	adenylate	I
13	kinase	I
14	gene	I
15	,	O
16	adk1	B
17	,	O
18	revealed	O
19	a	O
20	coding	O
21	region	O
22	of	O
23	660	O
24	nucleotides	O
25	.	O

1	Induction	O
2	of	O
3	proto	B
4	-	I
5	oncogene	I
6	fos	I
7	transcription	O
8	through	O
9	the	O
10	adenylate	B
11	cyclase	I
12	pathway	O
13	:	O
14	characterization	O
15	of	O
16	a	O
17	cAMP	O
18	-	O
19	responsive	O
20	element	O
21	.	O

1	Acoust	O
2	.	O

1	Detailed	O
2	molecular	O
3	organization	O
4	of	O
5	the	O
6	coding	O
7	and	O
8	upstream	O
9	regulatory	O
10	regions	O
11	of	O
12	the	O
13	murine	O
14	homeodomain	B
15	-	I
16	containing	I
17	gene	I
18	,	O
19	Msx	B
20	-	I
21	1	I
22	,	O
23	is	O
24	reported	O
25	.	O

1	We	O
2	describe	O
3	a	O
4	novel	O
5	method	O
6	using	O
7	Saccharomyces	O
8	cerevisiae	O
9	for	O
10	detecting	O
11	protein	O
12	-	O
13	truncating	O
14	mutations	O
15	in	O
16	any	O
17	gene	O
18	of	O
19	interest	O
20	.	O

1	The	O
2	strategy	O
3	has	O
4	been	O
5	used	O
6	to	O
7	determine	O
8	2	O
9	.	O
10	6	O
11	kilobases	O
12	of	O
13	nucleotide	O
14	sequence	O
15	in	O
16	the	O
17	Saccharomyces	B
18	cerevisiae	I
19	ADE	I
20	1	I
21	locus	I
22	.	O

1	A	O
2	diagnosis	O
3	of	O
4	MS	O
5	was	O
6	made	O
7	based	O
8	on	O
9	subtle	O
10	neurologic	O
11	signs	O
12	,	O
13	spinal	O
14	fluid	O
15	gamma	B
16	globulin	I
17	elevations	O
18	,	O
19	and	O
20	abnormalities	O
21	in	O
22	neuropsychological	O
23	testing	O
24	.	O

1	We	O
2	have	O
3	characterized	O
4	a	O
5	panel	O
6	of	O
7	6	O
8	monoclonal	O
9	antibodies	O
10	raised	O
11	against	O
12	human	B
13	platelet	I
14	talin	I
15	by	O
16	Western	O
17	blotting	O
18	,	O
19	immune	O
20	precipitation	O
21	,	O
22	and	O
23	immunofluorescence	O
24	,	O
25	and	O
26	shown	O
27	that	O
28	antibodies	B
29	TA205	I
30	and	O
31	TD77	B
32	disrupt	O
33	actin	B
34	stress	O
35	fibers	O
36	and	O
37	focal	O
38	adhesions	O
39	,	O
40	and	O
41	inhibit	O
42	cell	O
43	motility	O
44	when	O
45	microinjected	O
46	into	O
47	human	O
48	fibroblasts	O
49	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	hGCSFR	B
6	gene	I
7	was	O
8	chromosomally	O
9	localized	O
10	by	O
11	Southern	O
12	blot	O
13	analysis	O
14	of	O
15	its	O
16	segregation	O
17	pattern	O
18	in	O
19	a	O
20	panel	O
21	of	O
22	rodent	O
23	-	O
24	human	O
25	hybrid	O
26	DNAs	O
27	using	O
28	the	O
29	radiolabeled	O
30	cDNA	O
31	probe	O
32	.	O

1	Bacillus	O
2	cereus	O
3	cross	O
4	-	O
5	infection	O
6	in	O
7	a	O
8	maternity	O
9	-	O
10	unit	O
11	.	O

1	Those	O
2	radiological	O
3	aspects	O
4	were	O
5	distributed	O
6	in	O
7	two	O
8	categories	O
9	:	O
10	1	O
11	)	O
12	type	O
13	I	O
14	-	O
15	presenting	O
16	variable	O
17	sinusoidal	O
18	filling	O
19	.	O

1	Surprisingly	O
2	,	O
3	calf	B
4	thymus	I
5	CstF	I
6	contained	O
7	an	O
8	additional	O
9	,	O
10	novel	O
11	form	O
12	of	O
13	the	O
14	64	O
15	-	O
16	kDa	O
17	subunit	O
18	with	O
19	a	O
20	molecular	O
21	mass	O
22	of	O
23	70	O
24	kDa	O
25	.	O

1	The	O
2	level	O
3	of	O
4	subclinical	O
5	infection	O
6	was	O
7	75	O
8	%	O
9	among	O
10	seropositive	O
11	dogs	O
12	.	O

1	These	O
2	data	O
3	are	O
4	consistent	O
5	with	O
6	a	O
7	model	O
8	in	O
9	which	O
10	GATA	B
11	-	I
12	5	I
13	performs	O
14	a	O
15	unique	O
16	temporally	O
17	and	O
18	spatially	O
19	restricted	O
20	function	O
21	in	O
22	the	O
23	embryonic	O
24	heart	O
25	and	O
26	lung	O
27	.	O

1	We	O
2	have	O
3	examined	O
4	by	O
5	in	O
6	vitro	O
7	footprinting	O
8	a	O
9	region	O
10	located	O
11	downstream	O
12	of	O
13	the	O
14	human	O
15	immunodeficiency	O
16	virus	O
17	,	O
18	type	O
19	1	O
20	(	O
21	HIV	O
22	-	O
23	1	O
24	)	O
25	promoter	O
26	found	O
27	to	O
28	be	O
29	hypersensitive	O
30	to	O
31	DNase	B
32	I	I
33	digestion	O
34	in	O
35	vivo	O
36	.	O

1	195mPt	O
2	-	O
3	labeled	O
4	cisplatin	O
5	was	O
6	administered	O
7	iv	O
8	and	O
9	ip	O
10	to	O
11	control	O
12	mice	O
13	and	O
14	to	O
15	mice	O
16	bearing	O
17	Sarcoma	O
18	180	O
19	.	O

1	Unfolding	O
2	can	O
3	be	O
4	described	O
5	by	O
6	a	O
7	two	O
8	-	O
9	state	O
10	process	O
11	since	O
12	a	O
13	ratio	O
14	of	O
15	delta	O
16	Hcalorimetric	O
17	to	O
18	delta	O
19	Hvan	O
20	'	O
21	t	O
22	Hoff	O
23	equals	O
24	0	O
25	.	O
26	96	O
27	.	O

1	JPEG	O
2	53	O
3	,	O
4	resulting	O
5	in	O
6	a	O
7	compression	O
8	ratio	O
9	of	O
10	1	O
11	:	O
12	21	O
13	,	O
14	does	O
15	not	O
16	compromise	O
17	the	O
18	diagnostic	O
19	performance	O
20	in	O
21	general	O
22	.	O

1	A	O
2	mixture	O
3	of	O
4	human	B
5	albumin	I
6	5	O
7	%	O
8	and	O
9	hydroxy	O
10	-	O
11	ethyl	O
12	-	O
13	starch	O
14	was	O
15	used	O
16	as	O
17	a	O
18	solution	O
19	for	O
20	dilution	O
21	.	O

1	Since	O
2	the	O
3	UfAP	B
4	and	O
5	UTMP	B
6	share	O
7	many	O
8	biosynthetic	O
9	and	O
10	structural	O
11	features	O
12	that	O
13	include	O
14	site	O
15	of	O
16	biosynthesis	O
17	in	O
18	the	O
19	endometrium	O
20	,	O
21	P4	O
22	-	O
23	responsiveness	O
24	,	O
25	the	O
26	presence	O
27	of	O
28	the	O
29	mannose	O
30	6	O
31	-	O
32	phosphate	O
33	lysosomal	O
34	recognition	O
35	marker	O
36	,	O
37	and	O
38	considerable	O
39	sequence	O
40	similarity	O
41	,	O
42	the	O
43	UfAP	B
44	and	O
45	the	O
46	UTMP	B
47	may	O
48	have	O
49	homologous	O
50	function	O
51	which	O
52	for	O
53	both	O
54	still	O
55	remains	O
56	obscure	O
57	.	O

1	The	O
2	intranodal	O
3	mesothelial	O
4	cells	O
5	occupied	O
6	the	O
7	sinusoids	O
8	of	O
9	the	O
10	lymph	O
11	nodes	O
12	and	O
13	were	O
14	initially	O
15	suspected	O
16	of	O
17	being	O
18	metastatic	O
19	from	O
20	the	O
21	ovarian	O
22	tumor	O
23	in	O
24	each	O
25	case	O
26	.	O

1	We	O
2	have	O
3	identified	O
4	and	O
5	characterized	O
6	a	O
7	vitamin	O
8	D	O
9	response	O
10	element	O
11	(	O
12	VDRE	O
13	)	O
14	in	O
15	the	O
16	promoter	O
17	of	O
18	c	B
19	-	I
20	fos	I
21	.	O

1	Analysis	O
2	of	O
3	cell	O
4	cycle	O
5	proteins	O
6	showed	O
7	that	O
8	24	O
9	h	O
10	of	O
11	lovastatin	O
12	treatment	O
13	in	O
14	the	O
15	control	O
16	cells	O
17	caused	O
18	an	O
19	elevation	O
20	in	O
21	the	O
22	levels	O
23	of	O
24	the	O
25	cyclin	B
26	-	I
27	dependent	I
28	kinase	I
29	inhibitor	O
30	p27	B
31	(	O
32	kip1	B
33	),	O
34	inhibition	O
35	of	O
36	both	O
37	cyclin	B
38	E	I
39	-	I
40	and	I
41	cyclin	I
42	A	I
43	-	I
44	dependent	I
45	kinase	I
46	activity	O
47	,	O
48	and	O
49	decreased	O
50	levels	O
51	of	O
52	hyperphosphorylated	O
53	retinoblastoma	B
54	protein	I
55	(	O
56	pRb	B
57	).	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	Anu2p	B
6	is	O
7	the	O
8	yeast	B
9	homologue	I
10	of	I
11	mammalian	I
12	epsilon	I
13	-	I
14	COP	I
15	and	O
16	the	O
17	abrupt	O
18	accumulation	O
19	of	O
20	the	O
21	ER	O
22	membrane	O
23	caused	O
24	by	O
25	a	O
26	blockage	O
27	of	O
28	the	O
29	early	O
30	protein	O
31	transport	O
32	pathway	O
33	leads	O
34	to	O
35	alteration	O
36	of	O
37	nuclear	O
38	morphology	O
39	of	O
40	the	O
41	budding	O
42	yeast	O
43	cells	O
44	.	O

1	Oxygen	O
2	delivery	O
3	and	O
4	consumption	O
5	and	O
6	P50	O
7	in	O
8	patients	O
9	with	O
10	acute	O
11	myocardial	O
12	infarction	O
13	.	O

1	The	O
2	RAD18	B
3	gene	I
4	open	I
5	reading	I
6	frame	I
7	encodes	O
8	a	O
9	protein	O
10	of	O
11	487	O
12	amino	O
13	acids	O
14	,	O
15	with	O
16	a	O
17	calculated	O
18	molecular	O
19	weight	O
20	of	O
21	55	O
22	,	O
23	512	O
24	.	O

1	The	O
2	hp55	B
3	gamma	I
4	protein	I
5	interacts	O
6	strongly	O
7	with	O
8	the	O
9	activated	O
10	IGFIR	B
11	but	O
12	not	O
13	with	O
14	the	O
15	kinase	O
16	-	O
17	negative	O
18	mutant	O
19	receptor	O
20	.	O
21	hp55	B
22	gamma	I
23	also	O
24	interacts	O
25	with	O
26	the	O
27	insulin	B
28	receptor	I
29	(	O
30	IR	B
31	)	O
32	in	O
33	the	O
34	yeast	O
35	two	O
36	-	O
37	hybrid	O
38	system	O
39	.	O

1	Animals	O
2	may	O
3	be	O
4	immunized	O
5	by	O
6	oral	O
7	vaccination	O
8	,	O
9	but	O
10	natural	O
11	mechanisms	O
12	that	O
13	also	O
14	can	O
15	terminate	O
16	outbreaks	O
17	are	O
18	discussed	O
19	.	O

1	However	O
2	,	O
3	expression	O
4	of	O
5	sigma	B
6	3	I
7	from	O
8	S4	B
9	(	O
10	3	B
11	'	I
12	UTR	I
13	/	I
14	S1	I
15	),	O
16	which	O
17	included	O
18	the	O
19	PKR	B
20	activator	I
21	sequence	I
22	from	O
23	S1	B
24	within	O
25	the	O
26	3	B
27	'-	I
28	UTR	I
29	of	I
30	S4	I
31	,	O
32	was	O
33	comparable	O
34	to	O
35	that	O
36	from	O
37	wild	B
38	-	I
39	type	I
40	S4	I
41	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	the	O
6	primary	O
7	visual	O
8	cortex	O
9	of	O
10	the	O
11	rat	O
12	is	O
13	asymmetrical	O
14	in	O
15	volume	O
16	,	O
17	and	O
18	that	O
19	the	O
20	asymmetry	O
21	reflects	O
22	side	O
23	differences	O
24	in	O
25	the	O
26	number	O
27	of	O
28	neurons	O
29	.	O

1	Human	B
2	AP	I
3	-	I
4	2rep	I
5	repressed	O
6	both	O
7	reporter	O
8	expression	O
9	from	O
10	a	O
11	transiently	O
12	transfected	O
13	AP	B
14	-	I
15	2alpha	I
16	promoter	I
17	and	O
18	the	O
19	endogenous	O
20	AP	B
21	-	I
22	2alpha	I
23	gene	I
24	and	O
25	inversely	O
26	was	O
27	negatively	O
28	regulated	O
29	by	O
30	AP	B
31	-	I
32	2alpha	I
33	.	O

1	After	O
2	an	O
3	initial	O
4	titration	O
5	period	O
6	and	O
7	adjustment	O
8	of	O
9	the	O
10	therapeutic	O
11	dose	O
12	,	O
13	the	O
14	individual	O
15	doses	O
16	were	O
17	from	O
18	21	O
19	to	O
20	500	O
21	micrograms	O
22	/	O
23	24	O
24	hrs	O
25	(	O
26	mean	O
27	160	O
28	micrograms	O
29	/	O
30	24	O
31	hrs	O
32	).	O

1	The	O
2	localization	O
3	of	O
4	ZAP	B
5	-	I
6	70	I
7	to	O
8	the	O
9	cell	O
10	cortex	O
11	is	O
12	,	O
13	therefore	O
14	,	O
15	regulated	O
16	by	O
17	the	O
18	activity	O
19	of	O
20	SRC	B
21	-	I
22	family	I
23	kinases	I
24	,	O
25	independently	O
26	of	O
27	their	O
28	ability	O
29	to	O
30	phosphorylate	O
31	immunoreceptor	O
32	tyrosine	O
33	-	O
34	based	O
35	activation	O
36	motifs	O
37	of	O
38	the	O
39	TCR	B
40	.	O

1	Results	O
2	of	O
3	the	O
4	long	O
5	-	O
6	term	O
7	observation	O
8	and	O
9	treatment	O
10	of	O
11	patients	O
12	with	O
13	arterial	O
14	hypertension	O

1	Activation	O
2	of	O
3	nuclear	B
4	factor	I
5	(	I
6	NF	I
7	)-	I
8	kappaB	I
9	and	O
10	subsequent	O
11	proinflammatory	O
12	gene	O
13	expression	O
14	in	O
15	human	O
16	airway	O
17	epithelial	O
18	cells	O
19	can	O
20	be	O
21	evoked	O
22	by	O
23	oxidative	O
24	stress	O
25	.	O

1	Comparisons	O
2	with	O
3	the	O
4	available	O
5	amino	O
6	acid	O
7	residue	O
8	(	O
9	aa	O
10	)	O
11	sequence	O
12	information	O
13	from	O
14	the	O
15	complete	O
16	CPMV	B
17	RNA	I
18	1	I
19	sequence	I
20	and	O
21	the	O
22	partial	O
23	sequence	O
24	of	O
25	red	B
26	clover	I
27	mottle	I
28	virus	I
29	RNA	I
30	1	I
31	suggest	O
32	that	O
33	CPSMV	B
34	RNA	I
35	1	I
36	specifies	O
37	the	O
38	expected	O
39	set	O
40	of	O
41	five	O
42	mature	O
43	proteins	O
44	:	O
45	32K	B
46	proteinase	I
47	cofactor	I
48	,	O
49	58K	B
50	presumed	I
51	helicase	I
52	,	O
53	VPg	B
54	5	I
55	'-	I
56	linked	I
57	protein	I
58	of	O
59	the	O
60	genomic	O
61	RNAs	O
62	,	O
63	24K	B
64	proteinase	I
65	,	O
66	and	O
67	87K	B
68	presumed	I
69	polymerase	I
70	,	O
71	separated	O
72	by	O
73	four	O
74	cleavage	O
75	sites	O
76	.	O

1	Peroxisome	B
2	proliferator	I
3	-	I
4	activated	I
5	receptors	I
6	(	O
7	PPAR	B
8	)	O
9	modulate	O
10	transcription	O
11	by	O
12	binding	O
13	to	O
14	specific	O
15	peroxisome	O
16	proliferator	O
17	-	O
18	response	O
19	elements	O
20	(	O
21	PPRE	O
22	)	O
23	through	O
24	heterodimerization	O
25	with	O
26	the	O
27	9	B
28	-	I
29	cis	I
30	retinoic	I
31	acid	I
32	receptor	I
33	(	O
34	RXR	B
35	).	O

1	The	O
2	molecular	O
3	weight	O
4	of	O
5	in	O
6	vivo	O
7	-	O
8	labeled	O
9	proteins	O
10	was	O
11	increased	O
12	relative	O
13	to	O
14	that	O
15	of	O
16	in	O
17	vitro	O
18	-	O
19	translated	O
20	proteins	O
21	,	O
22	indicating	O
23	that	O
24	a	O
25	posttranslational	O
26	modification	O
27	had	O
28	occurred	O
29	.	O

1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	the	O
6	rat	O
7	larynx	O
8	to	O
9	be	O
10	an	O
11	important	O
12	organ	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	irritancy	O
18	of	O
19	inhaled	O
20	materials	O
21	.	O

1	To	O
2	study	O
3	the	O
4	regulation	O
5	of	O
6	mdr2	B
7	expression	O
8	,	O
9	the	O
10	promoter	O
11	of	O
12	the	O
13	mdr2	B
14	gene	I
15	has	O
16	been	O
17	isolated	O
18	from	O
19	a	O
20	murine	O
21	vinblastine	O
22	-	O
23	resistant	O
24	cell	O
25	line	O
26	,	O
27	J7	O
28	.	O
29	V2	O
30	-	O
31	1	O
32	,	O
33	and	O
34	characterized	O
35	.	O

1	Lipiodol	O
2	was	O
3	covalently	O
4	conjugated	O
5	with	O
6	EDTB	O
7	.	O

1	Structural	O
2	organization	O
3	and	O
4	expression	O
5	of	O
6	the	O
7	mouse	B
8	estrogen	I
9	receptor	I
10	.	O

1	Induction	O
2	of	O
3	both	O
4	potential	O
5	transcripts	O
6	follows	O
7	heat	O
8	shock	O
9	in	O
10	vivo	O
11	.	O

1	Finally	O
2	,	O
3	a	O
4	complementary	O
5	footprinting	O
6	analysis	O
7	of	O
8	the	O
9	upstream	O
10	region	O
11	of	O
12	the	O
13	constitutively	O
14	expressed	O
15	HSC82	B
16	gene	I
17	reveals	O
18	the	O
19	presence	O
20	of	O
21	three	O
22	discrete	O
23	protein	O
24	complexes	O
25	.	O

1	Deaths	O
2	stopped	O
3	11	O
4	hours	O
5	after	O
6	copper	O
7	concentrations	O
8	decreased	O
9	below	O
10	0	O
11	.	O
12	2	O
13	ppm	O
14	and	O
15	signs	O
16	of	O
17	distress	O
18	stopped	O
19	in	O
20	surviving	O
21	pinfish	O
22	by	O
23	approximately	O
24	6	O
25	hours	O
26	after	O
27	the	O
28	last	O
29	death	O
30	.	O

1	The	O
2	mean	O
3	body	O
4	mass	O
5	index	O
6	(	O
7	BMI	O
8	)	O
9	was	O
10	31	O
11	.	O
12	8	O
13	+/-	O
14	6	O
15	.	O
16	3	O
17	kg	O
18	/	O
19	m2	O
20	and	O
21	28	O
22	.	O
23	5	O
24	+/-	O
25	6	O
26	.	O
27	3	O
28	kg	O
29	/	O
30	m2	O
31	in	O
32	women	O
33	and	O
34	men	O
35	,	O
36	respectively	O
37	.	O

1	Apo	B
2	A	I
3	-	I
4	I	I
5	level	O
6	was	O
7	unrelated	O
8	to	O
9	age	O
10	,	O
11	but	O
12	increased	O
13	with	O
14	ethanol	O
15	consumption	O
16	and	O
17	decreased	O
18	with	O
19	adiposity	O
20	.	O

1	By	O
2	order	O
3	of	O
4	decreasing	O
5	rate	O
6	,	O
7	finger	O
8	flexors	O
9	,	O
10	jaw	O
11	,	O
12	crossed	O
13	adductors	O
14	,	O
15	and	O
16	triceps	O
17	reflexes	O
18	were	O
19	less	O
20	frequently	O
21	elicited	O
22	in	O
23	both	O
24	groups	O
25	.	O

1	At	O
2	necropsy	O
3	28	O
4	days	O
5	post	O
6	-	O
7	inoculation	O
8	,	O
9	F344	O
10	rats	O
11	had	O
12	no	O
13	gross	O
14	lung	O
15	lesions	O
16	,	O
17	even	O
18	those	O
19	given	O
20	the	O
21	maximum	O
22	dose	O
23	of	O
24	1	O
25	.	O
26	4	O
27	X	O
28	10	O
29	(	O
30	9	O
31	)	O
32	colony	O
33	-	O
34	forming	O
35	units	O
36	of	O
37	M	O
38	.	O
39	pulmonis	O
40	.	O

1	Mean	O
2	total	O
3	lung	O
4	capacity	O
5	,	O
6	functional	O
7	residual	O
8	capacity	O
9	,	O
10	and	O
11	residual	O
12	volume	O
13	increased	O
14	significantly	O
15	,	O
16	and	O
17	the	O
18	mean	O
19	closing	O
20	volume	O
21	,	O
22	the	O
23	lung	O
24	volume	O
25	above	O
26	residual	O
27	volume	O
28	at	O
29	which	O
30	phase	O
31	IV	O
32	begins	O
33	,	O
34	decreased	O
35	significantly	O
36	with	O
37	11	O
38	cm	O
39	H20	O
40	continuous	O
41	positive	O
42	airway	O
43	pressure	O
44	;	O
45	differences	O
46	at	O
47	5	O
48	cm	O
49	H20	O
50	were	O
51	not	O
52	significant	O
53	.	O

1	Angionephroscintigraphy	O
2	in	O
3	the	O
4	diagnosis	O
5	of	O
6	diseases	O
7	of	O
8	the	O
9	kidney	O

1	A	O
2	hospital	O
3	-	O
4	based	O
5	study	O
6	of	O
7	the	O
8	relationship	O
9	between	O
10	retained	O
11	placenta	O
12	and	O
13	mastitis	O
14	in	O
15	dairy	O
16	cows	O
17	.	O

1	With	O
2	0	O
3	.	O
4	5	O
5	vol	O
6	.-%,	O
7	the	O
8	corresponding	O
9	values	O
10	were	O
11	345	O
12	mumol	O
13	/	O
14	1	O
15	(	O
16	5	O
17	.	O
18	72	O
19	mg	O
20	/	O
21	100	O
22	ml	O
23	)	O
24	and	O
25	137	O
26	mumol	O
27	/	O
28	1	O
29	(	O
30	2	O
31	.	O
32	25	O
33	mg	O
34	/	O
35	100	O
36	ml	O
37	)	O
38	respectively	O
39	.	O

1	In	O
2	the	O
3	multivariate	O
4	analysis	O
5	,	O
6	six	O
7	variables	O
8	were	O
9	independently	O
10	correlated	O
11	with	O
12	survival	O
13	:	O
14	blood	O
15	urea	O
16	nitrogen	O
17	level	O
18	,	O
19	serum	B
20	aspartate	I
21	aminotransferase	I
22	level	O
23	,	O
24	community	O
25	-	O
26	acquired	O
27	vs	O
28	.	O
29	hospital	O
30	-	O
31	acquired	O
32	peritonitis	O
33	,	O
34	age	O
35	,	O
36	Child	O
37	-	O
38	Pugh	O
39	score	O
40	and	O
41	ileus	O
42	.	O

1	PURPOSE	O
2	:	O
3	Previous	O
4	WR	O
5	-	O
6	2721	O
7	human	O
8	pharmacokinetic	O
9	studies	O
10	were	O
11	limited	O
12	to	O
13	plasma	O
14	levels	O
15	in	O
16	patients	O
17	receiving	O
18	platinum	O
19	-	O
20	based	O
21	compounds	O
22	,	O
23	and	O
24	none	O
25	includes	O
26	the	O
27	effects	O
28	of	O
29	WR	O
30	-	O
31	2721	O
32	on	O
33	endogenous	O
34	thiols	O
35	.	O

1	In	O
2	vitro	O
3	translation	O
4	and	O
5	in	O
6	vivo	O
7	polysome	O
8	profile	O
9	analysis	O
10	indicated	O
11	that	O
12	transcripts	B
13	C	I
14	and	I
15	E	I
16	were	O
17	translated	O
18	with	O
19	similar	O
20	translational	O
21	efficiencies	O
22	that	O
23	are	O
24	substantially	O
25	greater	O
26	than	O
27	that	O
28	of	O
29	transcript	B
30	D	I
31	,	O
32	suggesting	O
33	that	O
34	5	O
35	'-	O
36	untranslated	O
37	regions	O
38	play	O
39	a	O
40	role	O
41	in	O
42	translational	O
43	control	O
44	.	O

1	Roentgenographically	O
2	,	O
3	the	O
4	lesion	O
5	was	O
6	usually	O
7	a	O
8	well	O
9	-	O
10	defined	O
11	and	O
12	benign	O
13	appearing	O
14	one	O
15	,	O
16	either	O
17	purely	O
18	lytic	O
19	(	O
20	3	O
21	cases	O
22	)	O
23	or	O
24	with	O
25	central	O
26	radiodensity	O
27	(	O
28	2	O
29	cases	O
30	).	O

1	Fusion	O
2	of	O
3	ubiquitin	B
4	to	O
5	pADPRP	B
6	increased	O
7	the	O
8	yield	O
9	of	O
10	pADPRP	B
11	approximately	O
12	10	O
13	-	O
14	fold	O
15	compared	O
16	to	O
17	that	O
18	of	O
19	the	O
20	unfused	O
21	enzyme	O
22	.	O

1	In	O
2	a	O
3	second	O
4	experiment	O
5	involving	O
6	an	O
7	18	O
8	-	O
9	h	O
10	lung	O
11	clearance	O
12	assay	O
13	,	O
14	we	O
15	used	O
16	the	O
17	mAb	B
18	3	I
19	.	I
20	2	I
21	.	I
22	3	I
23	to	O
24	deplete	O
25	rats	O
26	of	O
27	LGL	O
28	/	O
29	NK	O
30	cells	O
31	with	O
32	the	O
33	following	O
34	rationale	O
35	:	O
36	if	O
37	LGL	O
38	/	O
39	NK	O
40	cells	O
41	are	O
42	necessary	O
43	to	O
44	mediate	O
45	an	O
46	event	O
47	,	O
48	then	O
49	in	O
50	their	O
51	absence	O
52	,	O
53	that	O
54	event	O
55	should	O
56	not	O
57	occur	O
58	.	O

1	When	O
2	combined	O
3	with	O
4	independent	O
5	activating	O
6	mutations	O
7	in	O
8	the	O
9	c	B
10	-	I
11	abl	I
12	kinase	I
13	domain	I
14	or	O
15	NH2	O
16	-	O
17	terminus	O
18	,	O
19	the	O
20	G128R	B
21	mutation	O
22	blocked	O
23	transformation	O
24	by	O
25	the	O
26	double	O
27	mutant	O
28	,	O
29	suggesting	O
30	that	O
31	the	O
32	G128R	B
33	mutant	I
34	was	O
35	unable	O
36	to	O
37	transform	O
38	cells	O
39	for	O
40	trivial	O
41	reasons	O
42	.	O

1	The	O
2	beta	O
3	subunit	O
4	of	O
5	the	O
6	heterotrimeric	B
7	G	I
8	proteins	I
9	that	O
10	transduce	O
11	signals	O
12	across	O
13	the	O
14	plasma	O
15	membrane	O
16	is	O
17	made	O
18	up	O
19	of	O
20	an	O
21	amino	O
22	-	O
23	terminal	O
24	alpha	O
25	-	O
26	helical	O
27	segment	O
28	followed	O
29	by	O
30	seven	O
31	repeating	O
32	units	O
33	called	O
34	WD	O
35	(	O
36	Trp	O
37	-	O
38	Asp	O
39	)	O
40	repeats	O
41	that	O
42	occur	O
43	in	O
44	about	O
45	140	O
46	different	O
47	proteins	O
48	.	O

1	D5	B
2	/	I
3	D1	I
4	(	I
5	CT	I
6	)	I
7	or	O
8	D5	B
9	/	I
10	D1D	I
11	(	I
12	CT	I
13	)	I
14	tail	O
15	substitution	O
16	mutants	O
17	displayed	O
18	a	O
19	rank	O
20	order	O
21	of	O
22	potency	O
23	and	O
24	agonist	O
25	affinities	O
26	virtually	O
27	mimicking	O
28	wild	B
29	-	I
30	type	I
31	(	I
32	wt	I
33	)	I
34	D1	I
35	receptors	I
36	,	O
37	as	O
38	indexed	O
39	by	O
40	both	O
41	ligand	O
42	binding	O
43	and	O
44	dopamine	O
45	-	O
46	stimulated	O
47	cAMP	O
48	accumulation	O
49	assays	O
50	,	O
51	and	O
52	,	O
53	similar	O
54	to	O
55	wt	O
56	D1	B
57	receptors	I
58	,	O
59	did	O
60	not	O
61	exhibit	O
62	receptor	O
63	constitutive	O
64	activity	O
65	or	O
66	responsiveness	O
67	to	O
68	inverse	O
69	agonists	O
70	.	O

1	Here	O
2	we	O
3	report	O
4	that	O
5	the	O
6	proline	O
7	-	O
8	rich	O
9	region	O
10	of	O
11	CAP	B
12	is	O
13	recognized	O
14	by	O
15	the	O
16	SH3	B
17	domains	I
18	of	O
19	several	O
20	proteins	O
21	,	O
22	including	O
23	the	O
24	yeast	B
25	actin	I
26	-	I
27	associated	I
28	protein	I
29	Abp1p	I
30	.	O

1	Most	O
2	of	O
3	the	O
4	expressed	O
5	human	B
6	E3	I
7	polypeptides	I
8	(	O
9	five	O
10	bands	O
11	)	O
12	were	O
13	found	O
14	in	O
15	the	O
16	insoluble	O
17	pellet	O
18	while	O
19	primarily	O
20	full	B
21	-	I
22	length	I
23	mature	I
24	E3	I
25	was	O
26	found	O
27	in	O
28	the	O
29	soluble	O
30	fraction	O
31	.	O

1	Comparison	O
2	with	O
3	a	O
4	recently	O
5	described	O
6	c	B
7	-	I
8	sis	I
9	cDNA	I
10	clone	I
11	(	O
12	Collins	O
13	et	O
14	al	O
15	.,	O
16	Nature	O
17	316	O
18	,	O
19	748	O
20	-	O
21	750	O
22	(	O
23	1985	O
24	))	O
25	revealed	O
26	that	O
27	the	O
28	1	O
29	.	O
30	9	O
31	kbp	O
32	DNA	O
33	region	O
34	contained	O
35	a	O
36	large	O
37	5	B
38	'	I
39	c	I
40	-	I
41	sis	I
42	exon	I
43	of	O
44	at	O
45	least	O
46	1050	O
47	bp	O
48	.	O

1	The	O
2	percentage	O
3	RFR	O
4	reduction	O
5	at	O
6	the	O
7	end	O
8	of	O
9	CPB	O
10	showed	O
11	significant	O
12	correlation	O
13	with	O
14	1	O
15	)	O
16	CPB	O
17	duration	O
18	(	O
19	r	O
20	=	O
21	0	O
22	.	O
23	49	O
24	),	O
25	2	O
26	)	O
27	oxygen	O
28	flow	O
29	rate	O
30	index	O
31	(	O
32	OFRI	O
33	),	O
34	i	O
35	.	O
36	e	O
37	.	O
38	flow	O
39	/	O
40	min	O
41	in	O
42	the	O
43	bubble	O
44	oxygenator	O
45	/	O
46	m2	O
47	bsa	O
48	(	O
49	r	O
50	=	O
51	0	O
52	.	O
53	38	O
54	),	O
55	and	O
56	3	O
57	)	O
58	blood	O
59	flow	O
60	rate	O
61	index	O
62	(	O
63	BFRI	O
64	),	O
65	i	O
66	.	O
67	e	O
68	.	O
69	average	O
70	volume	O
71	of	O
72	blood	O
73	pumped	O
74	through	O
75	the	O
76	heart	O
77	-	O
78	lung	O
79	machine	O
80	/	O
81	min	O
82	CPB	O
83	time	O
84	/	O
85	m2	O
86	bsa	O
87	(	O
88	r	O
89	=	O
90	0	O
91	.	O
92	51	O
93	).	O

1	Recent	O
2	studies	O
3	have	O
4	revealed	O
5	unconventional	O
6	myosin	B
7	V	I
8	to	O
9	be	O
10	an	O
11	important	O
12	actin	B
13	-	O
14	based	O
15	molecular	O
16	motor	O
17	involved	O
18	in	O
19	vesicular	O
20	movement	O
21	.	O

1	Furthermore	O
2	,	O
3	rhoA	B
4	-	O
5	mediated	O
6	SRE	O
7	activation	O
8	was	O
9	blocked	O
10	by	O
11	dominant	O
12	negative	O
13	mutants	O
14	of	O
15	PKC	B
16	-	I
17	alpha	I
18	or	O
19	PKC	B
20	-	I
21	epsilon	I
22	.	O

1	Eastern	O
2	Cooperative	O
3	Oncology	O
4	Group	O
5	trial	O
6	E3186	O
7	was	O
8	initiated	O
9	to	O
10	explore	O
11	this	O
12	question	O
13	.	O

1	Here	O
2	,	O
3	we	O
4	identified	O
5	three	O
6	cis	O
7	-	O
8	elements	O
9	required	O
10	for	O
11	replication	O
12	within	O
13	the	O
14	200	O
15	bp	O
16	promoter	O
17	,	O
18	using	O
19	autonomously	O
20	replicating	O
21	plasmids	O
22	carrying	O
23	various	O
24	mutations	O
25	and	O
26	deletions	O
27	.	O

1	Two	O
2	soybean	O
3	cDNA	O
4	clones	O
5	,	O
6	SPK	B
7	-	I
8	3	I
9	and	O
10	SPK	B
11	-	I
12	4	I
13	,	O
14	encoding	O
15	putative	O
16	protein	O
17	kinases	O
18	were	O
19	isolated	O
20	and	O
21	characterized	O
22	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	the	O
6	neonate	O
7	differs	O
8	from	O
9	the	O
10	adult	O
11	in	O
12	respect	O
13	of	O
14	both	O
15	the	O
16	nature	O
17	of	O
18	effects	O
19	of	O
20	the	O
21	drug	O
22	and	O
23	sensitivity	O
24	to	O
25	it	O
26	.	O

1	The	O
2	human	O
3	cDNA	O
4	clone	O
5	NFBD1	O
6	(	O
7	previously	O
8	designated	O
9	KIAA0170	O
10	)	O
11	encodes	O
12	a	O
13	novel	O
14	protein	O
15	(	O
16	2089	O
17	amino	O
18	acids	O
19	in	O
20	length	O
21	;	O
22	calculated	O
23	molecular	O
24	mass	O
25	226	O
26	,	O
27	440	O
28	D	O
29	)	O
30	with	O
31	possible	O
32	BRCT	B
33	domains	I
34	at	O
35	its	O
36	carboxy	O
37	terminus	O
38	(	O
39	amino	O
40	acid	O
41	residues	O
42	1894	O
43	-	O
44	2089	O
45	).	O

1	Haplotype	O
2	mapping	O
3	and	O
4	sequence	O
5	analysis	O
6	of	O
7	the	O
8	mouse	O
9	Nramp	B
10	gene	I
11	predict	O
12	susceptibility	O
13	to	O
14	infection	O
15	with	O
16	intracellular	O
17	parasites	O
18	.	O

1	As	O
2	a	O
3	last	O
4	resort	O
5	,	O
6	it	O
7	may	O
8	be	O
9	possible	O
10	to	O
11	maintain	O
12	a	O
13	patient	O
14	on	O
15	dialysis	O
16	in	O
17	reasonable	O
18	health	O
19	with	O
20	a	O
21	DiaTAP	O
22	button	O
23	graft	O
24	complex	O
25	infected	O
26	with	O
27	Staphylococcus	O
28	epidermidis	O
29	and	O
30	intermittent	O
31	positive	O
32	blood	O
33	cultures	O
34	using	O
35	long	O
36	term	O
37	vancomycin	O
38	therapy	O
39	.	O

1	Transduction	O
2	of	O
3	the	O
4	human	O
5	leukemic	O
6	cell	O
7	line	O
8	K562	O
9	showed	O
10	that	O
11	viral	O
12	MRP1	B
13	-	O
14	PG13	O
15	supernatants	O
16	routinely	O
17	transfer	O
18	the	O
19	MRP1	B
20	gene	I
21	to	O
22	approximately	O
23	35	O
24	%	O
25	of	O
26	target	O
27	K562	O
28	cells	O
29	,	O
30	of	O
31	which	O
32	at	O
33	least	O
34	one	O
35	third	O
36	are	O
37	capable	O
38	of	O
39	proliferating	O
40	in	O
41	the	O
42	presence	O
43	of	O
44	otherwise	O
45	toxic	O
46	concentrations	O
47	of	O
48	etoposide	O
49	.	O

1	The	O
2	ipsilateral	O
3	breast	O
4	tumor	O
5	relapse	O
6	rate	O
7	was	O
8	similar	O
9	between	O
10	the	O
11	PALP	O
12	and	O
13	MGDET	O
14	groups	O
15	.	O

1	Twenty	O
2	-	O
3	eight	O
4	were	O
5	excluded	O
6	as	O
7	gallstones	O
8	were	O
9	not	O
10	proved	O
11	:	O
12	of	O
13	the	O
14	remainder	O
15	,	O
16	21	O
17	patients	O
18	received	O
19	glucagon	B
20	and	O
21	22	O
22	placebo	O
23	.	O

1	Two	O
2	such	O
3	genes	O
4	,	O
5	designated	O
6	hsiggll150	B
7	and	O
8	hsiggll295	B
9	,	O
10	were	O
11	cloned	O
12	and	O
13	sequenced	O
14	from	O
15	genomic	O
16	DNA	O
17	.	O

1	The	O
2	identification	O
3	of	O
4	viable	O
5	myocardium	O
6	with	O
7	both	O
8	99mTc	O
9	-	O
10	tetrofosmin	O
11	and	O
12	201Tl	O
13	can	O
14	be	O
15	greatly	O
16	enhanced	O
17	to	O
18	a	O
19	similar	O
20	degree	O
21	if	O
22	the	O
23	severity	O
24	of	O
25	reduction	O
26	in	O
27	activity	O
28	within	O
29	nonreversible	O
30	defects	O
31	is	O
32	considered	O
33	.	O

1	JNK	B
2	and	O
3	p38	B
4	are	O
5	constitutively	O
6	present	O
7	in	O
8	the	O
9	nucleus	O
10	,	O
11	and	O
12	DNA	O
13	-	O
14	bound	O
15	c	B
16	-	I
17	JUN	I
18	and	O
19	ATF	B
20	-	I
21	2	I
22	are	O
23	stably	O
24	contacted	O
25	by	O
26	JNK	B
27	and	O
28	p38	B
29	,	O
30	respectively	O
31	.	O

1	Cotransfection	O
2	of	O
3	either	O
4	construct	O
5	with	O
6	plasmids	O
7	encoding	O
8	PKI	B
9	(	I
10	1	I
11	-	I
12	31	I
13	)	I
14	inhibits	O
15	cAMP	O
16	-	O
17	stimulated	O
18	but	O
19	not	O
20	basal	O
21	-	O
22	or	O
23	phorbol	O
24	ester	O
25	-	O
26	stimulated	O
27	expression	O
28	.	O

1	Hybridization	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	size	O
7	of	O
8	the	O
9	mRNA	O
10	is	O
11	about	O
12	1	O
13	.	O
14	4	O
15	kilobases	O
16	.	O

1	This	O
2	is	O
3	predicted	O
4	to	O
5	encode	O
6	a	O
7	315	O
8	-	O
9	residue	O
10	protein	O
11	containing	O
12	seven	O
13	hydrophobic	O
14	helical	O
15	regions	O
16	and	O
17	a	O
18	17	O
19	amino	O
20	acid	O
21	motif	O
22	characteristic	O
23	of	O
24	the	O
25	R7G	B
26	family	I
27	of	O
28	G	B
29	-	I
30	protein	I
31	coupled	I
32	membrane	I
33	-	I
34	bound	I
35	receptors	I
36	.	O

1	Osteocalcin	B
2	(	O
3	OC	B
4	)	O
5	is	O
6	a	O
7	matrix	B
8	calcium	I
9	-	I
10	binding	I
11	protein	I
12	expressed	O
13	in	O
14	osteoblasts	O
15	and	O
16	odontoblasts	O
17	undergoing	O
18	mineralization	O
19	.	O

1	This	O
2	scFv	O
3	was	O
4	therefore	O
5	used	O
6	as	O
7	control	O
8	in	O
9	experiments	O
10	where	O
11	another	O
12	anti	B
13	-	I
14	Ras	I
15	scFv	I
16	(	O
17	Y259	B
18	scFv	I
19	,	O
20	derived	O
21	from	O
22	the	O
23	neutralizing	O
24	anti	B
25	-	I
26	Ras	I
27	mAb	I
28	Y13	I
29	-	I
30	259	I
31	)	O
32	blocked	O
33	the	O
34	Ras	B
35	pathway	O
36	in	O
37	vitro	O
38	and	O
39	led	O
40	to	O
41	tumor	O
42	regression	O
43	in	O
44	a	O
45	nude	O
46	mouse	O
47	model	O
48	[	O
49	Cochet	O
50	,	O
51	O	O
52	.,	O
53	Kenigsberg	O
54	,	O
55	M	O
56	.,	O
57	Delumeau	O
58	,	O
59	I	O
60	.,	O
61	Virone	O
62	-	O
63	Oddos	O
64	,	O
65	A	O
66	.,	O
67	Multon	O
68	,	O
69	M	O
70	.	O
71	C	O
72	.,	O
73	Fridman	O
74	,	O
75	W	O
76	.	O
77	H	O
78	.,	O
79	Schweighoffer	O
80	,	O
81	F	O
82	.,	O
83	Teillaud	O
84	,	O
85	J	O
86	.	O
87	L	O
88	.,	O
89	Tocque	O
90	,	O
91	B	O
92	.,	O
93	1998	O
94	.	O

1	BACKGROUND	O
2	:	O
3	Measurement	O
4	of	O
5	stereoacuity	O
6	at	O
7	varying	O
8	distances	O
9	,	O
10	by	O
11	real	O
12	or	O
13	simulated	O
14	depth	O
15	stereoacuity	O
16	tests	O
17	,	O
18	is	O
19	helpful	O
20	in	O
21	the	O
22	evaluation	O
23	of	O
24	patients	O
25	with	O
26	binocular	O
27	imbalance	O
28	or	O
29	strabismus	O
30	.	O

1	An	O
2	apparent	O
3	N	O
4	-	O
5	terminal	O
6	transit	O
7	peptide	O
8	in	O
9	the	O
10	coding	O
11	region	O
12	and	O
13	a	O
14	3	O
15	'	O
16	poly	O
17	(	O
18	A	O
19	)	O
20	tail	O
21	exist	O
22	in	O
23	the	O
24	cDNA	O
25	clone	O
26	indicated	O
27	that	O
28	this	O
29	chloroplast	O
30	protein	O
31	as	O
32	nuclear	O
33	encoded	O
34	.	O

1	99mTc	O
2	phytate	O
3	,	O
4	198Au	O
5	colloid	O
6	,	O
7	and	O
8	99mTc	O
9	antimony	O
10	sulfide	O
11	have	O
12	been	O
13	used	O
14	;	O
15	the	O
16	last	O
17	appears	O
18	to	O
19	have	O
20	been	O
21	the	O
22	most	O
23	satisfactory	O
24	.	O

1	Isoform	B
2	C	I
3	beta	I
4	2	I
5	,	O
6	an	O
7	unusual	O
8	form	O
9	of	O
10	the	O
11	bovine	O
12	catalytic	O
13	subunit	O
14	of	O
15	cAMP	B
16	-	I
17	dependent	I
18	protein	I
19	kinase	I
20	.	O

1	We	O
2	also	O
3	show	O
4	by	O
5	immunogold	O
6	electron	O
7	microscopy	O
8	immunocytochemistry	O
9	that	O
10	amphiphysin	B
11	I	I
12	is	O
13	localized	O
14	in	O
15	the	O
16	nerve	O
17	terminal	O
18	cytomatrix	O
19	and	O
20	is	O
21	partially	O
22	associated	O
23	with	O
24	endocytic	O
25	intermediates	O
26	.	O

1	Cytological	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	transgenes	O
7	associate	O
8	with	O
9	a	O
10	nucleolus	O
11	.	O

1	Tissue	O
2	necrosis	O
3	was	O
4	evaluated	O
5	using	O
6	triphenyltetrazolium	O
7	staining	O
8	and	O
9	was	O
10	related	O
11	to	O
12	two	O
13	major	O
14	baseline	O
15	predictors	O
16	of	O
17	infarct	O
18	size	O
19	:	O
20	anatomic	O
21	risk	O
22	zone	O
23	size	O
24	and	O
25	coronary	O
26	collateral	O
27	flow	O
28	.	O

1	Sodium	O
2	-	O
3	taurocholate	O
4	-	O
5	induced	O
6	acute	O
7	necrotizing	O
8	pancreatitis	O
9	does	O
10	not	O
11	affect	O
12	jejunal	O
13	oxygenation	O
14	in	O
15	pigs	O
16	.	O

1	NF	B
2	-	I
3	kappa	I
4	B	I
5	p65	I
6	,	O
7	p50	B
8	,	O
9	and	O
10	Rel	B
11	functionally	O
12	synergize	O
13	with	O
14	C	B
15	/	I
16	EBP	I
17	alpha	I
18	,	O
19	C	B
20	/	I
21	EBP	I
22	beta	I
23	,	O
24	and	O
25	C	B
26	/	I
27	EBP	I
28	delta	I
29	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	protein	B
6	-	I
7	tyrosine	I
8	kinase	I
9	domain	I
10	,	O
11	p56lck	B
12	possesses	O
13	Src	B
14	homology	I
15	2	I
16	and	I
17	3	I
18	(	O
19	SH2	B
20	and	O
21	SH3	B
22	)	O
23	domains	O
24	as	O
25	well	O
26	as	O
27	a	O
28	unique	O
29	N	O
30	-	O
31	terminal	O
32	region	O
33	.	O

1	In	O
2	human	O
3	proliferative	O
4	cells	O
5	,	O
6	the	O
7	NADP	O
8	-	O
9	dependent	O
10	ME	B
11	activity	O
12	is	O
13	poorly	O
14	expressed	O
15	and	O
16	barely	O
17	inducible	O
18	by	O
19	thyroid	O
20	hormones	O
21	.	O

1	Calibration	O
2	and	O
3	a	O
4	correction	O
5	of	O
6	blood	O
7	O2	O
8	content	O
9	measured	O
10	by	O
11	Po2	O
12	and	O
13	CO	O
14	saturation	O
15	.	O

1	Rev	B
2	-	O
3	erbAalpha	B
4	/	I
5	beta	I
6	),	O
7	Mxi	B
8	-	I
9	1	I
10	and	O
11	Mad	B
12	bHLH	O
13	-	O
14	zip	O
15	proteins	O
16	and	O
17	the	O
18	oncoproteins	O
19	PLZF	B
20	and	O
21	LAZ3	B
22	/	O
23	BCL6	B
24	is	O
25	mediated	O
26	by	O
27	the	O
28	corepressors	O
29	N	B
30	-	I
31	CoR	I
32	and	O
33	SMRT	B
34	.	O

1	A	O
2	great	O
3	deal	O
4	of	O
5	information	O
6	is	O
7	available	O
8	on	O
9	the	O
10	morphology	O
11	of	O
12	the	O
13	claustrum	O
14	in	O
15	various	O
16	animal	O
17	species	O
18	,	O
19	as	O
20	well	O
21	as	O
22	on	O
23	its	O
24	neuronal	O
25	distribution	O
26	and	O
27	relationships	O
28	with	O
29	the	O
30	cerebral	O
31	cortex	O
32	and	O
33	other	O
34	nuclei	O
35	.	O

1	356	O
2	,	O
3	93	O
4	-	O
5	98	O
6	].	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	cis	O
7	-	O
8	regulatory	O
9	elements	O
10	required	O
11	for	O
12	developmental	O
13	control	O
14	of	O
15	the	O
16	HaG3	B
17	-	I
18	A	I
19	helianthinin	I
20	gene	I
21	are	O
22	located	O
23	in	O
24	a	O
25	2	O
26	.	O
27	4	O
28	kb	O
29	upstream	O
30	region	O
31	of	O
32	this	O
33	gene	O
34	.	O

1	Nuclear	B
2	protein	I
3	phosphatase	I
4	2A	I
5	dephosphorylates	O
6	protein	B
7	kinase	I
8	A	I
9	-	O
10	phosphorylated	O
11	CREB	B
12	and	O
13	regulates	O
14	CREB	B
15	transcriptional	O
16	stimulation	O
17	.	O

1	The	O
2	current	O
3	study	O
4	demonstrates	O
5	that	O
6	T3	O
7	-	O
8	activated	O
9	transcription	O
10	of	O
11	the	O
12	NADPH	B
13	:	I
14	cytochrome	I
15	P450	I
16	oxidoreductase	I
17	(	O
18	P450R	B
19	)	O
20	gene	O
21	is	O
22	dependent	O
23	on	O
24	the	O
25	thyroid	O
26	hormonal	O
27	status	O
28	of	O
29	the	O
30	animal	O
31	,	O
32	with	O
33	both	O
34	transcriptional	O
35	and	O
36	post	O
37	-	O
38	transcriptional	O
39	pathways	O
40	being	O
41	important	O
42	in	O
43	regulating	O
44	the	O
45	cellular	O
46	P450R	B
47	mRNA	O
48	level	O
49	.	O

1	To	O
2	further	O
3	investigate	O
4	the	O
5	nature	O
6	of	O
7	the	O
8	site	O
9	specificity	O
10	a	O
11	set	O
12	of	O
13	deletion	O
14	mutants	O
15	of	O
16	the	O
17	160	O
18	bp	O
19	sequence	O
20	were	O
21	analysed	O
22	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	examined	O
6	hepatic	O
7	stellate	O
8	cell	O
9	regulation	O
10	of	O
11	M6P	B
12	/	O
13	IGFIIR	B
14	expression	O
15	and	O
16	found	O
17	that	O
18	M6P	B
19	/	O
20	IGFIIR	B
21	mRNA	O
22	transcript	O
23	levels	O
24	increased	O
25	in	O
26	stellate	O
27	cells	O
28	from	O
29	rats	O
30	exposed	O
31	to	O
32	carbon	O
33	tetrachloride	O
34	(	O
35	CCl4	O
36	),	O
37	a	O
38	potent	O
39	fibrogenic	O
40	stimulant	O
41	.	O

1	The	O
2	human	B
3	eps15	I
4	gene	I
5	,	O
6	encoding	O
7	a	O
8	tyrosine	B
9	kinase	I
10	substrate	O
11	,	O
12	is	O
13	conserved	O
14	in	O
15	evolution	O
16	and	O
17	maps	O
18	to	O
19	1p31	O
20	-	O
21	p32	O
22	.	O

1	Evaluation	O
2	of	O
3	desmopressin	O
4	for	O
5	dental	O
6	extractions	O
7	in	O
8	patients	O
9	with	O
10	hemostatic	O
11	disorders	O
12	.	O

1	New	O
2	Langevin	O
3	equations	O
4	for	O
5	a	O
6	translating	O
7	and	O
8	simultaneously	O
9	rotating	O
10	asymmetric	O
11	top	O
12	.	O

1	This	O
2	association	O
3	was	O
4	independently	O
5	significant	O
6	for	O
7	patients	O
8	treated	O
9	primarily	O
10	(	O
11	not	O
12	for	O
13	recurrence	O
14	).	O

1	Alternative	O
2	splicing	O
3	of	O
4	fibroblast	B
5	growth	I
6	factor	I
7	receptor	I
8	2	I
9	(	O
10	FGF	B
11	-	I
12	R2	I
13	)	O
14	is	O
15	an	O
16	example	O
17	of	O
18	highly	O
19	regulated	O
20	alternative	O
21	splicing	O
22	in	O
23	which	O
24	exons	O
25	IIIb	O
26	and	O
27	IIIc	O
28	are	O
29	utilized	O
30	in	O
31	a	O
32	mutually	O
33	exclusive	O
34	manner	O
35	in	O
36	different	O
37	cell	O
38	types	O
39	.	O

1	We	O
2	thus	O
3	conclude	O
4	that	O
5	the	O
6	NFAT	B
7	RIR	I
8	plays	O
9	an	O
10	essential	O
11	dual	O
12	role	O
13	in	O
14	DNA	O
15	recognition	O
16	and	O
17	cooperative	O
18	binding	O
19	to	O
20	AP	B
21	-	I
22	1	I
23	family	I
24	transcription	I
25	factors	I
26	.	O

1	A	O
2	rather	O
3	similar	O
4	pattern	O
5	of	O
6	results	O
7	was	O
8	obtained	O
9	with	O
10	respect	O
11	to	O
12	LMP2B	B
13	mRNA	I
14	expression	O
15	,	O
16	such	O
17	transcripts	O
18	being	O
19	detectable	O
20	only	O
21	in	O
22	a	O
23	subset	O
24	of	O
25	tumors	O
26	,	O
27	and	O
28	then	O
29	at	O
30	apparently	O
31	low	O
32	levels	O
33	.	O

1	In	O
2	the	O
3	IA	O
4	task	O
5	,	O
6	post	O
7	-	O
8	training	O
9	intraperitoneal	O
10	injections	O
11	of	O
12	picrotoxin	O
13	and	O
14	bicuculline	O
15	induced	O
16	a	O
17	dose	O
18	-	O
19	dependent	O
20	enhancement	O
21	of	O
22	retention	O
23	measured	O
24	24	O
25	h	O
26	after	O
27	the	O
28	training	O
29	,	O
30	while	O
31	retention	O
32	was	O
33	not	O
34	affected	O
35	by	O
36	bicuculline	O
37	methiodide	O
38	(	O
39	a	O
40	GABA	B
41	receptor	I
42	antagonist	O
43	that	O
44	does	O
45	not	O
46	readily	O
47	cross	O
48	the	O
49	blood	O
50	-	O
51	brain	O
52	barrier	O
53	).	O

1	These	O
2	results	O
3	suggested	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	fetus	O
9	played	O
10	some	O
11	role	O
12	in	O
13	the	O
14	production	O
15	of	O
16	E3	O
17	-	O
18	16	O
19	-	O
20	G	O
21	in	O
22	early	O
23	pregnancy	O
24	.	O

1	Immunoreactive	O
2	AR	B
3	content	O
4	in	O
5	transfected	O
6	COS	O
7	-	O
8	1	O
9	cells	O
10	was	O
11	not	O
12	influenced	O
13	by	O
14	exposure	O
15	to	O
16	8	O
17	-	O
18	Br	O
19	-	O
20	cAMP	O
21	.	O

1	We	O
2	also	O
3	present	O
4	evidence	O
5	for	O
6	a	O
7	negative	O
8	regulatory	O
9	element	O
10	in	O
11	the	O
12	5	O
13	'	O
14	flanking	O
15	region	O
16	of	O
17	the	O
18	Mlu	B
19	I	I
20	upstream	I
21	activation	I
22	sequence	I
23	.	O

1	Processivity	O
2	of	O
3	DNA	O
4	synthesis	O
5	by	O
6	the	O
7	mutant	O
8	holoenzyme	O
9	containing	O
10	pcna	B
11	-	I
12	79	I
13	was	O
14	unaffected	O
15	on	O
16	poly	O
17	(	O
18	dA	O
19	)	O
20	x	O
21	oligo	O
22	(	O
23	dT	O
24	)	O
25	but	O
26	was	O
27	dramatically	O
28	reduced	O
29	on	O
30	a	O
31	natural	O
32	template	O
33	with	O
34	secondary	O
35	structure	O
36	.	O

1	In	O
2	macrophages	O
3	,	O
4	LPS	O
5	-	O
6	inducible	O
7	HIV	O
8	-	O
9	1	O
10	gene	O
11	expression	O
12	is	O
13	mediated	O
14	in	O
15	part	O
16	by	O
17	binding	O
18	of	O
19	NF	B
20	-	I
21	kappa	I
22	B	I
23	to	O
24	identical	O
25	tandem	O
26	binding	O
27	sites	O
28	located	O
29	within	O
30	the	O
31	long	O
32	terminal	O
33	repeat	O
34	(	O
35	LTR	O
36	).	O

1	This	O
2	5	O
3	'	O
4	splice	O
5	site	O
6	sequence	O
7	was	O
8	required	O
9	for	O
10	enhanced	O
11	polyadenylation	O
12	and	O
13	was	O
14	recognized	O
15	by	O
16	both	O
17	U1	B
18	small	I
19	nuclear	I
20	ribonucleoproteins	I
21	(	O
22	snRNPs	O
23	)	O
24	and	O
25	alternative	B
26	splicing	I
27	factor	I
28	/	O
29	splicing	B
30	factor	I
31	2	I
32	(	O
33	ASF	B
34	/	O
35	SF2	B
36	).	O

1	Behavior	O
2	of	O
3	aspartate	B
4	aminotransferase	I
5	(	O
6	EC	B
7	2	I
8	.	I
9	6	I
10	.	I
11	1	I
12	.	I
13	1	I
14	)	O
15	and	O
16	alanine	B
17	aminotransferase	I
18	(	O
19	EC	B
20	2	I
21	.	I
22	6	I
23	.	I
24	1	I
25	.	I
26	2	I
27	)	O
28	in	O
29	rat	O
30	serum	O
31	during	O
32	the	O
33	course	O
34	of	O
35	acute	O
36	radiation	O
37	syndrome	O
38	following	O
39	whole	O
40	body	O
41	X	O
42	-	O
43	irradiation	O

1	The	O
2	relative	O
3	risk	O
4	of	O
5	graft	O
6	loss	O
7	after	O
8	conversion	O
9	to	O
10	azathioprine	O
11	compared	O
12	with	O
13	graft	O
14	loss	O
15	after	O
16	conversion	O
17	to	O
18	azathioprine	O
19	compared	O
20	with	O
21	cyclosporin	O
22	maintenance	O
23	was	O
24	0	O
25	.	O
26	71	O
27	(	O
28	0	O
29	.	O
30	37	O
31	-	O
32	1	O
33	.	O
34	38	O
35	)	O
36	and	O
37	the	O
38	relative	O
39	risk	O
40	of	O
41	patient	O
42	death	O
43	was	O
44	0	O
45	.	O
46	57	O
47	(	O
48	0	O
49	.	O
50	23	O
51	-	O
52	1	O
53	.	O
54	41	O
55	).	O

1	The	O
2	mRNA	O
3	was	O
4	converted	O
5	to	O
6	cDNA	O
7	and	O
8	amplified	O
9	by	O
10	the	O
11	polymerase	O
12	chain	O
13	reaction	O
14	technique	O
15	.	O

1	Furthermore	O
2	,	O
3	beta	B
4	2	I
5	-	I
6	adrenoceptor	I
7	sensitivity	O
8	appears	O
9	to	O
10	be	O
11	unaltered	O
12	in	O
13	BHT	O
14	.	O

1	In	O
2	the	O
3	10	O
4	patients	O
5	with	O
6	a	O
7	more	O
8	severe	O
9	degree	O
10	of	O
11	steatorrhea	O
12	the	O
13	decrease	O
14	in	O
15	fat	O
16	loss	O
17	approached	O
18	20	O
19	%	O
20	and	O
21	a	O
22	close	O
23	relationship	O
24	was	O
25	found	O
26	(	O
27	r	O
28	=	O
29	0	O
30	.	O
31	84	O
32	,	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	01	O
39	)	O
40	between	O
41	the	O
42	extent	O
43	of	O
44	the	O
45	fatty	O
46	acid	O
47	loss	O
48	on	O
49	placebo	O
50	and	O
51	the	O
52	decrease	O
53	of	O
54	this	O
55	loss	O
56	on	O
57	taurine	O
58	.	O

1	Polysome	O
2	analysis	O
3	further	O
4	indicated	O
5	that	O
6	these	O
7	germ	B
8	cell	I
9	-	I
10	specific	I
11	Sp1	I
12	mRNAs	I
13	are	O
14	translated	O
15	,	O
16	albeit	O
17	with	O
18	a	O
19	lower	O
20	efficiency	O
21	than	O
22	the	O
23	somatic	O
24	transcript	O
25	.	O

1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O

1	Pharmacoeconomic	O
2	assessment	O
3	of	O
4	HMG	B
5	-	I
6	CoA	I
7	reductase	I
8	inhibitor	O
9	therapy	O
10	:	O
11	an	O
12	analysis	O
13	based	O
14	on	O
15	the	O
16	CURVES	O
17	study	O
18	.	O

1	OBJECTIVE	O
2	:	O
3	Our	O
4	goal	O
5	was	O
6	to	O
7	determine	O
8	whether	O
9	chlamydia	O
10	-	O
11	infected	O
12	women	O
13	have	O
14	a	O
15	higher	O
16	rate	O
17	of	O
18	febrile	O
19	complications	O
20	after	O
21	postpartum	O
22	tubal	O
23	ligation	O
24	.	O

1	It	O
2	thus	O
3	appears	O
4	that	O
5	MAPK	B
6	functions	O
7	in	O
8	meiotic	O
9	maturation	O
10	by	O
11	preventing	O
12	unfertilized	O
13	eggs	O
14	from	O
15	proceeding	O
16	into	O
17	parthenogenetic	O
18	development	O
19	.	O

1	They	O
2	suggest	O
3	that	O
4	decreased	O
5	steady	O
6	-	O
7	state	O
8	levels	O
9	of	O
10	IME1	B
11	and	O
12	IME2	B
13	mRNA	I
14	were	O
15	not	O
16	merely	O
17	the	O
18	result	O
19	of	O
20	non	O
21	-	O
22	specific	O
23	adverse	O
24	affects	O
25	on	O
26	nucleic	O
27	acid	O
28	metabolism	O
29	caused	O
30	by	O
31	the	O
32	yvh1	B
33	disruption	O
34	.	O

1	In	O
2	study	O
3	2	O
4	,	O
5	the	O
6	correlation	O
7	coefficients	O
8	between	O
9	the	O
10	ISO2	O
11	measurements	O
12	obtained	O
13	at	O
14	the	O
15	ulcer	O
16	margin	O
17	and	O
18	at	O
19	the	O
20	adjacent	O
21	normal	O
22	mucosa	O
23	,	O
24	and	O
25	delta	O
26	ISO2	O
27	obtained	O
28	by	O
29	the	O
30	experienced	O
31	observer	O
32	and	O
33	one	O
34	of	O
35	the	O
36	three	O
37	learners	O
38	were	O
39	0	O
40	.	O
41	94	O
42	,	O
43	0	O
44	.	O
45	97	O
46	,	O
47	and	O
48	0	O
49	.	O
50	94	O
51	,	O
52	respectively	O
53	.	O

1	Activities	O
2	of	O
3	hepatic	O
4	cytochrome	B
5	P	I
6	-	I
7	450	I
8	-	O
9	dependent	O
10	metabolizing	O
11	enzymes	O
12	such	O
13	as	O
14	aminopyrine	B
15	-	I
16	and	I
17	TMO	I
18	N	I
19	-	I
20	demethylase	I
21	and	O
22	aniline	B
23	hydroxylase	I
24	activity	O
25	were	O
26	decreased	O
27	by	O
28	pretreatment	O
29	of	O
30	rats	O
31	with	O
32	cimetidine	O
33	,	O
34	whereas	O
35	in	O
36	the	O
37	rats	O
38	pretreated	O
39	with	O
40	ranitidine	O
41	,	O
42	these	O
43	enzyme	O
44	activities	O
45	were	O
46	not	O
47	changed	O
48	.	O

1	Sterile	O
2	mutants	O
3	of	O
4	Saccharomyces	O
5	cerevisiae	O
6	were	O
7	isolated	O
8	from	O
9	alpha	O
10	*	O
11	cells	O
12	having	O
13	the	O
14	a	B
15	/	I
16	alpha	I
17	aar1	I
18	-	I
19	6	I
20	genotype	O
21	(	O
22	exhibiting	O
23	alpha	O
24	mating	O
25	ability	O
26	and	O
27	weak	O
28	a	O
29	mating	O
30	ability	O
31	as	O
32	a	O
33	result	O
34	of	O
35	a	O
36	defect	O
37	in	O
38	a1	B
39	-	I
40	alpha	I
41	2	I
42	repression	O
43	).	O

1	The	O
2	DHEAS	O
3	levels	O
4	in	O
5	all	O
6	stages	O
7	of	O
8	decreased	O
9	BMD	O
10	were	O
11	significantly	O
12	lower	O
13	than	O
14	those	O
15	in	O
16	the	O
17	group	O
18	with	O
19	normal	O
20	BMD	O
21	.	O

1	The	O
2	position	O
3	,	O
4	transcription	O
5	orientation	O
6	,	O
7	and	O
8	imprinted	O
9	status	O
10	of	O
11	the	O
12	genes	O
13	immediately	O
14	flanking	O
15	Igf2r	B
16	have	O
17	been	O
18	assessed	O
19	.	O

1	A	O
2	transgenic	O
3	complementation	O
4	assay	O
5	was	O
6	used	O
7	to	O
8	test	O
9	whether	O
10	NIa	B
11	supplied	O
12	in	O
13	trans	O
14	could	O
15	rescue	O
16	amplification	O
17	-	O
18	defective	O
19	viral	O
20	genomes	O
21	encoding	O
22	altered	O
23	NIa	B
24	proteins	I
25	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	MTD	O
5	for	O
6	CPT	O
7	-	O
8	11	O
9	administered	O
10	in	O
11	a	O
12	3	O
13	consecutive	O
14	-	O
15	days	O
16	-	O
17	every	O
18	-	O
19	3	O
20	weeks	O
21	schedule	O
22	in	O
23	this	O
24	patient	O
25	population	O
26	is	O
27	115	O
28	mg	O
29	/	O
30	m2	O
31	/	O
32	day	O
33	.	O

1	For	O
2	this	O
3	reason	O
4	,	O
5	the	O
6	particle	O
7	forming	O
8	capacity	O
9	of	O
10	derivatives	O
11	of	O
12	the	O
13	HIV	B
14	-	I
15	1	I
16	group	I
17	specific	I
18	core	I
19	antigen	I
20	p55	I
21	gag	I
22	was	O
23	assayed	O
24	and	O
25	compared	O
26	dependent	O
27	on	O
28	various	O
29	expression	O
30	systems	O
31	:	O
32	recombinant	O
33	bacteria	O
34	,	O
35	vaccinia	O
36	-	O
37	and	O
38	baculoviruses	O
39	were	O
40	established	O
41	encoding	O
42	the	O
43	entire	O
44	core	B
45	protein	I
46	p55	I
47	either	O
48	in	O
49	its	O
50	authentic	O
51	sequence	O
52	or	O
53	lacking	O
54	the	O
55	myristylation	O
56	consensus	O
57	signal	O
58	.	O

1	A	O
2	unique	O
3	leucine	O
4	-	O
5	proline	O
6	repeat	O
7	element	O
8	found	O
9	N	O
10	-	O
11	terminal	O
12	to	O
13	the	O
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	of	O
19	EmBP	B
20	-	I
21	1	I
22	does	O
23	not	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	DNA	O
31	-	O
32	binding	O
33	or	O
34	dimerization	O
35	.	O

1	These	O
2	synergistic	O
3	effects	O
4	were	O
5	strongly	O
6	Jem	B
7	-	I
8	1	I
9	dose	O
10	-	O
11	dependent	O
12	.	O

1	The	O
2	loss	O
3	of	O
4	avirulence	O
5	activity	O
6	because	O
7	of	O
8	mutations	O
9	in	O
10	the	O
11	acidic	O
12	transcriptional	O
13	activation	O
14	domain	O
15	was	O
16	restored	O
17	by	O
18	addition	O
19	of	O
20	the	O
21	activation	O
22	domain	O
23	from	O
24	the	O
25	herpes	B
26	simplex	I
27	viral	I
28	protein	I
29	VP16	I
30	.	O

1	The	O
2	-	O
3	64	O
4	/-	O
5	37	O
6	region	O
7	interacted	O
8	with	O
9	purified	O
10	Sp1	B
11	and	O
12	an	O
13	unidentified	O
14	protein	O
15	(	O
16	s	O
17	),	O
18	proximal	B
19	regulatory	I
20	factor	I
21	(	I
22	s	I
23	)	I
24	I	I
25	(	O
26	PRF	B
27	-	I
28	I	I
29	).	O

1	Five	O
2	of	O
3	the	O
4	PDP1	B
5	isoforms	I
6	differ	O
7	by	O
8	the	O
9	substitution	O
10	or	O
11	insertion	O
12	of	O
13	amino	O
14	acids	O
15	at	O
16	or	O
17	near	O
18	the	O
19	N	O
20	-	O
21	terminal	O
22	of	O
23	the	O
24	protein	O
25	.	O

1	It	O
2	may	O
3	be	O
4	dependent	O
5	on	O
6	location	O
7	of	O
8	a	O
9	focus	O
10	(	O
11	according	O
12	to	O
13	EEG	O
14	)	O
15	as	O
16	well	O
17	as	O
18	on	O
19	the	O
20	character	O
21	and	O
22	manifestation	O
23	of	O
24	the	O
25	accompanying	O
26	neuropsychologic	O
27	symptomatology	O
28	.	O

1	In	O
2	reconstitution	O
3	experiments	O
4	,	O
5	we	O
6	first	O
7	showed	O
8	that	O
9	expression	O
10	in	O
11	the	O
12	RAW	O
13	264	O
14	.	O
15	7	O
16	cell	O
17	line	O
18	of	O
19	C	B
20	-	I
21	terminal	I
22	Src	I
23	kinase	I
24	(	O
25	Csk	B
26	)	O
27	inhibited	O
28	and	O
29	that	O
30	of	O
31	a	O
32	membrane	O
33	-	O
34	anchored	O
35	,	O
36	gain	O
37	-	O
38	of	O
39	-	O
40	function	O
41	Csk	B
42	abolished	O
43	the	O
44	Fc	B
45	gamma	I
46	R	I
47	-	O
48	mediated	O
49	signaling	O
50	that	O
51	leads	O
52	to	O
53	phagocytosis	O
54	in	O
55	a	O
56	kinase	O
57	-	O
58	dependent	O
59	manner	O
60	.	O

1	A	O
2	striking	O
3	feature	O
4	of	O
5	the	O
6	recombinant	B
7	H19	I
8	allele	I
9	is	O
10	the	O
11	occurrence	O
12	of	O
13	a	O
14	parental	O
15	imprint	O
16	set	O
17	on	O
18	the	O
19	neo	B
20	replacement	I
21	cassette	I
22	.	O

1	272	O
2	,	O
3	19107	O
4	-	O
5	19110	O
6	).	O

1	Therefore	O
2	the	O
3	procedure	O
4	of	O
5	Lich	O
6	-	O
7	Gregoir	O
8	is	O
9	not	O
10	to	O
11	be	O
12	recommended	O
13	in	O
14	adults	O
15	.	O

1	Cowpox	O
2	virus	O
3	contains	O
4	two	O
5	copies	O
6	of	O
7	an	O
8	early	B
9	gene	I
10	encoding	O
11	a	O
12	soluble	O
13	secreted	O
14	form	O
15	of	O
16	the	O
17	type	B
18	II	I
19	TNF	I
20	receptor	I
21	.	O

1	Haemodilution	O
2	in	O
3	cardiopulmonary	O
4	bypass	O
5	using	O
6	a	O
7	gelatine	O
8	derivative	O
9	for	O
10	priming	O
11	.	O

1	More	O
2	mRNA	O
3	corresponding	O
4	to	O
5	nagB	B
6	and	O
7	nagA	B
8	is	O
9	detected	O
10	than	O
11	that	O
12	corresponding	O
13	to	O
14	the	O
15	distal	O
16	genes	O
17	,	O
18	nagC	B
19	and	O
20	nagD	B
21	.	O

1	Five	O
2	healthy	O
3	male	O
4	subjects	O
5	inspired	O
6	air	O
7	for	O
8	20	O
9	min	O
10	and	O
11	then	O
12	5	O
13	%	O
14	CO2	O
15	/	O
16	95	O
17	%	O
18	O2	O
19	for	O
20	30	O
21	min	O
22	,	O
23	of	O
24	which	O
25	the	O
26	first	O
27	10	O
28	min	O
29	was	O
30	used	O
31	to	O
32	achieve	O
33	a	O
34	steady	O
35	-	O
36	state	O
37	end	O
38	-	O
39	tidal	O
40	CO2	O
41	measurement	O
42	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	the	O
6	general	O
7	clinical	O
8	criteria	O
9	for	O
10	inhalation	O
11	injury	O
12	--	O
13	presence	O
14	of	O
15	facial	O
16	or	O
17	oropharyngeal	O
18	burns	O
19	,	O
20	carboxyhemoglobin	B
21	levels	O
22	,	O
23	carbonaceous	O
24	sputum	O
25	,	O
26	or	O
27	closed	O
28	space	O
29	injury	O
30	--	O
31	did	O
32	not	O
33	differentiate	O
34	patients	O
35	with	O
36	airway	O
37	injury	O
38	only	O
39	from	O
40	those	O
41	with	O
42	parenchymal	O
43	injury	O
44	.	O

1	INTERVENTIONS	O
2	:	O
3	Patients	O
4	received	O
5	rt	B
6	-	I
7	PA	I
8	,	O
9	heparin	O
10	,	O
11	and	O
12	aspirin	O
13	.	O

1	Demonstration	O
2	of	O
3	tissue	O
4	lesions	O
5	after	O
6	intramuscular	O
7	injection	O
8	by	O
9	determination	O
10	of	O
11	creatine	B
12	kinase	I
13	in	O
14	blood	O

1	Furthermore	O
2	,	O
3	interactions	O
4	were	O
5	identified	O
6	between	O
7	endogenous	B
8	E	I
9	-	I
10	cadherin	I
11	and	O
12	the	O
13	chimera	O
14	containing	O
15	the	O
16	E	B
17	-	I
18	cadherin	I
19	extracellular	I
20	domain	I
21	and	O
22	the	O
23	desmoglein	B
24	1	I
25	intracellular	I
26	domain	I
27	providing	O
28	in	O
29	vivo	O
30	evidence	O
31	for	O
32	previously	O
33	predicted	O
34	lateral	O
35	interactions	O
36	of	O
37	E	B
38	-	I
39	cadherin	I
40	extracellular	I
41	domains	I
42	.	O

1	We	O
2	also	O
3	report	O
4	here	O
5	the	O
6	complete	O
7	structural	O
8	organization	O
9	of	O
10	the	O
11	goat	B
12	alpha	I
13	s1	I
14	-	I
15	casein	I
16	transcription	I
17	unit	I
18	,	O
19	deduced	O
20	from	O
21	polymerase	O
22	chain	O
23	reaction	O
24	experiments	O
25	.	O

1	MRI	O
2	disclosed	O
3	one	O
4	or	O
5	more	O
6	of	O
7	the	O
8	following	O
9	abnormalities	O
10	in	O
11	24	O
12	(	O
13	63	O
14	%)	O
15	of	O
16	38	O
17	treated	O
18	kidneys	O
19	:	O
20	(	O
21	1	O
22	)	O
23	loss	O
24	of	O
25	corticomedullary	O
26	differentiation	O
27	,	O
28	(	O
29	2	O
30	)	O
31	perirenal	O
32	fluid	O
33	,	O
34	(	O
35	3	O
36	)	O
37	subcapsular	O
38	hematoma	O
39	,	O
40	(	O
41	4	O
42	)	O
43	hemorrhage	O
44	into	O
45	a	O
46	renal	O
47	cyst	O
48	,	O
49	and	O
50	(	O
51	5	O
52	)	O
53	unexplained	O
54	abnormalities	O
55	.	O

1	Similarly	O
2	,	O
3	PCDFs	O
4	/	O
5	PCDDs	O
6	ratio	O
7	in	O
8	ESP	O
9	ash	O
10	was	O
11	lower	O
12	than	O
13	that	O
14	in	O
15	boiler	O
16	ash	O
17	.	O

1	Sequence	O
2	conservation	O
3	is	O
4	greatest	O
5	for	O
6	residues	O
7	located	O
8	near	O
9	the	O
10	active	O
11	centers	O
12	of	O
13	the	O
14	exo	B
15	and	O
16	pol	B
17	domains	I
18	of	O
19	the	O
20	E	B
21	.	I
22	coli	I
23	DNA	I
24	polymerase	I
25	I	I
26	structure	O
27	.	O

1	Six	O
2	out	O
3	of	O
4	ten	O
5	hearts	O
6	from	O
7	macerated	O
8	stillborn	O
9	infants	O
10	showed	O
11	varying	O
12	degrees	O
13	of	O
14	positive	O
15	staining	O
16	.	O

1	Magnetic	O
2	resonance	O
3	imaging	O
4	(	O
5	MRI	O
6	)	O
7	has	O
8	enabled	O
9	us	O
10	to	O
11	see	O
12	the	O
13	spinal	O
14	intramedullary	O
15	pathology	O
16	as	O
17	differences	O
18	in	O
19	signal	O
20	intensity	O
21	.	O

1	In	O
2	retrospect	O
3	,	O
4	the	O
5	diagnoses	O
6	were	O
7	reconsidered	O
8	applying	O
9	strict	O
10	criteria	O
11	.	O

1	New	O
2	technologies	O
3	in	O
4	diagnosis	O
5	and	O
6	classification	O
7	of	O
8	malignancy	O
9	.	O

1	Immunochemotherapy	O
2	with	O
3	schizophyllan	O
4	(	O
5	SPG	O
6	)	O
7	combined	O
8	with	O
9	chemotherapeutic	O
10	agents	O
11	was	O
12	evaluated	O
13	in	O
14	two	O
15	syngeneic	O
16	tumor	O
17	-	O
18	C3H	O
19	/	O
20	He	O
21	mouse	O
22	systems	O
23	.	O

1	The	O
2	accuracies	O
3	of	O
4	presence	O
5	or	O
6	absence	O
7	of	O
8	neuroblastoma	O
9	were	O
10	compared	O
11	between	O
12	131I	O
13	-	O
14	MIBG	O
15	imaging	O
16	and	O
17	several	O
18	tumor	O
19	markers	O
20	.	O

1	Comparative	O
2	studies	O
3	of	O
4	the	O
5	antithrombin	B
6	III	I
7	level	O
8	and	O
9	plasminogen	B
10	activator	I
11	activity	O
12	in	O
13	patients	O
14	with	O
15	thrombophlebitis	O

1	This	O
2	combined	O
3	intravenous	O
4	anaesthetic	O
5	regimen	O
6	gave	O
7	good	O
8	anaesthesia	O
9	and	O
10	analgesia	O
11	to	O
12	pigs	O
13	for	O
14	up	O
15	to	O
16	2	O
17	h	O
18	as	O
19	monitored	O
20	by	O
21	clinical	O
22	signs	O
23	.	O

1	The	O
2	eluting	O
3	solvent	O
4	was	O
5	methanol	O
6	-	O
7	chloroform	O
8	(	O
9	10	O
10	+	O
11	90	O
12	)	O
13	at	O
14	a	O
15	flow	O
16	rate	O
17	of	O
18	2	O
19	.	O
20	0	O
21	ml	O
22	/	O
23	min	O
24	.	O

1	A	O
2	canonical	O
3	TATA	O
4	box	O
5	was	O
6	not	O
7	detected	O
8	.	O

1	One	O
2	was	O
3	allowed	O
4	fresh	O
5	drinking	O
6	water	O
7	ad	O
8	libitum	O
9	whilst	O
10	the	O
11	other	O
12	received	O
13	Aludrox	O
14	in	O
15	their	O
16	drinking	O
17	water	O
18	.	O

1	Calves	O
2	fed	O
3	MCT	O
4	-	O
5	milk	O
6	had	O
7	significantly	O
8	lower	O
9	blood	O
10	cholesterol	O
11	than	O
12	calves	O
13	fed	O
14	T	O
15	-	O
16	or	O
17	SBO	O
18	-	O
19	milk	O
20	.	O

1	We	O
2	found	O
3	that	O
4	T3	O
5	(	O
6	10	O
7	(-	O
8	8	O
9	)	O
10	M	O
11	)	O
12	selectively	O
13	stimulates	O
14	transcription	O
15	from	O
16	rGH	B
17	-	O
18	TRE	O
19	-	O
20	and	O
21	TREpal	O
22	-,	O
23	but	O
24	not	O
25	ME	O
26	-	O
27	TRE	O
28	-	O
29	and	O
30	F2	O
31	-	O
32	TRE	O
33	-,	O
34	containing	O
35	templates	O
36	in	O
37	which	O
38	these	O
39	TREs	O
40	are	O
41	linked	O
42	in	O
43	front	O
44	of	O
45	the	O
46	rGH	B
47	minimal	I
48	promoter	I
49	containing	O
50	only	O
51	the	O
52	TATA	B
53	box	I
54	binding	I
55	protein	I
56	,	O
57	but	O
58	not	O
59	any	O
60	other	O
61	proximal	O
62	binding	O
63	protein	O
64	,	O
65	sequence	O
66	.	O

1	Effects	O
2	of	O
3	dioxins	O
4	on	O
5	thyroid	O
6	function	O
7	in	O
8	newborn	O
9	babies	O
10	.	O

1	Precision	O
2	measurement	O
3	of	O
4	the	O
5	pion	O
6	mass	O
7	difference	O
8	m	O
9	pi	O
10	--	O
11	m	O
12	pi	O
13	0	O
14	.	O

1	Hybridization	O
2	of	O
3	a	O
4	probe	O
5	from	O
6	this	O
7	region	O
8	to	O
9	electrophoretic	O
10	blots	O
11	of	O
12	RNAs	O
13	from	O
14	different	O
15	human	O
16	tissues	O
17	showed	O
18	a	O
19	predominant	O
20	2	O
21	.	O
22	8	O
23	-	O
24	kilobase	O
25	(	O
26	kb	O
27	)	O
28	message	O
29	accompanied	O
30	by	O
31	weaker	O
32	bands	O
33	4	O
34	.	O
35	1	O
36	and	O
37	2	O
38	.	O
39	1	O
40	kb	O
41	in	O
42	size	O
43	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	402	O
6	consecutive	O
7	autopsies	O
8	,	O
9	parietal	O
10	pleural	O
11	plaques	O
12	(	O
13	PP	O
14	)	O
15	were	O
16	found	O
17	in	O
18	68	O
19	individuals	O
20	above	O
21	40	O
22	years	O
23	of	O
24	age	O
25	.	O

1	Thus	O
2	,	O
3	ZNF74	B
4	sublocalization	O
5	in	O
6	nuclear	O
7	domains	O
8	enriched	O
9	in	O
10	pre	O
11	-	O
12	mRNA	O
13	maturating	O
14	factors	O
15	,	O
16	its	O
17	RNA	O
18	binding	O
19	activity	O
20	,	O
21	and	O
22	its	O
23	direct	O
24	phosphodependent	O
25	interaction	O
26	with	O
27	the	O
28	pol	B
29	IIo	I
30	,	O
31	a	O
32	form	O
33	of	O
34	the	O
35	RNA	B
36	polymerase	I
37	functionally	O
38	associated	O
39	with	O
40	pre	O
41	-	O
42	mRNA	O
43	processing	O
44	,	O
45	suggest	O
46	a	O
47	role	O
48	for	O
49	this	O
50	member	O
51	of	O
52	the	O
53	KRAB	B
54	multifinger	I
55	protein	I
56	family	I
57	in	O
58	RNA	O
59	processing	O
60	.	O

1	One	O
2	complex	O
3	appears	O
4	to	O
5	be	O
6	ubiquitous	O
7	but	O
8	enriched	O
9	in	O
10	lymphoid	O
11	cells	O
12	and	O
13	represents	O
14	the	O
15	binding	O
16	of	O
17	a	O
18	potentially	O
19	novel	O
20	factor	O
21	with	O
22	an	O
23	apparent	O
24	molecular	O
25	mass	O
26	of	O
27	approximately	O
28	50	O
29	kDa	O
30	.	O

1	HS	O
2	inducibility	O
3	required	O
4	the	O
5	HSE	O
6	which	O
7	was	O
8	bound	O
9	by	O
10	HS	B
11	transcription	I
12	factor	I
13	-	I
14	1	I
15	(	O
16	HSF	B
17	-	I
18	1	I
19	)	O
20	present	O
21	in	O
22	extracts	O
23	prepared	O
24	from	O
25	cells	O
26	exposed	O
27	to	O
28	HS	O
29	.	O

1	Deletion	O
2	of	O
3	both	O
4	prfA	B
5	and	O
6	ponA	B
7	resulted	O
8	in	O
9	extremely	O
10	slow	O
11	growth	O
12	and	O
13	a	O
14	reduction	O
15	in	O
16	sporulation	O
17	efficiency	O
18	.	O

1	The	O
2	antigen	B
3	-	I
4	specific	I
5	IgG4	I
6	antibody	I
7	seems	O
8	to	O
9	be	O
10	an	O
11	index	O
12	in	O
13	evaluating	O
14	immunotherapy	O
15	objectively	O
16	.	O

1	Identification	O
2	of	O
3	Ets	B
4	-	O
5	and	O
6	notch	B
7	-	O
8	related	O
9	subunits	O
10	in	O
11	GA	B
12	binding	I
13	protein	I
14	.	O

1	Rep	B
2	-	O
3	Rep	B
4	protein	O
5	interaction	O
6	was	O
7	confirmed	O
8	in	O
9	vitro	O
10	through	O
11	coimmunoprecipitation	O
12	experiments	O
13	with	O
14	a	O
15	bacterially	O
16	expressed	O
17	maltose	B
18	-	I
19	binding	I
20	protein	I
21	-	O
22	Rep78	B
23	fusion	O
24	protein	O
25	in	O
26	combination	O
27	with	O
28	[	O
29	35S	O
30	]	O
31	methionine	O
32	-	O
33	labeled	O
34	Rep78	B
35	synthesized	O
36	in	O
37	a	O
38	coupled	O
39	in	O
40	vitro	O
41	transcription	O
42	-	O
43	translation	O
44	system	O
45	.	O

1	The	O
2	GHR	B
3	mRNA	I
4	:	O
5	GHBP	B
6	mRNA	I
7	ratio	O
8	was	O
9	1	O
10	.	O
11	1	O
12	+/-	O
13	0	O
14	.	O
15	12	O
16	and	O
17	remained	O
18	unchanged	O
19	during	O
20	differentiation	O
21	.	O

1	These	O
2	results	O
3	provide	O
4	direct	O
5	evidence	O
6	for	O
7	differential	O
8	susceptibility	O
9	to	O
10	endonuclease	O
11	-	O
12	mediated	O
13	mRNA	O
14	decay	O
15	resulting	O
16	from	O
17	the	O
18	differential	O
19	affinity	O
20	of	O
21	a	O
22	RNA	O
23	-	O
24	binding	O
25	protein	O
26	for	O
27	cis	O
28	-	O
29	acting	O
30	stability	O
31	determinants	O
32	.	O

1	Despite	O
2	resolution	O
3	of	O
4	the	O
5	solid	O
6	portion	O
7	of	O
8	the	O
9	tumor	O
10	,	O
11	serial	O
12	MRI	O
13	showed	O
14	enlargement	O
15	of	O
16	a	O
17	bilobar	O
18	tumor	O
19	cyst	O
20	3	O
21	years	O
22	after	O
23	the	O
24	original	O
25	diagnosis	O
26	.	O

1	On	O
2	the	O
3	third	O
4	occasion	O
5	water	O
6	(	O
7	W	O
8	)	O
9	was	O
10	ingested	O
11	throughout	O
12	the	O
13	run	O
14	.	O

1	Pol32Delta	B
2	strains	O
3	are	O
4	weak	O
5	antimutators	O
6	and	O
7	are	O
8	defective	O
9	for	O
10	damage	O
11	-	O
12	induced	O
13	mutagenesis	O
14	.	O

1	Both	O
2	parents	O
3	are	O
4	clinically	O
5	normal	O
6	and	O
7	unrelated	O
8	.	O

1	The	O
2	impact	O
3	of	O
4	social	O
5	support	O
6	on	O
7	the	O
8	relationships	O
9	of	O
10	gay	O
11	male	O
12	couples	O
13	is	O
14	examined	O
15	.	O

1	Inspection	O
2	of	O
3	enhancer	O
4	mutants	O
5	suggests	O
6	that	O
7	trans	O
8	-	O
9	activation	O
10	by	O
11	hLEF	B
12	/	O
13	GAL4	B
14	is	O
15	especially	O
16	dependent	O
17	on	O
18	TCF	B
19	-	I
20	2	I
21	,	O
22	a	O
23	distinct	O
24	T	O
25	-	O
26	cell	O
27	-	O
28	enriched	O
29	protein	O
30	that	O
31	binds	O
32	to	O
33	sequences	O
34	flanking	O
35	the	O
36	hLEF	B
37	-	I
38	binding	I
39	site	I
40	in	O
41	the	O
42	enhancer	O
43	.	O

1	2	O
2	-	O
3	Chemical	O
4	occlusion	O
5	of	O
6	vas	O
7	is	O
8	quite	O
9	effective	O
10	in	O
11	producing	O
12	a	O
13	block	O
14	in	O
15	the	O
16	vas	O
17	deferens	O
18	of	O
19	dogs	O
20	.	O

1	When	O
2	phosphorylation	O
3	of	O
4	exogenous	O
5	peptide	O
6	substrates	O
7	was	O
8	measured	O
9	as	O
10	a	O
11	function	O
12	of	O
13	receptor	O
14	self	O
15	-	O
16	phosphorylation	O
17	,	O
18	tyrosine	B
19	kinase	I
20	activity	O
21	was	O
22	found	O
23	to	O
24	be	O
25	enhanced	O
26	two	O
27	to	O
28	threefold	O
29	at	O
30	1	O
31	-	O
32	2	O
33	mol	O
34	of	O
35	phosphate	O
36	per	O
37	mol	O
38	of	O
39	receptor	O
40	.	O

1	No	O
2	direct	O
3	repeats	O
4	flank	O
5	the	O
6	pseudogene	O
7	in	O
8	the	O
9	U2	B
10	/	I
11	4	I
12	locus	I
13	.	O

1	The	O
2	serum	O
3	levels	O
4	of	O
5	beta	B
6	-	I
7	human	I
8	chorionic	I
9	gonadotropin	I
10	(	O
11	HCG	B
12	)	O
13	and	O
14	placental	B
15	alkaline	I
16	phosphatase	I
17	(	O
18	PLAP	B
19	)	O
20	were	O
21	not	O
22	elevated	O
23	.	O

1	Expression	O
2	of	O
3	lacZ	B
4	from	O
5	the	O
6	promoter	O
7	of	O
8	the	O
9	Escherichia	B
10	coli	I
11	spc	I
12	operon	I
13	cloned	O
14	into	O
15	vectors	O
16	carrying	O
17	the	O
18	W205	O
19	trp	B
20	-	O
21	lac	B
22	fusion	O
23	.	O

1	One	O
2	gene	O
3	appears	O
4	ubiquitously	O
5	expressed	O
6	while	O
7	the	O
8	other	O
9	is	O
10	prominently	O
11	expressed	O
12	in	O
13	muscle	O
14	.	O

1	Retroviral	O
2	replication	O
3	requires	O
4	that	O
5	a	O
6	portion	O
7	of	O
8	the	O
9	primary	O
10	transcripts	O
11	generated	O
12	from	O
13	proviral	O
14	DNA	O
15	be	O
16	spliced	O
17	to	O
18	serve	O
19	as	O
20	mRNA	O
21	for	O
22	the	O
23	envelope	B
24	protein	I
25	and	O
26	in	O
27	Rous	O
28	sarcoma	O
29	virus	O
30	as	O
31	src	B
32	mRNA	I
33	.	O

1	During	O
2	both	O
3	encephalopathy	O
4	episodes	O
5	,	O
6	CSF	O
7	protein	O
8	and	O
9	immunoglobulin	B
10	G	I
11	(	O
12	IgG	B
13	)	O
14	levels	O
15	were	O
16	elevated	O
17	without	O
18	an	O
19	increased	O
20	IgG	B
21	index	O
22	or	O
23	IgG	B
24	synthesis	O
25	rate	O
26	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	time	O
6	to	O
7	engraftment	O
8	was	O
9	significantly	O
10	shorter	O
11	in	O
12	the	O
13	amifostine	O
14	arm	O
15	in	O
16	both	O
17	cohorts	O
18	.	O

1	Among	O
2	the	O
3	mixed	O
4	race	O
5	persons	O
6	one	O
7	Chukcha	O
8	-	O
9	Eskimo	O
10	had	O
11	AS	O
12	,	O
13	one	O
14	Eskimo	O
15	-	O
16	Russian	O
17	had	O
18	psoriatic	O
19	arthritis	O
20	(	O
21	PsA	O
22	).	O

1	Location	O
2	and	O
3	orientation	O
4	of	O
5	an	O
6	activating	O
7	region	O
8	in	O
9	the	O
10	Escherichia	O
11	coli	O
12	transcription	O
13	factor	O
14	,	O
15	FNR	B
16	.	O

1	In	O
2	rats	O
3	,	O
4	we	O
5	examined	O
6	the	O
7	effect	O
8	of	O
9	an	O
10	omentum	O
11	wrapping	O
12	on	O
13	the	O
14	vascularization	O
15	of	O
16	the	O
17	trachea	O
18	and	O
19	on	O
20	regeneration	O
21	of	O
22	the	O
23	mucosal	O
24	epithelium	O
25	in	O
26	the	O
27	very	O
28	early	O
29	stage	O
30	after	O
31	free	O
32	tracheal	O
33	grafting	O
34	.	O

1	A	O
2	comparative	O
3	study	O
4	was	O
5	undertaken	O
6	between	O
7	an	O
8	enzymatic	O
9	immunohistochemical	O
10	technique	O
11	(	O
12	EIT	O
13	)	O
14	developed	O
15	for	O
16	the	O
17	diagnosis	O
18	of	O
19	human	O
20	trichinellosis	O
21	and	O
22	the	O
23	indirect	O
24	immunofluorescence	O
25	test	O
26	(	O
27	IIF	O
28	),	O
29	analysing	O
30	sera	O
31	from	O
32	outbreaks	O
33	of	O
34	human	O
35	trichinellosis	O
36	in	O
37	Argentina	O
38	.	O

1	Dystonic	O
2	movement	O
3	of	O
4	the	O
5	left	O
6	upper	O
7	limb	O
8	in	O
9	a	O
10	case	O
11	of	O
12	the	O
13	right	O
14	pontine	O
15	hemorrhage	O

1	Calcitonin	B
2	simultaneously	O
3	regulates	O
4	both	O
5	periosteal	O
6	hyperostosis	O
7	and	O
8	trabecular	O
9	osteopenia	O
10	in	O
11	the	O
12	spinal	O
13	hyperostotic	O
14	mouse	O
15	(	O
16	twy	B
17	/	O
18	twy	B
19	)	O
20	in	O
21	vivo	O
22	.	O

1	In	O
2	the	O
3	studies	O
4	described	O
5	in	O
6	this	O
7	report	O
8	,	O
9	we	O
10	have	O
11	investigated	O
12	the	O
13	signaling	O
14	pathway	O
15	(	O
16	s	O
17	)	O
18	that	O
19	are	O
20	responsible	O
21	for	O
22	CREB	B
23	activation	O
24	in	O
25	normal	O
26	T	O
27	cells	O
28	.	O

1	HEF1	B
2	,	O
3	p130	B
4	(	O
5	Cas	B
6	),	O
7	and	O
8	Efs	B
9	/	O
10	Sin	B
11	constitute	O
12	a	O
13	family	O
14	of	O
15	multidomain	O
16	docking	O
17	proteins	O
18	that	O
19	have	O
20	been	O
21	implicated	O
22	in	O
23	coordinating	O
24	the	O
25	regulation	O
26	of	O
27	cell	O
28	adhesion	O
29	.	O

1	Bone	O
2	and	O
3	bones	O
4	.	O

1	In	O
2	most	O
3	subjects	O
4	,	O
5	markers	O
6	of	O
7	bone	O
8	formation	O
9	and	O
10	resorption	O
11	were	O
12	normal	O
13	.	O

1	Up	O
2	to	O
3	now	O
4	the	O
5	number	O
6	of	O
7	patients	O
8	examined	O
9	is	O
10	about	O
11	300	O
12	,	O
13	additionally	O
14	6	O
15	persons	O
16	who	O
17	underwent	O
18	binephrectomy	O
19	.	O

1	Detailed	O
2	mutagenesis	O
3	of	O
4	the	O
5	element	O
6	'	O
7	s	O
8	rare	O
9	-	O
10	codon	O
11	/	O
12	AU	O
13	-	O
14	rich	O
15	sequence	O
16	boundary	O
17	revealed	O
18	that	O
19	the	O
20	destabilizing	O
21	activity	O
22	of	O
23	the	O
24	MATalpha1	B
25	IE	I
26	is	O
27	observed	O
28	when	O
29	the	O
30	terminal	O
31	codon	O
32	of	O
33	the	O
34	element	O
35	'	O
36	s	O
37	rare	O
38	-	O
39	codon	O
40	interval	O
41	is	O
42	translated	O
43	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	GATA	B
6	-	I
7	5	I
8	may	O
9	have	O
10	specific	O
11	downstream	O
12	targets	O
13	and	O
14	that	O
15	GATA	B
16	-	I
17	4	I
18	,	I
19	-	I
20	5	I
21	,	I
22	and	I
23	-	I
24	6	I
25	can	O
26	only	O
27	partially	O
28	substitute	O
29	for	O
30	each	O
31	other	O
32	in	O
33	cardiogenesis	O
34	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	mitochondrial	O
6	presequences	O
7	interact	O
8	with	O
9	the	O
10	mt	B
11	-	I
12	hsp70	I
13	during	O
14	or	O
15	after	O
16	mitochondrial	O
17	protein	O
18	import	O
19	.	O

1	Consistent	O
2	with	O
3	the	O
4	hepatic	O
5	and	O
6	epidermal	O
7	expression	O
8	of	O
9	histidase	B
10	,	O
11	this	O
12	finding	O
13	suggests	O
14	that	O
15	histidase	B
16	transcription	O
17	may	O
18	be	O
19	regulated	O
20	by	O
21	these	O
22	factors	O
23	.	O

1	Cell	O
2	adhesion	O
3	and	O
4	migration	O
5	assays	O
6	demonstrate	O
7	that	O
8	alpha	B
9	6	I
10	beta	I
11	1	I
12	is	O
13	the	O
14	major	O
15	laminin	B
16	receptor	I
17	in	O
18	undifferentiated	O
19	F9	O
20	cells	O
21	as	O
22	well	O
23	as	O
24	F9	O
25	-	O
26	derived	O
27	PE	O
28	cells	O
29	.	O

1	Proceedings	O
2	:	O
3	Reversible	O
4	complete	O
5	heart	O
6	block	O
7	following	O
8	surgery	O
9	of	O
10	congenital	O
11	heart	O
12	defects	O

1	Although	O
2	the	O
3	Src	B
4	tyrosine	I
5	kinase	I
6	induces	O
7	constitutive	O
8	Stat3	B
9	phosphorylation	O
10	on	O
11	tyrosine	O
12	,	O
13	activation	O
14	of	O
15	Stat3	B
16	-	O
17	mediated	O
18	gene	O
19	regulation	O
20	requires	O
21	both	O
22	tyrosine	O
23	and	O
24	serine	O
25	phosphorylation	O
26	of	O
27	Stat3	B
28	.	O

1	We	O
2	used	O
3	two	O
4	approaches	O
5	to	O
6	ascertain	O
7	whether	O
8	CDP	B
9	/	O
10	cut	B
11	serves	O
12	as	O
13	a	O
14	repressor	O
15	of	O
16	gp91	B
17	-	O
18	phox	B
19	gene	O
20	expression	O
21	.	O

1	One	O
2	-	O
3	third	O
4	of	O
5	the	O
6	men	O
7	with	O
8	azoospermia	O
9	and	O
10	with	O
11	sperm	O
12	density	O
13	of	O
14	less	O
15	than	O
16	10	O
17	million	O
18	had	O
19	marked	O
20	FSH	B
21	elevation	O
22	and	O
23	our	O
24	experience	O
25	confirms	O
26	the	O
27	work	O
28	of	O
29	others	O
30	that	O
31	this	O
32	indicates	O
33	a	O
34	poor	O
35	prognosis	O
36	.	O

1	The	O
2	decline	O
3	in	O
4	the	O
5	activity	O
6	of	O
7	cytochrome	B
8	oxidase	I
9	,	O
10	peroxidase	B
11	and	O
12	in	O
13	the	O
14	lipid	O
15	content	O
16	of	O
17	peripheral	O
18	neutrophils	O
19	was	O
20	followed	O
21	by	O
22	a	O
23	decrease	O
24	in	O
25	the	O
26	phagocytic	O
27	activity	O
28	.	O

1	Furthermore	O
2	it	O
3	was	O
4	suggested	O
5	that	O
6	FK506	O
7	plasma	O
8	levels	O
9	were	O
10	concerned	O
11	with	O
12	the	O
13	appearance	O
14	of	O
15	side	O
16	effect	O
17	.	O

1	Based	O
2	on	O
3	213	O
4	determinations	O
5	,	O
6	the	O
7	control	O
8	mean	O
9	serum	B
10	CPK	I
11	activity	O
12	was	O
13	262	O
14	+/-	O
15	113	O
16	I	O
17	.	O
18	U	O
19	./	O
20	liter	O
21	.	O

1	CIITA	B
2	mRNA	I
3	is	O
4	normally	O
5	inducible	O
6	by	O
7	IFN	B
8	-	I
9	gamma	I
10	in	O
11	class	O
12	II	O
13	non	O
14	-	O
15	inducible	O
16	,	O
17	RB	O
18	-	O
19	defective	O
20	lines	O
21	,	O
22	and	O
23	in	O
24	one	O
25	line	O
26	,	O
27	re	O
28	-	O
29	expression	O
30	of	O
31	RB	B
32	has	O
33	no	O
34	effect	O
35	on	O
36	CIITA	B
37	mRNA	I
38	induction	O
39	levels	O
40	.	O

1	What	O
2	young	O
3	people	O
4	think	O
5	and	O
6	do	O
7	when	O
8	the	O
9	option	O
10	for	O
11	cystic	O
12	fibrosis	O
13	carrier	O
14	testing	O
15	is	O
16	available	O
17	.	O

1	Risks	O
2	of	O
3	chronicity	O
4	following	O
5	acute	O
6	hepatitis	O
7	B	O
8	virus	O
9	infection	O
10	:	O
11	a	O
12	review	O
13	.	O

1	Alanine	B
2	aminotransferase	I
3	in	O
4	clinical	O
5	practice	O
6	.	O

1	Ang	B
2	II	I
3	-	O
4	induced	O
5	fibronectin	B
6	mRNA	O
7	was	O
8	not	O
9	affected	O
10	by	O
11	PKC	B
12	inhibitors	O
13	or	O
14	PKC	B
15	depletion	O
16	,	O
17	whereas	O
18	specific	O
19	inhibition	O
20	of	O
21	EGF	B
22	-	I
23	R	I
24	function	O
25	by	O
26	a	O
27	dominant	B
28	negative	I
29	EGF	I
30	-	I
31	R	I
32	mutant	I
33	and	O
34	tyrphostin	O
35	AG1478	O
36	abolished	O
37	induction	O
38	of	O
39	fibronectin	B
40	mRNA	I
41	.	O

1	Histological	O
2	observations	O
3	on	O
4	the	O
5	decidua	O
6	in	O
7	the	O
8	second	O
9	half	O
10	of	O
11	pregnancy	O

1	Removal	O
2	of	O
3	all	O
4	core	B
5	histone	I
6	tail	O
7	domains	O
8	by	O
9	limited	O
10	trypsin	B
11	proteolysis	O
12	or	O
13	acetylation	O
14	of	O
15	the	O
16	core	B
17	histone	I
18	tails	O
19	significantly	O
20	relieves	O
21	this	O
22	inhibition	O
23	and	O
24	allows	O
25	TFIIIA	B
26	to	O
27	exhibit	O
28	high	O
29	-	O
30	affinity	O
31	binding	O
32	to	O
33	nucleosomal	O
34	DNA	O
35	.	O

1	We	O
2	established	O
3	that	O
4	the	O
5	2	O
6	.	O
7	6	O
8	kb	O
9	mRNA	O
10	V	O
11	-	O
12	1	O
13	and	O
14	the	O
15	2	O
16	.	O
17	3	O
18	kb	O
19	GGT	B
20	mRNA	O
21	V	O
22	-	O
23	2	O
24	derive	O
25	,	O
26	by	O
27	alternate	O
28	splicing	O
29	,	O
30	from	O
31	a	O
32	primary	O
33	transcript	O
34	initiated	O
35	on	O
36	a	O
37	distal	O
38	promoter	O
39	on	O
40	the	O
41	rat	B
42	GGT	I
43	gene	I
44	.	O

1	Biochemical	O
2	examinations	O
3	of	O
4	calcium	O
5	-	O
6	phosphorus	O
7	metabolism	O
8	included	O
9	ions	O
10	and	O
11	PTH	B
12	concentrations	O
13	in	O
14	blood	O
15	serum	O
16	,	O
17	and	O
18	the	O
19	activity	O
20	of	O
21	bone	O
22	isoenzyme	O
23	of	O
24	AP	B
25	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	the	O
6	observed	O
7	clinical	O
8	phenomena	O
9	in	O
10	response	O
11	to	O
12	morphine	O
13	can	O
14	be	O
15	explained	O
16	by	O
17	differences	O
18	in	O
19	expression	O
20	and	O
21	sensitivity	O
22	of	O
23	some	O
24	opioid	B
25	receptor	I
26	subtypes	O
27	in	O
28	migraine	O
29	.	O

1	Comparison	O
2	of	O
3	sequences	O
4	of	O
5	ovine	O
6	and	O
7	bovine	O
8	,	O
9	rat	O
10	and	O
11	guinea	B
12	-	I
13	pig	I
14	alpha	I
15	s1	I
16	-	I
17	casein	I
18	mRNAs	I
19	has	O
20	revealed	O
21	a	O
22	greater	O
23	homology	O
24	in	O
25	the	O
26	3	O
27	'	O
28	and	O
29	especially	O
30	5	O
31	'	O
32	non	O
33	coding	O
34	regions	O
35	.	O

1	Overall	O
2	,	O
3	these	O
4	findings	O
5	demonstrate	O
6	that	O
7	mutations	O
8	E768D	O
9	and	O
10	V804L	O
11	are	O
12	gain	O
13	-	O
14	of	O
15	-	O
16	function	O
17	mutations	O
18	that	O
19	confer	O
20	to	O
21	the	O
22	long	B
23	RET	I
24	isoform	I
25	the	O
26	capacity	O
27	to	O
28	exert	O
29	a	O
30	biological	O
31	effect	O
32	,	O
33	although	O
34	these	O
35	mutations	O
36	are	O
37	more	O
38	weakly	O
39	activating	O
40	than	O
41	the	O
42	MEN2A	B
43	and	O
44	MEN2B	B
45	mutations	O
46	.	O

1	Frog	O
2	type	O
3	I	O
4	(	O
5	Ft	O
6	I	O
7	)	O
8	and	O
9	frog	O
10	type	O
11	II	O
12	(	O
13	Ft	O
14	II	O
15	)	O
16	slowly	O
17	adapting	O
18	(	O
19	SA	O
20	)	O
21	units	O
22	produced	O
23	spikes	O
24	only	O
25	at	O
26	the	O
27	indentation	O
28	phase	O
29	,	O
30	and	O
31	the	O
32	threshold	O
33	response	O
34	phase	O
35	(	O
36	TRP	O
37	),	O
38	i	O
39	.	O
40	e	O
41	..	O
42	the	O
43	phase	O
44	of	O
45	the	O
46	first	O
47	spike	O
48	was	O
49	for	O
50	ca	O
51	.	O

1	Characterization	O
2	of	O
3	the	O
4	regulatory	O
5	regions	O
6	of	O
7	the	O
8	human	B
9	aromatase	I
10	(	O
11	P450arom	B
12	)	O
13	gene	O
14	involved	O
15	in	O
16	placenta	O
17	-	O
18	specific	O
19	expression	O
20	.	O

1	Plasma	O
2	concentrations	O
3	of	O
4	ANF	B
5	(	O
6	pANF	B
7	),	O
8	aldosterone	O
9	(	O
10	PAC	O
11	)	O
12	and	O
13	renin	B
14	(	O
15	PRC	B
16	)	O
17	were	O
18	measured	O
19	daily	O
20	,	O
21	as	O
22	were	O
23	hemodynamic	O
24	parameters	O
25	.	O

1	Further	O
2	studies	O
3	demonstrated	O
4	that	O
5	the	O
6	PPARalpha	B
7	ligand	O
8	8	O
9	(	O
10	S	O
11	)-	O
12	hydroxyeicosatetraenoic	O
13	acid	O
14	strongly	O
15	promotes	O
16	the	O
17	interaction	O
18	of	O
19	PPARalpha	B
20	with	O
21	the	O
22	co	O
23	-	O
24	activator	O
25	RIP	B
26	-	I
27	140	I
28	but	O
29	decreases	O
30	the	O
31	interaction	O
32	of	O
33	PPARalpha	B
34	with	O
35	the	O
36	co	O
37	-	O
38	repressor	O
39	SMRT	B
40	.	O

1	Changes	O
2	induced	O
3	in	O
4	the	O
5	gills	O
6	of	O
7	milkfish	O
8	(	O
9	Chanos	O
10	chanos	O
11	Forsskal	O
12	)	O
13	fingerlings	O
14	after	O
15	acute	O
16	exposure	O
17	to	O
18	nifurpirinol	O
19	(	O
20	Furanace	O
21	;	O
22	P	O
23	-	O
24	7138	O
25	).	O

1	In	O
2	the	O
3	infected	O
4	neonates	O
5	serum	O
6	alpha	B
7	-	I
8	amylase	I
9	value	O
10	,	O
11	as	O
12	determined	O
13	by	O
14	the	O
15	blue	O
16	starch	O
17	method	O
18	,	O
19	was	O
20	only	O
21	40	O
22	%	O
23	that	O
24	of	O
25	healthy	O
26	controls	O
27	;	O
28	the	O
29	mean	O
30	value	O
31	of	O
32	175	O
33	.	O
34	1	O
35	+/-	O
36	64	O
37	.	O
38	9	O
39	IU	O
40	/	O
41	l	O
42	for	O
43	healthy	O
44	neonates	O
45	was	O
46	significantly	O
47	higher	O
48	(	O
49	p	O
50	less	O
51	than	O
52	0	O
53	.	O
54	0010	O
55	)	O
56	than	O
57	the	O
58	value	O
59	of	O
60	82	O
61	.	O
62	8	O
63	+/-	O
64	44	O
65	.	O
66	4	O
67	IU	O
68	/	O
69	l	O
70	for	O
71	the	O
72	infected	O
73	neonates	O
74	.	O

1	These	O
2	mutant	O
3	proteins	O
4	retained	O
5	the	O
6	ability	O
7	to	O
8	competitively	O
9	inhibit	O
10	kappa	B
11	B	I
12	-	O
13	mediated	O
14	transcriptional	O
15	activation	O
16	of	O
17	the	O
18	human	B
19	immunodeficiency	I
20	virus	I
21	long	I
22	terminal	I
23	repeat	I
24	but	O
25	failed	O
26	to	O
27	efficiently	O
28	transform	O
29	chicken	O
30	lymphoid	O
31	cells	O
32	both	O
33	in	O
34	vitro	O
35	and	O
36	in	O
37	vivo	O
38	.	O

1	Like	O
2	the	O
3	elicitors	O
4	of	O
5	the	O
6	hypersensitive	O
7	reaction	O
8	(	O
9	HR	O
10	)	O
11	produced	O
12	by	O
13	E	O
14	.	O
15	chrysanthemi	O
16	(	O
17	HarpinEch	O
18	)	O
19	and	O
20	E	O
21	.	O
22	amylovora	O
23	(	O
24	HarpinEa	O
25	),	O
26	the	O
27	deduced	O
28	36	O
29	-	O
30	kDa	O
31	protein	O
32	does	O
33	not	O
34	possess	O
35	a	O
36	typical	O
37	signal	O
38	sequence	O
39	,	O
40	but	O
41	it	O
42	contains	O
43	a	O
44	putative	O
45	membrane	O
46	-	O
47	spanning	O
48	domain	O
49	.	O

1	The	O
2	glucose	O
3	areas	O
4	following	O
5	the	O
6	ingestion	O
7	of	O
8	the	O
9	foods	O
10	were	O
11	:	O
12	Study	O
13	1	O
14	:	O
15	glucose	O
16	11	O
17	.	O
18	7	O
19	,	O
20	orange	O
21	juice	O
22	7	O
23	.	O
24	3	O
25	,	O
26	sucrose	O
27	5	O
28	.	O
29	2	O
30	,	O
31	glucose	O
32	+	O
33	fructose	O
34	6	O
35	.	O
36	3	O
37	,	O
38	and	O
39	fructose	O
40	0	O
41	.	O
42	7	O
43	mmol	O
44	X	O
45	h	O
46	/	O
47	l	O
48	;	O
49	Study	O
50	2	O
51	:	O
52	glucose	O
53	14	O
54	.	O
55	6	O
56	,	O
57	orange	O
58	juice	O
59	7	O
60	.	O
61	3	O
62	,	O
63	apples	O
64	5	O
65	.	O
66	5	O
67	,	O
68	and	O
69	apple	O
70	juice	O
71	4	O
72	.	O
73	7	O
74	mmol	O
75	X	O
76	h	O
77	/	O
78	l	O
79	;	O
80	Study	O
81	3	O
82	:	O
83	glucose	O
84	12	O
85	.	O
86	6	O
87	,	O
88	ice	O
89	cream	O
90	8	O
91	.	O
92	1	O
93	,	O
94	milk	O
95	3	O
96	.	O
97	7	O
98	,	O
99	and	O
100	lactose	O
101	4	O
102	.	O
103	1	O
104	mmol	O
105	X	O
106	h	O
107	/	O
108	l	O
109	.	O

1	Heterogeneous	B
2	nuclear	I
3	ribonucleoprotein	I
4	(	I
5	hnRNP	I
6	)	I
7	core	I
8	protein	I
9	A1	I
10	is	O
11	a	O
12	major	O
13	component	O
14	of	O
15	mammalian	B
16	hnRNP	I
17	40	I
18	S	I
19	particles	I
20	.	O

1	The	O
2	Aa	B
3	-	I
4	Pri2	I
5	gene	I
6	,	O
7	specifically	O
8	expressed	O
9	during	O
10	basidiocarp	O
11	differentiation	O
12	of	O
13	the	O
14	mushroom	O
15	Agrocybe	O
16	aegerita	O
17	,	O
18	was	O
19	cloned	O
20	.	O

1	Thus	O
2	,	O
3	SPECT	O
4	was	O
5	not	O
6	as	O
7	sensitive	O
8	as	O
9	PET	O
10	in	O
11	this	O
12	activation	O
13	task	O
14	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	vacuolar	B
6	H	I
7	(+)-	I
8	ATPase	I
9	B2	I
10	subunit	I
11	gene	I
12	in	O
13	differentiating	O
14	THP	O
15	-	O
16	1	O
17	cells	O
18	.	O

1	T	O
2	.,	O
3	Mahasneh	O
4	,	O
5	A	O
6	.,	O
7	and	O
8	Cote	O
9	,	O
10	G	O
11	.	O

1	Forty	O
2	-	O
3	eight	O
4	10	O
5	-	O
6	12	O
7	-	O
8	week	O
9	-	O
10	old	O
11	male	O
12	Sprague	O
13	-	O
14	Dawley	O
15	rats	O
16	were	O
17	randomized	O
18	to	O
19	receive	O
20	,	O
21	daily	O
22	for	O
23	28	O
24	days	O
25	:	O
26	(	O
27	1	O
28	)	O
29	CsA	O
30	vehicle	O
31	p	O
32	.	O
33	o	O
34	.	O
35	plus	O
36	FB	O
37	vehicle	O
38	sc	O
39	;	O
40	(	O
41	2	O
42	)	O
43	CsA	O
44	(	O
45	15	O
46	mg	O
47	/	O
48	kg	O
49	)	O
50	p	O
51	.	O
52	o	O
53	.	O
54	plus	O
55	FB	O
56	vehicle	O
57	sc	O
58	,	O
59	(	O
60	3	O
61	)	O
62	CsA	O
63	vehicle	O
64	p	O
65	.	O
66	o	O
67	.	O
68	plus	O
69	FB	O
70	(	O
71	1	O
72	.	O
73	5	O
74	mg	O
75	/	O
76	kg	O
77	)	O
78	sc	O
79	;	O
80	and	O
81	(	O
82	4	O
83	)	O
84	CsA	O
85	(	O
86	15	O
87	mg	O
88	/	O
89	kg	O
90	)	O
91	p	O
92	.	O
93	o	O
94	.	O
95	plus	O
96	FB	O
97	(	O
98	1	O
99	.	O
100	5	O
101	mg	O
102	/	O
103	kg	O
104	)	O
105	sc	O
106	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	full	O
6	-	O
7	length	O
8	coding	O
9	cDNA	O
10	sequence	O
11	of	O
12	the	O
13	mouse	B
14	homologue	I
15	of	I
16	MPP3	I
17	.	O

1	Our	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	investigate	O
7	the	O
8	effect	O
9	of	O
10	MMF	O
11	on	O
12	in	O
13	vivo	O
14	bone	O
15	mineral	O
16	metabolism	O
17	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	a	O
6	sequence	O
7	match	O
8	between	O
9	enhancers	O
10	and	O
11	certain	O
12	promoter	O
13	elements	O
14	is	O
15	critical	O
16	.	O

1	Number	O
2	and	O
3	size	O
4	of	O
5	silver	O
6	-	O
7	stained	O
8	nucleoli	O
9	(	O
10	Ag	O
11	-	O
12	NOR	O
13	clusters	O
14	)	O
15	in	O
16	canine	O
17	seminomas	O
18	:	O
19	correlation	O
20	with	O
21	histological	O
22	features	O
23	and	O
24	tumour	O
25	behaviour	O
26	.	O

1	Neonatal	O
2	Chagas	O
3	disease	O
4	:	O
5	laboratory	O
6	diagnosis	O
7	during	O
8	the	O
9	first	O
10	year	O
11	of	O
12	life	O

1	A	O
2	second	O
3	large	O
4	group	O
5	of	O
6	disorders	O
7	in	O
8	pregnancy	O
9	is	O
10	caused	O
11	by	O
12	effects	O
13	of	O
14	infections	O
15	of	O
16	the	O
17	mother	O
18	without	O
19	pathogens	O
20	being	O
21	transmitted	O
22	to	O
23	the	O
24	embryo	O
25	or	O
26	the	O
27	placenta	O
28	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	stereotypy	O
6	can	O
7	be	O
8	evoked	O
9	also	O
10	in	O
11	the	O
12	case	O
13	when	O
14	the	O
15	striatal	O
16	dopaminergic	O
17	tone	O
18	is	O
19	normal	O
20	or	O
21	even	O
22	below	O
23	normal	O
24	:	O
25	it	O
26	is	O
27	the	O
28	equilibrium	O
29	of	O
30	the	O
31	striatal	O
32	cholinergic	O
33	-	O
34	dopaminergic	O
35	systems	O
36	which	O
37	must	O
38	be	O
39	shifted	O
40	towards	O
41	dopamine	O
42	,	O
43	which	O
44	is	O
45	necessary	O
46	for	O
47	the	O
48	development	O
49	of	O
50	this	O
51	behavioral	O
52	manifestation	O
53	.	O

1	As	O
2	a	O
3	result	O
4	,	O
5	the	O
6	subendocardial	O
7	/	O
8	subepicardial	O
9	blood	O
10	flow	O
11	ratio	O
12	(	O
13	ENDO	O
14	/	O
15	EPI	O
16	)	O
17	increased	O
18	from	O
19	0	O
20	.	O
21	44	O
22	+/-	O
23	0	O
24	.	O
25	09	O
26	during	O
27	control	O
28	stenosis	O
29	to	O
30	0	O
31	.	O
32	85	O
33	+/-	O
34	0	O
35	.	O
36	13	O
37	after	O
38	ITF	O
39	1129	O
40	(	O
41	10	O
42	micrograms	O
43	/	O
44	kg	O
45	/	O
46	min	O
47	i	O
48	.	O
49	v	O
50	.)	O
51	and	O
52	to	O
53	0	O
54	.	O
55	81	O
56	+/-	O
57	0	O
58	.	O
59	12	O
60	after	O
61	NTG	O
62	.	O

1	Therefore	O
2	the	O
3	binding	O
4	sites	O
5	for	O
6	liver	O
7	-	O
8	enriched	O
9	factors	O
10	,	O
11	present	O
12	in	O
13	the	O
14	hamster	B
15	CYP7A1	I
16	proximal	I
17	promoter	I
18	in	O
19	close	O
20	vicinity	O
21	and	O
22	conserved	O
23	between	O
24	species	O
25	,	O
26	constitute	O
27	a	O
28	regulatory	O
29	unit	O
30	important	O
31	for	O
32	basal	O
33	hepatic	O
34	expression	O
35	and	O
36	tissue	O
37	restriction	O
38	of	O
39	the	O
40	action	O
41	of	O
42	hormones	O
43	such	O
44	as	O
45	insulin	B
46	.	O

1	Unlike	O
2	the	O
3	MAR	O
4	-	O
5	binding	O
6	domain	O
7	,	O
8	the	O
9	homeodomain	B
10	when	O
11	isolated	O
12	binds	O
13	poorly	O
14	and	O
15	with	O
16	low	O
17	specificity	O
18	to	O
19	DNA	O
20	.	O

1	We	O
2	compare	O
3	the	O
4	results	O
5	of	O
6	this	O
7	algorithm	O
8	with	O
9	the	O
10	results	O
11	obtained	O
12	with	O
13	two	O
14	other	O
15	algorithms	O
16	,	O
17	the	O
18	optimal	O
19	algorithm	O
20	for	O
21	monochannel	O
22	nonoverlapping	O
23	noise	O
24	and	O
25	the	O
26	optimal	O
27	algorithm	O
28	for	O
29	multichannel	O
30	additive	O
31	noise	O
32	,	O
33	and	O
34	we	O
35	show	O
36	that	O
37	in	O
38	both	O
39	cases	O
40	improvement	O
41	can	O
42	be	O
43	obtained	O
44	.	O

1	A	O
2	mutational	O
3	analysis	O
4	has	O
5	resolved	O
6	a	O
7	region	O
8	of	O
9	seven	O
10	amino	O
11	acids	O
12	(	O
13	amino	O
14	acids	O
15	26	O
16	-	O
17	32	O
18	)	O
19	in	O
20	the	O
21	N	O
22	-	O
23	terminus	O
24	of	O
25	Bob1	B
26	that	O
27	are	O
28	important	O
29	for	O
30	contacting	O
31	the	O
32	DNA	B
33	binding	I
34	POU	I
35	domain	I
36	of	O
37	Oct	B
38	-	I
39	1	I
40	or	O
41	Oct	B
42	-	I
43	2	I
44	.	O

1	The	O
2	central	O
3	visual	O
4	fields	O
5	of	O
6	2165	O
7	normal	O
8	and	O
9	106	O
10	glaucoma	O
11	eyes	O
12	were	O
13	measured	O
14	using	O
15	a	O
16	threshold	O
17	related	O
18	suprathreshold	O
19	strategy	O
20	.	O

1	Hypoglycemic	O
2	action	O
3	of	O
4	"	O
5	he	O
6	xiang	O
7	zhuang	O
8	qi	O
9	gong	O
10	"	O
11	and	O
12	its	O
13	mechanism	O
14	on	O
15	diabetes	O
16	mellitus	O

1	Once	O
2	P	B
3	-	I
4	450scc	I
5	mRNA	I
6	is	O
7	induced	O
8	as	O
9	a	O
10	consequence	O
11	of	O
12	the	O
13	LH	B
14	/	O
15	hCG	B
16	surge	O
17	it	O
18	is	O
19	constitutively	O
20	maintained	O
21	by	O
22	luteinized	O
23	cells	O
24	in	O
25	vivo	O
26	(	O
27	0	O
28	-	O
29	4	O
30	days	O
31	)	O
32	and	O
33	in	O
34	vitro	O
35	(	O
36	0	O
37	-	O
38	9	O
39	days	O
40	)	O
41	in	O
42	the	O
43	absence	O
44	of	O
45	gonadotropins	B
46	,	O
47	is	O
48	susceptible	O
49	to	O
50	modulation	O
51	by	O
52	prolactin	B
53	and	O
54	is	O
55	no	O
56	longer	O
57	regulated	O
58	by	O
59	cAMP	O
60	.	O

1	Intracavitary	O
2	irradiation	O
3	was	O
4	carried	O
5	out	O
6	with	O
7	a	O
8	microSelectron	O
9	HDR	O
10	afterloading	O
11	device	O
12	and	O
13	usually	O
14	22	O
15	.	O
16	5	O
17	Gy	O
18	was	O
19	given	O
20	in	O
21	three	O
22	fractions	O
23	repeated	O
24	weekly	O
25	.	O

1	RESULTS	O
2	:	O
3	CK	B
4	-	O
5	MB	B
6	elevation	O
7	was	O
8	detected	O
9	in	O
10	313	O
11	patients	O
12	(	O
13	18	O
14	.	O
15	7	O
16	%),	O
17	with	O
18	1	O
19	-	O
20	3x	O
21	in	O
22	12	O
23	.	O
24	8	O
25	%,	O
26	3	O
27	-	O
28	5x	O
29	in	O
30	3	O
31	.	O
32	5	O
33	%	O
34	and	O
35	>	O
36	5x	O
37	normal	O
38	in	O
39	2	O
40	.	O
41	4	O
42	%	O
43	of	O
44	patients	O
45	.	O

1	A	O
2	full	O
3	-	O
4	length	O
5	cDNA	O
6	clone	O
7	isolated	O
8	from	O
9	a	O
10	rat	O
11	lung	O
12	library	O
13	was	O
14	predicted	O
15	to	O
16	encode	O
17	a	O
18	55	O
19	-	O
20	kDa	O
21	protein	O
22	containing	O
23	at	O
24	its	O
25	amino	O
26	terminus	O
27	a	O
28	targeting	O
29	domain	O
30	that	O
31	binds	O
32	to	O
33	the	O
34	ANP	B
35	-	I
36	receptor	I
37	kinase	I
38	-	I
39	like	I
40	domain	I
41	and	O
42	containing	O
43	at	O
44	its	O
45	carboxyl	O
46	terminus	O
47	a	O
48	putative	O
49	protein	B
50	-	I
51	serine	I
52	phosphatase	I
53	domain	O
54	.	O

1	Galoyan	O
2	has	O
3	summarized	O
4	the	O
5	results	O
6	of	O
7	his	O
8	discovery	O
9	of	O
10	cardioactive	O
11	neurohormones	O
12	.	O

1	Interestingly	O
2	,	O
3	Csx	B
4	/	O
5	Nkx2	B
6	.	O

1	HBB	O
2	concentration	O
3	in	O
4	the	O
5	fetuses	O
6	indicated	O
7	little	O
8	,	O
9	if	O
10	any	O
11	accumulation	O
12	.	O

1	The	O
2	hypothesis	O
3	of	O
4	Geisler	O
5	(	O
6	Brain	O
7	Res	O
8	.	O

1	Critique	O
2	of	O
3	"	O
4	Interactive	O
5	Effects	O
6	of	O
7	Test	O
8	Anxiety	O
9	and	O
10	Credit	O
11	/	O
12	No	O
13	Credit	O
14	or	O
15	A	O
16	-	O
17	F	O
18	Grade	O
19	Condition	O
20	upon	O
21	Short	O
22	-	O
23	term	O
24	and	O
25	Long	O
26	-	O
27	term	O
28	Recall	O
29	of	O
30	Course	O
31	Information	O
32	.	O

1	A	O
2	cAMP	O
3	-	O
4	responsive	O
5	element	O
6	-	O
7	like	O
8	(	O
9	CRE	O
10	-	O
11	like	O
12	,	O
13	TGACGTGA	O
14	)	O
15	promoter	O
16	sequence	O
17	and	O
18	a	O
19	protein	B
20	kinase	I
21	A	I
22	signaling	O
23	pathway	O
24	are	O
25	involved	O
26	in	O
27	this	O
28	induction	O
29	,	O
30	and	O
31	activation	O
32	of	O
33	both	O
34	CRE	B
35	binding	I
36	protein	I
37	(	O
38	CREB	B
39	)	O
40	and	O
41	activating	B
42	transcription	I
43	factor	I
44	-	I
45	2	I
46	(	O
47	ATF	B
48	-	I
49	2	I
50	)	O
51	is	O
52	required	O
53	in	O
54	the	O
55	above	O
56	process	O
57	.	O

1	Vacuum	O
2	Rabi	O
3	splitting	O
4	as	O
5	a	O
6	feature	O
7	of	O
8	linear	O
9	-	O
10	dispersion	O
11	theory	O
12	:	O
13	Analysis	O
14	and	O
15	experimental	O
16	observations	O
17	.	O

1	Significant	O
2	alterations	O
3	in	O
4	CBC	O
5	results	O
6	and	O
7	serum	B
8	CRP	I
9	concentration	O
10	,	O
11	compared	O
12	with	O
13	baseline	O
14	values	O
15	,	O
16	were	O
17	lacking	O
18	in	O
19	dogs	O
20	of	O
21	the	O
22	control	O
23	group	O
24	.	O

1	The	O
2	oral	O
3	temperature	O
4	rose	O
5	and	O
6	the	O
7	serum	B
8	creatine	I
9	kinase	I
10	levels	O
11	fell	O
12	only	O
13	in	O
14	those	O
15	patients	O
16	who	O
17	were	O
18	actively	O
19	warmed	O
20	.	O

1	Based	O
2	on	O
3	the	O
4	current	O
5	literature	O
6	,	O
7	the	O
8	mechanisms	O
9	involved	O
10	in	O
11	the	O
12	toxicity	O
13	of	O
14	OA	B
15	indicate	O
16	three	O
17	major	O
18	effects	O
19	:	O
20	(	O
21	1	O
22	)	O
23	inhibition	O
24	of	O
25	mitochondrial	O
26	respiration	O
27	correlated	O
28	with	O
29	a	O
30	depletion	O
31	of	O
32	ATP	O
33	;	O
34	(	O
35	2	O
36	)	O
37	inhibition	O
38	of	O
39	tRNA	B
40	-	I
41	synthetase	I
42	accompanied	O
43	by	O
44	a	O
45	reduced	O
46	protein	O
47	synthesis	O
48	;	O
49	and	O
50	(	O
51	3	O
52	)	O
53	enhanced	O
54	lipid	O
55	peroxidation	O
56	.	O

1	In	O
2	addition	O
3	,	O
4	REP21	O
5	plants	O
6	were	O
7	resistant	O
8	to	O
9	an	O
10	unusually	O
11	broad	O
12	range	O
13	of	O
14	tobamoviruses	O
15	including	O
16	tomato	O
17	mosaic	O
18	virus	O
19	,	O
20	tobacco	O
21	mild	O
22	green	O
23	mosaic	O
24	virus	O
25	,	O
26	TMV	O
27	-	O
28	U5	O
29	,	O
30	green	O
31	tomato	O
32	atypical	O
33	mosaic	O
34	virus	O
35	,	O
36	and	O
37	ribgrass	O
38	mosaic	O
39	virus	O
40	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	ROS	O
6	production	O
7	by	O
8	viable	O
9	spermatozoa	O
10	is	O
11	highly	O
12	correlated	O
13	with	O
14	the	O
15	concentration	O
16	of	O
17	PMN	B
18	elastase	I
19	and	O
20	the	O
21	number	O
22	of	O
23	both	O
24	peroxidase	B
25	-	O
26	positive	O
27	and	O
28	round	O
29	cells	O
30	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	ULK2	B
6	is	O
7	involved	O
8	in	O
9	a	O
10	previously	O
11	uncharacterized	O
12	signaling	O
13	pathway	O
14	in	O
15	mammalian	O
16	cells	O
17	.	O

1	Genomic	O
2	DNA	O
3	hybridization	O
4	suggests	O
5	that	O
6	SpSHR2	B
7	is	O
8	a	O
9	single	O
10	-	O
11	copy	O
12	gene	O
13	in	O
14	the	O
15	S	O
16	.	O
17	purpuratus	O
18	genome	O
19	.	O

1	[	O
2	14C	O
3	]-	O
4	beta	O
5	-	O
6	phenethylamine	O
7	,	O
8	its	O
9	distribution	O
10	after	O
11	administration	O
12	by	O
13	various	O
14	routes	O
15	to	O
16	cats	O
17	,	O
18	and	O
19	the	O
20	effects	O
21	of	O
22	monoamine	B
23	oxidase	I
24	inhibitors	O
25	.	O

1	A	O
2	limited	O
3	sampling	O
4	strategy	O
5	was	O
6	used	O
7	based	O
8	on	O
9	a	O
10	bayesian	O
11	parameter	O
12	estimation	O
13	algorithm	O
14	that	O
15	is	O
16	part	O
17	of	O
18	the	O
19	ADAPT	O
20	II	O
21	software	O
22	package	O
23	.	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	both	O
6	of	O
7	these	O
8	surgical	O
9	procedures	O
10	were	O
11	as	O
12	effective	O
13	as	O
14	pinealectomy	O
15	in	O
16	reversing	O
17	the	O
18	pineal	O
19	-	O
20	induced	O
21	alterations	O
22	in	O
23	the	O
24	reproductive	O
25	physiology	O
26	of	O
27	the	O
28	blind	O
29	-	O
30	anosmic	O
31	female	O
32	rat	O
33	.	O

1	This	O
2	study	O
3	describes	O
4	a	O
5	new	O
6	MADS	B
7	box	I
8	gene	I
9	,	O
10	nmhC5	B
11	,	O
12	which	O
13	along	O
14	with	O
15	nmh7	B
16	(	O
17	J	O
18	.	O

1	Radiation	O
2	-	O
3	induced	O
4	changes	O
5	in	O
6	the	O
7	area	O
8	of	O
9	alveoli	O
10	and	O
11	septa	O
12	as	O
13	well	O
14	as	O
15	collagen	B
16	content	O
17	were	O
18	seen	O
19	11	O
20	weeks	O
21	after	O
22	irradiation	O
23	.	O

1	Thus	O
2	,	O
3	the	O
4	association	O
5	of	O
6	PS1	B
7	fragments	I
8	may	O
9	be	O
10	maintained	O
11	during	O
12	cycles	O
13	of	O
14	phosphorylation	O
15	/	O
16	dephosphorylation	O
17	of	O
18	the	O
19	PS1	B
20	CTF	I
21	.	O

1	This	O
2	suggests	O
3	roles	O
4	for	O
5	both	O
6	the	O
7	CE1	O
8	and	O
9	CE2	O
10	elements	O
11	in	O
12	regulating	O
13	Hoxb1	B
14	gene	I
15	expression	O
16	during	O
17	development	O
18	.	O

1	Reviewing	O
2	manuscripts	O
3	:	O
4	developing	O
5	an	O
6	efficient	O
7	system	O
8	.	O

1	Weight	O
2	loss	O
3	reduces	O
4	arterial	O
5	pressure	O
6	by	O
7	a	O
8	decrease	O
9	in	O
10	intravascular	O
11	volume	O
12	and	O
13	cardiac	O
14	output	O
15	associated	O
16	with	O
17	a	O
18	fall	O
19	in	O
20	sympathetic	O
21	activity	O
22	.	O

1	Three	O
2	cDNAs	O
3	encoding	O
4	basic	B
5	leucine	I
6	zipper	I
7	(	I
8	bZIP	I
9	)-	I
10	type	I
11	ABRE	I
12	-	I
13	binding	I
14	proteins	I
15	were	O
16	isolated	O
17	by	O
18	using	O
19	the	O
20	yeast	O
21	one	O
22	-	O
23	hybrid	O
24	system	O
25	and	O
26	were	O
27	designated	O
28	AREB1	B
29	,	O
30	AREB2	B
31	,	O
32	and	O
33	AREB3	B
34	(	O
35	ABA	B
36	-	I
37	responsive	I
38	element	I
39	binding	I
40	protein	I
41	).	O

1	CONCLUSIONS	O
2	:	O
3	Use	O
4	of	O
5	the	O
6	first	O
7	method	O
8	was	O
9	associated	O
10	with	O
11	a	O
12	reduction	O
13	in	O
14	the	O
15	time	O
16	patients	O
17	remained	O
18	in	O
19	the	O
20	ICU	O
21	before	O
22	transfer	O
23	to	O
24	another	O
25	unit	O
26	and	O
27	savings	O
28	in	O
29	nursing	O
30	time	O
31	,	O
32	but	O
33	the	O
34	two	O
35	methods	O
36	did	O
37	not	O
38	differ	O
39	according	O
40	to	O
41	clinical	O
42	outcomes	O
43	.	O

1	T	O
2	-	O
3	cell	O
4	hybridomas	O
5	,	O
6	thymocytes	O
7	,	O
8	and	O
9	T	O
10	cells	O
11	can	O
12	be	O
13	induced	O
14	to	O
15	undergo	O
16	apoptotic	O
17	cell	O
18	death	O
19	by	O
20	activation	O
21	through	O
22	the	O
23	T	B
24	-	I
25	cell	I
26	receptor	I
27	.	O

1	The	O
2	results	O
3	suggested	O
4	that	O
5	,	O
6	depending	O
7	upon	O
8	the	O
9	cell	O
10	type	O
11	,	O
12	gene	O
13	cotransfer	O
14	using	O
15	aminoglycoside	O
16	resistance	O
17	as	O
18	a	O
19	selectable	O
20	marker	O
21	may	O
22	seriously	O
23	perturb	O
24	important	O
25	cellular	O
26	control	O
27	mechanisms	O
28	such	O
29	as	O
30	the	O
31	PKC	B
32	pathway	O
33	leading	O
34	to	O
35	activation	O
36	of	O
37	gene	O
38	expression	O
39	.	O

1	Letter	O
2	:	O
3	Salmonella	O
4	detection	O

1	Dd	B
2	PK1	I
3	RNA	I
4	decreases	O
5	after	O
6	6	O
7	h	O
8	of	O
9	starvation	O
10	to	O
11	re	O
12	-	O
13	accumulate	O
14	once	O
15	the	O
16	cells	O
17	have	O
18	aggregated	O
19	.	O

1	Pharmacologic	O
2	properties	O
3	of	O
4	serotonergic	O
5	agents	O
6	and	O
7	antidepressant	O
8	drugs	O
9	.	O

1	CONCLUSIONS	O
2	:	O
3	Significant	O
4	elevations	O
5	of	O
6	IL	B
7	-	I
8	1alpha	I
9	and	O
10	IL	B
11	-	I
12	1beta	I
13	occur	O
14	in	O
15	patients	O
16	with	O
17	bacterial	O
18	cystitis	O
19	and	O
20	microscopic	O
21	hematuria	O
22	.	O

1	The	O
2	T	B
3	-	I
4	cyt	I
5	promoter	I
6	,	O
7	although	O
8	of	O
9	bacterial	O
10	origin	O
11	is	O
12	active	O
13	in	O
14	planta	O
15	and	O
16	the	O
17	30	B
18	bp	I
19	cyt	I
20	-	I
21	1	I
22	element	I
23	is	O
24	located	O
25	within	O
26	a	O
27	region	O
28	that	O
29	is	O
30	essential	O
31	for	O
32	T	B
33	-	I
34	cyt	I
35	promotor	I
36	activity	O
37	in	O
38	leaf	O
39	,	O
40	stem	O
41	and	O
42	root	O
43	cells	O
44	of	O
45	tobacco	O
46	plants	O
47	.	O

1	3	O
2	.	O
3	04	O
4	+/-	O
5	1	O
6	.	O
7	2	O
8	,	O
9	P	O
10	<	O
11	0	O
12	.	O
13	0001	O
14	),	O
15	large	O
16	accelerations	O
17	/	O
18	30	O
19	min	O
20	(	O
21	1	O
22	.	O
23	46	O
24	+/-	O
25	1	O
26	.	O
27	96	O
28	vs	O
29	.	O

1	A	O
2	vector	O
3	containing	O
4	a	O
5	transcriptionally	O
6	inactive	O
7	neomycin	B
8	phosphotransferase	I
9	II	I
10	gene	I
11	was	O
12	used	O
13	to	O
14	select	O
15	promoter	O
16	sequences	O
17	from	O
18	a	O
19	pool	O
20	of	O
21	random	O
22	genomic	O
23	DNA	O
24	fragments	O
25	.	O

1	The	O
2	NF1	B
3	locus	I
4	encodes	O
5	a	O
6	protein	O
7	functionally	O
8	related	O
9	to	O
10	mammalian	B
11	GAP	I
12	and	O
13	yeast	B
14	IRA	I
15	proteins	I
16	.	O

1	Expression	O
2	and	O
3	regulation	O
4	by	O
5	interferon	B
6	of	O
7	a	O
8	double	B
9	-	I
10	stranded	I
11	-	I
12	RNA	I
13	-	I
14	specific	I
15	adenosine	I
16	deaminase	I
17	from	O
18	human	O
19	cells	O
20	:	O
21	evidence	O
22	for	O
23	two	O
24	forms	O
25	of	O
26	the	O
27	deaminase	O
28	.	O

1	Oligonucleotide	O
2	probes	O
3	corresponding	O
4	to	O
5	wild	O
6	-	O
7	type	O
8	and	O
9	mutant	O
10	EpRE	O
11	sequences	O
12	were	O
13	used	O
14	in	O
15	gel	O
16	-	O
17	shift	O
18	and	O
19	super	O
20	-	O
21	shift	O
22	analyses	O
23	to	O
24	identify	O
25	proteins	O
26	binding	O
27	.	O

1	Moreover	O
2	,	O
3	following	O
4	a	O
5	single	O
6	intravenous	O
7	injection	O
8	of	O
9	the	O
10	bicistronic	O
11	vector	O
12	complexed	O
13	to	O
14	cationic	O
15	liposomes	O
16	into	O
17	recipient	O
18	mice	O
19	,	O
20	delivery	O
21	of	O
22	MDR1	B
23	and	O
24	GC	B
25	cDNAs	I
26	was	O
27	achieved	O
28	in	O
29	all	O
30	the	O
31	organs	O
32	we	O
33	tested	O
34	.	O

1	Viral	O
2	cell	O
3	-	O
4	to	O
5	-	O
6	cell	O
7	movement	O
8	of	O
9	PVX	B
10	CP	I
11	mutant	I
12	was	O
13	complemented	O
14	in	O
15	Nicotiana	O
16	tabacum	O
17	cv	O
18	.	O

1	Based	O
2	on	O
3	these	O
4	results	O
5	,	O
6	a	O
7	new	O
8	model	O
9	for	O
10	the	O
11	regulation	O
12	of	O
13	nif	B
14	/	O
15	fix	B
16	gene	O
17	expression	O
18	in	O
19	A	O
20	.	O
21	caulinodans	O
22	is	O
23	proposed	O
24	.	O

1	Hemorrhagic	O
2	shock	O
3	and	O
4	bacterial	O
5	translocation	O
6	in	O
7	a	O
8	swine	O
9	model	O
10	.	O

1	Analysis	O
2	of	O
3	hematopoietic	B
4	growth	I
5	factor	I
6	prescriptions	O
7	in	O
8	19	O
9	french	O
10	cancer	O
11	centers	O

1	Kss1	B
2	binds	O
3	specifically	O
4	to	O
5	a	O
6	GST	B
7	-	O
8	Dig1	B
9	fusion	O
10	in	O
11	the	O
12	absence	O
13	of	O
14	any	O
15	other	O
16	yeast	O
17	protein	O
18	.	O

1	Response	O
2	to	O
3	treatment	O
4	was	O
5	better	O
6	in	O
7	patients	O
8	with	O
9	less	O
10	pretreatment	O
11	(	O
12	one	O
13	-	O
14	two	O
15	prior	O
16	treatments	O
17	)	O
18	than	O
19	in	O
20	heavily	O
21	pretreated	O
22	ones	O
23	(	O
24	more	O
25	than	O
26	three	O
27	)	O
28	and	O
29	this	O
30	relation	O
31	was	O
32	found	O
33	to	O
34	be	O
35	statistically	O
36	significant	O
37	(	O
38	p	O
39	<	O
40	0	O
41	.	O
42	05	O
43	).	O

1	This	O
2	paper	O
3	gives	O
4	an	O
5	overview	O
6	of	O
7	the	O
8	global	O
9	pattern	O
10	of	O
11	casualties	O
12	in	O
13	earthquakes	O
14	which	O
15	occurred	O
16	during	O
17	the	O
18	30	O
19	-	O
20	month	O
21	period	O
22	from	O
23	1	O
24	September	O
25	1993	O
26	to	O
27	29	O
28	February	O
29	1996	O
30	.	O

1	Six	O
2	putative	O
3	MDV	O
4	genome	O
5	products	O
6	,	O
7	including	O
8	one	O
9	Rep	B
10	and	O
11	five	O
12	non	O
13	-	O
14	Rep	B
15	proteins	O
16	,	O
17	show	O
18	high	O
19	(	O
20	70	O
21	.	O
22	4	O
23	-	O
24	90	O
25	.	O
26	9	O
27	%)	O
28	amino	O
29	acid	O
30	identity	O
31	to	O
32	the	O
33	corresponding	O
34	six	O
35	FBNYV	B
36	proteins	I
37	,	O
38	whereas	O
39	two	O
40	other	O
41	Rep	B
42	proteins	I
43	encoded	O
44	by	O
45	MDV	B
46	-	I
47	C2	I
48	and	O
49	C3	B
50	are	O
51	82	O
52	.	O
53	3	O
54	%	O
55	and	O
56	73	O
57	.	O
58	0	O
59	%	O
60	identical	O
61	to	O
62	those	O
63	encoded	O
64	by	O
65	SCSV	B
66	-	I
67	C2	I
68	and	O
69	C6	B
70	,	O
71	respectively	O
72	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	in	O
6	AIDS	O
7	patients	O
8	with	O
9	cryptococcosis	O
10	,	O
11	tolerance	O
12	to	O
13	ILd	O
14	-	O
15	AmB	O
16	was	O
17	acceptable	O
18	when	O
19	the	O
20	daily	O
21	dosage	O
22	did	O
23	not	O
24	exceed	O
25	1	O
26	mg	O
27	/	O
28	kg	O
29	,	O
30	but	O
31	the	O
32	higher	O
33	1	O
34	.	O
35	5	O
36	mg	O
37	/	O
38	kg	O
39	daily	O
40	dosage	O
41	was	O
42	associated	O
43	with	O
44	an	O
45	unacceptable	O
46	rate	O
47	of	O
48	nephrotoxicity	O
49	.	O

1	A	O
2	progressive	O
3	growth	O
4	of	O
5	blood	O
6	erythrocyte	O
7	membrane	O
8	injury	O
9	has	O
10	been	O
11	demonstrated	O
12	after	O
13	rats	O
14	were	O
15	exposed	O
16	to	O
17	gamma	O
18	-	O
19	irradiaton	O
20	at	O
21	a	O
22	dose	O
23	of	O
24	100	O
25	to	O
26	500	O
27	Gy	O
28	.	O

1	Since	O
2	sildenafil	O
3	came	O
4	on	O
5	the	O
6	market	O
7	,	O
8	it	O
9	seems	O
10	that	O
11	the	O
12	place	O
13	of	O
14	MUSE	O
15	is	O
16	reduced	O
17	because	O
18	comparative	O
19	studies	O
20	give	O
21	better	O
22	results	O
23	for	O
24	sildenafil	O
25	than	O
26	MUSE	O
27	(	O
28	70	O
29	%	O
30	vs	O
31	40	O
32	%)	O
33	and	O
34	of	O
35	course	O
36	with	O
37	a	O
38	better	O
39	acceptance	O
40	.	O

1	The	O
2	two	O
3	genes	O
4	code	O
5	for	O
6	polypeptides	B
7	of	I
8	420	I
9	amino	I
10	acids	I
11	(	I
12	M	I
13	.	I
14	HgiCI	I
15	)	I
16	and	O
17	345	O
18	amino	O
19	acids	O
20	(	O
21	R	O
22	.	O
23	HgiCI	O
24	).	O

1	Taurine	O
2	deficiency	O
3	significantly	O
4	depressed	O
5	the	O
6	amplitude	O
7	of	O
8	OP1	O
9	and	O
10	OP4	O
11	.	O

1	On	O
2	the	O
3	amount	O
4	and	O
5	significance	O
6	of	O
7	the	O
8	effective	O
9	glucose	O
10	level	O
11	in	O
12	tumors	O
13	.	O

1	Symptoms	O
2	,	O
3	however	O
4	,	O
5	appear	O
6	to	O
7	correlate	O
8	poorly	O
9	with	O
10	oesophagitis	O
11	;	O
12	hence	O
13	,	O
14	severe	O
15	symptoms	O
16	do	O
17	not	O
18	indicate	O
19	there	O
20	is	O
21	greater	O
22	oesophageal	O
23	damage	O
24	.	O

1	Our	O
2	study	O
3	reveals	O
4	that	O
5	the	O
6	modular	O
7	structure	O
8	of	O
9	the	O
10	FSH	B
11	receptor	I
12	gene	O
13	generates	O
14	motifs	O
15	that	O
16	allows	O
17	coupling	O
18	to	O
19	different	O
20	effectors	O
21	.	O

1	Children	O
2	born	O
3	from	O
4	chronic	O
5	alcoholic	O
6	mothers	O
7	have	O
8	shown	O
9	behavioral	O
10	teratogenic	O
11	effects	O
12	more	O
13	frequently	O
14	than	O
15	morphological	O
16	malformations	O
17	.	O

1	Although	O
2	popular	O
3	this	O
4	hypothesis	O
5	is	O
6	far	O
7	from	O
8	explaining	O
9	all	O
10	the	O
11	clinical	O
12	facts	O
13	,	O
14	namely	O
15	that	O
16	rigidity	O
17	is	O
18	equal	O
19	in	O
20	extensor	O
21	and	O
22	flexor	O
23	,	O
24	proximal	O
25	and	O
26	distal	O
27	muscles	O
28	.	O

1	We	O
2	use	O
3	the	O
4	term	O
5	corticosteroid	O
6	-	O
7	dependent	O
8	IA	O
9	to	O
10	refer	O
11	to	O
12	the	O
13	serious	O
14	problem	O
15	of	O
16	chronic	O
17	IA	O
18	requiring	O
19	maintenance	O
20	prednisone	O
21	therapy	O
22	.	O

1	Together	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	EGF	B
8	/	O
9	Ras	B
10	/	O
11	Raf	B
12	induces	O
13	transcription	O
14	via	O
15	combined	O
16	activation	O
17	of	O
18	ATF3	B
19	/	O
20	c	B
21	-	I
22	Jun	I
23	and	O
24	a	O
25	52	O
26	-	O
27	kDa	O
28	nuclear	O
29	factor	O
30	,	O
31	whereas	O
32	JunD	B
33	acts	O
34	as	O
35	a	O
36	repressor	O
37	of	O
38	this	O
39	response	O
40	.	O

1	Surprisingly	O
2	,	O
3	however	O
4	,	O
5	TCR	B
6	-	O
7	mediated	O
8	tyrosine	O
9	phosphorylation	O
10	of	O
11	phospholipase	B
12	C	I
13	gamma	I
14	1	I
15	remains	O
16	intact	O
17	in	O
18	the	O
19	Jurkat	O
20	cells	O
21	expressing	O
22	the	O
23	A2	B
24	/	O
25	HCP	B
26	chimera	O
27	.	O

1	Simultaneously	O
2	a	O
3	greater	O
4	NA	O
5	was	O
6	found	O
7	with	O
8	no	O
9	change	O
10	in	O
11	plasma	O
12	epinephrine	O
13	response	O
14	.	O

